

INCLIVA Scientific Report 2025



INCLIVA | VLC
Biomedical Research Institute

INCLIVA | VLC
Instituto de Investigación Sanitaria



INCLIVA Biomedical Research Institute
Avda. Menéndez Pelayo, 4 accesorio
46010 Valencia / España
T. 34 96 197 35 17
F. 34 96 197 35 40
www.INCLIVA.es
INCLIVA@INCLIVA.es

Published by:
Fundación para la Investigación
del Hospital Clínico de la Comunidad Valenciana
INCLIVA Biomedical Research Institute

Managing direction:
Mr Vicente de Juan Martín

Coordination and writing:
Scientific Management Department
Fundación para la Investigación
del Hospital Clínico de la Comunidad Valenciana
INCLIVA Biomedical Research Institute

Design:
Eugenio Simó

INCLIVA Scientific Report 2025



Index

1	INTRODUCTION	10
2	INCLIVA ORIGIN AND STRUCTURE	15
2.1	History	18
2.2	Organizational structure	18
2.2.1	Government structure	18
2.2.1.1	Board of trustees	18
2.2.1.2	Board of governors	19
2.2.1.3	Managing director	19
2.2.1.4	Scientific director	19
2.2.1.5	External scientific committee	19
2.2.1.6	Internal scientific committee	20
	Research commission	20
	Innovation commission	21
2.2.1.7	Drug Research Ethics Committee (CEIm)	22
2.2.2	Management structure	23
2.3	Core facilities	25
3	INCLIVA GLOBAL ANALYSIS	27
3.1	Scientific production global analysis	31
3.2	Financial resources	35
3.3	Cooperative research networks	39
3.4	Knowledge transfer activities	40
3.4.1	Knowledge transfer to the National Health System	40
3.4.2	Innovation and Knowledge Transfer	43
3.4.2.1	Intellectual Assets	44
3.4.2.2	Competitive innovation	45
3.4.2.3	Intrepreneurship	46
3.5	Gender perspective	47
4	SCIENTIFIC ACTIVITY	55
4.1	Scientific structure	59
4.2	Scientific translational programs	60
4.2.1	Overweight and cardiovascular and renal risk	60
4.2.2	Detection, risk prediction and control of ventricular dysfunction	62
4.2.3	Rare Diseases	64
4.2.4	Neurological Decline	69
4.2.5	Translational Oncology	72
4.2.6	Reproductive Medicine	74
4.2.7	Ageing and associated diseases	76
4.3	Research areas	81
4.3.1	Cardiovascular Area	84
4.3.2	Oncology Area	120

4.3.3	Metabolism and Organic Damage Area	158
4.3.4	Reproductive Medicine Area	210
4.3.5	Associated Clinical Groups Area	224
4.4	Other scientific contributions from scientific platforms	244
4.4.1	Spanish Clinical Research Network (SCReN), Clinical Research and Clinical Trials of the Clinical Trials Platform (UICEC INCLIVA)	244
4.4.2	Biobank	252
4.4.3	Precision Medicine Unit	262
4.4.4	Biomarker Analysis Unit	265
4.4.5	Molecular, Cellular, and In Vivo Analysis Unit	268
4.4.6	Biostatistics Unit	271
4.4.7	Bioinformatics Unit	274
4.4.8	Body Composition Unit	276
4.4.9	Analytical Liquid Chromatography Unit	278
4.4.10	Mass Spectrometry Unit	280
4.4.11	Data Science Platform	282
5	CLINICAL TRIALS AND OTHER STUDIES	289
5.1	Drug Research Ethics Committee (CEIm) activity	289
5.2	Clinical research activity performed by Valencia-Clínico Malvarrosa Health Department	291
5.2.1	Activity during 2025	291
5.2.2	Assessment activity during last 5 years	292
5.2.3	Ongoing studies	294
6	INITIATIVES FOR RESEARCH PROMOTION	301
6.1	Grants for external fellowships, Trainee students, Outgoing and Incoming Internships and new initiatives	301
6.2	Training and teaching activities	303
7	COMMUNICATION	317
7.1	Headlines	317
7.2	Communication Indicators	320
8	INCLIVA SOCIAL INITIATIVES	329
8.1	Public Engagement Projects	329
8.2	Philanthropic Projects	339
8.3	Private philanthropic donations and acknowledgments	340
9	PUBLICATION LIST	349



1 Introduction

We are pleased to present our most recent INCLIVA Annual Scientific Report, which summarizes the extensive scientific activity carried out and achievements obtained in 2025 by research groups from the Hospital Clínico Universitario de València and INCLIVA-affiliated groups of scientific excellence from the Faculty of Medicine and Dentistry of the University of Valencia and the Carlos Simón Foundation for Research in Women's Health.

This year is a particularly significant milestone for INCLIVA, marking 25 years since its creation as the first public hospital-affiliated foundation in the Region of Valencia, putting scientific knowledge at the service of society to improve people's health.

This anniversary has provided an opportunity to recognise the contribution of all individuals and institutions that have helped the institute to grow, face the future with renewed vision, and consolidate INCLIVA's position as a leading biomedical research institute.

Against this background, one of the year's landmarks was launching the Strategic Plan 2025–2029, a roadmap to guide the institute's development over the coming years and reinforce its commitment to scientific excellence, attracting and developing talent, innovation, knowledge transfer, internationalisation and the social impact of research.

The centrepiece of this plan has been the creation of a new Cooperative Scientific Project, aligned with INCLIVA's capabilities and priorities, which reorganises our research activity into five priority areas: Cancer; Cardiovascular; Women's health; Rare diseases and Ageing; and Inflammation and Chronic diseases; along with five cross-cutting programmes: Digital Transformation, Artificial Intelligence and Applications in Healthcare Processes; Personalised Medicine and Advanced Therapies; Immune-mediated Diseases and Therapies; Mental Health and Neuroscience; and Infectious Diseases.

In this context, 2025 saw the creation of a new Research Group on Kidney Disease and an Associated Clinical Group in Insomnia and Circadian Rhythms, further strengthening INCLIVA's research structure, which now comprises 41 consolidated groups and nine emerging groups.

INCLIVA has also increased its commitment to more open, collaborative, and society-oriented research by updating its institutional Open Science policy. In parallel, the institute has launched the Support Plan for Emerging Research Groups to stimulate scientific activity and support the development of early-career researchers and emerging research groups.

Throughout 2025, INCLIVA has continued to promote research excellence by securing competitive funding, reinforcing its scientific and technological infrastructures, and expanding its research portfolio in strategic areas. The Institute further consolidated its track record of success in highly competitive funding calls for proposals, maintaining the upward trajectory of recent years. In 2025, it secured nearly nine million euros to support 73 new national and regional research projects. Regarding personnel funding from the Carlos III Health Institute, in total, INCLIVA staff have received one *Juan Rodés* scholarship, one *Río Hortega* scholarship, three Miguel Servet contracts and two PFIS scholarships.

Internationalisation remains one of the key drivers of INCLIVA's research strategy. During the year, the Institute consolidated its leadership in European projects and international research collaborations, further increasing the visibility and impact of its scientific activity. Success in highly competi-

tive European Commission calls for proposals resulted in more than six million in funding for active projects as of March 2025, covering areas such as big data and artificial intelligence, oncology, nephrology, hypertension and digital innovation. A notable example is AIDA (An Artificially Intelligent Diagnostic Assistant for gastric inflammation), a four-year project coordinated by INCLIVA, which has attracted total funding of over one million euros. The portfolio was further expanded in 2025 with new projects focusing on dementia, respiratory diseases and oral health in rural populations.

Regarding scientific output, our research staff published 686 articles indexed in Journal Citation Reports during 2025 (of which 447 are INCLIVA-affiliated articles and reviews), with a cumulative impact factor of over 5127.4 points (201 publications have an impact factor over 7). Of these, 60.3% are from the first quartile and 25.8% from the first decile. Furthermore, 40.5% of our scientific output involved properly affiliated international collaborations. A total of 41 doctoral theses were also defended in 2025.

Turning to clinical trials, our Drug Research Ethics Committee (CEIm) at the Hospital Clínic Universitario de València, the first in the Region of València and among the first nationally to receive this certification, has participated as a review board of reference in 217 clinical studies since new legislation was approved in 2016. During 2025 INCLIVA initiated 179 new clinical studies and participated in 465 active studies.


In the field of innovation, INCLIVA has been awarded the ISO 56001 certification by AENOR, becoming one of the first entities in Spain to achieve this recognition. This milestone strengthens INCLIVA's innovation management capabilities, enabling the Institute to accelerate the transfer of its own technologies to the market, foster impactful collaborative projects, and support the development and validation of innovative health solutions.


To further promote translational research and innovation, INCLIVA launched a Living Lab that supports the valorisation of internally generated technologies through usability testing and regulatory validation services for medical devices, facilitating the CE marking process and accelerating their pathway to the market. At the same time, the Institute has intensified its co-creation activities, fostering multidisciplinary teams and collaborative environments that accelerate the generation and adoption of innovative healthcare solutions.

As we celebrate our 25th anniversary, we look back with pride on everything we have achieved together and ahead with confidence. The progress made throughout 2025 has further strengthened the Institute's scientific excellence, research capacity and societal impact, laying solid foundations for its reaccreditation as a Health Research Institute in 2026. Above all, it reaffirms the commitment that has defined INCLIVA from the very beginning: advancing excellent science to improve health and serve society.

Mr Andrés Cervantes Ruipérez, INCLIVA Scientific Director

Andrés



A glowing DNA double helix structure is shown against a dark, starry background. The DNA is rendered in a light purple/pink color, with the sugar-phosphate backbones forming the outer curve and the base pairs forming the rungs of the ladder. The background is a deep black with numerous small, white, out-of-focus stars or particles scattered throughout, creating a cosmic or microscopic feel.

2 | Origin and structure

2 INCLIVA ORIGIN AND STRUCTURE

- 2.1 History
- 2.2 Organizational structure
 - 2.2.1 Government structure
 - 2.2.1.1 Board of trustees
 - 2.2.1.2 Board of governors
 - 2.2.1.3 Managing director
 - 2.2.1.4 Scientific director
 - 2.2.1.5 External scientific committee
 - 2.2.1.6 Internal scientific committee
 - Research commission
 - Innovation commission
 - 2.2.1.7 Drug Research Ethics Committee (CEIm)
 - 2.2.2 Management structure
- 2.3 Core facilities

2. INCLIVA origin and structure

2.1. History

The *Hospital Clínico Universitario de Valencia* Research Foundation was constituted in the year 2000 as the first Valencian research foundation affiliated to a public hospital. Ten years later, various centres of excellence in biomedical research from the University of Valencia and Carlos Simón Foundation joined the Foundation via a series of specific agreements, and thus INCLIVA Biomedical Research Institute was created.

INCLIVA's main aims are to manage the biomedical research carried out by the *Hospital Clínico Universitario de Valencia* and its Health Department, and to encourage teaching and scientific activities, thus improving patient treatment and knowledge sharing.

In 2011 INCLIVA was accredited as a Biomedical Research Institute by the Ministry of Science and Innovation (*Ministerio de Ciencia e Innovación*) thus obtaining preferential treatment from the Carlos III Health Institute (*Instituto de Salud Carlos III*), in recognition of its excellence in research.

2.2.1. Government structure

As the highest governing body in the Foundation, the Board of Trustees is headed by the Valencian Government's Regional Minister for Health. This body appoints a Board of Governors (headed by the Chief Executive Officer of the Health Department), a Managing Director and Scientific Director. These are guided by two Research Committees: the External Scientific Committee and the Internal Scientific Committee.

2.2.1.1. BOARD OF TRUSTEES

President:

Mr Marciano Gómez

Honourable Councillor of the Higher Health Inspection of the *Conselleria de Sanidad* (Regional Public Health Department) of the Valencian Government

Vice-president:

Mr Álvaro Bonet

Chief Executive Officer of the *Hospital Clínico Universitario of Valencia* and of the Valencia Clínico – Malvarrosa Health Department

Board members:

Ms María Vicenta Mestre

Distinguished Dean of the University of Valencia

Ms Amparo Ruíz

Distinguished Dean of the Faculty of Medicine at the University of Valencia

Ms Ángela Pérez

President of the Social Council at the University of Valencia

Mr Juan Viña

President of Cañada Blanch Foundation

Mr Rafael Alcón Traver

President of Bancaja Foundation

In 2021 INCLIVA was officially reaccredited as a Biomedical Research Institute for the next five years.

2.2. Organizational Structure

2.2.1. Government structure

2.2.1.1. BOARD OF TRUSTEES

2.2.1.2. BOARD OF GOVERNORS

2.2.1.3. MANAGING DIRECTOR

2.2.1.4. SCIENTIFIC DIRECTOR

2.2.1.5. EXTERNAL SCIENTIFIC COMMITTEE

2.2.1.6. INTERNAL SCIENTIFIC COMMITTEE

RESEARCH COMMISSION

INNOVATION COMMISSION

2.2.1. 1. DRUG RESEARCHETHICS COMMITTEE (CEIm)

2.2.2. MANAGEMENT STRUCTURE

Mr José Bernardo Noblejas Pérez

Valencia Chamber of Commerce, Industry and Navigation

Mr Bernardo Valdivieso

Autonomous Secretary of Efficiency and Health Technology of the *Conselleria de Sanidad* (Autonomous Public Health Department) of the Valencian Government

Ms Mariola Penadés

General Director of Research and High Sanitary Inspection of the *Conselleria de Sanidad Universal y Salud Pública* (Autonomous Public Health Department) of the Valencian Government

Ms Núria Vizcarro Boix

Valencian Council of Culture

Mr Carlos Simón

Scientific Director of the Carlos Simón Foundation

Mr Rubén Ventura

Fero Foundation

Ms Almudena Amaya

FEDER (Spanish Federation of Rare Diseases) representative

Board members their own capacity:

Mr Carlos Pascual de Miguel

Mr Joaquín Ortega Serrano

Mr Tomás Trénor Puig

Ms Ana Lluch Hernández

Ms Ángela Nieto Toledano

2.2.1.2. BOARD OF GOVERNORS

President:

Mr Álvaro Bonet Pla

Chief Executive Officer of the *Hospital Clínico Universitario de Valencia* and of the Valencia Clínico – Malvarrosa Health Department

Vice-president:

Ms Amparo Ruíz

Distinguished Dean of the Faculty of Medicine at University of Valencia

Board Members:

Mr Andrés Cervantes Ruipérez

INCLIVA Scientific Director

Mr Vicente de Juan Martín

Managing Director

Ms M^a José Puchades Company

Primary Care Director of the *Hospital Clínico Universitario de Valencia* and of the Valencia Clínico – Malvarrosa Health Department

Ms Blanca Navarro Cubells

Medical Director of the *Hospital Clínico Universitario de Valencia* and of the Valencia Clínico – Malvarrosa Health Department

Ms Mariola Penadés

Director of Research and High Sanitary Inspection of the *Conselleria de Sanidad Universal y Salud Pública* (Autonomous Public Health Department) of the Valencian Government

Mr Pascual Medina Besó

Coordinator of Central Medical Research Unit of the Faculty of Medicine at University of Valencia

Mr Manuel Alós

Head of the Pharmacy Service of *Hospital Clínico Universitario de Valencia* and of the Valencia Clínico – Malvarrosa Health Department

Ms Marisa Luisa Calabuig

President of the Drug Research Ethics Committee

Mr Federico Pallardó

Department of Physiology Professor at the University of Valencia

Mr Carlos Simón

Scientific Director of the Carlos Simón Foundation

Ms Maite Sáenz

Secretary General

2.2.1.3. MANAGING DIRECTOR

Mr Vicente de Juan Martín

INCLIVA Managing Director from 2016 to 2022, has this year been appointed managing director of the institution by the Board of Trustees, at the proposal of the Governing Board. His functions are included in article 20 of the Statutes dated 3 May 2022. He is an ex officio member of the Governing Board and advisory member of the Board of Trustees. He is the designated representative of the Foundation in the absence of the President and Vice-Presidents, and directs the Foundation's economic policy, following the decisions of the governing bodies of the Foundation. He formulates the entity's Action Plan and Annual Accounts for approval by the Board of Trustees, holding the position of chief of staff.

2.2.1.4. SCIENTIFIC DIRECTOR

Mr Andrés Cervantes Ruipérez

Full Professor of Medicine at the University of Valencia, Head of the Oncology Service of the *Hospital Clínico Universitario de Valencia* and Director of the Cancer Area at the INCLIVA Biomedical Research Institute.

He trained as a resident medical intern at the *Hospital Clínico Universitario de Valencia*. After completing this residency, he obtained a predoctoral fellowship at the Free University Hospital in Amsterdam, where he obtained his Doctorate in the laboratory of cellular pharmacology, with work on multidrug resistance.

His areas of interest and research are gastrointestinal and gynaecological cancer, as well as phase I trials and new drugs development.

As a clinical researcher in rectal cancer, he has published several papers on the quality of multidisciplinary work as well as on quality assessment of mesorectal surgery, optimizing initial therapy choices and with special, focus on treating cancer of the upper third of the rectum.

He has been the President of the European Society of Medical Oncology (ESMO) since July 2019.

2.2.1.5. EXTERNAL SCIENTIFIC COMMITTEE

President:

Mr Josep Tabernero Caturla

Head of the Medical Oncology Service. Vall d'Hebrón Hospital.

Board Members:

Mr Antonio Vidal-Puig

Professor of Molecular Nutrition and Metabolism, University of Cambridge. Honorary consultant in metabolic medicine. Metabolic research laboratories. Addenbrooke´s Hospital, Cambridge, United Kingdom

Mr Juan Carlos Lacal Sanjuán

Research Professor at the CSIC. Institute of Biomedical Research, Madrid

Mr Manuel Tena Sempere

University Professor, Department of Cell Biology, Physiology and Immunology. University of Cordoba

Mr M Roser Torra Balcells

Nephrologist, Fundació Puigvert. Research line in the study of Hereditary Kidney Diseases

Ms Laura Saucek

Group leader at VHIO (Oncology Institute of the Vall d'Hebron Hospital). Head of Modelling of Anti-tumour Therapies in mice. Founding executive director (CEO) at Peptomycs SL

Ms Pura Muñoz Cánoves

Professor of Medicine, Department of Experimental and Health Sciences at Pompeu Fabra University. ICREA Research Professor

2.2.1.6. INTERNAL SCIENTIFIC COMMITTEE

Mr Andrés Cervantes Ruipérez

INCLIVA Scientific Director

Mr Vicente de Juan

Managing Director of INCLIVA

Mr Jon Alguacil

Medical Director of the Hospital Clínico-Malvarrosa

Ms Ana Sanmartín Almenar

Primary Care Director of the *Hospital Clínico Universitario deValencia* and of the Valencia Clínico – Malvarrosa Health Department

Mr Julio Núñez

Associate Professor of the Department of Medicine at the University of Valencia, attached to the Scientific Direction

Mr Vicente Bodí

Full Professor of the Department of Medicine at the University of Valencia

Mr Josep Redón

INCLIVA Emeritus Researcher

Mr Federico Pallardó

Full Professor of the Department of Physiology at the University of Valencia

Ms María Jesús Sanz Ferrando

Full Professor of the Department of Pharmacology at the University of Valencia

Ms Ana Lluch Hernández

Emeritus Professor of the Department of Medicine at the University of Valencia

Ms María del Mar Tormo García

Hematologist at the of the Valencia Clínico – Malvarrosa Health Department

Mr Felip Vilella

Principal Investigator of the Research Group on Maternal-Fetal Communication

Ms Aymara Más

Principal Investigator of the Research Group on Molecular Diagnosis of Gynaecological Tumours

Ms Mari Carmen Gómez Cabrera

Principal Investigator of the Research Group on Exercise, Nutrition and Healthy Lifestyle

Mr Luis Sabater

Principal Investigator of the Research Group on General and Digestive Surgery

Ms Maria Pilar Ballester

Emerging researcher of the Research Group on Neurological Impairment

Ms Raquel Cortés

Co-principal investigator of the Research Group on the Study of Cardiometabolic and Renal Risk

Mr Javier Hernández

Ramón y Cajal researcher of the Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST

Ms Belén Martínez Castedo

Experimental investigator of the Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST

Mr Iván de Amo Galán

Experimental investigator of the Research Group on Heart Failure

Ms Elena Carrió Argós

Head of the INCLIVA Innovation Unit

Mr Rafael Barajas

Quality and Data Protection Officer of INCLIVA

Ms Consuelo Ribera

Citizen

Mr Eduardo Pla

Citizen

RESEARCH COMMISSION

President:

Mr Luis Sabater Ortí

Section Head of General Surgery

Board Members:

Ms Alba Muler Arabí

Ms Ana Lloret Alcañiz

Ms Ana Monteagudo Sánchez

Ms Ana Ortega Gutiérrez

Ms Ana Pilar Gómez Escribano

Mr Antonio Martínez Sabater,
General supervisor at *Hospital Clínico Universitario de Valencia*

Ms Ariadna Bargiela Schönbrunn

Ms Aymara Mas Perucho

Ms Blanca Ferrer Lores

Mr Carlos Antúnez Muñoz

Mr Carlos Tornero Tornero

Head of the Anaesthesia/Reanimation Service

Carlos Vergara Uzcategui

Ms Carmina Montoliu Félix

Researcher at INCLIVA

Ms Carmen Espinós Armero

Ms Clara Bonanad Lozano

Ms Cristina Mas-Bargues

Mr César Ríos Navarro

Researcher at INCLIVA

Mr Damian Mifsut Miedes

Mr Daniel Monleón Salvado

Full Professor and Head of Department, Dept Pathology, University of Valencia

Mr David Moro Valdezate

Associate Physician, General Sugery

Ms Desamparados Roda Pérez

Associate Physician, Oncology

Ms Elena Crehuá Gaudiza

Ms Elena Jiménez Martí

Mr Enrique Santas Olmeda

Ms Eva Serna García

Mr Felipe Javier Chaves Martínez

Researcher at INCLIVA

Mr Felipe Vilella Mitjana

Researcher at INCLIVA

Mr Fernando Martínez García

Mr Francisco Dasí Fernández

Ms Gema Miñana Escrivá

Associate Physician, Cardiology

Ms Gloria Olaso González

Ms Herminia González Navarro

Researcher at INCLIVA

Ms Inmaculada Moreno Gimeno

Ms Isabel Gabaldón Sánchez

Valencia Clínico - Malvarrosa Health Department

Mr Jaime Signes-Costa

Pneumology Service Head

Mr Jaime Verdú Amorós

Mr Jose Vicente Arcos Machancoses

Mr José Javier Martín de Llano

Mr José Luis Górriz Teruel

Head of the Nephrology Service

Mr Juan Antonio Navarro Langa

Mr Juan Carlos Hernández Boluda

Mr Juan Gambini Buchón

Mr Juan Miguel Cejalvo Andújar

Mr Juan Nácher Roselló

Mr Julio Núñez Villota

Associate Physician, Cardiology

Ms Laura Piqueras Ruiz

Researcher at INCLIVA

Ms Lorena Peiró Chova

Biobank coordinator

Ms Maite Martínez Martínez

Mr Manuel Cabeza Segura

Mr Manuel Mata Roig

Ms María Dolores Mauricio Aviñó

Ms Marta Pérez Rando

Ms Marta Seco Cervera

Mr Miguel Angel García Pérez

Ms Mª Cruz González Villaescusa,

Associate Physician, Pneumology

Ms Mª José Terol Castera

Haematology and Hemotherapy

Associated Physician

Ms Nekane Romero García

Ms Nuria Cabedo Escrig

Researcher at INCLIVA

Ms Patricia Palau Sampio

Ms Patricia Roselló Millet

Associated Physician, Pediatrics

Ms Pilar Eroles Asensio

Researcher at INCLIVA

Ms Pilar González Cabo

Ms Pilar Rentero Garrido

Coordinator of Precision Medicine Unit

Ms Raquel Cortés Vergaz

Ms Raquel Llorens Chiralt

Head of projects unit at INCLIVA

Mr Raúl Gómez Gallego

Researcher at INCLIVA

Mr Rafael Badenes Quiles

Ms Rosa Noguera Salvá

Ms Rosa Zaragoza Colom

Researcher at INCLIVA

Mr Sergio García Blas

Mr Sergio Martínez Hervás

Associated Physician, Endocrinology and Nutrition

Ms Silvia Castillo Corullón

Ms Silvia Perez Debén

Ms Tania Fleitas Kanonnikoff

Ms Tamara Garrido Gómez

Mr Vicente José Bodí Peris

Professor of the Department of Medicine at the University of Valencia

Mr Víctor Manuel Víctor González

Commission Management Unit:

Ms María Domínguez Machín

INNOVATION COMMISSION

President:

Mr Andrés Cervantes Ruipérez,

INCLIVA Scientific Director

Commission Management:

Ms Elena Carrió Argos

Head of UAI

Mr Vicente de Juan Martín

Managing Director

Mr Jonatan Alguacil

Medical Director of the *Hospital Clínico Universitario de Valencia* and of the Valencia Clínico – Malvarrosa Health Department

Ms Patricia Fernández Saiz

Scientific Subdirector at INCLIVA

Ms Maite Sáenz González

Secretary General at INCLIVA

Mr Miguel Puche Torres

Clinical researcher with experience in the field of innovation

Mr Jose Luis García Gimeno

Basic researcher with experience in the field of innovation

Mr Rubén Artero Allepuz

Basic researcher with experience in the field of innovation

Ms Consuelo Borrás Blasco

Basic researcher with experience in the field of innovation

Mr Felip Vilella Mitjana

Basic researcher with experience in the field of innovation

Ms María Teresa Sánchez

Clinical researcher with experience in the field of innovation

Ms Carmina Montoliu

Clinical researcher with experience in the field of innovation

Mr Jorge Navarro Pérez

Clinical researcher with experience in the field of innovation

Ms Marta Viciano Chumillas

UAI manager

Ms Mariana Reina

UAI manager

Ms Esther Orgiler Castelló

UAI manager

Ms Helena Benito Escribá

UAI manager

2.2.1.7. DRUG RESEARCH ETHICS COMMITTEE (CEIm)

President:

Ms M^a Luisa Calabuig Muñoz
Specialist of the Haematology Department

Vicepresident:

Mr Esteban Morcillo Sánchez
Clinical pharmacologist

Technical Secretary:

Mr Manuel Alós Almiñana
Head of the Pharmacy Department

Board Members:

Mr Diego V. Cano Blanquer
Hospital Pharmacist

Mr David Juan López Ortega

Law Degree

Ms Carmen Celda Ortega

Nurse

Ms Stephanie García Botello

General surgery specialist.

Ms Patricia Roselló Millet

Specialist in the Paediatrics Department

Ms Tania Fleitas Kanonnikoff

Specialist in the Oncology Department

Mr Francisco Dasí Fernández

Stabilized Miguel Servet Researcher

Mr Antonio Ordóñez Sardaña

Lay member

Mr Rafael Barajas Cenobio

Responsible for Quality and Data Protection INCLIVA

Ms Berta Monleón López

Anesthesiology specialist

Ms M^a José Galindo Puerto

Head of the Infectious Diseases Unit

Mr Jorge Navarro Pérez

Primary Care specialist

Ms Encarnacion Isabel Gonzalvo Puchades

Primary Care Pharmacist

Mr Santos Ferrer Espinosa

Specialist in the Pneumology Department

Mr Enrique Santos Olmeda

Specialist in the Cardiology Department

Ms M^a José Fabià Valls

Specialist in the Internal Medicine Department

Ms M^a José Fabià Valls

Specialist in the Internal Medicine Department

Ms Begoña Bermejo de las Heras,

Specialist in the Oncology Department

Administrative:

Ms Maialen Llopis


Ms Ester Penadés

2.2.2. Management structure

The organizational chart, approved by the Board of Trustees, is comprised of two sub-directorates, economical and scientific. The first sub-directorate is responsible for the administrative area, which deals with financial and administrative matters as well as with human resource management.

The second sub-directorate is in charge of scientific activity management and innovation. It is responsible for integral sci-

entific management which includes controlling and monitoring clinical trials and research projects, organizing courses, conferences and seminars, and several general administration-related tasks. Furthermore, it acts as administrative support to the different affiliated scientific committees and to the Medical Research Central Unit. It comprises the innovation area in charge of quality and planning, innovation management, international programmes and scientific and innovative culture promotion (UCCI).



Administrative Area: Managing Director: Vicente de Juan Budget Control and Economic Management: Consuelo López Human Resources and Equality Unit: Ruth Cano Anabel Gil Mar Chanza Javier López Carlos Samper Ioana-Gabriela Mateescu Invoicing and Project Justification: Vera Marín Lorena Munuera Accounting: M ^a José Rosalén M ^a Pilar Boix Roberto Rosalén Purchasing Unit: Isabel Gomis Karen Iglesias Ana María Martín Irene Collado Concepción Villanueva María Romero Raquel Moreno General Services Unit: Cristina García Receptionists: Inmaculada Montalt Alicia Gumiel Angela Saiz Beatriz Debis.	Scientific Management Area: Scientific Subdirector: Patricia Fernández Scientific Culture Unit: Arantxa Martín Alexandra Muñoz Natividad Paz Maite Sanz International Projects Unit: Ana Ferrer Eugenia Flores Elvira del Pozo Miriam Gamero Mercedes Poveda Irene Sánchez Esther Illueca National Projects Unit: Raquel Llorens María Domínguez Jorge Martínez Alejandro Alejos Innovation Management Unit: Elena Carrió Marta Viciano Mariana Reina Ana Pérez Irene Cañigal María Pilar Tartaj Gabriela Natalia Campos Esther Orgiler Clinical Trials Management Unit: M ^a Carmen Román Rafael Roig Patricia Manuela Erasum Esther Penades Clinical Trials Platform: Ana Portolés Mercedes Peris	Sofía Galant Marta Martínez Training and Events Unit: Cristina García Natividad Paz CEIm Administrative Management: Maialen Llopis Data Quality and Protection: Rafael Barajas María Domínguez Silvia Cobos Scientific Production Unit: María Revenga Communication: Alexandra Muñoz Arantxa Martín Tomás Camarasa Computing Unit: Head of Information Systems and High-Performance Computing: Miguel Herreros Software engineer and IT systems administrator: Enrique Herreras Computer technicians: Antonio Macías Francisco Sánchez Secretary General: Head: Maite Sáenz Technician: Alejandro José Francisco
--	--	---

2.3. Core Facilities Research support platforms Genomics and Epigenetics Unit Personal Autonomy, Dependencies and Serious Mental Disorders Unit Cytometry and Cultures Unit Stabling and Experimental Operating Theatres Unit Microscopy Unit Medical Genetics and Genomics Section Biomedical Imaging and Metabolomics Section INCLIVA Platforms Biobank Precision Medicine Unit Biomarker Analysis Unit Molecular, Cellular and in vivo Analysis Unit Biostatistics Unit Bioinformatics Unit Body Composition Unit Analytical Liquid Chromatography Unit Mass Spectrometry Unit Clinical Research and Clinical Trials Unit Data Science Platform





- 3 INCLIVA GLOBAL ANALYSIS**
- 3.1 Scientific production global analysis
- 3.2 Financial resources
- 3.3 Cooperative research networks
- 3.4 Knowledge transfer activities
 - 3.4.1 Knowledge transfer to the National Health System
 - 3.4.2 Innovation and Knowledge Transfer
 - 3.4.2.1 Intellectual Assets
 - 3.4.2.2 Competitive innovation
 - 3.4.2.3 Intrepreneurship
- 3.5 Gender perspective

3.1 Scientific production global analysis


As in the previous year, INCLIVA continued an upward trend in the quality of scientific output in 2025. For this year data was extracted only from certified groups. The number of publications this year reached 686 (of which 447 are properly affiliated articles and reviews) with a cumulative impact factor of 5127.4 points, resulting in an average impact factor of 7.54029.


The following figures depict the number and quality of published papers expressed in terms of total and average impact factor (IF).

Cumulative impact factor	5127.4
Average impact factor	7.54029
Publications with IF>7	201
Publications	686
Properly affiliated articles and reviews	447


The distribution of publications by quartiles within their thematic categories is shown below. In 2025, 97.86% of the papers published in indexed journals belong to the first and second quartiles of their corresponding thematic categories:

The number and percentage of scientific publications according to category are as follows:





The distribution of publications by quartiles within their thematic categories is shown below. In 2025, 97.86% of the papers published in indexed journals belong to the first and second quartiles of their corresponding thematic categories:



The following table shows the impact analysis of output classified as excellent according to Instituto de Salud Carlos III indicators in 2025:

Normalised Impact or Crown Index¹

ESI Categories	Nº Publications	Total citations received WOS	Total citations expected	Count of [Measures]. [Indicador CROWN]
AGRICULTURAL SCIENCES	6	13	4.260	3.05
BIOLOGY & BIOCHEMISTRY	32	51	25.600	1.99
CHEMISTRY	17	16	15.980	1.00
CLINICAL MEDICINE	239	569	145.790	3.90
ENGINEERING	2	1	1.600	0.63
ENVIRONMENT/ECOLOGY	1	5	0.740	6.76
IMMUNOLOGY	23	64	16.790	3.81
MATERIALS SCIENCE	2	10	2.260	4.42
MICROBIOLOGY	10	17	6.200	2.74
MOLECULAR BIOLOGY & GENETICS	12	81	12.360	6.55
MULTIDISCIPLINARY	11	7	7.370	0.95
NEUROSCIENCE & BEHAVIOUR	15	36	9.750	3.69
PHARMACOLOGY & TOXICOLOGY	12	14	8.640	1.62
PLANT & ANIMAL SCIENCE	1	2	0.470	4.26
PSYCHIATRY/PSYCHOLOGY	17	16	6.800	2.35
SOCIAL SCIENCES, GENERAL	2	1	0.740	1.35
Total general	402	903	265.350	3.40


Global Impact²

ESI Categories	10% HCP	Nº Publications	Count of [Measures]. [Global Impact Indicator]
AGRICULTURAL SCIENCES	2	6	33.33
BIOLOGY & BIOCHEMISTRY	6	32	18.75
CHEMISTRY	2	17	11.76
CLINICAL MEDICINE	87	239	36.40
ENGINEERING	0	2	0.00
ENVIRONMENT/ECOLOGY	1	1	100.00
IMMUNOLOGY	6	23	26.09
MATERIALS SCIENCE	1	2	50.00
MICROBIOLOGY	5	10	50.00
MOLECULAR BIOLOGY & GENETICS	5	12	41.67
MULTIDISCIPLINARY	1	11	9.09
NEUROSCIENCE & BEHAVIOR	5	15	33.33
PHARMACOLOGY & TOXICOLOGY	2	12	16.67
PLANT & ANIMAL SCIENCE	1	1	100.00
PSYCHIATRY/PSYCHOLOGY	5	17	29.41
SOCIAL SCIENCES, GENERAL	0	2	0.00
Total general	129	402	32.09


1. According to Instituto de Salud Carlos III (ISCIII), the Normalized Impact or Crown Index is considered EXCELLENT when the calculated value is ≥ 2.5 , and ACCEPTABLE when the calculated value falls between 1.5 - 2.49.

2. According to the Carlos III Health Institute (ISCIII), Global Impact is considered EXCELLENT when the calculated value is $\geq 25\%$, and ACCEPTABLE when the calculated value falls between 20% -24%.

One of the main success factors for a biomedical research institution lies in its potential to establish high level scientific collaborations. The percentage of national and international collaborations which led to scientific output in 2025 is listed below:




Another key performance indicator is the leadership role in scientific publications. The chart below shows the number of published articles in which INCLIVA researchers sign as corresponding author, first or last author.





3.2 Financial Resources

INCLIVA's funding during 2025 totaled €28.120.576,00. Funds raised from competitive sources were higher than the average of recent years.



Funding sources for the indicated period are shown below. The remaining income corresponds to private funding sources, clinical trial revenues and grants, among others. The graph below shows this breakdown for the year 2025.





The following table shows a breakdown of the income obtained by the Foundation in its last fiscal year (2025).

INCOME		AMOUNT	OVERHEADS	TOTAL
TURNOVER		12,208,589.20	2,115,268.12	14,323,857.32
DONATIONS		230,345.01	40,320.25	270,665.26
GRANTS		10,861,176.50	946,837.24	11,808,013.74
CAPITAL GRANTS		1,187,219.19		1,187,219.19
FINANCIAL		528,705.49		528,705.49
EXTRAORDINARY		2,115.00		2,115.00
TOTAL INCOME		25,018,150.39	3,102,425.61	28,120,576.00

The Annual Accounts of 2025 approved by the Foundation’s Board of Trustees and audited by the General Intervention of the Generalitat Valenciana (through the audit firm DULA Auditores) is another source of information, providing details of expenses incurred, and explaining the use of the corresponding indirect costs.

EXPENSES		TOTAL
CASH FUNDING		138,703.33
SUPPLIES		2,623,504.44
OTHER FUNCIONAL EXPENSES (ACTIVITY)		5,381,788.05
STAFF COSTS		12,211,122.85
OTHER FUNCIONAL EXPENSES (STRUCTURAL)		733,266.01
EXTRAORDINARY EXPENSES		26,957.29
INVENTORY ITEM DONATION EXPENSES		0.00
AMORTIZATION OF FIXED ASSETS		1,589,158.80
TOTAL EXPENSES		22,704,500.77

The last table shows the balance sheet of the foundation in official format, extracted from the Annual Accounts of 2025:

ASSETS			FISCAL YEAR	FISCAL YEAR
			2025	2024
A)	NON-CURRENT ASSETS		11,724,412.62	12,395,394.34
	I.	Intangible assets	2,100,428.60	2,199,736.00
	2.	Concessions	2,082,641.02	2,172,872.82
	3.	Patents, licences, trademarks and similar rights	4,257.61	4,678.91
	5.	Computer software	13,529.97	22,184.27
	III.	Investment property	5,221,109.62	6,017,242.69
	1.	Land and buildings	1,361,887.50	1,009,842.47
	2.	Technical facilities and other tangible fixed assets	3,774,051.36	4,606,166.77
	3.	Fixed assets in progress and advances	85,170.76	401,233.45
	VI.	Deferred tax assets	4,402,874.40	4,178,415.65
	1.	Other government loans	1,914,958.2	297,947.00
	2.	Other government loan group and associated companies	1,080,662.73	165,209.80
	3.	Other loans from private entities	290,620.92	193,830.75
	4.	Other loans from private entity groups and associated compa-nies	0.00	0.00
	5.	Other European Union loans	1,116,632.03	3,521,428.10
B)	CURRENT ASSETS		50,561,318.23	45,868,124.59
	III.	Trade and other receivables	8,554,881.66	7,164,777.58
	1.	Trade and other receivables	8,507,889.48	7,116,432.53
	2.	Trade and other receivables group and associated companies	46,992.18	48,345.05
	IV.	Current investments in group companies and associates	11,234,759.47	15,242,283.64
	1.	Other government loans	6,620,162.81	8,984,841.68
	2.	Other government loan groups and associated companies	4,614,596.66	6,257,441.96
	VI.	Prepayments for current assets	16,132,446.00	15,060,941.70
	1.	Equity instruments	3,069,782.84	3,001,766.40
	2.	Credits to entities	15,218.56	27,759.30
	5.	Other financial assets	13,047,444.60	12,031,416.00
	VII.	Short-term periodicities	0.00	0.00
	VIII.	Cash and cash equivalents	14,639,231.10	8,400,121.67
	1.	Cash	14,639,231.10	8,400,121.67
TOTAL ASSETS (A + B)			62,285,730.85	58,263,518.93

EQUITY AND LIABILITIES			FISCAL YEAR	FISCAL YEAR
			2025	2024
A)	EQUITY		29,826,227.71	25,402,346.25
	A-1)	Capital and reserves without valuation adjustments	26,455,617.93	21,068,370.03
	I.	Endowments	617,482.67	617,482.67
	II.	Reserves	20,422,060.03	15,434,220.23
	2,	Other reserves		
	IV.	Profit (/loss) for the period	5,416,075.23	5,016,667.13
	A-3)	Grants, donations or gifts and legacies received	3,370,609.78	4,333,976.22
B)	NON-CURRENT LIABILITIES		4,845,559.08	7,154,044.58
	II.	Non-current payables	4,845,559.08	7,154,044.58
	5.	Other financial liabilities	3,689,448.86	5,953,195.09
	6.	Other short-term debts with group companies and associates	1,156,110.22	1,200,849.49
C)	CURRENT LIABILITIES		27,613,944.06	25,707,128.10
	II.	Current provisions	732,053.81	645,194.32
	1.	Other provisions	98,030.75	98,030.75
	2.	Other provisions with group companies and associates	634,023.06	547,163.57
	III.	Current payables	20,157,592.81	20,327,607.19
	5.	Other financial liabilities	18,456,556.43	18,644,612.43
	6.	Other short-term debts with group companies and associates	1,701,036.38	1,682,994.76
	V.	Beneficiaries-Creditors	2,108,931.81	484,533.92
	VI.	Trade creditors and other accounts payable	4,615,365.63	4,249,792.67
	1.	Suppliers	580,287.40	433,079.34
	3.0	Other payables	258,576.26	179,291.14
	3.1	Other payables, with group companies and associates	79,375.26	38,526.49
	4.	Personnel (salaries payable)	-193.30	-70.42
	5.	Current tax liabilities	0.00	0.00
	6.1	Public entities, other	2,753,375.01	2,753,174.19
	6.2	Public entities, with group companies and associates	565,461.93	517,493.97
	7.	Advances from customers	378,483.07	328,297.96
TOTAL EQUITY AND LIABILITIES (A + B + C)			62,285,730.85	58,263,518.93

3.3 Cooperative research networks

The Carlos III Health Institute (*Instituto de Salud Carlos III*) develops the creation of stable research network structures such as CIBER (Network of Centres for Biomedical Research) via the General Subdirection of Networks and Centres for Cooperative Research. INCLIVA participates in this research structure through its associated groups.

The following table shows our participation in scientific networks stratified by the prioritized research area, the centre and principal investigator.

CIBER

Research Area	INCLIVA PI	Scientific Network	Reference
Cardiovascular	Mr José Tomás Real Collado	<i>ciber</i> DEM	CB07/08/0018
	Ms Empar Lurbe i Ferrer	<i>ciber</i> OBN	CB06/03/0039
	Mr Vicent Bodí Peris	<i>ciber</i> CV	CB16/11/00486
	Mr Juan Sanchis Forés	<i>ciber</i> CV	CB16/11/00420
Metabolism and Organ Damage	Mr Federico V. Pallardó Calatayud	<i>ciber</i> ER	CB06/07/0073
	Mr Ruben Artero Allepuz	<i>ciber</i> ER	CB23/07/00005
	Mr Juan Nacher Roselló	<i>ciber</i> SAM	CB07/09/006
	Mr Rafael Tabarés Seisdedos	<i>ciber</i> SAM	CB07/09/0021
	Ms Mari Carmen Gómez Cabrera	<i>ciber</i> FES	CB16/10/00435
Oncology	Mr Andrés Cervantes Ruipérez	<i>ciber</i> ONC	CB16/12/00473
	Ms Rosa Noguera Salvá	<i>ciber</i> ONC	CB16/12/00484

3.4. Knowledge transfer activities

INCLIVA Biomedical Research Institute is fully committed to fulfilling its organizational mission by transferring created knowledge to both the National Health System and the industrial sector.

3.4.1. Knowledge transfer to the National Health System

Clinical guidelines and consensus documents are among the best indicators of knowledge transfer from research to clinical practice. The following table shows the guidelines published in indexed journals with participation from INCLIVA-affiliated authors.

Clinical guidelines	IF
13	298

1.

Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology’s Headache Study Group. García J, González N, Torres M, García D, Molina I, Beltrán I, Santos S et al. NEUROLOGIA. 2025 enero 01. 40 (1):118-137. DOI: 10.1016/j.nrl.2023.06.003. PMID:38431253.

2.

- ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Westphalen CB, Boscolo L, Aftimos P, Beltran H, Benary M, Chakravarty D, Collienue M et al. ANNALS OF ONCOLOGY. 2025 junio 01. 36 (6):614-625. DOI: 10.1016/j.annonc.2025.02.009. PMID:40194904.

3.

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer. Nag S, Coquard IR, Gupta S, Pathak A, Li N, Sari RM, Harano K et al. ESMO Open. 2025 junio 01. 10 (6):105125-105125. DOI: 10.1016/j.esmoop.2025.105125. PMID:40494042.

4.

Pneumonia definition in allogeneic hematopoietic cell transplant recipients: Update and challenges in 2024. Recommendations from the EBMT Infectious Diseases Working Party and Practice Harmonization and Guidelines committee. Neofytos D, Verweij PE, Averbuch D, Mikulska M, Styczynski J, Pinana JL, Cesaro S et al. Current Research in Translational Medicine. 2025 julio 01. 73 (3):103509-103509. DOI: 10.1016/j.retram.2025.103509. PMID:40157135.

5.

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Pagano L, Maschmeyer G, Lamothe F, Blennow O, Xhaard A, Spadea M, Busca A et al. LEUKEMIA. 2025 julio 01. 39 (7):1547-1557. DOI:10.1038/s41375-025-02586-7. PMID:40200079.

6.

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0). Cherny NI, Oosting SF, Dafni U, Latino NJ, Galotti M, Zygoura P, Dimopoulou G et al. ANNALS OF ONCOLOGY. 2025 agosto 01. 36 (8):866-908. DOI: 10.1016/j.annonc.2025.04.006. PMID: 40409995.

7.

Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hofheinz RD, Fokas E, Benhaim L, Price TJ, Arnold D, Beets R, Guren MG et al. ANNALS OF ONCOLOGY. 2025 septiembre 01. 36 (9):1007-1024. DOI: 10.1016/j.annonc.2025.05.528. PMID:40412553.

8.

American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. Batista MV, Chaer FE, Englund JA, Boeckh M, Carpenter PA, Dadwal SS, Waghmare A et al. Transplantation and Cellular Therapy. 2025 septiembre 01. 31 (9):624-638. DOI: 10.1016/j.jtct.2025.06.016. PMID:40516922.

9.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Tai D, Conroy T, Lee JJX, Chee CE, Hao CY, Wijaya I, Aggarwal S et al. ESMO Open. 2025 octubre 01. 10 (10):105826-105826. DOI: 10.1016/j.esmoop.2025.105826. PMID:41067164.

10.

SEOM-SOGUG clinical guideline for urothelial cancer (2025). Puente J, Rodriguez A, Sevillano E, Estevez SV, Fernández CA, Chirivella I, Climent MA et al. Clinical & Translational Oncology. 2025 noviembre 01. 27 (11):4142-4159. DOI: 10.1007/s12094-025-04045-2. PMID:40960583.

11.

Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee. Savarese G, Izquierdo MJ, Bonanad C, Wong A, Schmitt R, Ferraro PM, Dentali F et al. European Heart Journal-Cardiovascular Pharmacotherapy. 2025 noviembre 01. 11 (7):630-637. DOI: 10.1093/ehjcvp/pvaf055. PMID:40685253.

12.

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025). de la Peña FA, Novoa SA, Gregori JG, Cortijo LG, Carrasco FH, Martínez MT, Estévez CM et al. Clinical & Translational Oncology. 2025 noviembre 29. 28 (1):105-125. DOI: 10.1007/s12094-025-04139-x. PMID:41317270.

13.

SEOM-GEICO clinical guidelines on endometrial cancer (2025). Ramirez SP, Fidalgo AP, Ginesta MPB, Ferre AD, Madrid LF, Martinez AG, Montosa FG et al. Clinical & Translational Oncology. 2025 diciembre 01. 27 (12):4368-4380. DOI: 10.1007/s12094-025-04046-1. PMID:40986254.

Consensus documents	IF
8	108.7

1.

Development of a checklist for cognitive assessment requirements (CARE) based on a Delphi consensus study. Nejati V, Estaji R, Balanzá V, Balota DA, Barker S, Bell M, Berry JH et al. Scientific Reports. 2025 enero 24. 15 (1):3146-3146. DOI:10.1038/s41598-025-87380-2. PMID:39856338.

2.

Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology. Montero N, Oliveras L, Martínez A, Gorriz JL, Soler MJ, Fernández B, Quero M et al. NEFROLOGIA. 2025 abril 01. 451-26. DOI: 10.1016/j.nefro.2024.11.002. PMID:40222774.

3.

Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer. Perez A, Schmalefeldt B, George A, Gourley C, Pignata S, Lorusso D, Barretina MP et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2025 julio 01. 35 (7):101863-101863. DOI:10.1136/ijgc-2024-005497. PMID:39448084.

4.

Treatment-resistant depression and intranasal esketamine: Spanish clinical consensus on practical aspects. Ramos JA, Mora F, Arostegui S, Cardoner N, Etxeandia JI, Gómez R, Gómez M et al. EUROPEAN JOURNAL OF PSYCHIATRY. 2025 julio 01. 39 (3). DOI: 10.1016/j.ejpsy.2025.100313.

5.

Consensus document on neurosonological techniques in headaches. Vico JR, Domínguez JF, Villaverde FJJ, García NG, Fernández CGC, Sanchez AJ, Martín OA et al. NEUROLOGIA. 2025 julio 01. 40 (6):599-607. DOI: 10.1016/j.nrl.2024.06.001. PMID:40550312.

6.

Standardizing the Definition of Each Colon Cancer Segment: Delphi Consensus on Clinical Decision-Making for Oncologic Outcomes. Kuzu MA, Benlice C, Parvaiz A, Gorgun E, Bertelsen CA, Wexner S, Dozois EJ et al. DISEASES OF THE COLON & RECTUM. 2025 julio 01. 68 (7):835-844. DOI:10.1097/DCR.0000000000003739. PMID:40214091.

7.

Assessing the Potential Difficulty of Left Pancreatectomy: International Modified Delphi Consensus. Ramia JM, Villo-dre C, Serradilla M, Alcazar C, Blanco G, Rotellar F, Sabater L et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS. 2025 octubre 01. 241 (4):626-635. DOI:10.1097/XCS.0000000000001438. PMID:40341349.

8.

Consensus on the Diagnosis and Management of Patients with Breakthrough Cancer Pain (BTcP), Including Procedural BTcP: DIOPRO Study. Alarcón MDL, Estévez FV, Martínez JC, Albiach CF, Peidro JRP, Casterá MJT, Rivera IV. JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY. 2025 octubre 02. 39 (4):1-13. DOI:10.1080/15360288.2025.2546104. PMID:40823980.

Institutional documents	IF
8	43.6

1.

Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology’s Headache Study Group. García J, González N, Torres M, García D, Molina I, Beltrán I, Santos S et al. NEUROLOGIA. 2025 enero 01. 40 (1):118-137. DOI: 10.1016/j.nrl.2023.06.003. PMID:38431253.

2.

Homozygous Familial Hypercholesterolemia in Spain: Data From Registry of the Spanish Atherosclerosis Society. Sánchez RM, Ibarretxe D, Fuentes F, Martínez S, Blanco A, Cortés B, Rodríguez G et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2025 agosto 01. 110 (8):2280-2287. DOI:10.1210/clinem/dgae784. PMID:39514762.

3.

Associations Between Urinary Metal Levels and Incident Heart Failure A Multi-Cohort Analysis. Martinez I, Domingo A, Mayer M, Schilling K, Glabonjat RA, McGraw K, Sanchez TR et al. JACC-Heart Failure. 2025 agosto 01. 13 (8):102510-102510. DOI: 10.1016/j.jchf.2025.03.046. PMID:40532446.

4.

Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Maqueda MA, Quintáns AT, Cuatrecasas M, Aceñero MJF, Montes AF, Martín CG, Fonseca PJ et al. Clinical & Translational Oncology. 2025 septiembre 01. 27 (9):3580-3594. DOI:10.1007/s12094-025-03865-6. PMID:40072752.

5.

American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. Batista MV, Chaer FE, Englund JA, Boeckh M, Carpenter PA, Dadwal SS, Waghmare A et al. Transplantation and Cellular Therapy. 2025 septiembre 01. 31 (9):624-638. DOI: 10.1016/j.jtct.2025.06.016. PMID:40516922.

6.

Defining bloodstream and central venous catheter-related infections in patients following haematopoietic cell transplantation: position paper of the European Blood and Marrow Transplantation Society Infectious Diseases Working Party and Practice Harmonization and Guidelines Committee. Averbuch D, Mikulska M, Styczynski J, Bergeron A, Cesaró S, Greco R, Neofytos D et al. CLINICAL MICROBIOLOGY AND INFECTION. 2025 octubre 01. 31 (10): DOI: 10.1016/j.cmi.2025.06.037. PMID:40701237.

7.

Predicting Response to Pro-Cognitive Interventions in Mood Disorders: A Systematic Review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Tsapekos D, Kalfas M, Schandorff JM, Del Mar Bonnin C, Bowie CR, Balanzá Martínez V, Burdick KE et al. ACTA PSYCHIATRICA SCANDINAVICA. 2025 octubre 13. 153 (5):374-401. DOI:10.1111/acps.70038. PMID:41083219.

8.

Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. Pacheco V, Obispo B, Tomas E, de Torres CS, Quintanar T, Paez D, Leon L et al. Clinical & Translational Oncology. 2025 diciembre 23. 28 (6):2409-2422. DOI:10.1007/s12094-025-04171-x. PMID:41436708.

1.

Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group. García J, González N, Torres M, García D, Molina I, Beltrán I, Santos S et al. NEUROLOGIA. 2025 enero 01. 40 (1):118-137. DOI: 10.1016/j.nrl.2023.06.003. PMID:38431253.

2.

Santander Statement: Towards Global Convergence in Transplantation: Sufficiency, Transparency, and Oversight. Participants to the Global Summit in Transplantation OBYTO. TRANSPLANTATION. 2025 enero 01. 109 (1):7-9. DOI:10.1097/TP.0000000000005286. PMID:39636761.

3.

Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Maqueda MA, Quintáns AT, Cuatrecasas M, Aceñero MJF, Montes AF, Martín CG, Fonseca PJ et al. Clinical & Translational Oncology. 2025 septiembre 01. 27 (9):3580-3594. DOI:10.1007/s12094-025-03865-6. PMID:40072752.

4.

Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECp) expert consensus statement. Ospina AV, González JL, Nadal E, Trancho FH, Bosch J, Calvo V, Bolufer S et al. Translational Lung Cancer Research. 2025 septiembre 30. 14 (9). DOI: 10.21037/tlcr-2025-619. PMID:41132973.

Consensus statements	IF
4	13.8

3.4.2. Innovation and Knowledge Transfer

The Innovation Unit of INCLIVA fulfils one of the main objectives of the institution by supporting professionals in developing translational research to maximize its impact on society. The unit fosters innovation and collaboration with research centres and industry partners, bridging the gap between research and solutions that reach clinical practice.


A key responsibility of the unit is managing the innovation funnel, assessing the viability of innovative ideas at different stages to ensure that high-impact ideas reach the market.

The unit's main services include:

- Identification and analysis of ideas.
- Evaluation and management of intellectual property rights
- Commercialisation and technology transfer
- Project management of innovation projects
- Training activities to foster an innovation-driven culture

INCLIVA's innovation funnel in 2025 is shown in the following Table and Figure:

INNOVATION FUNNEL	ITC Health	Materials and Devices	Pharma	Bio and diagnosis	Imaging	Organizational	Other	Total
Detection	0	0	0	0	1	0	0	1
Assessment	7	4	3	34	1	3	3	55
Development	3	6	1	3	0	0	1	14
Transfer	6	1	5	1	0	0	0	13
Market	4	3	0	10	1	5	1	24
TOTAL	20	14	9	48	3	8	5	107



3.4.2.1. Intellectual Assets

The protection of knowledge is the first step to move scientific findings and ideas from researchers to the industry. Patents are the most common way to protect technologies that are new, innovative and have industrial application. Research institutions can exploit the patents they hold by licensing them to companies.

The following family patents and utility models were active in 2025:

Invention	Priority number	% INCLIVA	Status
2025. Method for monitoring of cancer using minimal residual disease analysis	EP25382212	87,5%	European Patent
2024. Prenylated tetrahydroquinolines and quinolines with PPAR agonist activity	EP24382406	50%	PCT extension
2024. Dispositivo para canalización de la sangre para hemodiálisis	P202330882	5,5%	PCT extension
2024. Lipid nanoparticles and their use in treatment	EP24389971	16%	PCT extension
2023. Development and validation of the AMMON-OHE model to risk stratify cirrhoticoutpatients for occurrence of overt hepatic encephalopathy	UK2303652	50%	Brazil, Europe and US National Phase
2022. Dispositivo de Lubricación Intrauretral pediátrica	U202230442	100%	Granted in Spain
2022. Method for assessing nicotinamide n-methyl transferase activity	EP22382866	10%	European Patent
2022 Reposicionamiento de haloperidol como tratamientos farmacológicos para atrofia muscular espinal	PCT/EP2022/087022	5%	Europe and US National Phase
2021. Use of Musashi 2 (msi2) as therapeutic target for the treatment of the characteristic myopathy of type 1 myotonic dystrophy	EP21382133	5%	Europe and US National Phase
2021. Compound comprising ruthenium(iii) and 2,2'-biimidazole (Runat-bi) and the therapeutic use thereof	P202130624	40%	Granted in Spain
2021. APC protein for the detection and prediction of septic shock	EP21382173	10%	Licensed
2021. Epigenetic signature for the diagnosis and prognosis of Spitzoid cutaneous melanocytic tumours	EP21382569	66,67%	Europe and US National Phase
2019. Oropharyngeal obturation device	P201900039	100%	Granted in Spain, Germany, France and Great Britain
2018. Injectable material for the regeneration of the articular cartilage	P201830730	29%	Granted in Spain
2016. Mass spectrometry-based methods for the detection of circulating histones h3 and h2b in plasma from sepsis or septic shock (ss) patients	EP16382509.4	6%	Licensed
2016. Intramedullary fixation device	P201631220	2,5%	Licensed

2016. Device for the exo-prosthetisation of limbs and other percutaneous applications	P201631218	2,5%	Licensed
2013. Maxillomandibular prosthesis and production method	P20130030734	33,33%	Licensed

3.4.2.2. Competitive innovation

Competitive calls offer technical and financial support for developing innovation ideas. Therefore, INCLIVA submits proposals to regional, national and international funding programs. In 2025, 16 innovation projects were granted for a total of €3,003,909.35.

Innovative competitive project	Total ammount (€)
DTS25/00163 (i2024_02) Nuevas tetrahidroquinoleínas y quinoleínas 2-preniladas como moduladores de los receptores PPAR en el tratamiento de enfermedades metabólicas y complicaciones asociadas	159,701.85
PI25/00046 (i2026_03) Investigación traslacional para mejorar el diagnóstico, el pronóstico y la terapia de pacientes con enfermedades raras neurodegenerativas	238,750.00
PI25/01762 (i2026_04) IMAGING MASLD: estudio longitudinal de progresión de la esteatosis hepática metabólica por imágenes de Resonancia Magnética y predicción de eventos clínicos extrahepáticos	84,125.00
PI25/01315(i2026_05) Estudio de nuevos mecanismos asociados a la disfuncion vascular y angiogenesis en la obesidad y la resistencia a insulina: impacto del agonismo dual GLP-1r y GIPR	152,500.00
PI25/01317 (i2026_06) Estudio Preclínico de Reposicionamiento de Antibióticos Beta-Lactamicos para el Tratamiento de Poliglutaminopatias	271,250.00
PI25/01353 (i2026_07) Radiofármacos dirigidos a DLL3: Un Enfoque Innovador para la Imagen y el Tratamiento del Cáncer de Pulmón de Células Pequeñas	150,000.00
PI25/00992 (i2026_08) Modulación terapéutica de MSI2 y miRNAs reguladores de MBNLs en distrofias miotónicas: de la caracterización molecular a la validación preclínica	190,000.00
PI25/00664 (i2026_09) Firmas Inmuno-omicas para la identificación de fenotipos en Sepsis. Hacia la comprensión de la heterogeneidad para Predecir la Progresión de la sepsis y mejorar el pronóstico	215,000.00
PI25/00219 (i2026_10) Estudio de los mecanismos moleculares asociados a las complicaciones cardiovasculares en la diabetes tipo 2: estrategias clínicas con los agonistas del receptor de GLP-1, GIP, y ejercicio físico	277,500.00
PI25/01500 (i2026_11) Comprehensive profiling of gastric cancer response to therapy: Identification and Validation of clinically relevant biomarkers	227,500.00
PI25/01667 (i2026_12) Desvelando los determinantes biológicos de la recaída tras la interrupción de la medicación en los trastornos psicóticos: un enfoque molecular, celular y de neuroimagen	281,250.00
PI25/02020 (i2026_13) TRIPLE EXO-TCE (3-EXO-TCE): Biomarcadores exosomales para la neuropronosticación en paciente con traumatismo craneoencefálico bajo terapia de tercer nivel	121,250.00
CIAPOT/2024/019 (i2025_02) Proteómica cuantitativa por espectrometría de masas para la identificación temprana de biomarcadores predictivos de eventos adversos en el síndrome coronario agudo	36,000.00
CIAPOT/2024/012 (i2025_06) Desarrollo preclínico de oligonucleótidos contra Musashi-2: nuevos impactos biomédicos y métodos de entrega a músculo.	36,000.00
CPP2024-011305 (i2025_18) Phase Ia/IbClinical Trial of ONA-255, a first-in-class ADC for refractory HR+ HER2-breast cancer patients	400,161.76

DIGITAL-SIMPLE- InnDIH - Valencia Region Digital Innovation Hub	107,920.74
InnoPathmaker-Boosting surgical capacity through process optimisation using PATHMAKER	–
VISIONARIUM (i2026_14) HIVision España: Inteligencia territorial para acelerar el fin de la epidemia por el VIH en España	55,000

3.4.2.3. Entrepreneurship

When the knowledge generated in INCLIVA is disruptive and the researchers are willing to exploit it by themselves, knowledge transfer is direct. Consequently, a new venture (also known as a spin-off or start-up) is created. The following companies are officially recognized as spin-offs from INCLIVA:



Epidesase S.L.

Company created in 2014 from a project led by researchers from INCLIVA and the Center for Research in Biomedicine Network (CIBER) in the Rare Diseases area to transfer knowledge in the field of epigenetics and biomedical sciences for the service of society.

Founding year: 2014

INCLIVA entrepreneurial team: Mr José Luis García Giménez and Mr Federico Pallardó

<http://www.epidisease.com/>



Sequencing Multiplex S.L.

This company was created in 2013, with the idea of generating solutions for research and clinical applications, using the introduction of new techniques and advanced genetic platforms, mainly next-generation sequencing (NGS), as a basis.

Founding year: 2013

INCLIVA entrepreneurial team: Mr Javier Chavés

<https://www.seqplexing.com/es>



Nela BioDynamics S.L.

The company emerged from the results of a final master thesis in biomedical engineering, which led to two patents on a novel intramedullary fixation system for joint endoprostheses, nails for fractures and exoprostheses; and a percutaneous ostomy collar. Both patents are currently licensed to the spin-off itself.

Founding year: 2020

INCLIVA entrepreneurial team: Mr José Expósito Ollero

<http://www.nelabiodynamics.com/>



ArtHex biotech S.L.

The company was created in 2020 at the University of Valencia to develop advanced RNA treatments against genetic diseases. AR-THEx Biotech's mission is to find effective treatments for unmet medical needs. The company is currently investigating anti-mi-croRNAs for the treatment of myotonic dystrophy type 1 (DM1).

Founding year: 2020

INCLIVA entrepreneurial team: Mr Rubén Artero

<http://www.arthexbiotech.com/>

PLATFORMS AND NETWORKS

INCLIVA has the status of affiliated centre to the **ITEMAS** Plat-form of the IISLaFe Node for the period 2024 to 2027.

INCLIVA has been included as a member of the **Health Commis-sion** of the Bioval association, which brings together companies, technological institutes, and other foundations from the Valencian Community, within this commission, strategies are defined and aligned, and joint opportunities in the health sector are explored.

The members of INCLIVA's Innovation Unit are part of the profes-sional **Redtransfer** network.

3.5. Gender perspective

As part of its commitment towards guaranteeing real equality between women and men, INCLIVA's Board of Trustees has approved the III INCLIVA Equality Plan (2024-2028) following approval by the Equality Committee. Through INCLIVA's III Equality Plan, different planned actions will be implemented throughout its four-year duration following established timelines.

Currently, 73% of INCLIVA employees are women. The data corresponding to activity in 2025 is as follows:

Total cost of INCLIVA staff	2025
Men	€3,494,065.61
Women	€8,713,456.26
TOTAL	€12,207,521.87

Total cost of INCLIVA Staff




A total of 319 employees joined INCLIVA in 2025, 73% of whom are women. The percentage of women hired has increased every year for the last three years.


The following graphs differentiate between personnel hired for administration tasks and research staff:

- Women comprise 84.78% of staff contracted to carry out administration tasks and 71.43% of those who perform research tasks.
- Within the administrative area, 69.23% of managerial/technician, 25.64% of auxiliary and 5.13% of subaltern positions are held by women.
- In research, 18.97% of those hired as nursing staff, 10.77% of administrative staff and 70.26% of research staff are women.

Percentage of employees by areas



Women in the Research and Administrative areas



Distribution by contrat type

The breakdown of contracts granted to women is shown in the following graphs:

- 80.43% of permanent contracts for administration tasks and 53.85% of permanent contracts for research tasks are for women.
- 4.35% of temporary contracts for administration tasks and 17.58% of temporary contracts for research tasks are for women.
- In administration: 100% of contracts for women are temporary contracts. Of these, 50% are contracts to carry out Managerial/Technician tasks and 50% for Auxiliary and Subordinate staff jobs. Fixed contracts for women within the administration are 100% for positions such as Managerial/Technician.
- In research: 67.61% of contracts awarded to women are temporary contracts. Of these, 63.68% of temporary contracts for research tasks, 4.23% of temporary contracts for nursing tasks are women.


Shared parental leave

Maternity/paternity leave was requested by 13 employees in 2025: four by men, nine by women.


Contracts by areas



Type of contracts
in the Administration area




Type of contracts
in the Research area



Shared parental leave

Maternity/paternity leave was requested by 13 employees in 2025: four by men, nine by women.

Maternity/Paternity leave




Organizational structure

In line with our staff structure, women are well represented in most of the governing bodies, scientific committees and research groups. The distribution in each is summarized below:

	Men	Women	Total 2025
Board of Trustees	11	8	19
Board of Governors	8	5	13
External Scientific Committee	5	2	7
Internal Scientific Committee	5	5	10
Research Committee	13	16	29
Innovation Committee	7	10	17
Clinical Research Ethics Committee	12	12	24
Training and Mobility Committee	8	11	19
Emerging researchers	7	8	15
R&D Group leader	40	20	60
R&D Group member	295	469	764

Breakdown of Research Group staff

A total of 862 researchers belong to consolidated, emerging and associated research groups, with the following EURAXESS profile distribution by research staff group in 2025.



Research projects

Throughout 2025, 50 new competitive projects were awarded, making a total of 194 currently active projects under competitive tender. The Principal Investigators of new projects are distributed as shown in the table. In total, 64% of national projects and 20% of international projects are led by women.

	Men	Women	Total 2025
National	35	47	73
International	4	1	5

ACTIVE COMPETITIVE PROJECTS (PUBLIC AND PRIVATE): 241 (including HR, regional, etc.). The AMPER and EPRIEX programs have been eliminated.

Clinical studies and trials

A total of 178 studies were managed throughout 2025. The table below indicates the distribution of Principal Investigators by gender.

	Men	Women	Total 2025
Principal Investigator	110	68	178

CEIm

Drug Research Ethics Committee (CEIm) members are distributed as follows:

	Men	Women	Total 2025
CEIm Evaluators	8	9	17

Transfer to the Productive Sector

Calls for proposals, innovation awards and patent portfolios during 2025 are distributed by gender as shown in the table:

	Men	Women	Total 2025
Patents y MU in portfolio (IPs that have inventorship of a patent)	9	4	11
UPV Clinical Applications	13	13	26
VLC Bioclinical Applications 2025	16	20	36
Applicants for Innovation Awards 2025	28	18	46

Bibliometric analysis: INCLIVA Biomedical Research Institute authorship position

Of the 697 INCLIVA publications in 2025, the ratio of men to women by significant authorship position (first, last or corresponding author) is 31.56% for female researchers and 36.73% for male researchers.

Training Activities

In total, 4.359 people participated in training activities carried out during 2025. According to registration questionnaires, 50.67% of participants were female (2,208), 21.32% were male (929), and 28.01% (1,226) chose not to indicate their gender. In 93.51% of activities, participation was mainly female.

Of 109 activities, one (listed below) provided training on equality, with content and participant data summarized in the following table.

Title	Date	Scope	Activity Type	Modality	Hours	Participants	Men	Women
III Encuentro con asociaciones de cáncer de mama	01/04/2025	Local	Scientific Conference	Face to face	4.5	14	0	14

YouTube link: https://youtu.be/laKouGG15_k

External stays

Of a total of six external stays, four were completed by women and two by men, while of the 18 external stays funded by INCLIVA, 11 were women. In total, 62.5% of stays were completed by women and 37.5% stays were completed by men.

Internal Stays

Of a total of five internal stays, four were completed by women and one was completed by a man, resulting in 80% of total internal stays completed by women and 20% by men .

Training placements

The classification and distribution by gender of training placements in 2025 is shown in the following table:

	Men	Women	Total 2025
Vocational training placements	5	37	42
Bachelor's placements including Bachelor's final project (TFG)	21	20	41
Master's placements including Master's final project (TFM)	13	23	36
Total	39	80	119

Doctoral thesis

Below is a breakdown by gender of the 41 doctoral theses defended or supervised by INCLIVA research staff: 63% of predoctoral researchers who defended their thesis in 2025 were women, and 28% of those supervising these theses were women.

	Men	Women	Total 2025
Doctoral students who defended their thesis in 2025	15 (37 %)	26 (63 %)	41 (100%)
Doctoral students hired by INCLIVA who defended their thesis in 2025	8 (38%)	13 (62%)	21 (100 %)
INCLIVA Doctoral Supervisors	39 (72 %)	15 (28 %)	54 (100 %)

4 | Scientific activity



4	SCIENTIFIC ACTIVITY
4.1	Scientific structure
4.2	Scientific translational programs
4.2.1	Overweight and cardiovascular and renal risk
4.2.2	Detection, risk prediction and control of ventricular dysfunction
4.2.3	Rare Diseases
4.2.4	Neurological Decline
4.2.5	Translational Oncology
4.2.6	Reproductive Medicine
4.2.7	Ageing and associated diseases
4.3	Research areas
4.3.1	Cardiovascular Area
4.3.2	Oncology Area
4.3.3	Metabolism and Organic Damage Area
4.3.4	Reproductive Medicine Area
4.3.5	Associated Clinical Groups Area
4.4	Other scientific contributions from scientific platforms
4.4.1	Spanish Clinical Research Network (SCReN), Clinical Research and Clinical Trials of the Clinical Trials Platform (UICEC INCLIVA)
4.4.2	Biobank
4.4.3	Precision Medicine Unit
4.4.4	Biomarker Analysis Unit
4.4.5	Molecular, Cellular, and In Vivo Analysis Unit
4.4.6	Biostatistics Unit
4.4.7	Bioinformatics Unit
4.4.8	Body Composition Unit
4.4.9	Analytical Liquid Chromatography Unit
4.4.10	Mass Spectrometry Unit
4.4.11	Data Science Platform

4.1 Scientific structure

INCLIVA structures its research into four areas of research, seven scientific programs, ten platforms and ten associated clinical groups.

Research areas constitute the basis from which the scientific work of the groups is structured:

- Cardiovascular area
- Oncology area
- Metabolism and organ damage area
- Reproductive medicine area
- Associated clinical groups

Scientific programs are aimed at specific diseases from a translational perspective:

- Program in Overweight and cardiovascular and renal risk
- Program in Detection and control of ventricular dysfunction
- Program in Rare diseases
- Program in Neurological decline
- Program in Translational oncology
- Program in Reproductive medicine
- Program in Ageing and associated diseases

Platforms provide research services to the entire institute:

- Clinical Research and Clinical Trials Unit (UICEC)
- Biobank
- Precision Medicine Unit
- Biomarker Analysis Unit
- Molecular, Cellular and in vivo Analysis Unit
- Biostatistics Unit
- Bioinformatics Unit
- Body Composition Unit
- Analytical Liquid Chromatography Unit
- Mass Spectrometry Unit

4.2 Scientific Translational Programs

4.2.1 Overweight and cardiovascular and renal risk

Obesity and overweight are fields in which new strategies are being developed for both prevention and treatment using traditional resources and new technologies. The present program is focused on the study of pathology in the first stages of obesity (overweight with or without metabolic syndrome), integrating different clinical and experimental research studies to assess associated cardio-renal complications with the application of new technologies. The analysis carried out to prepare the Strategic Plan prompted the creation of a new Big Data and Artificial Intelligence (AI) Programme, based on the policies and trends of the research environment (new Spanish R&D&I Strategy in AI within the framework of the Spanish Science, Technology and Innovation Strategy [EECTI, 2021-2027]), as well as INCLIVA's needs and resources.

Coordinators: Mr José Tomás Real Collado and Mr Josep Redon i Mas

Objectives:

- Deepen understanding of the early alterations, mechanisms and biomarkers that contribute to the development of obesity, vascular and renal alterations in overweight subjects
- Early application of new technologies for prevention and treatment of obesity, vascular and renal alterations in overweight subjects
- Assess and prevent cardio-renal damage in hypertension, diabetes and autoimmune disease by molecular approaches
- Uncover potential signaling pathways with potential as therapeutic targets by in vitro and in vivo models
- Apply Big Data and AI for digitisation of health data and integration into national and European data spaces
- Apply environmental epidemiology in exposome studies on obesity, metabolic and autoimmune disorders and organ damage associated with diabetes and hypertension

Research lines:

- Line 1: Investigation of early alterations, mechanisms and biomarkers that contribute to the development of obesity and vascular and renal alterations in overweight subjects and in animal models.
- Line 2: Analysis of the relationship between overweight and obesity with inflammatory axes and endothelial dysfunction to identify potential signaling pathways to serve as therapeutic targets
- Line 3: Biomarkers (biological, genomic, metabolomic and imaging) for better risk categorisation of progressing to obesity and developing associated metabolic, vascular and renal complications
- Line 5: New intervention procedures to halt the progression towards obesity and its metabolic, vascular and renal consequences in patients and animal models
- Line 6: Cardio-renal damage in hypertension and diabetes. Population studies
- Line 7: Role of extracellular vesicles in the development of renal and cardiac organ damage in hypertension, diabetes and autoimmune diseases
- Line 8: Molecular bases, cellular models and translational research in renal and cardiac organ damage in hypertension, diabetes and autoimmune diseases
- Line 9: Development of databases (Big Data) for epidemiological studies and application of AI models for clinical use and care planning and management
- Line 10: Development of predictive models based on AI
- Line 11: Impact of the interaction between exposome and genetics on metabolic, cardiovascular and renal alterations

Clinical groups:

- Research Group on the Study of Cardiometabolic and Renal Risk (Mr Josep Redón i Mas, Ms Raquel Cortés Vergaz)
- Cardiometabolic Research Group on Primary Care (Mr Jorge Navarro Pérez)
- Research Group for the Prevention of Cardiovascular Risk in Children and Adolescents (Ms Empar Lurbe i Ferrer)
- Research Group on Cardiometabolic Risk and Diabetes (Mr José Tomás Real Collado, Mr Sergio Martínez Hervás)
- Research Group on General and Digestive Surgery (Mr Luis Sabater Ortí)

- Research Group on Pediatric Nutrition (Ms Cecilia Martínez Costa)
- Research Group on Care INVESTENF-INCLIVA (Ms Cintia Borja Herrero)
- Research Group in Medical Chemistry for Drug Development (Ms Nuria Cabedo Escrig)

Experimental groups:

- Research Group on Endothelial Cells (LINCE) (Mr Carlos Hermenegildo Caudevilla, Ms Susana Novella del Campo)
- Research Group on Molecular Imaging and Metabolomics (Mr Daniel Monleón Salvado)
- Research Group on Inflammation (Ms Mª Jesús Sanz Ferrando, Ms Laura Piqueras Ruiz)
- Genomics and Diabetes Unit (Mr Felipe Javier Chaves Martínez)
- Research Group on Nuclear Receptors in Cardiometabolic Pathology (Ms Laura Piqueras Ruiz)
- Research Group on Metabolic Diseases (Ms Herminia González Navarro)
- Research Group on Exercise, Nutrition and Healthy Lifestyle (Ms Mª Carmen Gómez Cabrera)

OVERWEIGHT, OBESITY AND METABOLIC, VASCULAR AND RENAL RISK				
OBJECTIVES	STATUS			ACTIONS
	Achieved	Partially achieved	Not achieved	
Metabolic, vascular and renal evaluation of overweight patients (children and adults)			✖	
Characterize the relationship between overweight and vascular inflammation / endothelial function		✖		
Identify molecular markers that relate overweight with its associated diseases		✖		Metabolomic measurements (80 spectral features) of 3 cohorts (4500 subjects) for associations between obesity, associated diseases and morbidities and early alterations of metabolism. Focus on the metabolic interaction between host and gut microbiota. Cohorts: Rio Hortega (general population), AWHs (working population) and PIANCAVALLO (obese and morbid obese)
Identify metabolomic markers linking overweight with its associated morbidities		✖		Metabolomic measurements (80 spectral features) of 3 cohorts (4500 subjects) for associations between obesity, associated diseases and morbidities and early alterations of metabolism. Focus on the metabolic interaction between host and gut microbiota. Cohorts: Rio Hortega (general population), AWHs (working population) and PIANCAVALLO (obese and morbid obese)
Develop new early detection systems for obesity and its associated complications		✖		Metabolomic measurements (80 spectral features) of 3 cohorts (4500 subjects) for associations between obesity, associated diseases and morbidities and early alterations of metabolism. Focus on the metabolic interaction between host and gut microbiota. Cohorts: Rio Hortega (general population), AWHs (working population) and PIANCAVALLO (obese and morbid obese)
Identify molecular targets of obesity and its associated complications and develop new therapies			✖	

4.2.2 Detection, risk prediction and control of ventricular dysfunction

The program focuses on the pathophysiological mechanisms involved in myocardial injury and its structural, functional and electrophysiological repercussions, evaluating diagnostic tools and biomarkers, personalized risk prediction and new therapeutic approaches to prevent the adverse consequences of cardiac dysfunction. This translational research program capitalizes on the synergies between clinical and experimental research groups and includes specialists in cardiac imaging techniques and technological development experts. The multidisciplinary approach extends the possibilities of between-group collaboration opportunities, strengthens already existing ones and incorporates other groups into program activities. By developing analytical tools and biomarkers (imaging techniques such as cardiac magnetic resonance and electrophysiological mapping techniques), we can drive innovation in the field of technological development.

Coordinators: Dr Juan Sanchis Forés, Dr Vicente Bodí Peris and Dr Julio Núñez Villota

Objectives:

- Clinical studies aimed at validating clinical tools for diagnostic, personalized risk prediction and optimal management strategy selection in patients with ventricular dysfunction
- Ventricular remodelling: Evaluate the role of different mechanisms involved in the adverse consequences of myocardial damage (ischemia-reperfusion injury, microvascular damage, angiogenesis, fibrosis) and study potential therapeutic targets
- Electrical remodelling: Protection against arrhythmic vulnerability

Research lines:

- Prospective multicentre registries: Patients with acute and chronic coronary syndromes. CMR studies to advance in diagnosis, personalized risk stratification and management strategies. Study of different aspects such as myocardial viability, ventricular remodeling and microvascular obstruction
- Prospective Evaluation of the European Society of Cardiology 0/1h-algorithm's Safety and Efficacy for Triage of Patients with Suspected Myocardial Infarction (PRESC1SE-MI)
- Basic research in ischemia and myocardial infarction. Mechanisms involved in ischemia-reperfusion injury-related deterioration of systolic function, inflammation, fibrosis and inducibility of arrhythmias. Study of therapeutic targets to reduce structural damage and adverse consequences
- Prognostic value of geriatric conditions in older patients admitted for acute coronary syndromes
- CA125 biomarker-guided versus conventional treatment after transcatheter aortic valve implantation for severe aortic stenosis with heart failure. Randomized clinical trial
- Interventionism in structural heart disease
- Cardiac rehabilitation programs: Ischemic heart disease; heart failure
- Management strategies in patients with heart failure
- Diabetes and cardiovascular diseases
- Development of technical tools to study cardiac dysfunction and cardiac electrophysiology

Clinical Groups:

- Research Group on Clinical Cardiology (Dr Juan Sanchis Forés)
- Group on Translational Research in Ischemic Heart Disease (Dr Vicente Bodí Peris)
- Research Group on Heart Failure (Dr Julio Núñez Villota)
- Cardiometabolic Research Group on Primary Care (Dr Jorge Navarro Pérez)

Experimental Groups:

- Research Group on Cardiac Experimental Electrophysiology (Dr Francisco Javier Chorro Gascó, Dr Antonio M. Alberola Aguilar)
- Research Group on Inflammation (Dr M^a Jesús Sanz Ferrando, Dr Laura Piqueras Ruiz)
- Research Group on Nuclear Receptors in Cardiometabolic Pathology (Dr Laura Piqueras Ruiz)
- Research Group on Histopathology and Tissue Engineering (Dr Manuel Mara Roig)

DETECTION, RISK PREDICTION AND CONTROL OF VENTRICULAR DYSFUNCTION				
OBJECTIVES	ACTIONS	STATUS		
		Achieved	Partially achieved	Not achieved
Risk prediction through new analytical biomarkers	• Definition of new serological indicators with NMR-S to predict DR and fibrosis • Serum CA125, galectin-1 and galectin-3 markers • Safety and Efficacy of 0/1h-algorithms for Triage and Troponin extraction of Patients with Suspected Myocardial Infarction • Biomarkers in cardiorenal syndromes • Study of new therapeutic approaches to prevent the adverse consequences of cardiac dysfunction.		✖	
			✖ ✖ ✖ ✖	
Study of the basic mechanisms involved in myocardial damage	• Oxidative stress during reperfusion in acute myocardial infarction • Neoangiogenesis, the appearance of micro-vascular obstruction and impaired systolic function • New therapeutic targets • Deregulation of the immune system in acute myocardial infarction • Inflammation and fibrosis • Morphometric and molecular changes in the extracellular matrix	✖	✖	
		✖	✖ ✖ ✖	
Diagnosis through new MRI tools	• MRI micro-image to develop combinations of MRI sequences without contrast • Analysis of myocardial textures • Offline evaluation of myocardial tension • CMR for risk stratification and decision making in STEMI • Stress CMR for risk stratification and decision making in chronic coronary syndromes	✖ ✖ ✖	✖ ✖	
			✖ ✖ ✖	
Prevention	• DR prevention through multiple antioxidant treatment • Prevention of deterioration of systolic function, fibrosis and arrhythmias • Cardiac rehabilitation programs		✖ ✖ ✖	
			✖ ✖	
Interventions in structural heart disease	• Implementation and development of clinical applications • Useful prognostic indicators in the application of interventional techniques. Utility of CA125 in the indication of transcatheter aortic valve implantation (TAVI)		✖ ✖	
			✖ ✖	
Management strategies in patients with ventricular dysfunction	• Personalized treatment in heart failure patients	✖		
Electrical remodelling: Experimental studies on the protective effect against arrhythmic vulnerability	Protective effects of: • Nitric oxide donors • iSGLT2 • Inhibition of neprilysin, late sodium current and intracellular calcium overload	✖ ✖ ✖	✖	

4.2.3. Rare diseases

The program’s main objectives are to improve the diagnosis and current treatments of rare diseases (RDs), with a focus on developing new therapeutic strategies to treat these diseases. Human and animal model samples will be used to deepen understanding of the molecular basis of disease, evaluate the activity of candidate drugs, and discover new biomarkers. In this regard, we will identify and validate biomarkers for RDs which currently have no effective diagnostic and/or prognostic indicators.

The program seeks to bridge the gap between basic research and commercial development of diagnostic systems and treatments, aiming to transfer this knowledge to companies to transform biomedical knowledge into products and services that improve human health. To this end, we have established contacts with biotechnology and pharmaceutical companies that have shown interest in our program. Furthermore, we want to bring our discoveries closer to society through scientific dissemination, and use feedback mechanisms to inform research groups about patients’ real needs.

In summary, the program aspires to become a reference model in translational research for RDs. By promoting collaboration between academia, industry and society, the aim is to accelerate the transition from scientific findings to tangible clinical solutions.

Coordinators: Dr Francisco Dasí Fernández and Dr Pilar González Cabo

Objectives:

- Study the physiopathology, natural history, and fundamental epigenetic, genetic, and metabolic bases of (mainly neuromuscular, metabolic, or respiratory) rare diseases (RDs), such as Amyotrophic Lateral Sclerosis, Friedreich’s Ataxia, CANVAS Syndrome, Duchenne Muscular Dystrophy, Lafora Disease, Neonatal Sepsis, Prader-Willi Syndrome, Myotonic Dystrophy, Charcot-Ma-rie-Tooth disease, Spinal Muscular Atrophy, Dravet disease, Hereditary Spastic Paraplegia 7, Alpha-1 Antitrypsin Deficiency, Pri-mary Ciliary Dyskinesia, pulmonary interstitial diseases, idiopathic pulmonary fibrosis, Cystic Fibrosis and Wilson’s disease
- Generate new biomodels for RD research
- Develop new diagnostic and prognostic methods
- Explore therapeutic strategies and identification of molecular targets and drugs as potential treatments for these RDs
- Protect research results that can be transferred to the biotechnology sector for effective transformation into improvements in healthcare and the quality of life of patients
- Study respiratory problems in RDs, as well as the physiopathological aspects that interfere with the effectiveness of their manage-ment and therefore negatively influence the survival of patients
- Promote collaboration with services of the Clinical Hospital involved in the treatment of these RDs, emphasizing primary care to improve its diagnostic potential
- Disseminate research results following FAIR principles (Findability, Accessibility, Interoperability, and Reusability), as well as dis-semination of research results in society

Research lines:

- Physiopathology of rare neuromuscular diseases
- Epigenetic regulation of neonatal sepsis and Dravet disease
- Physiopathology of pulmonary fibrosis with telomere involvement
- Pathophysiology of alpha-1 antitrypsin deficiency, cystic fibrosis, primary ciliary dyskinesia, childhood interstitial diseases and Prader-Willi syndrome
- Genetic and epigenetic modifiers in Friedreich’s ataxia, CANVAS Syndrome and Wilson’s disease
- Gene therapy for the treatment of rare diseases
- Design and testing of new biomarkers for rare diseases
- Characterization of the cellular and molecular mechanisms associated with Myotonic Dystrophy, Limb-Girdle Muscular Dystro-phy D2 (LGMDD2), Friedreich’s ataxia, Hereditary Spastic Paraplegia 7 and CANVAS Syndrome, and identification of potential molecular targets susceptible to pharmacological modification for the development of new therapies
- Study of new experimental treatments in animal models

- Rare diseases affecting the musculoskeletal system: tumour pathology (multiple forms of benign cartilaginous tumours) and metabolic bone pathology
- Respiratory problems in rare diseases
- Rare epilepsies such as Lafora Disease

Clinical groups

- Research Group on Respiratory Diseases (Mr Jaime Signes-Costa Miñana)
- Research Group on Psychiatry and Neurodegenerative Diseases (Mr Juan Nacher Roselló)
- Cardiometabolic Research Group on Primary Care (Mr Jorge Navarro Pérez)
- Clinical Associated Group on Traumatology and Orthopaedics (Mr Antonio Silvestre Muñoz)

Experimental groups

- Research Group on Human Translational Genomics (Mr Rubén Artero Allepuz)
- Research Group on Rare Respiratory Diseases (RRD) (Mr Francisco Dasí Fernández)
- Research Group on Cellular and Organic Physiopathology of Oxidative Stress (Mr Federico V. Pallardó Calatayud)
- Research Group on Epigenomics and translational epigenetics (Mr José Luis García Giménez)
- Research group on Neurobiology and Molecular Physiopathology in Rare Diseases – NeurFisER (Ms Pilar González Cabo)
- Research Group on Genetics and Biomarkers of Rare Diseases (Ms Carmen Espinós Armero)

Clinical Services Associated with the Program

- Department of Paediatrics
- Department of Pneumology
- Department of Traumatology and Orthopaedic Surgery

RARE DISEASES				
OBJECTIVES	STATUS			ACTIONS
	Achieved	Partially achieved	Not achieved	
1. Título propiedad industrial registrada: Método para la predicción de la edad biológica según el sexo basado en el análisis de metilación de ELOVL2 Tipo de propiedad industrial: Secreto Industrial Derechos de autor: Sí Secreto empresarial: Sí Modalidad de know-how: Sí Inventores/autores/obtentores: José Luis García Giménez; Salvador Mena Mollá Entidad titular de derechos: INCLIVA y UV Cód. de referencia/registro: UV-SECRETO-202487R Nº de solicitud: UV-SECRETO-202487R País de inscripción: España, Comunitat Valenciana Fecha de registro: 10/10/2024 Licencias: Sí C. Autón./Reg. de explotación: Comunitat Valenciana, España	x			

2. Título propiedad industrial registrada: DISPOSITIVO PARA CANALIZACIÓN DE LA SANGRE PARA HEMODIÁLISIS Tipo de propiedad industrial: Patente de invención Inventores/autores/obtentores: Pascual Medina Besó; Valeriano Caballero Varón; José Angel Bahamonde; José Luis García Giménez Entidad titular de derechos: Universitat de València - INCLIVA País de inscripción: España Fecha de registro: 27/10/2023 Nº de patente: PCT/ES2024/000025				
3. Título propiedad industrial registrada: SepAsT Tipo de propiedad industrial: Marcas Inventores/autores/obtentores: José Luis García Giménez; Salvador Mena Mollá; Nieves Carbonell Monleón Entidad titular de derechos: Universitat de València Nº de solicitud: 018645153 País de inscripción: España, Comunitat Valenciana Fecha de registro: 28/05/2022	✖			
4. Título propiedad industrial registrada: Methods for the measurement of Protein C and activated protein C Tipo de propiedad industrial: Patente de invención Inventores/autores/obtentores: José Luis García Giménez; Federico V Pallardó Calatayud; Salvador Mena Mollá; Nieves Carbonell Monleón Entidad titular de derechos: Centro de Investigación Biomédica en Red-ISCIII Nº de solicitud: EP21382173.9 País de inscripción: España Fecha de registro: 01/03/2021 Nº de patente: EP21382173.9 Patente UE: Sí “Methods for the measurement of protein C and activated protein C” The patent family has been extended to Europe (EP4302095A1), Japan (JP2024513664A), USA. (US18/548,043), China (CN117677846A) and also extended the patent family to Canada (CA3211713A1). Licencias: Sí The patent was licensed to EpiDisease S.L. (Spin-Off del CIBERISCIII) in July 2024.				

5. Título propiedad industrial registrada: Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (SS) patients Tipo de propiedad industrial: Patente de invención Inventores/autores/obtentores: José Luis García Giménez; Federico Vicente Pallardó Calatayud; Carlos Romá Mateo Entidad titular de derechos: CIBER ENFERMEDADES RARAS (CIBERER) Nº de solicitud: EP16382509.4 País de inscripción: España Fecha de registro: 04/11/2016 Patente UE: Sí Patente internacional no UE: Sí Patente PCT: Sí The patent family has been granted in Europe (EP3535587B1), USA (US11740245B2), Japan (JP7173495B2), China (CN110325861B) and also extended to Canada (CA3042585A1) and Hong Kong (GP20803923HK). Licencias: Sí				
6. Título propiedad industrial registrada: Kit and method for the diagnosis/prognosis of Idopathic Scoliosis Descripción de cualidades: Contrato de Transferencia a EpiDisease S.L. Tipo de propiedad industrial: Patente de invención Inventores/autores/obtentores: José Luis García Giménez; Federico Pallardó Calatayud; Teresa Bas Hermida; Salvador Mena Mollá; David Hervás Entidad titular de derechos: Centro de Investigación Biomédica en Red (CIBER) Nº de solicitud: EP15382319.0 País de inscripción: España Fecha de registro: 16/06/2015 Nº de patente: EP15382319.0 Patente UE: Sí Patente internacional no UE: Sí Patente PCT: Sí The patent family titled “Kit and method for the diagnosis/prognosis of idiopathic scoliosis” has been granted Europe (EP3310926B1), Hong Kong (HK1253908B), USA. (US10975435B2), China (CN108368550B) y Canada (CA2989480C). Licencias: Sí C. Autón./Reg. de explotación: Bélgica / Canadá / China / Francia / Alemania / Italia / España / Reino Unido / Estados Unidos de América Explotación, en exclusiva: Sí Resultado: Éxito Productos: ScoliPro	✖			

Budget and resource acquisition from different programs	×			Department of Innovation, Universities, Science and Digital Society (2 new projects), Carlos III Health Institute - Co-financed FEDER (4 new projects), Ministry of Science and Innovation (4 new projects), ALBA synchrotron Centre of Excellence (1 new project), Society of Pneumology (2 projects), Alpha-1 antitrypsin deficiency patients' association (Generalitat Valenciana, 3 projects)
Carry out educational and outreach activities	×			• Subject "Enfermedades Raras": Medicine degree (UV) • Master course in Biomedical Research • Master "Enfermedades raras" • 2nd edition of the online course "Introducción a las EE.RR: investigación y atención clínica" • "Introduction to rare diseases". Program of the • University of Valencia La Nau Gran. • "Master's degree in alpha-1 antitrypsin deficiency". ". SEPAR- University CEU San Pablo. • TERRETA Meeting (Rare Diseases and Treatments: Advanced Therapeutic Strategies).

4.2.4. Neurological decline

Inflammation, which is associated with many chronic diseases (diabetes, liver cirrhosis, etc.), ageing and major surgeries, leads to neuroinflammation and brain alterations that eventually result in cognitive and functional impairment. This deterioration reduces quality of life and increases the risk of accidents, falls, fractures and adverse consequences, which results in increased hospitalisations and use of public resources.

Cognitive and functional impairment associated with ageing and many chronic diseases is one of the predominant challenges in improving life quality and ensuring the sustainability of health systems. Prevention, early detection and treatment of cognitive and functional impairment would improve the life quality in the elderly and those with chronic diseases and reduce the burden on the health system, improving sustainability. New approaches are therefore needed to address these challenges, based on advanced understanding of the mechanisms, early diagnosis, prevention and treatment of cognitive and functional impairment.

Coordinators: Dr Carmina Montoliu Féliz and Dr Vicente Felipe Ortiz

Objectives:

- Characterize the alterations in inflammation, neuroinflammation, neurotransmission, function and brain structure associated with the appearance of cognitive and functional impairment
- Characterize cognitive and functional disturbances in detail
- Identify biomarkers for the early detection of cognitive and functional impairment
- Identify the mechanisms by which:
 - a) peripheral inflammation leads to neuroinflammation
 - b) neuroinflammation leads to functional, structural and neurotransmission alterations in the brain
 - c) brain disorders lead to cognitive and functional impairment
- Identify therapeutic targets to reverse or prevent cognitive and functional impairment
- Design and test new therapeutic procedures to reverse or prevent cognitive and functional impairment

As progress is made on the above objectives, new lines of action will be included, focusing on:

- Developing new early diagnostic procedures for cognitive and functional impairment
- Transferring newly developed diagnostic procedures to clinical practice
- Evaluating the efficacy and utility in patients of new therapeutic procedures to prevent or reverse cognitive and functional impairment that has been effective in animal models
- Transferring new validated therapeutic procedures to clinical practice

Research lines:

- Characterization of cognitive and functional alterations
- Cognitive impairment in diabetes
- Cognitive impairment in major surgeries and anaesthesia
- Alzheimer's and mild cognitive impairment
- Cognitive and functional impairment in hyperammonaemia and liver disease

Clinical Groups:

- Research Group on Anaesthesiology and Reanimation (Dr Rafael Badenes Quiles)
- Cardiometabolic Risk and Diabetes (Dr José Tomás Real).
- Associated Clinical Group in Digestive Medicine (Dr Isabel Pascual Moreno)
- Research Group on Psychiatry and Neurodegenerative Diseases (Mr Julio Sanjuán Arias)
- Research Group on the Study of Cardiometabolic and Renal Risk (Dr Josep Redón i Mas, Dr Raquel Cortés Vergaz)
- Research Group on Care INVESTENF-INCLIVA (Dr Cintia Borja Herrero)

Experimental Groups:

- Research Group on Neurological Impairment (Dr Carmina Montoliu Félix)
- Research Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP) (Dr Rafael Tabarés Seisdedos)
- Research Group on Ageing and Physical Activity (Dr José Viña Ribes)
- Research Group on Psychiatry and Neurodegenerative Diseases (Dr Juan Nacher)
- Research Group on Inflammation (Dr M^a Jesús Sanz Ferrando, Dr Laura Piqueras Ruiz)

University Department Associated with the Program

- Biology Unit. Department of Pathology

NEUROLOGICAL DECLINE				
OBJECTIVES	STATUS			COMMENTS
	Achieved	Partially achieved	Not achieved	
1. Characterize alterations in inflammation, neuroinflammation, neurotransmission, function and brain structure associated with the appearance of cognitive and functional impairment		✖		We analysed the presence of neuroinflammation in post-mortem samples of the cerebellum from patients with different grades of liver disease, from mild steatohepatitis to cirrhosis. We analysed alterations in neural connectivity by functional magnetic resonance imaging. We demonstrated in MHE patients a lower functional connectivity in neural networks involved in processes of attention and executive control, and in learning and memory. We found that improved cognition after rifaximin treatment is associated with changes in intra and inter brain network functional connectivity.
2. Characterize cognitive and functional disturbances in detail		✖		Gait, balance, hand strength and motor speed performance were evaluated in cirrhotic patients to discover whether motor performance is a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis. Evaluation and characterization of sensory thresholds was also performed by quantitative sensory testing using a CASE IV. We are characterizing cognitive and functional disturbances in patients with other pathologies: MASLD (metabolic dysfunction-associated steatotic liver disease), diabetes mellitus, schizophrenia, bipolar disorder, and post-surgery patients. We showed that a relevant percentage of MASLD patients have cognitive impairment, and we identified some specific alterations of the immune system associated with the appearance of mild cognitive alterations in MASLD patients. We are better characterizing executive functions in cirrhotic patients by computerized tests.

3. Identify biomarkers for early detection of cognitive and functional impairment		✖	We are studying altered genes in peripheral blood cells and the relative pathways associated with the appearance of cognitive impairment; we are characterizing the changes in inflammation and metabolites associated with cognitive impairment. We are performing an integrated multiomics analysis to identify biomarkers of cognitive and functional impairment. We are characterizing eye movements in patients with different pathologies: cirrhosis, MASLD, and diabetes mellitus. We showed that patients with MHE have increased plasma levels of a parameter of axonal injury (neurofilament light chain protein) which decreased in patients who responded to rifaximin treatment. We studied the associations between blood ammonia, coordination, and quality of life, and the moderating influence of sex on these associations, finding that high ammonia and poor coordination significantly affected quality of life in women with MHE, but not men. We found sex differences in the mediating role of brain-derived neurotrophic factor (BDNF) between inflammation and memory in cirrhotic patients with MHE.
4. Identify the mechanisms by which: a) peripheral inflammation leads to neuroinflammation b) neuroinflammation leads to functional, structural and neurotransmission alterations in the brain c) brain disorders lead to cognitive and functional impairment		✖	We have identified alterations of the immune system associated with the appearance of neurological alterations in cirrhotic patients with MHE, and in MASLD patients. We have identified in animal models mechanisms by which peripheral inflammation induces neuroinflammation, and the way this alters neurotransmission and cognitive and motor function. We have shown that there is a dysregulation in the urea cycle in non-alcoholic fatty liver disease. We are analysing the role of exosomes as mediators of neuroinflammation and of alterations in neurotransmission and cognitive and motor function in animal models of MHE.
5. Identify therapeutic targets to reverse or prevent cognitive and functional impairment		✖	We have identified several therapeutic targets in animal models of MHE.
6. Design and test new therapeutic procedures to reverse or prevent cognitive and functional impairment		✖	We are testing the effect of treatments on cognitive impairment and immunophenotype in patients to reverse or prevent cognitive and functional impairment. We have designed several treatments that improve cognitive and motor function in animal models.
7. Programme activity: Neurological Impairment Program seminars		✖	Seminars are scheduled for the third Thursday of each month at 13:30h.

4.2.5. Translational oncology

The translational oncology program entitled “Identification of oncogenic biomarkers: mechanisms and clinical implications, detection in non-invasive samples, omics analysis” aims to apply genomic screening in human tumours to clinical practice.

The main objective is to assess cancer dynamics through non-invasive samples to detect minimal residual disease, early onset of markers after surgery and patient response to different treatments.

The high heterogeneity of cancer results in inefficient treatment, even in those aimed at specific molecular targets. The low availability of tumour specimens further complicates genomic studies.

In this sense, the use of liquid biopsies would facilitate the serial collection of samples to carry out molecular analysis and would guarantee minimum risk for the patient, thus improving follow-up and enabling a dynamic understanding of the evolution of patient genomic parameters.

This perspective benefits the National Health System as a whole by facilitating more specific patient treatments, avoiding those that would have been less effective, reducing hospitalizations and improving life expectancy and quality. It could also prevent generalized treatments, secondary toxicities and rapid treatment adequacy responses.

Finally, it would enhance patient inclusion in clinical trials which are stratified by molecular mutations.

Coordinator: Dr Andrés Cervantes Ruipérez

Objectives:

- Identify diagnostic biomarkers to help early identification of patients
- Identify biomarkers of resistance to treatment or relapses
- Develop functional models that mimic patient characteristics
- Develop decision support systems through data analysis

Research lines:

- Liquid biopsy as a diagnostic tool
- Functional organoid, murine and 3D bioprinted models to study resistance and drug screening
- Integration of molecular and image data to develop decision support systems
- Promote the development and implementation of programs in advanced therapies, particularly CAR-T cell therapy and other models
- Continuous improvement of patient inclusion in clinical trials, in coordination with primary care
- Economic evaluation of innovative therapies and digital health.

Clinical Groups:

- Research Group on Breast Cancer Biology (Ms Ana Lluch Hernández, Ms Pilar Eroles Asensio)
- Research Group on Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST (Mr Andrés Cervantes Ruipérez)
- Research Group on Hematopoietic Transplantation (Mr Carlos Solano Vercet)
- Research Group on Myeloid Neoplasms (Ms Mar Tormo Díaz)
- Research Group on Lymphoproliferative Disorders (Ms M^a José Terol Casterá)
- Translational Research Group on Paediatric Solid Tumours (Mr Samuel Navarro Fos, Ms Rosa Noguera Salvá)
- Research Group on General and Digestive Surgery (Mr Luis Sabater)
- Associated Clinical Group on Urology (Mr José Martínez Jabaloyas)
- Associated Clinical Group on Pharmacy (Mr Manuel Alós Almiñana)
- Research Group on Skin Cancer (Mr Carlos Monteagudo Castro)

Clinical Services Associated with the Program:

- Department of Pathology
- Department of Radiology
- Central Laboratory

Associated Program Platforms:

- Biobank
- Bioinformatics Unit
- Biostatistics Unit
- Precision Medicine Unit

TRANSLATIONAL ONCOLOGY				
OBJECTIVES	STATUS			ACTIONS
	Achieved	Partially achieved	Not achieved	
Identify biomarkers	✖ ✖ ✖ ✖			• Clinical recruitment characterization and storage; biobank data management • Subclassify tumours according to their profile • Identify biomarkers of inflammation / angiogenesis; miRs-detox from oxidative stress • Perform comprehensive omics data analysis with search of altered routes using biology of system
Validate promising biomarkers / mechanistic analysis	✖	✖ ✖ ✖		• Proof of concept on commercial cell lines • Establish cell lines with patient tumours • Establish tumours in mouse models (xenografts) • IHC antibodies in FFPE to validate expression / western blot in cell lines / xenotumours
Detect biomarkers in liquid biopsies to monitor disease progression	✖ ✖			• Start on biopsies of patients with advanced disease or disease progression • Implement technology optimized for initial detection, detection of residual disease, and disease evolution and response to treatment

4.2.6. Reproductive medicine

This program comprises three main lines:

1. Research in the field of reproductive medicine and women’s health, with particular focus on factors that cause infertility, and other gynaecological and obstetric pathologies
2. Molecular characterization at single-cell resolution of the human uterus as a basis for both understanding uterus health and disease, and improving diagnosis, monitoring and new therapies.
3. Study of maternal-embryonic communication mechanisms and their impact on reproductive health.

Coordinators: Dr Carlos Antonio Simón Vallés and Dr Felipe Vilella Mitjana

Objectives:

- Create a comprehensive reference map at single-cell resolution of the human uterus in health and disease
- Study the origin of fibroids at the single-cell level
- Study the origin of late gestational pathology focused on decidualization deficiency
- Establish maternal-foetal communication mechanisms before embryo implantation
- Provide early diagnosis and treatment of endometriosis and endometrial cancer
- Study the molecular mediators in hormone-dependent oncogenesis in endometrium and ovary
- Establish a successful strategy for implementing physical activity to reduce the risk of chronic disease in women

Research lines

- Study of endometrial receptivity and cell map of the human uterus. Previous research in our laboratory has established a transcriptomic signature of human endometrial receptivity
- Maternal–foetal communication
- Role of the endometrial microbiome in reproduction
- Ovarian ageing and rejuvenation
- Early diagnosis of preeclampsia and other complications of pregnancy
- Study at the single-cell level of the origin of uterine fibroids
- Early diagnosis and treatment of endometriosis and endometrial cancer
- Molecular factors involved in the initiation and progression of hormone-dependent tumours in the endometrium and ovary
- Implementation of physical activity as a strategy to improve health indicators in women
- Impact of the microbiome on the pathogenesis of ovarian endometriosis

Clinical groups:

- Research Group on Endometriosis and Endometrial Cancer Therapies (Dr Raúl Gómez Gallego)

Experimental groups:

- Research Group on Maternal–Foetal Communication (Dr Felip Vilella Mitjana)
- Research Group on Reproductive Medicine (Dr Carlos Antonio Simón Vallés)
- Research Group on Molecular Diagnosis of Gynaecological Tumours (Dr Aymara Mas Perucho)

Clinical Services Associated to the Program

- Department of Gynaecology and Obstetrics

REPRODUCTIVE MEDICINE				
OBJECTIVES	STATUS			ACTIONS
	Achieved	Partially achieved	Not achieved	
Advance understanding of the mechanisms that regulate maternal–foetal communication	✖			Ongoing project. Results published (7)
Single cell resolving molecular characterization of the human uterus with its implications for health and disease	✖			Finished project. Results published (7)
Single cell study of the origin of fibroids	✖			Finished project. Results published (1)
Study of resistance to decidualization at the origin of late gestational disease	✖			Finished project. Results published (2)
Early diagnosis and treatment of endometriosis and endometrial cancer		✖		Ongoing project (3)
Molecular mediators in hormone-dependent oncogenesis in endometrium and ovary		✖		Ongoing project
Successful strategy for implementing physical activity to reduce the risk of chronic disease in women		✖		Ongoing project

4.2.7. Ageing and age-associated diseases

This program prioritizes improving quality of life in the elderly and promoting longevity. The ageing population is a challenge for current health systems since the population over 65 years old contributes significantly to health expenditure. As life expectancy increases, so do age-associated diseases.

The concept of “healthspan” (quality of life) has emerged in this context and is applied in this program formed by many researchers and health professionals who believe that efforts to extend life at the expense of causing severe physical or psychic disability are undesirable, and that it is preferable to focus on lengthening the stages of life in which we can maintain autonomy, independence, productivity, and well-being.

A central guiding idea of this program is that people who achieve exceptional longevity (i.e., centenarians) serve as a model of satisfactory ageing. In contrast, the most serious problem facing the ageing population is the clinical condition of frailty, a geriatric syndrome characterized by increased vulnerability to external aggressions due to altered physiological reserves of multiple systems, leading to difficulties in maintaining homeostasis. Many over 65s fulfil several frailty criteria, and a quarter of those over the age of 85 are estimated to be frail. The program tries to identify specific molecular targets to intervene concretely and rationally to improve quality of life in the elderly.

In this respect, INCLIVA has a great advantage due the physical proximity and shared interests between the *Hospital Clínico Universitario de Valencia* and the Faculty of Medicine of the University of Valencia. This framework allows for close collaboration between basic research groups that analyse possible biomarkers associated with healthy ageing, frailty, or age-associated diseases and clinical research groups that provide biological human samples, and also facilitates the transfer of successful studies from bench to bedside.

In addition to this, INCLIVA has registered the first and only Spanish Group for the Study of Centenarians, which includes research groups working in this field distributed among different Spanish communities.

Coordinators: Dr José Viña Ribes, Dr Consuelo Borrás Blasco and Dr María Carmen Gómez Cabrera

Objectives:

- Determine oxidative stress and inflammation parameters associated with healthy ageing, frailty, and age-associated diseases
- Determine genetic biomarkers (microRNAs, mRNAs, and SNPs) associated with healthy ageing, frailty, and age-associated diseases
- Determine epigenetic biomarkers associated with healthy ageing, frailty, and age-associated diseases
- Determine metabolomic biomarkers associated with healthy ageing, frailty, and age-associated diseases
- Protocols of physical exercise and other healthy life interventions for the treatment and prevention of frailty.
- Regenerative medicine in ageing: role of stem cells and their extracellular vesicles in restoring intercellular communication in ageing.
- Muscle Regeneration and Sarcopenia

Research lines:

- Biomarkers of ageing
- Mechanisms of ageing with special attention to exceptional ageing: centenarians
- Healthy ageing: frailty and prevention of disability
- Intervention for successful ageing: physical exercise, nutrition, molecular interventions (extracellular vesicles)
- Age-associated diseases: cardiovascular and neurodegenerative diseases
- Mitochondrial implications in age-associated frailty
- Skeletal muscle repair, exercise, frailty, and sarcopenia
- Regenerative medicine in ageing and age-associated diseases

Clinical research groups:

- Research Group on the Study of Cardiometabolic and Renal Risk (Mr Josep Redón i Mas, Ms Raquel Cortés Vergaz)
- Cardiometabolic Research Group on Primary Care (Mr Jorge Navarro Pérez)
- Research Group on Clinical Cardiology (Mr Juan Sanchis Forés)
- Research Group on Care INVESTENF-INCLIVA (Ms Cintia Borja Herrera)

Experimental research groups:

- Research Group on Neurological Impairment (Ms Carmina Montoliu Félix)
- Research Group on Endothelial Cells (LINCE) (Mr Carlos Hermenegildo Caudevilla, Ms Susana Novella del Campo)
- Research Group on Exercise, Nutrition and Healthy Lifestyle (Ms Mª Carmen Gómez Cabrera)
- Research Group on Healthy Ageing (Ms Consuelo Borrás Blasco)
- Research Group on Ageing and Physical Activity (Mr José Viña Ribes)
- Research Group on Cellular and Organic Physiopathology of Oxidative Stress (Mr Federico V. Pallardó Calatayud)
- Research Group on Inflammation (Ms Mª Jesús Sanz Ferrando, Ms Laura Piqueras Ruiz)
- Research Group on Genetics of Osteoporosis (Mr Miguel Ángel García Pérez)
- Research Group on Molecular Imaging and Metabolomics (Mr Daniel Monleón Salvadó)

OBJECTIVES	STATUS			ACTIONS
	Achieved	Partially achieved	Not achieved	
Determination of parameters of oxidative stress and inflammation associated with healthy ageing, frailty, and diseases associated with ageing (mainly cardiovascular and neurodegenerative)		✖		• Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer's disease patients • Reductive Stress: a New Concept in Alzheimer's Disease • Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease • Glucose 6-P dehydrogenase delays the onset of frailty by protecting against muscle damage • Frailty is associated with oxidative stress in older patients with Type 2 Diabetes • RedOX-related biomarkers in physical exercise Project: CIBER de Fragilidad y envejecimiento (CIBERfes) Project: Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping Thesis title: Role of p16ink4a and bmi-1 in oxidative stress-induced premature senescence in human dental pulp stem cells Thesis title: Regulation of antioxidant defenses in the prevention of skeletal muscle deconditioning

Determination of genetic biomarkers (microRNAs, mRNAs, and SNPs) associated with healthy ageing, frailty, and diseases associated with ageing (mainly cardiovascular and neurodegenerative)	x		• In Search of ‘Omics’-Based Biomarkers to Predict Risk of Frailty and Its Consequences in Older Individuals: The FRAILOMIC • Managing Frailty. A comprehensive approach to promote a disability-free advanced age in Europe: the ADVANTAGE initiative. Joint actions (HP-JA). 3rd EU Health Programme • Scaling-up of an evidence-based intervention programme in older people with Diabetes and Frailty in Latin America. DIABFRAIL-LATAM • Multidomain Lifestyle Interventions Associated With Improved Functional Trajectories and Favourable Changes in Epigenetic Aging Markers in Frail Older Adults: Randomized Controlled Trials. • Human exceptional longevity: transcriptome from centenarians is distinct from septuagenarians and reveals a role of Bcl-xL in successful aging. Aging (Albany NY) • A translational approach from an animal model identifies CD80 as a candidate gene for the study of bone phenotypes in postmenopausal women • Centenarians maintain the miRNA biogenesis pathway while it is impaired in octogenarians. Mechanisms of ageing and development Thesis title: <i>Transcriptómica en centenarios: un ejemplo de envejecimiento satisfactorio</i>
Determination of epigenetic biomarkers associated with healthy ageing, frailty, and diseases associated with ageing (mainly cardiovascular and neurodegenerative)		x	• Epigenetic biomarkers for human sepsis and septic shock: insights from immunosuppression • Epigenetic regulation in the pathogenesis of Sjögren Syndrome and Rheumatoid Arthritis • Exercise training as a modulator of epigenetic events in prostate tumours • Exercise training as a modulator of epigenetic clocks. • Implementing precision medicine in human frailty through epigenetic biomarkers • Epigenetic biological age in mice models in ageing and frailty
Determination of metabolomic biomarkers associated with healthy ageing, frailty, and diseases associated with ageing (mainly cardiovascular and Neurodegenerative)		x	Sex Differences in Age-Associated Type 2 Diabetes in Rats-Role of Oestrogens and Oxidative Stress

Physical exercise protocols for the prevention of frailty		x	• A multicomponent exercise intervention that reverses frailty and improves cognition, emotion, and social networking in the community-dwelling frail elderly • Boosting the intrinsic myofiber self-repair mechanisms in skeletal muscle to prevent and treat frailty and sarcopenia (MYOLD) • Promoting health span and preventing frailty through mitohormetic targeted interventions (miTHOR) • Exercise training as a drug to treat age-associated frailty • Copenhagen consensus statement 2019: physical activity and ageing • Muscle repair after physiological damage relies on nuclear migration for cellular reconstruction Project: Novel multidomain therapeutic interventions to delay frailty and disability. Identification of molecular mechanisms with translational relevance Project: EXERNET. Red de ejercicio físico y salud Project: Personalized physical exercise as an intervention to reverse disability in older adults living in residences (RESIFIT) Thesis title: A multicomponent exercise program to prevent frailty, and for cognitive, emotional, and social improvement in frail elderly people Thesis title: Moderate overexpression of glucose-6-phosphate dehydrogenase improves healthspan in mice. Implications in skeletal muscle regeneration Thesis title: Impact of long-term physical exercise on neuroprotection in middle-aged subjects: study of the molecular mechanisms involved Thesis title: Modulation of the Immune System by G6PD Activity, Diet, and Physical Exercise, and Their Potential Impact on Aging, Inflammation, and Cancer.
---	--	---	---

Regenerative medicine in ageing: role of stem cells and their extracellular vesicles in restoring intercellular communication in ageing.		x	- Stem cell culture under physiological conditions for healthy status - Extracellular vesicles from healthy stem cells improve senescence in vitro - Extracellular vesicles from young mice isolated stem cells improve health in aged mice Project: Effect of treatment with extracellular vesicles of fat stem cells from young mice on ageing and fragility parameters in old mice Project: Study of the importance of extracellular vesicles as mediators of intercellular communication in ageing and frailty Project: Biomarkers in extracellular plasma vesicles in patients with traumatic brain injury. Project: Therapeutic potential of extracellular vesicles from mesenchymal stem cells in the regeneration of pressure ulcers associated with ageing: preclinical and clinical application (EVOLVE) Thesis title: Obtention of stem cells from dental pulp. characterization and adaptation to various oxygen conditions. Thesis title: Obtention and characterization of human dental pulp stem cells and interaction with b-phosphatotricalcium Thesis title: Role of p16 ink4a and bmi-1 in oxidative stress-induced premature senescence in human dental pulp stem cells Thesis title: Favourable effect of intercellular communication through extracellular vesicles derived from adipose tissue stem cells in aging. Thesis title: Role of resveratrol and other natural components on lipid catabolism, mitochondrial function, and longevity
Muscle Regeneration and Sarcopenia	x		- Generation of a multimodal cell atlas of the ageing human skeletal muscle. - Generation of a human skeletal muscle ageing and exercise atlas for targeted prevention of mobility loss - Demonstration that mitochondrial remodelling in skeletal muscle is a key mechanism underlying exercise-induced reversal of age-associated functional decline in mice and humans

4.3. Research areas

INCLIVA Biomedical Research Institute divides its scientific activity into four research areas. Although independent, they have a common objective: meeting health needs and improving R&D&i systems.

Their main aim is to establish a common reference framework to promote collaboration between INCLIVA affiliated researchers.

One or more advisers from the External Scientific Committee participate of each of these lines, which are led by the following coordinators:

Cardiovascular Area

- **Coordinator:** Mr Francisco Javier Chorro Gascó
- **Mission:** advance understanding of different aspects of cardiovascular disease (CVD) from its origins to its consequences.

Oncology Area

- **Coordinator:** Mr Andrés Cervantes Ruipérez
- **Mission:** advance understanding of different aspects of oncological diseases, at the stage of diagnosis and molecular characterization and selection of specific molecular targets of therapeutic interest.

Metabolism and Organ Damage Area


- **Coordinator:** Mr José Viña Ribes
- **Mission:** advance understanding of the aetiology, pathophysiology, diagnosis mechanisms and treatment of various metabolic diseases, or those in which organ damage is directly linked with its trigger action.

Reproductive Medicine Area

- **Coordinator:** Mr Carlos Antonio Simón Vallés
- **Mission:** advance understanding of human reproduction for translational application, improving the efficiency of assisted reproduction treatment and reducing adverse effects.

Scientific output analysis by research area

The following charts and figures summarize the main scientific activity indicators of the four research areas and the other Hospital Clínico de Valencia divisions.



It should be noted that the sum of publications by area exceeds INCLIVA's total scientific output as some scientific articles overlap two or more areas.

The following tables show scientific publications distributed by area in terms of number of articles and impact factor.

- In December 2025, internal changes are introduced across our research areas, coming into effect in January 2026.
- The Cardiovascular Area renewed its leadership, appointing Mr Sergio Martínez Hervás and Mr Julio Núñez Villota as the new Area Coordinators.
 - The Oncology Area was renamed the Cancer Area, and Ms Noelia Tarazona Lavero was appointed as the new Area Coordinator.
 - The Metabolism and Organ Damage Area was split and separated into two new areas:
 - The Rare Diseases Area, coordinated by Mr Federico Vicente Pallardó and Ms Carmen Espinós Armero.
 - The Ageing, Inflammation and Chronic Diseases Area, coordinated by Ms María Jesús Sanz Ferrando and Ms Consuelo Borrás Blasco.
 - The Reproductive Medicine Area was renamed the Women's Health Area, and Mr Carlos Antonio Simón Vallés and Mr Felipe Vilella Mitjana were appointed as the new Area Coordinators.

4.3.1 Cardiovascular Area

Groups

- Research Group on Cardiometabolic Risk and Diabetes
- Genomics and Diabetes Unit
- Research Group on Cardiac Experimental Electrophysiology
- Research Group on Endothelial Cells (LINCE)
- Research Group on Clinical Cardiology
- Research Group for the Prevention of Cardiovascular Risk in Children and Adolescents
- Cardiometabolic Research Group on Primary Care
- Research Group on the Study of Cardiometabolic and Renal Risk
- Research Group on Vascular Function
- Research Group on Pediatric Nutrition
- Group on Translational Research in Ischemic Heart Disease
- Research Group on Heart Failure
- Research Group on Renal Disease

Number of indexed publications		IF	Average IF	
194		1.171,2	6,0683	
National collaborations		International collaborations	Corresponding author	
118		60	93	
D1	Q1	Q2	First author	Last author
46	137	76	76	84



Key Publications

- Effect of exercise training in patients with chronotropic incompetence and heart failure with preserved ejection fraction: the TRAINING-HR randomized clinical trial. Palau P, de Amo I, Núñez G, Flor C, de la Espriella R, García C, Berlanga SE et al. European Journal of Preventive Cardiology. 2025 may 09. 33 (2):265-275. DOI:10.1093/eurjpc/zwaf269. PMID:40294211. IF: 7,50. Q1.
- Temporal and Spatial Dynamics in the Regulation of Myocardial Metabolism During the Ischemia-Reperfusion Process. De Dios E, Forteza MJ, Perez N, Molina T, Gavara J, Marcos V, Jimenez M et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 september 10. 26 (18):DOI:10.3390/ijms26188820. PMID:41009389. IF: 4,90. Q1.
- Ventricular arrhythmogenic remodelling in diet-induced metabolic syndrome driven by right-to-left regional differences in action potential duration and dominant frequency gradients. Arias OJ, Calvo CJ, Bizy A, Ortiz JE, Such L, Such L, Alberola A et al. JOURNAL OF PHYSIOLOGY-LONDON. 2025 may 01. 603 (10):2979-3000. DOI:10.1113/JP286516. PMID:40320918. IF: 4,40. Q1.
- Targeting Inflammation and Iron Deficiency in Heart Failure: A Focus on Older Adults. Maidana D, Arroyo Álvarez A, Barreres Martín G, Arenas Oriente A, Cepas Guillen P, Brigolin Garofo RT, Caravaca Pérez P et al. Biomedicines. 2025 february 01. 13 (2):DOI:10.3390/biomedicines13020462. PMID:40002874. IF: 3,90. Q1.
- Effects of Physical Training on Heart Rate Variability in Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis. Ortiz JE, Sánchez M, Prieto L, Arias OJ, Bizy A, Calvo CJ, Alberola A et al. Journal of Clinical Medicine. 2025 august 29. 14 (17):DOI:10.3390/jcm14176129. PMID:40943888. IF: 2,90. Q1.

Research Group on Cardiometabolic Risk and Diabetes

Consolidated
Principal Investigators: Jose Tomás Real Collado / Sergio Martínez Hervás

GROUP MEMBERS



Staff in the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Sergio Martínez Hervás. Hospital / UV
Jose Tomas Real Collado. Hospital / UV
Juan Francisco Ascaso Gimilio. Hospital
- Established Researcher:**
Francisco Javier Ampudia Blasco. Hospital / UV
Miguel Civera Andres. Hospital / UV
- Recognised Emerging Researcher:**
Vera Lucía Gomes Francisco. INCLIVA
- Recognised Researcher:**
Katherine García Malpartida. Hospital
Blanca Alabadí Pardiñes. INCLIVA
- First Stage Researcher:**
Carlos Bea Serrano. INCLIVA
Miriam Moriana Hernandez. Hospital
Sandra Amores Alandí. INCLIVA
- Staff-Collaborating Researcher:**
Amparo Bartual Rodrigo. Hospital
Esther Benito Casado. Hospital
- Staff-Nurse:**
Rafael José Cuenca Moreno. INCLIVA
Pilar Aguilar Santaisabel. Hospital

Emerging Researcher

Vera Lucía Gomes Francisco

Her work focuses on establishing new biomarkers and therapeutic targets in metabolic and cardiovascular diseases, highlighting the role of new adipokines and inflammatory axes.



STRATEGIC AIMS

In terms of scientific activity of the research group during 2022, our group is participating in the development of three competitive and multidisciplinary research projects that include the following aims:

- Project: Immunopharmacological modulation of the systemic inflammation associated to metabolic disorders. Search for new therapeutic targets and synthesis of novel drugs
- Project: Study of new inflammatory and angiogenic mechanisms associated to severe morbid obesity
- Project: Role of the inflammatory processes in metabolic diseases and associated complications
- Project: Evaluation of the efficacy of pharmacogenetics to improve the response to treatment in subjects with insufficiently controlled type 2 diabetes

MAIN LINES OF RESEARCH

- Adipokines, inflammatory axes, new therapeutic targets and cardiovascular risk in metabolic fatty liver disease.
- Ageing, frailty, sarcopenia and neurodegeneration in people with diabetes.
- Applying Big Data and Artificial Intelligence technologies to analyse cardiovascular risk in dyslipidemia and diabetes
- Body composition analysis.
- Diabetes and its complications.
- Effect of body composition analysis, vascular risk and treatment in people with diabetes.
- Impact of body composition analysis on prognosis, quality of life and therapeutic response in onco-haematological patients.

- New diabetes technologies.
- Pharmacogenetic-based personalized treatment in diabetes.
- Primary dyslipidemias: molecular mechanisms, insulin resistance and novel therapeutic targets.
- Role of inflammatory axes in the modulation of metabolic and vascular dysfunctions in obesity, insulin resistance and diabetes.

TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PI21/00220

Title: Estudio de nuevos ejes de quimiocinas como potenciales dianas de intervención en la obesidad y la resistencia a la insulina

Principal Investigators: Laura Piqueras Ruiz and José Tomas Real Collado

Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2025

Total budget: €204.490

Reference: PI22/00062

Title: Identificación de nuevas dianas terapéuticas y mecanismos de la modulación de la inflamación en las enfermedades metabólicas

Principal Investigators: Herminia González Navarro and Sergio Martínez Hervás

Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2025

Total budget: €147.620

Reference: ICI21/00020

Title: Evaluación de la eficacia de la farmacogenética para mejorar la respuesta al tratamiento en sujetos con diabetes tipo 2 insuficientemente controlada

Principal Investigator: Sergio Martínez Hervás

Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2025

Total budget: €267.300

Reference: 2023/108

Title: Composición corporal y distribución grasa, y su asociación con los procesos inflamatorios y la presencia de arteriosclerosis

Principal Investigator: Sergio Martínez Hervás

Funding Body: Fundación Privada Española de Arteriosclerosis
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2026

Total budget: €15.000

Reference: INNEST/2024/409

Title: Desarrollo de una metodología avanzada para evaluación morfofuncional integral en paciente obeso. FITME.

Principal Investigator: Miguel Civera Andrés

Funding Body: Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2026

Total budget: €144.764,61

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
26	92,7	3,86
National collaborations	International collaborations	Corresponding author
18	4	13

- Enrichment of RedoxifibromiR miR-21-5p in Plasma Exosomes of Hypertensive Patients with Renal Injury. Martinez O, Flores A, Mendez M, Martinez S, Martinez F, Forner MJ, Redon J et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 january 01. 26 (2): DOI:10.3390/ijms26020590. PMID:39859307. IF: 4,9. Q1
- Chagas Disease in a Non-Endemic Setting: Clinical Profile, Treatment Outcomes, and Predictors of Cure in a 15-Year Cohort Study. Bea C, de Gracia AI, Llenas J, Vela S, Belmonte A, Pinto C, Ferrer A et al. Tropical Medicine and Infectious Disease. 2025 june 11. 10 (6): DOI:10.3390/tropicalmed10060161. PMID:40559728. IF: 2,60. Q1.
- Assessment of Muscle-Specific Strength in Oncology Patients: Anthropometry as a Reliable Alternative to DXA. Alabadi B, Amores S, Moriana M, Wu NY, García K, Pedrón JA, Monrós C et al. Life-Basel. 2025 august 15. 15 (8): DOI:10.3390/life15081300. PMID:40868947. IF: 3,4. Q1

- Fecal Metabolomics for the Diagnosis of Clostridioides difficile Infection. Bea C, Belmonte A, Pinto C, Ferrer A, Vela S, de Gracia AI, de Castro A et al. Diagnostics. 2025 september 15. 15 (18): DOI:10.3390/diagnostics15182331. PMID:41008703. IF: 3,3. Q1.
- Increased CX3CL1/CX3CR1 Axis Is Related to Atherosclerosis in Subjects with Familial Combined Hyperlipidaemia, Which Is Modulated by Insulin Resistance but Not by Sex. Jiménez E, Espinosa C, Alabadi B, Hurtado G, Enrique A, Martín S, Casas V et al. Biomedicines. 2025 september 28. 13 (10): DOI:10.3390/biomedicines13102378. PMID:41153665. IF: 3,9. Q1.


Genomics and Diabetes Unit

Consolidated
Principal Investigador: Felipe Javier Chaves Martínez

GROUP MEMBERS

Staff in the period 01/01/2025 – 31/12/2025

- **Established Researcher:**
Felipe Javier Chaves Martínez. INCLIVA
Ana Bárbara García García. CIBERDEM
- **First Stage Researcher:**
Celeste Rosa Moya Valera. INCLIVA
María Elena Quiroz Podríguez. INCLIVA
Francisco Lara Hernández. INCLIVA



STRATEGIC AIMS

Study of genetic and environmental factors involved in the development of type 2 diabetes and related diseases by the use of genomics, bioinformatic and artificial intelligence tools
Study of transposable elements and circular extrachromosomal ADN in the development of cardiometabolic diseases.

Identify alterations of DNA methylation in relation to the development of type 2 diabetes and its potential use as biomarkers for prediction of cardiometabolic diseases. Identify genetic causes of rare diseases: Abeta and allergy to all food.

Study of somatic mutations and genomic alterations involved in the development of cardiometabolic diseases

MAIN LINES OF RESEARCH

- Analysis of methylated and hydroxymethylated regions in the genome in patients with specific phenotypes at baseline compared with phenotypes present eight years later, as pertains to type 2 diabetes.
- Identification of frequent and rare functional variants involved in high cardiovascular risk disease development and their interaction with environmental factors.
- Identification of relationships between different genes, environmental factors and pollutants in relation to type 2 diabetes and related traits.
- Development and application of bioinformatic and artificial intelligence tools to improve the identification of genetic variations (germinal and somatic including small and large alterations). and their interaction with environmental factors in the development of cardiometabolic diseases.
- Monitoring and molecular characterization of chronic lymphocytic leukaemia and study of molecular markers

RESEARCH PROJECTS

Reference: PI21/00506
Title: Estudio multifactorial para la identificación de nuevos factores genéticos y no genéticos mediante la secuenciación del exoma y técnicas de inteligencia artificial
Principal Investigator: Felipe Javier Chaves Martínez
Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2024 extended 2026
Total budget: €183,920

Reference: PMP21/00076
Title: ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2
Principal Investigator: Felipe Javier Chaves Martínez
Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2025
Total budget: €106,700

Reference: PMP22/00033
Title: *El primer estudio de asociación de genoma completo (GWAS) con enfermedad coronaria poblacional a 10 años en más de 100.000 participantes para personalizar la prevención cardiovascular en España*
Principal Investigator: Felipe Javier Chaves Martínez
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025

Reference: PI24/00338
Title: ADN_extracromosomico y elementos transponibles como mecanismos tempranos implicados en el desarrollo de la diabetes tipo 2 y marcadores tempranos.
Principal Investigator: Felipe Javier Chaves Martínez
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana-INCLIVA*
Duration: 2025-2027
Total budget: 233,750 €

Reference: ACIF/2021/229
Title: *Contrato predoctoral*
Principal Investigator: Francisco Lara Hernández
Funding Body: *Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2021-2025
Total budget: €93,878.40

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
7	58.7	8.38
National collaborations	International collaborations	Corresponding author
3	1	2

- Genetic interaction between oxidative stress and body mass index in a Spanish population. Lara F, Melero R, Quiroz ME, Moya C, Gallardo MD, Alvarez L, Valarezo IL et al. Redox Biology. 2025 march 01. 80103531-103531. DOI:10.1016/j.redox.2025.103531. PMID:39923398. IF: 11,90. Q1

- Characterization of Chronic Lymphocytic Leukemia Immunoglobulin Rearrangements from Partial Read Sequencing. Fuentes A, Serrano A, Ferrer B, Ventura L, Seda E, García AB, Navarro B et al. GENOMICS PROTEOMICS & BIOINFORMATICS. 2025 may 02. 23 (2):DOI:10.1093/gpbjnl/qzaf041. PMID:40315014. IF: 7,9. Q1
- A machine learning approach for type 2 diabetes diagnosis and prognosis using tailored heterogeneous feature subsets. Navarro JR, Pons P, Arnal L, Arlandis J, Llobet R, Perez JC, Lara F et al. MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING. 2025 september 01. 63 (9):2733-2752. DOI:10.1007/s11517-025-03355-5. PMID:40198441. IF: 2,6. Q2
- Array genotyping of transfusion-relevant blood cell antigens in 6946 ancestrally diverse study participants. Gleadall NS, Koets L, Shamardina O, Gollub J, Gottschalk AJ, Razeghi O, Ochoa G et al. BLOOD. 2025 september 18. 146 (12):1511-1524. DOI:10.1182/blood.2025028902. PMID:40499009. IF: 23,10. Q1
- Extrachromosomal Circular DNA and Transposable Elements in Type 2 Diabetes. Moya Valera,C, Arita,AF, Lara Hernández,F, García,AB, Chaves,FJ. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 november 27. 26 (23):DOI:10.3390/ijms262311516. PMID:41373670. IF: 4,90. Q1

THESIS

Thesis title: Interacción entre variables genéticas y no genéticas en el desarrollo de la Diabetes Mellitus Tipo 2 en la población española
Type: Thesis Doctoral
Doctoral candidate: Rebeca Melero Valverde
Director(s): Dr. Rafael Badenes Quiles
University: Universitat de València (Estudi General)
Date of the defense: 14/11/2025
Grade: Sobresaliente
Quality recognition/Award: Cum Laude

Research Group on Cardiac Experimental Electrophysiology

Consolidated

Principals Investigators: Francisco Javier Chorro Gascó / Antonio M. Alberola Aguilar

GROUP MEMBERS

Staff in the period 01/01/2025 – 31/12/2025


- **Leading Researcher:**
Francisco Javier Chorro Gascó. UV
Antonio M. Alberola Aguilar. UV
Luis Such Belenguer. UV
- **Established Researcher:**
Luis Such Miquel. UV
- **Recognised Researcher:**
Patricia Genovés Martínez. UV
Óscar Julián Arias Mutis. UV
Irene Del Canto Serrano. UV
Manuel Zarzoso Muñoz. UV
Isabel Trapero Gimeno. UV
- **First Stage Researcher:**
Johan Enrique Ortiz Guzman. UV

STRATEGIC AIMS

- Experimental studies on the protective effect against arrhythmic vulnerability by inhibition of neprilysin (sacubitril), late sodium current (eleclazine) and intracellular calcium overload (rimacalib, KN-93).
- Study of the protective effects of the inhibition of histone deacetylases in an experimental model of myocardial infarction. Effects on infarct size, fibrosis and inducibility of arrhythmias.
- Development of an experimental model of metabolic syndrome to analyze the electrophysiological modifications and the inducibility of cardiac arrhythmias. Analysis of the protective effects of iSGLT2.
- Effects of modifications of the basic electrophysiological properties on the mechanisms involved in the induction and maintenance of fibrillatory processes.
- Development of instruments for recording, processing and analysis of cardiac electrophysiological signals obtained with cardiac mapping systems (optical and electric mapping).

MAIN LINES OF RESEARCH

- Development and extension of technical tools for the recording, processing and analysis of cardiac electrophysiological signals based on multielectrodes and cardiac mapping systems.
- Experimental studies on the protective effect against arrhythmic vulnerability. Modifications of the signaling pathways involved in mechanoelectric coupling and activated in situations of mechanical stretch and metabolic overload.
- New therapeutic targets related to: a) calcium homeostasis; b) renin angiotensin aldosterone system/neprilysin inhibition; c) common nodes in the signaling pathways (CaMKII) and d) transmembrane ionic currents.
- Study of electrophysiological modifications and inducibility of cardiac arrhythmias in an experimental model of metabolic syndrome.
- Study of the mechanisms involved in the deterioration of the systolic function, fibrosis and the inducibility of arrhythmias in an experimental model of myocardial infarction.



TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: EU4H-2022-JA-03
Title: *Prevention of NCDs – cardiovascular diseases and diabetes*
Principal Investigator: Clara Bonanad Lozano, Josep Redón Mas
Funding Body: *European Comission*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2027
Total Budget: €684,947.66

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
11	38.3	4.25
National collaborations	International collaborations	Corresponding author
6	3	10

- Effects of Eleclazine (GS6615) on the proarrhythmic electrophysiological changes induced by myocardial stretch. Chorro FJ, Such L, Cuñat S, Arias O, Genovés P, Zarzoso M, Alberola A et al. *Frontiers in Physiology*. 2025 january 31. 161525836-1525836. DOI:10.3389/fphys.2025.1525836. PMID:39958692. IF: 3,40. Q1
- Sodium valproate reverses aortic hypercontractility in acute myocardial infarction in rabbits. Guerra S, Suarez A, Belmonte B, Marchio P, Genoves P, Arias OJ, Aldasoro M et al. *European Journal of Pharmacology*. 2025 february 05. 988177216-177216. DOI:10.1016/j.ejphar.2024.177216. PMID:39706463. IF: 4,70. Q1
- Ventricular arrhythmogenic remodelling in diet-induced metabolic syndrome driven by right-to-left regional differences in action potential duration and dominant frequency gradients. Arias OJ, Calvo CJ, Bizy A, Ortiz JE, Such L, Such L, Alberola A et al. *JOURNAL OF PHYSIOLOGY-LONDON*. 2025 may 01. 603 (10):2979-3000. DOI:10.1113/JP286516. PMID:40320918. IF: 4,40. Q1

- NT-proBNP to guide risk stratification after cardiac rehabilitation in patients with ST-segment elevation myocardial infarction. Pérez N, De Dios E, Gavara J, Ríos C, Marcos V, Merenciano H, Bertolín C et al. *European Journal of Internal Medicine*. 2025 july 01. 13783-89. DOI:10.1016/j.ejim.2025.04.027. PMID:40316461. IF: 6,10. Q1
- Effects of Physical Training on Heart Rate Variability in Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis. Ortiz JE, Sánchez M, Prieto L, Arias OJ, Bizy A, Calvo CJ, Alberola A et al. *Journal of Clinical Medicine*. 2025 august 29. 14 (17):DOI:10.3390/jcm14176129. PMID:40943888. IF: 2,90. Q1

THESIS

Thesis title: Modificaciones inducidas por la inhibición del co-transportador sodio/glucosa Tipo II sobre la variabilidad de la frecuencia cardíaca en un modelo experimental de síndrome metabólico
Type: Thesis Doctoral
Doctoral candidate: Johan Enrique Ortiz Guzman
Director(s): Manuel Zarzoso Muñoz, Óscar Julián Arias Mutis and Antonio M. Alberola Aguilar.
Date of the defense: 05/02/2025
University: Universitat de València
Academic Program: Programa Oficial de Doctorado en Fisiología por la Universitat de Valencia

Thesis title: Dispositivos de Acceso Venoso y sus complicaciones en el paciente hematológico: análisis del perfil de pacientes y tratamientos.
Type: Doctoral
Doctoral candidate: Lucía Brines Sirerol
Director(s): Cristina Buigues González, Carlos Solano Vercet, Isabel Trapero Gimeno
Date of the defense: 16/12/2025
University: Universitat de València

Research Group on Endothelial Cells (LINCE)

Consolidated

Principal Investigators: Susana Novella del Campo / Carlos Hermenegildo Caudevilla

GROUP MEMBERS

Staff in the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Carlos Hermenegildo Caudevilla. UV
Susana Novella Del Campo. UV
- **Recognised Researcher:**
Daniel Bernardo Pérez Cremades. UV
Elena Monsalve Villalba. UV
- **First Stage Researcher:**
Bianca Descals Beltran. UV
Cristina Rosales Ariza. UV

- To tune the experimental surgical procedure of AMI in the SAMR1/SAMP8 murine senescence model, which will allow us to evaluate the vascular effect of aging and sex and to verify that the change in expression of some miRNA observed in humans with AMI is reproduced.
- To incorporate new pre and postdoctoral researchers to our group.


MAIN LINES OF RESEARCH

- Identification and characterization of estradiol-regulated miRNA in endothelium and acute myocardial infarction murine model.
- Identification of new sex hormone-regulated signaling pathways in endothelium.
- Interaction of sex hormones with pro-atherogenic factors.
- Sex differences in cardiovascular research.
- Vascular effects of sex hormones-

RESEARCH PROJECTS

Reference: COST Action CA21153
Title: Network for implementing multiomics approaches in atherosclerotic cardiovascular disease prevention and research (AtheroNET)
Principal Investigator: Paolo Magni (Susana Novella as secondary partner Management Committee and Grant Award Coordinator (Leadership position)).
Funding body: European Commission
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2026

Reference: PI22/01083
Title: *Mecanismos moleculares de las rutas de señalización de los miRNA modificados por infarto agudo de miocardio. Influencia del sexo y el envejecimiento*
Principal Investigator: Susana Novella and Carlos Hermenegildo
Funding body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025 extended 2027
Total Budget: €111.320



STRATEGIC AIMS

- To analyze the levels of selected miRNA of acute myocardial infarction patients included in the studies of PI19/01714.
- To analyze the role of estrogen receptors on the regulation of miRNA by estradiol.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
4	17.2	4.3
National collaborations	International collaborations	Corresponding author
0	4	4

- Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies. Kardassis D, Vindis C, Stancu CS, Toma L, Gafencu AV, Georgescu A, Alexandru N et al. VASCULAR PHARMACOLOGY. 2025 march 01. 158107452-107452. DOI:10.1016/j.vph.2024.107452. PMID:39667548. IF: 3,5. Q2
- Divergent mechanisms of cardiovascular remodeling between men and women. 0000-0001-8303-7252, Gerdts,E, Kararigas,G. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 2025 august 11. 329 (2):505-514. DOI:10.1152/ajpheart.00129.2025. PMID:40643438. IF: 4,1. Q1
- Current status and challenges of multi-omics research using animal models of atherosclerosis. Mitic T, Georgescu A, Alexandru N, Davies MJ, Vindis C, 0000-0001-8303-7252, Gerdts E et al. Journal of Molecular and Cellular Cardiology Plus. 2025 september 01. 13100476-100476. DOI:10.1016/j.jmccpl.2025.100476. PMID:40726539. IF: 2,2. Q2
- Biological Sex and Cardiovascular Disease Prevention in Systemic Arterial Hypertension. Gerdts,E, 0000-0001-8303-7252, Devaux,Y, Magni,P, Marti,HP, Sopic,M, Kararigas,G. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2025 november 01. 45 (11):1973-1982. DOI:10.1161/ATVBAHA.125.322092. PMID:40931835. IF:7,4. Q1.

Research Group on Clinical Cardiology

Consolidated
Principal Investigator: Juan Sanchís Forés

GROUP MEMBERS

Staff in the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Juan Sanchís Forés. Hospital/ UV.
- **Recognised Researcher:**
Carlos Eduardo Vergara Uzcategui. INCLIVA/ Hospital
Sergio Garcia Blas. Hospital
Ernesto Valero Picher. Hospital
- **First Stage Researcher:**
Claudio Manuel Rivadulla Varela. Hospital
- **Staff-Nurse:**
Beatriz Silla Sobrecases. Hospital
Georgiana Zaharia. INCLIVA

STRATEGIC AIMS

- Publication of manuscripts in high IF journals.
- CIBER Cardiovascular.
- Development of FIS projects.

MAIN LINES OF RESEARCH


- Investigation line in interventional cardiology: Effect of changes in antigen carbohydrate 125 levels before percutaneous aortic valve prosthesis implant on prognosis after implantation.
- Plaque modification in calcified chronic total occlusions: the PLACCTON study.
- Prospective application of a bleeding and ischemic risks-adjusted antithrombotic protocol in elderly patients revascularized with everolimus-eluting stents: EPIC05-Sierra75 study.
- Research line in acute coronary syndrome: Randomized comparison between invasive and conservative strategies in frail elderly patients with non-ST-segment elevation myocardial infarction (MOSCA-FRAIL).
- Research line in heart failure:. - Beta Blocker Treatment Withdrawal in Patients with Heart Failure with Preserved Systolic Function and Evidence of Chronotropic Incompetence.
- Short-term effects of dapagliflozin on peak oxygen consumption in type 2 diabetic patients with heart failure with reduced systolic function.

TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PI23/01863
Title: Estrategia invasiva rutinaria y abordaje global sobre la fragilidad en ancianos frágiles sin discapacidad con infarto de miocardio sin elevación del segmento ST: El ensayo clínico aleatorizado MOSCA-FRAIL II.
Principal Investigator: Sergio García Blas
Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2026
Total budget: €103.750



JOURNAL PUBLICATION

Number of Publications	IF	Average FI
31	264.6	8,53
National collaborations	International collaborations	Corresponding author
25	6	25

- Prediction of left ventricular thrombus after myocardial infarction: a cardiac magnetic resonance-based prospective registry. Bertolin C, Marcos V, Merenciano H, Perez N, Pérez Del Villar C, Gavara J, Lopez MP et al. European Journal of Internal Medicine. 2025 january 01. 131104-112. DOI:10.1016/j.ejim.2024.09.015. PMID:39384454. IF: 6,10. Q1
- Effect of exercise training in patients with chronotropic incompetence and heart failure with preserved ejection fraction: the TRAINING-HR randomized clinical trial. Palau P, de Amo I, Núñez G, Flor C, de la Espriella R, García C, Berlanga SE et al. European Journal of Preventive Cardiology. 2025 may 09. 33 (2):265-275. DOI:10.1093/eurjpc/zwaf269. PMID:40294211. IF: 7,50. Q1
- NT-proBNP to guide risk stratification after cardiac rehabilitation in patients with ST-segment elevation myocardial infarction. Pérez N, De Dios E, Gavara J, Ríos C, Marcos V, Merenciano H, Bertolín C et al. European Journal of Internal Medicine. 2025 july 01. 13783-89. DOI:10.1016/j.ejim.2025.04.027. PMID:40316461. IF: 6,10. Q1
- Heart Failure in Advanced Chronic Kidney Disease Overlooked No More. De la Espriella R, Górriz JL, Cobo M, Marques M, Seller J, Méndez A, Soler MJ et al. JACC-Heart Failure. 2025 september 01. 13 (9):102581-102581. DOI:10.1016/j.jchf.2025.102581. PMID:40730127. IF: 11,80. Q1
- Longitudinal Assessment of Spot Urinary Sodium as Predictor of Clinical Outcomes in Chronic Heart Failure. Lorenzo M, Núñez E, De la Espriella R, Carratalá A, Rodríguez E, Górriz JL, Valls N et al. JACC-Heart Failure. 2025 december 01. 13 (12):102467-102467. DOI:10.1016/j.jchf.2025.03.028. PMID:40372298. IF: 11,80. Q1

THESIS

Thesis title: Utility of isolated determination of urinary sodium in the follow-up of outpatients with congestive heart failure
Type: Thesis Doctoral
Doctoral candidate: Miguel Lorenzo Hernández
Director(s): Dr. Julio Núñez Villota and Dr. Juan Sanchís Forés
University: Universitat de València (Estudi General)
Date of the defense: 23/05/2025
Grade: Sobresaliente
Quality recognition/Award: Cum Laude

Thesis title: Biomarcadores predictivos de fragilidad tras infarto agudo de miocardio
Type: Thesis Doctoral
Doctoral candidate: Adela Pozo Giráldez
Director(s): Juan Sanchis Forés and Enrique Rodríguez Borja
University: Universitat de València (Estudi General)
Date of the defense: 17/12/2025
Grade: Sobresaliente
Quality recognition/Award: Cum Laude

Research Group for the Prevention of Cardiovascular Risk in Children and Adolescents

Consolidated
Principal Investigator: Empar Lurbe Ferrer

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Empar Lurbe Ferrer. UV
- **Established Researcher:**
Francisco Aguilar Bacallado. UV
Maria Isabel Torro Domenech. UV
- **Recognised Researcher:**
Julio Carlos Alvarez Pitti. UV
- **First Stage Researcher:**
Ana De Blas Zapata. UV
- **Staff-Collaborating Researcher:**
Juan Jose Alcon Saez. UV
Rafael Gomez Zafra. UV
Nuria Garcia Carbonell. UV


STRATEGIC AIMS

The iPEDITEC Unit brings healthcare workers into daily contact with engineers developing software for signal capture through mobile devices. Studying the psychological parameters that facilitate personalized therapy has been a priority aim during 2025, resulting in improved treatment of obese paediatric patients in the Unit.

- The PAIDO Program is focused on personalized medical care extended through initiatives involving family, educators, nutritionists, physical education teachers and other social agents. Treatment goes beyond the hospital setting to include the child’s environment and personal sphere and is supported by state-of the art artificial intelligence technologies.
- Improve understanding of the influence of foetal life and postnatal growth on the development of cardiometabolic risk factors early in life. The KITE cohort is a prospective study starting at birth and assessing the determinants of cardiometabolic risk factors in the first decades of life. Analysis of the interaction between clinical data and available omics data from the umbilical cord may help to introduce actions at critical life stages and make a potential contribution to reducing cardiometabolic disease later in life. Dr Lurbe is the coordinator of the new document of the European Guidelines on Arterial Hypertension in Children and Adolescents.

MAIN LINES OF RESEARCH

- “Preventing lifetime obesity by early risk-factor identification, prognosis and intervention”. Record number: ep-rObes101080219.
- Arterial hypertension in children and adolescents.
- Cardiovascular and renal risk in diabetes.
- Childhood obesity: New insights in personalized treatment: Study of the cardiorespiratory capacity.
- Early origins of cardiometabolic risk factors assessed in a prospective study starting at birth (Cohort KITE).
- HyperChildNET: European Network for Research on Blood Pressure in Children and Adolescents.
- New technologies applied to the detection of congenital heart diseases and sepsis in asymptomatic newborn babies.
- New technologies applied to the treatment of obesity: Physical exercise preventing and treating obesity.



TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PI20/00269
Title: *Impacto del peso al nacer y el patrón de crecimiento en los factores de riesgo cardiometabólico en adolescentes pos-tpuberales: aproximación clínica y molecular*
Principal Investigator: Empar Lurbe i Ferrer
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2021-2023 extended to 2025
Total budget: €174,845

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
9	22.9	3.27
National collaborations	International collaborations	Corresponding author
5	4	4

- Emerging cardiovascular risk factors in childhood and adolescence: a narrative review. De Blas Zapata,A, Sastre Albiach,-JM, Baixauli López,L, Lopez Ruiz,R, Alvarez Pitti,J. EUROPEAN JOURNAL OF PEDIATRICS. 2025 april 14. 184 (5):298-298. DOI:10.1007/s00431-025-06102-y. PMID:40229626. IF: 2,60. Q1
- Hypertension in children with intellectual disabilities: a population not to be overseen. Wyszynska,J, Luszczki,E, Seeman,T, Simonetti,GD, Nyankovska,O, Wójcik,M, Koziol Kozakowska,A et al. JOURNAL OF HYPERTENSION. 2025 august 01. 43 (8):1277-1285. DOI:10.1097/HJH.0000000000004052. PMID:40421509. IF: 4,20. Q1
- Blood pressure values in healthy normal weight children and adolescents in eight European countries: auscultatory and oscillometric measurements. E L, RO C, GM, D, E S, VHC, ZK et al. European Journal of Internal Medicine. 2025 september 01. 139106382-106382. DOI:10.1016/j.ejim.2025.06.011. PMID:40541458. IF: 6,10. Q1 Editorial: Verdecchia P, Banati P. Modern data on blood pressure distribution in European children and adolescents. Eur J Intern Med. 2025 Sep; 139:106414. doi: 10.1016/j.ejim.2025.07.010. Epub 2025 Jul 12. PMID: 40653392.

- Taking a closer look at the early onset of childhood obesity risk. Lurbe E, Álvarez J, Sastre JM, Aguilar F. ANALES DE PEDIATRIA. 2025 december 01. 103 (6):504037-504037. DOI:10.1016/j.anpede.2025.504037. PMID:41271536. IF: 2,10. Q2
- Reflexiones sobre los orígenes del riesgo de obesidadinfantil. Lurbe E, Alvarez J, Sastre JM, Aguilar F. ANALES DE PEDIATRIA. 2025 december 01. 103 (6):DOI:10.1016/j.anpedi.2025.504037. IF: 2,10. Q2

THESIS

Thesis title: Vascular phenotype and markers of inflammation in overweight children and adolescents
Type: Doctoral Thesis
Doctoral candidate: Ana de Blas Zapata
Director(s): Dra. Empar Lurbe Ferrer and Dr. Julio Carlos Álvarez Pitti
University: Universitat de València (Estudi General)
Defence date: 09/05/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Cardiometabolic Research Group on Primary Care

Consolidated


Principal Investigator: Jorge Navarro Pérez

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Jorge Navarro Pérez. Primary Care/ UV
- **Established Researcher:**
Carolina Mir Sanchez. Primary Care/ UV
Jose Luis Trillo Mata. Primary Care
Alvaro Bonet Pla. Primary Care
- **Staff-Technician:**
Ismael Ejarque Domènech. Primary Care
Canales Luz De Myotanh Vázquez. Primary Care
Ester Robles Pastor. Primary Care
Paula Sala Ivars. Primary Care
Maria Aida Andreu Lledo. Primary Care
Idoia Aramburu Aizpiri. Primary Care
Verónica Ausina Márquez. Primary Care
Sofia Bauer Izquierdo. Primary Care
Alberto Belenguer Guillot. Primary Care
Esther Carrion Albert. Primary Care
María Consuelo Ferrús Domingo. Primary Care
M Jose Garzón Nieto. Primary Care
Margarita Giménez Loreiro. Primary Care
Marina Gimeno Gimeno. Primary Care
Ricardo Gonzalez Espadas. Primary Care/ UV
Verónica Lozano Rodríguez. Primary Care
Cristina Mas Lazaro. Primary Care
Tamara Miravalls Perez. Primary Care
Alex David Misle Morales. Primary Care
Lucia Navarro Salvador. Primary Care
Svitlana Nikítina Osadcha. Primary Care
Oscar Perez Quintana. Primary Care
Aaron Piera Torro. Primary Care
Celia Poveda Rocamora. Primary Care/ UV
Ignacio Ramos Manuel. Primary Care
Eduardo Rovira Cabrera. Primary Care
M Dolores Seligra Borrull. Primary Care
Alexandre Sorribes Ramirez. Primary Care
Vibiana Blanco Alvarado. Primary Care
Maria Isabel Gabaldon Sanchez. Primary Care/ UV
Marisa Gomez Arnero. Primary Care
Enrique Guinot Martinez. Primary Care

Irene Marco Moreno. Primary Care
Carmen Martinez Vernia. Primary Care
Mª Jose Puchades Company. Primary Care
Pablo Sabater Arnaldos. Primary Care
Tomas Sanchez Ruiz. Primary Care
Ruth Uribes Fillol. Primary Care
Maria Pilar Roca Navarro. Primary Care/ UV
Nidia Ruiz Varea. Primary Care
Antonio Fernández Giménez. INCLIVA
Eugenia Avelino Hidalgo. Primary Care
Victoria Gosalbes Soler. Primary Care



STRATEGIC AIMS

- The main objective of the group in 2025 was to consolidate and stabilise its main cardiometabolic research lines with enough members in Primary Care.
- Strengthen collaboration in existing transversal programmes, especially overweight, obesity and metabolic risk, ventricular dysfunction, rare diseases and ageing.
- The group expanded its scope by integrating new areas such as active ageing, liver diseases, paediatric research and vaccinology, and by consolidating research based on Real World Data and Big Data.
- New lines on mental health and genetics were opened, and links with other INCLIVA research groups (internal medicine, cardiology, nephrology and ageing) were reinforced to address inequities, diagnostic and therapeutic inertia and chronic care costs.
- In 2025, the group participated in the project “Salud pública y medicina preventiva de precisión combinando exploración física, hábitos de vida e información genómica: monitorización de la pandemia de obesidad a través de extensión de la Cohorte IMPaCT (OBES-IMPACT)” (PMP22/00003), developed through a collaboration agreement between FISABIO and INCLIVA for the CS Malvarrosa node. Sofía Bauer Izquierdo acted as coordinator of CS Malvarrosa, the centre where project activities were carried out.
- Members of the group also participated in the PRECOZIN study, promoted by the redGDPS Foundation and published in *BMJ Open* in 2025. Within the PRECOZIN Study Group, Sofía Bauer (CS Malvarrosa, Valencia) and María Ferrús (CS Malvarrosa, Valencia) are listed as collaborators, reflecting the group’s contribution from Primary Care.
- In the field of research training, Sonia Giner Molins developed the Master’s Thesis “Más de cien años de vida: factores de estilo de vida asociados a longevidad en población centenaria del Departamento de Salud Valencia-Clínico-Malvarrosa” at the Universitat de València, under the supervision of Gloria Olaso González and Sofía Bauer Izquierdo. This work was also presented as an international scientific communication at the WONCA World Conference, Lisbon (Portugal), under the title “Blue Zone: centenarians’ lifestyle unleashed and primary care innovations for longevity”.
- As additional scientific dissemination, Sofía Bauer Izquierdo co-authored the conference communication “Número necesario para tratar (NNT) y número necesario a vacunar (NNV) en intervenciones de Atención Primaria: una revisión narrativa de la literatura”, published as a poster in *Revista Clínica de Medicina de Familia* in 2025

MAIN LINES OF RESEARCH

- With an initial focus on cardiometabolic research, this group has extended the scope of its activity by integrating new lines such as active ageing, liver diseases and research in pediatrics, and has consolidated research based on big data. It has recently opened new research lines in mental health and genetics.
- We collaborate with other INCLIVA research groups, such as internal medicine, cardiology, nephrology and ageing.
- We have addressed issues such as the cardiovascular impact of risk factors (such as smoking, hypertension and diabetes), gender inequalities in care, the impact of social determinants, diagnostic and therapeutic inertia, potentially inappropriate prescribing, and cost stratification in the chronic population.

RESEARCH PROJECTS

Reference: PI21/01417
Title: *Cribado sistemático de insuficiencia cardíaca en pacientes con diabetes mellitus tipo 2. Estudio piloto*
Principal Investigator: Enrique Santas Olmeda and Jorge Navarro Pérez
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2024 extended to 2025
Total Budget: €90,871

Reference: S2/4.5/F0249
Title: *SUDOE. Evaluación de la Salud bucoDental en las zonas Rurales. ESOR.*
Principal Investigator: Verónica Ausina Márquez
Funding Body: *European Commission*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2028
Total Budget: €127,527.97

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
7	28.1	4.01
National collaborations	International collaborations	Corresponding author
6	1	1

- High Positive End-expiratory Pressure (PEEP) with Recruitment Maneuvers versus Low PEEP during General Anesthesia for Surgery: A Bayesian Individual Patient Data Meta-analysis of Three Randomized Clinical Trials. Mazzinari G, Zampieri FG, Ball L, Campos NS, Bluth T, Hemmes SNT, Ferrando C et al. ANESTHESIOLOGY. 2025 january 01. 142 (1):72-97. DOI:10.1097/ALN.0000000000005170. PMID:39042027. IF: 9,20. Q1
- Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial. Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, González L et al. Vaccine. 2025 february 15. 47 DOI:10.1016/j.vaccine.2024.126685. PMID:39809095. IF: 3,50. Q2
- Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study. Díaz J, Saurí I, Redon J, Navarro J, Fernández G, Hurtado C, Ferreira K et al. Journal of Clinical Medicine. 2025 april 03. 14 (7): DOI:10.3390/jcm14072441. PMID:40217891. IF: 2,90. Q1
- Effect of left bundle branch block on maximal functional capacity in asymptomatic individuals without structural heart disease. Palau P, Domínguez E, Mínguez S, Núñez G, Santas E, García C, de Amo I et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 november 01. 78 (11):957-966. DOI:10.1016/j.rec.2025.03.001. PMID:40122231. IF: 4,90. Q1
- Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study. López MJ, Vazquez MD, Alvarez M, Arribas JR, Arana E, Muñoz P, Navarro J et al. Human Vaccines & Immunotherapeutics. 2025 december 31. 21 (1): DOI: 10.1080/21645515.2025.2474775. PMID:40304691. IF: 3,50. Q2

THESIS

Thesis title: Análisis predictivo de la utilización de recursos y costes de la diabetes mellitus tipo 2 según riesgo renal y fragilidad, utilizando Real WORD data.
Type: Doctoral Thesis
Doctoral candidate: Maria Inmaculada Saurí Ferrer
Director(s): Dr Josep Redón Más, Dr Rut Uso Talamantes, and Jose Luis Trillo Mata
University: Universitat de València (Estudi General)
Defence date: 26/02/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Work title: Exercici, envelliment i genere en Atenció Primària.
Type: Final year Project
Candidate: Marina Carrillo Sala
Director(s): Dr Jorge Navarro Pérez
University: Universitat de València (Estudi General)
Defence date: 15/04/2025
Grade: Excellent
Quality recognition/Award: First-class honours

Work title: Cribado oportunista desde atención primaria de enfermedad hepática en población general con factores de riesgo.
Type: Final year Project
Candidate: Teresa Pérez Aguado
Director(s): Dr Jorge Navarro Pérez
University: Universitat de València (Estudi General)
Defence date: 15/04/2025
Grade: Excellent

Research Group on the Study of Cardiometabolic and Renal Risk

Consolidated
Principal Investigators: Josep Redón Mas / Raquel Cortés Vergaz

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025


- Leading Researcher:**
Josep Redón Mas. Hospital
- Established Researcher:**
Raquel Cortés Vergaz. INCLIVA
Fernando Martínez García. Hospital /UV
M^a Jose Forner Giner. Hospital /UV
M^a José Galindo Puerto. Hospital /UV
- Recognised Researcher:**
M^a Jose Fabia Valls. Hospital /UV
Elena Furio Rodríguez. Hospital
Adrian Ruiz Hernandez. Hospital
- Recognised Emerging Researcher:**
Anaïs Corma Gómez. Hospital
David Martí Aguado. Hospital
Ana María Ortega Gutiérrez. INCLIVA
- First Stage Researcher:**
Lesley Escriva Ardid. INCLIVA
Sara Vela Bernal. Hospital /UV
David Ruiz Raga. Hospital
Ana Flores Chova. INCLIVA
- Staff-Administrative Assistant:**
Iván Colmena Martínez. INCLIVA
- Staff-Collaborating Researcher:**
Alba Morales Cano. INCLIVA
Javier Díaz Carnicero. INCLIVA
Elena Solaz Moreno. Hospital /UV
- Staff-Nurse:**
Beatriz Peris Cuenca. INCLIVA
- Staff-Technician:**
Antonio Fernández Giménez. INCLIVA
Alba María Oltra Gómez. INCLIVA
Ernesto Peralta Macías. INCLIVA
Carlos Muñoz García. INCLIVA
Augusto Javier Ibáñez García. INCLIVA
Carlos Baeza Delgado. INCLIVA
Galán Manuel Ochoa Pareja. INCLIVA
María Inmaculada Saurí Ferrer. INCLIVA
Marta Méndez Debaets. INCLIVA

Emerging Researcher

Anaïs Corma Gómez
Dr Anaïs Corma’s main research line is focused on HIV prevention, sexually transmitted infections (STIs), and viral hepatitis, integrating epidemiological, clinical, and implementation research approaches. She coordinates a large national multicentre PrEP cohort in Spain, including more than 10,000 users, aimed at generating real-world evidence on HIV prevention, STI dynamics, adherence, retention, and predictive modelling.
Her work also includes developing community-based implementation strategies for HIV and HCV micro-elimination in vulnerable populations, with a particular focus on outreach interventions, emerging infections, and inequities in access to prevention and care. Additionally, she leads projects applying artificial intelligence and predictive modelling to HIV, HCV, and STI-related outcomes.

David Martí Aguado
He coordinates an international registry named “Virtual Liver Biopsy” that aims to generate and integrate multidimensional data to model computational tools based on Artificial Intelligence that define the biological processes involved in the phenotypic variability of MASLD, and to identify a disease signature that predicts risk of progression.

Ana María Ortega Gutiérrez
Dr Ana Ortega Gutiérrez’s main research line is centred on cellular and molecular bases and the search for biomarkers of renal damage derived from hypertension and diabetes. Different molecules (Rab GTPases, sirtuins, cell markers, miRNA, exosomes...) are analysed in urine and plasma patient samples and renal cell cultures in which in vitro cellular models have been developed to decipher the mechanisms and pathways in which these biomarkers participate and their implication in the onset and/or treatment of incipient renal damage.



STRATEGIC AIMS

- Analyse changes in podocytes and RPTEC (such as ncRNAs, apoptosis) and their intercellular communication (extracellular vesicles) under renal damage conditions.
- Identify circulating and exosomal non-coding RNA-mRNA interaction networks associated with renal damage progression.
- Characterize extracellular vesicle cargos through antigen surface, ncRNA and single vesicle analysis associated with renal damage.
- Develop an advanced diagnostic model to predict renal damage in hypertensive, diabetic or systemic lupus patients, combining levels of EV markers (surface and miRNA signatures) by supervised machine learning.
- Integrate metabolomics and genomics in the study of factors related to the development of cardiorenal damage.
- Develop studies for noninvasive hemodynamic characterization in vascular pathology.
- Analyse morbidity and mortality linked to the presence of hypertension and renal injury.

- Develop biomarkers in autoimmune diseases.
- Perform genetic studies related to obesity and overweight.
- Characterize and determine cardiovascular risk and alterations in renal function in HIV infected and HIV/HBV-HCV co-infected patients.
- Assess the comorbidities of patients with HIV and their impact on the development of frailty and quality of life.
- Develop biomarkers to diagnose and predict clinical events in patients with HIV infection, viral hepatitis and other infectious pathologies.
- Big Data and AI in primary and secondary uses in health.
- Develop phase III and IV clinical trials.

MAIN LINES OF RESEARCH

- Analysis of podocyte-renal proximal tubular epithelial cell communication as a key player in kidney damage progression (miRNAs and exosomes).
- Big Data and artificial intelligence (AI).
- Environmental epidemiology: exposome and genetic interaction.
- Factors associated with venous thrombosis.
- Genomics, proteomics and metabolomics of early cardiometabolic and renal disorders.
- Identification of polymorphisms related to control of BMI and waist circumference and the risk of obesity genes.
- Impact of cardiovascular risk factors and renal function in absolute morbidity and mortality in high-risk populations and in the general population.
- Impact of environmental toxins (metals) in cardiometabolic risk.
- Infectious diseases, cardiometabolic risk and clinical events.
- Inflammation and oxidative stress in chronic diseases.
- Molecular characterization of extracellular vesicles as biomarkers and intermediators in renal damage progression (ncRNA, surface antigens).
- Molecular mechanisms associated with activity changes and renal damage development in systemic lupus erythematosus.
- Relationship between risk of venous thromboembolic disease and arteriosclerosis.

TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PI21/00249
Title: *Identificación de ARN no codificantes en biopsia líquida con énfasis en exosomas como biomarcadores pronóstico de actividad en el lupus eritematoso sistémico. Implicación fisiopatológica en el daño renal*
Principal Investigator: Raquel Cortés Vergaz and M^a José Forner Giner
Funding body: *Instituto de Salud Carlos III* -Co-financed FEDER
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2026
Total budget: €135,520

Reference: PI23/01179
Title: *Caracterización de vesículas extracelulares para la identificación de biomarcadores de daño renal incipiente en pacientes diabéticos albuminúricos y no albuminúricos. Estudio clínico-experimental.*
Principal Investigator: Ana María Ortega Gutiérrez
Funding body: *Instituto de Salud Carlos III* -Co-financed FEDER
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total budget: €165,000
Reference: PI24/0736
Title: *Desarrollo de un modelo predictivo de infecciones de transmisión sexual en personas usuarias de profilaxis pre-exposición frente al VIH en España.*
Principal Investigator: Anaïs Corma Gómez
Funding body: *Instituto de Salud Carlos III* -Co-financed FEDER
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2027
Total budget: €77,500

Reference: CNS2022-136175
Title: Supervised learning algorithms to predict lupus nephritis based on extracellular vesicles markers (ExoLN)
Principal Investigator: Raquel Cortés Vergaz
Funding body: *Ministerio de Ciencia e Innovación*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €120,395

Reference: INTEGRA-CLOUD
Title: Creación de una plataforma abierta de acceso, captura, almacenamiento e intercambio descentralizado de los datos de salud en tiempo real del Departamento de Salud Clínico-Malvarrosa para la computación cloud-edge de sistemas predictivos, de toma de decisiones y de inteligencia artificial
Principal Investigator: Josep Redón i Mas
Funding body: *Ministerio de Asuntos Económicos y Transformación Digital*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €5,252,273.94

Reference: TSI-100121-2024
Title: *Creación del ecosistema Valenciano de Datos Sanitarios Integrando los Departamentos de Salud Clínico Malvarrosa, Gandía y Sagunto.*
Principal Investigator: Josep Redón i Mas
Funding body: *Ministerio para la Transformación Digital y de la Función Pública*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total budget: €1,048,930

Reference: SEED 2021. 2021/373
Title: *Cuantificación de la hemoglobina fecal para la estadificación del riesgo de neoplasia en pacientes incluidos en el programa de cribado de cáncer colorrectal.*
Principal Investigator: David Martí Aguado
Funding body: *Fundación Sociedad Española de Endoscopia Digestiva. SEED*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2021-2025
Total budget: €15,000

Reference: 2024/064
Title: *Deep Liver Biopsy: moving towards prognosis and monitoring MASLD.*
Principal Investigator: David Martí Aguado
Funding body: *Fundación Española para el estudio del hígado*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total budget: €36,000

Duration: 2023-2025
Total budget: €145,671.38

Reference: 101095480- Hypermarker
Title: Personalised pharmacometabolomic optimisation of treatment for hypertension
Principal Investigator: Josep Redón i Mas
Funding body: *European Comission*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2026
Total budget: €400,000

Reference: 2025/161 Guilead Scholar Program
Title: *The exPrEPsso Study: Ensuring Equitable Access and Retention in PrEP care in Spain*
Principal Investigator: Anaïs Corma Gómez
Funding body: *Guilead Sciences, INC*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2027
Total budget: €108,713.83

Reference: EU4H-2022-JA-03
Title: Multimodal Engagement and sustainable Lifestyle Interventions Optimizing breast cancer Risk reduction supported by Artificial intelligence. MELIORA. Dra. Cristina Hernando 2023
Principal Investigator: Clara Bonanad Lozano and Josep Redón i Mas
Funding body: *European Comission*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2027
Total budget: €758,377

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
30	165.8	5.92
National collaborations	International collaborations	Corresponding author
18	10	11

Reference: INTEGRA-DPs
Title: *Creación del ecosistema Valenciano de Datos Sanitarios Integrando los Departamentos de Salud Clínico Malvarrosa, Gandía y Sagunt.*
Principal Investigator: Josep Redón i Mas
Funding body: *Fundación Española para el estudio del hígado*
Beneficiary institution: *Ministerio para la Transformación Digital y de la Función Pública*
Duration: 2024-2026
Total budget: €1,048,930

Reference: GLD25/00122
Title: *GeoVIH-da: Geospatial strategy for early HIV diagnosis and access to care among underserved populations.*
Principal Investigator: Anaïs Corma Gómez
Funding body: *Gilead Sciences, S.L.U.*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2027
Total budget: €54,999.45

Reference: 945097-WELLBASED
Title: WELLBASED. Improving health, wellbeing and equality by evidenced-based urban policies for tackling energy poverty
Principal Investigator: Josep Redón i Mas
Funding body: *European Commission*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2021-2025
Total budget: €395,250

Reference: 101083002- INNDIH
Title: *Valencia Region Digital Innovation Hub*
Principal Investigator: Josep Redón i Mas
Funding body: *European Comission*
Beneficiary institution: *Inndromeda, Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €231,595.42

Reference: EUR00151- InnDIH
Title: *Valencia Region Digital Innovation Hub*
Principal Investigator: Josep Redón i Mas
Funding body: *Consellería Educación/ Innovación, Universidades, Ciencia y Sociedad Digital/ Empleo. Y Ministerio de Industria y Turismo*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

- Enrichment of RedoxifibromiR miR-21-5p in Plasma Exosomes of Hypertensive Patients with Renal Injury. Martinez O, Flores A, Mendez M, Martinez S, Martinez F, Forner MJ, Redon J et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 january 01. 26 (2):DOI:10.3390/ijms26020590. PMID:39859307. IF: 4,90. Q1
- Genetic interaction between oxidative stress and body mass index in a Spanish population. Lara F, Melero R, Quiroz ME, Moya C, Gallardo MD, Alvarez L, Valarezo IL et al. Redox Biology. 2025 march 01. 80103531-103531. DOI:10.1016/j.redox.2025.103531. PMID:39923398. IF: 11,90. Q1
- Inhibiting miR-200a-3p Increases Sirtuin 1 and Mitigates Kidney Injury in a Tubular Cell Model of Diabetes and Hypertension-Related Renal Damage. Martinez O, Flores A, Mendez M, Garcia L, Escrivá L, Forner MJ, Redón J et al. Biomolecules. 2025 july 11. 15 (7):DOI:10.3390/biom15070995. PMID:40723868. IF: 4,80. Q1
- Fecal Metabolomics for the Diagnosis of Clostridioides difficile Infection. Bea C, Belmonte A, Pinto C, Ferrer A, Vela S, de Gracia AI, de Castro A et al. Diagnostics. 2025 september 15. 15 (18):DOI:10.3390/diagnostics15182331. PMID:41008703. IF: 3,30. Q1
- Exosomal Specificity of MiR-15a-5p as Marker of Activity, Renal Damage, and Disease Flares in Systemic Lupus Erythematosus. Flores A, Martinez O, Puertes A, Vela S, Gorriz JL, Solis MA, Terradez L et al. AMERICAN JOURNAL OF NEPHROLOGY. 2025 october 01. 56 (5):529-542. DOI:10.1159/000544854. PMID:40081350. IF: 3,20. Q1

THESIS

Thesis title: Análisis predictivo de la utilización de recursos y costes de la diabetes mellitus tipo 2 según riesgo renal y fragilidad, utilizando Real WORD data.

Type: Doctoral Thesis

Doctoral candidate: María Inmaculada Saurí Ferrer

Director(s): Dr Josep Redón i Mas, Dr Ruth Uso Talamantes and Dr Jose Luis Trillo Mata

University: Universitat de València (Estudi General)

Defence date: 26/02/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Thesis title: Análisis de los factores predictores de transmisión materno fetal de la infección por VIH en una cohorte de gestantes entre 1984 a 2018.

Type: Doctoral Thesis

Doctoral candidate: Marta Montero Alonso

Director(s): Dr Maria José Galindo Puerto and Dr Alfredo Perales Marin

University: Universitat de València (Estudi General)

Defence date: 27/03/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Thesis title: Nuevas metodologías docentes en la Facultad de Medicina de la Universitat de València.

Type: Doctoral Thesis

Doctoral candidate: Conrado Fernández Rodríguez

Director(s): Dr Raúl Tárraga Mínguez and M^a José Forner Giner

University: Universitat de València (Estudi General)

Defence date: 30/07/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Research Group on Vascular Function

Consolidated

Principal Investigators: Jose María Vila Salinas / Maria Dolores Mauricio Aviñó

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Jose Maria Vila Salinas. UV
Maria Dolores Mauricio Aviño. UV
- **Established Researcher:**
Victor Manuel Victor Gonzalez. UV
Martin Aldasoro Celaya. UV
- **Recognised Researcher:**
Adrian Jorda Valles. UV
Lilian Soraya Valles Marti. UV
Solanye Guerra Ojeda. UV
Andrea Suarez Fortea. UV
Begoña Belmonte Alonso. UV
- **First Stage Researcher:**
Clara Luna Marco. INCLIVA

STRATEGIC AIMS

- Vascular changes associated with different pathologies.
- Regulation of blood flow.
- Study of molecular mechanisms involved in cardiometabolic diseases.

MAIN LINES OF RESEARCH

- Antioxidants targeting mitochondria: application to cardiometabolic diseases.
- Cardiovascular effects of SGLT-2 inhibitors in metabolic syndrome.
- Characterization of alterations in the control of vascular tone and endothelial function induced by aging.
- Characterization of calcium channels function in vascular physiology.
- Characterization of vascular alterations in metabolic syndrome.
- Circadian cycle and cardiometabolic diseases.
- Effects of histone deacetylase inhibitors in the treatment of acute myocardial infarction.
- Mechanism of action of anti-diabetic drugs: molecular mechanisms.
- Mitochondrial-endothelial dysfunction in cardiometabolic diseases.
- Novel nanoparticles and antioxidant compounds for the treatment of diseases.
- Physical exercise in obesity and diabetes: effect on endothelial function.
- Physiology and physiopathology of type 2 diabetes.
- Study of autophagy and endoplasmic reticulum stress in type 2 diabetes and obesity.
- Vascular alterations in acute myocardial infarction.
- Vascular effects of nanoparticles.


RESEARCH PROJECTS

Reference: PI22/00424

Title: *Nuevas perspectivas en la relación mitofagia, autofagia y disfunción mitocondrial en la diabetes tipo 2: implicaciones clínicas y complicaciones cardiovasculares asociadas*

Principal Investigator: Víctor Manuel Víctor González

Funding body: Instituto de Salud Carlos III -Co-financed FEDER



Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2023-2025 extended to 2026

Total budget: € 171,820

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
13	64.7	4.97
National collaborations	International collaborations	Corresponding author
12	1	11

- Sodium valproate reverses aortic hypercontractility in acute myocardial infarction in rabbits. Guerra S, Suarez A, Belmonte B, Marchio P, Genoves P, Arias OJ, Aldasoro M et al. European Journal of Pharmacology. 2025 february 05. 988177216-177216. DOI:10.1016/j.ejphar.2024.177216. PMID:39706463. IF: 4,70. Q:1
- Pomegranate Extract Modulates Oxidative Stress by Reducing Basal ROS Levels and Protecting White Blood Cells from Induced Oxidative Damage in Aging Mice. Verdú D, Valls A, Serna M, Herrera G, Ezzeddin M, Mauricio MD, Viña J et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 june 20. 26 (13):DOI:10.3390/ijms26135957. PMID:40649737. IF: 4,90. Q:1
- The Mitochondrial Puzzle: Why Obesity Affects Insulin Sensitivity Differently in Black and White Women. Vezza,T, Víctor,VM. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2025 august 01. 110 (8):2793-2794. DOI:10.1210/clinem/dgae686. PMID:39353066. IF: 5,10. Q:1
- Differential contribution of T-type voltage-gated calcium channels to vascular reactivity in the aorta and renal artery of healthy rabbits. Suarez A, Guerra S, Zarzoso M, Serna M, Vila JM, Serna E, Mauricio MD. EXPERIMENTAL PHYSIOLOGY. 2025 october 27. DOI:10.1113/EP093044. PMID:41145982. IF: 2,80. Q:2
- Cardiorespiratory fitness as a key predictor of metabolic, inflammatory, and oxidative stress biomarkers in adults with different physical activity levels. Hernández OA, Murillo B, Luna C, Cacace J, Hermo A, Ramírez V, Guevara M et al. FREE RADICAL BIOLOGY AND MEDICINE. 2025 december 01. 240735-744. DOI: 10.1016/j.freeradbiomed.2025.08.058. PMID:40889726. IF: 8,20. Q:1

THESIS

Thesis title: Efectos del ácido valproico sobre la función de la aorta abdominal en conejos con infarto agudo de miocardio.

Type: Doctoral Thesis

Doctoral candidate: Begoña Belmonte Alonso

Director(s): Dr Maria Dolores Mauricio Aviñó, Dr Eva Serna García and Dr Solanye Guerra Ojeda.

University: Universitat de València (Estudi General)

Defence date: 14/07/2025

Research Group on Paediatric Nutrition


Consolidated

Principal Investigator: Cecilia Martínez Costa

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Cecilia Martinez Costa. Hospital /UV
Javier Buesa Gomez. Hospital /UV
- **Established Researcher:**
Jose Vicente Arcos Machancoses. Hospital/ UV
Elena Crehua Gaudiza. Hospital /UV
Francisco Javier Estañ Capell. Hospital /UV
Laura Martínez Rodríguez. Hospital
Francisco Nuñez Gomez. Hospital /UV
- **Recognised Researcher:**
Elena Cubells Garcia. Hospital
Jose Luis Lopez-Prats Lucea. Hospital
Patricia Roselló Millet. Hospital
Angel Vicente Valls Arévalo. Primary Care
Ana Paula Grattarola Suárez. INCLIVA
- **First Stage Researcher:**
Ana Barres Fernandez. Hospital
Laura Núñez Martínez. Primary Care
Alba Peretó Moll. Hospital
Vicente Posadas Blazquez. Hospital
- **Staff- Nurse:**
Maria Angeles Montal Navarro. Hospital /UV
- **Staff- Technician:**
Isidro Robredo García. INCLIVA
Inmaculada Tarazona Casany. Hospital




STRATEGIC AIMS

- Cardiovascular area:
Study metabolome and microbiome in obese children with/without insulin resistance before and after personalized nutritional intervention and physical exercise.
- Area of human milk:
Characterise mother–infant microbiome in term and preterm infants. Influence of perinatal variables.
- Area of hospital malnutrition and artificial nutrition:
Validate paediatric screening tools for detecting the risk of malnutrition linked to chronic disease and paediatric hospitalization.

MAIN LINES OF RESEARCH

- Area of hospital malnutrition and artificial nutrition: Validate paediatric screening tools for detecting risk of malnutrition.
- Multicentre study of acceptance and quality of life in children treated with home enteral nutrition.
- Area of human milk: Analysis of nutritional and bioactive components in human milk:
- Influence of genotype FUT2 on oligosaccharides.
- Analyse mother–fetal microbiome in term and preterm infants. Influence of delivery mode, maternal diet and development. Impact on host response and intestinal function
- Cardiovascular area: Analysis of microbiota in obese children before and after intervention.
- Analysis of microbiota in obese children with/without insulin resistance.



- Analysis of metabolome in obese children with/without insulin resistance.
- Monitoring exercise and energy consumption in obese school-children and teenagers to adjust nutritional intervention.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
12	61.1	5.55
National collaborations	International collaborations	Corresponding author
7	3	8

- Time to positivity of Coagulase Negative Staphylococcus In Neonatal Blood Cultures as an adjunct tool to help discriminate between sepsis and contamination. Carbonell S, Olea B, Pérez R, Giménez E, Colomina J, Navarro D, Estañ J. Journal of Perinatology. 2025 january 01. 45 (1):111-115. DOI:10.1038/s41372-024-02158-0. PMID:39488666. IF: 2,40. Q1.
- Growth and gastrointestinal tolerance of healthy formula-fed infants: a multicentre, prospective observational study. Blesa L, Albors A, Samblas P, Maragat U, Coronel C, Abad B, Viciano E et al. BMC Pediatrics. 2025 march 25. 25 (1):229-229. DOI:10.1186/s12887-025-05446-6. PMID:40128711. IF: 2. Q2.
- Cost-utility analysis of sequential therapies for pediatric-onset eosinophilic esophagitis. Arcos JV, Crehuá E, Martínez C. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. 2025 august 01. 81 (2):295-303. DOI:10.1002/jpn3.70106. PMID:40485534. IF: 2,70. Q1.
- Impact of Nirsevimab immunoprophylaxis on professional exhaustion during two epidemics of respiratory syncytial virus. Barrés A, Calderon C, Ferrando S, Castillo S, Fullana M, González SI, Arcos JV. Journal of Pediatric Nursing-Nursing Care of Children & Families. 2025 september 01. 8482-87. DOI:10.1016/j.pedn.2025.05.018. PMID:40414172. IF: 2,30. Q1.
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids. Santiso C, Randazzo W, Carmona N, Peña N, Cárcamo R, Lopez S, Navarro N et al. Gut Microbes. 2025 december 31. 17 (1):2469716-2469716. DOI:10.1080/19490976.2025.2469716. PMID:40032727. IF: 11. Q1

Group on Translational Research in Ischemic Heart Disease

Consolidated
Principal Investigator: **Vicent Bodí Peris**

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Vicent Bodí Peris. Hospital /UV
- **Established Researcher:**
Amparo Ruiz Sauri. UV
- **Recognised Researcher:**
Josep Gavara Doñate. INCLIVA
Daznia Loiret Bompert Berroteran. INCLIVA
Francisca Esteve Claramunt. UV
César Rios Navarro. UV
- **Recognised emerging Researcher:**
Victor Marcos Garcés. Hospital
Clara Bonanad Lozano. Hospital /UV
- **First Stage Researcher:**
Carlos Ángel Bertolín Boronat. INCLIVA
Tamara Molina García. UV
Andrea Arroyo Álvarez. INCLIVA
Héctor Manuel Merenciano González. Hospital
Nerea Júlia Pérez Solé. INCLIVA
Elena Victoria de Dios Lluch. CIBERCV
- **Staff-Collaborating Researcher:**
Joaquin Canoves Femenia. Hospital
- **Staff-Nurse:**
Gema María Torres Fontes. Hospital
- **Staff-Technician:**
Daniela Alejandra Maidana Benítez. INCLIVA
Guillermo Barreres Martín. INCLIVA
Carles Muñoz Alfonso. INCLIVA
Javier Damiá Escrig. INCLIVA


Emerging Researcher

Clara Bonanad Lozano

Her line of research aims to evaluate the impact of geriatric syndromes and residual risk, specifically dyslipidaemia and inflammation, in patients with non-ST-segment elevation acute coronary syndrome.

Victor Marcos Garcés

His line of research is focused on clinical and preventive cardiology, cardiac rehabilitation and cardiac imaging techniques.



STRATEGIC AIMS

- Drawing upon our research experience of recent years in the clinical and experimental field related to ischemic cardiopathy, our current goal is to focus on a translational approach.
- In 2023 we continued elucidating abnormalities in coronary circulation after myocardial infarction using a swine model. Moreover, we have started to evaluate in vitro the role of endothelial injury after coronary reperfusion and the implication of angiogenesis in recovering microvasculature after myocardial infarction in animal models and patients.
- We have also developed new tools to study patients with ST-segment elevation myocardial infarction using cardiac magnetic resonance imaging.

MAIN LINES OF RESEARCH

- Multicentre registry of patients with chronic coronary syndrome studied with stress cardiac magnetic resonance imaging.
- Porcine and mice models of experimental myocardial ischemia and myocardial infarction for a better understanding of the pathophysiology of ischemia, necrosis, fibrosis, angiogenesis, and reperfusion injury and to test novel therapeutic avenues.
- Prospective registry of patients with first ST-segment elevation myocardial infarction studied with cardiac magnetic resonance imaging at acute and chronic phases.

TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PI23/01150
Title: *Obstrucción microvascular tras un infarto de miocardio. Avances hacia una cuantificación automatizada, biomarcadores basados en técnicas ómicas y una estratificación de riesgo a largo plazo personalizada.*
Principal Investigator: Vicente Bodí Peris y César Ríos Navarro
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total Budget: €71,250

Reference: PI23/01468
Title: *Ferropenia en el SCASEST: valor pronóstico y efecto sobre la inflamación y la inmunosenescencia.*
Principal Investigator: Clara Bonanad Lozano
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total Budget: €96,250

Reference: EU4H-2022-JA-03
Title: *Multimodal Engagement and sustainable Lifestyle Interventions Optimizing breast cancer Risk reduction supported by Artificial intelligence. MELIORA. Dr Cristina Hernando 2023*
Principal Investigator: Clara Bonanad Lozano
Funding Body: *European Commission*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2023-2027
Total Budget: €606,701
Title: *Incidental Coronary ArteRy calciUm in computerized tomography and Statin prescription. The ICARUS registry*
Principal Investigator: Víctor Marcos Gracés
Funding Body: *Sociedad Valenciana de Cardiología*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total Budget: €3,000

Title: *Estrategias para mejorar la tasa de vacunación preventiva en pacientes tras un síndrome coronario agudo durante un programa de rehabilitación cardíaca*
Principal Investigator: Víctor Marcos Gracés
Funding Body: *Sociedad Valenciana de Cardiología*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2026
Total Budget: €2,000

Title: *HI-COR-65: Hierro Intravenoso para Mejorar la Calidad de Vida en Pacientes Mayores con Síndrome Coronario Agudo.*
Principal Investigator: Clara Bonanad Lozano
Funding Body: *Fundación Astrazeneca*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total Budget: €225,000

Title: *Ferropenia, inflamación e inmunosenescencia en el paciente mayor tras SCASEST.*
Principal Investigator: Clara Bonanad Lozano
Funding Body: *Sociedad Española de Cardiología*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2027
Total Budget: €15,000

Title: *Impacto pronóstico de los biomarcadores Klotho alfa y FGF23 en el paciente mayor con SCA de alto riesgo.*
Principal Investigator: Clara Bonanad Lozano
Funding Body: *Fundación Casa del Corazón*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2028
Total Budget: €15,000

Reference: CIPROM/2024/28
Title: *Microvascular injury after myocardial infarction: Advances in the early diagnosis, risk stratification, pathophysiology and resolution.*
Principal Investigator: Vicente Bodí Peris y César Ríos Navarro
Funding Body: *Conselleria Educacion/Innovacion, Universidades, Ciencia Y Sociedad Digital/Empleo*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2029
Total Budget: €581,218

RESEARCH RESULTS

Invention: Lipid nanoparticles and their use in treatment of ischemic heart diseases
Priority Number: EP24389971
Status: PCT extension
Principal Investigator: César Ríos Navarro

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
29	204	7.03
National collaborations	International collaborations	Corresponding author
19	10	16

- Prediction of left ventricular thrombus after myocardial infarction: a cardiac magnetic resonance-based prospective registry. Bertolin C, Marcos V, Merenciano H, Perez N, Pérez Del Villar C, Gavara J, Lopez MP et al. European Journal of Internal Medicine. 2025 january 01. 131104-112. DOI:10.1016/j.ejim.2024.09.015. PMID:39384454. IF: 6,10. Q1.
- Prognostic role of persistent angina after percutaneous revascularization in chronic coronary syndrome with altered angiography and stress CMR. Pérez N, de Dios E, Monmeneu JV, López MP, Gavara J, Ríos C, Marcos V et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 may 01. 78 (5):425-436. DOI:10.1016/j.rec.2024.09.004. PMID:39370100. IF: 4,90. Q1
- NT-proBNP to guide risk stratification after cardiac rehabilitation in patients with ST-segment elevation myocardial infarction. Pérez N, De Dios E, Gavara J, Ríos C, Marcos V, Merenciano H, Bertolín C et al. European Journal of Internal Medicine. 2025 july 01. 13783-89. DOI:10.1016/j.ejim.2025.04.027. PMID:40316461. IF: 6,10. Q1.

- Temporal and Spatial Dynamics in the Regulation of Myocardial Metabolism During the Ischemia-Reperfusion Process. De Dios E, Forteza MJ, Perez N, Molina T, Gavara J, Marcos V, Jimenez M et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 september 10. 26 (18):DOI:10.3390/ijms26188820. PMID:41009389. IF: 4,90. Q1.
- Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation. Marcos Garcés,V, Bertolín Boronat,C, Merenciano González,H, Mas,MLM, Alberola,JIC, Lopez Bueno,L, Rubio,AP et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 november 12. 26 (22):DOI:10.3390/ijms262210964. PMID:41303447. IF: 4,90. Q1


Research Group on Heart Failure

Consolidated
Principal Investigator: Julio Núñez Villota

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Established Researcher:**
Julio Núñez Villota. Hospital /UV
- Recognised Researcher:**
Miguel Lorenzo Hernández. Hospital
Rafael De La Espriella Juan. Hospital
Gema Miñana Escríva. Hospital /UV
Patricia Palau Sampio. Hospital /UV
Enrique Santas Olmeda. Hospital /UV
Laura Lopez Bueno. UV
- First Stage Researcher:**
Cristina Flor Rufino. UV
Iván De Amo Galán. INCLIVA
Gonzalo Núñez Marín. Hospital
Sandra Villar Conejos. Hospital
- Staff-Technician:**
Evelin Idaly Bejarano Sandoval. INCLIVA
Teresa Benito Ferrer. INCLIVA
Carolina Martínez Botella. INCLIVA
Adriana Conesa Bona. INCLIVA
Francisco Javier Cebrián García. INCLIVA



STRATEGIC AIMS

- Phenotypic characterization of heart failure syndrome
- Deepen understanding of pathophysiological mechanisms in different disease phenotypes.
- Develop tools to improve the diagnostic process of heart failure.
- Risk stratification in patients with acute and chronic heart failure.
- Evaluate different therapeutic and monitoring strategies to improve the prognosis of heart failure.

MAIN LINES OF RESEARCH

- Biomarkers discovery in heart failure.
- Effect of dapagliflozin on functional capacity in patients with heart failure and reduced ejection fraction.
- Effect on functional capacity of withdrawal of beta-blockers in patients with heart failure and preserved ejection fraction and chronotropic incompetence.
- Myocardial effects of iron repletion.
- Pathophysiological characterization of heart failure.
- Prevalence and clinical implications of frailty in heart failure.
- Utility of intrarenal Doppler to evaluate intrarenal congestion and its clinical significance.
- Utility of the carbohydrate antigen 125 marker for evaluating congestion and a guide to titrate diuretic treatment.
- Utility of continuous ambulatory peritoneal dialysis to treat patients with heart failure and reduced ejection fraction.
- Utility of leg venous compression in treatment of patients with acute heart failure.

RESEARCH PROJECTS

Reference: PI21/01417
Title: *Cribado sistemático de insuficiencia cardíaca en pacientes con diabetes mellitus tipo 2. Estudio piloto*
Principal Investigator: Enrique Santas Olmeda and Jorge Navarro Pérez
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2024 extended to 2025
Total budget: €90,871

Reference: PI22/01948
Title: *Congestión como potencial catalizador de la progresión de la enfermedad renal crónica*
Principal Investigator: Rafael de la Espriella Juan and José Luis Górriz Teruel
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €87,120

Reference: PI22/00535
Title: *Efectos de un programa de entrenamiento físico supervisado en pacientes con insuficiencia cardíaca y función sistólica preservada e incompetencia cronotrópica sobre capacidad funcional*
Principal Investigator: Patricia Palau Sampio
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €44,770

Reference: PI23/00952
Title: *Terapia compresiva de miembros inferiores en pacientes con insuficiencia cardíaca descompensada y predominio de congestión sistémica tisular.*
Principal Investigator: Julio Núñez Villota
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total budget: €102,500

Reference: BIOTOOL-CHF
Title: *BIOMarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure*
Principal Investigator: Julio Núñez Villota
Funding Body: European Commission
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2028
Total budget: €282,625

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
63	458	7.27
National collaborations	International collaborations	Corresponding author
36	23	33

- Prediction of left ventricular thrombus after myocardial infarction: a cardiac magnetic resonance-based prospective registry. Bertolin C, Marcos V, Merenciano H, Perez N, Pérez Del Villar C, Gavara J, Lopez MP et al. European Journal of Internal Medicine. 2025 january 01. 131104-112. DOI:10.1016/j.ejim.2024.09.015. PMID:39384454. IF: 6,10. Q1.
- Effect of exercise training in patients with chronotropic incompetence and heart failure with preserved ejection fraction: the TRAINING-HR randomized clinical trial. Palau P, de Amo I, Núñez G, Flor C, de la Espriella R, García C, Berlanga SE et al. European Journal of Preventive Cardiology. 2025 may 09. 33 (2):265-275. DOI:10.1093/eurjpc/zwaf269. PMID:40294211. IF: 7,50. Q1.
- Invited Authors' Reply to: Letter to the Editor regarding 'Effect of exercise training in patients with chronotropic incompetence and heart failure with preserved ejection fraction: the TRAINING-HR randomized clinical trial'. Palau P, López L, Núñez J. European Journal of Preventive Cardiology. 2025 july 22. DOI:10.1093/eurjpc/zwaf359. PMID:40567178. IF: 7,50. Q1.
- Heart Failure in Advanced Chronic Kidney Disease Overlooked No More. De la Espriella R, Górriz JL, Cobo M, Marques M, Seller J, Méndez A, Soler MJ et al. JACC-Heart Failure. 2025 september 01. 13 (9):102581-102581. DOI:10.1016/j.jchf.2025.102581. PMID:40730127. IF: 11,80. Q1.
- Longitudinal Assessment of Spot Urinary Sodium as Predictor of Clinical Outcomes in Chronic Heart Failure. Lorenzo M, Núñez E, De la Espriella R, Carratalá A, Rodríguez E, Górriz JL, Valls N et al. JACC-Heart Failure. 2025 december 01. 13 (12):102467-102467. DOI:10.1016/j.jchf.2025.03.028. PMID:40372298. IF: 11,80. Q1

THESIS

Thesis title: Efecto de la modificación de los niveles de antígeno carbohidrato 125 antes del implante de prótesis valvular aórtica percutánea sobre el pronóstico tras el implante

Type: Doctoral Thesis

Doctoral candidate: Vicente Pernias Escrig

Director(s): Dr Julio Núñez Villota

University: Universitat de València (Estudi General)

Defence date: 02/04/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Thesis title: Utility of isolated determination of urinary sodium in the follow-up of outpatients with congestive heart failure

Type: Doctoral Thesis

Doctoral candidate: Miguel Lorenzo Hernández

Director(s): Dr Julio Núñez Villota and Dr Juan Sanchís Forés

University: Universitat de València (Estudi General)

Defence date: 23/05/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Research Group on Renal Disease


Consolidated

Principal Investigator: Jose Luis Górriz Teruel

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Jose Luis Górriz Teruel. Hospital/ UV
- Established Researcher:**
Isidro Torregrosa Maicas. Hospital
- Recognised Researcher:**
Maria Jesús Puchades Montesa. Hospital
- First Stage Researcher:**
Fernando Caballero Cebrián. INCLIVA
Elena Giménez Civera. Hospital
Boris Marcelo Gonzales Candia. Hospital
Miguel Angel Gonzalez Rico. Hospital
Isabel Juan Garcia. Hospital
Francesc Moncho Francés. INCLIVA
Marco Montomoli. Hospital
Nayara Panizo Gonzalez. Hospital
Irina Sanchis Muñoz. Hospital
Miguel Angel Solis Salguero. Hospital
- Staff-Nurse:**
Lorena Gandía Salmerón. INCLIVA
- Staff-Technician:**
Claudia Forquet Daroca. INCLIVA
- Staff-Collaborating Researcher:**
Maria Camila Solano Rivera. Hospital



STRATEGIC AIMS

The main scientific objectives of the group focus on research in chronic kidney disease. First, by maintaining the clinical trials unit, which allows us to evaluate new drugs in Nephrology and participate in multicentre working groups while also contributing to the group's funding.

Second, by continuing with independent research projects to assess their potential nephroprotective role.

The group's research lines are based on: detecting chronic kidney disease in individuals with risk factors, laboratory work and big data analysis, measuring kidney function in individuals with obesity and in oncology patients (therapeutic optimization of chemotherapy), and monitoring cytomegalovirus infection parameters in kidney transplantation (therapy guided by real-time monitoring systems).

MAIN LINES OF RESEARCH

- Changes in renal function and biomarkers in cardiorenal syndrome.
- Early detection of chronic kidney disease in at-risk populations.
- Early metabolic, vascular and renal alterations in overweight and obese subjects and animal models.
- Measurement of renal function in oncology patients and adjustment of chemotherapy doses.
- Measurement of renal function in people with obesity.
- Monitoring of cytomegalovirus infection parameters in renal transplants. Therapy guided by real-time monitoring systems.

RESEARCH PROJECTS

Reference: PI22/01948
Title: *Congestión como potencial catalizador de la progresión de la enfermedad renal crónica.*
Principal Investigator: Rafael de la Espriella Juan
Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2025 extended to 2026
Total budget: €87,120

Title: *Evaluación de la incidencia, causas e impacto de la hipo-fosfatemia en pacientes sometidos a terapia CAR-T en el HCUV.*
Principal Investigator: Isidro Torregrosa Maicas.
Funding Body: FUNDACION SENEFRO
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2025 extended to 2026
Total budget: €24,000

Title: *Nuevas estrategias de cribado de enfermedad renal crónica en pacientes de riesgo antes de alto riesgo.*
Principal Investigator: Jose Luis Górriz Teruel
Funding Body: BOEHRINGER INGELHEIM ESPAÑA S.A.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2026
Total budget: €25,000

Reference: 101095146
Title: *Personalized Drug Response: IMplementation and Evaluation in CKD. PRIME CKD 2022.*
Principal Investigator: Jose Luis Górriz Teruel
Funding Body: European Commission
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2027
Total budget: €420,562

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
22	140.9	6.40
National collaborations	International collaborations	Corresponding author
14	5	12

- Evaluation of the VIDAS Cytomegalovirus (CMV)-IGRA for Assessing CMV-Specific T-Cell Responses in Immunocompetent and Immunosuppressed Individuals. Giménez E, Albert E, Colomer E, Pérez A, Montomoli M, Piñana JL, Sanchis I et al. JOURNAL OF MEDICAL VIROLOGY. 2025 april 01. 97 (4):DOI:10.1002/jmv.70355. PMID:40232234. IF: 4,60. Q1.
- Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination. Sánchez A, Panizo N, Giménez E, Albert E, Montomoli M, Sanchis I, Kanter J et al. JOURNAL OF MEDICAL VIROLOGY. 2025 may 01. 97 (5):DOI:10.1002/jmv.70382. PMID:40326950. IF: 4,60. Q1.
- Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Sánchez A, Carretero D, Grau B, Martínez M, Albert E, Giménez E, Colomer E et al. JOURNAL OF MEDICAL VIROLOGY. 2025 june 22. 97 (6):DOI:10.1002/jmv.70463. PMID:40545672. IF: 4,60. Q1.
- The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management. Moncho F, Benlloch S, Górriz JL. Clinical Kidney Journal. 2025 august 12. 18 (9):DOI:10.1093/ckj/sfaf260. PMID:40927376. IF: 4,60. Q1 .
- Prospective evaluation of CAR-T cell therapy-related proteinuria and kidney dysfunction. Moncho F, Hernani R, Juan I, Benzaquén A, Solís MA, Pérez A, Navarro JF et al. Clinical Kidney Journal. 2025 october 01. 18 (10): DOI:10.1093/ckj/sfaf270. PMID:41059413. IF: 4,60. Q1

THESIS

Thesis title: Análisis predictivo de la utilización de recursos y costes de la diabetes mellitus tipo 2 según riesgo renal y fragilidad, utilizando Real WORD data.
Type: Doctoral Thesis
Doctoral candidate: Maria Inmaculada Saurí Ferrer
Director(s): Dr Josep Redón i Mas, Dr Ruth Uso Talamantes and Dr Jose Luis Trillo Mata
University: Universitat de València (Estudi General)
Date of the defense: 26/02/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Thesis title: Estudio de la correlación entre la densidad vascular retiniana medida por octa y el grado de nefropatía en pacientes con diabetes mellitus tipo 2.
Type: Doctoral Thesis
Doctoral candidate: Irene Gil Hernández
Director(s): Dr Jose Luis Górriz Teruel, Dr Antonio Duch Samper and Dr Delia Hernández Pérez
University: Universitat de València (Estudi General)
Date of the defense: 04/04/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Thesis title: Correlación entre distintos métodos de cuantificación de la proteinuria durante la gestación en gestantes con factores de riesgo para presentar preeclampsia.
Type: Doctoral Thesis
Doctoral candidate: Alenda Jimenez García
Director(s): Dr Jose Luis Górriz Teruel, Dr Maria Reyes Balanzá Chancosa and Dr Nerea Ruiza Sacedon.
University: Universitat de València (Estudi General)
Date of the defense: 10/05/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

4.3.2. Oncology Area

Groups

- Research Group on Histopathology and Tissue Engineering
- Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumours - InDeST
- Research Group on Breast Cancer Biology
- Research Group on Skin Cancer
- Translational Research Group on Paediatric Solid Tumors
- Research Group on Hematopoietic Transplantation
- Research Group on Lymphoproliferative Disorders
- Research Group on Myeloid Neoplasms
- Research Group on Molecular Imaging and Metabolomics
- Research Group on Molecular Microbiology and Microbial Pathogenesis
- Translational Research Group on Esophagogastric Cancer
- Medical Oncology Clinical Trials Unit: Phase I and experimental therapies

Number of indexed publications		IF	Average IF	
242		2154.9	9.288	
National collaborations		International collaborations	Corresponding author	
100		115	99	
D1	Q1	Q2	First author	Last author
63	160	44	81	90



Key Publications

- Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia. Muñoz I, Pérez R, Castillo N, Cordero T, Ochando A, Ortega S, Parras M et al. NATURE MEDICINE. 2025 february 01. 31 (2):502-513. DOI:10.1038/s41591-024-03407-7. PMID:39775038. IF: 50. Q1
- Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Martínez B, Camblor DG, Martín J, Carbonell JA, García B, Gambardella V, Huerta M et al. ANNALS OF ONCOLOGY. 2025 march 01. 36 (3):263-276. DOI:10.1016/j.annonc.2024.12.006. PMID:39675560. IF: 65,40. Q1
- Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Martín J, Gimeno F, Henriksen TV, García B, Martínez B, Gambardella V, Martínez C et al. Nature Cancer. 2025 june 01. 6 (6):1000-1016. DOI:10.1038/s43018-025-00960-z. PMID:40301653. IF: 28,50. Q1
- Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women. Garrido I, Tapia M, Carbonell J, Pena C, Torres S, Agreda A, Lameirinhas A et al. Cancer Communications. 2025 july 01. 45 (7):789-793. DOI:10.1002/cac2.70019. PMID:40207642. IF: 24,90. Q1
- Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations. Seguí V, Carbonell JA, Martín J, García M, Grimalt N, Martinez C, Gonzalez JF et al. ESMO Open. 2025 october 01. 10 (10):105771-105771. DOI:10.1016/j.esmoop.2025.105771. PMID:40997747. IF: 8,30. Q1


Research Group on Histopathology and Tissue Engineering

Consolidated
Principal Investigator: Manuel Mata Roig

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Manuel Mata Roig. UV
Cristina Martínez Ramos. UV
- Established Researcher:**
Jose Javier Martin De Llano. UV
Antonio Fons Font. UV
Francisco Forriol Brocal. Hospital
Genaro Galan Gil. Hospital /UV
Miguel Puche Torres. Hospital /UV
Carlos Tejerina Botella. Hospital /UV
Maria Sancho-Tello Valls. UV
Maria Fe Minguez Rey. Hospital
- Recognised Researcher:**
Javier Alcacer Fernandez-Coronado. Hospital
Lara Milián Medina. UV
- First Stage Researcher:**
Lucía Bravo Baranda. UV
Irene Monleon Guinot. UV
Angel Aguilar Hernandez. Hospital
- Staff-Collaborating Researcher:**
Mª Teresa Sagrado Vives. UV




STRATEGIC AIMS

The group obtained funding to continue working in the line of Tissue Engineering with the following new projects:

- Bone regeneration in prosthetic implants. Biological processes conditioned by age and gender. Design of new biomaterials.
- Biomimetic microgels for the study of the tumor microenvironment (TME) and mesenchymal epithelial transition (EMT) in lung cancer.
- Cartilage and bone regeneration techniques and their application in pathologies.

MAIN LINES OF RESEARCH

- Histopathology: - Ciliary pathology.
- Regenerative Medicine: - Articular cartilage regeneration.
- Bone regeneration. Effect of age and gender on the regeneration process.
- Use of dental pulp cells as precursors in regenerative therapies.
- Regeneration of dental and periodontal tissues.
- Tumor microenvironment using biomimetic microgels.



RESEARCH RESULTS

Invention: Intramedullary fixation device
Priority Number: US16/311478
Status: Licensed
Principal Investigator: Antonio Silvestre Muñoz

Invention: Maxillomandibular prosthesis and production method
Priority Number: P20130030734
Status: Licensed
Principal Investigator: Miguel Puche Torre

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
5	13.6	3.4
National collaborations	International collaborations	Corresponding author
4	0	3

- Articular cartilage regeneration with a microgel as a support biomaterial. A rabbit knee model. Zurriaga J, Antolinos CM, Ródenas J, Milián L, Pla J, Oguir Z, Sancho M et al. Biomaterials Advances. 2025 march 01. 168214125-214125. DOI:10.1016/j.bioadv.2024.214125. PMID:39615373. IF: 6. Q2.
- Advances and stagnation in airway surgery: A historical perspective. Martínez NJ, Estors M, Galbis JM, Mata M, Roig A. Cirugia Espanola. 2025 may 01. 103 (5):302-307. DOI:10.1016/j.cireng.2024.12.011. PMID:39864782.
- Cancer Epithelial Cells Participate in the Self-Organization of Lung Tumor Spheroids: A Morphological Approach. Monleón I, Bravo L, Milián L, Sancho M, Llop M, Galbis JM, Cremades A et al. CELLS TISSUES ORGANS. 2025 june 01. 214 (3):219-241. DOI:10.1159/000541524. PMID:39383853. IF: 1,90. Q2.
- "Mandibular subluxation using a putty splint: a strategy to optimize access to the distal internal carotid artery in a minimally invasive manner". Del Río DM, Casas GB, Mateo MM, Torres MP. Oral and Maxillofacial Surgery-Heidelberg. 2025 august 06. 29 (1):139-139. DOI:10.1007/s10006-025-01440-5. PMID:40768071. IF: 1,80. Q3.
- Experimental Airway Allogenic Transplantation Model with Decellularized Cryopreserved Tracheas. Martínez NJ, Milián L, Mas J, Roig A, Hervás D, Mata M. Biomedicines. 2025 september 30. 13 (10):DOI:10.3390/biomedicines13102401. PMID:41153684. IF: 3,90. Q1

Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors – InDeST

Consolidated
Principal Investigator: Andrés Cervantes Ruipérez

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Andrés Cervantes Ruiperez. Hospital /UV
- Established Researcher:**
Javier Hernández Gil. INCLIVA
Desamparados Roda Perez. Hospital
- Recognised Researcher:**
Jorge Martín Arana. INCLIVA
Clara Alfaro Cervelló. Hospital /UV
Francisco Gimeno Valiente. INCLIVA
Gema Bruixola Campos. Hospital
María del Sol Huerta Álvaro. Hospital /INCLIVA
María Carolina Martínez Ciarpaglini. Hospital /UV
Amelia Insa Molla. Hospital
Jose Alejandro Perez Fidalgo. Hospital /UV
Susana Roselló Keränen. Hospital
Maria José Molina Garrido. Hospita
- Recognised Emerging Researchers:**
Noelia Tarazona Llaveró. INCLIVA
Valentina Gambardella. INCLIVA
- First Stage Resercher:**
Daniel González Camblor. INCLIVA
Raquel Herrero Tejedor. INCLIVA
Belén Martínez Castedo. INCLIVA
Blanca García Micó. INCLIVA
Paloma Martin Martorell. Hospital
Inés González Barrallo. Hospital.
Jose Vicente Monton Bueno. INCLIVA
Javier Perea Rojo. Hospital.
Alba Inmaculada Viala Monleon. Hospital
Miguel García Bartolomé. INCLIVA
Francisco Martínez Picó. INCLIVA
- Staff-Administrative Assistant:**
Yolanda De La Cruz Robles. Administrative Coordinator. INCLIVA
Enrique Castelló Moreno. INCLIVA
Lorena Saz Lluch. INCLIVA
Roberto San Leandro García. INCLIVA
Laura Boix Bartual. INCLIVA
Paloma Campos Bañegil. INCLIVA

- María Burgos Guerra. Clinical Trial Assistant. INCLIVA.
Maria Rosa García Solaz. Clinical Trial Assistant INCLIVA
Iris Abad Amado. Clinical Trial Assistant INCLIVA
Maribel Gómez Núñez. Clinical Trial Assistant INCLIVA
- Staff-Project Manager:**
Mónica Gorbe Moya. INCLIVA
María Ángeles Bernabéu Valdés. INCLIVA
Victoria Lucía Doldán Martelli. INCLIVA
 - Research Nurse Staff:**
Inmaculada Blasco Blasco Coordinator INCLIVA
Ana Vinatea Elorrieta INCLIVA
María Montes De Oca Ortuño. INCLIVA
María Isabel Calzadilla Luz INCLIVA
Gloria Corredor Agulló INCLIVA
Silvia Moreno Magraner. INCLIVA
Ana María Ruiz Quílez. INCLIVA
Isamar Cabañero García. Nursing Assistant INCLIVA
Arantxa Sánchez Cosmo. Nursing Assistant INCLIVA
 - Staff-Technician:**
Paula Blasco Sánchez. INCLIVA
Laura González Castillo. INCLIVA
Ilza Victoria Freitas Durks. INCLIVA
Brenda Palomar De Lucas. INCLIVA
Carme María Ortega Albiach. INCLIVA
José Francisco González Muñoz. INCLIVA
Laura Olivares Ordóñez. INCLIVA
María Cristina Mongort Sanchís. INCLIVA
Maria Rodrigo Faus. INCLIVA
Verónica Repullés Martín. INCLIVA
Guillermo Moret Peiró. INCLIVA
Aitana Bolea Cortina. CIBERONC
Andrea Ghiuro. CIBERONC
Jesima Berenguer Llopis. INCLIVA
María Falcó Frigols. INCLIVA
 - Staff-Data Manager:**
Ignacio Castaño López. Coordinator Data Manager. INCLIVA
Rubén Sanz Moreno. INCLIVA
Núria Roig Sánchez. INCLIVA
Andrea Pascual Herrero. INCLIVA
Alejandro Asturiano Pérez-Chao. INCLIVA
María Carmen Martínez López. INCLIVA

Beatriz López Montero. INCLIVA
Ana Vercher Grau. INCLIVA

- Staff-Collaborating Researcher:**
Victor Seguí Manzaneque. INCLIVA

Emerging Researchers

Noelia Tarazona Llaveró*


Our scientific research is centred on utilizing liquid biopsy, specifically circulating tumour DNA in plasma, for various objectives including minimal residual disease detection and correlation with survival rates, understanding the mechanisms behind disease progression and therapy resistance, and identifying potential therapeutic targets.

Other research areas include:

- Application of circulating tumour cells in characterizing minimal residual disease, which can aid in its effective eradication.
- Establishing organoids derived from primary or metastatic tumours and circulating tumour cells obtained from patients with gastrointestinal cancers.
- Investigation of novel biomarkers (three of which have been recognised in March 2026) such as the lack of CDX2 expression in localized colon cancer. Are three recognised in march 2026

Valentina Gambardella

Our scientific interest is in improving precision medicine for cancer patients through genomic and transcriptomic analyses to identify specific druggable alterations beyond the standard biomarkers. These could provide a pathway to promising early clinical trials with both targeted agents and novel immunotherapies. Multi-omics evaluation of tumour and microenvironment features at baseline and at time of progression will help in understanding those molecular mechanisms related to resistance to anticancer drugs. Our particular interest is studying these mechanisms in KRAS mutant NSCLC patients.



STRATEGIC AIMS

Our group aims to improve patients' lives by developing new diagnostic and therapeutic methods. In addition to this main goal, we intend to implement strategies to advance precision medicine in solid tumours using innovative therapeutic approaches in colorectal and gastric cancer from different standpoints such as molecular classification and the use of predictive biomarkers.

MAIN LINES OF RESEARCH

- Expand current knowledge on the microenvironment of gastric cancer.
- Develop first-in-human Phase I trials of antineoplastic agents with innovative designs.
- Develop liquid biopsies (ctDNA, cmicroRNAs) for early diagnosis, monitoring and prediction of therapeutic effects in patients with gastro-intestinal malignancies.
- Implement the use of patient organoids (3D cell cultures) as functional models to elucidate the underlying causes of tumorigenesis and test the appropriateness of the treatments.
- Use the latest technologies to improve our knowledge of the molecular and genetic causes of cancer on an international level.

TEAM INVOLVED IN

eatris



RESEARCH PROJECTS

Reference: ICI20/00009
Title: *Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer stage II-III (CIRCULATE-SPAIN)*
Principal Investigator: Andrés Cervantes Ruipérez
Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2021-2024 extended to 2026
Total Budget: €1,039,970

Title Factores derivados del microambiente tumoral en cáncer de colon localizado: impacto clínico e implicaciones terapéuticas.
Principal Investigator: Andrés Cervantes Ruipérez
Funding Body: Fundación Científica de la Asociación Española Contra el Cáncer. AECC
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2020-2026
Total Budget: €332,970

Reference: PT23/00103
Title: *Plataforma ISCIII de soporte para la Investigación Clínica. Unidad de Investigación Clínica y Ensayos Clínicos de INCLIVA. (SCREEN).*
Principal Investigator: Andrés Cervantes Ruipérez
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2026
Total Budget: €273,180

Reference: UICM24/00020
Title: *Mejora de la Unidad de Investigación Clínica de INCLIVA.*
Principal Investigator: Andrés Cervantes Ruipérez
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2026
Total Budget: €1,093,464

Reference: RED2024-153888-E
Title: *Asesoramiento estratégico en políticas sanitarias contra el cáncer (Red ECON)*
Principal Investigator: Andrés Cervantes Ruipérez
Funding Body: Ministerio de Ciencia e Innovación
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2027
Total Budget: €60,000

Reference: 101057514 - Mypath
Title: *Developing and implementing innovative Patient-Centred Care Pathways for cancer patients*
Principal Investigator: Andrés Cervantes Ruipérez
Funding Body: European Commission
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2027
Total Budget: €400,625

Title: *Targeting Minimal Residual Disease And Artificial Intelligence-Based Radiomics For Predicting Response In Colon Cancer (GLADIATOR)*
Principal Investigator: Noelia Tarazona Llaveró
Funding Body: SEOM
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2026
Total Budget: €30,000

Title: *TargetinG Liver micrometAstatic Disease with Immunotherapy and Artificial inTelligence-based radiOmics for predicting Response in colorectal cancer.*
Principal Investigator: Noelia Tarazona Llaveró
Funding Body: Gilead Sciences, S.L.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2027
Total Budget: €55,000

Title: *Development of Innovative Approaches for Monitoring ctDNA and Designing liquid biopsy-based clinical trials with integration of Immuno-Oncology biomarkers (DIAMonD-IO).*
Principal Investigator: Noelia Tarazona Llaveró
Funding Body: Fundación PFIZER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2027
Total Budget: €4,000

Title: *Explorando nuevos horizontes: Inmunoterapia en enfermedad hepática micrometastásica y predicción de respuesta con un modelo radiómico en pacientes con cáncer de colon, sin considerar el estado de microsatélites.*
Principal Investigator: Noelia Tarazona Llaveró
Funding Body: Fundación Mutua Madrileña
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2027
Total Budget: €120,000

Reference: PI24/00103
Title: *Enfoque integral de la enfermedad micrometastásica hepática en cáncer colorrectal: caracterización multiómica de metástasis, respuesta inmune y abordaje de la enfermedad residual.*
Principal Investigator: Noelia Tarazona Llaveró
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2027
Total Budget: €271.250

Title: *El papel del estrés oxidativo en la resistencia a inhibidores selectivos de KRAS G12C en pacientes con cáncer de pulmón avanzado no microcítico.*
Principal Investigator: Valentina Gambardella
Funding Body: Fundación Sociedad Española De Oncología Médica. SEOM
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2026
Total Budget: €20,000

Reference: PI22/01173
Title: *El papel del estrés oxidativo y la vía NRF2 en determinar resistencia a quimioinmunoterapia de primera línea en pacientes con cáncer de pulmón no microcítico avanzado KRAS mutado*
Principal Investigator: Valentina Gambardella

Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2025
Total Budget: €111,320

Reference: PID2021-127408OA-I00
Title: *Desarrollo inteligente de "linfocitos T cargados con fármacos" en la lucha contra el cáncer.*
Principal Investigator: Javier Hernández Gil
Funding Body: Ministerio de Ciencia e Innovación
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2025
Total Budget: €35,470

Reference: PI22/02000
Title: *Hacia la medicina de precisión en el colangiocarcinoma: la relevancia de la radiogenómica que define el perfil molecular de un paciente individual en busca de nuevas oportunidades de tratamiento*
Principal Investigator: Desamparados Roda Pérez
Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2025 extended to 2027
Total Budget: €98,494

Title: *Estudio del papel del microambiente inmune y la vía de AXL en la resistencia a inhibidores de PARP en cáncer de ovario de alto grado*
Principal Investigator: Jose A. Pérez Fidalgo
Funding Body: Sociedad Española de Oncología Médica (SEOM)
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2026
Total budget: €35,000

Title: *El papel de la vía NRF2 en la resistencia a inhibidores de PARP en cáncer de ovario de alto grado: Estudio traslacional sobre líneas celulares resistentes a olaparib y modelo 3D de omento derivados de pacientes.*
Principal Investigator: Jose A. Pérez Fidalgo
Funding Body: Sociedad Española de Oncología Médica (SEOM)
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2026-2028
Total budget: €35,000

Reference: AP-22014/2025
Title: *MOLECULAR Project: Modelo Multi-Ómico y de Inteligencia Artificial para la Predicción y Tratamiento Personalizado del Cáncer de Cabeza y Cuello Localmente Avanzado.*
Principal Investigator: Gema Bruixola Campos
Funding Body: Fundación Mutua Madrileña
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2028
Total Budget: €300,000

Reference: RETOS245794PAZA
Title: *Small cell lung cancer: from biology networks to tailored therapy.*
Principal Investigator: Paloma Martín Matorrell
Funding Body: Fundación científica de la Asociación Española Contra el Cáncer. AECC
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total Budget: €20,500

Reference: INNOPANC CPP2021-009064
Title: *Tratamiento innovador con ABTL0812 para el cancer pancreático metastático: acortando los tiempos para su aprobación.*
Principal Investigator: Susana Roselló Keränen
Funding Body: Ministerio de Ciencia e Innovación
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2025
Total Budget: €180,600

RESEARCH RESULTS
Invention: Method for monitoring of cancer using minimal residual disease analysis
Priority Number: EP25382212
Status: European Patent
Principal Investigator: Noelia Tarazona Llaveró

JOURNAL PUBLICATIONS		
Number of Publications	IF	Average FI
68	926.9	13.84
National collaborations	International collaborations	Corresponding author
23	39	27

- Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Martínez B, Camblor DG, Martín J, Carbonell JA, García B, Gambardella V, Huerta M et al. ANNALS OF ONCOLOGY. 2025 march 01. 36 (3):263-276. DOI:10.1016/j.annonc.2024.12.006. PMID:39675560. IF: 65,40. Q1
- Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Martín J, Gimeno F, Henriksen TV, García B, Martínez B, Gambardella V, Martínez C et al. Nature Cancer. 2025 june 01. 6 (6):1000-1016. DOI:10.1038/s43018-025-00960-z. PMID:40301653. IF: 28,50. Q1
- Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. Wermke M, Gambardella V, Kuboki Y, Felipe E, Sanmamed MF, Alese OB, Sayehli CM et al. JOURNAL OF CLINICAL ONCOLOGY. 2025 september 20. 43 (27):3021-3031. DOI:10.1200/JCO-25-00363. PMID:40706016. IF: 43,40. Q1
- Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations. Seguí V, Carbonell JA, Martín J, García M, Grimalt N, Martinez C, Gonzalez JF et al. ESMO Open. 2025 october 01. 10 (10):105771-105771. DOI:10.1016/j.esmoop.2025.105771. PMID:40997747. IF: 8,30. Q1
- Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer. Bruixola G, Martín J, Gimeno F, Carbonell JA, García B, Martínez B, González D et al. ESMO Open. 2025 december 01. 10 (12):105904-105904. DOI:10.1016/j.esmoop.2025.105904. PMID:41270698. IF: 8,30. Q1

THESIS
Thesis title: Photosensitization by topical retinoid drugs
Type: Doctoral Thesis
Doctoral candidate: Juan Antonio Soler Orenes
Director(s): Dr Javier Hernández Gil and Dr Virginie Lhiaubet-Vallet
University: Universitat de València (Estudi General)
Defence Date: 08/09/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Research Group on Breast Cancer Biology

Consolidated
Principal Investigators: Ana Lluch Hernández / Pilar Eroles Asensio

GROUP MEMBERS


Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Ana Lluch Hernández. Hospital
Pilar Eroles Asensio. UV/ INCLIVA
- Established Researcher:**
Octavio Burgues Gasion. Hospital
Isabel Chirivella González. Hospital /UV
- Recognised Emerging Researcher:**
Juan Miguel Cejalvo Andujar. Hospital
- Recognised Researcher:**
Iris Garrido Cano. INCLIVA
Diego Miguel Soriano Mena. Hospital
Sandra Torres Ruiz. INCLIVA
Elvira Buch Villa. Hospital
María Teresa Martinez Martinez. Hospital
Begoña Bermejo De Las Heras. Hospital /UV
- First Stage Researcher:**
Yolanda Domínguez Núñez. INCLIVA
Marta López Nieto. INCLIVA
Paloma Sánchez Serrano. INCLIVA
Cristina Tébar Sánchez. INCLIVA
Marta Tapia Cespedes. INCLIVA
Ana María Agreda Roca. INCLIVA
Esther Jorda Sorolla. Hospital /UV
- Staff-Administrative Assistant:**
Francisca Fernández Olmo. INCLIVA
Paranee Archavarat Sianmekan. *Clinical Trial Assistant*
INCLIVA
- Staff-Nurse:**
Sheila Romero Chaveli. INCLIVA
Marta Castillo Ponce. INCLIVA
Ana Cosías Gómez. INCLIVA
Sara Rodríguez Pestano. INCLIVA
Silvia Coret Sinisterra. INCLIVA
- Staff-Technician:**
Júlia Soler Flores. INCLIVA
Elisa Alonso Yuste. INCLIVA

Emerging Researcher

Juan Miguel Cejalvo Andújar

Our research focuses on elucidating molecular pathways underlying resistance to targeted therapies in breast cancer with the aim of enhancing treatment efficacy. Additionally, we conduct comprehensive transcriptomic analyses to better understand disease heterogeneity and identify potential therapeutic targets.



STRATEGIC AIMS

- Resistance to treatment:
 - Study resistance mechanisms to anti-HER2 therapy in HER2+ breast cancer and search for therapeutic options.
 - Discover the mechanisms of resistance to therapy in triple negative breast cancer and search for alternative therapies.
 - Study mechanisms of resistance to ADC.
- Breast cancer in very young women:
 - Identify biomarkers and molecular characterization
- Prognosis and prediction:
 - Evaluate pathologic complete response rate to neoadjuvant immunotherapy in triple negative breast cancer.
 - Predict residual disease after neoadjuvant therapy in HER2-positive breast cancer.
 - Use of new diagnostic tools: HER2DX, AI.
 - Molecular characterization of oligometastatic breast cancer patients.
- Patient-Derived Models:
 - Establish patient-derived organoids.
 - Establish patient-derived xenografts.
- Lifestyle and physical exercise in breast cancer patients.

MAIN LINES OF RESEARCH

Our group focuses on understanding treatment resistance mechanisms in breast cancer, characterizing tumours in very young women, and identifying prognostic and predictive biomarkers. We also explore the use of advanced diagnostic tools (such as HER2DX and artificial intelligence) and develop patient-derived models including organoids and xenografts.

TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PI21/01351

Title: Predicción de enfermedad residual después de la terapia neoadyuvante en cáncer de mama HER2 positivo e identificación de estrategias para superar la resistencia.

Principal Investigator: Pilar Eroles Asensio

Funding Body: Instituto de Salud Carlos III

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2026

Total budget: €123,420

Title: Estudio de biomarcadores en biopsia líquida para diagnóstico precoz en síndromes hereditarios de predisposición a cáncer de mama (SHCM).

Principal Investigator: Isabel Chirivella González

Funding Body: Fundacion Sociedad Española de Oncología Médica SEOM

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2025

Total budget: €20,000

Title: Disección multidisciplinar de los mecanismos de resistencia a la quimioterapia en cáncer de mama triple negativo: Un paso hacia una mejor atención clínica.

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: Fundación Científica de la Asociación Española Contra el Cáncer. AECC

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2021-2026

Total budget: €268,500

Title: The role of AXL in modulating tumor microenvironment as potential therapeutic strategy for HER2-positive breast cancer.

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: Gilead Sciences, S.L.U.

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2025

Total budget: €49,350

Title: Clinical and molecular characterization of oligometastatic breast cancer: Revealing and improving the potential benefit of a local treatment on primary or metastatic sites. A multicentric study.

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: Asociación Cáncer de Mama Metastásico

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2025 extended to 2026

Total budget: €40,000

Title: Papel de AXL en la modulación del microambiente tumoral e implicaciones terapéuticas en cáncer de mama HER2 positivo

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: Fundacion Sociedad Española de Oncología Médica SEOM

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2025
Total budget: €30,000

Title: Dimerización de AXL--HER2 como mecanismo de resistencia adquirida a la terapia anti--HER2 en cáncer de mama HER2+: un paso hacia la medicina de precisión.

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: Adamed Laboratorios, S.L.U

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2020-2025
Total budget: €18,000

Reference: PI23/00848
Title: *El papel de AXL en la modulación de la resistencia a tratamiento y del microambiente tumoral en cáncer de mama Triple Negativo y HER2+.*

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: Instituto de Salud Carlos III

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2026
Total budget: €151,875

Title: *Overcoming resistance to trastuzumab deruxtecan in HER2+ metastatic breast cancer*

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: Asociación Cáncer de Mama Metastásico

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2025-2027
Total budget: €160,000

Title: *Estrategias dirigidas contra AXL para revertir la resistencia a la quimioterapia en cáncer de mama triple negativo*

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: Fundación HNA

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2025-2027
Total budget: €100,000

Reference: 101136791
Title: *Multimodal Engagement and sustainable Lifestyle Interventions Optimizing breast cancer Risk reduction supported by Artificial intelligence. MELIORA.*

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: European Commission

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2027
Total budget: €416,550

Reference: CPP2024-011305
Title: *Phase Ia/Ib Clinical Trial of ONA-255, a first-in-class ADC for refractory HR+HER2- breast cancer patients.*

Principal Investigator: Juan Miguel Cejalvo Andújar

Funding Body: Ministerio de ciencia e Innovación MICIIN

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2025-2028
Total budget: €400,161

Title: *The role of AXL and tumor microenvironment in determining resistance to anti-HER2 agents in HER2 amplified breast cancer models.*

Principal Investigator: Ana María Ágreda Roca

Funding Body: Fundación Científica de la Asociación Española Contra el Cáncer. AECC

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2025 extended to 2026
Total budget: €101,773

Reference: 965231-REBECCA
Title: REsearch on BrEast Cancer induced chronic conditions supported by Causal Analysis of multi-source data

Principal Investigator: Cristina Hernando Meliá and Begoña Bermejo de las Heras

Funding Body: European Commission

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2021-2025
Total budget: €466,125

Reference: PMP22/00032
Title: Integrating longitudinal patient-generated data and multi-omic profiling for comprehensive precision oncology in womens' cancers

Principal Investigator: Begoña Bermejo de las Heras

Funding Body: Fundación Centro Nacional de Investigaciones Oncológicas CNIO. Carlos III CNIO

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2026
Total budget: €85,915

Reference: PI24/01695
Title: *Caracterización preclínica y clínica del papel de LCOR y de la vía de señalización Hippo en la resistencia a las terapias anti-HER2 en el cáncer de mama HER2-positivo.*

Principal Investigator: Begoña Bermejo de las Heras

Funding Body: Instituto de Salud Carlos III

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2025-2027
Total budget: €132,500

Reference: CIAICO/2024/321
Title: *Desarrollo de moduladores de PPAR en la regulación del metabolismo energético y su impacto en la proliferación celular.*

Principal Investigator: Pilar Eroles as Co-IP

Funding Body: Conselleria Educación/Innovación, Universidades, Ciencia Y Sociedad Digital/Empleo

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2025-2028
Total budget: €90,000

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
28	236.2	8.43
National collaborations	International collaborations	Corresponding author
15	11	5

- Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer. Lameirinhas A, Torres S, Garrido I, Hernando C, Martínez MT, Rovira A, Albanell J et al. MOLECULAR MEDICINE. 2025 march 25. 31 (1):116-116. DOI:10.1186/s10020-025-01163-z. PMID:40133809. IF: 6,40. Q1.
- Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients. Fornas,G, Montón Bueno,J, Tortajada,T, Pérez,P, Guimerá,A, González,D, Iglesias,B et al. ESMO Open. 2025 may 01. 10 (5). 105064-105064. DOI:10.1016/j.esmoop.2025.105064. PMID:40233657. IF: 8,30. Q1.
- Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women. Garrido I, Tapia M, Carbonell J, Pena C, Torres S, Agreda A, Lameirinhas A et al. Cancer Communications. 2025 july 01. 45 (7):789-793. DOI:10.1002/cac2.70019. PMID:40207642. IF: 24,90. Q1

- Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations. Seguí V, Carbonell JA, Martín J, García M, Grimalt N, Martinez C, Gonzalez JF et al. ESMO Open. 2025 october 01. 10 (10):105771-105771. DOI:10.1016/j.esmoop.2025.105771. PMID:40997747. IF: 8,30. Q1
- SCOUT® Radar Reflector for Nonpalpable Breast Lesion Localization: Clinical Outcomes from a Single-Center Experience. Puente J, Muñoz E, Lopez V, Adrianzén M, Huntley D, Kadzhaya G, Soriano D et al. Cancers. 2025 november 28. 17 (23). DOI:10.3390/cancers17233816. PMID:41375017. IF: 4,40. Q2

THESIS

Thesis title: Descifrando el perfil transcriptómico del cáncer de mama en mujeres jóvenes. Nuevas perspectivas.

Type: Doctoral Thesis

Doctoral candidate: Marta Tapia Céspedes

Director(s): Dr. Juan Miguel Cejalvo Andújar and Dra. Begoña Bermejo de las Heras.

University: Universitat de València (Estudi General)

Defence date: 25/06/2025

Grade: Excellent


Quality recognition/Award: Cum Laude

Research Group on Skin Cancer

Consolidated
Principal Investigator: Carlos Monteagudo Castro

GROUP MEMBERS
Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Carlos Monteagudo Castro. Hospital /UV
- **Recognised Researcher:**
Silvia Pérez Debén. INCLIVA
Jose María Martín Hernandez. Hospital /UV
Liria Terradez Mas. Hospital /UV
- **Staff-Technician:**
Esther Álvarez Vilanova. Hospital



STRATEGIC AIMS

- Transcriptomic identification of miRNA-205 target genes potentially involved in metastasis and survival of cutaneous malignant melanoma.
- Search for a genetic and/or epigenetic signature which permits a more precise diagnosis and prediction of the metastatic potential of ambiguous melanocytic lesions, and particularly of spitzoid tumours.
- Identify circulating miRNAs which may serve as prognostic and/or staging biomarkers in patients with primary cutaneous melanoma.
- Create a public dataset of whole slide images of spitzoid melanocytic tumours for use in deep learning analysis.
- Create a whole slide image dataset of cutaneous spindle cell tumours for AI analysis.
- Study a large retrospective case series to evaluate eccrine coil elastosis as a new cutaneous biomarker for components of the metabolic syndrome.

MAIN LINES OF RESEARCH

- Artificial intelligence techniques for the classification of spindle cell tumours of the skin.
- Deep Learning analysis of methylation and miRNA profile of ambiguous melanocytic tumours to improve diagnosis and prognosis.
- Improvement by circulating biomarkers of melanoma staging schedule at the time of diagnosis.
- Machine learning analysis of whole slide images of spitzoid melanocytic tumours to improve diagnosis and prognosis decision making.
- Methylation biomarkers for diagnosis and prognosis of ambiguous, spitzoid and non-spitzoid, melanocytic tumours.
- New histologic cutaneous biomarkers of ageing, metabolic and cardiovascular risk factors.
- Prognostic value of intratumoral and circulating microRNAs in melanoma tumour progression and clinical outcome.

RESEARCH PROJECTS

Reference: PI23/01408
Title: *Análisis integrado mediante inteligencia artificial de las imágenes dermatoscópicas e histopatológicas con la secuenciación genética y epigenética para un pronóstico preciso de los pacientes con melanoma.*
Principal Investigator: José María Martín Hernández - Co-IP: José Carlos Monteagudo Castro
Funding body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total Budget: €152,500

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
9	41.8	4.64
National collaborations	International collaborations	Corresponding author
4	4	6

- Beyond nest size: the clinicopathological spectrum of large nested melanocytic tumours and the value of comparative genomic hybridisation and messenger RNA expression analysis. Mosquera A, Pérez S, Porcar S, Casabó G, Martínez M, Garzón MJ, García E et al. PATHOLOGY. 2025 february 01. 57 (1):40-48. DOI:10.1016/j.pathol.2024.08.002. PMID:39489642. IF: 3. Q2
- When breast cancer spreads below the belt - A case of rectal metastasis from invasive lobular carcinoma. Puente J, Pérez L, Terrádez L, Pla V, Casado D, Martín J, Moro D et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 2025 july 04. 117 (9):543-544. DOI:10.17235/reed.2025.11378/2025. PMID:40613528. IF: 4. Q1
- Epithelial elements in superficial angiomyxomas: mimicry of adnexal development, and mesenchymal-to-epithelial transition. Monteagudo C, Terrádez L, Alvarez E, Masiá P, Espino M, Ortega M. HISTOPATHOLOGY. 2025 august 01. 87 (2):321-328. DOI:10.1111/his.15478. PMID:40462396. IF: 4,10. Q1
- Exosomal Specificity of MiR-15a-5p as Marker of Activity, Renal Damage, and Disease Flares in Systemic Lupus Erythematosus. Flores A, Martinez O, Puertes A, Vela S, Gorriz JL, Solis MA, Terradez L et al. AMERICAN JOURNAL OF NEPHROLOGY. 2025 october 01. 56 (5):529-542. DOI:10.1159/000544854. PMID:40081350. IF: 3,20. Q1

- Eccrine Coil Elastosis: A New Dermatopathological Feature Associated With Prediabetes and Diabetes. Monteagudo C, Martínez M, García E, Pérez S, Terrádez L, Álvarez E, Martín JM. JOURNAL OF CUTANEOUS PATHOLOGY. 2025 november 01. 52 (11):720-727. DOI:10.1111/cup.14864. PMID:40889882. IF: 1,10. Q3


Translational Research Group on Paediatric Solid Tumors

Consolidated
Principal Investigators: Samuel Navarro Fos / Rosa Noguera Salva

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Samuel Navarro Fos. Hospital /UV
Rosa Noguera Salva. UV
- Established Researcher:**
Desamparados Compañ Quilis. Hospital
Jaime Verdu Amoros. Hospital
Inmaculada Noguera Salvá. UV
Isidro Machado Puerto. UV
- Recognised Researcher:**
María Amparo López Carrasco. INCLIVA
Ezequiel Monferrer Garzarán. UV
Meryem El Ouardi El Hamidy. CIBERONC
Sofía Granados Aparici. CIBERONC
- First Stage Researcher:**
Isaac Vieco Martí. INCLIVA
- Staff-Technician:**
Carlos Estellés Díaz. INCLIVA
- Staff-Collaborating Researcher:**
Karina Alexandra Parra Haro. CIBERONC



STRATEGIC AIMS

- Genomic heterogeneity in neuroblastoma (NB).
- 3D in vitro and xenotransplant models of NB.
- Morphological and molecular analysis of neuroblastic and malignant infantile skeletal tumours.
- Importance of extracellular matrix and stroma cells (including immune cells) in tumours using digital analysis.

MAIN LINES OF RESEARCH

- Digital analysis of diagnostic, prognostic and therapeutic biomarkers in tumours.
- Genetic analysis in neuroblastoma. At the European level, participation in the establishment of a uniform nomenclature, standard practices and quality validation studies, essential to obtain and maintain high quality in genetic results used for therapeutic stratification.
- Identification of new genetic factors with prognostic value in neuroblastic and malignant infantile skeletal and soft tissue tumours.
- Preclinical models. Obtaining and characterizing cell lines in vivo and in vitro (2D and 3D) from fresh tumour material.
- Tumour microenvironment studies in tumours.

TEAM INVOLVED IN



RESEARCH PROJECTS

Title: Proyecto SLPS Seguimiento a largo plazo de supervivientes.
Principal Investigator: Jaime Verdú Amorós
Funding body: Asociación de Padres de Niños con Cáncer. AS-PANION
Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2023 extended to 2025
Total budget: €62,037

Reference: PMP21/00107
Title: INtegrative GENomic, digital Imaging and clinical informa-tion towards Precision Oncology Optimization - INGENIO
Principal Investigator: Rosa Noguera Salva
Funding body: Ministerio de Ciencia e Innovación
Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2025
Total budget: €22,925

Title: Artificial Intelligence and Radiomics in pediatric Lympho-ma: focus on residual disease at early response assessment
Principal Investigator: Jaime Verdú Amorós
Funding body: Fundacion de la Sociedad Española de Hemato-logia y Oncología Pediátrica (FSEHOP)
Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2026
Total budget: €20,000

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
22	156	7.09
National collaborations	International collaborations	Corresponding author
8	14	12

- Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia. Muñoz I, Pérez R, Castillo N, Cordero T, Ochando A, Ortega S, Parras M et al. NATURE MEDICINE. 2025 february 01. 31 (2):502-513. DOI:10.1038/s41591-024-03407-7. PMID:39775038. IF: 50. Q1.
- Tackling ALT-positive neuroblastoma: is it time to redefine risk classification systems? A systematic review with IPD meta-analysis. Avinent Pérez,M, Westermann,F, Navarro,S, López Carrasco,A, Noguera,R. NEOPLASIA. 2025 february 01. 60101106-101106. DOI:10.1016/j.neo.2024.101106. PMID:39733691. IF: 7,70. Q1.

- Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents. Mato S, Carità L, Colmenero A, Andrés M, Balagué O, Andión M, Astigarraga I et al. BRITISH JOURNAL OF HAEMATOLOGY. 2025 may 01. 206 (5):1390-1396. DOI:10.1111/bjh.20012. PMID:40011029. IF: 3,90. Q1.
- Primary cutaneous rhabdomyosarcoma with EWSR1/FUS::T-FCP2 fusion: four new cases with distinctive morphology, immunophenotypic, and genetic profile. Machado I, Wardelmann E, Zhao M, Song J, Wang YL, Braun SA, Catasús L et al. VIRCHOWS ARCHIV. 2025 june 01. 486 (6):1187-1198. DOI:10.1007/s00428-024-04007-z. PMID:39692858. IF: 3,10. Q2.
- Integration of an OS-Based Machine Learning Score (AS Score) and Immunoscore as Ancillary Tools for Predicting Immunotherapy Response in Sarcomas. Machado I, López R, Giner E, Fernández A, Requena C, Llombart B, Giner F et al. Cancers. 2025 august 01. 17 (15):DOI:10.3390/cancers17152551. PMID:40805246. IF: 4,40. Q2

THESIS


Thesis title: Importancia del reconocimiento del efecto de la programación fetal y perinatal en el neuroblastoma
Type: Doctoral Thesis
Doctoral candidate: Nuria Benavent García
Director(s): Dr Rosa Noguera Salva
University: Universitat de València (Estudi General)
Defence date: 28/11/2025
Grade: Excellence
Quality recognition/Award: Cum Laude

Research Group on Hematopoietic Transplantation

Consolidated
Principal Investigator: Carlos Solano Vercet

GROUP MEMBERS
Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Carlos Solano Vercet. Hospital /UV
- Established Researcher:**
Jose Luis Piñana Sanchez. Hospital
- Recognised Researcher:**
Paula Amat Martínez. Hospital /UV
Mª Jose Remigia Pellicer. Hospital
- First Stage Researcher:**
Julia Carrió Fito. INCLIVA
Marina Hernández Aliaga. Hospital
Rut Meseguer Naturil. INCLIVA
Rafael Hernani Morales. Hospital
Ariadna Perez Martinez. Hospital
- Staff-Administrative assistant:**
Susana Albi Ponce. INCLIVA
Eva María Barri Sabatés. INCLIVA
- Staff-Collaborating Researcher:**
Daniela Morello González. Hospital
Ana Benzaquen Vallejos. Hospital
Rosa Goterris Vicedo. Hospital
- Staff-Nurse:**
María Carmen Hurtado Fontelles. INCLIVA
Teresa Barber Ballester. UV
- Staff-Technician:**
Laura López Molero. INCLIVA
Vicent Cuevas Mauricio. INCLIVA
Clara Seherazade Osca Gómez. INCLIVA
Diana Campos Beltrán. INCLIVA
María Del Pilar Ortiz Gavilán. INCLIVA



- STRATEGIC AIMS
- Translational research on biology and treatment of graft-versus-host disease after allogeneic transplantation of hematopoietic progenitor cells. Infection and immune reconstitution after haematopoietic transplant.
 - Develop an Advanced Therapies- clinical and translational program in Hospital Clínico Universitario de Valencia – INCLIVA.
 - Design and implement an outpatient programme in hematopoietic transplant and cellular therapy.

- MAIN LINES OF RESEARCH
- Clinical application of gene and cellular therapy using CAR-T and other immune effector cells.
 - Infection and immune reconstitution after hematopoietic transplantation.
 - Scientific and logistical implications of implementing a transplant programme in the outpatient setting.
 - Translational research of alloreactivity in the context of new modalities of allogeneic transplantation from compatible and incompatible alternative donors (haploidentical transplant).
 - Translational research on complications of allogeneic hematopoietic transplantation: graft-versus-host disease

RESEARCH PROJECTS

Reference: PI21/01628

Title: *Inmunobiología de células NK expandidas con criterios GMP de donantes seleccionados de banco de linfocitos para inmunoterapia adoptiva después de TPH alogénico o trasplante de órgano sólido*

Principal Investigator: Carlos Solano Vercet

Funding body: Instituto de Salud Carlos III-Co-financed FEDER

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2024 extended to 2026

Total budget: €102,850

Title: *Immunobiology of GMP-compliant expanded NK cells from selected lymphocyte-bank-registry donors for adoptive immunotherapy after allogeneic HSC in hematological neoplasias or solid organ transplantat.*

Principal Investigator: Rut Meseguer Naturil

Funding body: Fundación Científica de la Asociación Española Contra el Cáncer. AECC

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2025 extended to 2026

Total budget: €88,000

Reference: IC124/00050

Title: *Ensayo clínico de fase I/II con escalada de dosis para evaluar la seguridad y eficacia de linfocitos T específicos frente a CMV expandidos en condiciones GMP de banco de donantes voluntarios para tratar infección refractaria por CMV post-TPH-Alogénico.*

Principal Investigator: Carlos Solano Vercet

Funding body: Instituto de Salud Carlos III

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2025-2028
Total budget: €679,206

JOURNAL PUBLICATIONS		
Number of Publications	IF	Average FI
40	242.6	6.06
National collaborations	International collaborations	Corresponding author
22	14	14

- Evaluation of the VIDAS Cytomegalovirus (CMV)-IGRA for Assessing CMV-Specific T-Cell Responses in Immunocompetent and Immunosuppressed Individuals. Giménez E, Albert E, Colomer E, Pérez A, Montomoli M, Piñana JL, Sanchis I et al. JOURNAL OF MEDICAL VIROLOGY. 2025 april 01. 97 (4);DOI:10.1002/jmv.70355. PMID:40232234. IF: 4,60. Q1
- Early ribavirin reduce RSV symptoms duration in post-allogeneic stem cell transplant: challenges in symptoms duration assessment. Piñana,JL, Micó Cerdá,M, Gómez,D, Pérez,A, Montoro,J, Hernani,R, Choraó,P et al. BONE MARROW TRANSPLANTATION. 2025 may 01. 60 (5):740-742. DOI:10.1038/s41409-025-02549-7. PMID:40119132. IF: 5,20. Q1
- Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Sánchez A, Carretero D, Grau B, Martínez M, Albert E, Giménez E, Colomer E et al. JOURNAL OF MEDICAL VIROLOGY. 2025 june 22. 97 (6);DOI:10.1002/jmv.70463. PMID:40545672. IF: 4,60. Q1
- Community-Acquired Respiratory Virus Infections: A Threat to Long-Term Survivors After Allogeneic Stem Cell Transplant?. Piñana JL, Carbonell JA, Gómez D, Montoro J, Pérez A, Hernani R, Chorão P et al. CLINICAL INFECTIOUS DISEASES. 2025 september 15. 81 (3):570-580. DOI:10.1093/cid/ciae602. PMID:39657017. IF: 7,30. Q1
- Cytomegalovirus UL21-5 mRNAemia as a Marker of Active Virus Replication in Allogeneic Hematopoietic Transplant Recipients. de la Asunción,CS, Ocete,MD, Gimenez,E, Albert,E, Gimeno,C, Piñana,JL, Solano,C et al. JOURNAL OF MEDICAL VIROLOGY. 2025 september 23. 97 (10);DOI:10.1002/jmv.70617. PMID:40985324. IF: 4,60. Q1

THESIS

Thesis title: Dispositivos de Acceso Venoso y sus complicaciones en el paciente hematológico: análisis del perfil de pacientes y tratamientos

Type: Doctoral Thesis

Doctoral candidate: Lucía Brines Sirerol

Director(s): Dr Cristina Buigues González, Dr Carlos Solano Ver-cet and Dr Isabel Trapero Gimeno

University: Universitat de València (Estudi General)

Defence Date: 16/12/2025

Grade: Excellence

Quality recognition/Award: Cum Laude

Research Group on Lymphoproliferative Disorders


Consolidated

Principal Investigator: M^a Jose Terol Castera

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
M^a José Terol Castera. Hospital /UV
- Established Researcher:**
Antonio Ferrandez Izquierdo. Hospital /UV
- Recognised Researcher:**
Edelmira Martí Sáez. Hospital
Blanca Ferrer Lores. Hospital
Alicia Serrano Alcalá. INCLIVA
Anabel Teruel Casasus. Hospital /UV
- First Stage Researcher:**
Laura Ventura López. INCLIVA
- Staff-Technician:**
Ana Saus Carreres. Hospital
María Mercedes Bou Moreno. INCLIVA
Esther Lozano García. INCLIVA



- STRATEGIC AIMS**
- During 2025:
- First, we analysed the mutational status of IgVH in CLL and its prognostic impact in a wide series of patients, as well as collaborating in the design of a new NGS technique to study this mutational status. New molecular markers (mutations TP53, BIRC3, MYD88, NOTCH1 and SF3B1) have also been studied in CLL by new generation sequencing techniques. In addition, ongoing collaboration in the GENOMA CLL sequencing project, with a clinical-evolutionary update.
 - Second, we analysed and integrated data from conventional lymphoma evaluation tests performed for clinical practice, including clinical, molecular and imaging biomarkers using new imaging interpretation tools (artificial intelligence, deep learning and radiomics), disease-specific molecular markers (lymphoma clonotype through liquid biopsies) and CAR-T cell monitoring (digital PCR) to accurately predict disease response at one year of CAR-T cell infusion.
 - Third, we began identifying patients and samples of lymphoma patients diagnosed at our centre who could benefit from personalized genomic precision medicine and participation in the PREGENLINF project.
 - Finally, we have expanded our participation in clinical research projects in CLL, refractory lymphomas and multiple myeloma, in both the incorporation of new drugs and the design and development of new therapeutic options in the context of phase 1–3 clinical trials.

- MAIN LINES OF RESEARCH**
- New therapeutic options for CLL/lymphoma/ MM patients refractory to chemoimmunotherapy.
 - Study of new molecular markers (mutations of IgVH, TP53, BIRC3, MYD88, NOTCH1 and SF3B1) in CLL: conventional versus NGS techniques. Implication in clonal evolution associated with tumour progression.
 - Analyse the value of new molecular markers in lymphoma established by Next Generation Sequencing Techniques (NGS) to facilitate diagnosis of certain types of lymphoproliferative diseases as well as the prognostic impact in term of response to treatment and future targeted therapy.

- Integrate and analyse data obtained from lymphoma evaluation tests, using new imaging interpretation tools (artificial intelligence, deep learning and radiomics), disease-specific molecular markers (lymphoma clonotype through liquid biopsies) and CAR-T cell monitoring (digital PCR) to accurately predict disease response at one year of CAR-T cell infusion.

RESEARCH PROJECTS

Title: *Cart-Ai-Radiomics in Lymphomas: Predictive value of artificial intelligence in non-hodgkin lymphoma treated with Car-t therapy.*

Principal Investigator: M^a José Terol Castera

Funding body: *Gilead Sciences, S.L.U.*

Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2024 extended to 2025

Total budget: €49,967

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
12	134.4	11.2
National collaborations	International collaborations	Corresponding author
6	6	5

- Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR-T Therapy. Hernani R, Ventura L, Heras B, Serrano A, Rivada M, Martínez C, Benzaquén A et al. eJHaem. 2025 march 19. 6 (2). DOI: 10.1002/jha2.70015. PMID:40110072. IF: 1,20. Q4
- Characterization of Chronic Lymphocytic Leukemia Immunoglobulin Rearrangements from Partial Read Sequencing. Fuentes A, Serrano A, Ferrer B, Ventura L, Seda E, García AB, Navarro B et al. GENOMICS PROTEOMICS & BIOINFORMATICS. 2025 may 02. 23 (2). DOI: 10.1093/gpbjnl/qzaf041. PMID:40315014. IF: 7,90. Q1
- Digital pathology and lipid droplet size as a key determinant of discrepancies between histology and MRI gradings in steatotic liver disease. Marti D, Alfaro C, Fernández M, Ten A, Cerdá L, Crespo A, Navarrete I et al. EUROPEAN RADIOLOGY. 2025 august 08. DOI:10.1007/s00330-025-11919-0. PMID:40781513. IF: 4,70. Q1

- Prospective evaluation of CAR-T cell therapy-related proteinuria and kidney dysfunction. Moncho F, Hernani R, Juan I, Benzaquén A, Solís MA, Pérez A, Navarro JF et al. Clinical Kidney Journal. 2025 october 01. 18 (10). DOI: 10.1093/ckj/sfaf270. PMID:41059413. IF: 4,60. Q1
- Patterns of immune recovery after axicabtagene ciloleucel for aggressive B-cell lymphoma. Pardal AA, Benzaquén A, Granados P, Amat P, Hernani R, Balaguer A, Pérez A et al. HemaSphere. 2025 october 05. 9 (10). DOI: 10.1002/hem3.70229. PMID:41054768. IF: 14,60. Q1

Research Group on Myeloid Neoplasms

Consolidated

Principal Investigator: Maria Del Mar Tormo Diaz

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Maria Del Mar Tormo Diaz. Hospital /UV
Juan Carlos Hernandez Boluda. Hospital /UV
- **Established Researcher:**
Eva Villamón Ribate. INCLIVA
- **Recognised Researcher:**
Iván Martín Castillo. INCLIVA
Marisa Calabuig Muñoz. Hospital
- **First Stage Researcher:**
Alicia Borrero Abarca. INCLIVA
Irene Pastor Galan. Hospital
- **Staff-Collaborating Researcher:**
Montserrat Gomez Calafat. Hospital
Carlos Carretero Marquez. Hospital
- **Staff-Technician:**
María José Otálvaro Roa. INCLIVA
Ana Riera Calabuig. INCLIVA
Aurora Fernández Férriz. INCLIVA

STRATEGIC AIMS

- Determine the risk factors for thrombosis in myelofibrosis.
- Analyse Myelodysplastic syndromes with 20q deletion.
- Analyse patients diagnosed with acute myeloid leukaemia and Myelodysplastic syndromes with 7q deletion.

MAIN LINES OF RESEARCH

- Collaborative studies with the CETLAM group (LMA, SMD), PETHEMA (LLA, LMA), the Spanish Philadelphia-negative chronic myeloproliferative disorders group (GEMFIN), the Spanish LMC group (GELMC), the Spanish SMD group (GESMD) and Spanish Group of Advanced Systemic Mastocytosis (GEMAST).
- Study of acute myeloid leukaemia with 7q deletion.
- Study of mechanisms involved in leukemic transformation in myeloproliferative neoplasms.
- Study of myelodysplastic syndromes with 20q deletion.
- Study of myelodysplastic syndromes with 7q deletion.
- Study of risk factors for thrombosis in myelofibrosis.

RESEARCH PROJECTS

Reference: PI21/00538

Title: *Factores clinicobiológicos y genéticos asociados al riesgo de trombosis en la mielofibrosis*

Principal Investigator: Juan Carlos Hernández Boluda

Funding Body: *Instituto de Salud Carlos III-Co-financed FEDER*

Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2022-2024 extended to 2025

Total Budget: €96,800

Reference: PMP24/00025

Title: *UMBRELLA-SUMMA Legacy: Unified platforM for a Better integRal Evaluation of myeLodyspLastic syndromes in spAin-Strategy for Unraveling personalized genoMic Medicine in public heAlth system incorporating patient reported outcomes*


Principal Investigator: Maria del Mar Tormo Díaz

Funding Body: *Instituto de Salud Carlos III-Co-financed FEDER*

Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2025-2026

Total Budget: €47,190



JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
27	211.5	7.83
National collaborations	International collaborations	Corresponding author
17	9	9

- Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. Oñate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M, Diaz M et al. Blood Cancer Journal. 2025 january 11. 15 (1):4-4. DOI:10.1038/s41408-024-01205-5. PMID:39799145. IF: 11,60. Q1
- Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study. Pérez Lamas,L, Diaz,AS, Delgado,RG, Alvarez Larrán,A, Senin,MA, Mora,E, Fox,ML et al. Blood Cancer Journal. 2025 april 17. 15 (1):67-67. DOI:10.1038/s41408-025-01275-z. PMID:40246837. IF: 11,60. Q1
- Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis. Hernández JC, Mosquera A, Gras L, Koster L, Tuffnell J, Kröger N, Gambella M et al. BLOOD. 2025 june 26. 145 (26):3139-3152. DOI:10.1182/blood.2024027287. PMID:40145857. IF: 23,10. Q1
- Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes. Novoa S, Huber S, Gabarrós M, Chen TH, Torres S, Carrillo S, Santiago M et al. LEUKEMIA. 2025 july 01. 39 (7):1791-1794. DOI:10.1038/s41375-025-02629-z. PMID:40335618. IF: 13,40. Q1
- Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial. Jabbour E, Lussana F, Martínez P, Torrent A, Rifón JJ, Agrawal V, Tormo M et al. Lancet Haematology. 2025 july 01. 12 (7):529-541. DOI:10.1016/S2352-3026(25)00144-9. PMID:40532723. IF: 17,70. Q1


Research Group on Molecular Imaging and Metabolomics

Consolidated
Principal Investigator: Daniel Monleón Salvado

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Daniel Monleon Salvado. UV
- **Recognised Researcher:**
Rafael Benito Alcaraz. Hospital
Vannina Gonzalez Marrachelli. UV
María Martín Grau. UV
Jose Manuel Morales Tatay. UV
Maria Mercedes Pardo Tendero. UV
Antonio Pellin Carcelen. UV
Javier Megías Vericat. UV
Lisandra Muñoz Hidalgo. UV
Teresa C. San Miguel Diez. UV
- **First Stage Researcher:**
Pilar Casanova Querol. UV
Geraldine Rocha Correal. UV
- **Staff-Collaborating Researcher:**
Monica Garcia Simon. Hospital
- **Staff-Technician:**
Clara Francés Gómez. UV
Jose Francisco Haro Estévez. UV
Laura Moreno Morcillo. UV




STRATEGIC AIMS

- Identify new metabolomic markers of tumour aggressiveness in brain cancer.
- Explore the role of tumour metabolites as epigenetic drivers of chemo and radio sensitivity.
- Identify new metabolomic cardiovascular risk markers based on the microbiota-host interaction.
- Identify new mechanisms for metabolite epigenetic effects on cardiometabolic disease.
- Explore applications in nutrition of NMR metabolomics.

MAIN LINES OF RESEARCH

- Exploration of the brain tumour microenvironment through MRI microimaging and multivoxel magnetic resonance spectroscopy.
- Metabolic profiles in the progression of cardiometabolic risk modulated by the microbiota–host interaction.
- Metabolic profiles of healthy ageing vs frailty.
- MRI microimaging study of porcine cardiac tissue samples to develop new detection methods.
- Tumour metabolism through metabolic profiles in biopsies, biofluids and cells (brain cancer, glioblastoma multiforme, prostate, bladder).



TEAM INVOLVED IN

eatris

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
12	56.9	4.74
National collaborations	International collaborations	Corresponding author
6	4	10

- Microbiota Co-Metabolism Alterations Precede Changes in the Host Metabolism in the Early Stages of Diet-Induced MASLD in Wistar Rats. Martín M, Casanova P, Moreno L, Morales JM, Marrachelli VG, Monleón D. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 february 01. 26 (3). DOI:10.3390/ijms26031288. PMID:39941056. IF: 4,90. Q1.
- Isocitrate Dehydrogenase-Wildtype Glioma Adapts Toward Mutant Phenotypes and Enhanced Therapy Sensitivity Under D-2-Hydroxyglutarate Exposure. Rocha G, Francés C, Megías J, Muñoz L, Casanova P, Haro JF, Teruel V et al. Biomedicines. 2025 june 28. 13 (7).DOI:10.3390/biomedicines13071584. PMID:40722659. IF: 3,90. Q1.
- The Hidden Players of the Fecal Metabolome: Metabolic Dysregulation Beyond SCFAs Under a High-Fat Diet. Martín M, Casanova P, Morales JM, Marrachelli VG, Monleón D. Metabolites. 2025 october 07. 15 (10): DOI:10.3390/metabo15100660. PMID:41149638. IF: 3,70. Q2.
- Metabolomics in Prostate Cancer: A Minimally Invasive Method Using Urine after Prostatic Massage to Predict Gleason Grade. Panach J, González V, Morales JM, García F, Sales MÁ, Monleón D, Martínez JM. ARCHIVOS ESPANOLES DE UROLOGIA. 2025 november 01. 78 (9):1132-1142. DOI:10.56434/j.arch.esp.urol.20257809.148. PMID:41339219. IF: 0,90. Q4.
- Urine metabolic analysis as a non-invasive method to predict biochemical recurrence in prostate cancer. Panach J, González V, Morales JM, García F, Sales MÁ, Monleón D, Martínez JM. Translational Andrology and Urology. 2025 november 30. 14 (11):3708-3717. DOI:10.21037/tau-2025-592. PMID:41368247. IF: 1,70. Q3

Research Group on Molecular Microbiology and Microbial Pathogenesis

Consolidated
Principal Investigator: David Navarro Ortega

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
David Navarro Ortega. Hospital /UV
- **Established Researcher:**
Jesus Rodriguez Diaz. UV
Estela Berenice Gimenez Quiles. Hospital /UV
- **Recognised Researcher:**
Carlos Solano De La Asunción. Hospital
Roberto Gozalbo Rovira. UV
Nazaret Peña Gil. UV
Enric Cuevas Ferrando. INCLIVA
Beatriz Olea Miguel. Hospital
- **Recognised Emerging Researcher:**
Eliseo Alejandro Albert Vicent. Hospital
Ignacio Torres Fink. Hospital
- **First Stage Researcher:**
Sonia Llanos Villatoro. UV
Roberto Cárcamo Calvo. UV
Sergi Lopez Navarro. UV
Ángela Sánchez Simarro. INCLIVA
- **Staff-Collaborating Researcher:**
Maria Angeles Clari Pons. Hospital
Francisco Javier Colomina Rodríguez. Hospital
- **Staff-Technician:**
Ester Colomer Roig. INCLIVA
Patricia Navarro Rodríguez. INCLIVA


Emerging Researchers

Eliseo Alejandro Albert Vicent

The main objective is the study of infection in immunosuppressed patients, particularly in Cytomegalovirus and Alphatorquevirus infection in patients undergoing allogeneic hematopoietic stem cell transplantation.

Ignacio Torres Fink

The project managed by the researcher consists of evaluating immune T-specific reconstitution against Cytomegalovirus in patients who underwent an allogenic hematopoietic precursor transplantation and receive Letermovir.



STRATEGIC AIMS

- Study basic aspects of infectious diseases.
- Study the microorganisms that cause human pathology: characterization, biology and physiopathogenesis.
- Implement and optimize the use of new diagnostic technologies in the clinical management of infectious patients, particularly in the context of basic onco-haematological pathology.
- Create multidisciplinary “diagnostic stewardship” Units (Programs for optimization of the use of diagnostic techniques PRODIM-) with other services (Oncology/Haematology/ICU/Resuscitation, Primary Care).
- Study and characterise the immunobiology of patients with infectious diseases and the clinical impact on individuals and society.

MAIN LINES OF RESEARCH

- Analytical validation of diagnostic techniques. - Study concordance between diagnostic techniques and linearity.
- Study of sensitivity, specificity, predictive values and robustness.
- Clinical validation of diagnostic techniques. - Clinical validation field studies of diagnostic techniques.
- Economic evaluations of diagnostic techniques and algorithms.
- Design and evaluation of diagnostic algorithms, applicability and actions associated with the result of analytical techniques and development of new diagnostic strategies. - Use of MALDI-TOF technology (Matrix-assisted laser desorption ionisation-time-of- flight) for early identification and preliminary characterization of the resistotype in a blood sample from a patient with bacteraemia.
- Use of MALDI-TOF (Matrix-assisted laser desorption ionisation-time-of-flight) technology for early identification and preliminary characterization of the resistotype in urine samples in patients with suspected pyelonephritis.
- Immunobiology of cytomegalovirus infection in patients undergoing allogeneic transplantation of hematopoietic precursors and haematological neoplasms. Cytomegalovirus, pathophysiology of infection and study of mortality in transplant patients.
- Study of genotypic resistance of cytomegalovirus using Next Generation Sequencing techniques.
- Study of T adaptive immunity against cytomegalovirus in haematological patients.
- Immunobiology of SARS-CoV-2 infection. - Post-vaccination B and T adaptive immunity in a high-risk population.
- Study of the virological characteristics of SARS-CoV-2 and its relationship with the clinical evolution of Covid-19 patients.
- Molecular characterization of Neisseria gonorrhoeae.
- Viroma study, in particular the utility of monitoring anelloviruses, their quantity and distribution, as a tool to quantify the degree of immunosuppression or immune reconstitution in allogeneic hematopoietic precursor transplantation (Alo-HSCT), in solid organ transplantation (SOT) and in autoimmune diseases treated with immunosuppressants.
- Study of Torque tenovirus as a surrogate marker of reconstitution or immunosuppression in allo-HSCT.
- Study of Torque tenovirus as a tool to guide the degree of immunosuppression in solid organ transplant patients.
- Study of the virome as a tool to generate a multifactorial score for prognostic purposes in different pathologies with an important immunological pathophysiogenic component.

RESEARCH PROJECTS

Reference: PI21/00563
Title: *Inmunidad adaptativa de linfocitos B y T frente a SARS-CoV-2 tras la vacunación de pacientes en riesgo de sufrir COVID-19 severa*
Principal Investigator: David Navarro Ortega (Estela Giménez as co-IP)
Funding body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2024
Total budget: €169,400

Reference: 896932
Title: Personalisation of immunosuppression by monitoring viral load post kidney transplantation - a randomised controlled phase II trial
Principal Investigator: David Navarro Ortega
Funding body: European Commission
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2021-2026
Total budget: €85,625

Title: *Impacto de implementación de nuevas estrategias de cribado para microeliminación de Hepatitis C en el Departamento de Salud Valencia Clínico-Malvarrosa.*
Principal Investigator: María Desamparados Escudero García and David Navarro Ortega
Funding body: Gilead Sciences, S.L.U.
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €23,594

Reference: PI24/01844
Title: *Mejora del tratamiento de la infección activa por citomegalovirus en receptores de trasplante alogénico de células madre hematopoyéticas sometidos a profilaxis con Letermovir*
Principal Investigator: David Navarro Ortega
Funding body: *Instituto de Salud Carlos III*
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2027
Total budget: €181,250

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
36	201.3	6.1
National collaborations	International collaborations	Corresponding author
13	10	27

- Estimating SARS-CoV-2 Omicron XBB.1.5 Spike-Directed Functional Antibody Levels From an Anti-Receptor Binding Domain Wuhan-Hu-1-Based Commercial Immunoassay Results. Sánchez A, Cuevas E, Fernández D, Grau B, Albert E, Giménez E, Avilés AI et al. JOURNAL OF MEDICAL VIROLOGY. 2025 january 15. 97 (1):DOI:10.1002/jmv.70130. PMID:39812228. IF: 4,60. Q1.
- Evaluation of the VIDAS Cytomegalovirus (CMV)-IGRA for Assessing CMV-Specific T-Cell Responses in Immunocompetent and Immunosuppressed Individuals. Giménez E, Albert E, Colomer E, Pérez A, Montomoli M, Piñana JL, Sanchis I et al. JOURNAL OF MEDICAL VIROLOGY. 2025 april 01. 97 (4):DOI:10.1002/jmv.70355. PMID:40232234. IF: 4,60. Q1
- Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination. Sánchez A, Panizo N, Giménez E, Albert E, Montomoli M, Sanchis I, Kanter J et al. JOURNAL OF MEDICAL VIROLOGY. 2025 may 01. 97 (5):DOI:10.1002/jmv.70382. PMID:40326950. IF: 4,60. Q1.
- Early ribavirin reduce RSV symptoms duration in post-allogeneic stem cell transplant: challenges in symptoms duration assessment. Piñana,JL, Micó Cerdá,M, Gómez,D, Pérez,A, Montoro,J, Hernani,R, Chorao,P et al. BONE MARROW TRANSPLANTATION. 2025 may 01. 60 (5):740-742. DOI:10.1038/s41409-025-02549-7. PMID:40119132. IF: 5,20. Q1.
- Community-Acquired Respiratory Virus Infections: A Threat to Long-Term Survivors After Allogeneic Stem Cell Transplant?. Piñana JL, Carbonell JA, Gómez D, Montoro J, Pérez A, Hernani R, Chorão P et al. CLINICAL INFECTIOUS DISEASES. 2025 september 15. 81 (3):570-580. DOI:10.1093/cid/ciae602. PMID:39657017. IF: 7,30. Q1

THESIS

Thesis title: Immunobiology of cytomegalovirus infections in haploidentical allogeneic stem cell transplantation with post-transplantation cyclophosphamide.
Type: Doctoral Thesis
Doctoral candidate: Dixie Huntly
Director(s): Dr David Navarro Ortega
University: Universitat de València (Estudi General)
Defence Date: 12/02/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Thesis title: Respuesta de anticuerpos funcionales frente a SARS-CoV-2 (variante Ómicron) en la población general.
Type: Doctoral Thesis
Doctoral candidate: Jorge Camacho Marín
Director(s): Dr David Navarro Ortega
University: Universitat de València (Estudi General)
Defence Date: 27/02/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Thesis title: Virología e inmunología de la infección por el citomegalovirus (CMV) en el paciente con neoplasias hematológicas en la era de las nuevas bioterapias.
Type: Doctoral Thesis
Doctoral candidate: Carlos Solano de la Asunción
Director(s): Dr David Navarro Ortega and Dr Eliseo Alejandro Albert Vicent
University: Universitat de València (Estudi General)
Defence Date: 11/12/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Translational Research Group on Esophagogastric Cancer


Emergent

Principal Investigator: Tania Carolina Fleitas Kanonnikoff

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Established Researcher:**
Tania Carolina Fleitas Kanonnikoff. Hospital
- Recognised Researcher:**
Manuel Cabeza Segura. INCLIVA
Josefa Castillo Aliaga. UV
Mari Carmen Fernandez Moreno. Hospital
- First Stage Researcher:**
Alba Aguilar Cifre. INCLIVA
Arturo González Vilanova. INCLIVA
- Staff-Collaborating Researcher:**
Ricardo Gadea Mateo. Hospital
Maria Eugenia Barrios Carvajal. Hospital
Fernando Lopez Mozos. Hospital /UV
Rosa Ana Villagrasa Manzano. Hospital
Almudena Vera Gonzalez. Hospital
- Staff-Technician:**
Andrea Marín Alonso. INCLIVA
- Staff-Project Manager:**
Ana María Miralles Marco. INCLIVA
- Staff-Data Manager:**
Sergio Romero Alcaide. INCLIVA
- Research Nurse Staff:**
Matteo Stocco. INCLIVA




STRATEGIC AIMS

- Identify biomarkers to stratify gastric cancer patients by sensitivity to immunotherapy.
- Develop and integrate tools for identifying individuals at risk of developing gastric cancer as a prevention strategy.
- Deepen understanding of the risk factors and biological characteristics of gastric tumours in the young population.
- Generate a biobank of organoids for analysing the biological characteristics of each patient's tumour and screening for sensitivity to therapies as a validation tool.

MAIN LINES OF RESEARCH

- Clinical, epidemiological, biological and microbiome characteristics of gastric tumours in young patients.
- Immune microenvironment of advanced gastric cancer and mechanisms of resistance to immunotherapy.
- Models for risk stratification of developing gastric cancer and the establishment of prevention strategies.
- Generation of organoid models as a tool for personalized medicine strategies in gastric cancer.



RESEARCH PROJECTS

Reference: PI21/00693

Title: Perfil de biomarcadores inmunes como herramienta para la identificación de pacientes con cáncer gástricos subsidiarios de inmunoterapia

Principal Investigator: Tania Fleitas Kanonnikoff

Funding Body: Instituto de Salud Carlos III-Co-financed FEDER

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2024 extended to 2025

Total Budget: €208,120

Title: Descifrando el microambiente del cáncer gástrico: un nuevo paso hacia la inmunoterapia de precisión.

Principal Investigator: Tania Fleitas Kanonnikoff

Funding Body: Fundación Científica de la Asociación Española Contra el Cáncer AECC

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2025

Total Budget: €180,000

Title: Inmunoterapia en cáncer gastroesofágico. Hacia una nueva estrategia terapéutica a través de la inhibición de las proteínas HCK y/o FGR implicadas en la atenuación de la respuesta inmune.

Principal Investigator: Tania Fleitas Kanonnikoff

Funding Body: Fundación Mutua Madrileña

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2026

Total Budget: €110,000

Title: Prognostic and predictive impact of the microbiome and the tumor immune microenvironment on advanced gastric cancer across young patients (<50 YO): VERO-2 project

Principal Investigator: Tania Fleitas Kanonnikoff

Funding Body: Gilead Fellowship Program

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2025, extended to 2026

Total budget: €49,980

Reference: 101095359 - AIDA

Title: An Artificially Intelligent Diagnostic Assistant for gastric inflammation. AIDA

Principal Investigator: Tania Fleitas Kanonnikoff

Funding Body: European Commission

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2026

Total Budget: €6,334,803.75 (INCLIVA: €1,138,750)

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
21	198.1	11
National collaborations	International collaborations	Corresponding author
3	15	13

- Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypND and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study. Lordick F, Mauer ME, Stocker G, Cella CA, Ben I, Piessen G, Wyrwicz L et al. ANNALS OF ONCOLOGY. 2025 february 01. 36 (2):197-207. DOI:10.1016/j.annonc.2024.10.829. PMID:39542422. IF: 65,40. Q1
- Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression. Martinez C, Barros R, Caballero C, Boggino H, Alarcón L, Peleteiro B, Ruiz E et al. Gastric Cancer. 2025 march 01. 28 (2):160-173. DOI:10.1007/s10120-024-01578-3. PMID:39755998. IF: 5,10. Q1.
- Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project. Dienstmann R, Ruiz E, Alsina M, Ruiz F, Groen TS, Martínez C, Fernández EA et al. ESMO Open. 2025 march 01. 10 (3):104482-104482. DOI:10.1016/j.esmoop.2025.104482. PMID:40036904. IF: 8,30. Q1
- Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence. van TS, Cabeza M, Ferreira RM, Martínez C, Barros R, Santos J, Costa A et al. BRITISH JOURNAL OF CANCER. 2025 may 18. 132 (9):783-792. DOI:10.1038/s41416-025-02979-6. PMID:40113862. IF: 6,80. Q1
- The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations. Higgins K, Nyssen OP, Southern J, Laponogov I, AIDA C, Vesselkov D, Gisbert JP et al. Nature Communications. 2025 july 14. 16 (1):6472-6472. DOI:10.1038/s41467-025-61329-5. PMID:40659612. IF: 15,70. Q1

THESIS
Thesis title: Characterization of the immune microenvironment and patient-derived tumor organoids to identify biomarkers of response and therapy resistance mechanisms in advanced gas-
tric cancer
Type: Doctoral Thesis
Doctoral candidate: Miguel Cabeza Segura
Director(s): Dr Tania Fleitas Kanonnikoff and Dr Josefa Castillo Aliaga
University: Universitat de València (Estudi General)
Defence Date: 14/01/2025
Grade: Excellent
Quality recognition/Award: Cum Laude International Distinc-
tion

Medical Oncology Clinical Trials Unit: Phase I and Experimental Therapies

Principal Investigator: Andrés Cervantes Ruipérez

GROUP MEMBERS
Staff during the period 01/01/2025 – 31/12/2025
Principal Investigator:
Andrés Cervantes Ruipérez. Hospital. University

Research Team:
Alba Viala Monleón. Hospital
Amelia Insa Mollá. Hospital
Begoña Bermejo de las Heras. Hospital. University
Desamparados Roda Pérez. Hospital
Gema Bruixola Campos. Hospital
Inés González Barrallo. Hospital
Isabel Chirivella González. Hospital. University
José Vicente Montón Bueno. Hospital
Jose A. Pérez Fidalgo. Hospital
Juan Miguel Cejalvo Andújar. Hospital
Maite Martinez Martinez. Hospital
Marisol Huerta Álvaro. Hospital
Marta Tapia Céspedes. Hospital
Noelia Tarazona Llaveró. Hospital
Paloma Martín Martorell. Hospital
Susana Roselló Keranen. Hospital
Tania Fleitas Kanonnikoff. Hospital
Valentina Gambardella. Hospital
Victor Seguí Manzaneque. Hospital

Nurses:
Inma Blasco Blasco. Nurse Coordinator INCLIVA
Cecilia Ramón Mascarell. INCLIVA
María Isabel Calzadilla Luz. INCLIVA
Matteo Stocco. INCLIVA
Nuria Aguado Machancoses. INCLIVA
Silvia Moreno Magraner. INCLIVA
Gloria Corredor Agulló. INCLIVA
María Montes de Oca. INCLIVA
Mónica Ferrer Aguado. INCLIVA
Paula Martínez Lucas. INCLIVA
Grace Steffania Ruiz. INCLIVA
Ana Vinatea. INCLIVA
Cristian Pérez. INCLIVA
Silvia Coret. INCLIVA
Marta Castillo. INCLIVA

Sara Rodríguez. INCLIVA
Cristina Tebar. INCLIVA
Ana Cosías. INCLIVA
Maria Jose Sansó. INCLIVA

CTAE (qualified auxiliary nurses):
Andreea Ghiuro. CIBERONC
Arantxa Sánchez Cosmo. INCLIVA
Isamar Cabañero INCLIVA

Laboratory technicians
Jesmina Berenguer. INCLIVA
María Falco. INCLIVA

Data Managers:
Ignacio Castaño López. Coordinator Data Manager. INCLIVA
Alejandro Asturiano. INCLIVA
Ana Vercher Grau. INCLIVA
Andrea Pascual Herrero. INCLIVA
Beatriz López Montero. INCLIVA
Júlia Soler Flores. INCLIVA
Mª Carmen Martínez López. INCLIVA
Sergio Romero Alcaide. INCLIVA
Rubén Sanz. INCLIVA
Alejandro Asturiano. INCLIVA

Administrative assistants:
Yolanda de la Cruz. Administrative Coordinator. INCLIVA
Paqui Fernández. CTA INCLIVA
Lorena Saz Lluch. CTA INCLIVA
Maria Burgos CTA INCLIVA
Paloma Campos CTA. INCLIVA
Maribel Gómez. CTA_Unit Recepcionist INCLIVA
Iris Abad. CTA_Unit Recepcionist INCLIVA
Enrique Castelló. Administrative_economic management
INCLIVA
Paranee Archavarat. Administrative_economic management
INCLIVA
Roberto San Leandro. Administrative_economic management
INCLIVA

INCLIVA is the only hospital in Valencia and among only a few in Spain to perform phase I cancer clinical trials (trials in which a substance or product is tested in humans for the first time). Through their Oncology Department INCLIVA is conducting 251 clinical trials, 178 of which concern treatment in the early stages of testing (85 phase I or “first in human” and 69 phase II). INCLIVA's new facilities provide a full floor and a half specifically dedicated to this unit.

The unit aims to develop and select new drugs through clinical trials and to perform studies related to pathogenesis, prognosis and new experimental therapies in solid tumours.

FUNCTIONS:

The unit focuses on developing new drugs through clinical trials, studies on pathogenesis, prognosis and new experimental therapies for solid tumours. Its principal activity consists of developing clinical trials of a pronounced international character, promoted by the leading companies in the pharmaceutical sector. The first administration of medication to humans (PHASE I) is carried out by identifying patients from the Oncology Department of the Hospital Clínico Universitario de Valencia and other referral centres whose characteristics are in line with the target population of the drugs under investigation. Unlike other units carrying out phase I clinical trials, no action is performed on healthy subjects. The innovative approach of this unit, which deals with cancer diagnosis and treatment based on the complete sequencing of the human genome, is achieving promising results using specific treatments against molecular alterations detectable in sequencing processes and developing new immunotherapy combinations, thus enabling the development of new therapies and implementing precision medicine. These new drugs are less toxic and more specific to each type of cancer, and some of them have now entered phase II.

LOCATION:

The Medical Oncology Clinical Trials Unit: Phase I and Experimental Therapies has two separate centres for patient care, where the researchers and research nursing staff are based:

- 2nd and 3rd floors, INCLIVA Biomedical Research Institute: main activities are coordination of phase I clinical trials, and trials for gastrointestinal, gynaecological, genitourinary, head and neck, and melanoma cancers
- 8th floor, Maternity Block at the Hospital Clínico de Valencia: coordination activities for breast and lung cancer clinical trials are carried out

EQUIPMENT

2nd and 3rd floors of INCLIVA Biomedical Research Institute:

Located on the 2nd floor:

- -80° C Freezer
- -20° C Freezer
- 2 Refrigerated desktop centrifuge
- 2 cientific refrigerator
- Conventional fridge
- Defibrillator
- Electrocardiographic equipment
- 7 monitors (blood pressure, heart rate and O2 saturation)
- 7 double medication infusion pumps
- 7 heads gases (oxygen and vacuum)

Located on the 3rd floor:

- Conventional refrigerator
- Refrigerated tabletop centrifuge
- Electrocardiography equipment
- Defibrillator
- Ultrasound scanner
- 5 Philips counter monitors
- 2 voltage monitors
- 4 arches with 8 sockets/heads + 2 in the rooms

The following facilities are located on the second floor:

- Reception and waiting room
- 2 Consulting rooms
- Staff room
- Meeting room
- Therapy room

The third floor hosts the following facilities:

- Clinical trials office
- Monitoring room
- Clinical trials archives

EQUIPMENT

8th floor of the Maternity Block at Hospital Clínico de Valencia

- Freezer at -80°C
- Centrifuge
- Scales
- Pulse oximeter
- Blood pressure monitor
- Electrocardiography equipment

RESEARCH PROJECTS

Reference: 2020/111 - TUMICC

Title: Tumor microenvironment-derived factors in localized colon cancer: clinical impact and therapeutic implications

Principal Investigator: Andrés Cervantes Ruipérez

Funding Body: Asociación Española Contra el Cáncer

Beneficiary Institution: Fundación Investigación Hospital Clínico Universitario de Valencia

Duration: 2020-2025

Total budget: €992,665 (INCLIVA: €332,970)

Reference: CIRCULATE-SPAIN-01

Title: Ensayo clínico aleatorizado, fase II, para evaluar el efecto de la quimioterapia adyuvante intensiva frente a la estándar en el cáncer de colon localizado con ADN tumoral circulante.

Principal Investigator: Andrés Cervantes Ruipérez

Funding Body: Instituto de Salud Carlos III

Beneficiary Institution: Fundación Investigación Hospital Clínico Universitario de Valencia

Duration: 2021-2026

Total budget: 1,039,967.68

Reference: PI21/00689

Title: Profiling and targeting minimal residual disease in localised colon cancer: a step forward towards precision medicine in adjuvant treatment

Principal Investigator: Andrés Cervantes Ruipérez (CO-IP senior), Noelia Tarazona.

Funding Body: Instituto de Salud Carlos III

Beneficiary Institution: Fundación Investigación Hospital Clínico Universitario de Valencia

Duration: 2022-2025

Total budget: €232,000

Reference: 101057514 - MyPath

Title: Developing and implementing innovative Patient-Centred Care Pathways for cancer patients

Principal Investigator: Andrés Cervantes Ruipérez (CO-IP)

Funding Body: European Commission

Beneficiary Institution: Fundación Investigación Hospital Clínico Universitario de Valencia

Duration: 2022- 2027

Total budget: €4,773,470 (INCLIVA: €388,125)

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
11	124.3	11.3
National collaborations	International collaborations	Corresponding author
2	2	1

- Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Harrington K, Kitano S, Gambardella V, Parkes EE, Moreno I, Alonso G, Doi T et al. Future Oncology. 2025 january 14. 21 (2):195-200. DOI:10.1080/14796694.2024.2441107. PMID:39817655.
- Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors. Luke JJ, Pinato DJ, Juric D, Lorusso P, Hosein PJ, Desai AM, Haddad R et al. Journal for ImmunoTherapy of Cancer. 2025 february 20. 13 (2):DOI:10.1136/jitc-2024-010511. PMID:39979069.
- Safety and Antitumor Activity of a Novel aCD25 Treg Depletter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors. Gambardella V, Ong M, Rodriguez ME, Machiels JP, Sanmamed MF, Galvao V, Spreafico A et al. Cancer Research Communications. 2025 march 01. 5 (3):422-432. DOI:10.1158/2767-9764.CRC-24-0638. PMID:39983024.
- Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. Bedard PL, Jhaveri KL, Accordino MK, Cervantes A, Gambardella V, Hamilton E, Italiano A et al. EUROPEAN JOURNAL OF CANCER. 2025 may 15. 221115397-115397. DOI:10.1016/j.ejca.2025.115397. PMID:40203765.
- Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03. Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A et al. Journal of Thoracic Oncology. 2025 june 01. 20 (6):799-808. DOI:10.1016/j.jtho.2024.12.028. PMID:39755168.
- Phase II study of elraglusib (9-ING-41), a GSK-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer. Mahalingam D, Saeed A, Powell SF, Huerta M, Sahai V, Coveler AL, Davis EJ et al. ESMO Open. 2025 june 01. 10 (6):105122-105122. DOI:10.1016/j.esmoop.2025.105122. PMID:40403387.
- Safety overview and management of inavolisib alone and

in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). Gambardella V, Accordino MK, Bedard PL, Cervantes A, Hamilton E, Italiano A, Kalinsky K et al. ESMO Open. 2025 july 01. 10 (7):105303-105303. DOI:10.1016/j.esmoop.2025.105303. PMID:40513140.


- A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer. Manso L, Sánchez R, Guerra JA, Cortés A, Cejalvo JM, García JA, Morales S et al. Cancer Research Communications. 2025 september 01. 5 (9):1728-1737. DOI:10.1158/2767-9764.CRC-25-0428. PMID:40928353.
- Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed MF, Alese OB, Sayehli CM et al. JOURNAL OF CLINICAL ONCOLOGY. 2025 september 20. 43 (27):3021-3031. DOI:10.1200/JCO-25-00363. PMID:40706016.
- Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLT1-1904 ACROPOLI trial. Seguí E, Brasó F, Pascual T, Sanfeliu E, Victoria I, Saura C, Hierro C et al. ESMO Open. 2025 october 01. 10 (10):105838-105838. DOI:10.1016/j.esmoop.2025.105838. PMID:41033278.
- Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. Elez E, Siena S, Sartore A, Ros J, Ciardello F, Martinelli E, Steeghs N et al. ESMO Open. 2025 december 01. 10 (12):105892-105892. DOI:10.1016/j.esmoop.2025.105892. PMID:41337858.

4.3.3 Metabolism and Organ Damage Area

Groups

- Research Group on Genetics of Osteoporosis
- Research Group on Neurological Impairment
- Research Group on Inflammation
- Research Group on Psychiatry and Neurodegenerative Diseases
- Research Group on Respiratory Diseases
- Research Group on Tissue Biochemistry
- Research Group on Ageing and Physical Activity
- Research Group on Anesthesiology and Reanimation
- Research Group on Human Translational Genomics
- Research Group on General and Digestive Surgery
- Research Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP)
- Research Group on Cellular and Organic Physiopathology of Oxidative Stress
- Research Group on Nuclear Receptors in Cardiometabolic Pathology
- Research group on Metabolic Diseases
- Research Group on Rare Respiratory Diseases (RRD)
- Research Group on Healthy Ageing (MiniAgeing)
- Research Group on Exercise, Nutrition and Healthy Lifestyle
- Research Group on Epigenomics and Translational Epigenetics
- Research Group on Medical Chemistry for Drug Development
- Research Group on Neurobiology and Molecular Physiopathology in Rare Diseases – NeuroFisER
- Research Group on Genetics and Biomarkers of Rare Diseases
- Mixed Unit on Neurological Impairment.

Number of indexed publications		IF		Average IF	
233		1381.8		5.9304	
National collaborations		International collaborations		Corresponding author	
119		92		106	
D1	Q1	Q2	First author		Last author
59	147	50	79		52



Key Publications


- Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women. Garrido I, Tapia M, Carbonell J, Pena C, Torres S, Agreda A, Lameirinhas A et al. Cancer Communications. 2025 july 01. 45 (7):789-793. DOI:10.1002/cac2.70019. PMID:40207642.
- Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Martín J, Gimeno F, Henriksen TV, García B, Martínez B, Gambardella V, Martínez C et al. Nature Cancer. 2025 june 01. 6 (6):1000-1016. DOI:10.1038/s43018-025-00960-z. PMID:40301653.
- Bcl-xL overexpression in T cells preserves muscle mitochondrial structure and function and prevents frailty in old mice. Mas C, Román A, Sanz J, Romero N, Huete J, Dromant M, Cuervo AM et al. Science Advances. 2025 march 19. 11 (12). DOI:10.1126/sciadv.adr1378. PMID:40106552.
- Molecular mechanism involved in sarcopenia and frailty, diagnosis and therapy. Viña J, Gomez Cabrera MC. MOLECULAR ASPECTS OF MEDICINE. 2025 october 01. 105101387-101387. DOI: 10.1016/j.mam.2025.101387. PMID:40781035.
- Neurological outcomes and mortality following hyperoxemia in adult patients with acute brain injury: an updated meta-analysis and meta-regression. Romero N, Robba C, Monleón B, Ruiz A, Pascual M, Ruiz A, Perdomo F et al. CRITICAL CARE. 2025 april 23. 29 (1):167-167. DOI: 10.1186/s13054-025-05387-7. PMID:40270034.

Research Group on Genetics of Osteoporosis

Consolidated
Principal Investigator: Miguel Ángel García Pérez

GROUP MEMBERS
Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Miguel Ángel García Pérez. UV
Juan Jose Tarin Folgado. UV
- **Staff-Collaborating Researcher:**
María Loreto Suay Llopis. UV
Rosa María Aliaga Corachan. UV



STRATEGIC AIMS
Identify genes and polymorphisms associated with bone phenotypes such as bone mineral density and fragility fracture. Identify miRNAs as biomarkers of fragility fracture and osteoarthritis. Develop animal models of accelerated bone loss as a source of candidate genes for study in humans. Functional characterization of genetic variants associated with quantitative phenotypes.

MAIN LINES OF RESEARCH
- Development of animal models of accelerated bone loss and cellular models of osteogenesis.

- Functional analysis of genetic variants.
- Genetic and epigenetic biomarkers of prevalent bone phenotypes.
- Genetics of postmenopausal osteoporosis

RESEARCH PROJECTS
Reference: PID2022-137515OB-I00. **Title:** *Biomarcadores genéticos y epigenéticos en la osteoporosis postmenopáusica.*
Principal Investigator: Miguel Ángel García Pérez.
Funding body: *Ministerio de Ciencia e Innovación.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2026.
Total budget: €115.000.

JOURNAL PUBLICATIONS		
Number of Publications	IF	Average FI
3	9.5	3.166
National collaborations	International collaborations	Corresponding author
1	2	1

- The Final Phases of Ovarian Aging: A Tale of Diverging Functional Trajectories. Bochynska S, García Pérez MÁ, Tarín JJ, Szeliga A, Meczekalski B, Cano A. Journal of Clinical Medicine. 2025 august 18. 14 (16). DOI: 10.3390/jcm14165834. PMID:40869659. IF: 2,90. Q1.
- Effects of L-Arginine on Bone Metabolism: Evidence from In Vitro and In Vivo Models. Pertusa C, Carrasco A, Aliaga R, Suay L, Alonso E, Cano A, Tarin JJ et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 september 01. 26 (17). DOI: 10.3390/ijms26178484. PMID:40943405. IF: 4,90. Q1.
- Genetic variants of the androgen receptor and frailty in postmenopausal women. Monllor A, García MA, Tarín JJ, García A, Artero A, Cano A. GYNECOLOGICAL ENDOCRINOLOGY. 2025 december 31. 41 (1):2565238-2565238. DOI: 10.1080/09513590.2025.2565238. PMID:41047731. IF: 1,70. Q3.

Research Group on Neurological Impairment


Consolidated
Principal Investigator: Carmina Montoliu Félix

GROUP MEMBERS
Staff in the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Carmina Montoliu Félix. UV
- **Established Researcher:**
Andrea Cabrera Pastor. UV
Jose Ballester Fayos. Hospital
Maria Desamparados Escudero Garcia. UV
- **Recognised Researcher:**
Paula Izquierdo Altarejos. INCLIVA
Paula Cases Bergon. Hospital
Nicolas Peñaranda Sarmiento. Hospital
Rut Victorio Muñoz. Hospital
Cristina Monton Rodríguez. Hospital
María Amparo Urios Lluch. INCLIVA
- **Recognised Emerging Researcher:**
Maria Pilar Ballester Ferre. Hospital
- **First Stage Researcher:**
Dana Campos Hoyos. UV
Lylia Lakehal. INCLIVA
Adrià López Gramaje. UV
- **Staff-Collaborating Researcher:**
Mika Aiko Gesler. Hospital
Jose Luis León Guijarro. ASCIRES
Roberto Aliaga Méndez. ASCIRES
- **Research Nurse Staff:**
María Jesús Campa Santiago. Hospital
- **Staff-Technician:**
Laura Ávila Fernández. INCLIVA
María Oliver Ferrándiz. INCLIVA

Emerging Researcher
Maria Pilar Ballester Ferre
Specialist in Hepatology and performs her medical activity at Hospital Clínico Universitario de Valencia, Spain. She recently obtained a Juan Rodés contract 2024-2028 (JR23/00029) of the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III. She obtained her cum laude PhD at University of Valencia in 2021 by studying the immune dysfunction associated with cognitive impairment in patients with cirrhosis, obtaining an extraordinary doctorate award from University of Valencia. The project was also selected as the best oral presentation in

the regional conference from Sociedad Valenciana de Patología Digestiva in 2018. Her PhD was funded through a competitive grant (Rio Hortega contract -CM19/00011-) from Instituto de Salud Carlos III. As a pre-doctorate, she spent two months in the University of Pittsburgh Medical Centre under the supervision of Professor Ramon Bataller, with the support of a fellowship from INCLIVA-Biomedical Research Institute. Soon after finishing, she performed a postdoctoral stay at University College London, United Kingdom, supervised by Professor Rajiv Jalan; which was funded through two grants (INCLIVA-Biomedical Research Institute and Sociedad Valenciana de Patología Digestiva). In London, she studied the role of ammonia in the pathogenesis and treatment of complications of cirrhosis, creating the Ammon Consortium, which she currently coordinates. She obtained a regional competitive grant as Principal Investigator by Sociedad Valenciana de Patología Digestiva in 2020, a national grant from Asociación Española para el Estudio del Hígado in 2023 and a national competitive-funded project by Instituto de Salud Carlos III in 2024 as co-Investigator. She has also collaborated in three funded research projects from Instituto de Salud Carlos III, Fundación Ramón Areces and Programa Prometeo Consellería de Educación Generalitat Valenciana. Recently, she also obtained her first patent. She is part of the International Society of Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) Translational steering committee and member of the European Association for the Study of the Liver. Dr Ballester has supervised 1 doctoral Thesis, 5 final degree projects, 1 final master's project and she is currently co-directing 3 doctoral thesis at University of Valencia.



STRATEGIC AIMS

Characterize cognitive, functional and brain alterations in cirrhotic patients with minimal hepatic encephalopathy (MHE)

Characterize immunological, inflammatory, microbiota and neuroinflammatory alterations associated with onset of MHE

Identify biomarkers for early detection of mild cognitive impairment in MHE

Characterize inflammatory processes and create a bioinformatic model of molecular and cellular events of the immune system associated with MHE onset. Assess its utility to predict or diagnose MHE

Evaluate the effects of treatment with rifaximin and the mechanisms involved

Study cognitive and motor impairment in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Characterize immunological alterations in microbiota, inflammation and neuroinflammation associated with cognitive impairment in MASLD. Molecular and cellular mechanisms

MAIN LINES OF RESEARCH

Main Line of research:

Characterization of neurological and brain alterations in patients with liver disease. Mechanisms: role of changes in inflammation, immune system, microbiota and extracellular vesicles.

Diagnostic and therapeutic implications.

Research lines in liver cirrhosis:

- Characterization of cognitive, functional and cerebral alterations in patients with (MHE).
- Characterization of immunological, inflammatory, and neuroinflammatory changes associated with the onset of MHE.
- Identification of biomarkers for the early detection of mild cognitive impairment in MHE.
- Evaluation of the effects of rifaximin/tadalafil treatments and the mechanisms involved.

Research line in Metabolic and Liver Disease (MASLD):

- Study of cognitive and motor impairments in patients with MASLD.
- Characterization of immunological, inflammatory, and neuroinflammatory changes associated with the onset of cognitive alterations in MASLD. Molecular and cellular mechanisms.

RESEARCH PROJECTS

Reference: DKSVPD-MSD.

Title: Adherencia al programa de cribado de Cáncer Colorrectal en la Enfermedad Inflamatoria Intestinal. Principal Investigator: Maria Pilar Ballester Ferre.

Funding body: Sociedad Española de Patología Digestiva y Sociedad Valenciana de Patología Digestiva.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2020-2025.

Total budget: € 10.000.

Title: Impacto de implementación de nuevas estrategias de cribado para microeliminación de Hepatitis C en el Departamento de Salud Valencia Clínico-Malvarrosa.

Principal Investigator: David Navarro Ortega and Maria Desamparados Escudero Garcia.

Funding body: Gilead Sciences, S.L.U.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2025.

Total budget: € 23.594,32.

Reference: RAMMON.

Title: Role de las medidas repetidas de amonio para la monitorización de pacientes con cirrosis (REP-AMMON).

Principal Investigator: Maria Pilar Ballester Ferre.

Funding body: Fundacion española para el estudio del hígado.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2023-2026.

Total budget: € 36.000,00.

Reference: PI23/00204.

Title: Papel de las vesículas extracelulares en comorbilidades asociadas a obesidad mórbida: implicaciones diagnósticas, terapéuticas y mecanismos.

Principal Investigator: Andrea Cabrera Pastor.

Funding body: Instituto Salud Carlos III.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2026.

Total budget: € 140.000,00.

Reference: PI23/00062.

Title: Mecanismos que conducen al deterioro cognitivo y motor leve en pacientes con enfermedad hepática: Papel de los cambios en la microbiota, el sistema inmunitario y las vesículas extracelulares.

Principal Investigator: Carmina Montoliu Félix.

Funding body: Instituto Salud Carlos III.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2026.

Total budget: € 252.500.

Reference: CA23146.

Title: European vascular liver diseases network. COST ACTION: EURO-VALDI-NET.

Principal Investigator: Maria Pilar Ballester Ferre.

Duration: 2024-2028.

RESEARCH RESULTS

Invention: A computer implemented method and a device for determining risk of a subject developing overt hepatic encephalopathy over time and a computer implemented method of training a mathematical model

Priority Number: GB202303652

Status: Europe, GB, and US National Phase

Principal Investigator: Juan Antonio Cabonell Asíns

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
23	121.4	5.3
National collaborations	International collaborations	Corresponding author
13	9	9

- Extracellular vesicles from L. paracasei improve neuroinflammation, GABA neurotransmission and motor incoordination in hyperammonemic rats. Arenas YM, Pérez G, Montoliu C, Llansola M, Felipo V. BRAIN BEHAVIOR AND IMMUNITY. 2025 january 01. 123556-570. DOI: 10.1016/j.bbi.2024.10.002. PMID:39384052. IF: 7,60. Q1
- Extracellular vesicles from Lactacisibacillus paracasei reduce neuroinflammation in hippocampus and restore some cognitive functions in hyperammonemic rats. Izquierdo P, Arenas YM, Montoliu C, Pérez G, Llansola M, Felipo V. MICROBIOLOGICAL RESEARCH. 2025 may 01. 294128101-128101. DOI: 10.1016/j.micres.2025.128101. PMID:39978142. IF: 6,90. Q1
- Sex differences in the mediating role of brain-derived neurotrophic factor between inflammation and memory in cirrhotic patients with minimal hepatic encephalopathy. Batallas D, Gallego JJ, Casanova F, López A, Rivas P, Megías J, Escudero D et al. Brain Behavior & Immunity-Health. 2025 july 01. 46100998-100998. DOI:10.1016/j.bbih.2025.100998. PMID:40343108. IF: 3,50. Q1
- Digital pathology and lipid droplet size as a key determinant of discrepancies between histology and MRI gradings in steatotic liver disease. Marti D, Alfaro C, Fernández M, Ten A, Cerdá L, Crespo A, Navarrete I et al. EUROPEAN RADIOLOGY. 2025 august 08. 36 (2):1050-1060. DOI:10.1007/s00330-025-11919-0. PMID:40781513. IF: 4,70. Q1
- The analysis of the gut microbiome during liver disease progression led to the identification of biomarkers for related mild cognitive impairment. Giner L, Gallego JJ, Giménez C, Batallas D, Jarquín VH, Casanova F, Fiorillo A et al. Frontiers in Microbiology. 2025 september 16. 161670512-1670512. DOI:10.3389/fmicb.2025.1670512. PMID:41035890. IF: 4,50. Q1
- Sex-Specific Differences and a Predictive Model Based on Clinical and Biochemical Parameters for Minimal Hepatic Encephalopathy. Gallego JJ, Casanova F, Fiorillo A, Benlloch S, Urios A, López A, Oliver M et al. LIVER INTERNATIONAL. 2025 november 19. 45 (12). DOI: 10.1111/liv.70452. PMID:41255242. IF: 5,20. Q1

THESIS

Thesis title: Estudio de las alteraciones neurológicas y bioquímicas en pacientes con obesidad mórbida y enfermedad hepática metabólica. Impacto de la cirugía bariátrica.

Type: Thesis Doctoral

Doctoral candidate: Concepcion Gomez Medina.

Director(s): Carmina Montoliu Félix, Desamparados Escudero Garcia and Maria Pilar Ballester Ferre.

University: Universitat de València (Estudi General).

Date of the defense: 19/06/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Research Group on Inflammation

Consolidated

Principal Investigator: María Jesús Sanz Ferrando and Laura Piqueras Ruiz

GROUP MEMBERS

Staff in the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
María Jesús Sanz Ferrando. UV
Laura Piqueras Ruiz. UV
Esteban Morcillo Sánchez. UV
- Established Researcher:**
Jose Luis Ortiz Belda. UV
- Recognised Researcher:**
Patrice Gomes Marques. UV
Cristina Arce Recatala. UV
Elena Domingo Pérez. INCLIVA
- First Stage Researcher:**
Álvaro Gómez Martín. INCLIVA
Carmen de la Fuente Gómez. INCLIVA
- Staff-Technician:**
Ángela Vea Badenes. INCLIVA
Inés Descalzo Arenas. INCLIVA

STRATEGIC AIMS

Study cellular and soluble inflammatory mediators in early chronic obstructive pulmonary disease.

Study systemic inflammation associated with primary hypercholesterolemia, metabolic syndrome and Nonalcoholic Fatty Liver Disease (NAFLD).

Study the CCL11/CCR3 axis in primary hypercholesterolemia and atherosclerosis.

Study the CCL11/CCR3 axis in abdominal aortic aneurism development.

Study the CXCL16/CXCR6 axis in (NAFLD) and nonalcoholic steatohepatitis (NASH).

Pharmacological modulation of (NAFLD) and (NASH) by combining drugs targeting LXR and PPARAlpha.

Synthesis of new panPPAR agonists and evaluation of their pharmacological impact in ob/ob mice.


Study new panPPAR agonists in (NAFLD) and (NASH).

Study and characterize the role of the CCR4 receptor and its ligands CCL17 / TARCE, CCL22 / MDC and CKLF1 in angiogenesis and inflammation associated with obesity and in response to bariatric surgery

Study new pharmacological agonists of GIPR and GLP1R and their role in the development of abdominal aortic aneurysm and endothelial dysfunction.

MAIN LINES OF RESEARCH

- New immune players in atherosclerosis, abdominal aortic aneurism development, (NAFLD) and (NASH).
- Systemic inflammation in early chronic obstructive pulmonary disease (COPD).
- Vascular inflammation induced by different risk factors of atherosclerosis: metabolic syndrome, primary and familial hypercholesterolemia and (NAFLD).
- Pharmacological effects in controlling cardiometabolic disorders of new dual PPARα/γ and panPPAR agonists.
- Identifying new mechanisms involved in angiogenesis and inflammation in obese patients.
- New pharmacological agonists of GIPR and GLP1R in the development of abdominal aortic aneurysm and endothelial dysfunction.



TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PI21/00220.
Title: *Estudio de nuevos ejes de quimiocinas como potenciales dianas de intervención en la obesidad y la resistencia a la insulina.*
Principal Investigator: Laura Piqueras Ruiz.
Funding body: *Instituto Salud Carlos III.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2025.
Total budget: € 204.490.

Reference: CIPROM/2022/45.
Title: *A traslational approach to study systemic inflammation as main driver of cardiovascular diseases in metabolic disorders. Search for new molecular and cellular mechanism and therapeutic targets.*
Principal Investigator: María Jesús Sanz Ferrando.
Funding body: *Conselleria Educacion/Innovacion, Universidades, Ciencia y Sociedad Digital/Empleo.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2026.
Total budget: € 599.636.

Reference: PID2023-152677OB-I00. **Title:** *Nuevos immunoactores en desórdenes metabólicos: Nuevas dianas terapéuticas? (INMUNCARDIMETAB).* **Principal Investigator:** María Jesús Sanz Ferrando.
Funding body: *Ministerio de Ciencia e Innovación.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2028.
Total budget: € 362.500.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
4	22.9	5.72
National collaborations	International collaborations	Corresponding author
2	2	2

- CXCL16/CXCR6 axis arises as a potential peripheral biomarker of early COPD development - results from a pilot study. Marques P, Bocigas I, Domingo E, Francisco V, Tarrasó J, Piqueras L, Signes J et al. *Frontiers in Medicine*. 2025 julio 09. 121636360-1636360. DOI:10.3389/fmed.2025.1636360. PMID:40703254. IF:3. Q1
- Individual and combined effects of chemical and mechanical power on postoperative pulmonary complications: a secondary analysis of the REPEAT study. Müller LM, Lilien TA, Patterson WM, Ott S, Francis R, Gama de Abreu M, Serpa A et al. *ANAESTHESIA*. 2025 diciembre 01. 80 (12):1510-1518. DOI:10.1111/anae.16725. PMID:40827607. IF:7,50. Q1
- Association of intraoperative end-tidal CO(2) levels with postoperative outcomes: a patient-level analysis of two randomised clinical trials. Nasa P, van DMP, Paulus F, Ferrando C, Bluth T, Gama de Abreu M, Ball L et al. *BRITISH JOURNAL OF ANAESTHESIA*. 2025 diciembre 01. 135 (6):1761-1769. DOI:10.1016/j.bja.2025.07.076. PMID:40930872. IF:9,20. Q1
- Sodium-glucose cotransporter-2 inhibitors and risk of diabetic retinopathy in type 2 diabetes: a network meta-analysis of randomised clinical trials. Ortiz Seller A, Ortiz Seller D, Morcillo E, Ortiz JL. *International Journal of Clinical Pharmacy*. 2025 diciembre 19. 48 (1):80-92. DOI:10.1007/s11096-025-02071-2. PMID:41417177. IF:3,20. Q2

Research Group on Psychiatry and Neurodegenerative Diseases

Consolidated
Principal Investigator: Juan Nacher Roselló

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025


- **Leading Researcher:**
Juan Nacher Roselló. UV
- **Established Researcher:**
Olga María Rivero Martín. INCLIVA
Eduardo Jesús Aguilar García-Iturrospe. Hospital/UV
M. Dolores Moltó Ruiz. UV
- **Recognised Researcher:**
Patrycja Anna Klimczak. INCLIVA
Héctor Carceller Cerdá. INCLIVA
Jon Iñaki Etxeandia Pradera. Hospital
Carlos Cañete Nicolas. Hospital/UV
Miguel Hernandez Viadel. Hospital
Maria José Escartí Fabra. Hospital
Marien Gadea Doménech. UV
Jose Carlos Gonzalez Piqueras. Hospital
Esther Lorente Rovira. Hospital/UV
Marta Perez Rando. UV
Gracián García Martí. CIBERSAM
Mónica Alba Ahulló Fuster. INCLIVA
- **First Stage Researcher:**
Clara Gil Carbonell. UV
Alba Mora Morell. UV
Celia Muñoz Menzinger. INCLIVA
Ricardo Ruiz Miguel. INCLIVA
Gabriel Daniel Flores Gómez. UV
Marc Beltran Martinez. UV
Yaiza Gramuntell Roch. UV

Javier David Lluesma. UV
Julia Alcaide Pozo. UV

- **Staff-Technician:**
Hristina Vasileva Uzunova. INCLIVA
- Staff-Collaborating Researcher:**
Alba Postiguillo GiralDOS. IISPV

Emerging Researchers

Olga María Rivero Martín
Her main line of research is focused on the generation of neuronal cell lines from healthy subjects and first episode of psychosis (FEP) patients, obtained from human induced pluripotent stem cells and olfactory neuroepithelial cells, in order to identify biomarkers of psychosis and poor medication response.



STRATEGIC AIMS

Develop a mobile application linked to clinical records to improve treatment adherence in patients with first episode psychosis.

Publish results from gene-environment interaction projects related to first-episode psychosis.

Develop new diagnostic techniques for psychosis using fMRI and machine learning approaches.

Develop animal models for severe mental disorders.

Develop new in vitro patient-specific neuronal models to study psychoses.

Predictive modelling of treatment response in first-episode psychosis.

Identify genetic risk factors and biomarkers associated with the development of schizophrenia and medication response.

Identify modifier genes, new targets and molecules to treat Friedreich's ataxia.

MAIN LINES OF RESEARCH

- Design and coordination of clinical, genetic and neuroimaging data bases oriented to performing multicenter projects.
- Development of interactive systems for improving therapeutic adherence Study of the efficiency of psycho-social intervention techniques in serious mental illness.
- Epigenetic studies of candidate genes involved in psychosis and other mental illnesses.
- Development of models for studying neurodegenerative diseases (Friedreich Ataxia) using invertebrate animals (Drosophila).
- Identifying abnormal patterns in neuroimaging (morphometry, functional, spectroscopy) in patients with psychosis.
- Identifying genetic and environmental risk factors in affective and psychotic disorders.
- Identifying risk-associated polymorphisms in psychosis and affective disorders.
- Research using animal models to study severe mental illness

TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PI20/00473

Title: *Estudio longitudinal de una cohorte representativa: superando la heterogeneidad clínica y biológica en primeros episodios psicóticos*

Principal Investigator: Julio Sanjuán Arias and Co-IP M. Dolores Moltó Ruiz

Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER

Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2021-2023 extended to 2025

Total budget: €68.970

Reference: PI22/01985

Title: *Desarrollo y caracterización de nuevos modelos preclínicos celulares de medicina personalizada en psicosis*

Principal Investigator: Olga María Rivero Martín and M^a José Escartí Fabra

Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER

Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2023-2025 extended 2027

Total budget: €117.370

Reference: CIPROM/2023/28

Title: *Exploring the role of the thalamus and early life adversity on the etiopathology and treatment of schizophrenia: a translational and multidisciplinary approach.*

Principal Investigator: Juan Nacher Roselló

Funding Body: *Conselleria de Educació /Innovación, Universidades, Ciencia y Sociedad Digital /Empleo*

Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2024-2028

Total budget: €600.000

Title: Efecto de las experiencias traumáticas en la vida temprana sobre la estructura, función y conectividad del tálamo en pacientes psicóticos.

Principal Investigator: Juan Nácher Roselló

Funding Body: Fundacion Mutua Madrileña.

Duration: 2024-2027

Total budget: €110.000

Reference: PMP24/00026

Title: *SMARTomicS: prevención de la conducta suicida mediante intervenciones terapéuticas guiadas por fenotipo digital y farmacogenética.*

Principal Investigator: Eduardo Jesús Aguilar García-Iturraspe

Funding Body: *Instituto de Salud Carlos III*

Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2025-2026

Total budget: €68.970

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
21	100.2	4.77
National collaborations	International collaborations	Corresponding author
14	7	2

- How Do Psychiatry Residents View Their Training in Spain? A Mixed-Method Survey. Carrasco JP, Etxeandia JI, Esteve J, Aguilar EJ. ACTAS ESPANOLAS DE PSIQUIATRIA. 2025 january 01. 53 (1):26-37. DOI: 10.62641/aep.v53i1.1760. PMID:39801409. IF:1,6. Q3.
- Use of TeamManagement software to optimize communication and organization of a psychiatry clinical placement. Rojo LM, Ortiz CS, Pradas FB, Rodríguez PB, Alarcón VS, García E. Spanish Journal of Medical Education. 2025 january 01. 6 (2):DOI:10.6018/edumed.647621. IF:0,7. Q3.
- Altered volume of thalamic nuclei and genetic expression in first-episode psychotic patients, and their association with childhood adversity. Elvira U, Rivero O, Postiguillo A, García G, Escarti MJ, Aguilar EJ, David J et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY. 2025 june 20. 139111371-111371. DOI:10.1016/j.pnpbp.2025.111371. PMID:40250785. IF:3,90. Q1.
- Development of the Undergraduate Rotation Satisfaction Questionnaire and its Validation in a Psychiatry Clerkship. Rojo LM, Carrasco JP, Granda AR, Martinez J, Aguilar Garcia EJ. ACTAS ESPANOLAS DE PSIQUIATRIA. 2025 december 01. 53 (6):1308-1319. DOI:10.62641/aep.v53i6.1955. PMID:41437756. IF:1,60. Q3.
- Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice. Aguilar L, Flores GD, Nacher J, Morales JC, Flores G. NEUROCHEMICAL RESEARCH. 2025 december 29. 51 (1):23-23. DOI:10.1007/s11064-025-04627-0. PMID:41460391. IF:3,80. Q2

THESIS

Thesis title: Effect of voluntary exercise and CDH13 deficiency on the expression of genes related to motivation and reward circuitries in the mouse brain.

Type: Thesis Doctoral.

Doctoral candidate: Tatjana Becker. **Director(s):** Klaus-Peter Lesch and Olga María Rivero Martín.

University: University De Würzburg. **Defence Date:** 27/01/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Thesis title: Plasticity of inhibitory networks in neuropsychiatric disorders: from animal models to patients.

Type: Thesis Doctoral.

Doctoral candidate: Julia Alcaide Pozo.

Director(s): Juan Nacher Roselló.

University: Universitat de València (Estudi General).

Defence Date: 04/04/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Thesis title: The brain extracellular matrix in psychiatric disorders: from animal models to patients.

Type: Thesis Doctoral.

Doctoral candidate: Patrycja Anna Klimczak.

Director(s): Juan Nacher Roselló and Marta Perez Rando.

University: Universitat De València (Estudi General).

Defence Date: 07/07/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Thesis title: Estudio de los antecedentes psiquiátricos y sociodemográficos en el funcionamiento social de un primer episodio psicótico.

Type: Thesis Doctoral.

Doctoral candidate: Maria José Montaner Ferrer.

Director(s): Marien Gadea Doménech.

University: Universitat de València (Estudi General).

Defence Date: 07/07/2025

Grade: Excellent

Quality recognition/Award: Cum Laude


Research Group on Respiratory Diseases

Consolidated
Principal Investigator: Jaime Signes-Costa Miñana

GROUP MEMBERS
Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Jaime Signes-Costa Miñana Hospital /UV
- **Established Researcher:**
Francisco Dasí Fernández. Hospital
Jose Norberto Sancho Chust. Hospital
Jose Franco Serrano Hospital /UV
Jesus Ignacio Sancho Chinesta. Hospital
Mª Luisa Briones Urtiaga. Hospital
Mari Cruz Gonzalez Villaescusa. Hospital
- **Recognised Researcher:**
Silvia Castillo Corullon. UV
Carmen Muñoz Esteban. Hospital
Alba Mulet Arabí. Hospital
Santos Ferrer Espinosa. Hospital
Jose Luis Diaz Cordobés. UV
Francisco Carrión Valero. Hospital
- **First Stage Researcher:**
Álvaro García Carrasco. UV
Júlia Tarrasó Castillo. INCLIVA
Paola Lisseth Ordoñez Gomez. Hospital
Elia Gimenez Samblas. Hospital
- **Staff-Collaborating Researcher:**
Paula Melgar Barcelona. INCLIVA
Vanesa Alaeddine Marcano. Hospital
Guillermo Ruiz Matutano. Hospital
Miriam Bernaola Garrido. Hospital
Ramón Cercos González. Hospital

- Irene Tur Cruces. Hospital
Carlos Alonso Ruzo. Hospital
Andres Vales Veiga. Hospital
Antonio Herrera Cuadros,
Ana Ferrer Pons. Hospital
Nieves Navarro Soriano. Hospital
Pablo Royo Simo. Hospital
Erick Monclou Garzon. Hospital
Heidi Mora Bastida. Hospital
Enric Bures Sales. Hospital
Miriam García Alfaro. Hospital
M. Pilar Bañuls Polo. Hospital
Ana María Ferrer Marti. Hospital
Yolanda García Sanjuan. Hospital
- **Research Nurse Staff:**
Carlos Martinez Ferraro. UV
 - **Staff-Technician:**
Joaquin Carrasco Luna. UV



STRATEGIC AIMS
Study of respiratory complications in patients with neuromuscular diseases. Utility of mechanical ventilation and other respiratory supports.
Implication of early diagnosis of obstructive airway diseases in the prognosis and follow-up of patients. Emphysema early detection program. Program for early detection of Alpha 1 Antitrypsin Deficiency.
Early follow-up program for COPD with exacerbator phenotype. Severe asthma control program.
Control of respiratory disorders during sleep as prevention of cardiovascular risk factors.
Early diagnosis of idiopathic interstitial respiratory diseases (IPF) and secondary diseases (drug toxicity and post-BMT).

- MAIN LINES OF RESEARCH**
- Follow-up of patients admitted for bilateral COVID19 pneumonia: changes in pulmonary function tests for the early diagnosis of pulmonary fibrotic sequelae.
 - Identify cardiac morphological changes in patients with sleep-disordered breathing and ischemic heart disease treated with CPAP.
 - Improve the effectiveness of mechanically assisted cough procedures in patients with ALS, as well as the precision of the clinical tools available to evaluate frontotemporal dementia in them.
 - Study of the early stages of COPD in smokers. GOLD classification paradigm 0.
 - Study of oxidative stress and inflammatory mechanisms underlying acute lung damage caused by SARS-CoV-2.
 - Usefulness of non-invasive ventilation in the weaning process of patients with prolonged mechanical ventilation.

RESEARCH PROJECTS
Title: GOLD 0-DLCO 1. Una mirada más allá de la obstrucción. ¿Es suficiente la Espirometría en el screening de EPOC?
Principal Investigator: Mari Cruz Gonzalez Villaescusa.
Funding body: Fundación de Neumología de la Comunidad Valenciana; Sociedad Valenciana de Neumología.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2020-2026.
Total budget: € 12.000.

Title: Estudio de los micro-RNAs circulantes como biomarcadores pronósticos en pacientes con déficit de alfa-1-antitripsina.
Principal Investigator: Francisco Dasí Fernández.

Funding body: Fundación de Neumología de la Comunidad Valenciana.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2021-2025.
Total budget: € 6.000,00.

Title: Estudio de la utilidad clínica de los exosomas plasmáticos en la discinesia ciliar primaria.
Principal Investigator: Francisco Dasí Fernández.
Funding body: Fundación de Neumología de la Comunidad Valenciana; Sociedad Valenciana de Nefrología.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2025.
Total budget: € 12.000.

Title: Estudio de la aparición de cambios fibróticos pulmonares.
Principal Investigator: Jaime Signes-Costa Miñana.
Funding body: Fundación de Neumología de la Comunidad Valenciana.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2030.
Total budget: € 12.000.

Title: Ecoinintensidad (EI) diafragmática en la valoración de la Esclerosis Lateral Amiotrófica.
Principal Investigator: Santos Ferrer Espinosa, Antonio Quezada Reynoso.
Funding body: Fundación de Neumología de la Comunidad Valenciana.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2028.
Total budget: € 6.000.

Title: Estudio de la utilidad de las terapias antioxidantes en el déficit de alfa-1 antitripsina.
Principal Investigator: Francisco Dasí Fernández.
Funding body: Fundación de Neumología de la Comunidad Valenciana.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2028.
Total budget: € 6.000.

Title: Cultivos 3D derivados del lavado broncoalveolar para predecir la evolución de la fibrosis pulmonar.

Principal Investigator: Alba Mulet Arabí.

Funding body: Fundación de Neumología de la Comunidad Valenciana.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2030.

Total budget: € 6.000.

Title: Estudio de las subpoblaciones leucocitarias como marcadores de progresión en la enfermedad pulmonar obstructiva crónica (EPOC).

Principal Investigator: Mari Cruz Gonzalez Villaescusa and Irene Bocigas Huescar.

Funding body: Fundación de Neumología de la Comunidad Valenciana.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2028.

Total budget: € 3.000,00.

Reference: PMP21/00090.

Title: P4COPD: Predicción, prevención, tratamiento personalizado y preciso de la EPOC en adulto jóvenes.

Principal Investigator: Mari Cruz Gonzalez Villaescusa.

Funding body: Fundacio de Recerca Clinic Barcelona-IDIBAPS; Instituto Salud Carlos III.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2026.

Total budget: € 2.640.

Reference: 101183391.

Title: Joint Action on REspiratory Diseases. JARED. Dr. Signes-Costa. 2023.

Principal Investigator: Jaime Signes-Costa Miñana.

Funding body: European Commission.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2027.

Total budget: € 8.560.

Title: Estudio observacional y de extensión de las secuelas pulmonares asociadas a la infección por SARS-CoV-2 a largo plazo.

Principal Investigator: Júlia Tarrasó Castillo.

Funding body: Fundación de Neumología de la Comunidad Valenciana.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2025-2028.

Total budget: € 12.000.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
13	58,4	4,92
National collaborations	International collaborations	Corresponding author
7	5	5

- Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge. Botello M, Tarrasó J, Mulet A, Presa L, Fernández E, Portal J, Ros JA et al. JOURNAL OF MEDICAL VIROLOGY. 2025 marzo 01. 97 (3):DOI:10.1002/jmv.70289. PMID:40088077. IF: 4,60. Q1.
- CXCL16/CXCR6 axis arises as a potential peripheral biomarker of early COPD development - results from a pilot study. Marques P, Bocigas I, Domingo E, Francisco V, Tarrasó J, Piqueras L, Signes J et al. Frontiers in Medicine. 2025 julio 09. 121636360-1636360. DOI:10.3389/fmed.2025.1636360. PMID:40703254. IF: 3. Q1.
- Estimating Caloric Intake per Breastfeeding Session in Infants: A Probabilistic Approach. Barrés A, Arcos JV, Castillo S, González SI, Fullana M, Ferrando S. Nutrients. 2025 septiembre 30. 17 (19):DOI:10.3390/nu17193136. PMID:41097213. IF: 5. Q1.
- Different Regulation of Alpha-1 Antitrypsin Production in Neutrophils of ZZ-AATD Patients Under Hypoxic Conditions. Magallón M, Bañuls L, Castillo S, Romero T, Martínez C, Pellicer D, Herrejón A et al. ARCHIVOS DE BRONCONEUMOLOGIA. 2025 noviembre 01. 61 (11):707-709. DOI:10.1016/j.arbres.2025.06.007. PMID:40617754. IF:9,20. Q1.
- Noninvasive Ventilation Effectiveness in Amyotrophic Lateral Sclerosis. Sancho J, Ferrer S, Signes Costa J. Journal of Clinical Medicine. 2025 diciembre 04. 14 (23):DOI:10.3390/jcm14238609. PMID:41375912. IF: 2,90. Q1

THESIS

Thesis title: Utilidad de la ecografía diafragmática para la indicación de ventilación mecánica no invasiva en la esclerosis lateral amiotrófica.

Type: Thesis Doctoral

Doctoral candidate: Santos Ferrer Espinosa.

Director(s): Emilio Servera Pieras and Jesus Ignacio Sancho Chinesta. **University:** Universitat de València (Estudi General)

Date of the defense: 29/10/2025

Thesis title: Effects of COVID-19 infection on telomere length and its relationship with the evolution of pulmonary fibrosis.

Type: Thesis Doctoral

Doctoral candidate: Alba Mulet Arabí.

Director(s): Jaime Signes-Costa Miñana and Pilar González Cabo.

University: Universitat de València (Estudi General)

Date of the defense: 04/11/2025

Grade: Sobresaliente

Quality recognition/Award: Cum Laude


Research Group on Tissue Biochemistry

Consolidated
Principal Investigator: Juan Viña Ribes

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Juan Viña Ribes. UV
Elena Ruiz García Trevijano. UV
- Established Researcher:**
Luis Torres Asensi. UV
Rosa Zaragoza Colom. UV
- Recognised Researcher:**
Elena Ortiz Zapater. UV
- Staff-Collaborating Researcher:**
Sara Puebla Planas. UV



STRATEGIC AIMS

- Study the influence of age at pregnancy and duration of breastfeeding on risk of breast cancer, and specifically, the role of calpain-2 as a regulatory node.
- Decipher the role of CAPN2 functions on mammary gland involution by identifying its primary output in conditional KO-CAPN2 mice.
- Identify CAPN2 targets at 48h of mammary gland involution after lactation via proteomic approaches to obtain a molecular signature linking age/short-breastfeeding to risk of breast cancer. Data comparison between our murine model and in-silico analysis of human mammary glands.
- Study the mechanisms that control respiratory homeostasis, as well as the dysregulation of molecular and cellular pathways in respiratory pathological processes, such as vitamin A deficiency, allergic inflammation, pulmonary fibrosis and muscular dystrophies.

MAIN LINES OF RESEARCH

- Identification and analysis of calpain activity end-products in the post-lactation breast and their potential use in identifying patients at risk for pregnancy-associated breast cancer.
- Influence of age at pregnancy and duration of lactation on breast cancer risk.
- Investigation of molecular and cellular pathways involved in inflammatory respiratory diseases, particularly pulmonary fibrosis.
- Participation of calpains in the development of various pathologies associated with ECM alterations: pulmonary fibrosis, muscular dystrophies, and cancer.
- Role of calpain-2 as a regulatory node in post-lactation involution and neoplastic development.
- Search for early markers of pulmonary fibrosis with prognostic value.
- Study of ECM alteration in liver and lung in chronic vitamin A deficiency models

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
8	31.4	3.92
National collaborations	International collaborations	Corresponding author
8	-	6


- Nutrition, Lifestyle, and Environmental Factors in Lung Homeostasis and Respiratory Health. Pouptsis A, Zaragoza R, García Trevijano ER, Viña JR, Ortiz Zapater E. Nutrients. 2025 marzo 09. 17 (6):DOI:10.3390/nu17060954. PMID:40289995. IF:5. Q1.
- Association Between Lycopene and Metabolic Disease Risk and Mortality: Systematic Review and Meta-Analysis. Viña I, Robles A, Viña JR. Life-Basel. 2025 junio 12. 15 (6):DOI:10.3390/life15060944. PMID:40566597. IF:3,40. Q1.
- Association of Lycopene and Male Reproductive Health: Systematic Review and Meta-Analysis. Viña I, Viña JR. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 julio 25. 26 (15):DOI:10.3390/ijms26157224. PMID:40806357. IF:4,90. Q1.
- Ubiquitous calpains show differential dynamics and function during adipocyte differentiation. Rodríguez L, Zaragoza R, Viña JR, García ER. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS. 2025 octubre 01. 772110557-110557. DOI:10.1016/j.abb.2025.110557. PMID:40701348. IF:3. Q2.
- The Length of Lactation and Model of Weaning Modulate Key Regulatory Nodes of Murine Mammary Gland Involution. Puebla S, Gimeno A, Ortíz E, Zaragoza R, Viña JR, García ER. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 octubre 29. 26 (21):DOI:10.3390/ijms262110501. PMID:41226539. IF:4,90. Q1

Research Group on Ageing and Physical Activity

Consolidated
Principal Investigator: José Viña Ribes

GROUP MEMBERS
Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
José Viña Ribes. UV
- Established Researcher:**
Eva Serna García. UV
Ana Lloret Alcañiz. UV
- Recognised Researcher:**
Jose Viña Almunia. UV
- First Stage Researcher:**
Rut Campos Jimenez. FCS
Alicia Valls Arrufat. UV
- Staff-Technician:**
Cristina Amézcuca García. UV



STRATEGIC AIMS
Regenerative medicine in ageing.
Identify physical training as a drug to treat age-related frailty.
Demonstrate that G6PD protects against oxidative damage and improves lifespan in mice.
Lifestyle modulation for treatment of Alzheimer’s including stress control and supplement interventions.
Modulation of the AhR signaling pathway via microbiota-derived metabolites and plant-derived polyphenols of interest for healthy ageing.

- MAIN LINES OF RESEARCH**
- Ageing: identifying genes associated with ageing, particularly those specific to centenarians. Role of estrogens and phytoestrogens in preventing age-related damage. Research into the involvement of the aryl hydrocarbon receptor (AhR) signaling pathway in the ageing process.
 - Physical activity: identifying the molecular mechanisms by which physical activity is good for health. Identifying how physical activity and antioxidant supplements help prevent primary and secondary sarcopenia in both human and animal studies. Identifying the best exercise interventions to delay and treat frailty in humans.
 - Physiopathology of Alzheimer’s disease: identifying the mechanisms by which free radicals (originators of oxidative stress) are used to unleash cell signals that lead to cell death in Alzheimer’s disease.
 - Studying AhR pathway modulation by identifying endogenous and exogenous ligands (including nutritional supplements and microbiota-derived metabolites) aimed at improving and treating pathological conditions. This includes evaluating their impact on diseases and age-related physiological decline.

TEAM INVOLVED IN

eatris

ciber | FES

RESEARCH PROJECTS
Reference: AC20/00026
Title: Asociación de chocolate fortificado con Vitamina E y ejercicio físico para reducir el riesgo de malnutrición proteica en personas mayores con deterioro cognitivo.
Principal Investigator: José Viña Ribes
Funding Body: Instituto de Salud Carlos III-Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2021-2025
Total Budget: €169.097,50

Reference: CB16/10/00435
Title: CIBER de Fragilidad y Envejecimiento (CIBERFES)
Funding body: Instituto de Salud Carlos III - Cofinanciado FEDER
Principal Investigator: María Carmen Gómez Cabrera.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2017 to present

Number of Publications	IF	Average FI
8	50.5	7.21
National collaborations	International collaborations	Corresponding author
4	2	7

- Sodium valproate reverses aortic hypercontractility in acute myocardial infarction in rabbits. Guerra S, Suarez A, Belmonte B, Marchio P, Genoves P, Arias OJ, Aldasoro M et al. European Journal of Pharmacology. 2025 febrero 05. 988177216-177216. DOI:10.1016/j.ejphar.2024.177216. PMID:39706463. IF:4,70. Q1
- Bcl-xL overexpression in T cells preserves muscle mitochondrial structure and function and prevents frailty in old mice. Mas C, Román A, Sanz J, Romero N, Huete J, Dromant M, Cuervo AM et al. Science Advances. 2025 marzo 19. 11 (12):DOI:10.1126/sciadv.adr1378. PMID:40106552. IF:12,50. Q1
- Pomegranate Extract Modulates Oxidative Stress by Reducing Basal ROS Levels and Protecting White Blood Cells from Induced Oxidative Damage in Aging Mice. Verdú D, Valls A, Serna M, Herrera G, Ezzeddin M, Mauricio MD, Viña J et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 junio 20. 26 (13):DOI:10.3390/ijms26135957. PMID:40649737. IF:4,90. Q1

- Molecular mechanism involved in sarcopenia and frailty, diagnosis and therapy. Viña J, Gomez Cabrera MC. MOLECULAR ASPECTS OF MEDICINE. 2025 octubre 01. 105101387-101387. DOI:10.1016/j.mam.2025.101387. PMID:40781035. IF:10,30. Q1
- Differential contribution of T-type voltage-gated calcium channels to vascular reactivity in the aorta and renal artery of healthy rabbits. Suarez A, Guerra S, Zarzoso M, Serna M, Vila JM, Serna E, Mauricio MD. EXPERIMENTAL PHYSIOLOGY. 2025 octubre 27. 111 (3):1498-1512. DOI:10.1113/EP093044. PMID:41145982. IF:2,80. Q2

THESIS
Thesis title: Efectos del ácido valproico sobre la función de la aorta abdominal en conejos con infarto agudo de miocardio.
Type: Doctoral thesis.
Doctoral candidate: Begoña Belmonte Alonso.
Director(s): María Dolores Mauricio Aviñó, Eva Serna García and Solanye Guerra Ojeda.
University: Universitat de València (Estudi General).
Defence date: 14/07/2025

Research Group on Anesthesiology and Reanimation


Consolidated
Principal Investigator: Rafael Badenes Quiles

<https://incliva.portalinvestigacion.com/grupos/296>
<http://anestesiaticlinicovalencia.org>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Rafael Badenes Quiles. Hospital /UV
- Established Researcher:**
Gerardo Aguilar Aguilar. Hospital/ UV
Carlos Tornero Tornero. Hospital /UV
- Recognised Researcher:**
Laura García Vargas. Hospital
Berta Monleón López. Hospital
Nekane Romero Garcia. Hospital
Maria Luisa Garcia Perez. Hospital/ UV
Andrea Gutierrez Valcarcel. Hospital/ UV
Ana Mugarra Llopis. Hospital
Rosa Herrera Castro. Hospital
- Staff-Collaborating Researcher:**
Eva Amores Parra. INCLIVA
Antonio Guillen Bañuelos. Hospital
Cristina Elena Crisán Ovidiu. Hospital
Jose Antonio Carbonell Lopez. Hospital
Maria Jose Parra Gonzalez. Hospital
Ernesto Pastor Martinez. Hospital
- Staff-Technician:**
Maria Angeles Casas Lopez. UV




STRATEGIC AIMS

- Open lung approach for respiratory management.
- Management of chronic pain.
- Performance analysis of homecare and ICU ventilators (bench model).
- Respiratory management in ARDS COVID19 patients.
- Controlled donation after circulatory determination of death with the use of normothermic regional perfusion.
- Determination of death by neurological criteria.
- Prevalence and risk factors for delirium.
- Advance neuromonitoring of neurocritical care patients.
- COVID 19 (SARS-CoV-2) ICU management.
- Pharmacokinetics and pharmacodynamics (PK/PD) of antimicrobials in critically ill patients with extracorporeal devices.
- Use of rapid diagnostic tests in septic patients.
- Adsorptive therapies in septic patients.

MAIN LINES OF RESEARCH

- COVID 19 (SARS-CoV-2) critically ill patients.
- Delirium critically ill patients.
- Development of new strategies and drugs for pain treatment.
- Organ donation and transplantation.
- Retrospective analysis of COVID 19 patient management.
- Severe traumatic brain injury



TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: InnoMatch
Title: Inno-PATHMAKER: Boosting surgical capacity through process optimisation using PATHMAKER
Principal Investigator: Rafael Badenes Quiles
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2026
Total Budget: €35.000

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
25	192.2	8
National collaborations	International collaborations	Corresponding author
7	15	10

- Bcl-xL overexpression in T cells preserves muscle mitochondrial structure and function and prevents frailty in old mice. Mas C, Román A, Sanz J, Romero N, Huete J, Dromant M, Cuervo AM et al. Science Advances. 2025 marzo 19. 11 (12):DOI:10.1126/sciadv.adr1378. PMID:40106552. IF: 12,50. Q1.
- Neurological outcomes and mortality following hyperoxemia in adult patients with acute brain injury: an updated meta-analysis and meta-regression. Romero N, Robba C, Monleón B, Ruiz A, Pascual M, Ruiz A, Perdomo F et al. CRITICAL CARE. 2025 abril 23. 29 (1):167-167. DOI:10.1186/s13054-025-05387-7. PMID:40270034. IF: 9,30. Q1.
- Extracellular vesicles as a biomarkers in traumatic brain injury: a systematic review of animal and clinical studies. Romero N, Ruiz A, Huete J, Monleón B, Vicente A, Mas C, Sanz J et al. CRITICAL CARE. 2025 julio 24. 29 (1):324-324. DOI:10.1186/s13054-025-05477-6. PMID:40707934. IF: 9,30. Q1.

- Off-label use of the BIOFIRE® Blood Culture Identification 2 Panel for multidrug-resistant bacteria colonization surveillance in critical care unit patients: A retrospective study. Cano S, Clari MA, Colomina J, Garcia L, Sanchis C, Torres I, Aguilar G et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2025 octubre 01. 113 (2):116930-116930. DOI:10.1016/j.diagmicrobio.2025.116930. PMID:40449156. IF: 1,8. Q3.
- Ventilator-associated lower respiratory tract infections and bacteremia in medical and surgical critical care patients colonized by multidrug-resistant bacteria. Torres I, Ferrer J, Colomina J, Clari MA, Olea B, Giménez E, Albert E et al. BMC INFECTIOUS DISEASES. 2025 noviembre 14. 25 (1):1583-1583. DOI:10.1186/s12879-025-12027-6. PMID:41239254. IF: 3,00. Q2

THESIS

Thesis title: Association of sedation level, delirium and 28-day mortality: a COVID 19 cohort multicenter study
Type: Doctoral Thesis
Doctoral candidate: Berta Monleón López
Director(s): Dr. Rafael Badenes Quiles
University: Universitat de València (Estudi General)
Date of the defense: 31/01/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Research Group on Human Translational Genomics


Consolidated
Principal Investigator: Ruben Artero Allepuz

<https://incliva.portalinvestigacion.com/grupos/301>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Ruben Artero Allepuz. UV
Manuel Perez Alonso. UV
- Established Researcher:**
Arturo López Castel. UV
- Recognised Researcher:**
Brenda Eloisa Garcia Sanchez. UV
Luís Orduña Rubio. INCLIVA
Ariadna Bargiela Schonbrunn. INCLIVA
Raquel Pérez Gómez. INCLIVA
Javier Poyatos García. INCLIVA
Raquel Atienzar Aroca. UV
Irene Gonzalez Martinez. UV
Maria Sabater Arcis. UV
Dulce Peris Moreno. CIBERER
Alba Timón Gómez. CIBERER
- First Stage Researcher:**
Yasmine Ferchichi. UV
Àngela Natividad I Mateu. UV
Paola Jazmin Yanez Atiencia. UV
Anna Colom Rodrigo. UV
Alicia Novella Estelles. UV
Natalia Mariel Riedel Bistoco. UV
- Staff-Nurse:**
Álvaro Gómez-Ferrer Ardid. INCLIVA
- Staff-Technician:**
Aroa Roca Valera. INCLIVA
Alberto García Martín. INCLIVA
Iván Gimeno Martínez. INCLIVA
Ana Ballestar Carrión. INCLIVA



STRATEGIC AIMS

Medium-term scientific aims include elucidating the mechanisms underlying disease pathogenesis and developing candidate therapeutic strategies for Myotonic Dystrophy type 1 and type 2 (DM1 and DM2), LGMDD2, CANVAS, and cancer-induced cachexia. In parallel, the group focuses on the design and development of novel antisense oligonucleotides targeting emerging therapeutic candidates, as well as on refining and optimizing oligonucleotide delivery methods. Additional objectives comprise completing a nationwide DM1 patient registry enriched with genomic and epigenomic data, studying nutrigenomics in relation to citrus fruit consumption and identifying new biomarkers.

MAIN LINES OF RESEARCH

Research activities centre on elucidating pathogenic mechanisms and evaluating therapeutic candidates for DM1, DM2, LGMDD2 and CANVAS; defining the molecular drivers of muscle atrophy in cancer cachexia; enhancing muscle uptake of therapeutic oligonucleotides; functionally characterizing genomic and epigenomic variants and biomarkers in DM1 patient cohorts; using Drosophila as a tool for translational rare disease modeling; and investigating metabolic and dietresponsive pathways relevant to neuromuscular disease.

TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PI21/00311
Title: *Caracterización de una nueva diana terapéutica en disfunción muscular en la distrofia miotónica de tipo 1*
Principal Investigator: Manuel Pérez Alonso
Funding Body: Instituto de Salud Carlos III Co-financed FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2024 extended to 2025
Total budget: €141,570

Reference: DTS22/00088
Title: *Optimización de parámetros PK/PD de una terapia farmacológica reutilizada para pacientes con AME*
Principal Investigator: Rubén Artero Allepuz
Funding Body: Instituto de Salud Carlos III-Cofinanced FEDER
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2024 extended to 2025
Total budget: €134,200

Title: *miR-107 represses DMPK and is sequestered by CUG repeats triggering the MSI2/miR-7 pathogenesis axis*
Principal Investigator: Ariadna Bargiela Schonbrunn
Funding Body: Myotonic Dystrophy Foundation USA
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025
Total budget: €3,448
Reference: 29595

Title: *MSImer MSImer Advanced Therapeutic Strategies Using Antisense Oligonucleotides Targeting MSI2 for the Treatment of Myotonic Dystrophies*
Principal Investigator: Ariadna Bargiela Schonbrunn
Funding Body: AFM Théléthron
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2026
Total budget: €50,000

Reference: PMPER24/00007
Title: *Creación de un nodo integral para la Distrofia Miotónica tipo 1 en España: registro clínico, mapas genómicos, epigenómicos y proteómicos (DM1-Hub).*
Principal Investigator: Arturo López Castel
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana. Proyecto en Consorcio (Institución líder: IGTP)
Duration: 2025-2026
Total budget: € 1,575,224 (Total Budget €3.5 M)

Title: *Análisis nutrigenómico de dietas suplementadas con cítricos.*
Principal Investigator: Arturo López Castel
Funding Body: Conselleria d´Agricultura, Generalitat Valenciana. Research contract between Instituto de Investigación Sanitaria INCLIVA and Fundación Valenciana de Agricultura y Medio Ambiente (FUVAMA)
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2025
Total budget: €178,000

RESEARCH RESULTS

Invention: MSI2 as a therapeutic target for the treatment of myotonic dystrophy
Priority Number: EP22707100
Status: Europe and US National Phase
Principal Investigator: Ruben Artero Allepuz

Invention: Haloperidol for use in the treatment of spinal muscular atrophy
Priority Number: EP22843657
Status: Europe and US National Phase
Principal Investigator: Ruben Artero Allepuz

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
4	36.8	9.2
National collaborations	International collaborations	Corresponding author
2	2	1

- Clinical features, mutation spectrum and factors related to reaching molecular diagnosis in a cohort of patients with distal myopathies. Muelas N, Carretero L, Martí P, Azorín I, Frasquet M, Poyatos J, Portela S et al. JOURNAL OF NEUROLOGY. 2025 january 01. 272 (1):97-97. DOI:10.1007/s00415-024-12821-3. PMID:39775307. IF: 4,60. Q1.
- Use of HSALR female mice as a model for the study of myotonic dystrophy type I. Carrascosa M, Colom A, González I, Pérez R, García A, Piqueras D, Ballestar A et al. LAB ANIMAL. 2025 april 01. 54 (4):92-102. DOI:10.1038/s41684-025-01506-7. PMID:40016516. IF: 3,90. Q1.
- miR-107 represses DMPK and is sequestered by CUG repeats triggering the MSI2/miR-7 pathogenesis axis in myotonic dystrophy. Moreno N, Sabater M, Espinosa J, Mulet L, García E, González J, Seoane D et al. MOLECULAR THERAPY NUCLEIC ACIDS. 2025 september 09. 36 (3):102584-102584. DOI: 10.1016/j.omtn.2025.102584. PMID:40599975. IF: 6,10. Q1.
- Pre- and postsynaptic upregulation of FasII synergistically underlies neuropathological and behavioral phenotypes in a Drosophila model of myotonic dystrophy. Koon AC, Yeung KYW, Wu Y, Leong LI, Cheung JTP, Chen ZS, Peng SI et al. Nature Communications. 2025 december 18. 17 (1). DOI: 10.1038/s41467-025-67738-w. PMID:41413387.

THESIS

Thesis title: Preclinical development of an innovative drug for Myotonic Dystrophy

Type: Doctoral thesis

Doctoral candidate: Irene González Martínez

Director(s): Dr. Rubén Artero Allepuz and Dra. Estefanía Cerro Herreros

University: Universitat de València (Estudi General)

Defense Date: 01/12/2025

Grade: Excellent

Quality recognition/Award: Cum Laude. International recognition.

Research Group on General and Digestive Surgery

Consolidated

Principal Investigator: Luis Sabater Orti



<https://incliva.portalinvestigacion.com/grupos/297>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Luis Sabater Orti. Hospital /UV
- **Established Researcher:**
Mónica Millán Scheiding. Hospital
Stephanie Garcia Botello. Hospital /UV
Jose Martin Arevalo. Hospital /UV
David Moro Valdezate. Hospital
Dimitri Dorcaratto. Hospital
Norberto Cassinello Fernández. Hospital /UV
Marina Garces Albir. Hospital /UV
Elena Muñoz Forner. Hospital /UV
Vicente Pla Martí. Hospital
- **Recognised Researcher:**
David Casado Rodrigo. Hospital
Raquel Alfonso Ballester. Hospital
- **First Stage Researcher:**
Guillermo Pou Santonja. Hospital
Ernesto Muñoz Sornosa. Hospital
María Lapeña Rodríguez. Hospital
Vicente Lopez Flor. Hospital
Leticia Pérez Santiago. Hospital
Isabel Mora Oliver. Hospital
Rosa Maria Martí Fernandez. Hospital
Ricardo Gadea Mateo. Hospital

- Marcos Adrianzen Vargas. Hospital
Francisco Castillejos Ibáñez. Hospital
- **Staff-Collaborating Researcher:**
Carlos Leon Espinosa. Hospital
Elena Martí Cuñat. Hospital
Ángel Sanahuja. Hospital
 - **Staff-Nurse:**
Esther Alarcó Sereno. Hospital
Margarita Fernández Guardiola. Hospital
Victoria Alejandra Lopez Callejón. Hospital



STRATEGIC AIMS

1. Generate high impact clinical knowledge:
Promote multicentre studies and clinical trials that will position us as a reference department for surgical evidence at national and international levels.
2. Promote technological innovation applied to surgery.
Develop and validate advanced surgical technologies (robotisation, augmented reality, AI applied to the operating theatre) in alliance with technological institutes, universities and medical start-ups.
3. Promote precision surgical medicine
research biomarkers, genomic profiles and predictive variables to personalise surgical decisions and improve outcomes in specific patient subgroups.
4. Reduce clinical variability and improve health outcomes:
Identify key surgical quality indicators and conduct best practice implementation studies to optimise safety, efficiency and patient experience.
5. Promote translational research in surgery:
Establish bridges between basic research (biomaterials, immunology, microbiota, tissue regeneration) and its application in advanced surgical techniques and new post-operative therapies.
6. Train surgical research talent:
Create specific training programmes for residents and assistants in clinical and translational research, including internships, master's degrees and competitive projects with mentoring.
7. Enhance inter-institutional collaboration:
Lead or actively participate in cooperative research networks and data-sharing platforms with other hospitals, research centres and international organisations.

MAIN LINES OF RESEARCH

- **Abdominal wall:** new developments in surgical meshes, laparoscopic abdominal wall surgery.
- **Bariatric and Endocrine surgery:** pathophysiology of post-operative changes after bariatric procedures by robotic or laparoscopic surgery. Robotic adrenal tumour resection, intra-operative localization of parathyroid adenomas, ambulatory surgery in hyperparathyroidism.
- **Breast surgery:** fibrin sealants in seroma. Selective sentinel node biopsy. Axilla assessment in DCIS. Laparoscopic mastectomy.
- **Coloproctology:** quality standards for coloproctology, 3D endorectal ultrasound, sacral neuromodulation and perianal fistula surgery, robotic surgery.
- **Gastroesophageal and oncologic peritoneal surgery:** mutations in GIST tumours, overexpression of HER2 and HER3 in gastric tumours, perioperative QT in advanced

- gastric cancer, preoperative gastric arteryies embolization in oesophageal surgery, PIPAC technique in carcinomatosis surgery.
- **Hepato-biliaryo-pancreatic surgery:** acute pancreatitis, gene transfection, pancreatico-duodenectomy, robotic surgery, 3D reconstruction models.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
48	318	6.765
National collaborations	International collaborations	Corresponding author
20	13	22

- Current evidence on powered versus manual circular staplers in colorectal surgery: a systematic review and meta-analysis. Martin J, Moro D, Pérez L, López F, Peña CJ, Asins J, Rodrigo DC et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2025 enero 15. 40 (1):13-13. DOI:10.1007/s00384-025-04807-y. PMID:39814974. IF:2,30. Q2.
- The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Rangelova E, Stoop TF, van T, Ali M, van EA, Javed AA, Hashimoto D et al. ANNALS OF ONCOLOGY. 2025 mayo 01. 36 (5):529-542. DOI: 10.1016/j.annonc.2024.12.015. PMID:39814200. IF:65,40. Q1.
- Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Martín J, Gimeno F, Henriksen TV, García B, Martínez B, Gambardella V, Martínez C et al. Nature Cancer. 2025 junio 01. 6 (6):1000-1016. DOI: 10.1038/s43018-025-00960-z. PMID:40301653. IF:28,50. Q1.
- Blumgart Anastomosis Versus Invaginating Pancreatogastrostomy for Reconstruction after Pancreatoduodenectomy. Dorcaratto D, Garcés M, Palomares S, Sánchez S, Suárez G, Jorba R, Blanco G et al. ANNALS OF SURGERY. 2025 noviembre 01. 282 (5):699-708. DOI: 10.1097/SLA.0000000000006873. PMID:40747945. IF:6,50. Q1.
- Learning curve for direct nasofibrolaryngoscopy in an endocrine surgery unit. Fernández NC, Cardona MR, Silvestre AJ, Ballester RA, Fernández RMM, Rodríguez ML. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES. 2025 noviembre 17. 40 (2):1288-1296. DOI: 10.1007/s00464-025-12359-z. PMID:41249536. IF:2,70. Q1

Research Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP)

Consolidated
Principal Investigator: Rafael Tabarés Seisdedos

<https://incliva.portalinvestigacion.com/grupos/302>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Rafael Tabarés Seisdedos. UV
Vicente Balanza Martinez. Hospital /UV
Manuel Gomez Beneyto. Hospital
- **Established Researcher:**
Manuel Girón Giménez. Hospital
Jose Salazar Fraile. INCLIVA
Patricia Correa Ghisays. CIBERSAM
Inmaculada Fuentes Dura. UV
Gabriel Selva Vera. Hospital /UV
- **Recognised Researcher:**
Pablo Soldevila Matias. UV
Joan Vicent Sánchez Ortí. INCLIVA
Jaume Fores Martos. UV
Diego Macías Saint-Gerons. INCLIVA
Constanza Isabel San Martín Valenzuela. UV


STRATEGIC AIMS

- Help prevent signs of frailty and cognitive and functional impairment in populations at risk.
- Favor the identification of biomarkers and endophenotypes associated with cognitive deficits and functional impairment in people with severe mental disorders and other chronic diseases that occur with deterioration in these areas.
- Understand the unexpected associations between apparently different diseases such as cancer and central nervous system diseases.
- Further study the increased burden of disease due to mental disorders and neurological diseases such as dementia.
- Participate in expert groups to reach consensus on nutritional medicine and other clinical practices in modern psychiatry.

MAIN LINES OF RESEARCH

- Neurocognition, frailty, and social functioning in severe mental disorder and other diseases with chronic development.
- Direct and inverse multimorbidity in patients with complex diseases such as central nervous system disorders, cancer or metabolic diseases.
- Epidemiology and disability associated with severe mental disorder.
- Global burden of disease studies.
- Identification of biomarkers in severe mental disorder.
- Nutritional psychiatry.
- Transdiagnostic cognitive impairment, pre-frailty or frailty, and decreased social functioning in severe mental disorders and other diseases with chronic development.
- Validation and identification of neurocognitive endophenotypes in severe mental disorders (MICEmi)

TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: PID2021-129099OB-I00.
Title: *MULTImorbilidad en personas con trastornos del Sistema Nervioso Central: una prioridad para la salud global desde los registros médicos electrónicos hasta los datos MULTI-ómic.*
Principal Investigator: Rafael Tabarés Seisdedos.
Funding body: *Ministerio de Ciencia e Innovación.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2026.
Total budget: €104.060.

Reference: PI23/00881.
Title: *Estilos de vida y aptitud física y sus correlatos biológicos como marcadores de síntomas de depresión y ansiedad en estudiantes universitarios: estudio de casos y controles anidado en la Cohorte UNILIFE-M.*
Principal Investigator: Vicente Balanza Martinez.
Funding body: *Instituto Salud Carlos III.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026.
Total budget: € 83.750.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
24	88.2	3.83
National collaborations	International collaborations	Corresponding author
10	13	11

- Clinical outcomes and anti-inflammatory mechanisms predict maximum heart rate improvement after physical activity training in individuals with psychiatric disorders and comorbid obesity. Soldevila P, Sánchez JV, Correa P, Balanzá V, Selva G, Sanchis R, Iglesias N et al. PLoS One. 2025 january 03. 20 (1):DOI:10.1371/ journal.pone.0313759. PMID:39752432. IF:2,60. Q2.
- Specific immune-inflammatory profiles and neurocognitive deficits predict illness trajectories in people with type 2 diabetes mellitus or psychiatric disorders. Sánchez JV, Correa P, Balanzá V, Selva G, Victor VM, Valenzuela CS, Soldevila P et al. Brain Behavior & Immunity-Health. 2025 march 01. 44100962-100962. DOI:10.1016/j.bbih.2025.100962. PMID:40046177. IF:3,50. Q1.

- Editorial: Standardizing cognitive endophenotype profiling in bipolar disorder and schizophrenia. Soldevila Matias P, de Filippis R, Sanchez Orti JV, Fuentes Dura I, Ayesa Arriola R, Correa Ghisays P. Frontiers in Psychology. 2025 april 30. 161606517-1606517. DOI:10.3389/fpsyg.2025.1606517. PMID:40376496. IF:2,90. Q1.
- Inflammation and weight change related to neurocognitive and functional impairment in diabetes and psychiatric disorders. Sánchez JV, Balanzá V, Correa P, Selva G, Vila J, Magdalena R, San C et al. Spanish Journal of Psychiatry and Mental Health. 2025 october 01. 18 (4):256-265. DOI:10.1016/j.sjpmh.2024.05.001. PMID:38740330. IF:2,80. Q2.
- Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis. San Martín C, Gallego JJ, Urios A, Correa P, Tabares R, Montoliu C. PLoS One. 2025 october 08. 20 (10): DOI: 10.1371/journal.pone.0333029. PMID:41060950. IF:2,60. Q2

THESIS

Thesis title: Identificación y validación de marcadores inflamatorios, daño oxidativo y cardiovascular para el rendimiento neurocognitivo en población con enfermedad mental grave y diabetes mellitus tipo 2.
Type: Doctoral Thesis.
Doctoral candidate: Joan Vicent Sánchez Ortí.
Director(s): Patricia Correa Ghisays and Vicente Balanza Martinez.
University: Universitat de València (Estudi General).
Date of the defense: 29/05/2025

Research Group on Cellular and Organic Physiopathology of Oxidative Stress


Consolidated
Principal Investigator: Federico Vicente Pallardó Calatayud

<https://incliva.portalinvestigacion.com/grupos/272>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Federico Vicente Pallardó Calatayud. UV
- **Established Researcher:**
Juan Antonio Navarro Langa. UV
Carlos Roma Mateo. UV
José Manuel Torres Ibañez. UV
- **Recognised Researcher:**
Marta Seco Cervera. UV
Ana Pilar Gómez Escribano. CIBERER
- **First Stage Researcher:**
Blanca Amparo Romero Llopis. INCLIVA
Patricia Rodríguez Tascón. UV
Alexandre Llorens Trujillo. INCLIVA
Enric Dolz Andrés. CIBERER



STRATEGIC AIMS

- Develop new therapies to treat neuromuscular diseases.
- Develop new therapies to treat neurodegenerative diseases.
- Notable achievements include extending the European patent "Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (ss) patients" (PCT/EP2017/078362) to PCT phase in China.

MAIN LINES OF RESEARCH

- Pathophysiology of Friedreich's Ataxia and other mitochondrial diseases.
- Pathophysiology of PolyGlutamine-driven ataxias and diseases.
- Pathophysiology of Rare childhood epilepsies.
- Developing new therapeutic strategies for Friedreich's Ataxia.
- Drug repopositioning as new therapeutic avenue for rare diseases.
- Epigenetic regulation in the pathophysiology of rare diseases.
- Epigenetic regulation of immunosuppression events in Intensive Care Units patients.
- Developing new biomarkers in both adult and neonatal sepsis.

TEAM INVOLVED IN



RESEARCH PROJECTS

Reference: CDEI-04/20-C.
Title: *Drosophila melanogaster as model to study the impact of ferroptosis in Friedreich ´s Ataxia. DrosoNeuroMetal.*
Principal Investigator: Juan Antonio Navarro Langa.
Funding body: *Conselleria De Sanidad.* **Beneficiary Institution:** *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2020-2023 extended 2025
Total budget: €117,500 + 242,000€ (PI Salary)

Reference: PI22/00507
Title: *Reposicionamiento de fármacos como tratamiento para la enfermedad de Huntington y la ataxia espinocerebelosa de tipo 3. Estudios en cultivos primarios de pacientes y en modelos animales transgénicos*
Principal Investigator: Federico V. Pallardó Calatayud and Juan Antonio Navarro Langa
Funding Body: *Instituto de Salud Carlos III - Cofinanciado FEDER*
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2025 extended 2026
Total budget: €147,620

Reference: ASSOASL-HSP_2025_Navarro.
Title: *Pharmacological Screening in Drosophila and Cellular Models of Hereditary Spastic Paraplegia 7 (PharmaFlyHSP7)*
Principal Investigator: Juan Antonio Navarro Langa.
Funding body: *ASS Fondation Maladies Rares.*
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2026
Total budget: €25,000

Reference: CIAICO/2023/248.
Title: *Regulación de la expresión de frataxina mediante edición genética y epigenética dirigida y su impacto en el desarrollo de terapias para la ataxia de Friedreich.*
Principal Investigator: Federico Vicente Pallardó Calatayud, Pilar González Cabo and M^a Teresa Sevilla Mantecón.
Funding body: *Conselleria Educacion/Innovacion, Universidades, Ciencia Y Sociedad Digital/Empleo.*
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2027.
Total budget: €89,994

Title: *Evaluación de Betalactámicos en SCA3.*
Principal Investigator: Juan Antonio Navarro Langa.
Funding body: *Federación Española de Ataxias (FEDAES).*
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 31/03/2025-31/03/2026.
Total budget: €6,000

RESEARCH RESULTS
Invention: Methods for the measurement of protein C and activated protein C
Priority Number: EP22708174

Status: Licensed
Principal Investigator: José Luis García Gimenez

Invention: Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasmafrom sepsis or septic shock(SS) patients
Priority Number: EP17800461
Status: Licensed
Principal Investigator: José Luis García Gimenez

JOURNAL PUBLICATIONS		
Number of Publications	IF	Average FI
5	26.4	5.28
National collaborations	International collaborations	Corresponding author
3	2	3

- Epigenome-wide DNA methylation profiling in septic and non-septic patients with similar infections: potential use as sepsis biomarkers. López I, García JL, Madrazo M, García J, Piles L, Pallardó FV, Artero A. *Frontiers in Cellular and Infection Microbiology*. 2025 enero 24. 141532417-1532417. DOI:10.3389/fcimb.2024.1532417. PMID:39926115. IF:4,80. Q1.
- Editorial: Molecular and cellular pathways leading to mitochondrial dysfunction and neurodegeneration: lessons from in vivo models, volume II. Hannan SB, De Lazzari F, Gomez Duran A, Navarro JA, Brea Calvo G, Sanchez Martinez A. *Frontiers in Neuroscience*. 2025 enero 29. 191557013-1557013. DOI:10.3389/fnins.2025.1557013. PMID:39944887. IF:3,20. Q2.
- Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention. Pagano G, Lyakhovich A, Thomas PJ, Catalayud FVP, Tiano L, Zatterale A, Trifuoggi M. *INFLAMMOPHARMACOLOGY*. 2025 febrero 01. 33 (2):431-441. DOI:10.1007/s10787-024-01613-w. PMID:39656417. IF:5,30. Q1.
- A Sex-Specific Minimal CpG-Based Model for Biological Aging Using ELOVL2 Methylation Analysis. Ibáñez JS, Sandoval J, Pallardó FV, García JL, Mena S. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*. 2025 abril 04. 26 (7):DOI:10.3390/ijms26073392. PMID:40244262. IF:4,90. Q1.
- Oxidative stress and central metabolism pathways impact epigenetic modulation in inflammation and immune response. García Giménez JL, Cánovas Cervera I, Nacher Sendra E, Dolz Andrés E, Sánchez Bernabéu A, Agúndez AB, Hernández Gil J et al. *FREE RADICAL BIOLOGY AND MEDICINE*. 2025 junio 01. 233378-399. DOI:10.1016/j.freeradbiomed.2025.04.004. PMID:40185167. IF:8,20. Q1.

Research Group on Nuclear Receptors in Cardiometabolic Pathology


Emergent
Principal Investigator: Laura Piqueras Ruiz.
This research group merged with the “Research Group on Inflammation” during the middle of the year

GROUP MEMBERS
Staff in the period 01/01/2025 – 09/06/2025
• **Established Researcher:**
Laura Piqueras Ruiz. UV
First Stage Researcher:
Álvaro Gómez Martín. INCLIVA
• **Staff-Technician:**
Ángela Vea Badenes. INCLIVA

STRATEGIC AIMS
Identify of new mechanisms involved in angiogenesis and inflammation in obese patients.
Study and characterize the role of the CCR4 receptor and its ligands CCL17 / TARCE, CCL22 / MDC and CKLF1 in angiogenesis and inflammation associated with obesity and in response to bariatric surgery.
Study and characterize the role of the CCR9 receptor and its ligand CCL25 in angiogenesis and inflammation associated with morbid obesity.
Study the role of new agonists of GIPR and GLP1R in the development of abdominal aortic aneurysm.
Evaluate the effect of tirzepatide in an animal model of abdominal aortic aneurysm and investigate the possible anti-inflammatory effect of tirzepatide in dysfunction endothelial.

- MAIN LINES OF RESEARCH**
- Identification of new mechanisms involved in angiogenesis and inflammation in obese patients. Role of CCR4 chemokine receptor ligands and constitutive nuclear androstane receptors
 - Study the role of new agonists of GIPR and GLP1R in the development of abdominal aortic aneurysm

RESEARCH PROJECTS
Reference: PI21/00220.
Title: *Estudio de nuevos ejes de quimiocinas como potenciales dianas de intervención en la obesidad y la resistencia a la insulina.*
Principal Investigator: Laura Piqueras Ruiz.
Funding body: *Instituto Salud Carlos III.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2024 extended to 2025
Total budget: €204.490



JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
1	9.20	9.20
National collaborations	International collaborations	Corresponding author
1	1	-

- High Positive End-expiratory Pressure (PEEP) with Recruitment Maneuvers versus Low PEEP during General Anesthesia for Surgery: A Bayesian Individual Patient Data Meta-analysis of Three Randomized Clinical Trials. Mazzinari G, Zampieri FG, Ball L, Campos NS, Bluth T, Hemmes SNT, Ferrando C et al. ANESTHESIOLOGY. 2025 january 01. 142 (1):72-97. DOI:10.1097/ALN.0000000000005170. PMID:39042027. IF:9,20. Q1

Research Group on Metabolic Diseases


Emergent
Principal Investigator: Herminia González Navarro

<https://incliva.portalinvestigacion.com/grupos/371>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Established Researcher:**
Herminia González Navarro. UV
- **Recognised Researcher:**
Amparo Galán Albiñana. UV
Elena Jiménez Martí. UV
Gema Hurtado Genovés. INCLIVA
Konstantinos Karakostis. UV
- **First Stage Researcher:**
Susana Martín Vañó. INCLIVA
- **Research Nurse Staff:**
Eva González Gea. Hospital



STRATEGIC AIMS

- Study the effect of inflammatory mediators of the lymphotoxin family and their receptors on the development of metabolic associated fatty liver disease.
- Study the cytokine LIGHT and its effect on plaque stability during the progression of atherosclerosis.
- Characterize immune populations in human metabolic diseases.

MAIN LINES OF RESEARCH

- Identification and characterization of tissue immune populations associated with metabolic diseases.
- Identification of novel cellular plasticity mechanisms involved in atheroma plaque stability.
- Novel biomarkers for the stratification of patients with diabetes and atherosclerosis

RESEARCH PROJECTS

Title: Factores derivados del microambiente tumoral en cáncer de colon localizado: impacto clínico e implicaciones terapéuticas.
Principal Investigator: Andrés Cervantes Ruipérez and Elena Jiménez Martí.
Funding Body: Fundación Científica de la Asociación Española Contra el Cáncer AECC
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2020-2025 extended 2026
Total Budget: € 332.970

Reference: PI22/00062
Title: Identificación de nuevas dianas terapéuticas y mecanismos de la modulación de la inflamación en las enfermedades metabólicas
Principal Investigator: Herminia González Navarro
Funding Body: Instituto de Salud Carlos III - Cofinanciado FEDER
Beneficiary institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2025 extended to 2026
Total budget: € 147.620

RESEARCH RESULTS

Invention: Prenylated tetrahydroquinolines and quinolines with PPAR agonist activity

Priority Number: EP24382406

Status: PCT extension

Principal Investigator: Nuria Cabedo Escrig

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
8	49.1	6.14
National collaborations	International collaborations	Corresponding author
2	6	8

- Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression. Martinez C, Barros R, Caballero C, Boggino H, Alarcón L, Peleteiro B, Ruiz E et al. Gastric Cancer. 2025 march 01. 28 (2):160-173. DOI:10.1007/s10120-024-01578-3. PMID:39755998. IF: 5,10. Q1
- Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project. Dienstmann R, Ruiz E, Alsina M, Ruiz F, Groen TS, Martínez C, Fernández EA et al. ESMO Open. 2025 march 01. 10 (3):104482-104482. DOI: 10.1016/j.esmoop.2025.104482. PMID:40036904. IF: 8,30. Q1
- Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence. van TS, Cabeza M, Ferreira RM, Martínez C, Barros R, Santos J, Costa A et al. BRITISH JOURNAL OF CANCER. 2025 may 18. 132 (9):783-792. DOI:10.1038/s41416-025-02979-6. PMID:40113862. IF: 6,80. Q1
- Increased CX3CL1/CX3CR1 Axis Is Related to Atherosclerosis in Subjects with Familial Combined Hyperlipidaemia, Which Is Modulated by Insulin Resistance but Not by Sex. Jiménez E, Espinosa C, Alabadi B, Hurtado G, Enrique A, Martín S, Casas V et al. Biomedicines. 2025 september 28. 13 (10). DOI:10.3390/biomedicines13102378. PMID:41153665. IF: 3,90. Q1
- Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium. Carbonell JA, Jiménez E, Romero S, García E, Miralles A, Lopez B, Huerta M et al. JOURNAL OF CANCER EDUCATION. 2025 october 01. 40 (5):804-811. DOI:10.1007/s13187-025-02578-2. PMID:39939517. IF: 1,30. Q3

THESIS

Thesis title: Mecanismos moleculares de las células inmunes en la enfermedad del hígado graso no alcohólica asociada a la resistencia a insulina.

Type: Doctoral Thesis.

Doctoral candidate: María Aguilar Ballester.

Director(s): Herminia González Navarro.

University: Universitat de València (Estudi General).

Date of the defense: 19/06/2025

Thesis title: New molecular mechanisms of LIGHT/TNFSF14 in the development of atherosclerosis.

Type: Doctoral Tesis.

Doctoral candidate: Gema Hurtado Genovés.

Director(s): Herminia González Navarro.

University: Universitat de València (Estudi General).

Date of the defense: 17/10/2025

Research Group on Rare Respiratory Diseases (RRD)

Emergent

Principal Investigator: Francisco Dasí Fernández

This research group merged with the “Research Group on Respiratory Diseases” during the middle of the year

GROUP MEMBERS

Staff during the period 01/01/2025 – 09/06/2025

- **Established Researcher:**
Francisco Dasí Fernández. Hospital
Selene Valero Moreno. UV
- **Recognised Researcher:**
Silvia Castillo Corullon. Hospital /UV
- **First Stage Researcher:**
Álvaro García Carrasco. UV
- **Research Nurse Staff:**
Carlos Martinez Ferraro. UV
- **Staff-Technician:**
Joaquin Carrasco Luna. UV

STRATEGIC AIMS

Dr Dasí’s group focuses on investigating the molecular and cellular aspects of rare respiratory diseases (RRDs) to understand their pathophysiological mechanisms. The group aims to identify new molecular targets for diagnosis, prognosis, and treatment with a special interest in discovering biomarkers in biological fluids. Additionally, the group aims to translate their findings into gene therapy techniques for clinical applications. Finally, the group is dedicated to informing and collaborating with patients and families on RRDs related advancements.

MAIN LINES OF RESEARCH

- Develop cellular models from RRD patient cells, to facilitate research in these diseases.
- The group is currently conducting active basic research on two rare (RRDs); Alpha-1 Antitrypsin Deficiency (AATD) and primary ciliary dyskinesia (PCD).
- Characterize the molecular mechanisms (especially those aspects related to REDOX regulation) involved in the development of disease in AATD and PCD.
- Develop new therapeutic strategies based on gene therapy.
- To evaluate the diagnostic and/or prognostic value of circulating nucleic acids in plasma/serum.
- Generate social awareness of RRD, through the scientific dissemination of biomedical advances and social and health policies aimed at improving patient quality of life.

RESEARCH PROJECTS

Reference: 2024/054.

Title: Estudio de la utilidad de las terapias antioxidantes en el déficit de alfa-1 antitripsina.


Principal Investigator: Francisco Dasí Fernández.

Funding body: Fundación de Neumología de la Comunidad Valenciana.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2028.

Total budget: € 6.000.



Reference: 2021/164.
Title: *Estudio de la utilidad clínica de los exosomas plasmáticos en la discinesia ciliar primaria.*
Principal Investigator: Francisco Dasí Fernández.
Funding body: *Fundación de Neumología de la Comunidad Valenciana; Sociedad Valenciana de Nefrología.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2025.
Total budget: € 12.000.

Reference: 2020/011.
Title: *Estudio de los micro-RNAs circulantes como biomarcadores pronósticos en pacientes con déficit de alfa-1-antitripsina.*
Principal Investigator: Francisco Dasí Fernández.
Funding body: *Fundación de Neumología de la Comunidad Valenciana.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2021-2025.
Total budget: € 6.000.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
11	31	2.82
National collaborations	International collaborations	Corresponding author
8	3	3

- Affective states and stress in health-professional caregivers of people with functional diversity: the important role of empathy and social support as mediators of this relationship. García E, Pérez M, Martínez A, Valero S. Investigacion y Educacion en Enfermeria. 2025 january 01. 43 (1). DOI: 10.17533/udea.iee.v43n1e12. PMID:40382008. IF: 1.6 Q3.
- Psychological Risk and Protective Factors for the Development of Prolonged Grief in Mourners. Ribera O, Pérez M, Valero S. Family Journal. 2025 january 13. DOI: 10.1177/10664807241312201. IF: 1.1 Q3.
- Grief and Psychopathology in Bereaved Caregivers of Palliative Care Patients: The Mediating and Moderating Roles of Distress, Burden and Social Support. Ribera O, Pérez M, Valero S. JOURNAL OF ADVANCED NURSING. 2025 may 19. 821382-1394. DOI: 10.1111/jan.17018. PMID:40387389. IF: 3.8 Q1.

- Impact of Nirsevimab immunoprophylaxis on professional exhaustion during two epidemics of respiratory syncytial virus. Barrés A, Calderon C, Ferrando S, Castillo S, Fullana M, González SI, Arcos JV. Journal of Pediatric Nursing-Nursing Care of Children & Families. 2025 september 01. 8482-87. DOI: 10.1016/j.pedn.2025.05.018. PMID:40414172. IF: 2.6 Q1.
- Is bronchial asthma a risk factor for emotional well-being in adolescence? A comparative study. Valero S, Montoya I, Pérez M. PSYCHOLOGY & HEALTH. 2025 october 03. 40 (10):1685-1702. DOI:10.1080/08870446.2024.2349644. PMID:38715417. IF: 2 Q2.

Research Group on Healthy Aging


Consolidated
Principal Investigator: Consuelo Borrás Blasco

<https://incliva.portalinvestigacion.com/grupos/366>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Established Researcher:**
Consuelo Borrás Blasco. UV
- **Recognised Researcher:**
Ana Díaz Cuevas. UV
María Del Mar Dromant Jarque. UV
Marta Inglés De La Torre. UV
Cristina Mas Bargues. UV
- **First Stage Researcher:**
Marta Arnal Forné. UV
Nimra Razzaq. UV
Javier Huete Acevedo. UV
- **Staff-Collaborating Researcher:**
Jorge Sanz Ros. Stanford University



STRATEGIC AIMS

- Understand the molecular mechanisms underlying aging and frailty.
Develop potential biomarkers to evaluate them.
Create possible evaluation methods.
Formulate suitable intervention strategies.
Determine a quality-of-life index in experimental animals.
Develop human imaging biomarkers for diagnosing frailty.
Investigate interventions to delay aging and prevent frailty:
- Therapy using small extracellular vesicles.
 - Investigate the role of the antiapoptotic gene Bcl-xL.

MAIN LINES OF RESEARCH

- Development of a quality-of-life index related to healthy aging in experimental animals, derived from intervention studies on aging. Frailty biomarkers based on ultrasound image analysis include echo intensity, fractals, and textures.
- Development of image biomarkers in the diagnosis of frailty, focusing on fragility biomarkers from ultrasound image analysis, including echo intensity, fractals, and textures
- Examination of Bcl-xL as a longevity gene, referencing previous studies involving centenarians.
- Interventions aimed at promoting healthy aging: stem cell-derived extracellular medicine, based on previous studies on stem cells and senescence.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
14	64.2	5.35
National collaborations	International collaborations	Corresponding author
6	5	11

- Bcl-xL overexpression in T cells preserves muscle mitochondrial structure and function and prevents frailty in old mice. Mas C, Román A, Sanz J, Romero N, Huete J, Dromant M, Cuervo AM et al. Science Advances. 2025 marzo 19. 11 (12):DOI:10.1126/sciadv.adr1378. PMID:40106552. IF:12,50. Q1
- Exosomal miR-302b as a novel strategy for reversing cellular senescence and promoting healthy aging. Borr C. Extracellular Vesicles and Circulating Nucleic Acids. 2025 abril 02. 6 (1):191-194. DOI:10.20517/evcna.2025.24. PMID:40852595. IF:4,80. Q1
- Extracellular Vesicles as Epigenetic Regulators of Redox Homeostasis: A Systematic Review and Meta-Analysis. Mas Bagues C, Huete Acevedo J, Arnal Forné M, Sireno L, Pérez V, Borrás C. Antioxidants. 2025 abril 29. 14 (5):DOI:10.3390/antiox14050532. PMID:40427414. IF:6,60. Q1
- Extracellular vesicles as a biomarkers in traumatic brain injury: a systematic review of animal and clinical studies. Romero N, Ruiz A, Huete J, Monleón B, Vicente A, Mas C, Sanz J et al. CRITICAL CARE. 2025 julio 24. 29 (1):324-324. DOI:10.1186/s13054-025-05477-6. PMID:40707934. IF:9,30. Q1
- Characterization of Infarct Size and Remodeling Using CMR and PET in Mice Models of Reperfused and Non-Reperfused Myocardial Infarction. Gavara J, Molina T, Ezzeddin M, Diaz A, Perez N, Ortega M, Marcos V et al. Diagnostics. 2025 noviembre 22. 15 (23):DOI:10.3390/diagnostics15232960. PMID:41374341. IF:3,30. Q1

Research Group on Exercise, Nutrition and Healthy Lifestyle


Consolidated
Principal Investigator: María Carmen Gómez Cabrera

<https://incliva.portalinvestigacion.com/grupos/369>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Established Researcher:**
María Carmen Gómez Cabrera. UV
Juan Gambini Buchon. UV
Gloria Olaso Gonzalez. UV
- **Recognised Researcher:**
Eva Tamayo Torres. UV
Aitor Carretero Martínez. UV
Fernando Millan Domingo. UV
Esther Garcia Dominguez. UV
Kristine Stromsnes. UV
- **First Stage Researcher:**
Abril Gorgori González. UV
Silvana Javiera Soto Rodríguez. UV
Ángela García Correas. UV
Remus Iulian Lupu Lupu. INCLIVA
- **Staff-Collaborating Researcher:**
Miriam Martínez Cantón. UV
Juan Ignacio Cervera Miguel. Hospital



STRATEGIC AIMS

Investigate the physiological mechanisms of skeletal muscle dysfunction in ageing, disuse, and pathological conditions. Identify molecular and cellular pathways involved in muscle mass and strength loss to better understand sarcopenia and related disorders. Develop and optimize personalized physical exercise programs tailored to individuals with varying functional limitations or disease states. Integrate nutritional strategies with physical activity to enhance muscle preservation and recovery. Explore and evaluate pharmacological interventions as adjuncts to improve muscle function where appropriate. Translate basic research findings into clinically relevant interventions to improve the quality of life in sarcopenic, frail, diabetic, and cancer cachexia patients, among others. Promote multidisciplinary approaches combining physiology, nutrition, exercise science, and pharmacology to address muscle dysfunction holistically.

MAIN LINES OF RESEARCH

- Exercise Biology and Redox Regulation in Skeletal Muscle
 - Characterize cell signaling pathways activated during different modalities of physical exercise in skeletal muscle.
 - Analyse the role of oxidative stress and antioxidant supplementation in modulating exercise responses and protecting against muscle damage.
- Mitochondrial Therapeutics in Ageing
 - Investigate the role of nicotinamide riboside (NR), piceid and harmol as a mitotherapeutic agent to reverse age-associated energy collapse and improve mitochondrial function in skeletal muscle.
 - Explore how glucose-6-phosphate dehydrogenase (G6PD) activation influences redox balance and energy metabolism and assess its potential in preventing or reversing frailty.
- Multimodal Lifestyle Interventions in Ageing and Frailty.
 - Develop and evaluate integrated interventions combining multicomponent physical exercise programs with nutritional supplementation to reverse or prevent frailty.

- Assess the impact of high-intensity interval training (HIIT) on physical function, muscle health in ageing populations.
- Study the effects of glucosamine supplementation on physical performance and musculoskeletal integrity in older adults.
- Muscle Regeneration and Sarcopenia.
 - Develop strategies to enhance intrinsic myofiber self-repair mechanisms and regenerative capacity to prevent sarcopenia and muscle wasting in frail individuals.
 - Elucidate the molecular pathways involved in muscle atrophy, focusing on the contribution of oxidative stress and disuse in clinical and preclinical models.
- Translational Research and Clinical Application.
 - Use molecular and cellular approaches in both animal and human models to define the biological mechanisms modulated by exercise and nutrition.
 - Design clinical trials to translate basic research findings into interventions that enhance quality of life and promote healthy ageing.

RESEARCH PROJECTS

Reference: INVEST/2023/218.
Title: *Subvencions per a la contractació de persones joves demandants d'ocupació en la realització d'iniciatives d'investigació i innovació a la Comunitat Valenciana programa Investigo 2023.*
Principal Investigator: María Carmen Gómez Cabrera.
Funding body: *Conselleria Educacion/Innovacion, Universidades, Ciencia Y Sociedad Digital/Empleo.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €132,435.68
Reference: CB16/10/00435
Title: CIBER de Fragilidad y Envejecimiento (CIBERFES)
Funding body: Instituto de Salud Carlos III - Cofinanciado FEDER
Principal Investigator: María Carmen Gómez Cabrera.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2017 - present

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
10	69.5	7.72
National collaborations	International collaborations	Corresponding author
3	5	

- Training-Induced Metabolic Adaptations in Skeletal Muscle. Garcia E, Gomez MC, Gonzalez GO. Advances in Experimental Medicine and Biology. 2025 january 01. 1478491-510. DOI:10.1007/978-3-031-88361-3_21. PMID:40879953.
- Unlocking athletic potential: Exploring exercise physiology from mechanisms to performance. Gómez Cabrera MC, Handschin C. FREE RADICAL BIOLOGY AND MEDICINE. 2025 march 16. 23048-49. DOI:10.1016/j.freeradbiomed.2025.01.036. PMID:39889892. IF: 8,2. Q1
- Molecular mechanism involved in sarcopenia and frailty, diagnosis and therapy. Viña J, Gomez Cabrera MC. MOLECULAR ASPECTS OF MEDICINE. 2025 october 01. 105101387-101387. DOI: 10.1016/j.mam.2025.101387. PMID:40781035. IF: 10,30. Q1
- NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC. Pulido I, Garcia JC, Rodriguez ML, Becker JH, López A, Aupi M, Aparisi S et al. CANCER LETTERS. 2025 november 28. 633 DOI: 10.1016/j.canlet.2025.218032. PMID:40935282. IF: 10,10. Q1
- Chaperone-mediated autophagy sustains muscle stem cell regenerative functions but declines with age. Ramírez I, Campanario S, Chavda B, Santiago O, Flández M, Grima M, Cisneros A et al. Nature Metabolism. 2025 december 01. 7 (12):2571-2588. DOI:10.1038/s42255-025-01411-w. PMID:41339968. IF: 20,80. Q1

THESIS

Thesis title: Valoración del impacto de la simulación y la gamificación en su aplicación en la enseñanza de ecografía mamaria en estudiantes de medicina. **Type:** Doctoral thesis.
Doctoral candidate: Sebastián Rivadeneira.
Director(s): Juan Gambini Buchon and Florentina Guzmán Aroca.
University: Universitat de València (Estudi General).
Defence Date: 04/07/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Research Group in Translational Epigenetics and Epigenomics


Consolidated
Principal Investigator: Jose Luis García Giménez

<https://incliva.portalinvestigacion.com/grupos/378>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Established Researcher:**
Jose Luis Garcia Gimenez. UV
Nieves Carbonell Monleón. Hospital
Salvador Mena Molla. UV
Javier Hernández Gil. INCLIVA
- **Recognised Researcher:**
Marta Seco Cervera. UV
- **First Stage Researcher:**
Beatriz Quevedo Sanchez. Hospital
David Bolado Lopez De Andujar. Hospital
Georgia García Fernández. Hospital
Irene Canovas Cervera. UV
Elena Nácher Sendra. INCLIVA
Maria Rodriguez Gimillo. Hospital
- **Staff-Technician:**
José Santiago Ibáñez Cabellos. INCLIVA
Rosa Pura Calpe Fortea. UV
Elena Climent Martínez. INCLIVA
Enric Dolz Andrés. CIBERER




STRATEGIC AIMS

Further characterize the epigenetic mechanisms that produce phenotypic variability in human diseases, to uncover diagnostic and prognostic biomarkers that can be implemented in precision medicine:

- Identify epigenetic mechanisms and biomarkers in rare diseases.
- Identify epigenetic and proteomic biomarkers in sepsis and neonatal sepsis.
- Understand the mechanisms mediating the heterogeneity and complexity of sepsis by generating new organoid models

MAIN LINES OF RESEARCH

- Artificial intelligence for improved critically-ill patient management using epigenetic biomarkers.
- Clinical and biological data integration for molecular medicine.
- Identification of biomarkers for diagnosis, prognosis and monitoring of therapies in sepsis and septic shock.
- Identification of molecular mechanisms related to epigenetic dysregulation and oxidative stress in rare diseases.
- Mass spectrometry proteomics to identify blood circulating biomarkers.
- Organoids as models to evaluate tissue damage mediated by circulating histones.



RESEARCH PROJECTS

Reference: CPP2021-008643
Title: *Identificación y validación de biomarcadores mediante el uso de las ómicas y la Inteligencia Artificial para el diagnóstico temprano y mejora del manejo clínico de la sepsis*
Principal Investigator: Nieves Carbonell Monleón (José Luis García Giménez as collaborating researcher)
Entidad financiadora: *Ministerio de Ciencia e Innovación*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2025
Total budget: €150.269

Reference: PID2021-127408OA-I00
Title: Desarrollo inteligente de “linfocitos T cargados con fármacos” en la lucha contra el cáncer
Principal Investigator: Javier Hernández Gil
Funding Body: *Ministerio de Ciencia e Innovación*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2025
Total budget: €35.470

Reference: PI22/00990
Title: *Biomarcadores de pronóstico de escoliosis idiopática en adolescentes*
Principal Investigator: Salvador Mena Mollá
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €123.420

Reference: PI22/00481
Title: *Hacia la comprensión de la heterogeneidad de la sepsis. Pronóstico a corto y largo plazo mediante epigenómica, proteómica e inteligencia artificial*
Principal Investigator: Jose Luis García Giménez
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €185.000

Reference: CIAICO/2023/168
Title: Grupo de investigación en fisiopatología y biomarcadores de la sepsis
Principal Investigator: Jose Luis García Giménez /Salvador Mena Mollá
Funding Body: *Consellería de Educación/ Innovación, Universidades, Ciencia y Sociedad Digital /Empleo*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2027
Total budget: €89.917

Reference: DTS24/00094.
Title: *Proteómica cuantitativa por espectrometría de masas para la identificación temprana de biomarcadores predictivos de eventos adversos en el síndrome coronario agudo.*
Principal Investigator: Jose Luis García Giménez.
Funding body: *Instituto Salud Carlos III.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2026.
Total budget: € 143.660.

RESEARCH RESULTS

Invention: Methods for the measurement of protein C and activated protein C
Priority Number: EP22708174
Status: Licensed
Principal Investigator: José Luis García Gimene

Invention: Dispositivo para canalización de la sangre para hemodiálisis
Priority Number: P202330882
Status: PCT extension
Principal Investigator: José Ángel Bahamonde Romano

Invention: Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasmafrom sepsis or septic shock(SS) patients
Priority Number: EP17800461
Status: Licensed
Principal Investigator: José Luis García Gimenez

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
15	72	5.14
National collaborations	International collaborations	Corresponding author
7	4	10

- Epigenome-wide DNA methylation profiling in septic and non-septic patients with similar infections: potential use as sepsis biomarkers. López I, García JL, Madrazo M, García J, Piles L, Pallardó FV, Artero A. *Frontiers in Cellular and Infection Microbiology*. 2025 january 24. 141532417-1532417. DOI:10.3389/fcimb.2024.1532417. PMID:39926115. IF: 4,80. Q1.
- Potential of Pterostilbene as an Antioxidant Therapy for Delaying Retinal Damage in Diabetic Retinopathy. de las Matas RBS, Torres I, Millán I, Desco MD, Oblaré C, Asensi M, Mena S et al. *Antioxidants*. 2025 february 20. 14 (3):DOI:10.3390/antiox14030244. PMID:40227230. IF: 6,60. Q1.
- Status of Sepsis Care in European Hospitals Results from an International Cross-Sectional Survey. Scheer CS, Giamarellos EJ, Ferrer R, Idelevich EA, Annane D, Artigas A, Aslan AT et al. *AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE*. 2025 april 01. 211 (4):587-599. DOI:10.1164/rccm.202406-1167OC. PMID:39787606. IF: 19,40. Q1.
- Oxidative stress and central metabolism pathways impact epigenetic modulation in inflammation and immune response. García Giménez JL, Cánovas Cervera I, Nacher Sendra E, Dolz Andrés E, Sánchez Bernabéu A, Agúndez AB, Hernández Gil J et al. *FREE RADICAL BIOLOGY AND MEDICINE*. 2025 june 01. 233378-399. DOI: 10.1016/j.freeradbiomed.2025.04.004. PMID:40185167. IF: 8,20. Q1.
- Down-regulation of MIR-378A-3P expression associated with inflammation: The effects of restoring its levels. Seco M, Gisbert L, Macias DC, Ortiz D, Cosín J, Bauset C, Heras B et al. *PLoS One*. 2025 august 11. 20 (8). DOI: 10.1371/journal.pone.0329685. PMID:40788903. IF: 2,60. Q2

Research Group on Medical Chemistry for Drug Development


Emergent
Principal Investigator: Nuria Cabedo Escrig

<https://incliva.portalinvestigacion.com/grupos/379>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Established Researcher:**
Nuria Cabedo Escrig. UV
- Recognised Researcher:**
Alvaro Bernabeu Sanchís. INCLIVA
Ainhoa Natividad García Martín. INCLIVA
- Staff-Collaborating Researcher:**
Paloma Marín Vivanco. UV
Jordi Ferri Ciscar. Hospital
Diego Cortes Martinez. UV
- Staff-Technician:**
Laura Vila Dasí. INCLIVA



STRATEGIC AIMS

- Peroxisome proliferator activator receptor (PPAR) ligands.
- Dopamine receptor ligands.
- Serotonergic receptor ligands.
- Biomarkers of inflammation.
- Cytotoxic molecules for tumor cell lines.

MAIN LINES OF RESEARCH

- Development of new bioactive molecules as potential drug candidates:
- Mainly focused on treatment of cardiometabolic diseases such as metabolic syndrome, obesity and type 2 diabetes.
 - Also targeting other diseases of special relevance such as neurological diseases, cancer and rare diseases.

RESEARCH PROJECTS

Reference: PI21/02045
Title: *Desarrollo de nuevos moduladores multidiana de receptores nucleares y biomarcadores lipídicos para el tratamiento del síndrome metabólico y las comorbilidades asociadas*
Principal Investigator: Nuria Cabedo Escrig
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2022-2024
Total Budget: €174.240

Reference: CIAICO/2024/321.
Title: *Desarrollo de moduladores de PPAR en la regulación del metabolismo energético y su impacto en la proliferación celular.*
Principal Investigator: Nuria Cabedo Escrig. Co-IP: Pilar Eroles Asensio.
Funding body: *Conselleria Educacion/ Innovacion, Universidades, Ciencia y Sociedad Digital/ Empleo.*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2028.
Total budget: € 90.000.

RESEARCH RESULTS

Invention: Prenylated tetrahydroquinolines and quinolines with PPAR agonist activity
Priority Number: EP24382406
Status: PCT extension
Principal Investigator: Nuria Cabedo Escrig

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
2	8.6	4.3
National collaborations	International collaborations	Corresponding author
1	1	1

- Development of 2-and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome. Villarroel C, Martínez M, García A, Vila L, Zibar K, Schiel MA, Hennuyer N et al. BIOORGANIC CHEMISTRY. 2025 june 15. 160108450-108450. DOI: 10.1016/j.bioorg.2025.108450. PMID:40215945. IF: 5,1. Q1
- Synthesis of 2-(3-aminopropyl) benzopyrans as potential antipsychotic agents targeting D2/D3 and 5-HT2A receptors. Bernabeu Á, Varela MJ, García A, Villarroel C, Vila L, Loza MI, Brea J et al. BIOORGANIC & MEDICINAL CHEMISTRY. 2025 november 01. 129118300-118300. DOI: 10.1016/j.bmc.2025.118300. PMID:40633512. IF: 3,5. Q1

THESIS

Thesis title: Síntesis de benzopiranos dopaminérgicos y serotoninérgicos, y Síntesis de benzopiranos y quinoleínas citotóxicas.
Type: Doctoral Thesis.
Doctoral candidate: Alvaro Bernabeu Sanchís.
Director(s): Diego Cortes Martinez and Nuria Cabedo Escrig.
University: Universitat de València (Estudi General).
Date of the defense: 30/05/2025

Research Group on Neurobiology and Molecular Physiopathology in Rare Diseases – NeuroFisER


Emergent

Principal Investigator: Pilar González Cabo

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Established Researcher:
Pilar González Cabo
- First Stage Researcher:
Rita Noverques Chermé,
Lorena Baquero Anson
- Staff-Collaborating Researcher:
Marta Roldán Lázaro



STRATEGIC AIMS

Physiopathology of Friedreich's ataxia: identify new therapeutic targets that allow new treatments to be implemented.

Develop new strategies for advanced gene therapy: CRISPR/ Cas9 system and anti-miRNAs.

Huntington's disease: use of nanobodies as a therapeutic tool to reduce mutant huntingtin levels and modify the course of the disease.

Develop a new study model for CANVAS Syndrome (Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome): generation of iPSCs from skin biopsies of CANVAS patients, and their subsequent differentiation into sensory neurons.

Effect of COVID-19 infection on telomere length and its relationship with the evolution of idiopathic-type pulmonary fibrosis.

- MAIN LINES OF RESEARCH
- Characterization of the phenotype of different models of rare diseases to study the pathophysiology and thus understand the molecular mechanisms underlying these diseases.
 - Development of different pharmacological and genetic pre-clinical therapeutic approaches.
 - Identification of biomarkers

RESEARCH PROJECTS

Reference: CIAICO/2023/248.

Title: Regulación de la expresión de frataxina mediante edición genética y epigenética dirigida y su impacto en el desarrollo de terapias para la ataxia de Friedreich.

Principal Investigator: Federico Vicente Pallardó Calatayud and Pilar González Cabo.

Funding body: Conselleria Educacion/Innovacion, Universidades, Ciencia y Sociedad Digital/Empleo.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2027.

Total budget: €89.994.

THESIS

Thesis title: Effects of COVID-19 infection on telomere length and its relationship with the evolution of pulmonary fibrosis.

Type: Doctoral Thesis.

Doctoral candidate: Alba Mulet Arabí.

Director(s): Jaime Signes-Costa Miñana and Pilar González Cabo.

University: Universitat De València (Estudi General).

Defense Date: 04/11/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Research Group on Genetics and Biomarkers of Rare Diseases


Consolidated
Principal Investigator: Carmen Espinós Armero

<https://incliva.portalinvestigacion.com/grupos/403>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Carmen Espinós Armero. UV
- Recognised Researcher:**
Esther Martínez Martínez. CIPF
- First Stage Researcher:**
Edna Ripollés Campos. CIPF
- Staff-Technician:**
Christian Palacios Martínez. CIPF
Sofía Domenech Dauder. CIPF



STRATEGIC AIMS

Molecular bases of rare movement disorders: We aim to determine the causative mutations using short and long read genome sequencing in patients belonging to an in-depth phenotyping series. Another aim is to discover novel genes/mutations and mutational mechanisms and broaden clinical pictures.

Wilson’s disease (WD): WD is caused by mutations in ATP7B, a copper transporter. Our goals are: (i) identify the microRNA profile useful for prognosis; and (ii) define the contribution of the microbiome to the clinical picture.

Diagnosis of childhood epilepsy: We work with four cohorts: focal, generalised, structural and epileptic encephalopathy, with the goal of establishing the microRNA signature associated with each one to improve diagnosis and enable their stratification.

MAIN LINES OF RESEARCH

- Diagnosis of childhood epilepsy. We work with four cohorts (focal, generalised, structural and epileptic encephalopathy) to establish the microRNA signature associated with each one to improve diagnosis and stratify them.
- Molecular bases of rare movement disorders: We aim to determine the causative mutations using genome sequencing (short and long read) in patients from an in-depth phenotyping series. Another aim is to discover novel genes/mutations and mutational mechanisms and broaden clinical pictures.
- Rare diseases programme.
- Wilson’s disease (WD): WD is caused by mutations in ATP7B, a copper transporter. Our goals are: (i) identify the microRNA profile useful for prognosis; and (ii)define the contribution of the microbiome to the clinical picture.

RESEARCH PROJECTS

Reference: PI21/00103
Title: Estudios clínicos; bases genéticas y biomarcadores pronóstico en enfermedades raras neurodegenerativas
Principal Investigator: Carmen Espinós
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2022-2024 extended to 2025
Total budget: €54,679.42

Reference: CIAORG/2024/116
Title: Simposio internacional sobre la enfermedad de Wilson/
International symposium on Wilson disease
Principal Investigator: Carmen Espinós
Funding Body: Conselleria Educacion/Innovacion,
Universidades, Ciencia y Sociedad Digital/Empleo
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025
Total budget: €9,000

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
2	156	7.09
National collaborations	International collaborations	Corresponding author
2	-	-

- The Spanish Polygenic Score reference distribution: a resource for personalized medicine. Carmona R, Roldán G, Fernández JL, Navarro A, Peña M, Crowdsourcing CSVS, Dopazo J et al. EUROPEAN JOURNAL OF HUMAN GENETICS. 2025 abril 24. DOI:10.1038/s41431-025-01850-9. PMID:40275119. IF: 4,60. Q1.
- A new genotype of the IDH3A gene causes retinitis pigmentosa, generating functional dyschromatopsia from early childhood. Rosell N, Sierra A, Tortosa J, Monferrer C, Montero J, Espinós C, Rodríguez R. OPHTHALMIC GENETICS. 2025 noviembre 02. 46 (6):707-712. DOI:10.1080/13816810.2025.2563909. PMID:40993038. IF: 1. Q4.

Mixed Unit on Neurological Impairment

Consolidated
Principal Investigators: Carmina Montoliu, Carmen Espinós and Jose Tomás Real Collado,

https://incliva.portalinvestigacion.com/grupos/407

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:
Carmen Montoliu Félix. INCLIVA
Carmen Espinós. INCLIVA
Jose Tomás Real. INCLIVA
Sergio Martínez. INCLIVA
Vicente Felipo Orts. CIPF
Regina Rodrigo. CIPF
- Established Researcher:
Amparo Urios. INCLIVA
Andrea Cabrera. INCLIVA
Mª Pilar Ballester. INCLIVA
José Ballester. INCLIVA
Desamparados Escudero. INCLIVA
Paloma Lluch. INCLIVA
Marta Llansola. CIPF
Mar Martínez. CIPF
- Recognised Researcher:
Paula Izquierdo Atarejos. INCLIVA
Joan Tosca. INCLIVA
Cristina Montón. INCLIVA
Gergana Ivaylova Mincheva. CIPF
M. Carmen Castro. CIPF
- First Stage Researcher:
Concepción Gómez. INCLIVA
Adrià López. INCLIVA
Andrea Palomares. CIPF
Yaiza Arenas Ortiz. CIPF
Sheyla Velasco. CIPF
- Staff-technicians:
María Oliver. INCLIVA
Laura Ávila. INCLIVA

STRATEGIC AIMS

Research into the molecular mechanisms of neurological deterioration.
Identification of new therapeutic targets for treatment.
Design and test new therapeutic procedures to reverse or prevent neurological deterioration.
To transfer the identified therapeutic treatments to the clinic.
To identify and put into clinical practice new early diagnostic procedures for neurological deterioration in patients.

MAIN LINES OF RESEARCH

- Detailed characterisation of alterations in attention, coordination, perception, spatial and working memory and other aspects of cognitive and motor function in cirrhotic patients with minimal hepatic encephalopathy (MHE).
- Identification of alterations in brain function using structural and functional MRI (oedema, brain atrophy, alterations in structure and connectivity of neural tracts) in patients with MHE.
- Identification of alterations in brain function using neurophysiological techniques (EEG, brain mapping, etc.) in patients with MHE. Analysis of their utility in MHE diagnosis.
- Characterisation of immunophenotype changes associated with the development of MHE in cirrhotic patients. Identify changes in molecular and cellular events in the immune response associated with MHE: changes in gene expression, miRNAs, activation of signalling pathways in lymphocytes and monocytes and in extracellular components.
- Evaluation of the effects of rifaximin treatment on neurological, immunological and brain structure and function alterations analysed by MRI.
- Identification of peripheral markers of MHE. Identification of metabolites useful for early diagnosis of MHE. Search for inflammation-related markers as possible indicators of the presence of MHE.

RESEARCH PROJECTS

Reference: CIPROM/2021/082
Title: Molecular mechanisms of the neurological (cognitive and motor) alterations in hyperammonemia and hepatic encephalopathy. Therapeutic implications
Principal Investigator: Vicente Felipo
Coordinating Entity: FCIPF
Funding Entity: Conselleria de Educacio. Generalitat Valenciana.
Programme/grant: Ayuda para Grupos de Investigación de Excelencia. Programa Prometeo
Duration: 2022-2025

Reference: PI23/00062
Title: Mecanismos que conducen al deterioro cognitivo y motor leve en pacientes con enfermedad hepática: Papel de los cambios en la microbiota, el sistema inmunitario y las vesículas extracelulares
Principal Investigator: Carmina Montoliu and Mª Pilar Ballester
Coordinating Entity: INCLIVA
Funding Entity: Instituto de Salud Carlos III. (FIS) Ministerio de Sanidad y Consumo, co-financiado con Fondos FEDER
Programme/grant: Proyectos de Investigación en Salud
Duration: 01/01/2024 - 31/12/2026

Title: Study to assess if golexanolone could slow the progres-sion of the pathology in a rat model of Parkinson's disease. 4 weeks of treatment
Principal Investigator: Vicente Felipo
Funding Entity: Umeocrine Cognition AB. Sweden
Duration: December 2023 – December 2025
Total Budget: €86,686

Title: Study to assess if golexanolone could slow the progres-sion of the pathology in a rat model of Parkinson's disease. 8 weeks of treatment
Principal Investigator: Vicente Felipo
Funding Entity: Umeocrine Cognition AB. Sweden
Duration: March 2024 – April 2025
Total Budget: €95,608

Title: Study to assess if golexanolone could slow the progres-sion of the pathology in a rat model of Parkinson's disease. 2 weeks of treatment
Principal Investigator: Vicente Felipo
Funding Entity: Umeocrine Cognition AB. Sweden
Duration: April 2024 – December 2025
Total Budget: €66,028

Title: Study to analyze additional mechanisms involved in the beneficial effects of golexanolone in the 6-OHDA rat model of parkinson's disease
Principal Investigator: Vicente Felipo
Funding Entity: Umeocrine Cognition AB. Sweden
Duration: December 2024 – December 2025
Total Budget: €32,038

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
23	128.8	5.6
National collaborations	International collaborations	Corresponding author
15	8	13


- Assessment of Muscle-Specific Strength in Oncology Patients: Anthropometry as a Reliable Alternative to DXA. Alabadi B, Amores S, Moriana M, Wu NY, García K, Pedrón JA, Monrós C et al. Life-Basel. 2025 agosto 15. 15 (8). DOI: 10.3390/life15081300. PMID:40868947. IF:3.9; Q1.
- The analysis of the gut microbiome during liver disease progression led to the identification of biomarkers for related mild cognitive impairment. Giner L, Gallego JJ, Giménez C, Batallas D, Jarquín VH, Casanova F, Fiorillo A et al. Frontiers in Microbiology. 2025 septiembre 16. 161670512-1670512. DOI:10.3389/fmicb.2025.1670512. PMID:41035890. IF:5.8; Q1.
- Increased CX3CL1/CX3CR1 Axis Is Related to Atherosclerosis in Subjects with Familial Combined Hyperlipidaemia, Which Is Modulated by Insulin Resistance but Not by Sex. Jiménez E, Espinosa C, Alabadi B, Hurtado G, Enrique A, Martín S, Casas V et al. Biomedicines. 2025 septiembre 28. 13 (10). DOI: 10.3390/biomedicines13102378. PMID:41153665. IF:4.5; Q2.
- Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis. San Martín C, Gallego JJ, Urios A, Correa P, Tabares R, Montoliu C. PLoS One. 2025 octubre 08. 20 (10). DOI: 10.1371/journal.pone.0333029. PMID:41060950. IF:2.8; Q2.
- Sex-Specific Differences and a Predictive Model Based on Clinical and Biochemical Parameters for Minimal Hepatic Encephalopathy. Gallego JJ, Casanova F, Fiorillo A, Benlloch S, Urios A, López A, Oliver M et al. LIVER INTERNATIONAL. 2025 noviembre 19. 45 (12). DOI: 10.1111/liv.70452. PMID:41255242. IF:6.2; Q1.

4.3.4 Reproductive Medicine Area

Groups

- Research Group on Reproductive Medicine
- Research Group on Therapies Against Endometriosis and Endometrial Cancer
- Research Group on Maternal–Fetal Communication
- Research Group on Molecular Diagnosis of Gynaecological Tumours
- Mixed Unit of Reproductive Medicine

Number of indexed publication		IF	Average IF	
15		144.1	9.60	
National collaborations		International collaborations	Corresponding author	
5		9	8	
D1	Q1	Q2	First author	Last author
8	12	2	5	7



Key Publications

- Mapping Human Uterine Disorders Through Single-Cell Transcriptomics. Boldu S, Lliberos C, Simon C, Mas A. Cells. 2025 january 21. 14 (3): DOI:10.3390/cells14030156. PMID:39936948. IF: 5,20. Q2
- Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia. Muñoz I, Pérez R, Castillo N, Cordero T, Ochando A, Ortega S, Parras M et al. NATURE MEDICINE. 2025 february 01. 31 (2):502-513. DOI:10.1038/s41591-024-03407-7. PMID:39775038. IF: 50. Q1
- Single-cell technology: the key to an improved understanding of the human endometrium in health and disease. Gonzalez Fernandez J, Zaragozano S, Monteagudo Sánchez A, Simon C, Vilella F. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025 april 01. 232 (4):44-54. DOI: 10.1016/j.ajog.2024.08.042. PMID:40253082. IF: 8,40. Q1
- Asherman syndrome at single-cell resolution. Pardo Figueruez M, Simon C, Santamaria X. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025 april 01. 232 (4):148-159. DOI: 10.1016/j.ajog.2024.12.023. PMID:40253078. IF: 8,40. Q1
- Fusobacterium nucleatum is not significantly present in eutopic endometrium from patients with minimal-mild and moderate-severe endometriosis. Graciano MDC, Barnhart K, Gonzalez M, Arenas M, Legro RS, Thomas TR, Rush MA et al. FERTILITY AND STERILITY. 2025 november 01. 124 (5):1071-1081. DOI: 10.1016/j.fertnstert.2025.06.035. PMID:40588151. IF: 7. Q1

Research Group on Reproductive Medicine

Consolidated


Principal Investigator: Carlos Antonio Simón Vallés

<https://incliva.portalinvestigacion.com/grupos/273>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Carlos Antonio Simón Vallés. FCS /UV
- **Recognised Researcher:**
Emilia Scharrig. FCS
María Guerrero Sánchez. FCS
María Cristina Carbajo García. UV
Teresa Cordero Cucart. FCS
Xavier Santamaria Costa. FCS
Inmaculada Moreno Gimeno. FCS
Tamara Garrido Gomez. FCS
Petr Volkov. FCS
François-José Serra. FCS
- **First Stage Researcher:**
Maria Del Carmen Graciano España. FCS
Carla Montagud Almarcha. INCLIVA
José Pascual Serrano Serrano. FCS
Irene Muñoz Blat. FCS
Marta González Monfort. FCS
- **Staff-Administrative Assistant:**
Jaime Herrero Hernandez. FCS
- **Staff-Technician:**
Ana Ochando Hernandez. FCS
Yolanda Castelló Martínez. FCS
Maria Lloret Perez. FCS
Jaime Llera Oyola. FCS




STRATEGIC AIMS

Our activity predominantly involves research in the field of reproductive medicine and women's health, with a particular focus on factors that cause infertility and other gynaecological and obstetric pathologies.

Among our aims is single-cell resolution characterization of the human uterus to gain unprecedented insight at transcriptomic, genomic and spatial levels of changes in this important female organ not only throughout the menstrual cycle but also across the lifespan. Comparison between healthy and diseased conditions also fall within our scope.

MAIN LINES OF RESEARCH

- Adult stem cells in the human endometrium: We have identified the existence of human endometrial stem cells and also demonstrated the therapeutic potential of autologous bone marrow CD133+ stem cells to treat non-curable endometrial pathologies such as Asherman's syndrome and endometrial atrophy.
- Study endometrial receptivity and participate in the Cell Atlas of the human uterus: we discovered the transcriptomic signature of human endometrial receptivity. We currently form part of the International Human Cell Atlas initiative to create the first human cell atlas of the uterus.
- The endometrial microbiome in human reproduction: Our research group has described the existence of the endometrial microbiome and its clinical implications in reproductive outcomes. We investigate uterine microbiome dysbiosis and its clinical impact.



- Maternal involvement in the origins of pre-eclampsia: Our research has provided evidence that endometrial decidualization resistance is implicated in the pathogenesis of this disease. This finding offers a new perspective based on the maternal contribution to gestation, aiming to develop a tool that will diagnose pre-eclampsia.

RESEARCH PROJECTS

Reference: PID2022-140744OB-I00
Title: *Identificación de dianas celulares y moleculares maternas a nivel de célula única para la predicción temprana y tratamiento de preeclampsia (PREdict)*
Principal Investigator: Carlos Simón Vallés, Tamara Garrido Gómez
Funding Body: *Ministerio de Ciencia e Innovación*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2026
Total budget: €383,750

Reference: PI24/00722
Title: *Impacto microbiota en la patogénesis de la endometriosis ovárica.*
Principal Investigator: Inmaculada Moreno Gimeno
Funding Body: *Instituto de Salud Carlos III*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2025-2027
Total budget: €215,000

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
9	118.8	13.2
National collaborations	International collaborations	Corresponding author
4	4	7

- Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia. Muñoz I, Pérez R, Castillo N, Cordero T, Ochando A, Ortega S, Parras M et al. NATURE MEDICINE. 2025 february 01. 31 (2):502-513. DOI:10.1038/s41591-024-03407-7. PMID:39775038. IF:50. Q1
- Single-cell technology: the key to an improved understanding of the human endometrium in health and disease. Gonzalez Fernandez J, Zaragozano S, Monteagudo Sánchez A, Simon C, Vilella F. AMERICAN JOURNAL OF OBSTETRICS AND

- GYNECOLOGY. 2025 april 01. 232 (4):44-54. DOI:10.1016/j.ajog.2024.08.042. PMID:40253082. IF:8,40. Q1
- Maternal plasma cell-free RNA as a predictor of early and late-onset preeclampsia throughout pregnancy. Castillo N, Cordero T, Igual M, Muñoz I, Gómez C, Bernat N, Gaspar A et al. Nature Communications. 2025 october 20. 16 (1):9208-9208. DOI:10.1038/s41467-025-64215-2. PMID:41115885. IF:15,70. Q1
 - Fusobacterium nucleatum is not significantly present in eutopic endometrium from patients with minimal-mild and moderate-severe endometriosis. Graciano MDC, Barnhart K, Gonzalez M, Arenas M, Legro RS, Thomas TR, Rush MA et al. FERTILITY AND STERILITY.2025 november 01. 124 (5):1071-1081. DOI:10.1016/j.fertnstert.2025.06.035. PMID:40588151. IF:7,00. Q1
 - Capturing aberrant cell behaviors producing defects in human embryos via live imaging. Akizawa H, Domingo A, Pardo M, Hernandez B, Ardestani G, Skory RM, Venturas M et al. Science Advances. 2025 november 21. 11 (47):DOI:10.1126/sciadv.ady6402. PMID:41259532. IF:12,50. Q1

THESIS

Thesis title: Using organoids to decipher endometrial regeneration in Asherman syndrome patients.
Type: Doctoral Thesis.
Doctoral candidate: Javier Gonzalez Fernandez.
Director(s): Felipe Vilella Mitjana, Xavier Santamaria Costa, and Carlos Antonio Simón Vallés.
University: Universitat de València (Estudi General).
Defence Date: 25/02/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Thesis title: Determinación de variantes genéticas asociadas al desplazamiento de la ventana de implantación.
Type: Doctoral Thesis.
Doctoral candidate: Jose Alberto Miravet Valenciano.
Director(s): Carlos Antonio Simón Vallés and David Blesa Jarque.
University: Universitat de València (Estudi General).
Defence Date: 06/05/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Thesis title: Cribado de enfermedades monogénicas, recesivas y ligadas a X, en población árabe.
Type: Doctoral Thesis.
Doctoral candidate: Ana Bover Catalá. **Director(s):** Carlos Antonio Simón Vallés and Ana Cristina Cervero Sanz.
University: Universitat de València (Estudi General).

Defence Date: 06/05/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Thesis title: International, randomized and controlled clinical study, to evaluate the clinical benefit of the ERA test in infertile patients undergoing assisted reproduction treatment and medical indication of PGT-A. **Type:** Doctoral Thesis.
Doctoral candidate: Tamar Barbakadze. **Director(s):** Carlos Antonio Simón Vallés and Xavier Santamaria Costa.
University: Universitat de València (Estudi General).
Defence Date: 13/05/2025
Grade: Excellent
Quality recognition/Award: Cum Laude

Thesis title: Estudio clínico prospectivo, aleatorizado del análisis de la receptividad endometrial (ERA) en el diagnóstico de la infertilidad para la transferencia embrionaria personalizada (pET) versus transferencia embrionaria en fresco (fET) versus transferencia embrionaria diferida (EDET).
Type: Doctoral Thesis.
Doctoral candidate: Carlos Gómez De La Cruz.
Director(s): Diana María Valbuena Perilla and Carlos Antonio Simón Vallés.
University: Universitat de València (Estudi General).
Defence Date: 13/05/2025
Grade: Excellent
Quality recognition/Award: Cum Laude


Research Group on Therapies Against Endometriosis and Endometrial Cancer

Emergent
Principal Investigator: Raúl Gómez Gallego

<https://incliva.portalinvestigacion.com/grupos/370>

GROUP MEMBERS
Staff during the period 01/01/2025 – 31/12/2025

- Established Researcher:
Raúl Gómez Gallego. INCLIVA
- Staff-Technician:
Carles Antúnez Muñoz. INCLIVA
- Staff-Collaborating Researcher:
Francisco Bonilla Bartret. Hospital /UV
Mª Jose Fernandez Ramirez. Hospital /UV
Cesar Lizan Tudela. Hospital /UV



STRATEGIC AIMS

Refine homologous and heterologous animal models developed in the laboratory to enable them to reproduce endometriosis in a more physiological way, elucidating the pain and infertility associated with this disease to achieve greater transferability of findings to the clinic.

Use these optimized endometriosis animal models to evaluate whether immunomodulatory compounds such as those currently marketed for clinical use in non-hormonal treatment of osteoporosis are effective in pain remission and fertility improvement.

Pinpoint the molecular mechanisms involved in improving the parameters under study to refine therapeutic targets.

Evaluate the clinical feasibility of early non-invasive diagnosis of endometriosis through combined analysis of multiple biomarkers.

- MAIN LINES OF RESEARCH
- Development of animal models of pain and infertility associated with endometriosis and testing of the therapeutic role of immunomodulators in these models.
 - Dysregulation of the angiogenic component in endometriosis appearance and maintenance.
 - Early non-invasive diagnosis of endometriosis through combined analysis of multiple biomarkers.

RESEARCH PROJECTS

Reference: CNS2023-145222

Title: *Refinement and validation of endometriosis associated pain models as a platform for drug testing (REDONE).*

Principal Investigator: Raúl Gómez Gallego

Funding Body: *Ministerio de Ciencia e Innovación. MICIIN*

Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2024-2026

Total Budget: €199,997.05

Reference: PID2024-163058OB-I00

Title: *Evaluación del efecto terapéutico del bloqueo de CXCL 13/ CXCR5 en endometriosis.*

Principal Investigator: Raúl Gómez Gallego

Funding Body: *Ministerio de Ciencia e Innovación. MICIIN*

Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2025-2028

Total Budget: €111,500

Number of Publications	IF	Average FI
5	15.20	3.04
National collaborations	International collaborations	Corresponding author
-	4	1

- WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Heterologous): heterologous rodent models. Hull ML, Gomez R, Nothnick WB, Gruemmer R, Burns KA, Johan MZ, Land IR et al. MOLECULAR HUMAN REPRODUCTION. 2025 january 01. 31 (3):DOI:10.1093/molehr/gaaf022. PMID:40628402. IF: 3,50. Q1.
- WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Pain): methods to assess pain behaviour in rodent models of endometriosis. Dodds KN, Fattori V, Andrews NA, Appleyard CB, Christianson JA, Gomez R, McAllister SL et al. MOLECULAR HUMAN REPRODUCTION. 2025 january 01. 31 (3):DOI:10.1093/molehr/gaaf023. PMID:40628399. IF: 3,50. Q1.
- WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Homologous): homologous rodent models. Burns KA, Peterse D, Appleyard CB, Chandler R, Guo SW, Pearson A, Persoons E et al. MOLECULAR HUMAN REPRODUCTION. 2025 january 01. 31 (3):DOI:10.1093/molehr/gaaf021. PMID:40628400. IF: 3,50. Q1.
- WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Organoids): endometrial organoids as an emerging technology for endometriosis research. Marr EE, Gneco JS, Missmer SA, Hawkins SM, Osteen KG, Hummelshoj L, Greaves E et al. MOLECULAR HUMAN REPRODUCTION. 2025 july 03. 31 (3):DOI:10.1093/molehr/gaaf024. PMID:40628401. IF: 3,50. Q1.

- Fertility preservation counselling and practice among women with lymphomas: a retrospective study. Martínez MH, Tudela CL, Gamón BC, Navarro LG. JOURNAL OF OBSTETRICS AND GYNAECOLOGY. 2025 december 01. 45 (1):2449679-2449679. DOI:10.1080/01443615.2025.2449679. PMID:39810553. IF: 1,20. Q4

THESIS

Thesis title: Exploring new perspectives in the evaluation and treatment in advanced ovarian cancer.

Type: Doctoral Thesis.

Doctoral candidate: Maria Teresa Climent Marti.

Director(s): Raúl Gómez Gallego and Antonio Cano Sanchez.

University: Universitat de València (Estudi General).

Defence Date: 30/05/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Research Group on Maternal-Fetal Communication

Consolidated
Principal Investigator: Felipe Vilella Mitjana

<https://incliva.portalinvestigacion.com/grupos/372>



GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Established Researcher:**
Felipe Vilella Mitjana. INCLIVA
- Recognised Researcher:**
Lorenzo Abad De Velasco. Hospital
Diego Amoros Cerdan. FCS
Francisco Raga Baixauli. Hospital /UV
- Recognised Emerging Researcher:**
Ana Monteagudo Sánchez. INCLIVA
First Stage Researcher:
Sofía Zaragozano Martinez. FCS
Javier Gonzalez Fernandez. FCS/UV
- Staff-Technician:**
Anna Quirant Pellin. FCS
Ana Ochando Hernandez. FCS

Emerging Researchers
Ana Monteagudo Sánchez

The main research line of Dr Ana Monteagudo focuses on the role of epigenetic mechanisms in female reproductive health, particularly in ovarian ageing and endometrial function. Her work aims to decipher how DNA methylation and chromatin dynamics regulate fertility and embryo implantation, with the goal of identifying novel biomarkers and developing innovative therapeutic strategies.



STRATEGIC AIMS

Origin of diseases: functional capacity of miRNAs secreted into endometrial fluid in obese and type 2 diabetic patients to determine their capacity for transcriptomic and/or epigenetic modification of mouse embryos.

Transcriptomic and epigenetic modifications in human embryos: obtain the target genes of miRNA miR-30d in human embryos to obtain a list of regions potentially susceptible to methylation. These regions will be used to design the PCRs of bisulfite regions by miSeq sequencing.

Function of DNA and RNA contained in extracellular vesicles secreted by the human endometrium on the pre-implantation embryo: endometrial fluid has been reported to be secreted by a series of extracellular vesicle populations (apoptotic bodies, microvesicles and exosomes) that act as conveyance systems. We propose that these vesicles contain biomolecules of different natures (focusing specifically on the different RNA and DNA types) and that their composition in these chemical species varies throughout the menstrual cycle and depending on the sub-population of vesicles analysed.

Ovarian ageing and rejuvenation: building upon our expertise in reproductive biology, this new line aims to explore the molecular mechanisms underlying ovarian ageing and develop inno-

vative strategies to promote ovarian rejuvenation. By applying single-cell sequencing, we aim to map age-related changes in ovarian tissue and assess reprogramming techniques to extend female reproductive longevity and fertility potential. Embryo-maternal adhesion dynamics in ADOC: using our microfluidic endometrium-on-a-chip platform (ADOC), composed of organoid-derived endometrial epithelial cells and primary stromal cells cultured in interconnected compartments under dynamic flow, this line aims to define the molecular and cellular mechanisms governing early human embryo adhesion in a physiologically controlled setting. By combining live imaging, functional genomics, and targeted perturbation approaches, we will dissect epithelial-stromal crosstalk regulating polar trophoctoderm attachment, trophoblast spreading, and early lineage reorganization, and determine how endometrial dysfunction, microbiome-derived signals, and candidate therapeutic compounds alter embryo adhesion and implantation potential.

MAIN LINES OF RESEARCH

- Maternal-Fetal Communication.
- Ovarian ageing and rejuvenation, with a focus on extending reproductive longevity and improving fertility outcomes through single-cell analysis and reprogramming technologies.
- Study of endometrial receptivity, search for new minimally invasive methods for predicting endometrial receptivity

RESEARCH PROJECTS

Reference: 101080219
Title: Preventing lifetime obesity by early risk-factor identification, prognosis and intervention. eprObes.
Principal Investigator: Felip Vilella Mitjana
Funding Body: European Commission
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2028
Total budget: €111,393.35

Reference: CIAICO/2022/242
Title: Identificación de células progenitoras en el tejido endometrial humano
Principal Investigator: Felip Vilella Mitjana
Funding Body: Conselleria de Educación, Universidades y Empleo
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2025
Total budget: €90,000

Reference: CNS2022-135696
Title: Identificación de células progenitoras en el endometrio humano y demostración de su capacidad regenerativa (EndoProg)
Principal Investigator: Felipe Vilella Mitjana
Funding Body: Agencia Estatal de la Investigación
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2023-2025
Total budget: €108,700

Reference: CIGE/2023/217
Title: Estudio de los mecanismos moleculares y epigenéticos que impulsan el envejecimiento ovárico.
Principal Investigator: Ana Monteagudo Sánchez
Funding Body: Conselleria de Educación, Universidades y Empleo
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2024-2025
Total budget: €20,000

Reference: PI24/01784
Title: Rejuvenecimiento ovárico mediante reprogramación celular parcial.
Principal Investigator: Felip Vilella Mitjana and Ana Monteagudo Sánchez
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2027
Total budget: €190,000

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
3	25.5	8.5
National collaborations	International collaborations	Corresponding author
-	2	2

- DNA methylation shapes the Polycomb landscape during the exit from naive pluripotency. Richard J, Urli T, Monteagudo A, Le A, Sultanova A, David A, Scarpa M et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY. 2025 february 01. 32 (2):346-357. DOI:10.1038/s41594-024-01405-4. PMID:39448850. IF:10,10. Q1.

- Single-cell technology: the key to an improved understanding of the human endometrium in health and disease. Gonzalez Fernandez J, Zaragozano S, Monteagudo Sánchez A, Simon C, Vilella F. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025 april 01. 232 (4):44-54. DOI:10.1016/j.ajog.2024.08.042. PMID:40253082. IF:8,40. Q1-
- Fusobacterium nucleatum is not significantly present in eutopic endometrium from patients with minimal-mild and moderate-severe endometriosis. Graciano MDC, Barnhart K, Gonzalez M, Arenas M, Legro RS, Thomas TR, Rush MA et al. FERTILITY AND STERILITY. 2025 november 01. 124 (5):1071-1081. DOI:10.1016/j.fertnstert.2025.06.035. PMID:40588151. IF:7. Q1

THESIS

Thesis title: Using organoids to decipher endometrial regeneration in Asherman syndrome patients.

Type: Doctoral Thesis.

Doctoral candidate: Javier Gonzalez Fernandez.

Director(s): Felipe Vilella Mitjana, Xavier Santamaria Costa and Carlos Antonio Simón Vallés.

University: Universitat De València (Estudi General).

Defence Date: 25/02/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Research Group on Molecular Diagnosis of Gynaecological Tumours

Emergent


Principal Investigator: Aymara Mas Perucho

<https://incliva.portalinvestigacion.com/grupos/402>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Established Researcher:**
Aymara Mas Perucho. INCLIVA
- **First Stage Researcher:**
Paula Punzón Jiménez. INCLIVA
Sandra Boldú Fernandez. INCLIVA
- **Staff-Technician:**
Yasmina Cuartero Aguado. FCS
Carles Moreno Soriano. FCS
Esther Lara Cuesta. FCS



STRATEGIC AIMS

Our research is focused mainly on gynaecological pathologies, with a particular interest in myometrial and ovarian tumours. We aim to transform prognostic and therapeutic strategies by targeting distinct cellular subpopulations rather than addressing the tumour mass as a whole. We also aim to develop predictive models based on liquid biopsy for early differential diagnosis, to avoid the risk of malignant tumours of unknown primary.

- MAIN LINES OF RESEARCH**
- Molecular profiling of the human uterus at single-cell resolution to explore its roles in health and disease. Building on our recent publication in Nature Communications, we aim to expand this research by achieving spatially precise analysis of myometrial tumours using high-plex spatial transcriptomics and proteomics across whole tissue sections.
 - Assessment of uterine tumour heterogeneity through single-cell sequencing, aimed at generating a high-resolution map of the tumour microenvironment (TME) and refining an organoid-based experimental model.
 - Development of diagnostic predictive models based on liquid biopsy techniques. This involves comparing transcriptomic profiles from uterine and ovarian tissues and extrapolating the findings by identifying circulating genetic material in plasma and facilitating differential diagnosis of gynaecological tumours.

RESEARCH PROJECTS

Reference: PI23/00536

Title: Heterogeneidad tumoral inferida por secuenciación de célula única: nuevas aproximaciones terapéuticas frente a tumores uterinos.

Principal Investigator: Aymara Más Perucho

Funding Body: Instituto de Salud Carlos III

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2024-2026

Total Budget: €226,875

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
1	5.20	5.20
National collaborations	International collaborations	Corresponding author
1	-	1

- Mapping Human Uterine Disorders Through Single-Cell Transcriptomics. Boldu S, Lliberos C, Simon C, Mas A. Cells. 2025 january 21. 14 (3);DOI:10.3390/cells14030156. PMID:39936948. IF:5,20. Q2

Mixed Unit of Reproductive Medicine

Consolidated
Principal Investigator: Carlos Antonio Simon Vallés

<https://incliva.portalinvestigacion.com/grupos/408>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Carlos Antonio Simon Valles. FCS
- **Established Researcher:**
Felipe Vilella Mitjana. INCLIVA
Aymara Más Perucho. INCLIVA
Francisco Raga Baixauli. INCLIVA
Inmaculada Moreno Gimeno. FCS
Tamara Garrido Gomez. FCS
Xavier Santamaria Costa. FCS
- **Recognised Researcher:**
Lorenzo Abad De Velasco. INCLIVA
Ana Monteagudo Sanchez. FCS
Diego Amoros Cerdan. FCS
Teresa Cordero Cucart. FCS
María Cristina Carbajo García. FCS
Petr Volkov. FCS
Javier Gonzalez Fernandez. FCS
Sören Stahlschmidt FCS
François Serra FCS
Maria Guerrero FCS
Yasmina Cuartero Aguado. FCS
Emilia Scharrig. FCS
- **First Stage Researcher:**
Paula Punzón Jiménez. INCLIVA
Sandra Boldú Fernandez. INCLIVA
Carla Montagud Almarcha. INCLIVA
Sofia Zaragozano Martinez. FCS
José Pascual Serrano Serrano. FCS
Maria Del Carmen Graciano España. FCS
Marta González Monfort. FCS
Irene Muñoz Blat. FCS
- **Staff-administrative:**
Jaime Herrero Hernandez. FCS
Adrian Gonzalez Fernandez. FCS
Maria Lloret Perez. FCS
Rut Campos Jiménez. FCS
- **Staff-Collaborating Researcher:**

Francisco José Bonilla Bartret. INCLIVA
Mª Jose Fernandez Ramirez. INCLIVA

- **Staff-technicians:**
Ana Ochando Hernandez. FCS
Anna Quirant Pellin. FCS
Yolanda Castelló Martínez. FCS
Jaime Llera Oyola. FCS
Esther Lara Cuesta. FCS
Carles Moreno Soriano. FCS
Sheila Ortega. FCS

STRATEGIC AIMS

Our activity predominantly involves research in the field of reproductive medicine and women's health, with a particular focus on factors that cause infertility, and other gynaecological and obstetric pathologies.
One of our aims is single-cell resolution characterization of the human uterus, to gain unprecedented insight into transcriptom-ic, genomic and spatial changes in this important female organ throughout not only the menstrual cycle but also across the lifespan. Comparison between healthy and diseased conditions also falls within our scope..

MAIN LINES OF RESEARCH

- Adult stem cells in the human endometrium: We have identi-fied the existence of human endometrial stem cells, and also demonstrated the therapeutic potential of autologous bone marrow CD133+ stem cells to treat non-curable endometrial pathologies such as Asherman's syndrome and endometrial atrophy
- Molecular diagnosis of myometrial tumours: Our previous work has demonstrated the genomic differential character-ization of myomas and leiomyosarcomas. We aim to shift the diagnostic and therapeutic focus of uterine leiomyomas and leiomyosarcomas through genomic characterization
- Study of endometrial receptivity and participation in the Cell Atlas of the human uterus: we discovered the transcriptom-ic signature of human endometrial receptivity. We currently form part of the International Human Cell Atlas initiative to create the first human cell atlas of the uterus

- The endometrial microbiome in human reproduction: Our research group has described the existence of the endometrial microbiome and its clinical implications in reproductive outcomes. We investigate uterine microbiome dysbiosis and its clinical impact
- Maternal involvement in the origins of pre-eclampsia: Our research has provided evidence that endometrial decidualization resistance is implicated in the pathogenesis of this disease. This finding offers a new perspective based on the maternal contribution to gestation, with the aim of developing a tool to diagnose pre-eclampsia
- Maternal–embryonic communication: The maternal–embryonic communication research line focuses on understanding the intricate cellular and molecular dialogues that occur between mother and embryo during the preimplantation stage. Specifically, the team investigates how maternal factors can genetically influence the preimplantation embryo, reshaping our understanding of early human development and its long-term outcomes.

RESEARCH PROJECTS

Reference: PID2022-140744OB-I00
Title: Identificación de dianas celulares y moleculares maternas a nivel de célula única para la predicción temprana y tratamiento de preeclampsia (PREdict)
Principal Investigator: Carlos Simón Vallés, Tamara Garrido Gómez
Coordinating Entity: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Funding Entity: Agencia Estatal de la Investigación
Programme/grant: Proyectos de Generación de Conocimiento
Duration: 2023–2026

Reference: PI23/00536
Title: Heterogeneidad tumoral inferida por secuenciación de célula única: nuevas aproximaciones terapéuticas frente a tumores uterinos
Principal Investigator: Aymara Mas Perucho
Coordinating Entity: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Funding Entity: Instituto de Salud Carlos III
Programme/grant: Proyectos de I+D+I en Salud
Duration: 2024–2026

Reference: CIGE/2023/217
Title: Estudio de los mecanismos moleculares y epigenéticos que impulsan el envejecimiento ovárico
Principal Investigator: Ana Monteagudo Sánchez
Coordinating Entity: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Funding Entity: Consellería de Educación, Innovación, Universidades, Ciencia y Sociedad Digital, Empleo
Programme/grant: Subvenciones para grupos de investigación emergentes
Duration: 2024–2025

Reference: CIAICO/2022/242
Title: Identificación de células progenitoras en el tejido endometrial humano
Principal Investigator: Felip Vilella Mitjana
Coordinating Entity: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Funding Entity: Consellería de Educación, Innovación, Universidades, Ciencia y Sociedad Digital, Empleo
Programme/grant: Subvenciones para grupos de investigación consolidados
Duration: 2023–2025

Reference: PI24/01784
Title: Rejuvenecimiento ovárico mediante reprogramación celular parcial
Principal Investigator: Felip Vilella Mitjana
Coordinating Entity: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Funding Entity: Instituto de Salud Carlos III
Programme/grant: Proyectos de I+D+I en Salud
Duration: 2025–2027

Reference: PI24/00722
Title: Impacto del microbioma en la patogénesis de la endometriosis ovárica
Principal Investigator: Inmaculada Moreno Gimeno
Coordinating Entity: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Funding Entity: Instituto de Salud Carlos III
Programme/grant: Proyectos de I+D+I en Salud
Duration: 2025–2027

Reference: CNS2022-135696
Title: Identificación de células progenitoras en el endometrio humano y demostración de su capacidad regenerativa (EndoProg)
Principal Investigator: Felip Vilella Mitjana
Coordinating Entity: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Funding Entity: Agencia Estatal de la Investigación
Programme/grant: Consolidación Investigadora
Duration: 2023–2025

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
10	140.4	12.76
National collaborations	International collaborations	Corresponding author
5	5	7

- Mapping Human Uterine Disorders Through Single-Cell Transcriptomics. Boldu S, Lliberos C, Simon C, Mas A. Cells. 2025 january 21. 14 (3). DOI: 10.3390/cells14030156. PMID:39936948. IF: 6. Q2
- Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia. Muñoz I, Pérez R, Castillo N, Cordero T, Ochando A, Ortega S, Parras M et al. NATURE MEDICINE. 2025 february 01. 31 (2):502-513. DOI:10.1038/s41591-024-03407-7. PMID:39775038. IF: 52.5. Q1
- Single-cell technology: the key to an improved understanding of the human endometrium in health and disease. Gonzalez Fernandez J, Zaragozano S, Monteagudo Sánchez A, Simon C, Vilella F. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025 april 01. 232 (4):44-54. DOI: 10.1016/j.ajog.2024.08.042. PMID:40253082. IF: 7.9 Q1
- Maternal plasma cell-free RNA as a predictor of early and late-onset preeclampsia throughout pregnancy. Castillo N, Cordero T, Igual M, Muñoz I, Gómez C, Bernat N, Gaspar A et al. Nature Communications. 2025 october 20. 16 (1):9208-9208. DOI:10.1038/s41467-025-64215-2. PMID:41115885. IF: 18.1 Q1
- Fusobacterium nucleatum is not significantly present in eutopic endometrium from patients with minimal-mild and moderate-severe endometriosis. Graciano MDC, Barnhart K, Gonzalez M, Arenas M, Legro RS, Thomas TR, Rush MA et al. FERTILITY AND STERILITY. 2025 november 01. 124 (5):1071-1081. DOI: 10.1016/j.fertnstert.2025.06.035. PMID:40588151. IF: 8.1 Q1

THESIS

Thesis title: Using organoids to decipher endometrial regeneration in Asherman syndrome patients.
Type: Doctoral Tesis.
Doctoral candidate: Javier Gonzalez Fernandez.
Director(s): Felipe Vilella Mitjana, Xavier Santamaria Costa, and Carlos Antonio Simón Vallés.
University: Universitat de València (Estudi General).
Defence Date: 25/02/2025
Grade: Excellence
Quality recognition/Award: Cum Laude

Thesis title: Determinación de variantes genéticas asociadas al desplazamiento de la ventana de implantación.
Type: Doctoral Tesis.
Doctoral candidate: Jose Alberto Miravet Valenciano.
Director(s): Carlos Antonio Simón Vallés and David Blesa Jarque.
University: Universitat de València (Estudi General).
Defence Date: 06/05/2025
Grade: Excellence
Quality recognition/Award: Cum Laude

Thesis title: Cribado de enfermedades monogénicas, recesivas y ligadas a X, en población árabe.
Type: Doctoral Tesis.
Doctoral candidate: Ana Bover Catalá. **Director(s):** Carlos Antonio Simón Vallés and Ana Cristina Cervero Sanz.
University: Universitat de València (Estudi General).
Defence Date: 06/05/2025
Grade: Excellence
Quality recognition/Award: Cum Laude

Thesis title: International, randomized and controlled clinical study, to evaluate the clinical benefit of the ERA test in infertile patients undergoing assisted reproduction treatment and medical indication of PGT-A.
Type: Doctoral Tesis.
Doctoral candidate: Tamar Barbakadze.
Director(s): Carlos Antonio Simón Vallés and Xavier Santamaria Costa.
University: Universitat de València (Estudi General).
Defence Date: 13/05/2025
Grade: Excellence
Quality recognition/Award: Cum Laude

Thesis title: Estudio clínico prospectivo, aleatorizado del análisis de la receptividad endometrial (ERA) en el diagnóstico de la infertilidad para la transferencia embrionaria personalizada (pET) versus transferencia embrionaria en fresco (fET) versus transferencia embrionaria diferida (EDET).
Type: Doctoral Tesis.
Doctoral candidate: Carlos Gómez De La Cruz.
Director(s): Diana María Valbuena Perilla and Carlos Antonio Simón Vallés.
University: Universitat de València (Estudi General).
Defence Date: 13/05/2025
Grade: Excellence
Quality recognition/Award: Cum Laude

4.3.5 Associated Clinical Groups Area

Groups

- Clinical Associated Group in Care. INVESTENF-INCLIVA
- Clinical Associated Group in Urology Group in Urology
- Clinical Associated Group in Digestive Medicine Group in Digestive Medicine
- Clinical Associated Group in Traumatology and Orthopedics Group in Traumatology and Orthopedics
- Clinical Associated Group in Neurology Group in Neurology
- Clinical Associated Group in Pharmacy Group in Pharmacy
- Clinical Associated Group in Nuclear Medicine
- Clinical Associated Group in Otorhinolaryngology
- Clinical Associated Group in Insomnia and Circadian Rhythm

Number of indexed publications		IF	Average IF	
75		245.9	3.415	
National collaborations		International collaborations	Corresponding author	
42		21	35	
D1	Q1	Q2	First author	Last author
9	31	18	28	41



Key Publications

- Propensity Score Analysis of the Utility of Supervised Perioperative Abdominal Wall Exercises for the Prevention of Parastomal Hernia. López VA, Yuste A, Murad M, Navarro R, Pérez L, Martín J, Moro D et al. Nursing Reports. 2025 february 01. 15 (2). DOI: 10.3390/nursrep15020062. PMID:39997798.
- Reply to: Recompensation After TIPS for Patients With Advanced Cirrhosis: A New Way to Reverse the Outcomes?. Sánchez J, González S, Lluch P, Ballester MP. LIVER INTERNATIONAL. 2025 april 01. 45 (4). DOI: 10.1111/liv.16166. PMID:39535389.
- Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis. Martinez BI, Insa A, Ygual GC, Gascón F, Moran J, Martín P. LUNG CANCER. 2025 april 01. 202108464-108464. DOI: 10.1016/j.lungcan.2025.108464. PMID:40058137.
- Low-Density Lipoprotein Cholesterol Reduction and Therapeutic Adherence During Cardiac Rehabilitation After Myocardial Infarction. Bertolín C, Merenciano H, Marcos V, Mas MLM, Alberola J, Civera JM, Reig MV et al. Journal of Clinical Medicine. 2025 june 14. 14 (12). DOI: 10.3390/jcm14124242. PMID:40565987.
- Assessment of Muscle-Specific Strength in Oncology Patients: Anthropometry as a Reliable Alternative to DXA. Alabadi B, Amores S, Moriana M, Wu NY, García K, Pedrón JA, Monrós C et al. Life-Basel. 2025 august 15. 15 (8). DOI: 10.3390/life15081300. PMID:40868947.

Clinical Associated Group in Care. INVESTENF-INCLIVA

Clinical Associated

Principal Investigator: Cintia Borja Herrero



<https://incliva.portalinvestigacion.com/grupos/377>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Cintia Borja Herrero. Primary Care
- **Recognised Researcher:**
Laura Fernandez Puerta. Hospital
Nuria Gregori Flor. Hospital
Rut Navarro Martinez. UV
Raquel Valera Lloris. Hospital /UV
Evelin Balaguer López. Hospital /UV
Pablo García Molina. UV
Antonio Martínez Sabater. Hospital /UV
- **First Stage Researcher:**
Alexis Caballero Bonafe. Hospital
Juan Ramon De Moya Romero. Hospital /UV
Purificación Ferreros Gomez. Hospital
Jose Antonio Pedron Barbera. Hospital
Paula Segura Daroca. Hospital
- **Research Nurse Staff:**
Sandra Mora Cercos. Hospital
Ana Boyero Granades. Hospital
Raquel Castello Manzano. Hospital
María Dolores Cervera Lopez. Hospital
José Manuel Civera Gómez. Hospital
Sara Lerma Garcia. Hospital
Patricia Martínez Belenguer. Hospital
Coral Pastor Redondo. Hospital

- Andrea Peinado Vila. Hospital
Estrella Ponz Requena. Hospital
Raquel Sanchez Balanza. Hospital
Anabela Espinosa Briones. Hospital
Nuria Garrido Zafra. UV
Sonia Mora Navarro. Hospital
María Luisa Muñoz Illescas. Hospital
Mª Del Carmen Rodriguez Dolz. Hospital /UV
Laura Almudéver Campo. Hospital
Manuel Ruescas López. Hospital
- **Staff-Technician:**
David Palanca Broseta. Hospital
 - **Staff-Collaborating Researcher:**
Omar Cauli. UV
Beatriz García Carrera. Hospital
Blanca Gisela Pardo Sievers. UV



STRATEGIC AIMS

- Contribute to scientific nursing evidence to improve paediatric nursing care.
- Conduct research in paediatric nursing to disseminate new knowledge.
- Work to advance the quality and safety of paediatric nursing care.

MAIN LINES OF RESEARCH

- Care in aging, fragility and chronicity.
- Child and adolescent health care.
- Mental health care.
- Nursing care and quality of life in patients with hematologic cancer.
- Skin care and skin integrity.

RESEARCH PROJECTS

Title: *Prevalencia de edadismo en profesionales sanitarios en un hospital terciario. Propuesta y puesta en marcha de una intervención para disminuir los prejuicios, actitudes y discriminación hacia las personas mayores.*

Principal Investigator: Laura Fernandez Puerta.

Funding body: *Fundació Victor Grifols I Lucas.*

Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2024-2026

Total budget: €6,000

Title: *Prevalencia de edadismo en profesionales sanitarios en un hospitalterciario. Propuesta y puesta en marcha de una intervención para disminuir los prejuicios, actitudes y discriminación hacia las personas mayores.*

Principal Investigator: Raquel Valera Lloris.

Funding body: *Universitat Internacional Valenciana, SL.*

Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2025-2026

Total budget: €3,000

Title: *Implementación de Inteligencia Artificial para la evaluación y planificación de cargas de trabajo de enfermería en Unidades de Hospitalización: IA4Nurse.*

Principal Investigator: Raquel Valera Lloris.

Funding body: *Fundación Española de Directivos de la Salud.*

Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2025-2026

Total budget: €12,500

RESEARCH RESULTS

Invention: Dispositivo visor para detección de lesiones de la piel

Priority Number: U201831162

Status: Granted in Spain

Principal Investigator: Evelin Balaguer López

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
28	73.6	2.63
National collaborations	International collaborations	Corresponding author
16	11	13

- Propensity Score Analysis of the Utility of Supervised Perioperative Abdominal Wall Exercises for the Prevention of Parastomal Hernia. López VA, Yuste A, Murad M, Navarro R, Pérez L, Martín J, Moro D et al. Nursing Reports. 2025 february 01. 15 (2);DOI:10.3390/nursrep15020062. PMID:39997798. IF: 2. Q2.
- Relationship of sociodemographic and clinical characteristics to mechanical restraint used in a psychiatric hospital in Spain. Ros MC, Fernández IA, Madrigal MM, Delegido AB, Ibañez CL, Haro G. JOURNAL OF ADVANCED NURSING. 2025 march 01. 81 (3):1300-1311. DOI:10.1111/jan.16305. PMID:39046147. IF: 3,40. Q1.
- Low-Density Lipoprotein Cholesterol Reduction and Therapeutic Adherence During Cardiac Rehabilitation After Myocardial Infarction. Bertolín C, Merenciano H, Marcos V, Mas MLM, Alberola J, Civera JM, Reig MV et al. Journal of Clinical Medicine. 2025 june 14. 14 (12);DOI:10.3390/jcm14124242. PMID:40565987. IF: 2,90. Q1.
- Assessment of Muscle-Specific Strength in Oncology Patients: Anthropometry as a Reliable Alternative to DXA. Alabadi B, Amores S, Moriana M, Wu NY, García K, Pedrón JA, Monrós C et al. Life-Basel. 2025 august 15. 15 (8);DOI:10.3390/life15081300. PMID:40868947. IF: 3,40. Q1.
- Prevalence and risk factors of dependence-related skin lesions in neonatal units: A multicentre study across Spanish hospitals. Balaguer E, Mora IM, Buck Sainz P, Rodríguez MC, Plá L, Garcia P. Journal of Tissue Viability. 2025 november 01. 34 (4):100945-100945. DOI:10.1016/j.jtv.2025.100945. PMID:40848669. IF: 2,80. Q1

THESIS

Thesis title: Implementación de un programa de indicadores de calidad en los cuidados de enfermería en los accesos vasculares.

Type: Doctoral Thesis

Doctoral candidate: Sonia Casanova Vives.

Director(s): Pablo Garcia Molina and Maria Luisa Ballestar.

University: Universitat de València (Estudi General).

Defence Date: 30/04/2025

Grade: Excellent

Quality recognition/Award: Cum Laude

Clinical Associated Group in Urology


Clinical Associated
Principal Investigator: Jose María Martinez Jabaloyas

<https://incliva.portalinvestigacion.com/grupos/383>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Jose María Martinez Jabaloyas. Hospital /UV
- **Recognised Researcher:**
Jorge Panach Navarrete. Hospital /UV
- **Staff-Technician:**
José Pascual Gimeno Ferrer. INCLIVA
Ana Castello Porcar. Hospital
Marcos Antonio Lloret Durá. Hospital



STRATEGIC AIMS

Study the use of metabolic analysis in urine and tissue in patients with prostate cancer.
Study the use of performing liquid biopsy in bladder cancer using digital PCR.

MAIN LINES OF RESEARCH

- Liquid biopsy in bladder cancer
- Utility of metabolomic analysis in the diagnosis and prognosis of prostate cancer

RESEARCH RESULTS

Invention: Dispositivo de lubricación intrauretral pediátrico
Priority Number: U202230442
Status: Granted in Spain
Principal Investigator: Jorge Panach Navarrete

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
10	10.5	1.17
National collaborations	International collaborations	Corresponding author
5	0	10

- Direct and Indirect Radionuclide Cystography: Can They Predict the Absence of Infectious Complications in Vesicoureteral Reflux?. Panach J, Esteve P, Valls L, Rodríguez H, Ferrando S, Marín J, Gil R et al. ARCHIVOS ESPANOLES DE UROLOGIA. 2025 april 01. 78 (3):272-279. DOI:10.56434/j.arch.esp.urol.20257803.37. PMID:40340991. IF: 0,90. Q4
- Wet colostomy - A surgical technique for combined urinary and faecal diversion-A video vignette. Puente Monserrat J, Castelló Porcar A, Pérez Santiago L, Moro Valdezate D, Pla Martí V, García Botello SA. Colorectal Disease. 2025 june 01. 27 (6):DOI:10.1111/codi.70143. PMID:40537923. IF: 2,70. Q1

- A comparative study between two ultrasound classifications for postnatal urinary tract dilatation. Panach J, Hernández P, Valls L, Gil R, Ferrando S, Marín J, Rodríguez H et al. RADIOLOGIA. 2025 september 01. 67 (5):DOI:10.1016/j.rx.2024.02.009. IF: 1,10. Q4
- Use of the Allium stent for management of ureteral pathology: A real-world clinical practice study. Panach J, Valls L, Lloret MA, Diéguez L, Martínez JM. Urologia Journal. 2025 november 01. 92 (4):650-656. DOI:10.1177/03915603251341399. PMID:40413607. IF: 0,70. Q4
- Urine metabolic analysis as a non-invasive method to predict biochemical recurrence in prostate cancer. Panach J, González V, Morales JM, García F, Sales MÁ, Monleón D, Martínez JM. Translational Andrology and Urology. 2025 november 30. 14 (11):3708-3717. DOI:10.21037/tau-2025-592. PMID:41368247. IF: 1,70. Q3

Clinical Associated Group in Digestive Medicine



Clinical Associated
Principal Investigator: Isabel Pascual Moreno

https://incliva.portalinvestigacion.com/grupos/384

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Isabel Pascual Moreno. Hospital /UV
- Established Researcher:**
Marta Maia Bosca Watts. Hospital
Paloma Lluch Garcia. Hospital /UV
Andrés Peña Aldea. Hospital
Vicente Sanchiz Soler. Hospital
Joan Tosca Cuquerella. Hospital /UV
- Recognised Researcher:**
Pilar Mas Mercader. Hospital
Marta Ponce Romero. Hospital
Ana Sanahuja Martinez. Hospital
- First Stage Researcher:**
Eva Romero Gonzalez. Hospital
Carles Suria Bolufer. Hospital
- Research Nurse Staff:**
Amparo Ruiz Alvarez. Hospital
Nuria Casasús Moya. Hospital
- Staff-Collaborating Researcher:**
Maria Rosario Anton Ausejo. Hospital
Consuelo Galvez Castillo. Hospital
Pablo Roberto Navarro Cortés. Hospital
Sherly Violeta Hernandez. Hospital
- Staff-Technician:**
María Lorena Boronat Cifre. INCLIVA Desamparados
Giménez Choví. INCLIVA



STRATEGIC AIMS

- Diagnosis and treatment of minimal hepatic encephalopathy, hepatocarcinoma, portal hypertension and Non-Alcoholic Steatohepatitis (NASH)
- Diagnosis and treatment of functional digestive pathology.
- Diagnosis and treatment of pancreatic pathology.
- Establish a translational research team in inflammatory bowel, pancreatic and liver diseases.

MAIN LINES OF RESEARCH

- Ano-rectal function in inflammatory bowel disease (IBD).
- Blood immune profile in liver cancer and cirrhosis.
- Caustic ingestion: risk stratification and diagnostic modalities.
- Endoscopic treatment in Zencker diverticulum and pancreatic disease.
- Evaluation of different therapies in hepatocarcinoma.
- Evaluation of new treatment strategies in acute and chronic pancreatitis.
- Evaluation of prognostic factors in acute and chronic pancreatitis.
- Inflammatory markers and immune regulation in IBD.
- Liver disease: alcohol, virus and autoimmune.
- Local biologic treatment of IBD.
- Natural history of acute and chronic pancreatitis.
- Stem cell treatment in fistulizing (IBD).

- Studies in the healthy population of the physiological motor characteristics of the upper and lower digestive tract.
- Therapeutic endoscopic ultrasound: different drainages and lumen-apposing metal stent gastrojejunostomy
- Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma. Merino V, Abril C, Segarra G, Ballester MP, Tosca J, Aguilar P, Medina P et al. HEPATOLOGY RESEARCH. 2025 diciembre 01. 55 (12):1663-1674. DOI:10.1111/hepr.70026. PMID:40848271. IF: 3,40. Q2

RESEARCH PROJECTS

Reference: 2019/194.
Title: Proyecto Piloto del Tratamiento de la Enfermedad Perianal Mediante la Inyección Local de Infliximab Guiada por Ecografía. Serie de Casos.MBW-2017-01.
Principal Investigator: Marta Maia Bosca Watts.
Funding body: Sociedad Española de Patología Digestiva; Sociedad Valenciana de Patología Digestiva.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration:
Total budget: €6,600

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
8	58.3	7.29
National collaborations	International collaborations	Corresponding author
3	4	3

- Ammonia and beyond - biomarkers of hepatic encephalopathy. Gallego JJ, Ballester MP, Fiorillo A, Casanova Ferrer F, López Gramaje A, Urios A, Arenas YM et al. METABOLIC BRAIN DISEASE. 2025 enero 15. 40 (1):100-100. DOI:10.1007/s11011-024-01512-7. PMID:39812958. IF: 3,50. Q2
- Reply to: Recompensation After TIPS for Patients With Advanced Cirrhosis: A New Way to Reverse the Outcomes?. Sánchez J, González S, Lluch P, Ballester MP. LIVER INTERNATIONAL. 2025 abril 01. 45 (4):DOI:10.1111/liv.16166. PMID:39535389. IF: 5,20. Q1
- Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography. Marti D, Carot JM, Villalba A, Siddiqi H, Vallejo RM, Lara C, Martín M et al. Clinical Gastroenterology and Hepatology. 2025 junio 01. 23 (7):DOI:10.1016/j.cgh.2024.10.014. PMID:39551253. IF: 12,20. Q1
- Development of a Clinical Prediction Model for Anastomotic Leakage in Colorectal Surgery. Ochs V, Taha S, Lavanchy JL, Steinemann D, Müller BP, Rosenberg R, Flaifel M et al. JAMA Network Open. 2025 octubre 01. 8 (10):DOI:10.1001/jama-networkopen.2025.38267. PMID:41114976. IF: 9,70. Q1

Clinical Associated Group in Traumatology and Orthopedics


Clinical Associated
Principal Investigator: Antonio Silvestre Muñoz

<https://incliva.portalinvestigacion.com/grupos/382>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Antonio Silvestre Muñoz. Hospital /UV
- Established Researcher:**
Maria Fe Minguez Rey. Hospital /UV
Pablo Renovell Ferrer. Hospital /UV
Rosa Maria Cibrian Ortiz De Anda. UV
- Recognised Researcher:**
Laura Pino Almero. Hospital
Mª Rosario Salvador Palmer. UV
- Staff-Collaborating Researcher:**
José Expósito Ollero. Hospital
José Albelda Vitoria. Hospital



STRATEGIC AIMS

Non-invasive imaging in orthopaedics
New prosthesis fixation systems applied to traumatology.
Mechanisms of inflammation and oxidative stress in bone pathologies

MAIN LINES OF RESEARCH

- Cellular mechanisms to regulate the inflammatory response in chronic inflammatory diseases.
- Cellular oxidative stress and its relationship with idiopathic femoral osteonecrosis.
- Diagnosis and monitoring of the diabetic foot using infrared thermography.
- Local mechanical stimulation of mesenchymal cells for osteogenic and chondrogenic differentiation in regenerative medicine.
- Protection strategies against osteoarticular deterioration.
- Rehabilitation to improve results after a randomized prospective study of total knee arthroplasty.
- Robotics for precision in orthopaedic reconstructive surgery.
- Sequential muscle contraction: importance in early detection of lumbopelvic, cervical and shoulder girdledysfunction.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
9	22.6	2.825
National collaborations	International collaborations	Corresponding author
3	4	1

- Profiles of muscle-specific oxygenation responses and thresholds during graded cycling incremental test. Sendra C, Encarnacion A, Salvador R, Murias JM, Priego JI. EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY. 2025 enero 01. 125 (1):237-245. DOI:10.1007/s00421-024-05593-1. PMID:39259396. IF: 2,70. Q2

- Evaluation of leg symmetry in muscle oxygen saturation during submaximal to maximal cycling exercise. Sendra C, Priego JI, Murias JM, Carpes FP, Salvador R, Encarnación A. European Journal of Sport Science. 2025 enero 01. 25 (1):DOI:10.1002/ejsc.12230. PMID:39632540. IF: 3. Q1
- Impact on Quality of Life of Full-time and Night-time Braces in Adolescent Idiopathic Scoliosis A Randomized Clinical Trial. Peiro A, Garcia RG, Martin V, Vilalta I, Gonzalez L, Martin JM, Silvestre A. SPINE. 2025 febrero 15. 50 (4):231-237. DOI:10.1097/BRS.0000000000005228. PMID:39632385. IF: 3,50. Q1
- Fractura-luxación subastragalina lateral irreductible por interposición del paquete neurovascular tibial posterior: a propósito de un caso. Guillén E, Polo I, Blasco C, Forriol F, Silvestre A. Acta ortopedica mexicana. 2025 julio 01. 39 (4):242-248. PMID:40925852.
- Muscular excitation and oxygen extraction responses in power-generating and stabilizing muscles during a graded cycling test. Sendra C, Encarnación A, Murias JM, de la Fuente C, Salvador R, Martin F, Priego JI. JOURNAL OF SPORTS SCIENCES. 2025 agosto 18. 43 (16):1675-1684. DOI:10.1080 /02640414.2025.2518015. PMID:40509629. IF: 2,50. Q2
- Between-subject factors influencing hand skin temperature response after cold stress test in a general adult population. Priego JI, Domingo M, Canada M, de Anda R, Garcia V, Bellot C. JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY. 2025 septiembre 01. 150 (17):13193-13200. DOI:10.1007/s10973-025-14577-y. IF: 3,10. Q2

Clinical Associated Group in Neurorology


Clinical Associated
Principal Investigator: Jose Miguel Santonja Llabata

https://incliva.portalinvestigacion.com/grupos/381

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:
Jose Miguel Santonja Llabata. Hospital
Jose Miguel Lainez Andrés. Hospital /UV
- Recognised Researcher:
Rosario Gil Gimeno. Hospital
Ana Piera Balbastre. Hospital
Alejandro Ponz De Tienda. Hospital /UV
- Research Nurse Staff:
Miriam Iborra Perales. INCLIVA
- Staff-Collaborating Researcher:
José Andrés Domínguez Morán. Hospital
Jésica García Ull. Hospital
Francisco Gascon Gimenez. Hospital
Begoña Lopez Pesquera. Hospital
Ana Pareja Martinez. Hospital
Jose Maria Salom Juan. Hospital



STRATEGIC AIMS

- Cognitive impairment and dementia
- Cerebrovascular diseases
- Demyelinating diseases
- Epilepsy
- Extrapyramidal pathology
- Pain/headaches

MAIN LINES OF RESEARCH

- Cognitive impairment and dementia
- Cerebrovascular diseases
- Demyelinating diseases
- Epilepsy
- Extrapyramidal pathology.
- Pain/headaches

RESEARCH PROJECTS

Reference: 101183247.
Title: JADE Joint Action addressing DEmentia and HEALTH.
JADE. JM Lainez. 2023.
Principal Investigator: Jose Miguel Lainez Andrés.
Funding body: European Commission.
Beneficiary Institution: Fundación para la Investigación del
Hospital Clínico de la Comunitat Valenciana
Duration: 2025-2027
Total budget: €139,293.83

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
4	14.6	3.65
National collaborations	International collaborations	Corresponding author
3	-	2

- Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group. García J, González N, Torres M, García D, Molina I, Beltrán I, Santos S et al. NEUROLOGIA. 2025 enero 01. 40 (1):118-137. DOI:10.1016/j.nrl.2023.06.003. PMID:38431253. IF: 3,10. Q2
- Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis. Martinez BI, Insa A, Ygual GC, Gascón F, Moran J, Martín P. LUNG CANCER. 2025 abril 01. 202108464-108464. DOI:10.1016/j.lungcan.2025.108464. PMID:40058137. IF: 4,40. Q1
- Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study. López A, Mínguez A, Nieves C, Ruibal M, Sánchez NM, Navarro MP, Alpuente A et al. HEADACHE. 2025 junio 01. 65 (6):994-1004. DOI:10.1111/head.14913. PMID:40135519. IF: 4. Q1
- Consensus document on neurosonological techniques in headaches. Vico JR, Domínguez JF, Villaverde FJJ, García NG, Fernández CGC, Sanchez AJ, Martín OA et al. NEUROLOGIA. 2025 julio 01. 40 (6):599-607. DOI:10.1016/j.nrl.2024.06.001. PMID:40550312. IF: 3,10. Q2

Clinical Associated Group in Pharmacy



Clinical Associated
Principal Investigator: Manuel G. Alós Almiñana

<https://incliva.portalinvestigacion.com/grupos/380>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Leading Researcher:**
Manuel G. Alós Almiñana. Hospital /UV
- Established Researcher:**
María Teresa Torrecilla Junyent. Hospital /UV
- Recognised Researcher:**
Carmen Carrion Carrion. Hospital /UV
Francisco Ferriols Lisart. Hospital /UV
Rafael Ferriols Lisart. Hospital /UV
- Research Nurse Staff:**
Elena Molina Quesada. INCLIVA
Adrián - Alexandru Sin Voicu. INCLIVA
Maria Jose Colubí Martínez. INCLIVA
- Staff-Technician:**
José Luís Pedrajas Vázquez. INCLIVA
María Del Mar Mallea Durbán. INCLIVA
Bárbara Michelle Muñoz Ponce. INCLIVA
Raúl Torrejón Bastante. INCLIVA
- Staff-Collaborating Researcher:**
Verónica Guillot Yacyszyn. INCLIVA
José Enrique Muñoz Cebriá. INCLIVA
Diego Vicente Cano Blanquer. Hospital
Carlos Ezquer Garín. INCLIVA
Mercedes Jimenez Heredia. Hospital
Raquel Pardillo Armuña. INCLIVA



STRATEGIC AIMS

Pharmacokinetics and biopharmaceutics.
Economic evaluation of medicines and health technologies.
Antimicrobial stewardship program.

MAIN LINES OF RESEARCH

- Implementation of a new therapeutical drug monitoring system in a clinical analytical laboratory. for pharmacokinetic control of antibiotic, antifungal and antineoplastic agents in the hospitalized patient, with the aim of optimal and rational use of pharmacological treatment.
- Observational Study of population pharmacokinetic model of voriconazole in allogeneic stem cell transplantation. Study approved by the Agencia Española del medicamento y Productos Sanitarios with code CSV-VOR-2014-01.
- Study of pharmacokinetics of caspofungin in patients under hemodiafiltration. Study approved by the Agencia Española del Medicamento y Productos Sanitarios with code MERCAS-2013-01.
- Study of pharmacokinetics of Ceftolozane in critical patients. Study pending of approval by the Agencia Española del Medicamento y Productos Sanitarios with code CEFT-TCRR-2017.
- Study of Physico-chemical stability of a new mycophenolate mofetil intravenous solution in polypropilene infusion bag at different storage conditions.
- Study of Physico-chemical stability of a new ophthalmic eye-drop formulation at different storage conditions

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
4	10.9	3.63
National collaborations	International collaborations	Corresponding author
3	1	2

- Allergic contact dermatitis triggered by castor oil-containing dressings. Delgado A, Valls M, Ferriols F, Sastre A, Tarrasó B, Morales A, Morales C. CONTACT DERMATITIS. 2025 enero 01. 92 (1):84-85. DOI:10.1111/cod.14705. PMID:39375443. IF: 4,60. Q1
- Antimicrobial Dosing During Continuous Venovenous Hemodiafiltration in Septic Shock Patients: A Prospective, Multi-center Study Protocol. Harwood A, Fernández MM, Garin CE, Alvarez FJ, Herrero RL, Tamayo E, Aguilar G. Antibiotics-Basel. 2025 abril 21. 14 (4):DOI:10.3390/antibiotics14040420. PMID:40298573. IF: 4,60. Q1
- Validated HPLC-UV Detection Method for Cefiderocol Quantification in a Critical Patient Receiving Fetcroja and Treated With Extracorporeal Replacement Therapies. Ezquer C, Ferriols R, Alós M, Carbonell JA, Hurtado L, García L, Aguilar G. BIOMEDICAL CHROMATOGRAPHY. 2025 junio 01. 39 (6):DOI:10.1002/bmc.70104. PMID:40320257. IF: 1,70. Q3
- Uso de la impresión 3 D para la fabricación de cárriers con antibiótico en el tratamiento de las infecciones osteoarticulares. Yago AO, Gar ´in CE, Bessó PM, García FB, Tarragó JF. Revista Espanola de Cirugia Ortopedica y Traumatologia. 2025 julio 01. DOI:10.1016/j.recot.2025.06.017.

Clinical Associated Group in Nuclear Medicine



Clinical Associated
Principal Investigator: Mª Del Puig Cozar Santiago

<https://incliva.portalinvestigacion.com/grupos/392>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Rafael Diaz Exposito. Hospital /UV
- **Established Researcher:**
Mª Del Puig Cozar Santiago. Hospital /UV
- **Recognised Researcher:**
Hector Rodriguez Parra. Hospital
Monica Romero Otero. Hospital
- **First Stage Researcher:**
Alba Cruz Saez. Hospital
Antonio Stacey Solis. Hospital
Pablo Antonio Soto Muñoz. Hospital
Laura Blanco Verdejo. Hospital
Nicolas Alberto Colombo Vina. Hospital
Carolina Castillo Arias. Hospital
- **Staff-Collaborating Researcher:**
Celia Rillo Mena. Hospital
Aurora Ángela Crespo De La Jara,
Tomás Mut Dolera. Hospital
Laura Casas Fernandez. Hospital
Andrea Palazon Palazon. Hospital
Patricia Olivan Sasot. Hospital
Carmen Redal Peña. Hospital
Maria Toscano Sanchez. Hospital



STRATEGIC AIMS

Develop and implement PET-CT in various tumour conditions, particularly in combination with intravenous contrast agents, and its application in radiotherapy planning for various tumour conditions.
Develop radio-guided surgery for various conditions.
Advance the treatment of liver tumours and metastases using radioembolization.

MAIN LINES OF RESEARCH

- Radioembolization of hepatocarcinoma using Ytrium-90 and Holmium-166-labelled resin microspheres.
- Selective detection of sentinel node in patients with gynaecological tumours using hybrid tracer (indocyanine green radiopharmaceutical).
- Utility of PET-MRI in patients with multiple sclerosis.
- Development of CXCR4-specific PET imaging agents in neuroendocrine tumours by using a multidisciplinary approach (Smart_PET_tracers).
- Digital management of variables, automated creation of structured reports and exploitation of nuclear medicine data.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
3	4.8	1.6
National collaborations	International collaborations	Corresponding author
2	1	2

- PET-TC [18F]F-Choline and intraoperative PTH in the surgical treatment of the primary hyperparathyroidism without preoperative location. García F, Cassinello N, Rodríguez J, Martí R, Lapeña M, Alfonso R, Díaz R et al. Revista Espanola de Medicina Nuclear e Imagen Molecular. 2025 january 01. 44 (1):500066-500066. DOI: 10.1016/j.remnm.2024.500066. PMID:39349175.
- Evaluation of [18F]FDG distribution and uptake via micro PET/CT in a murine model of myocardial infarction. Ayoub ME, Rios C, Sanjuan MM, Díaz A, Bodi V, Giménez FP, Otero MR. Ars Pharmaceutica. 2025 july 01. 66 (3):335-348. DOI: 10.30827/ars.v66i3.32674.
- Combining QSAR and Molecular Docking for the Methodological Design of Novel Radiotracers Targeting Parkinson's Disease. Castillo JA, Soria M, Mena K, Romero M, Pérez V, Torrens F, Pérez F. Applied Sciences-Basel. 2025 july 22. 15 (15). DOI: 10.3390/app15158134.

Clinical Associated Group in Otorhinolaryngology


Clinical Associated
Principal Investigator: Jaime Marco Algarra

<https://incliva.portalinvestigacion.com/grupos/388>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- **Leading Researcher:**
Jaime Marco Algarra. Hospital
- **Staff-Collaborating Researcher:**
Mª de la Paz Martínez Beneyto. Hospital
Antonio Morant Ventura. Hospital
Miguel Orts Alborch. Hospital
Tomas Perez Carbonell. Hospital
Ignacio Pla Gil. Hospital
- **Staff-Technician:**
Ester Calabuig Rodríguez. INCLIVA



STRATEGIC AIMS

The group's research objectives are to study the auditory performance of cochlear and bone conduction implantable hearing devices. Research currently focuses primarily on new indications for these devices, such as unilateral or bilateral hearing loss, and the connection between devices from different families, such as cochlear implants and hearing aids. Another research interest of this group is radiological images of cochlear implants to determine their exact position within the cochlea and the relationship with neural response and auditory performance.

MAIN LINES OF RESEARCH

- Neurophysiological function of stimulation with cochlear implants depending on the position of The electrode guide.
- Study of binaural hearing acquired through implantable devices.
- Study of hearing performance by connecting devices between both ears with bimodal stimulation (cochlear implant and hearing aid).
- Study of the evolution of the Oticon Medical osseointegrated implant

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
7	11.4	1.628
National collaborations	International collaborations	Corresponding author
6	1	2

- Prospective study of sound localization in patients with single sided deafness and asymmetric hearing loss treated with cochlear implant. Redó MA, Gil IP, Pérez T, González CE, Ventura AM, Algarra JM. Acta Otorrinolaringologica Espanola. 2025 january 01. 76 (1):1-10. DOI:10.1016/j.otorri.2024.05.002. IF: 1.1 Q3

- Normal hearing and verbal discrimination in real sounds environments. Colatosti AL, Gil IP, Ventura AM, Monteagudo EL, Aranda LC, Algarra JM. Acta Otorrinolaringologica Espanola. 2025 january 01. 76 (1):11-19. DOI:10.1016/j.otorri.2024.05.005. PMID:38908790. IF: 1.1 Q3
- Beyond frequency: duration, intensity, and quality of life in Ménière's disease. Pérez T, Orts M, Pérez V, Pla I, Espina C, Aragonés M, Marco J. JOURNAL OF LARYNGOLOGY AND OTOTOLOGY. 2025 august 01. 139 (8):723-729. DOI:10.1017/S0022215125102624. PMID:40552577. IF: 0.8 Q3
- Factors Associated with Elective and Emergency Tracheostomy in an Otorhinolaryngology Department: A Retrospective Study. Jimenez A, Perez T, Escorihuela V, Marco J. Indian Journal of Otolaryngology and Head & Neck Surgery. 2025 september 26. 77 (12):5654-5659. DOI:10.1007/s12070-025-06037-8. IF: 0.4 Q4
- Unilateral Versus Bilateral Spreader Grafts to Correct Cartilaginous Deviations in Structural Rhinoplasty: A Comparative Study on the Aesthetic and Functional Outcomes. Gimeno L, Calvo J, Pérez T, Rosello MV, Vallejo A, Marrero JC, Marco J. FACIAL PLASTIC SURGERY. 2025 november 27. DOI:10.1055/a-2750-9411. PMID:41265885. IF: 1.4 Q3

Clinical Associated Group in Insomnia and Circadian Rhythms


Clinical Associated
Principal Investigator: Manuel de Entrambasaguas Barretto

<https://incliva.portalinvestigacion.com/grupos/405>

GROUP MEMBERS

Staff during the period 01/01/2025 – 31/12/2025

- Established Researcher:**
Manuel De Entrambasaguas Barretto. Hospital
- First Stage Researcher:**
Javier Francisco Salas Jordan. Hospital
Yamaris Vera Castillo. Hospital
- Staff-Collaborating Researcher:**
Pedro Pablo Tenllado Matoses. Hospital
Ana Isabel Arizón Benito. Hospital
Marta Moya Ayza. Hospital



STRATEGIC AIMS

To present research at a national scientific meeting on the relationship between the chronotype as measured by the MCTQ (Munich Chronotype Questionnaire), the severity of insomnia as measured by the ISI (Insomnia Severity Index), and the ITQ (Insomnia Type Questionnaire) subtypes of chronic insomnia disorder.

To initiate doctoral dissertation research on the relationship between chronotype and ITQ insomnia disorder subtypes, and their response to cognitive-behavioural therapy for insomnia in a clinical population.

The aim of this thesis has been revised and modified, with the final research project to be presented in 2026.

To publish a research paper in an international journal on insomnia severity and hyperarousal after cognitive-behavioural therapy for insomnia and the case of non-responders in a clinical population.

MAIN LINES OF RESEARCH

- The relationship between chronotype and ITQ subtypes of insomnia disorder and their response to cognitive-behavioural therapy for insomnia (CBT-I). The aim is to study the severity of insomnia syndrome, chronotype and ITQ subtyping in a clinical population of patients with chronic insomnia, determining whether there are differences in response to CBT-I according to chronotype and ITQ subtype, and to compare subjective (questionnaires) and objective (dim-light melatonin onset) measures for determining chronotype in a clinical population with insomnia.
- To investigate the clinical differences between responders and non-responders to CBT-I in a clinical population with chronic insomnia, including comorbidities, as well as the circumstances surrounding non-attendance.

JOURNAL PUBLICATIONS

Number of Publications	IF	Average FI
2	8	4
National collaborations	International collaborations	Corresponding author
2	0	0

- Insomnia Subtypes in Clinical Population According to the Insomnia Type Questionnaire (ITQ): A Multi-Centre Study in Spanish Sleep Clinics. Canellas F, de Entrambasaguas M, Romero O, Alvarez A, Wix R, Puertas FJ, Pujol J et al. JOURNAL OF SLEEP RESEARCH. 2025 June 25. 35 (1). DOI: 10.1111/jsr.70116. PMID:40562392.
- Primary Care Records and Population Prevalence of Chronic Insomnia: Do They Match? Pujol J, García C, de Entrambasaguas M, Malla M, Martínez J. Healthcare. 2025 december 03. 13 (23). DOI: 10.3390/healthcare13233152. PMID:41373368.

4.4 Other scientific contributions from scientific platforms

4.4.1. Spanish Clinical Research Network (SCReN), Clinical Research and Clinical Trials of the Clinical Trials Platform (UICEC INCLIVA)

TEAM	Sara Jordá Climent. INCLIVA
Principal Investigator:	Miriam Stumpf. INCLIVA
Andrés Cervantes Ruipérez. Hospital. University	Jacobo Bolinches Ferrandis. INCLIVA
Associated Members:	Hired Members:
Esteban Jesús Morcillo Sánchez. Hospital. INCLIVA	Ana Portolés Monzón. INCLIVA
José Enrique Muñoz Cebriá. INCLIVA	Mercedes Peris Costa. INCLIVA
Julio Núñez Villota. Hospital. INCLIVA	Marta Martínez Muniesa. INCLIVA
Luis Sabater Ortí. Hospital. INCLIVA	UICEC helps ensure that observational studies and clinical trials
Verónica Guillot Yacyszyn. INCLIVA	are developed correctly, in accordance with applicable legal reg-
Sofía Galant Parrado. INCLIVA	ulations and standards of good clinical practice.

Their current portfolio of services includes the following activities:

1.

Methodological and regulatory support: Study design; drafting and review of all documentation (protocol, Patient Information Sheet – Informed Consent, etc.); economic feasibility assessment and funding search; Case Report Form (CRF) design, and identifying and selecting participating sites.
2.

Start-up: Managing approvals from competent authorities (AEMPS and Ethics Committee), contract management with participating sites, processing civil liability insurance, and registration and maintenance of the study on clinicaltrials.gov and REEC.
3.

Monitoring: Developing a monitoring plan; conducting initiation, monitoring, and close-out visits; and preparing the corresponding reports.
4.

Study conduct: Overall study management (medication management, biological sample management, report review, adverse event reporting, etc.); preparing and maintaining the Trial Master File, Investigator File, and Pharmacy File; notifications to regulatory agencies; submitting amendments to regulatory authorities, and preparing annual and final reports.

ACTIVITIES DEVELOPED

During 2025, UICEC has collaborated in the development of the following clinical trials, interventional and observational studies:

CLINICAL TRIALS /INTERVENTIONAL STUDIES

Study:	KEEP-ON
Title:	Ensayo clínico fase III, multicéntrico, abierto y aleatorizado para evaluar la eficacia del Ciclosilicato de Sodio y Zirconio (Lokelma) en comparación con el tratamiento estándar para controlar la hiperpotasemia en pacientes con enfermedad renal crónica (ERC) y antecedentes de insuficiencia cardíaca.
EUDRACT:	2020-003229-47
Sponsor:	Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase:	III
Study:	SHOP-HF
Title:	Pacemaker implantation in patients with heart failure with preserved ejection fraction, chronotropic incompetence and small ventricular volume.
EU CT:	Not applicable. Clinical research with medical devices
Sponsor:	Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase:	Not applicable. Clinical research with medical devices

Study:	HI-COR-65
Title:	Ensayo clínico aleatorizado, multicéntrico, abierto, de grupos paralelos, para definir la mejor estrategia para el manejo de la insuficiencia cardíaca y la enfermedad renal crónica en pacientes ancianos con o con alto riesgo de hiperpotasemia en España mediante la optimización del uso de iSRAA con CSZ: Estudio SENEKA
EU CT:	2025-522421-36-00
Sponsor:	Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase:	III

Study:	CoLeBu2017
Title:	Seguridad hemodinamica de la levobupivacaina isobarica frente a la bupivacaina isobarica para anestesia subaracnoida en pacientes de mas de 65 años, intervenidos de fractura de cadera.
EU CT:	2025-520970-21-00
Sponsor:	Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase:	IV

Study:	PULMESCELL-2
Title:	Ensayo clínico fase II para establecer la seguridad del uso de células mesenquimales troncales fetales alogénicas de cordón umbilical expandidas en pacientes prematuros con displasia broncopulmonar. Pulmescell-2
EUDRACT:	2022-002653-26
Sponsor:	Fundación para la Investigación Biomédica Hospital Ramón y Cajal (FIBIO)
Phase:	II

Study:	RML-TB
Title:	Multicentre Controlled Open Randomized Clinical Trial to evaluate the efficacy and safety profile of an anti-TB drug combination based on High Dose Rifampicin, High Dose Moxifloxacin and Linezolid daily for DS AFB smear positive pulmonary TB patients during the initial 8 weeks of treatment.
EUDRACT:	2021-001626-22
Sponsor:	Vall d’Hebron Institut de Recerca (VHIR)
Phase:	II

Study:	RAPIDO
Title:	Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemoradiotherapy and surgery and optional adjuvant chemotherapy.
EU CT:	2010-023957-12
Sponsor:	UMCG, Groningen, The Netherlands
Phase:	III

Study:	HaploMUDStudy
Title:	Matched unrelated vs. haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GVHD prophylaxis – a randomized prospective European trial
Sponsor:	University Medical Center Hamburg-Eppendorf Investigator Initiated Trial (IIT) (financial support by DKMS)
Phase:	Non-pharmacological, interventional study

Study: PANGASBLUM
Title: *Pancreatic anastomosis following pancreatoduodenectomy: pancreatogastrostomy versus bLumgart ´s anastomosis. A randomized, prospective, multicenter study*
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: Non-pharmacological, interventional study

Study: CIRCULATE-SPAIN-01
Title: *Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA*
EUDRACT: 2021-000507-20
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: II

Study: FOVOCIP
Title: Un ensayo aleatorizado multicéntrico de fosfomicina frente a ciprofloxacino para la neutropenia febril en pacientes hematológicos: eficacia y seguridad microbiológica
EU CT: 2021-000354-25
Sponsor: Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturias (FINBA)
Phase: III

Study: SHORTEN
Title: Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por *Pseudomonas aeruginosa*: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR
EU CT: 2021-003847-10
Sponsor: FISEVI
Phase: IV

Study: EARLY-GENE
Title: EARLY treatment with Candesartan vs Placebo in asymptomatic GENETic carriers of Dilated Cardiomyopathy (EARLY-GENE trial)
EU CT: 2021-004577-30
Sponsor: Fundacion Investigacion biomédica hospital Puerta de hierro Majadahonda
Phase: III

Study: DAPA-DP
Title: Un estudio aleatorizado, abierto, cruzado, paralelo, de 2 secuencias, 2 períodos, 2 tratamientos. Se propone un estudio cruzado para que cada paciente pueda controlarse, debido a la alta variabilidad de la membrana peritoneal de cada individuo, que afecta el transporte peritoneal de sodio y agua.
EU CT: 2023-505571-78-00
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: IV

Study: EPCS-01-22
Title: Resultados de las anastomosis colorrectales con la nueva grapadora circular motorizada en comparación con las grapadoras circulares manuales. Un ensayo controlado multicéntrico aleatorizado
EU CT: Not applicable. Clinical research with medical devices
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: Not applicable. Clinical research with medical devices

Study: SENEKA
Title: Ensayo clínico aleatorizado, multicéntrico, abierto, de grupos paralelos, para definir la mejor estrategia para el manejo de la insuficiencia cardíaca y la enfermedad renal crónica en pacientes ancianos con o con alto riesgo de hiperpotasemia en España mediante la optimización del uso de iSRAA con CSZ: Estudio SENEKA
EU CT: 2024-513971-42-00
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: III

Study: EPHIC-DIA2
Title: *Single-blinded, double-arm, controlled, randomized, multicentre clinical trial to evaluate the impact of pharmacogenetic-guided treatment in patients with insufficiently controlled type 2 diabetes*
EU CT: 2025-520686-46-00
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: IV

Study: FINE-START
Title: *A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in participants with chronic kidney disease not using renin-angiotensin-system inhibitors*
EU CT: 2022-503024-27-00
Sponsor: University Medical Center Groningen
Phase: III

Study: COMPRESSION-HF
Title: Terapia compresiva de miembros inferiores en pacientes con insuficiencia cardíaca descompensada y predominio de congestión sistémica tisular
EU CT: Not applicable. Clinical research with medical devices
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: Not applicable. Clinical research with medical devices

Study: FLUDEX
Title: *Phase III randomized, double-blind, multicenter clinical trial evaluating the efficacy and safety of dexamethasone compared to placebo in patients with severe influenza infection. (FLUDEX assay)*
EU CT: 2023-506391-27-00
Sponsor: ISABIAL
Phase: III

Study: TAILOR/3
Title: *Evaluation of a dual-hormone artificial pancreas with closed-loop glucose control versus singlehormone with carbohydrate recommendations under unannounced exercise and meal challenge inadults with type 1 diabetes.*
EU CT: Not applicable. Clinical research with medical devices
Sponsor: UPV
Phase: Not applicable. Clinical research with medical devices

Study: IBV-SO IBV-TA
Title: Protocolo de medida para la recogida de datos para la mejora del modelo de estimación de la saturación de oxígeno en sangre y presión arterial.
EU CT: Not applicable. Clinical research with medical devices

Sponsor: Instituto de biomecánica de Valencia – IBV
Phase: Not applicable. Clinical research with medical devices
Study: HOPE
Title: Ensayo aleatorizado de optimización hemodinámica de la perfusión cerebral tras tratamiento endovascular en pacientes con ictus isquémico agudo.
EU CT: 2021-000022-10
Sponsor: Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau – IIB Sant Pau
Phase: IV
Study: CARTemis_1
Title: Terapia con linfocitos T con receptor de antígeno quimérico Anti-BCMA (CARTemis-1) en el tratamiento de pacientes con mieloma múltiple en recaída tras trasplante alogénico: expresión de EGFR como mecanismo de control de las complicaciones derivadas del tratamiento.
EU CT: 2022-503063-15-00
Sponsor: Fundación Pública para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
Phase: III
Study: COLCHIREN
Title: Eficacia de la colchicina en prevención secundaria de eventos vasculares y progresión renal en pacientes con enfermedad renal crónica
EU CT: 2023-505868-11-00
Sponsor: Fundación para la Investigación Biomédica del Hospital Gregorio Marañón (FIBHGM)
Phase: III
Study: RELEASE
Title: <i>A multicenter, open, prospective, randomized, parallelgroup, 12-month trial of REDuced immunosuppression for oLdEr Adult kidney tranSplant rEcipients: the RELEASE study.</i>
EU CT: 2025-520535-16-00
Sponsor: Fundacion Instituto Hospital del Mar de Investigaciones Médicas (fimim)
Phase: IV
Study: REVIDAH
Title: <i>REstoration with calcifediol of VItamin D deficiency in pulmonary Arterial Hypertension patients.</i>
EU CT: 2025-521694-14-00
Sponsor: Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
Phase: IV
Study: FOXHIPECT4
Title: <i>Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer: A phase III multi-arm, randomized and controlled clinical trial</i>
EU CT: 2025-520471-29-00
Sponsor: Fundación para la Investigación Biomédica de Córdoba (FIBICO)
Phase: III

Study: AMICO
Title: Explorando los efectos anti envejecimiento de la Metformina en la EPOC
EU CT: 2025-520972-24
Sponsor: Instituto de Investigación Sanitaria de Navarra (IdiSNA)
Phase: III

OBSERVATIONAL STUDIES

Study: GOLD 0 -DLCO 1
Title: <i>GOLD 0 - DLCO 1: A look beyond obstruction. Is spirometry sufficient in COPD screening?</i>
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Phase: NI-PASS

Study: TRAINNING
Title: Efectos de un programa de entrenamiento físico supervisado en pacientes con insuficiencia cardiaca y función sistólica preservada e incompetencia cronotrópica sobre capacidad funcional.
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: NI-PASS

Study: BRI
Title: Efectos del bloqueo de rama izquierda sobre capacidad funcional, disincronía electromecánica y función cardiaca en población general sin patología cardiovascular.
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: NI-PASS


Study: 3D-PANC
Title: ¿Es la tecnología de imagen en tres dimensiones superior a la tomografía computerizada para evaluar la respuesta al tratamiento neoadyuvante en los pacientes con adenocarcinoma de páncreas borderline o localmente avanzado?
Sponsor: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana (INCLIVA)
Phase: Proyecto de Investigación

Study: EBMT
Title: EBMT CAR-T data collection initiative at Spanish CAR-T sites
Sponsor: EBMT
Phase: Not applicable

UNIT ACTIVITY DURING LAST 5 YEARS


During the last five years, the unit has initiated 35 studies (26 clinical trials and 9 observational studies), distributed by year in the table below.

Year	Clinical trials	Observational Studies	Total
2021	4	2	6
2022	3	2	5
2023	3	2	5
2024	9	1	10
2025	7	2	9



Including new and ongoing studies, the Unit has an average of 26 active studies per year, shown stratified by type of study and year in the following table:

	2021	2022	2023	2024	2025
Phase I	1	0	0	0	0
Phase II	0	1	4	4	3
Phase III	6	6	6	7	13
Phase IV	10	6	2	2	7
Medical Devices	0	1	1	4	5
Other Designs	6	4	4	6	3
Observational	9	8	5	2	3
Total	32	26	22	25	34



RESEARCH PROJECTS

Reference: PT23/00103
Title: Spanish Clinical Research Network (SCReN)
Principal Investigator: Andrés Cervantes Ruipérez
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025

4.4.2 Biobank

biobanco@incliva.es

TEAM

Scientific Director:

Clara Alfaro Cervelló. Hospital. University.

Coordinator/Manager:

Lorena Peiró Chova. INCLIVA

Biobank Laboratory Manager:

Olga Bahamonde Ponce. INCLIVA

Technicians

Marta Belda Moscardó. INCLIVA

Àngela Bañuls Alemany. INCLIVA

Laura Blasco Maza. INCLIVA

ACTIVITIES DEVELOPED

Incorporation of samples in pre-existing collections within the biobank regime in 2025:

Oncological Node:

- Collection of solid tumours: 16 new sample donations
- Collection of peripheral blood and derivative products in breast cancer patients (including Aurk-Seom project cases): 324 new sample donations
- Collection of peripheral blood and derivative products in lung cancer patients: 677 new sample donations
- Collection of peripheral blood and derivative products in melanoma patients: 33 new sample donations
- Collection of peripheral blood and derivative products in gastrointestinal cancer patients (including colorectal, pancreatic, cholangiocarcinoma and gastric cancer, and TFK project cases): 1151 new sample donations
- Collection of peripheral blood and derivative products in head and neck tumour patients: 224 new sample donations
- Collection of peripheral blood and derivative products in brain tumour patients: no new sample donations
- Collection of peripheral blood and derivative products in gynaecological tumour patients (including Aurk-Seom project cases): 2 new sample donations
- Collection of peripheral blood and derivative products in sarcoma patients: no new sample donations
- Collection of peripheral blood, derivative products and urine in bladder cancer patients: no new sample donations
- Hereditary cancer collection: peripheral blood and derivative products in patients with this pathology: no new sample donations
- Collection of peripheral blood and derivative products in patients with other cancer types (phase I): 29 new sample donations

Immunological Diseases Node:

- Collection of peripheral blood and derivative products in patients with systemic lupus erythematosus or other autoimmune diseases: 13 new sample donations

Cardiovascular Node:

- Collection of peripheral blood and derivative products and urine in patients with hyperaldosteronism: no new sample donations
- Collection of peripheral blood and derivative products in patients with hypertension: no new sample donations
- Collection of peripheral blood and derivative products and urine in patients with acute heart failure: no new sample donations
- Collection of peripheral blood and derivative products in patients with ST-segment elevation myocardial infarction: 103 new sample donations
- Collection of peripheral blood and derivative products in patients with acute coronary syndrome: 55 new sample donations
- Collection of peripheral blood and derivative products in patients with atrial fibrillation: no new sample donations

Endocrinology Node:

- Collection of peripheral blood and derivative products and urine in patients with endocrine diseases (DM1, DM2 and controls): no new sample donations

Reproductive Medicine Node:

- Single cell cryopreserved human endometrial sample collection; viable cells from endometrial biopsy or from endometrial fluid taken from women at different phases of their menstrual cycle: no new sample donations

Other collections:

- Collection of peripheral blood and derivative products in patients with sepsis gravis, septic shock and non-septic patients from ICU: 44 new sample donations
- Collection of peripheral blood and derivative products in patients with multiple sclerosis: no new sample donations
- Collection of peripheral blood and derivative products and urine in standard population (including OBENOUTEC subcollection cases): 8 new sample donations
- Collection of peripheral blood and derivative products in patients with COVID-19 disease and follow-up: 57 new sample donations
- Collection of peripheral blood and derivative products in patients with pulmonary emphysema disease: 13 new sample donations
- COVID-19-vaccinated collection; peripheral blood mononuclear cells from standard population vaccinated against COVID-19 disease: no new sample donations

Incorporation of new collections within the biobank regime in 2025:

No new sample collections have been incorporated in 2025.

In total, 2749 new sample donations have been received, 15089 samples have been processed, and 43409 aliquots have been stored in 2025 at INCLIVA Biobank facilities from collections within the biobank regime.

In addition, Biobank has surplus diagnostic samples from the HCUV Pathology and Haematology services that may be used in research provided they have the corresponding Biobank Informed Consent.

Incorporation of samples in pre-existing collections outside the biobank regime in 2025.

The collections are outside the organizational structure of the biobank, and they are generated in the scope of projects and/or private clinical trials. The biobank manages the storage and custody and traceability of the samples, as well as the processing and shipment of the same in almost all cases.

- PancreaDix study: processing, conservation and shipment of processed samples for the *Study for the development and validation of a genetic fingerprint for the diagnosis of pancreatic cancer and precursor lesions*. Multicentre study, AMD-CPA-2016-01, Amadix: custody of 6 cryoboxes.
- Renas study: custody of samples for the clinical trial *Effect of CPAP in the Worsening of Renal Function in Early Stages of Chronic Kidney Disease (CKD) (Renas)*. 195/2015, NCT03319888, PI15/00137 (ISCIII), sponsor Spanish Society of Pneumology and Thoracic Surgery: custody of 2 cryoboxes.
- Rolando study: custody of samples for translational study within the framework of the ROLANDO trial: *Multicenter and uncontrolled phase II clinical trial to evaluate the safety and efficacy of the combination of Olaparib and Pegylated Liposomal Doxorubicin (DLP) in patients with peritoneal carcinoma primary ovarian and resistant platinum fallopian tubes*. GEICO-1601 ROLANDO: custody of 7 cryoboxes.
- European LEGACy project: custody of samples for this international project. European Union's Horizon 2020 research and innovation programme, grant agreement No 825832: custody of 7 cryoboxes.
- ALFAΩMEGA/PEGASUS studies, sponsored by IFOM ETS - The AIRC Institute of Molecular Oncology. Custody of samples for

these clinical trials: *A Master Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA)*, NCT04120935, IFOM-CPO003/2018/PO002; *Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial*, NCT04259944, IFOM-CPT005/2019/PO004, EudraCT Number 2019-002074-32: custody of 3 cryoboxes.

- iPROVE-O2 study: custody of samples for the clinical trial *Individualized Perioperative Open-luna Ventilatory Strategy With High Versus Conventional Inspiratory Oxygen Fraction (iPROVE-O2). A Comparative, Prospective, Multicenter, Randomized Controlled Trial*. EudraCT: 2016-002936-34, NCT02776046, sponsor INCLIVA: custody of 10 cryoboxes.
- Diabetic Nephropathy study: processing, conservation and shipment of processed samples for the study: *Early detection of histological lesions in nephrectomy pieces of diabetic patients. Anatomoclinical correlation. Analysis of the expression of Klotho in healthy kidney tissue vs tumor tissue*. Internal project, INCLIVA: custody of 5 cryoboxes.
- Cytosorb study: processing, conservation and shipment of processed samples for the randomized clinical trial *Hemoabsorption with Cytosorb vs usual clinical practice to analyze its effect on kidney damage biomarkers in asystole donation controlled with ECMO*. Fundación Mutua Madrileña, INCLIVA: custody of 2 cryoboxes.
- 4D-Tools study: processing, conservation and shipment of processed samples for the study *New techniques and biomarkers for diagnosis/prognosis of pathologies of the ascending aorta through image techniques*. ASCIRES, INCLIVA: 74 sample donations.
- CON-REN study: processing, conservation and shipment of processed samples, and custody of external samples for the study *Congestion as a catalyst for the progression of chronic kidney disease*, multicentre study. Spanish Society of Cardiology - SEC: 96 new sample donations.
- IC-DM2 study: processing, conservation and shipment of processed samples for the study *Systematic screening for heart failure in patients with type 2 diabetes mellitus*. PI21/01417, ISCIII: 106 sample donations.
- GOLD study: custody of external samples for the study *GOLD 0 - DLCO 1: A look beyond the obstruction: Is spirometry sufficient in COPD screening?*. Prospective, observational, multicenter study, grants from SEPAR (Spanish Society of Pulmonology and Thoracic Surgery) and the Valencian Society of Pulmonology: custody of 1 cryobox with external samples.
- OBERON study: processing, conservation and shipment of processed samples for the clinical trial *A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (OBERON)*. NCT05166889, D9180C00003, EudraCT Number 2021-003797-30, Registry CTIS 2023-503571-19-00, sponsor AstraZeneca: 1 sample donation.
- PROSPERO study: processing, conservation and shipment of processed samples for the clinical trial *A phase III, multicenter, randomized, double-blind, parallel-group, chronic-dose, placebo-controlled extension trial to evaluate the long-term efficacy and safety of tozorakimab in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations -PROSPERO*. NCT05742802, D9180C00008, EU CT Number 2022-501063-41-00, sponsor AstraZeneca: 6 sample donations.
- AGILE study: processing, conservation and shipment of processed samples for the clinical trial *A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744GSK3511294*. NCT05243680, 212895, EU CT 2023-505203-23-01, sponsor GlaxoSmithKline: 2 sample donations.
- ATYR1923-C-004 (SARCOIDOSIS) study: processing, conservation and shipment of processed samples for the clinical trial *A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis*. EudraCT number 2022-001012-26, ATYR1923-C-004, sponsor aTyr Pharma, Inc.: 14 sample donations.
- GB44332_ARNASA study: processing, conservation and shipment of processed samples for the clinical trial *A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease*. NCT05595642, GB44332, EU Trial CTIS 022-502234-70-00, sponsor Hoffmann-La Roche: 4 sample donations.
- TILIA study: processing, conservation and shipment of processed samples for the clinical trial *A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)*. NCT05624450, D9185C00001, CTIS 2023-507031-38-00, EudraCT 2022-003107-15, sponsor AstraZeneca: 6 sample donations.

- CIRCULATE-SPAIN-01 study: processing, conservation and shipment of processed samples for the clinical trial *Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localized colon cancer with circulating tumor DNA*. International multicenter study, SCReN code 21010, INCLIVA: 130 sample donations.
- PI21/00693 (ISCIII) and VERO study (GEMCAD SCHOLARSHIP 2022): management (reception, processing, conservation, registration, etc.) of external samples for these two projects: *Immune biomarker profiling as a tool to identify gastric cancer patients subsidiary of immunotherapy; Prognostic and predictive value of response of the gastric cancer microenvironment in young people*. VERO project: 10 sample donations.
- EOCCR2-22 AUDREY study: processing, conservation and shipment of processed samples for the clinical trial *A global multicenter phase 1/2 trial of EO4010, a novel microbial-Derived peptide theRapeutic vaccine, in combination with nivolumab and/or bevacizumab, for trEatment of patients with previously treated metastatic colorectal carcinoma*. NCT05589597, EO-CRC2-22, sponsor Enterome: 1 sample donation.
- NOUS-209-01-00 study: processing, conservation and shipment of processed samples for the clinical trial *A Phase I/IIa, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors*. NCT04041310, NOUS-209-01, FDA IND #018954, EudraCT 2021-002823-40, sponsor Nouscom SRL: 4 sample donations.
- AIDA study: processing, conservation and shipment of processed samples for the study *An Artificially Intelligent Diagnostic Assistant for gastric inflammation*. Multicenter study, CORDIS-EU, Grant agreement ID 101095359, HORIZON 2.1.1: 14 sample donations.
- 1346-0014 study: processing, conservation and shipment of processed samples for the clinical trial *An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials(CONNEX-X)*. NCT05211947, 1346-0014, EudraCT 2020-003745-11, sponsor Boehringer Ingelheim: 2 sample donations.

Incorporation of new collections outside the biobank regime in 2025:

- MITIGATE study: processing, conservation and shipment of processed samples for the study *Role of the intestinal microbiota and related metabolites in the quality of anticoagulation with vitamin K antagonists in patients with mechanical heart valve prostheses* (multicentre study of the Spanish Society of Cardiology - SEC): 13 sample donations.
- PreMYO study: processing, conservation and shipment of processed samples for the study *Precision biomarkers for improving the diagnosis and treatment of inflammatory myocardium disease (PreMYO)* (multicenter study, PMP22/00105, ISCIII-Next-GenerationEU): 2 sample donations.
- GENOTIME-COHORT study: processing, conservation and shipment of processed samples for the study *Optimization of the duration of antibiotic treatment in abdominal sepsis based on the kinetics of transcriptomic and clinical biomarkers (GENOTIME-COHORT study)* (AESI 2023, ISCIII, multicentre study PI23CIII/00010): 31 sample donations.
- LEVANTE study: processing, conservation and shipment of processed samples for the clinical trial *A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations (Levante)* (NCT06529419, D6830C00003, sponsor AstraZeneca): 22 sample donations.
- ALNASA study: processing, conservation and shipment of processed samples for the clinical trial *A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease* (NCT05878769, GB43374, sponsor Hoffmann-La Roche): 15 sample donations.
- LONG-COVID study: processing, conservation and shipment of processed samples, and custody of external samples for the study *Observational and extension study of long-term pulmonary sequelae associated with SARS-CoV-2 infection* (internal project, INCLIVA): 57 sample donations.
- DAPA-DP study: processing, conservation and shipment of processed samples for the clinical trial *Effect of the use of dapagliflozin in diuresis, natriuresis and in ultrafiltration and peritoneal elimination of sodium, in patients with refractory heart failure (DAPA-DP)* (ESR-21-21339, NCT06578520, sponsor INCLIVA): 35 sample donations.
- VVD-130037-001 study: processing, conservation and shipment of processed samples for the clinical trial *A Phase 1, Open-label, Multicentre, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors* (NCT05954312, VVD-130037-001, 2023-506199-28-00, sponsor Vividion Therapeutics):45 sample

- donations.
- CO-SABR study: processing, conservation and shipment of processed samples for the study *Stereotactic ablative radiotherapy (SABR) in oligometastatic cancer (OC): a radiomic, multi-omic, and machine learning approach for clinical decision-making. CO-SABR multicentre project* (multicentre study, PI22/00770, ISCIII): 10 sample donations.
 - HISTSHOCK study: processing, conservation and shipment of processed samples for the trial *The clinical performance evaluation of HistShock for the diagnosis and prognosis of sepsis and septic shock (SS)* (E.92/HISTSHOCK, CDTI SoE - Seal of Excellence, Next Generation EU / CDTI funds, multicentre international trial, sponsor EpiDisease SL): 43 sample donations.

In summary, 743 new sample donations have been received, 1997 samples have been processed, and 3743 aliquots have been stored in 2025 at INCLIVA Biobank facilities from studies outside the biobank regime. In addition, 3487 aliquots have been supplied for studies outside the biobank regime in 2025.

Transfer of samples from within the biobank regime in 2025

Project	Ref./Agency	Principal Researcher, Institution	Samples
<i>BBI_10/2021</i> <i>TuMiCC. TUmor Mlcroenvironment-derived factors in localized Colon Cancer: clinical impact and therapeutic implications.</i>	GCAEC20030CERV, AECC	Dr Andrés Cervantes, HCUV / INCLIVA	Colorectal cancer: 104 plasma aliquots and 3 DNA aliquots.
<i>BBI_14/2021</i> <i>Development of diagnostic and prognostic models based on intratumoural Fusobacterium infection and associated intestinal microbiota in localised colorectal cancer. FUSOMAP</i>	Fundación Mútua Madrileña (Exp. MMADRILEÑA/ PREMI/2020CCAA_ NUCIFORO)	Dr P. Nuciforo, Vall d'Hebron Institute of Oncology (VHIO).	Colorectal cancer: 32 stool aliquots and 32 saliva aliquots.
<i>BBI_02/2022</i> <i>Characterisation and management of minimal residual disease in localised colorectal cancer: a step towards precision medicine.</i>	PI21/00689, ISCIII	Dr N. Tarazona, HCUV / INCLIVA	Colorectal cancer: 16 plasma aliquots.
<i>BBI_16/2023</i> <i>Detection and monitoring of ctDNA in locally advanced head and neck squamous cancer (HNSCC) treated with chemoradiotherapy with radical intent.</i>	NA, Guardant Health, Inc	Dr G. Bruixola Campos, HCUV / INCLIVA	Head and neck cancer: 131 plasma aliquots.
<i>BBI_19/2023</i> <i>Detection of resistance and tumor progression mechanisms and identification of new therapeutic targets through genomic and epigenomic análisis of circulating tumor DNA in advanced colorectal cancer. METACC Project.</i>	NA, Ayudas Predoctorales AECC 2024	Dr N. Tarazona, INCLIVA / HCUV	Standard population: 30 plasma aliquots.
<i>BBI_21/2023</i> <i>Immune biomarker profiling as a tool to identify gastric cancer patients subsidiary of immunotherapy.</i>	PI221/00693, ISCIII	Dr T. Fleitas Kanonnikoff, HCUV / INCLIVA	Gastric cancer: 7 plasma aliquots.

<i>BBI_01/2024</i> <i>Evaluation of a proposal for implementing pharmacogenetics in the national health system for mental and cardiovascular health.</i>	PMP22/00134, ISCIII	Dr MJ. Herrero, UV/ La Fe	IAMEST collection: 47 viable cells aliquots.
<i>BBI_04/2024</i> <i>The role of AXL in modulating treatment resistance and tumor microenvironment in Triple Negative and HER2+ Breast Cancer.</i>	PI23/00848, ISCIII	Dr JM. Cejalvo Andújar, HCUV / INCLIVA	Breast cancer: 5 viable cells aliquots.
<i>BBI_13/2024</i> <i>Cytotoxicity induced by nuclear macromolecules: molecular mechanisms and potential for the development of sepsis and septic shock biomarkers (NUCLEOSEPSIS).</i>	PID2020-119127RA-I00, Agencia Estatal de Investigación – Ministerio de Ciencia e Innovación.	Dr C. Roma Mateo, Universitat de València	Sepsis and septic shock collection: 100 plasma aliquots.
<i>BBI_14/2024_RVB24017CPR</i> <i>Characteristics of suicide attempts in personality disorders in the Elda Health Department (STPE22), project framed within the European project “TrePsy - Towards new treatments of psychiatric disorders - a systems-oriented approach”.</i>	NA, Horizon Europe, Grant Agreement nº 101079256.	Dr J Manzanares Robles, Instituto de Neurociencias UMH-CSIC	Standard population: 15 PBMC aliquots.
<i>BBI_16/2024 (Addendum BBI_04/2023)</i> <i>Towards the comprehension of sepsis heterogeneity. Short-term and long-term prognosis by means of epigenomics, proteomics and artificial intelligence.</i>	PI22/00481, ISCIII	Dr JL. García Giménez, UV / INCLIVA	Sepsis and septic shock: 202 DNA aliquots and 9 plasma aliquots. Standard population: 10 plasma aliquots.
<i>RVB22007CHER</i> <i>Deciphering Lynch-like Syndrome.</i>	PI21/01243, ISCIII	Dr JL. Soto, HGU Elche, FISABIO	Hereditary cancer: 6 FFPE samples
<i>BBI_01/2025</i> <i>Study of the humoral immune response directed against the coronavirus nucleocapsid protein as a basis for the design of universal vaccines.</i>	CIGE/2023/169, GVA	Dr S Landeras, Universidad CEU Cardenal Herrera	COVID collection: 120 serum aliquots. Standard population: 60 serum aliquots.
<i>BBI_02/2025</i> <i>Genomic Precision Medicine in Lymphoid Neoplasms (PREGENLINF).</i>	PMP21/00015, ISCIII_ FEDER	Dr E. Campos Guerri, IDIBAPS. IP local: MJ. Terol, HCUV / INCLIVA	Lymphoid neoplasms: 29 DNA and 11 RNA aliquots
<i>BBI_03/2025</i> <i>Comprehensive approach to hepatic micrometastatic disease in colorectal cancer: multi-omic characterization of metastases, immune response, and management of residual disease.</i>	PI24/00103, ISCIII	Dr N. Tarazona, HCUV / INCLIVA	Colorectal cancer: 311 plasma aliquots and 7 DNA aliquots.
<i>BBI_04/2025</i> <i>TAV16: A tumor-agnostic MRD detection method using ctDNA analysis for cancer recurrence monitoring.</i>	CI25-20474, La Caixa Foundation	Dr J. Martín Arana, INCLIVA	Cancer collections: 321 plasma aliquots and 20 DNA aliquots.

<i>BBI_05/2025</i> <i>Development of EOSAL technology for its application in genetic diagnosis.</i>	NA, Sequencing Multiplex	Dr AB. García, INCLIVA	Lymphomas: 20 DNA aliquots
<i>BBI_06/2025</i> <i>Integration of genomic, digital imaging, and clinical information for the optimization of precision oncology (INGENIO).</i> <i>Task 4.2. To describe and validate a reverse identification strategy for actionable genomic aberrations in biliary tract tumors through the integration of digital pathology and radiomics.</i>	PMP21/00107, PMP21/00137, PMP21/00171, ISCIII, NextGenerationEU.	IP Task 4.2: Dr. A. Cervantes, HCUV / INCLIVA	Cholangiocarcinoma collection: 238 plasma aliquots.
<i>BBI_07/2025</i> <i>Association between Alphatorquevirus DNAemia and the development and prognosis of heart failure.</i>	NA	Dr E. Albert, INCLIVA	Acute heart failure collection: 135 plasma aliquots and 10 serum aliquots.
<i>BBI_08/2025</i> <i>Functional characterization of germline variants in hereditary myeloid neoplasms (GERMVAR).</i>	PDI2022-13666OOb-i00, Ministerio de Ciencia, Innovación y Universidades	Dr A. Sanjuan, La Fe	Acute leukaemia, Myelodysplastic syndromes: 2 DNA aliquots
<i>BBI_09/2025</i> <i>Detection and monitoring of ctDNA in localized non-small cell lung cancer: collaborative project with Natera.</i>	Pending Research Agreement Natera, INC-INCLIVA	Dr V. Gambardella, HCUV / INCLIVA	No samples delivered.
<i>BBI_10/2025</i> <i>ALK Translocation in Non-Small Cell Lung Cancer (NSCLC): Current Identification Methods, Limitations, and the Need for New Diagnostic Techniques: a collaborative project with Guardant Health.</i>	Research Agreement GuardantHealth-INCLIVA	Dr V. Gambardella, HCUV / INCLIVA	No samples delivered.
<i>BBI_11/2025</i>	PI22/02000, ISCIII	Dr D. Rosa, HCUV / INCLIVA	Cholangiocarcinoma collection: 288 plasma aliquots.
<i>BBI_12/2025</i> <i>Quantitative proteomics based on mass spectrometry for the early identification of predictive biomarkers of adverse events in acute coronary syndrome.</i>	DTS24/00094, ISCIII	Dr JL. García Giménez, UV / INCLIVA	No samples delivered.

In summary, 2325 aliquots were transferred in 2025.

In addition, specialized technical services (e.g. PBMC isolation and counting, DNA isolation, temporary custody of material, etc.) were provided by INCLIVA Biobank in 2025 to the following studies:

- Clinical Trial: *A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer.* NCT05855200, 219606, EU Trial CTIS 2023-503265-27-00, sponsor GlaxoSmithKline.

- Research project: *Molecular characterization and identification of novel treatments through liquid biopsy in patients with metastatic colorectal cancer (METACC).* AECC 2024, INCLIVA.
- Temporary custody of material from EpiDisease SL
- Research project: *Tumour microenvironment-derived factors in localized colon cancer: clinical impact and therapeutic implications,* TuMiCC, AECC, INCLIVA, VHI, HMRIB.
- Research project: *Prognostic Biomarkers of Idiopathic Scoliosis in Adolescents.* PI22/00990, ISCIII, INCLIVA.

PUBLICATIONS

Note that some of these are 2025 scientific publications derived from the use of samples or services provided by the biobank.

- Marti-Aguado D, Carot-Sierra JM, Villalba-Ortiz A, Siddiqi H, Vallejo-Vigo RM, Lara-Romero C, Martín-Fernández M, Fernández-Patón M, Alfaro-Cervello C, Crespo A, Coello E, Merino-Murgui V, Madamba E, Benloch S, Pérez-Rojas J, Puglia V, Ferrández A, Aguilera V, Monton C, Escudero-García D, Lluch P, Aller R, Loomba R, Romero-Gomez M, Marti-Bonmati L. Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography. Clin Gastroenterol Hepatol. 2025 Jun;23(7):1183-1193.e5. doi: 10.1016/j.cgh.2024.10.014. Epub 2024 Nov 16. PMID: 39551253.
- Bruixola G, Dualde-Beltrán D, Jimenez-Pastor A, Nogué A, Bellvís F, Fuster-Matanzo A, Alfaro-Cervelló C, Grimalt N, Salhab-Ibáñez N, Escorihuela V, Iglesias ME, Maroñas M, Alberich-Bayarri Á, Cervantes A, Tarazona N. CT-based clinical-radiomics model to predict progression and drive clinical applicability in locally advanced head and neck cancer. Eur Radiol. 2025 Jul;35(7):4277-4288. doi: 10.1007/s00330-024-11301-6. Epub 2024 Dec 20. PMID: 39706922; PMCID: PMC12165904.
- Marti-Aguado D, Alfaro-Cervello C, Fernández-Patón M, Ten-Esteve A, Cerdá-Alberich L, Crespo A, Navarrete-Pérez I, Ballester MP, Perez-Girbes A, Montón C, Pérez-Rojas J, Puglia V, Ferrández A, Aguilera V, Escudero-García D, Benloch S, Jimenez-Pastor A, Alberich-Bayarri Á, Sirlin CB, Marti-Bonmati L. Digital pathology and lipid droplet size as a key determinant of discrepancies between histology and MRI gradings in steatotic liver disease. Eur Radiol. 2026 Feb;36(2):1050-1060. doi: 10.1007/s00330-025-11919-0. Epub 2025 Aug 8. PMID: 40781513; PMCID: PMC12953288.
- Bruixola G, Martín-Arana J, Gimeno-Valiente F, Carbonell-Asins JA, García-Micó B, Martínez-Castedo B, González-Camblor D, Grimalt N, García-Bartolomé M, Alfaro-Cervelló C, Escorihuela V, Iglesias ME, Maroñas M, Dualde D, Cervantes A, Tarazona N. Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer. ESMO Open. 2025 Dec;10(12):105904. doi: 10.1016/j.esmoop.2025.105904. Epub 2025 Nov 20. PMID: 41270698; PMCID: PMC12670099.
- Seguí V, Carbonell-Asins JA, Martín-Arana J, García-Bartolomé M, Grimalt N, Martinez-Ciarpaglini C, Gonzalez-Muñoz JF, Martín-Martorell P, Gonzalez-Barrallo I, Viala A, Tapia M, Huerta M, Bruixola G, Insa A, Cejalvo JM, Fleitas T, Tarazona N, Cervantes A, Roda D, Gambardella V. Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations. ESMO Open. 2025 Oct;10(10):105771. doi: 10.1016/j.esmoop.2025.105771. Epub 2025 Sep 24. PMID: 40997747; PMCID: PMC12495086.
- Dienstmann R, Ruiz-García E, Alsina M, Ruiz-Pace F, Groen-van Schooten TS, Martínez-Ciarpaglini C, Fernández-Figueroa EA, Herrera-Goepfert R, Díaz-Romero C, Lino-Silva L, Hernandez-Guerrero AI, Valdez-Reyes NM, León-Takahashi A, Falcón-Martínez JC, Pouw RE, Romero S, Villagrasa R, Cabeza-Segura M, Alarcón-Molero L, Jimenez-Martí E, Miralles A, Boggino H, Gauna C, Pereira R, Lezcano H, Cantero D, Vivancos A, Matito J, Martin A, Gómez M, Castillo E, Vila M, Ferreira RM, Barros R, Santos-Antunes J, Mendes-Rocha M, Costa A, Riquelme E, Roa JC, Latorre G, Freile B, Caro L, Esteso F, O'Connor J, Riquelme A, Owen G, Garrido M, Díez-García M, Figueiredo C, Caballero C, Lordick F, Farrés J, Derks S, Carneiro F, Cervantes A, Fleitas T. Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project. ESMO Open. 2025 Mar;10(3):104482. doi: 10.1016/j.esmoop.2025.104482. Epub 2025 Mar 3. PMID: 40036904; PMCID: PMC11926697.
- Sánchez-Simarro Á, Panizo N, Giménez E, Albert E, Montomoli M, Sanchis I, Kanter J, Górriz JL, Navarro D. Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination. J Med Virol. 2025 May;97(5):e70382. doi: 10.1002/jmv.70382. PMID: 40326950.
- Sánchez-Simarro Á, Carretero D, Grau B, Martínez-Pérez M, Albert E, Giménez E, Colomer E, Panizo N, Hernani R, Espert AH, Solano C, Piñana JL, Górriz JL, Geller R, Navarro D. Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a

Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. *J Med Virol.* 2025 Jun;97(6):e70463. doi: 10.1002/jmv.70463. PMID: 40545672.

- Martín Castillo I, Mora E, Hernani R, Cervera JV, Fernandez MJ, Ferrer-Lores B, Such E, Calabuig M, Abellán R, Díaz-Beyá M, Hernández-Boluda JC, Solano C, Villamón E, Tormo M. Rapid Screening and Monitoring of UBA1 Mutations in VEXAS Syndrome. *J Mol Diagn.* 2025 Jun;27(6):431-437. doi: 10.1016/j.jmoldx.2025.03.004. Epub 2025 Apr 14. PMID: 40239805.
- Flores-Chova A, Martinez-Arroyo O, Puertes A, Vela-Bernal S, Gorriz JL, Solis-Salguero MA, Terradez L, Ortega A, Forner MJ, Cortes R. Exosomal Specificity of MiR-15a-5p as Marker of Activity, Renal Damage, and Disease Flares in Systemic Lupus Erythematosus. *Am J Nephrol.* 2025;56(5):529-542. doi: 10.1159/000544854. Epub 2025 Mar 13. PMID: 40081350.
- Azahara Fuentes-Trillo, Alicia Serrano-Alcalá, Blanca Ferrer-Lores, Laura Ventura-López, Enrique Seda, Ana-Bárbara García-García, Blanca Navarro, María José Terol, Felipe Javier Chaves, Characterization of Chronic Lymphocytic Leukemia Immunoglobulin Re-arrangements from Partial Read Sequencing, Genomics, Proteomics & Bioinformatics, Volume 23, Issue 2, April 2025, qzaf041, <https://doi.org/10.1093/gpbjnl/qzaf041>.
- Zhao W, Zhang T, Hua X, Hoang PH, Mirafteb M, Saha M, McElderry JP, Sang J, Lee OW, Hartman C, Khandekar A, Sharma S, Colón-Matos FJ, Anyaso-Samuel S, Wang D, Jones K, Hutchinson A, Hicks B, Rosenbaum J, Zhong X, Yang Y, Pesatori AC, Consonni D, Christiani DC, Leung KC, Wong MP, Manczuk M, Lissowska J, Świątkowska B, Mukeria A, Shangina O, Zaridze D, Holcatova I, Mates D, Milosavljevic S, Ognjanovic S, Savic M, Kontic M, Gaborieau V, Brennan P, Arrieta O, Bossé Y, Edell ES, Schabath MB, Hofman P, Mas L, Yendamuri SS, Chen CY, Chang IS, Hsiung CA, Liu G, Martinez Santamaria J, Gould Rothberg BE, Mutreja K, Lawrence S, Rothman N, Alexandrov LB, Leduc C, Baine MK, Joubert P, Sholl LM, Travis WD, Homer R, Lan Q, Chanock SJ, Yang L, Yang SR, Shi J, Landi MT. A prognostic signature for lung adenocarcinoma in patients who have never smoked. *Cancer Discov.* 2025 Oct 30. doi: 10.1158/2159-8290.CD-25-0581. Epub ahead of print. PMID: 41165571.
- Villamón E, Guerrero P, Gil ML, Martín I, Amat P, Gozalbo D, Yáñez A. TLR7/8 ligands R848 and imiquimod induce differentiation of bone marrow cells from patients with myelodysplastic syndrome towards mature neutrophils. *Sci Rep.* 2025 Aug 26;15(1):31496. doi: 10.1038/s41598-025-15859-z. PMID: 40858756; PMCID: PMC12381240.
- García-Gimenez JL, Ruiz-Rodríguez JC, Ferrer R, Durá R, Artigas A, Bajaña I, de Andujar DBL, Cánovas-Cervera I, Ceccato A, Chiscano-Camón L, Climent-Martinez E, García Fernández G, Goma G, Monforte V, Quevedo-Sánchez B, Ruiz-Sanmartín A, Sierra-Rivera A, Carbonell Monleón N. Circulating histones as clinical biomarkers in critically ill conditions. *FEBS Lett.* 2025 Nov;599(22):3174-3195. doi: 10.1002/1873-3468.70093. Epub 2025 Jun 17. PMID: 40527588; PMCID: PMC12643065.
- Martín-Arana J, Gimeno-Valiente F, Henriksen TV, García-Micó B, Martínez-Castedo B, Gambardella V, Martínez-Ciarpaglini C, Palomar B, Huerta M, Cambor DG, García Bartolomé M, Carbonell-Asins JA, Frydendahl A, Gotchalck KA, Fleitas T, Tébar-Martínez R, Moro D, Pla V, Pérez-Santiago L, Martín-Arévalo J, Casado D, García-Botello S, Espí A, Roselló S, Roda D, Andersen CL, Cervantes A, Tarazona N. Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. *Nat Cancer.* 2025 Jun;6(6):1000-1016. doi: 10.1038/s43018-025-00960-z. Epub 2025 Apr 29. PMID: 40301653; PMCID: PMC12202492.
- Botello-Marabotto M, Tarrasó J, Mulet A, Presa-Fernández L, Fernández-Fabrellas E, Portal JAR, Ros JA, Lozano-Vicente D, Bernardos A, Martínez-Bisbal MC, Martínez-Mañez R, Signes-Costa J. Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge. *J Med Virol.* 2025 Mar;97(3):e70289. doi: 10.1002/jmv.70289. PMID: 40088077.
- Hernani R, Ventura L, Heras B, Serrano A, Rivada M, Martínez-Ciarpaglini C, Benzaquén A, Ferrer-Lores B, Pérez A, Piñana JL, Hernández-Boluda JC, Arroyo I, Amat P, Pastor-Galán I, Remigia MJ, Goterris R, Gómez M, Teruel A, Saus A, Ortí C, Terol MJ, Ferrández-Izquierdo A, Solano C. Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR-T Therapy. *EJHaem.* 2025 Mar 19;6(2):e270015. doi: 10.1002/jha2.70015. PMID: 40110072; PMCID: PMC11920814.
- Martínez-Ciarpaglini C, Barros R, Caballero C, Boggino H, Alarcón-Molero L, Peleteiro B, Ruiz-García E, Fernandez-Figueroa E, Herrera-Goepfert R, Díaz-Romero C, Ferreira R, Groen-van Schooten TS, Gauna C, Pereira R, Cantero D, Lezcano H, Estes O, Connor J, Riquelme A, Owen GI, Garrido M, Roa JC, Ruiz-Pace F, Vivancos A, Díez-García M, Alsina M, Matito J, Martin A, Gómez M, Castillo E, Vila M, Santos-Antunes J, Costa A, Lordick F, Farrés J, Palomar-De Lucas B, Cabeza-Segura M, Villagrasa R, Jimenez-Martí E, Miralles-Marco A, Dienstmann R, Derks S, Figueiredo C, Cervantes A, Carneiro F, Fleitas-Kanonnikoff T. Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression. *Gastric Cancer.* 2025 Mar;28(2):160-173. doi: 10.1007/s10120-024-01578-3. Epub 2025 Jan 5. PMID: 39755998; PMCID: PMC11842524.

- McElderry JP, Zhang T, Zhao W, Hoang PH, Anyaso-Samuel S, Sang J, Khandekar A, Hartman C, Colón-Matos FJ, Mirafteb M, Saha M, Lee O, Sharma S, Jones KM, Zhu B, Díaz-Gay M, Mas L, Arrieta O, Edell ES, Santamaria JM, Schabath MB, Yendamuri S, Manczuk M, Lissowska J, Świątkowska B, Mukeria A, Shangina O, Zaridze D, Holcatova I, Janout V, Mates D, Ognjanovic S, Savic M, Kontic M, Bossé Y, Gould Rothberg BE, Christiani DC, Gaborieau V, Brennan P, Liu G, Hofman P, Wong MP, Leung KC, Chen CY, Hsiung CA, Rothman N, Leduc C, Baine MK, Travis WD, Sholl LM, Joubert P, Homer R, Yang SR, Lan Q, Nowak MA, Wedge DC, Alexandrov LB, Chanock SJ, Vogtmann E, Abnet CC, Shi J, Landi MT. Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations. *Nat Commun.* 2025 Dec 12;17(1):192. doi: 10.1038/s41467-025-66780-y. PMID: 41387456; PMCID: PMC12780107.
- Pulido I, García-Cañaveras JC, Rodríguez ML, Becker JH, López A, Aupí M, Aparisi S, Chuliá-Peris L, Tamayo-Torres E, Carreres-Rey C, Alcácer Fernández-Coronado J, Benet M, Montero S, Mena S, Sandoval J, Pereda J, Alcácer J, Calabuig-Fariñas S, Jantus-Lewintre E, Cremades A, Galbis-Caravajal JM, Martín-Martorell P, Insa A, Massad MG, Juan-Vidal O, Lahoz A, Shimamura T, Carretero J. NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC. *Cancer Lett.* 2025 Sep 9;633:218032. doi: 10.1016/j.canlet.2025.218032. Epub ahead of print. PMID: 40935282.
- M. Cabeza Segura, A. Aguilar-Cifre, A. González-Vilanova, A. Marín-Alonso, B.P. de Lucas, R. Villagrasa, N. Grimalt, M.C. Fernandez, M.E. Barrios, R. Gadea-Mateo, F. López-Mozos, A. Vera, C. Martinez Ciarpaglini, A. Cervantes, T.C. Fleitas, J. Castillo. Tumour heterogeneity governs the pro-tumoral effects of M2 macrophages in gastric cancer organoids. DOI: 10.1016/j.esmoop.2025.105785 [https://www.esmooopen.com/article/S2059-7029\(25\)01654-0/fulltext](https://www.esmooopen.com/article/S2059-7029(25)01654-0/fulltext)
- DeDiego ML, López-Fernández-Sobrino R, Pedragosa J, López-García D, Nogales A, Durbán J, Cardona F, Llucià-Carol L, Rivero V, Vazquez-Utrilla P, Sanchez-Grande LP, Cobo M, Lloret L, Márquez-Kisinousky L, Ruiz-Jaén F, Lozano F, Sibila O, Faner R, Castro P, Domingo C, Robles V, Bedini JL, Rico V, Agüero D, Soriano A, Nalda AM, Martínez AP, Colobran R, Soler-Palacín P, Serra-Llovich A, Dietl B, Arranz MJ, Dalmau D, Signes-Costa J, Gil-Carbonell J, Todolí J, Martínez J, Rojo S, Fiz-López A, Arribas E, Cal-Sabater P, Bernado D, Vogel M, Wiemann S, Abolhassani H, Pan-Hammarström Q, Pujol A; COVID Human Genetic Effort; Su HC, Lee D, Zhang SY, Casanova JL, Fernández-Cadenas I, Pérez-Tur J, Planas AM. *OAS1* and *OAS3* genetic variants enhance inflammatory responses to SARS-CoV-2. *iScience.* 2025 Nov 11;28(12):113966. doi: 10.1016/j.isci.2025.113966. PMID: 41438061; PMCID: PMC12719101.
- Apperloo EM, Gorris JL, Soler MJ, Cigarrán Guldri S, Cruzado JM, Puchades MJ, López-Martínez M, Waanders F, Laverman GD, van der Aart-van der Beek A, Hoogenberg K, van Beek AP, Verhave J, Ahmed SB, Schmieder RE, Wanner C, Cherney DZI, Jongs N, Heerspink HJL. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. *Nat Med.* 2025 Jan;31(1):278-285. doi: 10.1038/s41591-024-03327-6. Epub 2024 Oct 25. PMID: 39455729.
- Papaccio F, Cabeza-Segura M, García-Micó B, Gimeno-Valiente F, Zúñiga-Trejos S, Gambardella V, Gutiérrez-Bravo MF, Martinez-Ciarpaglini C, Rentero-Garrido P, Fleitas T, Roselló S, Carbonell-Asins JA, Huerta M, Moro-Valdezate D, Roda D, Tarazona N, Sánchez Del Pino MM, Cervantes A, Castillo J. Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids. *J Exp Clin Cancer Res.* 2025 Feb 28;44(1):77. doi: 10.1186/s13046-025-03308-8. PMID: 40022181; PMCID: PMC11869439.
- Rozalén C, Sangrador I, Avalué S, Blasco-Benito S, Tzortzi P, Sanz-Flores M, Palomeque JÁ, Torren-Duran P, Dalmau M, Brunel H, Coll-Manzano A, Pérez-Núñez I, Martos T, Servitja S, Pérez-Buira S, Chacón JI, Guerrero-Zotano Á, Martínez de Dueñas E, Guillén Y, Comerma L, Bermejo B, Bigas A, Casanova-Acebes M, Alemany A, Rojo F, Albanell J, Celià-Terrassa T. TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak. *Cancer Cell.* 2025 Aug 11;43(8):1549-1567.e9. doi: 10.1016/j.ccell.2025.06.015. Epub 2025 Jul 10. PMID: 40645187; PMCID: PMC12416865.
- Wirth C, Zhang T, Díaz-Gay M, Steele CD, Hoang PH, Yang Y, Khandekar A, Zhao W, Sang J, Leduc C, Baine MK, Travis WD, Sholl LM, Joubert P, Homer R, Yang SR, Tran TV, McElderry JP, Hartman C, Mirafteb M, Lee OW, Jones KM, Zhu B, Santamaria JM, Schabath MB, Yendamuri SS, Manczuk M, Lissowska J, Świątkowska B, Mukeria A, Shangina O, Zaridze D, Holcatova I, Janout V, Mates D, Ognjanovic S, Savic M, Kontic M, Bossé Y, Gould Rothberg BE, Christiani DC, Gaborieau V, Brennan P, Liu G, Hofman P, Wong MP, Leung KC, Chen CY, Chang IS, Hsiung CA, Pesatori AC, Consonni D, Rothman N, Lan Q, Nowak MA, Chanock SJ, Shi J, Yang L, Alexandrov LB, Wedge DC, Landi MT. Revealing the Drivers Underlying Distinct Evolutionary Trajectories in Lung Adenocarcinoma. *bioRxiv* [Preprint]. 2025 Dec 23:2025.12.19.695410. doi: 10.64898/2025.12.19.695410. PMID: 41509216; PMCID: PMC12776081.
- Almonte-Loya A, Wang W, Houshdaran S, Tang X, Flynn E, Liu B, Kushnoor D, Nezhat C, Vilella F, Simon C, Vo KC, Casillas A, Khan U, Serras CP, Oskotsky TT, Huang D, Vallve-Juanico J, Irwin J, Combes A, Sirota M, Fragiadakis G, Giudice L. Single-Cell Profiling Reveals Altered Endometrial Cellular Features Across the Menstrual Cycle in Endometriosis Patients. *bioRxiv* [Preprint]. 2025 Aug 14:2025.07.21.666016. doi: 10.1101/2025.07.21.666016. PMID: 40777241; PMCID: PMC12330773.

4.4.3. Precision Medicine Unit

medicinaprecision@incliva.es

TEAM

Principal Investigator:

Andrés Cervantes Ruipérez. Hospital. University

Coordinator:

Pilar Rentero Garrido. INCLIVA

Technicians:

Enrique Seda García. INCLIVA

Laura González Castillo. INCLIVA

Laura Olivares Ordóñez. INCLIVA

Sebastián Blesa Luján. INCLIVA

The Precision Medicine Unit was established in March 2018. Since then, the group have developed a robust, wide portfolio of services to support research at INCLIVA.

The unit has an ongoing close collaboration with the Oncology Phase I Clinical Trial Unit, jointly developing an integrated screening system to support personalized patient care and thus implementing the latest techniques in clinical practice. In addition, the unit currently collaborates in several research projects from different groups at INCLIVA.

The group integrates professional profiles from multiple disciplines (Medical Oncology, Molecular Biology, Bioinformatics and Biochemistry) with broad professional experience in Human Genetics and Genomics.

FUNCTIONS

Our mission is to drive, promote and carry out quality translational research, providing support to the scientific community in molecular biology and data analysis techniques.

LABORATORY EQUIPMENT

- Two high-throughput sequencers with Illumina chemistry: MiSeq and NextSeq550
- iScan System to scan Illumina microarrays
- nanoString n-Counter platform
- Bio-Rad ddPCR (QX-200)
- Chromium Single Cell System (10X Genomics)
- Digital Scan Pannoramic® 300 Flash Dx
- Glomax Discovery System (Promega)
- Maxwell RSC (Promega)
- Quantitative thermalcycler (CFX96 Bio-Rad)
- Standard thermal cyclers
- TapeStation system to visualize DNA and RNA
- Laminar cabins, centrifuges, heat blocks, ovens, etc.

LOCATION

- INCLIVA, 4th floor, Menéndez y Pelayo 4, acc.

SERVICES

1. Next-Generation Sequencing (NGS):

- Design, development, validation and sequencing of custom gene panels
- Exome sequencing and analysis
- Whole-genome sequencing
- Sequencing small genomes “*de novo*”
- RNA-sequencing (total RNA, poly(A) fraction, rRNA depleted...)
- Microtranscriptome sequencing (small RNA/miRNA...)

2. Microarrays:

- Genotyping arrays
- Methylation arrays

3. Digital PCR (Droplet Digital PCR BIORAD)

4. NanoString platform

5. Chromium Single Cell System (10X genomics)

6. Other molecular biology techniques:

- Nucleic acid isolation
- Nucleic acid quantification (absorbance and fluorescence)
- Luminescence analysis
- Uniplex and Multiplex PCR
- Quantitative PCR

7. Digital Scan Pannoramic® 300 Flash Dx

8. Additional services:

- Advice and methodological support in writing protocols, research project proposals, scientific papers
- Bachelor, master and doctorate student mentoring
- On demand training
- Consulting services

ACTIVITIES DEVELOPED

Molecular testing aimed at minimizing treatment-related toxicity and optimizing therapeutic decision-making has been carried out in approximately 1,500 oncology patients.

As a genomic platform, the UMP has participated in 93 research projects involving 29 institutions across Spain (including FINBA, IDIBAPS, FIHGM, UPV, UV, and EpiDisease), as well as supporting internal users. These projects have encompassed analysing more than 600 samples for DNA methylation studies and over 3,800 samples genotyped for genome-wide association studies (GWAS) across different species. In addition, the Unit has processed more than 300 whole-exome sequencing (WES) datasets derived from PBMCs, FFPE samples, and circulating cell-free DNA (cfDNA) for oncological research projects.

RESEARCH PROJECTS AND GRANTS FOR RESEARCH

Reference: 101095359 - AIDA

Title: An Artificially Intelligent Diagnostic Assistant for gastric inflammation (AIDA)

Principal Investigator: Tania Fleitas Kanonnikoff

Funding Body: *European Commission*

Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2026
Total budget: €1,138,750 (Total: €6,334,803.75)

Title: Tumor microenvironment-derived factors in localized colon cancer: clinical impact and therapeutic implications (TUMMIC)
Principal Investigator: Andrés Cervantes Ruipérez
Funding Body: *Fundación AECC (Asociación Española Contra el Cáncer)*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2020-2025
Total budget: €992,996

Reference: PI22/02000
Title: Hacia la medicina de precisión en el colangiocarcinoma: la relevancia de la radiogenómica que define el perfil molecular de un paciente individual en busca de nuevas oportunidades de tratamiento.
Principal Investigator: Desamparados Roda
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €98,494

Reference: PI22/01173
Title: El papel del estrés oxidativo y la vía NRF2 en determinar resistencia a quimioinmunoterapia de primera línea en pacientes con cáncer de pulmón no microcitico avanzado KRAS mutado.
Principal Investigator: Valentina Gambardella
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €111,320

- PUBLICATIONS**
- Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids. Papaccio F, Cabeza M, García B, Gimeno F, Zúñiga S, Gambardella V, Gutiérrez MF et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2025 february 28. 44 (1):77-77. DOI:10.1186/s13046-025-03308-8. PMID:40022181.
 - Characterization of Chronic Lymphocytic Leukemia Immunoglobulin Rearrangements from Partial Read Sequencing. Fuentes A, Serrano A, Ferrer B, Ventura L, Seda E, García AB, Navarro B et al. GENOMICS PROTEOMICS & BIOINFORMATICS. 2025 may 02. 23 (2):DOI:10.1093/gpbjnl/qzaf041. PMID:40315014.
 - Non-genetic and genetic determinants of serum selenium and selenium species in the Aragon Workers Health Study. Rodriguez Z, Paredes A, Galvez M, Grau M, Sotos M, Rentero P, Gonzalez M et al. FREE RADICAL BIOLOGY AND MEDICINE. 2025 june 01. 233365-377. DOI:10.1016/j.freeradbiomed.2025.03.044. PMID:40164364.

4.4.4. Biomarker Analysis Unit

TEAM
Coordinator
Carmina Montoliu Félix. UV

Technicians
Amparo Urios Luch. INCLIVA
María Oliver Ferrándiz. INCLIVA

The Biomarker Analysis Unit is a core facility created in 2024. The Biomarker Analysis platform, equipped with state-of-the-art technology, is primarily aimed at detecting and quantifying biomarkers in various types of samples, both human and from animal models (serum, plasma, urine, tissue extracts, blood, tears, saliva, extracellular vesicles, etc.).

FUNCTIONS
The potential utility of biomarker determinations using SIMOA technology applies to a wide range of scientific and technological fields: neurology, oncology, cardiology, inflammation, and infectious diseases. One of the main applications of biomarker identification lies with- in the field of neurology: the study of neurofilaments, which are relevant to conditions such as multiple sclerosis and Alzheimer’s disease, or the search for biomarkers in biological fluids for diagnosis and prognosis of cognitive decline associated with various pathologies. It is also relevant in the field of oncology, where SIMOA technology is being applied to cancer diagnosis through assays detecting tumour-de- rived extracellular vesicles.

EQUIPMENT
The SIMOA HD-X Analyzer is an ultra-sensitive platform based on Single Molecule Array® technology, which enables biomarker de- tection at femtogram per millilitre (fg/ml) sensitivity levels—greater than those of conventional ELISA kits. The SIMOA HD-X is fully automated and provides the following advantages: i) High sensitivity: 1,000 times higher than is offered by current immunoassays; ii) Accuracy: the results obtained have a CV <10%; iii) Automation: decreases assay time and variability derived from manual operation; iv) Flexibility: the possibility to design your own antibody assays against specific analytes; v) Simultaneity: allows multiplex option and for measuring up to 6 analytes in the same sample.

SERVICES
The SIMOA system offers a portfolio of over 80 assays plus the option to develop customised assays. The SIMOA HD-X system and biomarker analysis is applicable to various biological samples through the following assays:

- Single-plex assays (SIMOA BEAD-BASED ADVANTAGE ASSAYS)
- Multiplex assays (SIMOA MULTIPLEX BEAD-BASED ADVANTAGE ASSAYS)

RESEARCH PROJECTS AND GRANTS FOR RESEARCH
Reference: PI23/00062
Title: Mecanismos que conducen al deterioro cognitivo y motor leve en pacientes con enfermedad hepática: Papel de los cambios en la microbiota, el sistema inmunitario y las vesículas extracelulares.
Principal Investigator: Mª del Carmen Montoliu Félix
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2024-2026
Total budget: € 252,500

Reference: 246
Title: Development of a new simultaneous diagnostic methodology of Hepatic Fibrosis and inflammation from Magnetic Resonance.
Principal Investigator: Carmina Montoliu/José Manuel Santabárbara/Roberto Aliaga.
Funding Body: Generalitat Valenciana, Agencia Valenciana de Innovación (AVI). Consolidacion Cadena Valor.
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 3 years
Total budget: € 64,000

Reference: CIPROM2021/082
Title: Molecular mechanisms of the neurological (cognitive and motor) alterations in hyperammonemia and hepatic encephalopathy. Therapeutic implications.
Principal Investigator: Vicente Felipo
Funding Body: Conselleria de Educacio. Generalitat Valenciana. Ayuda para Grupos de Investigación de Excelencia – Programa Pro-meteo
Beneficiary Institution: Centro de Investigación Principe Felipe de Valencia, Fundación INCLIVA, Universidad de Valencia, Instituto de Agroquímica y Tecnología de Alimentos de Valencia (CSIC)
Duration: 2022-2025
Total budget: € 600,000

Reference: PRV00225
Title: Deterioro Neurológico
Principal Investigator: Carmina Montoliu
Funding Body: Donación Fca. Sarabia
Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana
Duration: 2021 to present
Total budget: € 50,000

PUBLICATIONS

- Ammonia and beyond - biomarkers of hepatic encephalopathy. Gallego JJ, Ballester MP, Fiorillo A, Casanova Ferrer F, López Gram-aje A, Urios A, Arenas YM et al. METABOLIC BRAIN DISEASE. 2025 january 15. 40 (1):100-100. DOI:10.1007/s11011-024-01512-7. PMID:39812958.
- Arenas YM, Pérez-Martinez G, Montoliu C, Llansola M, Felipo V. Extracellular vesicles from L. paracasei improve neuroinflamma-tion, GABA neurotransmission and motor incoordination in hyperammonemic rats. Brain Behav Immun. 2025. 123:556-570. doi: 10.1016/j.bbi.2024.10.002. PMID: 39384052
- Valproate Damaging Effect on Erythrocyte Metabolism as a Decisive Factor in the Development of Encephalopathy. Tikhonova L, Maevsky E, Montoliu C, Kosenko E. Biomolecules. 2025 april 15. 15 (4):588 DOI:10.3390/biom15040588. PMID:40305337.
- Extracellular vesicles from Lacticaseibacillus paracasei reduce neuroinflammation in hippocampus and restore some cognitive functions in hyperammonemic rats. Izquierdo P, Arenas YM, Montoliu C, Pérez G, Llansola M, Felipo V. MICROBIOLOGICAL RE-SEARCH. 2025 may 01. 294128101-128101. DOI:10.1016/j.micres.2025.128101. PMID:39978142.
- Blood ammonia and eye-hand coordination negatively affect health-related quality of life in women with minimal hepatic enceph-alopathy. Batallas D, Gallego JJ, Casanova F, Fiorillo A, Rivas P, López A, Arenas YM et al. QUALITY OF LIFE RESEARCH. 2025 june 01. 34 (6):1669-1682. DOI:10.1007/s11136-025-03920-3. PMID:40167844.
- Sex differences in the mediating role of brain-derived neurotrophic factor between inflammation and memory in cirrhotic patients with minimal hepatic encephalopathy. Batallas D, Gallego JJ, Casanova F, López A, Rivas P, Megías J, Escudero D et al. Brain Behav-ior & Immunity-Health. 2025 july 01. 46100998-100998. DOI:10.1016/j.bbih.2025.100998. PMID:40343108.
- The analysis of the gut microbiome during liver disease progression led to the identification of biomarkers for related mild cogni-tive impairment. Giner L, Gallego JJ, Giménez C, Batallas D, Jarquín VH, Casanova F, Fiorillo A et al. Frontiers in Microbiology. 2025 september 16. 161670512-1670512. DOI:10.3389/fmicb.2025.1670512. PMID:41035890.

- Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis. San Martín C, Gallego JJ, Urios A, Correa P, Tabares R, Montoliu C. PLoS One. 2025 october 08. 20 (10). DOI:10.1371/journal.pone.0333029. PMID:41060950.
- Sex-Specific Differences and a Predictive Model Based on Clinical and Biochemical Parameters for Minimal Hepatic Encephalop-athy. Gallego JJ, Casanova F, Fiorillo A, Benlloch S, Urios A, López A, Oliver M et al. LIVER INTERNATIONAL. 2025 november 19. 45 (12). DOI:10.1111/liv.70452. PMID:41255242.

4.4.5. Molecular, Cellular, and In Vivo Analysis Unit

TEAM

Coordinators

Juan Antonio Navarro Langa. UV
Arturo López Castel. UV

The Molecular, Cellular, and *In Vivo* Analysis Unit is a cross-disciplinary research support platform available to any researcher, aimed at promoting, supporting, and conducting high-quality translational research. The platform is equipped with unique and exclusive scientific-technological instruments for sample analysis, available for use by both INCLIVA Foundation staff and personnel from other public and private institutions.

FUNCTIONS

The unit provides researchers with high-precision, high-sensitivity, and high-performance infrastructure. It is equipped for separating and counting large particles and precise for DNA quantification, with a cryo-sectioning system for biological samples with freezing and disinfection options, and a confocal laser scanning microscopy system.

EQUIPMENT

COPAS FP1000 Large-Particle Flow Cytometer
QuantStudio™ 5 Real-Time PCR System by Applied Biosystems
Leica CM1950 Cryostat – Cryo-sectioning service for biological samples
Zeiss LSM 800 confocal laser scanning microscope

SERVICES

Use of the COPAS FP-1000 large-particle flow cytometry system
Use of the QuantStudio™ 5 real-time PCR system by Applied Biosystems
Use of the Leica CM1950 Cryostat
Use of the Zeiss LSM 800 confocal laser scanning microscope

RESEARCH PROJECTS AND RESEARCH GRANTS

Title: Obtención de mutantes de Drosophila para el gen DFH mediante movilización de elementos transponibles. CDEI-04/20-C
Principal Investigator: Juan Antonio Navarro Langa
Funding Body: *Consellería de Sanidad*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2020-2025
Total budget: €117,500

Title: Reposicionamiento del Ácido Clavulánico como tratamiento para la enfermedad de Huntington y la ataxia espinocerebelosa de tipo 3. Estudios en cultivos primarios de pacientes y en modelos animales transgénicos. PI22/00507
Principal Investigator: Juan Antonio Navarro Langa y Federico Vicente Pallardó Calatayud
Funding Body: *Instituto de Salud Carlos III*-Co-financed FEDER
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2025
Total budget: €147,620

Title: Drosophila melanogaster como herramienta de diagnóstico molecular para la Paraparesia Espástica Hereditaria 7 (HSP7). Reference: AP-2021-014.
Principal Investigator: Juan Antonio Navarro Langa

Funding agency: Programa VLC Bioclinic 2021. Universitat de València y la Fundación para la investigación del Hospital Clínico Universitario de Valencia-Instituto de investigación Sanitaria INCLIVA
Total budget: €4,750
Funded Period: October 2021 – September 2022

Title: Intracellular iron deposits in a Drosophila Model of Friedreich ´s Ataxia. Reference: 2021095290.
Principal Investigator: Juan Antonio Navarro Langa
Funding agency: Center of Excellence ALBA synchrotron.
Total budget: €51,471.36
Funded Period: Shifts during 26-27th of March and 24-25th of May 2022.

Title: Drug repositioning of Clavulanic Acid as a treatment for Huntington Disease and Spinocerebellar ataxia type 3. Studies in primary cultures from patients and transgenic animal models. Reference: PI22/00507.
Principal Investigator: Prof Dr Federico V. Pallardó Calatayud.
Funding agency: Instituto de Salud Carlos III.
Total budget: €147,620
Funded Period: 01/01/2023 - 30/06/2026.

Title: Impact of iron overload in a Drosophila Model of Friedreich ´s Ataxia. Reference: 2022097067.
Principal Investigator: Juan Antonio Navarro Langa
Funding agency: Center of Excellence ALBA synchrotron.
Total budget: €41,394.96
Funded Period: Shifts from 30 May to 2 June 2023

Title: Rastreo Farmacológico en modelos de Drosophila de Paraplejia Espástica Hereditaria 7. PharmaFlyHSP7. Referencia PI-2023-005
Principal Investigator: Juan Antonio Navarro Langa
Funding agency: Programa VLC Bioclinic 2023. Universitat de València y la Fundación para la investigación del Hospital Clínico Universitario de Valencia-Instituto de investigación Sanitaria INCLIVA.
Total budget: €20,000
Funded Period: May 2024 - October 2025

Title: Pharmacological Screening in Drosophila and Cellular Models of Hereditary Spastic Paraplegia 7 (PharmaFlyHSP7). Ref: AS-SOASL-HSP_2025_Navarro
Principal Investigator: Juan Antonio Navarro Langa
Funding agency: The French Foundation For Rare Diseases and the Association Strümpell-Lorrain HSP-France
Total budget: €25,000
Funded Period: January 2025 - December 2026.

Title: Evaluación de Betalactámicos en SCA3.
Principal Investigator: Juan Antonio Navarro Langa
Funding agency: Federación Española de Ataxias (FEDAES)
Total budget: €6,000
Funded Period: 31/03/2025-31/03/2026.
Title: Estudio Preclínico de Reposicionamiento de Antibióticos Beta-Lactámicos para el Tratamiento de Poliglutaminopatías. Ref: PI25/01317
Principal Investigator: Juan Antonio Navarro Langa
Funding agency: Instituto de Salud Carlos III

Total budget: €271,250.00
Funded Period: January 2026 - December 2028.

Title: Análisis de Precisión de la función mitocondrial en modelos celulares y de Drosophila de Enfermedades del Cerebelo. MitoBrain. Referencia 2025-034.
Principal Investigator: Juan Antonio Navarro Langa
Funding agency: Programa VLC Bioclinic 2025. Universitat de València y la Fundación para la investigación del Hospital Clínico Universitario de Valencia-Instituto de investigación Sanitaria INCLIVA.
Total budget: €15,000
Funded Period: May 2026 - October 2027.

Reference: PLEC2022-009367
Title: Nuevas herramientas en moscas y cultivos en 3D para el desarrollo de oligonucleótidos terapéuticos.
Principal Investigator: Arturo López Castel
Funding Body: Ministerio de Ciencia e Innovación
Beneficiary Institution: Universidad de Valencia
Duration: 2022-2025
Total Budget: €250,000

Title: Generación y caracterización de modelos celulares en CANVAS
Principal Investigator: Arturo López Castel
Funding Body: Convocatoria VLC Bioclinic
Beneficiary Institution: Universidad de Valencia
Duration: 2024-2025
Total Budget: €5,000

Reference: PID2021-125978OB-C22
Proyectos de Generación de Conocimiento.
Title: Comprensión de la atrofia muscular inducida por TNPO3 mutante: modelos preclínicos y aproximaciones terapéuticas en LGMDD2
Principal Investigator: Rubén Artero
Funding Body: Ministerio de Ciencia e Innovación
Beneficiary Institution: Universidad de Valencia
Duration: 2022-2025
Total Budget: €242,000

- PUBLICATIONS**
- Editorial: Molecular and cellular pathways leading to mitochondrial dysfunction and neurodegeneration: lessons from in vivo models, volume II. Hannan SB, De Lazzari F, Gomez Duran A, Navarro JA, Brea Calvo G, Sanchez Martinez A. Frontiers in Neuroscience. 2025 january 29. 191557013-1557013. DOI: 10.3389/fnins.2025.1557013. PMID:39944887.
 - Moreno N, Sabater-Arcis M, Espinosa-Espinosa J, Mulet-Rivero L, García-España E, González-García J, Seoane-Miraz D, Wood MJA, Varela MA, Ohana J, Sevilla T, Perez Alonso M, Bargiela A, Artero R. miR-107 represses DMPK and is sequestered by CUG repeats triggering the MSI2/miR-7 pathogenesis axis in myotonic dystrophy. Mol Ther Nucleic Acids. 2025 Jun 4;36(3):102584. DOI: 10.1016/j.omtn.2025.102584. PMID: 40599975; PMCID: PMC12212150.

4.4.6. Biostatistics Unit

TEAM
Coordinator
Juan Antonio Carbonell Asins. INCLIVA

Technician
Carlos Peña de los Santos. INCLIVA

The Biostatistics Unit is a core facility created in 2022. Its main role is collaborating in different research projects, providing statistical advice and support to researchers in the design, workflow implementation, and development of their research projects.

FUNCTIONS
Our mission is to drive, promote and carry out quality clinical and translational research through methodological and analytical support.

EQUIPMENT
INCLIVA has a computing facility with 100 cores, 400GB of RAM memory 80TB of redundant network storage and 20TB of solid state storage for high I/O processes such as those applied to omics data analysis.

- SERVICES**
- Design of clinical and epidemiological studies
 - Sample size estimation
 - Simulation techniques
 - Supervised and unsupervised analysis techniques
 - Predictive modelling
 - Advice and methodological support to write protocols, research project proposals, articles, doctoral/MSc/BSc thesis
 - Data mining and exploratory analysis of databases
 - Graphical representation of research results
 - Database curation and analysis
 - Consulting

RESEARCH PROJECTS AND GRANTS FOR RESEARCH
Reference: 101095359 - AIDA
Title: An Artificially Intelligent Diagnostic Assistant for gastric inflammation. AIDA
Principal Investigator: Tania Fleitas Kanonnikoff
Funding Body: European Commission
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2026
Total budget: €6,334,803.75 (INCLIVA: €1.138.750)

Title: *Impacto pronóstico y predictivo del microbioma y el microambiente inmune tumoral en el cáncer gástrico avanzado en pacientes jóvenes (menores de 50 años): proyecto VERO-2"*
Principal Investigator: Tania Fleitas Kanonnikoff
Funding Body: *GILEAD*
Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*
Duration: 2023-2026
Total budget: €50,000

Title: Validación clínica de la cirugía bariátrica como tratamiento de la obesidad mórbida en la disfunción neurológica asociada a la enfermedad hepática metabólica e implementación de una estrategia multimodal de precisión para la identificación de perfiles de respuesta terapéutica (NeurObes)

Principal Investigator: María Pilar Ballester Ferré

Funding Body: VLC-BIOCLINIC. Fundacion Investigacion Hospital Clínico Valencia. Universidad De Valencia

Duration: 2024-2025

Total budget: €10,000

Reference: 101057547 - MELIORA

Title: Meaningful Engagement for Life Improvement with Oncology Research Activities

Principal Investigator: Cristina Hernando (INCLIVA)

Funding Body: European Commission — Horizon Europe

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: 2022-2026

Total budget: €5,857,735

Title: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer stage II-III (CIRCULATE-SPAIN)

Principal Investigator: Noelia Tarazona Llaveró (INCLIVA)

Funding Body: Instituto de Salud Carlos III (ISCIII)

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana

Duration: Ongoing (desde 2021)

Total budget: €1,000,000

Title: EGFR Ligand-Based Patients Hyperselection in Neoadjuvant Therapy: Transforming Treatment Strategies for Localized Colon Cancer through PAVAN-Spain clinical trial

Principal Investigator: Clara Montagut Viladot (Hospital del Mar Research Institute, Barcelona)

Funding Body: AECC — Fundación Científica Asociación Española Contra el Cáncer

PUBLICATIONS

- Current evidence on powered versus manual circular staplers in colorectal surgery: a systematic review and meta-analysis. Martin J, Moro D, Pérez L, López F, Peña CJ, Asins J, Rodrigo DC et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2025 january 15. 40 (1):13-13. DOI:10.1007/s00384-025-04807-y. PMID:39814974.
- Risk of developing neuroblastoma influenced by maternal stressful life events during pregnancy and congenital pathologies. Benavent N, Cañete A, Moreno L, Gros L, Verdú J, Salinas JA, Navarro S et al. PEDIATRIC BLOOD & CANCER. 2025 february 01. 72 (2):DOI:10.1002/pbc.31402. PMID:39618320.
- Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids. Papaccio F, Cabeza M, García B, Gimeno F, Zúñiga S, Gambardella V, Gutiérrez MF et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2025 february 28. 44 (1):77-77. DOI:10.1186/s13046-025-03308-8. PMID:40022181.
- Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Martínez B, Cambor DG, Martín J, Carbonell JA, García B, Gambardella V, Huerta M et al. ANNALS OF ONCOLOGY. 2025 march 01. 36 (3):263-276. DOI:10.1016/j.annonc.2024.12.006. PMID:39675560.
- Frequency and Distribution of KIR Genotypes of Donors-Recipient Pairs in the Haploidentical Haematopoietic Stem Cell Transplantation Setting: Collaborative Study by the Spanish Working Group in Histocompatibility and Transplant Immunology (GETHIT) and the Spanish Haematopoietic Transplantation and Cell Therapy Group (GETH-TC). Luis M, Planelles D, Piñana JL, Carbonell J, Amat P, Gómez I, Guerreiro M et al. HLA. 2025 may 01. 105 (5). DOI:10.1111/tan.70248. PMID:40396700.
- Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence. van TS, Cabeza M, Ferreira RM, Martínez C, Barros R, Santos J, Costa A et al. BRITISH JOURNAL OF CANCER. 2025 may 18. 132 (9):783-792. DOI:10.1038/s41416-025-02979-6. PMID:40113862.

- Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Martín J, Gimeno F, Henriksen TV, García B, Martínez B, Gambardella V, Martínez C et al. Nature Cancer. 2025 june 01. 6 (6):1000-1016. DOI:10.1038/s43018-025-00960-z. PMID:40301653.
- Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women. Garrido I, Tapia M, Carbonell J, Pena C, Torres S, Agreda A, Lameirinhas A et al. Cancer Communications. 2025 july 01. 45 (7):789-793. DOI:10.1002/cac2.70019. PMID:40207642.
- A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer. Prieto C, Carbonell JA, Bueno A, Gómez A, Busto M, Alcolado AB, Jimenez A et al. ESMO Open. 2025 august 01. 10 (8):105495-105495. DOI:10.1016/j.esmoop.2025.105495. PMID:40674919.
- Community-Acquired Respiratory Virus Infections: A Threat to Long-Term Survivors After Allogeneic Stem Cell Transplant?. Piñana JL, Carbonell JA, Gómez D, Montoro J, Pérez A, Hernani R, Chorão P et al. CLINICAL INFECTIOUS DISEASES. 2025 september 15. 81 (3):570-580. DOI:10.1093/cid/ciae602. PMID:39657017.
- Comparing the effectiveness of prophylactic strategies for parastomal hernia prevention: a network meta-analysis. Martin Arevalo J, López Callejon VA, Moro Valdezate D, Perez Santiago L, López Mozos F, Asins JAC, Rodrigo DC et al. Techniques in Coloproctology. 2025 september 25. 29 (1):169-169. DOI:10.1007/s10151-025-03211-6. PMID:40996571.
- Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium. Carbonell JA, Jiménez E, Romero S, García E, Miralles A, Lopez B, Huerta M et al. JOURNAL OF CANCER EDUCATION. 2025 october 01. 40 (5):804-811. DOI:10.1007/s13187-025-02578-2. PMID:39939517.
- Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations. Seguí V, Carbonell JA, Martín J, García M, Grimalt N, Martinez C, Gonzalez JF et al. ESMO Open. 2025 october 01. 10 (10):105771-105771. DOI:10.1016/j.esmoop.2025.105771. PMID:40997747.
- Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer. Bruixola G, Martín J, Gimeno F, Carbonell JA, García B, Martínez B, González D et al. ESMO Open. 2025 december 01. 10 (12):105904-105904. DOI:10.1016/j.esmoop.2025.105904. PMID:41270698.

4.4.7. Bioinformatics Unit

TEAM

Coordinator

Sheila M. Zúñiga Trejos. INCLIVA

Technicians

María Guaita Céspedes. INCLIVA

The unit is focused mainly on collaboration on various research projects, providing advice and support to researchers in design, implementation of workflows, computational strategy development and data analysis.

FUNCTIONS

The Bioinformatics Unit is a biomedical research support platform that provides specialized services in omics data analysis and bioinformatics, including genetic sequencing, exome analysis, RNASeq, metagenomics, and methylation studies, as well as scientific software development and methodological consulting. Its main role is to provide computational, analytical, and technological support to researchers and companies to advance translational research and personalized medicine projects using high-performance infrastructures and advanced biomedical data analysis tools.

EQUIPMENT

INCLIVA has its own Data Processing Centre (DPC) housing different servers with a total capacity of 350 CPUs, 700 execution threads, 6.5 TB of ECC RAM, ~350 TB of redundant HDD storage, 20 TB of solid-state storage (SSD) and more than 600 TB of secondary storage for backups. In addition, the DPC has servers with CUDA parallelized computing capabilities supported by two Nvidia A40 GPUs.

SERVICES

Our mission is to provide specialized services in biomedical and omics data analysis and management to support translational research and personalized medicine projects. These services include design and analysis of genetic panels based on next-generation sequencing (NGS), exome analysis, RNASeq and single-cell analysis, metagenomics, methylation studies, and small RNA analysis. The unit also offers integration and visualization of complex data, data mining, database curation, custom scientific software development, graphical representation of results, as well as methodological support, training, and consulting for scientific projects, publications, and theses. In addition, it provides high-performance computational infrastructure for advanced processing of biomedical data.

LOCATION

INCLIVA, Menéndez y Pelayo, 3. Valencia.

RESEARCH PROJECTS

Title: PDI – IMPaCT Digital Platform for the capture, integration, and modeling of biomedical data associated with the IMPaCT Cohort and IMPaCT-PMP projects.

Beneficiario: Sheila Zúñiga Trejos

Funding Body: Instituto de Salud Carlos III

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA)

Duration: 2025-2026

Total budget: €42,000

The unit has supported the following projects

Title: Identification of Progenitor Cells in Human Endometrial Tissue. CIAICO/2022/242.

Beneficiario: Felip Vilella i Mitjana

Funding Body: CONSELLERIA EDUCACION/INNOVACION, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO. Subvenciones para grupos de investigación consolidables 2023 (AICO 2023)

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA)

Title: Development and characterisation of novel cellular preclinical models for personalised medicine in psychosis. PI22/01985.

Beneficiario: Olga Rivero Martín

Funding Body: Instituto de Salud Carlos III

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA)

Title: Integrated analysis using artificial intelligence of dermoscopic and histopathological images combined with genetic and epigenetic sequencing for an accurate prognosis of patients with melanoma. PI23/01408.

Beneficiario: José María Martín Hernández

Funding Body: Instituto de Salud Carlos III

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA)

Title: Tumor heterogeneity inferred through single-cell sequencing: new therapeutic approaches for uterine tumors. PI23/00536.

Beneficiario: Aymara Mas Perucho

Funding Body: Instituto de Salud Carlos III.

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA)

Title: Genetic and epigenetic biomarkers in postmenopausal osteoporosis. PID2022-137515OB-I00

Beneficiario: Miguel Ángel García Pérez

Funding Body: Agencia Estatal de Investigación - Ministerio de Ciencia, Innovación y Universidades

Beneficiary Institution: Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA)

PUBLICATIONS

- Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids. Papaccio F, Cabeza M, García B, Gimeno F, Zúñiga S, Gambardella V, Gutiérrez MF et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2025 february 28. 44 (1):77-77. DOI:10.1186/s13046-025-03308-8. PMID:40022181.

4.4.8. Body Composition Unit

TEAM

Coordinator

Miguel Civera Andrés. HOSPITAL

Technicians

Blanca Alabadí Pardiñes. INCLIVA

Ning Yun Wu Xiong. HOSPITAL

The activities carried out by the Body Composition Unit have gained particular importance in recent years due to their close relationship with the development, morbidity, and mortality of various high-prevalence pathologies in our healthcare system. Assessment of body composition and morphofunctionality provides a more comprehensive view of an individual's health status and allows for improved tailoring of interventions or medical treatments.

FUNCTIONS

The unit offers researchers access to various techniques such as Total Body Densitometry, Bone Densitometry, Multifrequency Bioimpedance, Single-Frequency Bioimpedance, Nutritional Ultrasound, and Dual-Energy X-ray Absorptiometry (DEXA) used to diagnose of conditions such as malnutrition, obesity, sarcopenia, sarcopenic obesity, frailty, and osteoporosis/osteopenia.

EQUIPMENT

- Hologic Horizon Wi Densitometer
- INBODY 770 Multifrequency Bioelectrical Impedance Analyzer
- Akern NutriLab® Single-Frequency Bioelectrical Impedance Analyzer
- Mindray Z50 Ultrasound Machine
- Jamar® Hydraulic Hand Dynamometer

SERVICES

- Osteoporosis diagnosis through hip and spine bone densitometry.
- Sarcopenia diagnosis using hand dynamometry, functional testing, and total body densitometry to assess muscle mass.
- Sarcopenia diagnosis using hand dynamometry, functional testing, and multifrequency/single frequency bioimpedance for muscle mass evaluation.
- Estimation of skeletal muscle morphofunctional parameters using nutritional ultrasound.
- Comprehensive assessment of body composition and muscular morphofunctionality (total body densitometry, bioimpedance, nutritional ultrasound, and functional tests).

RESEARCH PROJECTS

Reference: INNEST/2024/409

Title: Desarrollo de una metodología avanzada para evaluación morfofuncional integral en paciente obeso.

Principal Investigator: Miguel Cierva Andrés

Funding Body: *Agencia Valenciana de Innovación*

Beneficiary Institution: *Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana*

Duration: 2024-2026

Total budget: €144,764.61

PUBLICATIONS

- Medical Nutrition Therapy and Physical Exercise for Acute and Chronic Hyperglycemic Patients with Sarcopenia. Abad A, Veses S, Pla M, Civera M, García K, Sánchez C, Artero A et al. Nutrients. 2025 february 01. 17 (3). DOI:10.3390/nu17030499. PMID:39940355.
- Accuracy of the “Timed Up and Go” Test for Predicting Low Muscle Mass in a xq Prehabilitation Program for Colorectal Cancer. Pérez L, Garzón LP, Martín J, Pla V, Moro D, Casado D, Riera M et al. Journal of Clinical Medicine. 2025 march 19. 14 (6). DOI:10.3390/jcm14062088. PMID:40142896.
- Assessment of Muscle-Specific Strength in Oncology Patients: Anthropometry as a Reliable Alternative to DXA. Alabadi B, Amores S, Moriana M, Wu NY, García K, Pedrón JA, Monrós C et al. Life-Basel. 2025 august 15. 15 (8). DOI:10.3390/life15081300. PMID:40868947.
- The Influence of Muscle Morphology on Oncological Outcomes: A Review. Bastijns S, Alabadi B, Barbosa TG, Beaudart C, Brockhattingen K, Lamers S, Piotrowicz K et al. Journal Of Frailty, Sarcopenia And Falls. 2025 september 01. 10 (3):163-199. DOI:10.22540/JFSF-10-163. PMID:40901339.
- Increased CX3CL1/CX3CR1 Axis Is Related to Atherosclerosis in Subjects with Familial Combined Hyperlipidaemia, Which Is Modulated by Insulin Resistance but Not by Sex. Jiménez E, Espinosa C, Alabadi B, Hurtado G, Enrique A, Martín S, Casas V et al. Biomedicines. 2025 september 28. 13 (10). DOI:10.3390/biomedicines13102378. PMID:41153665.

4.4.9. Analytical Liquid Chromatography Unit

TEAM

Coordinator
Nuria Cabedo Escrig. UV

Technician
Laura Vila Dasí. INCLIVA

The mission of the Analytical Liquid Chromatography platform is to provide services and support to public and private entities in the Clinical, Pharmaceutical, Agrochemical, or Food sectors. The platform's services are available to personnel both from the INCLIVA Foundation and from other public and private institutions.

FUNCTIONS

The unit staff have over 15 years of experience in various chromatographic techniques, as well as in identifying and quantifying metabolites. The team includes highly specialized personnel proficient in both laboratory sample preparation techniques and sample analysis.

EQUIPMENT

Ultra-High Performance Liquid Chromatography system (UHPLC, Nerexa model, Shimadzu) coupled with a triple quadrupole mass spectrometry detector (LCMS-8040 model, Shimadzu).

SERVICES

- Sample preparation and extraction.
- Identification and/or quantification of selected organic compounds (targeted) (analytes, MW: 50 – 2,000 Da) in complex samples using UHPLC–MS/MS, including:
 - Natural or synthetic products (flavonoids, steroids, fatty acids, alkaloids, etc.)
 - Drugs and/or their structural derivatives
 - Drugs of abuse and narcotics
 - Insecticides or herbicides
 - Biomarkers
- Data analysis of samples examined by Ultra-High Performance Liquid Chromatography coupled with Tandem Mass Spectrometry (UHPLC–MS/MS)
- Consulting for projects based on UHPLC–MS/MS

RESEARCH PROJECTS

Title: Development of new multitarget modulators of nuclear receptors and lipid biomarkers for the treatment of metabolic syndrome and associated comorbidities (PI21/02045).

Principal Investigator: Nuria Cabedo.
Funding Body: Instituto de Salud Carlos III.
Beneficiary Institution: INCLIVA.
Duration: 01/01/2022-31/12/2025
Total Budget: €144,000

Title: Development of PPAR modulators in the regulation of energy metabolism and their impact on cell proliferation (CIAICO/2024/321).
Principal Investigator: Nuria Cabedo y Pilar Eroles
Funding Body: Generalitat Valenciana
Beneficiary Institution: INCLIVA.
Duration: 01/09/2025-31/08/2028
Total Budget: €90,000

The unit has supported the following projects

Title: Evaluación del potencial papel terapéutico de la inhibición de RANK en modelos optimizados de dolor e infertilidad asociados a endometriosis (PI20/01835).
Principal Investigator: Raúl Gómez.
Funding Body: Instituto de Salud Carlos III.
Beneficiary Institution: INCLIVA.
Duration: 01/01/2022-31/12/2025
Total Budget: €98,010

Title: Identificación de nuevas dianas terapéuticas y mecanismos de la modulación de la inflamación en las enfermedades metabólicas (PI22/00062).
Principal Investigator: Herminia González y Sergio Martínez.
Funding Body: Instituto de Salud Carlos III.
Beneficiary Institution: INCLIVA.
Duration: 01/01/2023-31/12/2025
Total Budget: €147,620

PUBLICATIONS

- Development of 2-and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome. Villarroel C, Martínez M, García A, Vila L, Zibar K, Schiel MA, Hennuyer N et al. BIOORGANIC CHEMISTRY. 2025 june 15. 160108450-108450. DOI:10.1016/j.bioorg.2025.108450. PMID:40215945.
- Synthesis of 2-(3-aminopropyl)benzopyrans as potential antipsychotic agents targeting D2/D3 and 5-HT2A receptors. Bernabeu Á, Varela MJ, García A, Villarroel C, Vila L, Loza MI, Brea J et al. BIOORGANIC & MEDICINAL CHEMISTRY. 2025 november 01. 129118300-118300. DOI:10.1016/j.bmc.2025.118300. PMID:40633512.
- *N*-Tosyl hydrazone benzopyran, a new ligand of PPAR α obtained from mapping the conformational space of its active site. Schiel A, Tosso RD, Angelina E, Garcia A, Hennuyer N, Cortes D, Cabedo N, Enriz RD. JOURNAL OF CHEMICAL INFORMATION AND MODELING 2025, 65, 298–311. DOI: 10.1021/acs.jcim.4c01887. PMID: 39720903

4.4.10. Mass Spectrometry Unit

TEAM

Coordinator

José Luis García Giménez. UV
Javier Hernández Gil. INCLIVA

The Mass Spectrometry Unit is a core facility created in 2024. The unit is a cross-disciplinary platform supporting research, offering a portfolio of services accessible to any researcher. Its mission is to drive, promote, and conduct high-quality translational research by providing support in pharmacology, clinical studies, and proteomics.

FUNCTIONS

The Unit provides mass spectrometry-based methodologies with a high capacity to identify and quantify with high precision and sensitivity a wide variety of molecules, even at extremely low concentrations (sub-femtomol). Its high specificity allows differentiation of structurally similar compounds, while its multiplexing capability facilitates the simultaneous analysis of multiple analytes in a single injection.

EQUIPMENT

Hybrid LC-MS3 Mass Spectrometry System with Triple Quadrupole and Linear Ion Trap QTrap 6500+.
High-precision M5 MicroLC Sciex Micro-Liquid Chromatography System.
State-of-the-art data acquisition and processing system: SciexOS.
Open-source software for reviewing quantification results with a unified interface for calibration curves, quantification data, and spectra for peak reintegration, with support for time-scheduled MRM (Skyline).
Redundant data storage system.

SERVICES

- Methodological advice and support in writing protocols, research projects, articles, undergraduate/master’s theses, and doctoral dissertations.
- Enzymatic digestion of samples from various biological matrices.
- Sample preparation for LC-MS using SPE purification.
- Protein characterization via LC-MS peptide fingerprinting: MRM.
- Protein identification via LC-MS peptide fingerprinting: DDA.
- Data analysis using quantification software (Skyline and SciexOS).
- On-demand training in sample preparation protocols for both proteins and small molecules.
- Mass spectrometry-based project consulting.

RESEARCH PROJECTS

Code: DTS24/00094
Title: Proteómica cuantitativa por espectrometría de masas para la identificación temprana de biomarcadores predictivos de eventos adversos en el síndrome coronario agudo.
Funding Body: Programa de Desarrollo Tecnológico en Salud.
Principal Investigator: José LUIS Garcia Giménez.
Beneficiary Institution: Instituto de Investigación Sanitaria INCLIVA.
Duration: 01/01/2025- 31/12/2026.

Code: PI22/00481
Title: Hacia la comprensión de la heterogeneidad de la sepsis. Pronóstico a corto y largo plazo mediante epigenómica, proteómica e inteligencia artificial.

Funding Body: Ministerio de Ciencia e Innovación.
Beneficiary Institution: Instituto de Investigación Sanitaria INCLIVA.
Duration: 01/01/2023- 31/12/2025.
Total Budget: €183,920

Code: CIAICO/2023/168
Grupo de investigación en fisiopatología y biomarcadores de la sepsis.
Funding Body: Consellería de Educación, Cultura, Universidades y Empleo.
Principal Investigator: José Luis García Giménez y Salvador Mena Mollá
Beneficiary Institution: INCLIVA.
Duration: 01/11/2024- 31/08/2027.
Total Budget: €89,700

Code: CIAPOT/2024/019
Contractació de personal de suport vinculat a un projecte de transferència tecnològica (APOTI/2025).
Principal Investigator: José Luis García Giménez
Duration: 01/07/2025-30/06/2027
Total Budget: €36,000.00

PUBLICATIONS

- Role of miRNAs as epigenetic regulators of immune checkpoints in lung cancer immunity. Cánovas I, Nacher E, Suay G, Lahoz A, García JL, Mena S. International Review of Cell and Molecular Biology. 2025 january 01. 390109-139. DOI:10.1016/bs.ircmb.2024.08.002. PMID:39864893.
- Epigenome-wide DNA methylation profiling in septic and non-septic patients with similar infections: potential use as sepsis biomarkers. López I, García JL, Madrazo M, García J, Piles L, Pallardó FV, Artero A. Frontiers in Cellular and Infection Microbiology. 2025 january 24. 141532417-1532417. DOI:10.3389/fcimb.2024.1532417. PMID:39926115.
- A Sex-Specific Minimal CpG-Based Model for Biological Aging Using ELOVL2 Methylation Analysis. Ibáñez JS, Sandoval J, Pallardó FV, García JL, Mena S. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 april 04. 26 (7):DOI:10.3390/ijms26073392. PMID:40244262.
- Oxidative stress and central metabolism pathways impact epigenetic modulation in inflammation and immune response. García Giménez JL, Cánovas Cervera I, Nacher Sendra E, Dolz Andrés E, Sánchez Bernabéu A, Agúndez AB, Hernández Gil J et al. FREE RADICAL BIOLOGY AND MEDICINE. 2025 june 01. 233378-399. DOI:10.1016/j.freeradbiomed.2025.04.004. PMID:40185167.
- Circulating histones as clinical biomarkers in critically ill conditions. García Gimenez JL, Ruiz Rodríguez JC, Ferrer R, Durá R, Artigas A, Bajaña I, de Andujar DBL et al. FEBS LETTERS. 2025 june 17. 599 (22):3174-3195. DOI:10.1002/1873-3468.70093. PMID:40527588.
- Mapping the Antibiofilm Peptide Space with Similarity Networks and Curated Negative Sets. Castillo K, Marrero Y, Marquez EA, Garcia JL, Antunes A, Agüero G. ACS Omega. 2025 december 02. 10 (49):60457-60476. DOI:10.1021/acsomega.5c07679. PMID:41427215.

4.4.11. Data Science Platform

cienciadedatos@incliva.es

TEAM

Principal Investigator:

Josep Redón i Mas. INCLIVA

Coordinator:

María Inmaculada Saurí Ferrer. INCLIVA

The Data Science Platform is a cross-cutting platform designed to support research, healthcare management, and clinical decision-making using Big Data and Artificial Intelligence (AI). The Platform integrates information from outpatient and hospital care services covering the population of the Valencia Clínico-Malvarrosa Health Department, which serves approximately 350,000 inhabitants. Through predictive analytics techniques, AI models, and the development of telemedicine interfaces, the platform helps identify inefficiencies in operational and clinical workflows, optimize healthcare processes, and promote the implementation of 5P Medicine (predictive, preventive, personalized, population-based, and participatory).

The Data Science Platform was created based on the INTEGRA-CLOUD Platform, developed at INCLIVA through funding awarded ad personam by the Spanish Ministry of Economic Affairs and Digital Transformation under the UNICO I+D Cloud Program, within the framework of the European Recovery, Transformation and Resilience Plan in 2023.

FUNCTIONS

The Data Science Platform provides comprehensive support for research and healthcare management projects through scientific and technical consultancy, data protection guidance, and liaison with healthcare authorities. In addition, it enables the advanced processing and analysis of interoperable clinical data, the creation of patient cohorts, and the development of artificial intelligence models. The Platform also promotes collaboration in clinical trials and national and European projects, as well as specialised training and capacity-building activities.

LABORATORY EQUIPMENT

On-site cluster designed for creating a data lake capable of storing and processing data from corporate applications of the Regional Ministry of Health. This infrastructure is connected to the Arterias network (the corporate network of the Regional Ministry of Health). Two high-performance servers, each equipped with:

- Processors: 48 cores / 96 processing threads
- Memory: 2 TB RAM
- SSD storage in RAID1 configuration for the hypervisor and base software
- Each server includes an NVIDIA GPU based on the Ampere A30 architecture, with CUDA and GPU support

This cluster is connected to three storage arrays, each designed to meet different specific requirements:

- SAN storage: 18 TB on NVMe drives, configured as iSCSI volumes, designed to ensure high availability and maximum performance
- NAS storage:
 - High-performance scale-out array: 216 TB combining SSD and HDD drives, with support for secondary storage, NFS, S3, and Data Lake functionalities
 - Conventional array: 95 TB primarily dedicated to backups, providing reliable and optimised storage for backup and recovery tasks

In addition, connected to RedIRIS (the Spanish academic and research network), there are two machines capable of hosting applications and analytical environments external to the Arterias network.

Each machine includes:

- 24 cores / 48 processing threads
- 1.5 TB RAM
- 24 TB HDD storage (RAID6) for moderate-speed volume storage
- 5 TB SSD storage (RAID5) for system disks and high-speed access

LOCATION

- INCLIVA, Menéndez y Pelayo 3. Valencia.

SERVICES

- Scientific and technical consultancy
- Liaison and administrative procedures with Health Authorities
- Data analysis and processing
- Training and capacity-building activities

RESEARCH PROJECTS

Code: TSI-100121-2024-44

Title: Creation of the Valencian Health Data Ecosystem by Integrating the Clínico Malvarrosa, Gandía and Sagunto Health Departments (INTEGRA-DPs).

Duration: 2024 – 2026

Total Budget: €1,048,930.00

Title: Creation of an open platform for the access, capture, storage and decentralised exchange of real-time health data from the Clínico-Malvarrosa Health Department for the cloud-edge computing of predictive systems, decision-making and artificial intelligence. INTEGRA-CLOUD.

Duration: 2023- 2026

Total Budget: €5,252,274.00

PUBLICATIONS

Díaz Carnicero, J.; Saurí-Ferrer, I.; Redón, J.; Navarro, J.; Fernández, G.; Hurtado, C.; Ferreira, K.; Álvarez-Ortega, C.; Gómez, A.; Martos-Rodríguez, Martí-Aguado, D.; Escudero, D.; Cedenilla; M. Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study. *J.Clin. Medicina.* 2025 , 14, 2441. <https://doi.org/10.3390/jcm14072441>



5 | Clinical trials and other studies

5	CLINICAL TRIALS AND OTHER STUDIES
5.1	Drug Research Ethics Committee (CEIm) activity
5.2	Clinical research activity performed by Valencia-Clínico Malvarrosa Health Department
5.2.1	Activity during 2025
5.2.2	Assessment activity during last 5 years
5.2.3	Ongoing studies

5. Clinical trials and other studies

5.1. Activity of the Ethical Committee for investigation with medicinal products (CEIm)

The Ethical Committee for Investigation with Medicinal Products is an independent, multidisciplinary board whose main purpose is to oversee the protection of the rights, safety and well-being of subjects participating in clinical studies and biomedical research projects.


As a result of its activity in 2025, the CEIm has processed a total of 35 studies (clinical trials and observational studies), 34 of which were positively valued.

Of the 34 approved studies, 16 were approved in the first evaluation and 18 after requesting clarification to the promoter.

Of the 21 clinical trials with drugs evaluated, none have been evaluated through the Voluntary Harmonisation Procedure (VHP) process.

The following table shows the number of clinical trials and other studies by typology.

TYPE OF EVALUATED STUDIES	2025
CLINICAL TRIALS WITH MEDICINAL PRODUCTS	21
PHASE 0	0
PHASE I	5
PHASE II	4
PHASE III	10
PHASE IV	2
CLINICAL TRIALS WITH MEDICAL DEVICES	13
CLINICAL TRIALS WITH SUPPLEMENTS	0
OBSERVATIONAL STUDIES WITH MEDICINAL PRODUCTS	1
OBSERVATIONAL STUDIES WITH MEDICAL DEVICES	0
RESEARCH PROJECTS	225
TOTAL	260



The following table shows clinical studies distributed by the department where they are performed:

CLINICAL TRIALS BY DEPARTMENT	Nº
Cardiology	6
Endocrinology and Nutrition	3
Haematology	1
General and Gastrointestinal Surgery	1
Nephrology	3
Neurology	1
Oncology	12
O.R.L	1
Paediatrics	1
Pathological Anatomy	1
Pharmacy	1
Tutelage	2
Urology	2
TOTAL	35

The following table shows research projects stratified by the department where they are performed:

RESEARCH PROJECTS BY DEPARTMENT	Nº
Anaesthesiology and Reanimation	11
Cardiology	26
Dermatology	2
Digestive Medicine	9
Emergencies	5
Endocrinology and Nutrition	4
Pharmacy	1
General Surgery	16
Gynaecology	4
Haematology	6
INCLIVA Research Groups	7
IPSC	2
Intensive Medicine	2
Internal Medicine	17
Maxillofacial surgery	1
Microbiology	5
Pneumology	7
Neurology	3
Nuclear Medicine	1
Nursery	4
Ophthalmology	2

Oncology	21
Orthopaedic and Traumatology Surgery	5
Otorhinolaryngology	3
Pathological Anatomy	2
Paediatrics	12
Primary Care	13
Psychiatry	5
Physiotherapy	1
Radiodiagnostics	2
Rheumatology	1
Urology	3
Others	22
TOTAL	225

Turning to clinical trials, our Drug Research Ethics Committee (CEIm) at the Hospital Clínico Universitario de València, the first in the Valencian Community and among the first nationally to receive this certification, has been a review board of reference in 217 clinical studies since the new legislation was approved in 2016.

5.2. Clinical research activity performed by Valencia-Clínico Malvarrosa Health Department


5.2.1. Activity in 2025

INCLIVA Biomedical Research Institute manages the clinical studies (trials, observational studies, and research projects) carried out by the *Hospital Clínico Universitario de Valencia* and the Valencia Clínico-Malvarrosa Health Department researchers.


In 2025, INCLIVA managed a total of 178 studies (clinical trials and observational studies).

These trials, distributed by phase, are as follows: Phase I: 26; Phase II: 43; Phase III: 60, Phase IV: 5, Observational studies: 36, others: 8. The following table shows the number of clinical trials and other studies according to their phase and department.

	Phase I	Phase II	Phase III	Phase IV	Others	Observational	TOTAL
Oncology	24	24	21	0	1	9	79
Cardiology	0	5	14	0	5	4	28
Haematology	2	3	8	0	0	6	17
Nephrology	0	3	4	1	0	0	10
Infectious disease Unit	0	0	0	0	0	6	6
Neurology	0	0	2	1	0	3	6
Rheumatology	0	1	4	0	0	0	5
Others	0	7	7	3	2	8	27
TOTAL	26	43	60	5	8	36	178



The Department of Medical Oncology leads in the number of trials evaluated in INCLIVA, followed by the departments of Cardiology and Hematology. These three departments make up over 69% of the total processed trials.



Regarding the distribution of studies per sponsor, 21 trials are considered as Independent Clinical Research (trials from associations, groups, foundations, and private individuals), two of which have been promoted by researchers from the *Hospital Clínico Universitario de Valencia* and INCLIVA and the rest promoted by the pharmaceutical industry.


PROMOTOR	Nº
HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA RESEARCHERS AND INCLIVA	2
INDEPENDENT CLINICAL RESEARCH	19
COMMERCIAL RESEARCH	157

5.2.2. Research assessment activity during the last 5 years

The table below shows the number of studies processed yearly.


Year	Processed studies
2021	211
2022	105
2023	175
2024	189
2025	178

One of INCLIVA's main goals is to develop clinical research at its early stages, thus contributing to translational research that moves scientific knowledge from bench to bedside. During the period 2021-2025, Phase I and Phase II trials were prioritised and their numbers remain stable, as shown in the table and graph below.




PHASE	2021	2022	2023	2024	2025
Phase I	24	15	19	26	26
Phase II	56	41	49	42	43
Phase III	67	31	65	75	60
Phase IV	3	2	4	4	5
Observational	57	4	36	35	36
Others	4	12	2	7	8

Evolution of Clinical Studies distribution by phase




5.2.3. Ongoing studies

A total of 465 studies were active during 2025. The distribution of clinical trials per department analysed below uses a semilogarithmic scale due to the great difference between the Department of Medical Oncology and the remaining departments.



Ongoing trials and other studies are distributed by typology as follows:

Other	12
Observational	106
Phase IV	18
Phase III	171
Phase II	96
Phase I	62



6 | Initiatives for research promotion



6 INITIATIVES FOR RESEARCH PROMOTION

- 6.1 Grants for external fellowships, Trainee students, Outgoing and Incoming Internships and new initiatives
- 6.2 Training and teaching activities

6. Research promotion initiatives

6.1. Grants for external fellowships, trainee students, out-going and incoming internships and new initiatives

To give researchers the opportunity to acquire new knowledge for clinical and research techniques, every year INCLIVA provides sponsorship grants for research internships (Training Stay Grants) at centres of excellence. In 2025 we awarded 18 grants.

List of beneficiaries and destination centres of the INCLIVA Training Stays Grants during 2025:

- Ana Mª Agreda Roca -Department of Immunology, Genetics and Pathology, Uppsala University (SWEDEN).
- Carlos Bea Serrano - Institute of Tropical Medicine, Antwerp (BELGIUM).
- Manuel Cabeza Segura -i3S, Instituto de Investigação e Inovação em Saúde. Porto (PORTUGAL).
- Francisco Calleja Casado- Royal Victorian Eye and Ear Hospital. Melbourne (AUSTRALIA).
- Mª Cristina Carbajo García- University of Geneva (SWITZERLAND).
- Arnau Devís Peiró- Royal Melbourne Hospital ICU (AUSTRIA).
- Arturo González Vilanova – Imperial College London. London (UNITED KINGDOM).
- Francisco Lara Hernández- Instituto Murciano de Investigación Biosanitaria Pascual Parrilla. El Palmar-Murcia (SPAIN).
- Alexandre Llorens Trujillo- École Supérieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris) (FRANCE).
- Belén Martínez Castedo -Cancer Center Clínica Universidad de Navarra, Pamplona- Navarra (SPAIN).
- Almudena Núñez Fernández-Shaw -McGill University- Quebec (CANADA).
- Elena Ortiz Zapater - King ´s College London. London (UNITED KINGDOM).
- Laura Ramos Monsoriu- Instituto de Psicoanálisis Multifamiliar en el Centro de Día DITEM. Buenos Aires (ARGENTINA).
- Geraldine Rocha Correal - Charite Universitatkllinikum Berlin (GERMANY).
- Nekane Romero García -Hospital Sant Joan de Deu y Hospital Clínic de Barcelona (SPAIN).
- Claudia Ana Sánchez -Hospital General de Niños Pedro de Elizalde- Buenos Aires (ARGENTINA).
- Silvana Javiera Soto Rodríguez -Centro Nacional de Investigaciones Cardiovasculares (CNIC). Madrid (SPAIN).
- Noelia Tarazona Llaveró -Massachusetts General Hospital / Harvard Medical School (EEUU).

OUTGOING INTERNSHIPS

The following table lists researchers from our INCLIVA who carried out external training stays in national or foreign centres during in 2025:

- Celeste Moya Valera -Instituto Tecnológico de Informática (ITI) – Universidad Politécnica de Valencia (UPV). (SPAIN).
- Gema Hurtado Genovés - Gulbenkian Institute for Molecular Medicine (GIMM). Lisboa (PORTUGAL).
- Paula Izquierdo Altarejos- University of Innsbruck (AUSTRIA).
- Daniel González Camblor- Instituto de Investigación contra la Leucemia Josep Carreras- Badalona- Barcelona (SPAIN).
- Olga Rivero Martín- Instituto de Investigación Biomédica de Bellvitge (IDIBELL). L' Hospitalet de Llobregat –Barcelona (SPAIN).
- Ricardo Ruiz Miguel- Instituto de Investigación Biomédica de Bellvitge (IDIBELL). L' Hospitalet de Llobregat –Barcelona (SPAIN).

INCOMING INTERNSHIPS

Incoming researchers in 2025 are shown in the following table:

- Adriana-Estefa Muñoz-Groza - Fellowships within the ICF and ESMO Fellowship Programme - Hospital Clinico de Urgencias de Craiova, Universidad de Medicina de Craiova - ROMANIA - Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST and Breast Cancer Biology Research Group.
- Alexandru Marius Furau - Fellowships within the ICF and ESMO Fellowship Programme - Arad County Clinical Hospital - ROMANIA - Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumours - InDeST.
- Irina -Alexandra Chirea - Fellowships within the ICF and ESMO Fellowship Programme-Institute of Oncology “Prof. Dr. Aleaxndru Trestioreanu”, Bucharest - ROMANIA - Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST.
- Nika de Wilde - Hospital Universitario de Gante (BELGIUM) - Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST.
- Begoña Pla Peris Hospital General Universitario de Castellón (SPAIN) - Research Group on Cardiometabolic Risk and Diabetes.

TRAINEE STUDENTS

The following table lists the number of Vocational Qualification, Bachelor and Master’s degree students who were accepted and carried out training practices in different research groups in INCLIVA in 2025:

- 24 Bachelor degree students at the University of Valencia (including TFD students).
- 15 Bachelor degree students at the Polytechnic University of Valencia (including TFD students).
- 13 Master’s degree students at the University of Valencia (including TFM students).
- 4 Master’s degree students at the Polytechnic University of Valencia (including TFM students).
- 2 Bachelor degree students from other universities (including TFD students).
- 19 Master’s degree students from other universities (including TFM students).
- 42 Higher Vocational Qualification students of public and/or private centres in the Valencian Community (including double Vocational Qualification students).

Final Year Project (TFD) and Master’s Thesis (TFM)

In 2025, no call for TFD and TFM tutoring was published. TFD and TFM students were accepted, but outside the call for applications. A list of available positions was published on our website, but not as part of a call for applications.

6.2 Training and teaching activities
COURSES

Title: Programa de excelencia y actualización en el manejo multidisciplinar de la dislipemia en la enfermedad vascular aterosclerótica y fibrilación auricular en el paciente mayor. Foco en nuevas guías de enfermedad arterial periférica, síndrome coronario crónico y fibrilación auricular.

Date: 01/01/2025 - 03/31/2025

Organised by: Bonanad Lozano, Clara

Group Name: Group on Translational Research in Ischemic Heart Disease

Research Area: Cardiovascular

Title: 4ª ed. Curso de estadística básica aplicada a la medicina
Date: 01/21/2025 - 01/30/2025
Organised by: Carbonell Asins, Juan Antonio
Group Name: INCLIVA Management

Title: Programa de Formación para la Unidad de Consejo Genético. Sesión 1: Introducción y Conformación de la Unidad
Date: 01/21/2025 - 01/21/2025
Organised by: Fleitas Kanonnikoff, Tania Carolina
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: 1ª sesión: IC con FEVlp en el paciente mayor de 70 años: caminando hacia la cardiología geriátrica. Complejidad del manejo y de su diagnóstico diferencial. Epidemiología y diagnóstico de la IC
Date: 01/27/2025 - 01/27/2025
Organised by: Bonanad Lozano, Clara
Group Name: Group on Translational Research in Ischemic Heart Disease
Research Area: Cardiovascular

Title: 2º curso de formación continuada en medicina nuclear e imagen molecular: La Medicina Nuclear en el cáncer de próstata.
Date: 01/29/2025 - 01/29/2025
Organised by: Díaz Exposito, Rafael
Group Name: Clinical Associated Group in Nuclear Medicine
Research Area: Clinical Associated Groups

Title: Qué es y cómo se elabora un currículum narrativo
Date: 02/03/2025 - 02/05/2025
Organised by: Llorens Chiralt, Raquel
Group Name: INCLIVA Management

Title: XII workshop internacional de ecografía y resonancia anorrectal
Date: 02/05/2025 - 02/07/2025
Organised by: Garcia Botello, Stephanie
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: 2ª sesión: IC con FEVlp en el paciente mayor de 70 años: caminando hacia la cardiología geriátrica. Complejidad del manejo y de su diagnóstico diferencial. Biomarcadores e Intervencionismo estructural en IC
Date: 02/10/2025 - 02/10/2025
Organised by: Bonanad Lozano, Clara
Group Name: Group on Translational Research in Ischemic Heart Disease
Research Area: Cardiovascular

Title: Curso de Buenas Prácticas Clínicas
Date: 02/10/2025 - 02/13/2025
Organised by: Barajas Cenobio, Soyel Rafael
Group Name: INCLIVA Management

Title: VI Curso de Laparoscopia experimental del Servicio Urología.
Date: 02/10/2025 - 02/11/2025
Organised by: Martínez Jabaloyas, José Mª
Group Name: Clinical Associated Group in Urology
Research Area: Clinical Associated Groups

Title: Programa de Formación para la Unidad de Consejo Genético. Sesión 2: Aspectos Éticos en el Consejo Genético
Date: 02/11/2025 - 02/11/2025
Organised by: Fleitas Kanonnikoff, Tania Carolina
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: Programa formativo en innovación 2025. Sesión 1: Regulación de producto sanitario
Date: 02/12/2025 - 02/12/2025
Organised by: Carrio Argos, Maria Elena
Group Name: INCLIVA Management

Title: Normativa de protección de datos para proyectos de investigación biomédica
Date: 02/18/2025 - 02/25/2025
Organised by: Barajas Cenobio, Soyel Rafael
Group Name: INCLIVA Management

Title: In-Hospital Training: Minimal Invasive Colorectal Surgery
Date: 02/20/2025 - 02/21/2025
Organised by: Pla Martí, Vicente
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: Curso de Inmersión en la técnica Totalmente Extraperitoneal (TEP) para el tratamiento de la hernia inguinal.
Date: 02/24/2025 - 02/24/2025
Organised by: Pou Santonja, Guillermo
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: 2º Curso en Medicina Nuclear e Imagen Molecular: Medicina Nuclear en la hemato oncología.
Date: 02/26/2025 - 02/26/2025
Organised by: Diaz Exposito, Rafael
Group Name: Clinical Associated Group in Nuclear Medicine
Research Area: Clinical Associated Groups

Title: Curso BeArt. 4ªEd: mano
Date: 02/28/2025 - 03/01/2025
Organised by: De la Morena Barrio, Isabel
Group Name: Without Group

Title: Proyecto FORMATE360 2.0
Date: 03/01/2025 - 06/30/2025
Organised by: Martinez Garcia, Fernando
Group Name: Research Group on the Study of Cardiometabolic and Renal Risk
Research Area: Cardiovascular

Title: 3ª sesión: IC con FEVIp en el paciente mayor de 70 años: caminando hacia la cardiología geriátrica. Complejidad del manejo y de su diagnóstico diferencial. iSGLT2 y tratamiento de la insuficiencia cardíaca y síndrome cardio-reno metabólico
Date: 03/03/2025 - 03/03/2025
Organised by: Bonanad Lozano, Clara
Group Name: Group on Translational Research in Ischemic Heart Disease
Research Area: Cardiovascular

Title: Programa Sanofi 2025
Date: 03/05/2025 - 11/30/2025
Organised by: Bonanad Lozano, Clara
Group Name: Group on Translational Research in Ischemic Heart Disease
Research Area: Cardiovascular

Title: EMEA Instructional Course: Building Confidence in Performing Colorectal Surgery
Date: 03/06/2025 - 03/07/2025
Organised by: Pla Martí, Vicente
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: Programa de Formación para la Unidad de Consejo Genético. Sesión 3: Consentimiento Informado y Determinaciones Moleculares
Date: 03/11/2025 - 03/11/2025
Organised by: Fleitas Kanonnikoff, Tania Carolina
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: II Workshop Nasofibrolaringoscopia Cirugia Endocrina
Date: 03/25/2025 - 03/25/2025
Organised by: Cassinello Fernández, Norberto
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: 2º Curso en Medicina Nuclear e Imagen Molecular: Valor del PET-TC en tumores del Sistema Nervioso Central.
Date: 03/26/2025 - 03/26/2025
Organised by: Diaz Exposito, Rafael
Group Name: Clinical Associated Group in Nuclear Medicine
Research Area: Clinical Associated Groups

Title: In-Hospital Training: Building Confidence in performing Colorectal Surgery
Date: 03/26/2025 - 03/27/2025
Organised by: Pla Martí, Vicente
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: Curso de patronaje en técnicas oncoplásticas en el cáncer de mama
Date: 03/28/2025 - 03/25/2025
Organised by: Buch Vila, Elvira
Group Name: Research Group on Breast Cancer Biology
Research Area: Oncology

Title: 4ª sesión: IC con FEVIp en el paciente mayor de 70 años: caminando hacia la cardiología geriátrica. Complejidad del manejo y de su diagnóstico diferencial. Tras todo lo aprendido, visión y experiencia del médico de atención

Date: 03/31/2025 - 03/31/2025
Organised by: Bonanad Lozano, Clara
Group Name: Group on Translational Research in Ischemic Heart Disease
Research Area: Cardiovascular

Title: Fase III: Programa de formación progresiva en cirugía laparoscópica colorrectal
Date: 04/01/2025 - 12/31/2025
Organised by: Pla Martí, Vicente
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: Debates y nuevos avances en nefropatía diabética y síndrome cardiorrenal
Date: 04/08/2025 - 04/10/2025
Organised by: Górriz Teruel, Jose Luis
Group Name: Research Group on Renal Disease
Research Area: Cardiovascular

Title: Curso de Protección de Datos para personal de laboratorios y ensayos clínicos
Date: 04/08/2025 - 04/08/2025
Organised by: Barajas Cenobio, Soyel Rafael
Group Name: INCLIVA Management

Title: Programa formativo en innovación 2025. Sesión 2: Patentabilidad de invenciones implementadas por ordenador
Date: 04/10/2025 - 04/10/2025
Organised by: Carrio Argos, Maria Elena
Group Name: INCLIVA Management

Title: Programa de Formación para la Unidad de Consejo Genético. Sesión 4: Cáncer de Mama y Ovario Hereditario
Date: 04/15/2025 - 04/15/2025
Organised by: Fleitas Kanonnikoff, Tania Carolina
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: Curso de soporte vital avanzado-ERC
Date: 04/30/2025 - 05/31/2025
Organised by: Florea, Raluca
Group Name: Without Group

Title: Curso: “Guía rápida para la creación de datos abiertos”
Date: 05/05/2025 - 05/06/2025

Organised by: Barajas Cenobio, Soyel Rafael
Group Name: INCLIVA Management

Title: Curso “Inteligencia Artificial y su relación con la Investigación Biomédica”
Date: 05/06/2025 - 05/05/2025
Organised by: Ferragut Gil, Fernando
Group Name: INCLIVA Management

Title: Programa de formación del Servicio de Nefrología
Date: 05/06/2025- 05/07/2025
Organised by: Górriz Teruel, Jose Luis
Group Name: Research Group on Renal Disease
Research Area: Cardiovascular

Title: Programa de Formación para la Unidad de Consejo Genético. Sesión 5: Cáncer Colorrectal Hereditario
Date: 05/13/2025 - 05/13/2025
Organised by: Fleitas Kanonnikoff, Tania Carolina
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: Curso “Inteligencia Artificial como herramienta para el personal de gestión”
Date: 05/13/2025 - 05/15/2025
Organised by: Ferragut Gil, Fernando
Group Name: INCLIVA Management

Title: Curso “Plan de gestión de datos para proyectos de I+D+i (AES/AEI)”
Date: 05/14/2025 - 05/14/2025
Organised by: Barajas Cenobio, Soyel Rafael
Group Name: INCLIVA Management

Title: Curso “Presentaciones orales”
Date: 05/19/2025 - 05/20/2025
Organised by: Fernández Saiz, Patricia
Group Name: INCLIVA Management

Title: 2ª Ed. Preceptorship avanzado de Cáncer Gástrico
Date: 05/26/2025 - 05/27/2025
Organised by: Fleitas Kanonnikoff, Tania Carolina
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: 2º Curso en Medicina Nuclear e Imagen Molecular: Inmunoterapia y PET-TC. Criterios de respuesta metabólica en inmunoterapia.
Date: 05/28/2025 - 05/28/2025
Organised by: Diaz Exposito, Rafael
Group Name: Clinical Associated Group in Nuclear Medicine
Research Area: Clinical Associated Groups

Title: Programa de formación sobre terapia intratecal y el uso de ziconotide en el tratamiento del dolor no oncológico
Date: 06/01/2025 - 12/31/2025
Organised by: Tornero Tornero, Carlos
Group Name: Research Group on Anesthesiology and Reanimation
Research Area: Metabolism and Organic Damage

Title: Curso “Ciencia ciudadana, cocreación e investigación participativa”
Date: 06/04/2025 - 06/27/2025
Organised by: Fernández Saiz, Patricia
Group Name: INCLIVA Management

Title: Programa de Formación para la Unidad de Consejo Genético. Sesión 6: Impacto Psicológico del Cáncer Hereditario
Date: 06/10/2025 - 06/10/2025
Organised by: Fleitas Kanonnikoff, Tania Carolina
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: Debates y nuevos avances en nefropatía diabética y síndrome cardiorrenal
Date: 06/10/2025 - 06/12/2025
Organised by: Górriz Teruel, Jose Luis
Group Name: Research Group on Renal Disease
Research Area: Cardiovascular

Title: XIII workshop internacional de ecografía y resonancia anorrectal
Date: 06/10/2025 - 06/12/2025
Organised by: Garcia Botello, Stephanie
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: Formación hospitalaria en Enfermedad Injerto contra Receptor para personal de SANOFI
Date: 06/16/2025 - 06/20/2025

Organised by: Solano Vercet, Carlos
Group Name: Research Group on Hematopoietic Transplantation
Research Area: Oncology

Title: 2º Curso en Medicina Nuclear e Imagen Molecular: SPECT en cardiología.
Date: 06/18/2025 - 06/18/2025
Organised by: Diaz Exposito, Rafael
Group Name: Clinical Associated Group in Nuclear Medicine
Research Area: Clinical Associated Groups

Title: Hands-on course Anatomy applied to Neurosurge
Date: 06/28/2025 - 07/03/2025
Organised by: Quilis Quesada, Vicent
Group Name: Without Group

Title: Formación en producto Echelon 3000 y Echelon Circular Motorizada y su correcta aplicación en la técnica quirúrgica
Date: 07/02/2025 - 07/03/2025
Organised by: Pla Martí, Vicente
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: Curso “Modelos animales en Investigación Cardiovascular”
Date: 09/11/2025 - 09/11/2025
Organised by: Bodí Peris, Vicent
Group Name: Group on Translational Research in Ischemic Heart Disease
Research Area: Cardiovascular

Title: Curso de Ecografía Abdominal
Date: 09/18/2025 - 09/23/2025
Organised by: Pascual Moreno, Isabel
Group Name: Clinical Associated Group in Digestive Medicine
Research Area: Metabolism and Organic Damage

Title: Programa formativo en innovación 2025. Sesión 3: Guía de nuevas prácticas en innovación participativa y RRI
Date: 09/23/2025 - 09/23/2025
Organised by: Carrio Argos, Maria Elena
Group Name: INCLIVA Management

Title: 2ª ed. Curso de estadística avanzada aplicada a la medicina
Date: 09/23/2025 - 10/02/2025
Organised by: Carbonell Asins, Juan Antonio
Group Name: INCLIVA Management

Title: Programa formativo Servicio de Anestesia (octubre 2025)
Date:10/07/2025 - 10/28/2025
Organised by: Badenes Quiles, Rafael
Group Name: Research Group on Anesthesiology and Reanimation
Research Area: Metabolism and Organic Damage

Title: Curso “ Claves para investigar con éxito”
Date: 10/14/2025 - 11/24/2025
Organised by: Fernández Saiz, Patricia
Group Name: INCLIVA Management

Title: 13º Ed. Curso de anatomía quirúrgica aplicada hepato-bilio-pancreática
Date: 10/23/2025 - 10/23/2025
Organised by: Sabater Ortí, Luis
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: Programa formativo en innovación 2025. Sesión 4: Fortalecimiento de capacidades y aprovechamiento de oportunidades en Compra Pública de Innovación (CPI)
Date: 11/04/2025 - 11/04/2025
Organised by: Carrio Argos, Maria Elena
Group Name: INCLIVA Management

Title: 5ª ed. Curso de estadística básica aplicada a la medicina
Date: 11/04/2025 - 11/13/2025
Organised by: Carbonell Asins, Juan Antonio
Group Name: INCLIVA Management

Title: Curso de CENS básica y avanzada 2025
Date: 11/17/2025 - 11/18/2025
Organised by: Ferrer Baixauli, Felip
Group Name: Without Group

Title: XVIII Curso de anatomía aplicada a las técnicas quirúrgicas y toma de decisiones en coloproctología
Date: 11/19/2025 - 11/21/2025
Organised by: Pla Martí, Vicente
Group Name: Research Group on General and Digestive Surgery
Research Area: Metabolism and Organic Damage

Title: EMEA Instructional Course: Building Confidence in Performing Colorectal Surgery (26th-28th november 2025)
Date: 11/26/2025 - 11/28/2025
Organised by: Pla Martí, Vicente
Group Name: Research Group on General and Digestive Surgery

Research Area: Metabolism and Organic Damage

Title: Técnicas quirúrgicas de Cirugía de mama, con procedimientos en paciente
Date:11/27/2025 - 11/27/2025
Organised by: Buch Vila, Elvira
Group Name: Research Group on Breast Cancer Biology
Research Area: Oncology

Title: II Curso de Rinoplastia secuencial ultrasónica
Date: 11/28/2025 - 11/29/2025
Organised by: Ferrer Baixauli, Felip
Group Name: Without Group

Title: Curso ESD/POEM y Suturas
Date: 12/03/2025 -12/04/2025
Organised by: Peña Aldea, Andrés
Group Name: Clinical Associated Group in Digestive Medicine
Research Area: Metabolism and Organic Damage

Title: Curso “ Redacción de artículos científicos”
Date: 12/09/2025 - 12/16/2025
Organised by: Fernández Saiz, Patricia
Group Name: INCLIVA Management

DISSEMINATION CONFERENCES

Title: Jornada “Nuevas guías de práctica clínica y Highlights del Congreso Europeo de Cardiología”
Date: 01/15/2025 - 01/15/2025
Organised by: Bonanad Lozano, Clara
Group Name: Group on Translational Research in Ischemic Heart Disease
Research Area: Cardiovascular

Title: Jornada sobre genética clínica y Atención Primaria
Date: 01/17/2025 - 01/17/2025
Organised by: Ejarque Doménchec, Ismael
Group Name: Cardiometabolic Research Group on Primary Care
Research Area: Cardiovascular

Title: I Jornada “TERRETA”: Enfermedades por expansión de repeticiones
Date: 03/03/2025 - 03/03/2025
Organised by: González Cabo, Pilar
Group Name: Research Group on Neurobiology and Molecular Physiopathology in Rare Diseases - NeuroFisER
Research Area: Metabolism and Organic Damage

Title: III Encuentro con asociaciones de cáncer de mama
Date: 04/01/2025- 04/01/2025
Organised by: Miralles Marco, Ana
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: Jornada “Cribado de fibrosis hepática”
Date: 05/19/2025 - 05/19/2025
Organised by: Navarro Pérez, Jorge
Group Name: Cardiometabolic Research Group on Primary Care
Research Area: Cardiovascular

Title: Jornada “Impulsando la Innovación Sanitaria”
Date: 07/24/2025 - 07/24/2025
Organised by: Carrio Argos, María Elena
Group Name: INCLIVA Management

Title: VI Jornada INCLIVA de investigacion en Atencion Primaria
Date: 09/30/2025 - 09/30/2025
Organised by: Navarro Pérez, Jorge
Group Name: Cardiometabolic Research Group on Primary Care
Research Area: Cardiovascular

Title: Jornada INCLIVA 2025
Date: 11/05/2025 - 11/05/2025
Organised by: Fernández Saiz, Patricia
Group Name: INCLIVA Management

Title: 16ª-17ª Jornada Valenciana de Tabaquisme i Respiració: “Tabaquismo, Prevención y Cirugía”
Date: 11/18/2025 - 11/18/2025
Organised by: Carrión Valero, Francisco
Group Name: Research Group on Respiratory Diseases
Research Area: Metabolism and Organic Damage

Title: EORTC gastrointestinal tract cancer group meeting (november 2025)
Date:11/22/2025 - 11/22/2025
Organised by: Fleitas Kanonnikoff, Tania Carolina
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: Jornada Plataformas INCLIVA 2025
Date: 12/17/2025 - 12/17/2025
Organised by: Cañigral Cárcel, Irene
Group Name: INCLIVA Management

TRAINING CONFERENCE
Title: Sesiones formación en técnicas quirúrgicas de cirugía mama
Date: 02/06/2025 - 02/06/2025
Organised by: Buch Vila, Elvira
Group Name: Research Group on Breast Cancer Biology
Research Area: Oncology

Title: Presentación del Portal de Investigación de INCLIVA
Date: 02/14/2025 - 02/14/2025
Organised by: Revenga Saiz, María
Group Name: INCLIVA Management

Title: Jornada: Atención al paciente frágil en Urgencias
Date: 03/24/2025- 03/24/2025
Organised by: Sánchez Moreno, Maria Teresa
Group Name: Without Group

Title: Jornada de Innovación: Presentación de Ayudas 2025 de IVACE+ien Salud
Date: 03/27/2025 - 03/27/2025
Organised by: Tartaj Garcia, Maria Pilar
Group Name: INCLIVA Management

Title: Sesiones formación en técnicas quirúrgicas de cirugía mama
Date: 04/14/2025 - 04/14/2025
Organised by: Buch Vila, Elvira
Group Name: Research Group on Breast Cancer Biology
Research Area: Oncology

Title: Actualización en derivación y manejo del paciente post CAR-T (Castellón 22.05.2025)
Date: 05/22/2025 - 05/14/2025
Organised by: Terol Castera, Mª Jose
Group Name: Research Group on Lymphoproliferative Disorders
Research Area: Oncology

Title: Taller: “Programa Horizonte Europa y convocatorias previstas año 2025”
Date: 05/29/2025 - 05/29/2025
Organised by: Ferrer Albero, Ana
Group Name: INCLIVA Management

Title: Sesión de Investigación e Innovación Responsable (RRI)
Date: 06/03/2025 - 06/03/2025
Organised by: Fernández Saiz, Patricia
Group Name: INCLIVA Management

Title: Actualización en derivación y manejo del paciente post CAR-T (Valencia 05.06.2025)
Date: 06/05/2025 - 06/05/2025
Organised by: Terol Castera, Mª Jose
Group Name: Research Group on Lymphoproliferative Disorders
Research Area: Oncology

Title: Actualización en derivación y manejo del paciente post CAR-T (Alicante 09.06.2025)
Date: 06/09/2025 - 06/09/2025
Organised by: Terol Castera, Mª Jose
Group Name: Research Group on Lymphoproliferative Disorders
Research Area: Oncology

Title: Jornada “Controversias en Enfermedad Inflamatoria Intestinal”
Date: 06/19/2025 - 06/19/2025
Organised by: Bosca Watts, Marta Maia
Group Name: Clinical Associated Group in Digestive Medicine
Research Area: Metabolism and Organic Damage

Title: Comunicación social de la ciencia para personal investigador
Date: 06/19/2025 - 06/19/2025
Organised by: Martín López, María Aranzazu
Group Name: INCLIVA Management

Title: Sesiones formación en técnicas quirúrgicas de cirugía mama
Date: 06/26/2025 - 06/26/2025
Organised by: Buch Vila, Elvira
Group Name: Research Group on Breast Cancer Biology
Research Area: Oncology

Title: Curso Básico de Divulgación científica
Date: 09/24/2025 - 09/24/2025
Organised by: Martín López, María Aranzazu
Group Name: INCLIVA Management

Title: Curso avanzado de Divulgación científica
Date: 09/24/2025 - 09/24/2025
Organised by: Martín López, María Aranzazu
Group Name: INCLIVA Management

Title: Jornada de investigación responsable: ética, protección de datos y buenas prácticas
Date: 10/01/2025 - 10/01/2025
Organised by: Fernández Saiz, Patricia
Group Name: INCLIVA Management

Title: Jornada de actualización sobre el manejo de infecciones en el paciente crítico UCI de anestesia (UCIA)
Date: 10/21/2025 - 10/21/2025
Organised by: Badenes Quiles, Rafael
Group Name: Research Group on Anesthesiology and Reanimation
Research Area: Metabolism and Organic Damage

Title: Impacto de la consulta de alta resolución y manejo del paciente con DM2 vulnerable
Date: 10/28/2025 - 10/28/2025
Organised by: Navarro Pérez, Jorge
Group Name: Cardiometabolic Research Group on Primary Care
Research Area: Cardiovascular

Title: Formación en Innovación: Inteligencia Artificial para el análisis de procesos sanitarios usando Process Mining
Date: 11/20/2025 - 11/20/2025
Organised by: Carrió Argós, Elena
Group Name: INCLIVA Management

Title: Comunicación social de la ciencia para personal investigador
Date: 12/04/2025 - 12/04/2025
Organised by: Martín López, María Aránzazu
Group Name: INCLIVA Management

Title: II Jornada multidisciplinar de Patología Inflamatoria Inmuno-mediada del Departamento Clínico – Malvarrosa
Date: 12/05/2025- 12/05/2025
Organised by: Trénor Larraz, Maria Pilar
Group Name: Without Group

INCLIVA SEMINARS / MEET THE EXPERT
Title: Seminario INCLIVA Dr. Enrique Javier Arenas Lahuerta: “Maximizando la eficacia de las inmunoterapias del cáncer: mecanismos de resistencia, nuevos tratamientos combinatorios y biomarcadores predictivos de respuesta”
Date: 01/29/2025 - 01/29/2025
Organised by: Cejalvo Andujar, Juan Miguel
Group Name: Research Group on Breast Cancer Biology
Research Area: Oncology

Title: Taller: ¿Qué puedo hacer con mi dinero?
Date: 02/12/2025 - 02/12/2025
Organised by: Sáenz González, Mª Teresa
Group Name: INCLIVA Management

Title: Seminario INCLIVA Prof. José Manuel Jerez Aragonés: Producción de resultados de vida real en oncología mediante IA y PLN
Date: 02/26/2025 - 02/26/2025
Organised by: Cervantes Ruiperez, Andres
Group Name: Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST
Research Area: Oncology

Title: Webinarios: Novedades sobre Cardiología año 2024.
Date: 03/01/2025 - 06/30/2025
Organised by: Bonanad Lozano, Clara
Group Name: Group on Translational Research in Ischemic Heart Disease
Research Area: Cardiovascular

Title: Seminario INCLIVA Dra. Hanneke W.M. van Laarhoven: “Transdisciplinary approaches to improve outcomes of patients with gastroesophageal cancer”
Date: 03/26/2025 - 03/26/2025
Organised by: Fleitas Kanonnikoff, Tania Carolina
Group Name: Translational Research Group on Esophagogastric Cancer
Research Area: Oncology

Title: Seminario: Single-Cell Multiomics: haciendo simple lo complejo
Date: 05/13/2025 - 05/13/2025
Organised by: Rentero Garrido, Pilar
Group Name: INCLIVA Management



Title: Seminario INCLIVA Dr. Christopher M. Gomez: Single Purkinje cell nuclear RNA seq reveals selective vulnerabilities and resistance in spinocerebellar ataxia, type 6 (SCA6)
Date: 09/30/2025 - 09/30/2025
Organised by: Sanz Ferrando, Mª Jesus
Group Name: Research Group on Inflammation
Research Area: Metabolism and Organic Damage

Title: Webinar: Manejo Integral de Toxicidades en Terapias CAR-T
Date: 11/12/2025 -11/12/2025
Organised by: Hernani Morales, Rafael
Group Name: Research Group on Hematopoietic Transplantation
Research Area: Oncology

Title: Seminario INCLIVA: Dra. Mª Jesús Sanz. “Nuevos actores inmunológicos en hipercolesterolemia primaria y desarrollo de arteriosclerosis”.
Date: 09/30/2025 - 09/30/2025
Organised by: Sanz Ferrando, Maria Jesus
Group Name: Research Group on Inflammation
Research Area: Metabolism and Organic Damage

Title: Conferencia Nuria López-Bigas: “Mutaciones tumorigénicas en tejido sano”. **Date:** 11/26/2025 - 11/26/2025
Organised by: Fernández Saiz, Patricia
Group Name: INCLIVA Management

Title: Seminario INCLIVA Profesor Mourad Aribi: “Innate immunity at the crossroads of physiology: emerging insights and perspectives for a Tlemcen–Valencia collaboration on sepsis”
Date: 12/05/2025 - 12/05/2025
Organised by: Pallardó Calatayud, Federico
Group Name: Research Group on Cellular and Organic Physiopathology of Oxidative Stress
Research Area: Metabolism and Organic Damage



7 | Communication



7	COMMUNICATION
7.1	Headlines
7.2	Communication Indicators

7.1 Headlines

January

Scientists from the Carlos Simón Foundation, INCLIVA and the University of Valencia discover key molecular mechanisms for understanding the uterine changes that cause pre-eclampsia

Andrés Cervantes awarded an honorary doctorate by the National and Kapodistrian University of Athens in recognition of the impact on the scientific community of his work in medical oncology

INCLIVA recognises the clinical innovation of the Departamento de Salud Clínico-Malvarrosa

INCLIVA implements new management system for its scientific and technological platforms to optimise access to and quality of its services

A study led by INCLIVA develops an innovative model to predict left ventricular thrombus following acute myocardial infarction, a serious and potentially fatal complication

INCLIVA takes part in a project to establish a national network aimed at tackling the challenges posed by myotonic dystrophy type 1 (DM1) and advancing precision medicine

February

INCLIVA study examines whether adverse experiences in early life lead to changes in the thalamus that may predispose individuals to schizophrenia

INCLIVA researchers share personal experiences to inspire, guide and encourage young women interested in health research

INCLIVA organises an interactive open day on childhood cancer

INCLIVA to develop a programme for improving health literacy on neurodegenerative diseases and stroke

INCLIVA conducts pioneering study to validate an invertebrate model of Friedreich's ataxia

March

INCLIVA celebrates 25th anniversary since its establishment as the first foundation in the Valencian Community to be affiliated with a public hospital

INCLIVA hosts first edition of TERRETA, which focuses on rare diseases caused by repeat expansions

INCLIVA launches a new edition of the 'Proyecto Futura' initiative to develop leadership skills and abilities of female researchers

INCLIVA participates in a study which confirms the clinical impact of the HER2DX® genomic test in early-stage HER2+ positive breast cancer

Early detection system for chronic kidney disease at INCLIVA-Hospital Clínico de València has identified 6,000 patients with kidney disease and 800 at high risk of requiring dialysis

INCLIVA participates in BIOTOOL-CHF, a European project that aims to revolutionise the management of heart failure

A study by INCLIVA and the University of Valencia supports the hypothesis of a key role for genetics in healthy ageing and paves the way for future therapeutic strategies

INCLIVA, the University of Valencia and Klus Life Systems SLU develop an innovative haemodialysis device

April

INCLIVA launches new open science policy to promote access to scientific research and its impact on society

INCLIVA and Hospital Clínico de València hold meeting to bring research closer to breast cancer patients and hear their concerns

N-acetylcysteine examined as a new therapeutic strategy for the treatment of alpha-1 antitrypsin deficiency

INCLIVA takes part in first national study to describe how tumour cells move during pancreatic cancer surgery

INCLIVA studies key genes involved in body mass index that may serve as therapeutic targets for reducing obesity


INCLIVA leads study showing that breast cancer in women under 35 exhibits distinct molecular behaviour

Groundbreaking research improves detection of micrometastases in colorectal cancer through blood test and paves the way for immunotherapy in the early stages

May INCLIVA leads study identifying biomarker in liquid biopsy associated with kidney damage and flare-ups in systemic lupus erythematosus	A study shows the impact of adverse experiences in early life on thalamic volume in patients experiencing a first psychotic episode	INCLIVA takes part in JACARDI's third General Assembly, which explores equality and gender differences in cardiovascular health	INCLIVA takes part in European project aimed at improving the oral health of older people and those with chronic conditions in remote areas
INCLIVA recognises the research and innovation work of women in the early stages of their careers	International project AIDA presents AI system capable of personalising and optimising treatment for Helicobacter pylori, the bacterium most commonly associated with gastric cancer	INCLIVA investigates the impact of arginine on prevention and treatment of osteoporosis	INCLIVA awarded grant to make HIV prevention measures and sexual health services more accessible to most vulnerable people
INCLIVA investigates resistance in certain patients to trastuzumab deruxtecan, a drug demonstrating very high efficacy in metastatic HER2-positive breast cancer	A study by INCLIVA and CIBERCV suggests that NT-proBNP may be a powerful and accessible tool for predicting the risk of a new cardiovascular event following an acute myocardial infarction	INCLIVA researchers among the top 2% most cited worldwide, according to Stanford University ranking	INCLIVA steps up efforts to transform the prevention and early detection of dementia in Europe
INCLIVA and the University of Valencia develop a family of compounds to improve the treatment of metabolic diseases	INCLIVA awarded the AENOR R+D+I Management System Certificate (ISO 56001), confirming its position as a leading organisation in biomedical research	INCLIVA hosts conference on mental health to exchange ideas on the development of new research projects into psychosis and depression	INCLIVA invites you to give the gift of research this Christmas
June INCLIVA takes part in national study aimed at improving understanding of relapsed mature B-cell lymphoma in children and adolescents	The TRAINING-HR study demonstrates the benefits of physical training for people with heart failure with preserved ejection fraction (HFpEF)	Researchers at INCLIVA analyse lipid control in post-heart attack patients, one of the main objectives of their follow-up care to prevent relapses	INCLIVA recognises the clinical innovation of the Departamento de Salud Clínico-Malvarrosa at the 6th edition of the Innovative Ideas Competition
Innovative project on triple-negative breast cancer is recognised for its potential to improve treatment and patient response	September INCLIVA researchers identify new factors associated with recovery from Chagas disease in study aimed at optimising the treatment and monitoring of this condition	INCLIVA holds conference to mark 25th anniversary as the first foundation in the Valencian Community to be affiliated with a public hospital	INCLIVA showcases the potential of its scientific and technological platforms at a conference aimed at promoting biomedical research
Poor blood sugar control in type 2 diabetes increases the risk of developing cardiovascular disease	INCLIVA, EpiDisease and the Spine Research Foundation join forces to investigate the genetics and epigenetics of adolescent idiopathic scoliosis (AIS) in India	November INCLIVA Biomedical Research Institute pays tribute to the individuals and organisations that have helped to establish its reputation within the scientific community	INCLIVA presents findings of the Integra Cloud project, a pioneering platform for advanced use of healthcare data
A study by INCLIVA and the University of Valencia identifies mechanisms through which metabolic syndrome may contribute to fatal ventricular arrhythmias	INCLIVA leads pioneering projects to improve early diagnosis and prognosis of sepsis, with the aim of implementing precision medicine in intensive care units	INCLIVA evaluates accuracy of digital pathology to clarify discrepancies between biopsy and MRI results in fatty liver disease diagnosis	INCLIVA receives over €4 million in funding from Strategic Health Initiative to support health research and research staff recruitment
INCLIVA launches the first screening programme for cardiovascular diseases and diabetes as part of the European JACARDI Project	INCLIVA brings together researchers, clinicians and patients with myotonic dystrophy type 1 (MD1) to discuss the current state of research and challenges associated with this condition	INCLIVA investigates potential biomarker for detecting kidney damage and as therapeutic target to slow disease progression in patients with high blood pressure and diabetes	
INCLIVA and FUVAMA renew partnership to further research into the health benefits of citrus fruits	INCLIVA and ASVAH explore new research and proposals to improve the well-being of people living with ataxia	INCLIVA researchers investigate the effect of dapagliflozin on patient quality of life following transcatheter aortic valve implantation	
July INCLIVA coordinates project aimed at integrating scientific knowledge into public policy to improve the fight against cancer	October INCLIVA expands its Clinical Research Unit with new facilities for its scientific trials and a new oncology laboratory	A pioneering study led by INCLIVA and FUVAMA reveals that increasing intake of oranges or mandarins in the diet has a significant effect on the genome and may provide new insights for health interventions	
INCLIVA coordinates a pioneering study to improve the management of locally advanced head and neck cancer through molecular analysis and artificial intelligence	INCLIVA obtains certification guaranteeing the security of electronic systems, data and services within the public sector	December INCLIVA launches study to detect microvascular damage at early stages following acute myocardial infarction	
INCLIVA investigates benefits of an invasive strategy compared with a conservative strategy in elderly and frail patients admitted for myocardial infarction			

7.2. Communication Indicators 2025

Press Office
In 2025, INCLIVA issued a total of 124 press releases on the Web.



	Jan-25	Feb-24	Mar-25	Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25
Total press releases	10	12	12	10	7	11	12	0	15	13	12	10
Total media appearances	114	48	118	173	61	90	228	2	98	90	145	84



Social Media Users 2025

	Facebook		X		LinkedIn		Instagram
7.461		6.403		23.543		3.716	

INCLIVA Website 2025

Website users	Website sessions	Website new sessions
143.321	261.738	137.213

Outreach 2025

Issued press releases	Newspieces on INCLIVA's website	News on Radio	News on TV
72	124	18	19

In 2025, INCLIVA's Scientific Culture and Innovation Unit (UCC+I) accredited by the Spanish Foundation for Science and Technology (FECYT) carried out different activities to disseminate science to the public.

The Unit organised visits for students from different educational levels, workshops for patients on advances in research into various diseases, under the title CONECTA INCLIVA, and a roundtable discussion among female researchers from INCLIVA's four research areas, as part of International Day of Women and Girls in Science, aimed at an audience consisting mainly of medical students, with the goal of inspiring and guiding students and young female researchers interested in pursuing a career in health research.

INCLIVA collaborates with other prominent organizations in Valencia to organize outreach events:

Together with the University of Valencia, the Fisabio Foundation, ISABIAL, and the FIHGUV, it organized the 8th edition of the video contest "De major vull ser com..." featuring women scientists and technologists. The contest, aimed at students from any educational institution in the Region of Valencia, seeks to recognize the key role women play in scientific and technological disciplines

and to inspire young girls and teenagers to pursue careers in these fields. This year, around twenty schools from Castellón, Valencia, and Alicante participated, submitting a total of 41 videos.


Furthermore, together with the Fisabio Foundation, the Polytechnic University of Valencia (UPV), the University of Valencia (UV), and the Spanish National Research Council (CSIC) Delegation in the Region of Valencia, organized series of science talks called "Ciencia y Cañas", in which researchers from the five institutions present INCLIVA their most innovative projects through brief and interactive talks, and the European Research Night at the Viveros Gardens in Valencia with more than 30 educational workshops led by research staff and nearly 2,000 elementary and middle school students. This event is part of the European initiative European Researchers' Night, which takes place simultaneously in 400 cities to bring science closer to society to encourage children's interest in scientific careers and to share with the public the work carried out by researchers.

Finally, training sessions on scientific communication and outreach were conducted for research staff with the aim of helping them effectively disseminate research findings and improve their engagement with various communication channels and initiatives.





8 | INCLIVA Social Initiatives



8 INCLIVA SOCIAL INITIATIVES

- 8.1 Public Engagement Projects
- 8.2 Philanthropic Projects
- 8.3 Private philanthropic donations and acknowledgments

8. INCLIVA Social Initiatives

8.1 Public Engagement Projects

In 2025, a total of **69 active projects** funded through national and international public calls were identified, excluding human resources and mobility grants. Of these, **20 projects involved at least one non-scientific key stakeholder**, representing **28.99% of the total**. This result substantially exceeds the **10% threshold required by the Instituto de Salud Carlos III (ISCIII)** and confirms compliance with the indicator for the **second consecutive year**.

The percentage of projects involving non-scientific key stakeholders increased relative to 2024, rising from **25.64% to 28.99%**, an increase of **3.35 percentage points**. The absolute number of projects with participation remained stable at **20 projects**.

The main difference is observed between international and national projects. At the **international level, 15 of the 19 active projects** included non-scientific key stakeholders (**78.95%**). At the **national level, 5 of the 50 active projects** did so (**10%**). Therefore, participation is particularly high in international projects, while national projects meet the minimum required threshold exactly.

Overall, the 2025 data indicate **stable and well-established participation**. International projects account for the majority of this engagement, while there remains room for growth in the national portfolio.

Indicator	Result
Active projects 2025	69
Projects with non-professional participation	20
Projects without non-professional participation	49
Overall participation	28.99%
International participation	15 of 19 projects (78.95%)
National participation	5 of 50 projects (10%)
Institutional threshold	10%
Difference from threshold	+18.99 percentage points
Change compared with 2024	+3.35 percentage points

In 2025, INCLIVA Biomedical Research Institute celebrated its 25th anniversary and adopted the slogan *25 years of science improving your health* as its motto for the year.

Below are some highlights and key milestones in sponsorship:

INCLIVA launches a new edition of the Women's Leadership Program with the support of Caixa Popular



INCLIVA Biomedical Research Institute has launched a new edition of 'Proyecto Futura', an initiative aimed at strengthening the leadership skills and professional development of women researchers through coaching and specialised training adapted to the scientific environment.

The programme, promoted by ASEDEC+I+A (Spanish Association for Executive Development in Science, Innovation and Art), forms part of INCLIVA's Female Leadership Programme, now in its second year with the support of Caixa Popular, recognised as an 'Honorary Ambassador of INCLIVA' for its commitment to health research.

The Female Leadership Programme is structured around three strategic areas: training, visibility and networking, and leader-

ship development. The training strand includes courses for pre-doctoral and postdoctoral researchers on oral presentations, scientific writing, research project development, and strategies for successful research careers. The visibility strand promotes awards and initiatives designed to support women researchers in the early stages of their scientific careers.

In 2025 eight INCLIVA researchers participated in 'Proyecto Futura', twice as many as in 2024. Six researchers took part in individual coaching sessions, while two others completed online leadership training programmes.

Through this initiative, INCLIVA aims to foster female leadership, support career progression in science and promote innovation and gender equality in biomedical research.

'Corazón Solidario' raises nearly €24,000 for INCLIVA's breast and childhood cancer research



'Corazón Solidario contra el Cáncer' has raised €23,978 over the past year to support INCLIVA's research into childhood cancer and breast cancer. The initiative takes part in the organisation's ongoing commitment to funding cancer research and raising awareness of the scientific work carried out at INCLIVA.

INCLIVA has once again expressed its gratitude for the initiative's efforts, which over the last four years have generated a total of € 73,659 in donations for research into these diseases. This achievement has been made possible thanks to the collaboration of local Fallas committees, businesses, and individual supporters who have contributed to fundraising activities and community events.

'Corazón Solidario contra el Cáncer' was established in Valencia in October 2020 as a joint initiative promoted by Chus García and Carmen Caballero. Since its creation, the project has grown steadily, bringing together volunteers and supporters from several Fallas associations who share a commitment to supporting cancer research and helping improve patient outcomes.

The funds raised will contribute to INCLIVA's ongoing research projects focused on improving prevention, treatment, and quality of life for patients affected by childhood and breast cancer.

'Valentes i Positives'
donates €16,000
to INCLIVA for lung
and colon cancer
research

The theatre association 'Valentes i Positives' has donated €16,000 to INCLIVA to support research into lung and colon cancer. The donation corresponds to the funds raised during the group's 2024 season through theatrical performances organised in different municipalities with the support of local councils.

'Valentes i Positives' is a group formed by women from Pedreguer who have experienced cancer personally. Through theatre, the association combines artistic expression, social awareness and solidarity fundraising, dedicating the proceeds of its performances to cancer research.

The symbolic presentation of the donation took place on 20 February at INCLIVA's facilities. The members of the association were welcomed by Dr. Andrés Cervantes, Scientific Director of INCLIVA and coordinator of the Oncology Area, who thanked the group for its commitment to supporting biomedical research and improving outcomes for cancer patients.

The initiative represents an example of how cultural and community activities can contribute to scientific progress while also creating spaces for empowerment, visibility, and collective support among people affected by cancer. By transforming personal experiences into positive social action, 'Valentes i Positives' has succeeded in mobilizing communities across different towns and encouraging public engagement with cancer research.

INCLIVA has highlighted the importance of initiatives such as this one, led by women who have faced cancer with courage and determination. Their contribution not only provides financial support for research projects but also helps strengthen social awareness of the importance of continued investment in oncology research and patient care.

Alicia Conesa's circle
donates more than
€32,000 to INCLIVA
for Triple-Negative
breast cancer
research

Family and friends of Alicia Conesa, who died two years ago from triple-negative breast cancer, have donated €32,784 to INCLIVA to support research into this disease. The funds were raised through the solidarity campaign 'Todas conmigo', launched by Alicia herself to raise awareness of triple-negative breast cancer and support scientific research.

The symbolic presentation took place on 21 February, when Alicia's mother, María Luisa Pérez, her partner, Jorge Carbonell, and her friend Paqui García travelled from La Torrealta, near Molina de Segura in Murcia, to deliver the donation. They were welcomed by INCLIVA Managing Director Vicente de Juan, together with researchers Dr Juan Miguel Cejalvo and Cristina Tébar from the breast cancer Biology Research Group.

Alicia Conesa first contacted INCLIVA in January 2024 with the intention of launching her own fundraising campaign. Before her death in February of that year, she had already raised almost €22,000 through charity initiatives including handcrafted crochet hats, the 'Sombrero Solidario' gala held at Murcia's Teatro Romea, and the sale of her book 'Todas conmigo', which recounts her personal experience with cancer.

Following her death, relatives and friends continued the campaign in tribute to her determination and commitment to cancer research. Her legacy continues through the ongoing campaign and through the support her fundraising efforts now provide for biomedical research.

'Mi padre es tu padre'
donates €3,100 to
INCLIVA's prostate
cancer research



The initiative 'Mi padre es tu padre' has raised €3,100 for INCLIVA's prostate cancer research project focused on exercise and nutrition to improve quality of life and survival of patients with prostate cancer.

The campaign was created by Roberto Heredia del Rey following the death of his father from prostate cancer in 2019. Conceived as both a tribute and a fundraising campaign, the project aims to honour all those affected by the disease while increasing public awareness of prostate cancer and the importance of research.

The donation was presented to INCLIVA by Roberto Heredia del Rey together with Juan Ignacio Sánchez, representing Jalance Corre, organiser of the Trail de Jalance race. The contribution was received by Dr Isabel Chirivella, an oncology researcher at INCLIVA and oncologist at the Hospital Clínico Universitario de València who thanked the organisers for their support in advanc-

ing cancer research. Since its launch, 'Mi padre es tu padre' has organised several fundraising activities, including 12-hour continuous training and running events held in 2020 and 2021, involving hundreds of participants both online and in person. More recently, the initiative collaborated with the IX Trail Jalance 2024, held on 21 September 2024, raising funds through race registrations and donations from supporters.

Beyond its fundraising impact, the initiative seeks to give visibility to prostate cancer and to acknowledge the experiences of patients and families affected by the disease. According to the Spanish Society of Medical Oncology (SEOM), prostate cancer is one of the most frequently diagnosed cancers worldwide, with more than 32.000 new cases expected in Spain in 2025.

**Castellón shows that
every step counts at
the XI 'Paseo por la
Vida', organised with
Fundación Le Cadó**



Castellón once again demonstrated its commitment to breast cancer research during the eleventh edition of the solidarity walk 'Un Paseo por la Vida', organised by the Official College of Nurses of Castellón and 'Fundación Le Cadó' to mark International Breast Cancer Day on 19 October.

Hundreds of participants joined the event, creating a symbolic "pink tide" through the streets of the city in support of research and patient care. During the event, the organisation received three solidarity cheques worth €15,000 each, bringing the total raised to €45,000 through registrations, charity activities and donations collected throughout the year.

The funds will support three research initiatives. Two are linked to INCLIVA's breast cancer biology research group. The first one

consists of the third phase of the study 'Breast Cancer in young women', led by Dr Maite Martínez under the supervision of Dr Ana Lluch. The second one is the EMBARCAM project developed by GEICAM to support women who have overcome breast cancer and wish to become mothers, involving Dr Begoña Bermejo and Dr Juan Miguel Cejalvo.

The third project supports the Chair of Physical Activity and Oncology at Universitat Jaume I. The event also included the announcement of the 'Aula Le Cadó for breast cancer research', a collaborative initiative between Fundación Le Cadó, Universitat Jaume I and the Chair of Physical Activity and Oncology.

Sinarcas donates
€9,200 to support
INCLIVA's biomedical
research



Sinarcas Council has donated €9,200 to INCLIVA in support of its institutional mission and biomedical research programmes. The donation was formally presented by the Mayor of Sinarcas, María José Clemente Ramírez, following a fundraising campaign organised by the local community during the summer, which included a public collection and a charity dinner.

The representatives of Sinarcas were welcomed at INCLIVA by Scientific Director Dr Andrés Cervantes and Managing Director Vicente de Juan, together with Dr Marisol Huerta, from the Colorectal Cancer and Novel Therapeutic Developments in Solid Tumours Research Group, and Dr Jorge Navarro, from the Primary Care Research Group and a resident of Sinarcas.

During the meeting, INCLIVA representatives expressed their gratitude for the municipality's commitment to supporting health

research and scientific progress. They also highlighted the solidarity shown by the residents of Sinarcas, whose support extends beyond healthcare initiatives to include environmental causes and programmes for older people.

The donation reflects the growing role that local communities and civic institutions play in promoting biomedical research and contributing to advances in cancer care and other areas of health innovation. Through collective initiatives such as these, municipalities can help strengthen the connection between society and scientific research while fostering awareness of the importance of sustained investment in healthcare and innovation.

The American School
of Valencia unites in
support of cancer
research and raises
more than €4,000 for
INCLIVA



The American School of Valencia (ASV) has demonstrated its commitment to solidarity and scientific research through the second edition of the ASV FundRun, a charity race organised to support cancer research led by INCLIVA. At the time of publication, the initiative had raised €4,169, with donations remaining open until 15 January 2026.

Held on 19 December 2025 at the ASV campus, the event brought together pupils of all ages, families, alumni and staff in a festive and inclusive atmosphere designed to mark the end of the autumn term. Over the course of 90 minutes, students took turns completing laps around the school circuit, encouraging teamwork and community spirit across different classes and age groups. The opening lap, shared by the youngest and oldest students, symbolized unity across the school community.

Beyond its sporting and fundraising dimension, the initiative also carried a strong emotional significance. Over its 45-year history,

the ASV community has lost students, alumni and members of staff to cancer. The FundRun was created to honour their memory by transforming grief into collective action and hope through support for biomedical research.

The initiative also included an educational component. Prior to the race, researchers Dr Tania Fleitas, Dr Josefa Castillo and Dr Manuel Cabeza visited the school to speak with senior students about oncology research and the importance of scientific innovation in improving patient outcomes.

The funds raised will contribute to INCLIVA's ongoing efforts to advance cancer research and develop new strategies to improve patients' quality of life.

'Canals contra el
Cáncer' donates
€10,000 to INCLIVA's
childhood cancer
research



The association 'Canals contra el Cáncer' has donated €10,000 to INCLIVA in support of a childhood cancer research project coordinated by Dr Jaime Verdú, from INCLIVA's Translational Research Group on Paediatric Solid Tumours. The project focuses on clinical and translational research into non-Hodgkin lymphoma in children and teenagers.

Representatives of the association attending the symbolic presentation included Toñi García, Carmen Juan, María Carmen González, Mati Gramaje, María José Mollà and Reyes Huertas. They were welcomed by INCLIVA Scientific Director Dr Andrés Cervantes, Managing Director Vicente de Juan and the oncologist Dr. Jaime Verdú.

This is not the first collaboration between the organisation and INCLIVA. Previously, 'Canals contra el Cáncer' donated €8,000 to support a precision medicine project in oncology, reinforcing

the association's long-term commitment to biomedical research and innovation in cancer care.

Founded in 2015, 'Canals contra el Cáncer' works to support people affected by cancer and their families while raising funds for healthcare and social initiatives. Through fundraising activities and community engagement, the association seeks to provide both practical and emotional support to patients while contributing to scientific progress.

INCLIVA has thanked the association for its continued support of oncology research and for helping advance studies aimed at improving diagnosis, treatment and survival among paediatric cancer patients. The donation highlights the important role played by local organisations and civic initiatives in supporting translational research and promoting greater awareness of childhood cancer

8.2 Philanthropic Projects



Le Cadó Foundation

The Le Cadó Foundation was created in 2010 under the leadership of its president, Elvira Monferrer Daudi. This initiative seeks to unite efforts and resources to support research into this cancer type, currently the fourth leading cause of death in women.

The *Le Cadó* Foundation collaborates with INCLIVA in funding the research project "Study of breast cancer in young women aged under 35 years," led by Dr M^a Teresa Martínez Martínez. Other researchers also participating include Dr Isabel Chirivella (physician specializing in genetic diagnosis) and the entire team led by oncologists Dr Ana Lluch and Dr Pilar Eroles.



Corazón Solidario Initiative

Los Retos de Marta was founded in January 2021 with the aim of raising awareness of Marta's story and raising funds to pay for the therapies she needs whilst she awaits a treatment for her condition. Marta developed normally until the age of two, when she began to experience problems with her balance, coordination, and vision. After five years of tests and consultations with various specialists, she was diagnosed with an ultra-rare degenerative neurological condition for which there is no cure or treatment. They are currently working with Dr Antonio Navarro on a research project called 'Martimoscas', which aims to gain a deeper understanding of this mutation to improve its diagnosis and treatment.



Amunt contra el càncer

Based in Denia in the Alicante province, Amunt Contra el Càncer provides various services and carries out initiatives aimed at improving the life quality of cancer patients and their families. This association organizes informational talks, provides psychological support for patients, and promotes various activities to raise funds for research, donating at total of €53,250 this year.



Las Triples Association

The Las Triples Association works to support triple-negative breast cancer research, raise awareness about this type of cancer, and disseminate current knowledge. This association has collaborated with INCLIVA since 2022, supporting the research of Dr Juan Miguel Cejalvo and Dr Pilar Eroles.

8.3 Private philanthropic donations and acknowledgments

On behalf of INCLIVA, we would like to thank everyone who has contributed to our research through their donations for their support and solidarity. This collaboration means much more to us than a financial contribution: it is the encouragement we need to continue our research and our work in this field.

MIRON LOPEZ, FRANCISCO JAVIER
GONZALEZ HERNANDEZ, ASUNCION
DEL CARPIO PEREZ, MONICA
PASCUAL SAGUAR, NURIA
SCHROPP , JUAN PABLO
BRAVO VIDAL, FRANCISCO
SERRANO MONEDERO, MARIA INMACULADA
IGUALADA CARRETERO, CARLOS
ANDRES COCO, CRISTINA
CALVO ALFARO, Mª PILAR
CORDERO GONZALEZ, PILAR
PACHECO ALFONSO, TOMÁS
DEUDORES VARIOS POR DONACIONES
HORNAS GARCÍA, MARISOL
LOMBARTE CUARTIELLES, SARA
PARDO MAS, VICENTE
PUNTER COSTA, MARIA JESUS
DOMÍNGUEZ CERVERA, MARÍA ISABEL
BENITO MILLA, MARÍA TERESA
SEGURA VALDIVIESO, EMILIA
CABALLER MOLINA, RAFAEL PASCUAL
PULIDO CARRILLO, ANTONIO
LAMELA TROBAT, INÉS
GARCÍA COLLADO, MARIA JESÚS
GALLART NAVARRO, LUIS MIGUEL
SAMPERE VILAR, FRANCISCO VICENTE
CARRIO MIÑANA, FRANCISCO
BENAVENT CAMARENA, FAUSTINA
BIXQUERT HUGUET, ANA M
SABATER ORENGO, FERNANDO FRASCICO
FRASQUET PARRA, ROSA
PELLICER CARDONA, XELO
MONTAGUT CAMARENA, MARIA JOSE
HUGUET MALAVÉS, JOSÉ MARÍA
PELLICER LLOPIS, YOLANDA
ANDRES GUILLEM, MILAGROS
SIGNES TARRASO, VERONICA
PEIRO FERRER, YASMINA
SUAY PAYA, RAQUEL
PARDO MARTI, JOSE MANUEL
MARTINEZ ESPINOSA, ALICIA
SANCHEZ-BARCAIZTEGUI ALVAREZ, MARAVILLAS


PONZ PINEDA, OLGA
ALBERT PARDO, JAIME
AGUSTI ALTABA, ANA CRISTINA
JORDA , VICENT
SANZ VALLEJO, CARLOS
SANCHEZ PALOP, ANGEL JOSE
MUÑOZ FERRER, ALEJANDRA
SANCHIS GIL, MARIA JESUS
MARTINEZ CORBI, ADELA
BRIZ NADAL, RAFAEL
CALVO CARO, MARIA CRISTINA
ARANDA CAMPOS, GEMMA
GIL RADAL, MARIA
CALPE BARBERA, INMACULADA
BALLESTER SEBASTIA, EVA
MIRALLES , ROS MARI
GIL RADAL, SUSANA
CABALLERO SANCHIS, MARTA
GARCIA MARTORELL, MARIA DOLORES
CUARTERO CEJALVO, JUAN
FERNANDEZ GOMIS, ROSANNA
IBORRA , NEUS
CAPSI LLOBET, ANGEL
ROMERO GONZALEZ, SARA
BAELLO CATALA, EDU
SANCHIS GIL, LAURA
SANCHIS GIL, ALICIA
TALENS TALENS, MAR
FEMENIA CABRERA, FRANCISCA
PARDO VALLS, PILAR
PLA PEIDRO, LOURDES
ALONSO VALLECILLO, CARLOS
DOMINGUEZ GONZALBEZ, CAROLINA
CABALLERO TURIÑO, CARMEN
LOPEZ MARMOL, JUANA
CONESA LÓPEZ, FRANCISCO
MARTINEZ MARIN, ISIDRO
ARNALDOS SERRANO, CONSUELO
ARNALDOS SERRANO, ISABEL
GOZALBES DE CECILIO, RAFAEL
DE VARGAS MONTESINOS, MARIA LUISA
ALONSO SALA, MARÍA CONCEPCIÓN

SIERRA BERNAD, MARÍA DOLORES
SANCHEZ GONZALEZ, MARÍA JOSÉ
ALBUIXECH FERRANDIS, ENRIQUE
EBRI MENDEZ, MARIA LUISA
LÓPEZ AGUSTÍ, GERMÁN
JIMENEZ MONTES, JOSE NICOLAS
BLASCO TELLO, JESÚS
GARCIA COLLADO, LUISA
SANCHEZ MANZANO, MARI CARMEN
BORREDA BOLINCHES, MARIA ISABEL
SERRANO MONEDERO, MARÍA JULIA
ARNAU PASCUAL, RICARDO
BENLLIURE BAIXAULI, OLGA
LLISO JULIÁ, SUSANA
CABALLERO DEL, ELENA
REGAÑO DIONIS, FÉLIX
JUAN MARCO, MARIA JOSE
CANTERO MILAN, LAURA
ARNALDOS SERRANO, MARI GUIA
ASUNCIÓN FERNANDEZ, ROSARIO
CONESA ALMEDA, MARIA
IBÁÑEZ PARRA, JOSE MARÍA
INTERNATIONAL CANCER FOUNDATION
NAVARRO ANTON, EDITH
PASTOR PIÑERO, JUANI
LOPEZ LOPEZ, JOSE
LOPEZ MARMOL, DOMINGO
MESEGUER CONTRERAS, MARIA DEL PILAR
ARNALDOS SERRANO, MARIA JOSE
MARTINEZ , NATALIA
LAANDETE BENAVENTE, SAMUEL
RODRÍGUEZ LORA, ISABEL
MARTÍNEZ RIOS, SARA
MORENO GARCIA, HERMINIA
ESPLUGUES ALCALÁ, JOSÉ JUAN
VERDEGUER SANCHO, MERCEDES
VILAR GIMENO, ANA
MIRAVET VELA, ISABEL
LERIN AGUADO, MARIA
CINOSI DEL SASTRE, VERONICA
GARCIA FERNANDEZ, PAQUI
JORDAN CARACENA, SANDRINA
CARAVACA MARTINEZ, MONICA
LATORRE ESTEVE, SARA
BORREDA BOLINCHES, FRANCISCO
LOPEZ RUIZ, ANA
GALI PICÓ, CARLES

GERKEN SCHLEIF, ANJA
SANABRIA CODESAL, ESTEBAN
FENOLLAR ITUREN, TERESA
FRANCO FERRANDO, NURIA
MIRAVET MANTILLA, MAR
ANTON DE SALAS, JUAN
HINOJOSA LÁZARO, GUILLERMO
GARCIA RAMON, DOLORES
MARCO PUCHOL, RAÚL
VATRAL , ELEONORA
LADERA PESCADOR, IRIS
LADERA PESCADOR, ALBA
MARTINEZ GALLEGO, ANA
MOSCOSO PINO, EVA
CARRASCO TOMERO, BEATRIZ
GANDIA PASTOR, VERONICA
MOLINA BRAVO, LUCAS
CERRO HERREROS, ESTEFANIA
CAMPANALS SUBIRATS, DIDAC
PLA SANCHIS, EMILI
PATÓN MARTÍ, NOEMÍ
PALOMAR SALDAÑA, ERUNDINA
ROMERO GOMEZ, JUAN
MARIN IILAN, JUAN JOSE
CONESA GARRIDO, RAQUEL
VICENTE RIQUELME, LUZ MARIA
EXPOSITO CANO, MARGARITA
CONESA GARRIDO, FRANCISCO JAVIER
PEREZ FERNANDEZ, VIRGINIA
MESEGUER ALMELA, REMEDIOS
DOLERA MOLINA, ANA BELEN
MARMOL OLIVA, MARISA
LOPEZ PEÑALVER, JOSE
SANCHEZ HIDALGO, ROSA MARÍA
PEREZ TREIGUEROS, ESTELA
FERNANDEZ MONDEJAR, VICENTE
PEREZ MOLINA, NOELIA
PEREZ MOLINA, DIANA
CARBONELL PALAZÓN, JORGE
CARBONELL PALAZON, ELOY
CARBONELL PALAZON, JOSE
MARTINEZ SOLER, NURIA
IBÁÑEZ LOPEZ, ANTONIO JESÚS
SANCHEZ MARTINEZ, ROCIO
CARRILLO TORNERO, ARIADNA
ALBERCA BERNAL, JORGE
MARTINEZ SOLER, GEMA
SALMERON BAÑOS, MARIA

COLLADO CABANILLAS, IRENE GÓMEZ MÁRMOL, ANTONIO JOSÉ SOLER MONREAL, CONSUELO MARTINEZ PELLICER, ANABEL TELLO MARTIN, ROBERTO SERRANO , NOELIA CANO EXPOSITO, REBECA LOZANO CÁNOVAS, MARÍA RUBIO MARTINEZ, ALFONSO RAMIREZ ZEGARRA, JOSE FERNANDO VICENTE PEREZ, LUZ MARIA MARIN PEREZ, JUAN JOSE MARIN PEREZ, ALEJANDRO CONESA JIMENEZ, ISABEL MARÍA GELLA MONTERO, MANUEL FERNANDEZ ALCOLADO, EVA MATILLA MATILLA, ELENA LOPEZ DE FRANCISCO, BLANCA NAVARRO CHALVER, SARA NAVARRO JIMENEZ, MARIA JULIA GINER ANDRES, MARÍA ISABEL MARCO HURTADO, MARCOS MIGUEL SANZ MOLINER, ANA GOMEZ SANCHEZ, MILAGROS MORENO MONDEJAR, ANTONIO GARCIA ESTEVEZ, MARIA CARDONA CASELLES, MAIKEL ARENAS ARENAS, ALEXANDRA ARRIBAS MARTIN, JOOSE TOMAS PARYAG SUBIES, ELIZABETH ALONSO BANDE, JOSE MANUEL CARPIO ALMELA, ANA BELEN MARIN PEREZ, VIRGINIA BUCHBINDER VOLKOVA, ALINA GONZÁLEZ FRESNEDA, MIGUEL ÁNGEL GINES LATORRE, VIRGINIA CASTILLO SUBIAS, ESTER TENA MUÑOZ, TOMAS GARIBO GUILLEM, JOSE PEREZ RODRIGO, SUSANA GUERRERO GÓMEZ, MARCELINA SIGNES TARRASO, TERESA LACRUZ GARCIA, ALMUDENA GIL RADAL, MARIA JOSE NAVALON , SONIA SANCHEZ MUÑOZ, VICENTA CASTILLO CONGOST, ROSA GIL RADAL, ALICIA	PEREZ SOLER, MARIANO CANO ROSAURO, ENCARNA PEÑALVER PARADA, FRANCISCA GARCÍA TORRANO, JESÚS PEREZ LOPEZ, JUAN CARAVACA AKOUBEINENIF, ALEXANDR LLISTERRI CARO, INMACULADA MEIJOMENCE , MARIA ISABEL RUIZ SOTO, JOSEFA GARCIA MARTINEZ, ENRIQUETA MAYOR SALAR, MARIA ISABEL SANCHO NAVARRO, MARI CARMEN RODRÍGUEZ DEVAL, Mª DOLORES CUÑAT NATIVIDAD, INMACULADA ORGANISATIONS NICOLÁS NICOLÁS, SAN AUTO CHRISTIAN SA CENTRO PORTURARIO DE EMPLEO DE ALICANTE, S.A. CORPORACIÓN F. TURIA, S. A., PASCUAL ARNANDIS MARTINEZ S.A TORSE, S.A. PALETS RIBELLES SA TERMINALES MARITIMAS DEL SURESTE, SA FET AL FORN, SL PIZZERIA GIUSEPPE GIL COMPRESORES ANTONIO GIL SL QUILMEDIC, SL DIARIO DE UNA CIENTÍFICA CREACIÓN DE CONTENIDOS S.L VOULEZ-VOUS ÉCOLE DE FRANÇAIS SLL. VINABAS FORMULATIONS SL VICENTE BRAVO, S.L. GESTION DE ÁREAS INDUSTRIALES BY ROMINA MOYA JUAN MOTILLA S.L. THE TASTING ROOM,SL KAIZEN TRANSFORMA, S.L. PRODUCTOS CONGELADOS SELECTOS 3000 S.L CONMOCHILA PROJECTS S.L DOCTAFORUM SERVICIOS ADAMED LABORATORIOS, S.L.U LABORATORIOS NEUM SPAIN. S.L HORNO CAÑIZARES, S.L INFORMÁTICA MÉDICO FARMACÉUTICA S.L ABONOS ORGANICOS MONTAGUT VICENT RIBERA PLANA S.L.U JBZ DISEÑO TECNICO, SLU CEMENTVAL MATERIALES DE CONSTRUCCION,SL YAGU FUTURA, S.L. ASOCIACION COST (COOPERACION EUROPEA EN CIENCIA Y	TECNOLOGIA) ASOCIACION UN MAR DE CORAZONES CONTRA EL CÁNCER ASOCIACIO PEL TEU SOMRIURE FUNDACIÓN VINATEA EDITORIAL DE LA COMUNITAT VALEN- CIANA ASOC.VALENCIANA PERSONAS AFECTADAS ATAXIAS ASOCIACION SAN NICOLAS DE BARI ASOCIACION LA VIRGEN DE LOS DOLORES FUNDACIÓN LECADÓ ASOCIACION LOS RETOS DE MARTA ASSOCIACIÓ AFECTATS DANY CEREBRAL ADQUIRIT CERE- BRUM ASOCIACIÓN KUKI ASOCIACIÓN CULTURAL FALLA COLÓN SAN VICENTE PAUL AMUNT CONTRA EL CANCER FUNDACION DE LA COMUNIDAD VALENCIANA MARQUES DE DOS AGUAS ASOCIACION RECREATIV-CULTURAL FALLA OLIVERETA ACC FALLA GAYANO LLUCH A.C. FALLA HUERTO SAN VALERO - AV.PLATA SOCIETAT MUSICAL DE BONREPOS I MIRAMBELL ASSOCIACIÓ CONTRA EL CÀNCER DE PEGO (ASSOCIACIÒ ESPERANÇA) AGRUPACIÓN SAGUNT-QUART FALLA AVENIDA DELS FURS I VOLTANTS ASOC FALLA AV ECUADOR – ALCALDE GURREA - FALLA PLAZA PINTOR SEGRELLES ASOCIACIÓN CULTURAL FALLA ALPELIC I ADY AGRUPACIÓN FALLAS RASCANYA ASOCIACIÓN CULTURAL FALLA ALEMANIA - EL BACHILLER FALLA PLA DE L'ARC ASOCIACIÓN DE MUJERES Y HOMBRES AFECTADOS DE CÁN- CER DE MAMA CANALS CONTRA EL CANCER MOU-TE PER ELLES BIOMED CENTRAL LIMITED/SPRINGER HEALTHCARE LTD (GB823826326) COMISION DE FIESTAS TORREALTA , TORREALTA AYUNTAMIENTO DE PUZOL AYUNTAMIENTO DE SINARCAS FALLA PLAZA PEDRALBA LIRIA ASOCIACIÓN DE AMAS DE CASA Y CONSUMIDORES TYRIUS DE AYORA FUNDACIÓN PARA LA PROMOCIÓN DE ACCIONES SOLIDARIAS ASOCIACIÓN TEATRAL VALENTES I POSITIVES LAS CHICAS DEL CALENDARIO	FOREIGN DONORS MEDINA AMAYA, DIANA CAROLINA MASTENBROEK , AURORA HOTOYAN HOTOYAN, MARAL WANG WANG, ZIWEN KHAN KHAN, KATE LEE LEE, LINDSEY ULKUMEN , MELISA KARPENKO , ALINA ZHANG , ANGELINA ZHANG , CHRISTOPHER SCHILLING , MICHAEL KOVTUN KOVTUN, IVAN HUIFEN , LIN CHUBRINOVSKI CHUBRINOVSKI, NENAD COOK COOK, JENNIFER LAZANEO LAZANEO, ROSSINA MENDEZ , MARCIA WAN , XIA RIDER RIDER, ADAM ELAM , JENNIFER MURPHY , HEATHER
--	--	--	--

9 | Publications



9. Publication list

List of 686 JCR indexed scientific publications derived from IN-CLIVA activity.

1.

Urgent repair of the anal sphincter complex after type IV obstetric tear: a video vignette. Moreno AI, Hernández LPG, García EL, Mora Oliver I, Santiago LP, Botello SAG. Colorectal Disease. 2025 January 01. 27 (1):DOI:10.1111/codi.17050. PMID:38853382.

2.

Prevalence and associated factors of burnout among health sciences students in Spain: a systematic review. Olmos Bravo ZM, Sánchez Ortí JV, Grevet EH, Balanzá Martínez V. Trends in Psychiatry and Psychotherapy. 2025 January 01. 47DOI:10.47626/2237-6089-2024-0805. PMID:38833324.

3.

Prediction of left ventricular thrombus after myocardial infarction: a cardiac magnetic resonance-based prospective registry. Bertolin C, Marcos V, Merenciano H, Perez N, Pérez Del Villar C, Gavara J, Lopez MP et al. European Journal of Internal Medicine. 2025 January 01. 131104-112. DOI:10.1016/j.ejim.2024.09.015. PMID:39384454.

4.

Allergic contact dermatitis triggered by castor oil-containing dressings. Delgado A, Valls M, Ferriols F, Sastre A, Tarrasó B, Morales A, Morales C. CONTACT DERMATITIS. 2025 January 01. 92 (1):84-85. DOI:10.1111/cod.14705. PMID:39375443.

5.

Time to positivity of Coagulase Negative Staphylococcus In Neonatal Blood Cultures as an adjunct tool to help discriminate between sepsis and contamination. Carbonell S, Olea B, Pérez R, Giménez E, Colomina J, Navarro D, Estañ J. Journal of Perinatology. 2025 January 01. 45 (1):111-115. DOI:10.1038/s41372-024-02158-0. PMID:39488666.

6.

Impact of the microscopic quality of endotracheal aspirates on the performance of the Filmarray® pneumonia plus panel in intensive care unit patients with suspected lower respiratory tract infection. Cano S, de Michelena P, Clari MÁ, Liñan J, Olea B, Torres I, Carbonell N et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2025 January 01. 44 (1):27-35. DOI:10.1007/s10096-024-04967-9. PMID:39466545.

7.

Impact of automated nucleic acid extraction platforms on plasma Cytomegalovirus DNA loads quantitated by real-time PCR normalized to the 1st WHO international standard. Sánchez A, Albert E, Michelena P, Giménez E, Navarro D. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2025 January 01. 43 (1):28-31. DOI:10.1016/j.eimc.2024.07.008.

8.

Enrichment of RedoxifibromiR miR-21-5p in Plasma Exosomes of Hypertensive Patients with Renal Injury. Martinez O, Flores A, Mendez M, Martinez S, Martinez F, Forner MJ, Redon J et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 January 01. 26 (2):DOI:10.3390/ijms26020590. PMID:39859307.

9.

Pericytes in Glioblastoma: Hidden Regulators of Tumor Vasculature and Therapy Resistance. Salazar Saura I, Pí-nilla Sala M, Megías J, Navarro L, Roselló Sastre E, San Miguel T. Cancers. 2025 January 01. 17 (1):DOI:10.3390/cancers17010015. PMID:39796646.

10.

Affective states and stress in health-professional caregivers of people with functional diversity: the important role of empathy and social support as mediators of this relationship. García E, Pérez A, Martínez A, Valero S. Investigación y Educacion en Enfermeria. 2025 January 01. 43 (1):DOI:10.17533/udea.iee.v43n1e12. PMID:40382008.

11.

Role of miRNAs as epigenetic regulators of immune checkpoints in lung cancer immunity. Cánovas I, Nach-er E, Suay G, Lahoz A, García JL, Mena S. International Review of Cell and Molecular Biology. 2025 January 01. 390109-139. DOI:10.1016/bs.ircmb.2024.08.002. PMID:39864893.

12.

Effect of TikTok on Self-Harm and Suicidal Behavior in the Adolescent Population: Protocol for a Systematic Review. García Fenollar C, Sánchez Ortí JV, Rojo Bofill LM, Tabarés Seisdedos R. JMIR Research Protocols. 2025 January 01. 14DOI:10.2196/78600. PMID:41172321.

13.

Antidepressant and Antipsychotic Drug Use and Cancer Risk: Protocol for an Overview of Systematic Reviews and Meta-Analyses. Sánchez Ortí JV, Forés Martos J, Doan V, Vicente Martínez P, Saint Gerons DM, Flores Rodero M, Sánchez Valle J et al. JMIR Research Protocols. 2025 January 01. 14DOI:10.2196/78596. PMID:41435370.

14.

Normal hearing and verbal discrimination in real sounds environments. Colatosti AL, Gil IP, Ventura AM, Monteagudo EL, Aranda LC, Algarra JM. Acta Otorrinolaringologica Espanola. 2025 January 01. 76 (1):11-19. DOI:10.1016/j.otorri.2024.05.005. PMID:38908790.

15.

Prospective study of sound localization in patients with single sided deafness and asymmetric hearing loss treated with cochlear implant. Redó MA, Gil IP, Pérez T, González CE, Ventura AM, Algarra JM. Acta Otorrinolaringologica Espanola. 2025 January 01. 76 (1):1-10. DOI:10.1016/j.otorri.2024.05.002.

16.

Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment. Gutiérrez L, Vendrell J, Ramos JA, Etx-

eandia JI, Aguilar E, De Santiago AI, Hernández D et al. JOURNAL OF PSYCHOPHARMACOLOGY. 2025 January 01. 39 (1):38-48. DOI:10.1177/02698811241267837. PMID:39113255.

17. Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. Gonzalez C, Morgades M, Lopes T, Fuster F, Montesinos P, Barba P, Diaz M et al. HAEMATOLOGICA. 2025 January 01. 110 (1):206-211. DOI:10.3324/haematol.2024.285416. PMID:39113657.

18. PET-TC [18F]F-Choline and intraoperative PTH in the surgical treatment of the primary hyperparathyroidism without preoperative location. García F, Cassinello N, Rodríguez J, Martí R, Lapeña M, Alfonso R, Díaz R et al. Revista Espanola de Medicina Nuclear e Imagen Molecular. 2025 January 01. 44 (1):500066-500066. DOI:10.1016/j.remnm.2024.500066. PMID:39349175.

19. Extracellular vesicles from *L. paracasei* improve neuroinflammation, GABA neurotransmission and motor incoordination in hyperammonemic rats. Arenas YM, Pérez G, Montoliu C, Llansola M, Felipo V. BRAIN BEHAVIOR AND IMMUNITY. 2025 January 01. 123556-570. DOI:10.1016/j.bbi.2024.10.002. PMID:39384052.

20. Adherence to patient blood management strategy in patients with gastrointestinal bleeding: a prospective nationwide multicenter study. Tejedor J, Ballester MP, Del Castillo FJ, García S, Domper MJ, Parada P, Saiz RM et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 2025 January 01. 37 (1):15-23. DOI:10.1097/MEG.0000000000002843. PMID:39324889.

21. Navigating 'grey areas' and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT. Polverelli N, Hernández JC, Gagelmann N, Gurnari C, Malagola M, Duarte FB, Funke V et al. BONE MARROW TRANSPLANTATION. 2025 January 01. 60 (1):10-18. DOI:10.1038/s41409-024-02437-6. PMID:39402189.

22. Profiles of muscle-specific oxygenation responses and thresholds during graded cycling incremental test. Sendra C, Encarnacion A, Salvador R, Murias JM, Priego JI. EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY. 2025 January 01. 125 (1):237-245. DOI:10.1007/s00421-024-05593-1. PMID:39259396.

23. Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ". Fornaro M, Caiazza C, Bil-

leci M, Berk M, Marx W, Balanza V, De Prisco M et al. MOLECULAR PSYCHIATRY. 2025 January 01. 30 (1):168-187. DOI:10.1038/s41380-024-02645-y. PMID:39026098.

24. Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children. Theron A, Alonso A, Dapena JL, López M, Diaz de Heredia C, Verdú J, Sarrate E et al. BRITISH JOURNAL OF HAEMATOLOGY. 2025 January 01. 206 (1):186-194. DOI:10.1111/bjh.19862. PMID:39463072.

25. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Apperloo EM, Gorriz JL, Soler MJ, Cigarrán S, Cruzado JM, Puchades MJ, López M et al. NATURE MEDICINE. 2025 January 01. 31 (1):278-285. DOI:10.1038/s41591-024-03327-6. PMID:39455729.

26. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Andel PCM, van I, Augustinus S, Berrevoet F, Besselink MG, Bhojwani R, Boggi U et al. JAMA Surgery. 2025 January 01. 160 (1):74-84. DOI:10.1001/jamasurg.2024.5024. PMID:39504033.

27. High Positive End-expiratory Pressure (PEEP) with Recruitment Maneuvers versus Low PEEP during General Anesthesia for Surgery: A Bayesian Individual Patient Data Meta-analysis of Three Randomized Clinical Trials. Mazzinari G, Zampieri FG, Ball L, Campos NS, Bluth T, Hemmes SNT, Ferrando C et al. ANESTHESIOLOGY. 2025 January 01. 142 (1):72-97. DOI:10.1097/ALN.0000000000005170. PMID:39042027.

28. Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group. García J, González N, Torres M, García D, Molina I, Beltrán I, Santos S et al. NEUROLOGIA. 2025 January 01. 40 (1):118-137. DOI:10.1016/j.nrl.2023.06.003. PMID:38431253.

29. Optimizing therapeutic approaches for HR+/HER2advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression. Andújar JMC, de la Peña FA, Vila MM, Pascual J, Tolos P, Pages C, Cuenca N et al. Cancer Drug Resistance. 2025 January 01. 85-5. DOI:10.20517/cdr.2024.169. PMID:39935426.

30. Depression and Accelerated Aging: The Eveningness Chronotype and Low Adherence to the Mediterranean Diet Are Associated with Depressive Symptoms in Older Subjects. Sorlí JV, de la Cámara E, Fernández R, Asensio EM, Portolés O, Ortega C, Pérez A et al. Nutrients. 2025 January 01. 17 (1):DOI:10.3390/nu17010104. PMID:39796538.

31. The Interactive Effects of Fruit Intake Frequency and Serum miR-484 Levels as Biomarkers for Incident Type 2 Diabetes in a Prospective Cohort of the Spanish Adult Population: The Di@bet.es Study. Lago A, Oualla W, Maldonado C, Valdés S, González I, Doulatram V, Delgado E et al. Biomedicines. 2025 January 01. 13 (1):DOI:10.3390/biomedicines13010160. PMID:39857744.

32. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis. Schettini F, Nucera S, Pascual T, Martínez O, Sánchez R, Conte B, Buono G et al. CANCER TREATMENT REVIEWS. 2025 January 01. 132102865-102865. DOI:10.1016/j.ctrv.2024.102865. PMID:39709655.

33. Interest, uptake, and feasibility trial of a real-life digital health intervention to improve lifestyle in Brazil. De Boni RB, Mota JC, Duncan M, Linconl L, Costa G, Pimentel S, Sales KP et al. Digital Health. 2025 January 01. 11DOI:10.1177/20552076251316719. PMID:39886095.

34. Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence. Giordano A, Pérez I, Gisbert JP, Ricart E, Martín MD, Mesonero F, Parga MLD et al. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2025 January 01. 120 (1):194-203. DOI:10.14309/ajg.0000000000003207. PMID:39745305.

35. Efficacy and safety of bempedoic acid in acute coronary syndrome. Design of the clinical trial ES-BempeDACS. Raposeiras S, Abu E, Rivera J, Pérez PJ, López AA, Tejedor AV, Pascual MJC et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 January 01. 78 (1):56-63. DOI:10.1016/j.rec.2024.05.017. PMID:39059729.

36. Evaluation of leg symmetry in muscle oxygen saturation during submaximal to maximal cycling exercise. Sendra C, Priego JI, Murias JM, Carpes FP, Salvador R, Encarnación A. European Journal of Sport Science. 2025 January 01. 25 (1):DOI:10.1002/ejsc.12230. PMID:39632540.

37. Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT. Angelillo P, Tomas AA, Campodonico E, Novak U, Gabellier L, Blau IW, Kwon M et al. BONE MARROW TRANSPLANTATION. 2025 January 01. 60 (1):100-102. DOI:10.1038/s41409-024-02451-8. PMID:39455896.

38. Santander Statement: Towards Global Convergence in Transplantation: Sufficiency, Transparency, and Over-

sight. Participants to the Global Summit in Transplantation OBYTO. TRANSPLANTATION. 2025 January 01. 109 (1):7-9. DOI:10.1097/TP.0000000000005286. PMID:39636761.

39. Addressing Renal Sodium Avidity in Chronic Heart Failure: There Is Always More than One Way to Skin a Cat. Montomoli M, Gonzalez M, Gorriz JL, Puchades MJ, Nuñez Marín G, Lecueder MS. CardioRenal Medicine. 2025 January 01. 15 (1):399-412. DOI:10.1159/000545017. PMID:40228493.

40. Gamification as a Tool for Understanding Mental Disorders in Nursing Students: Qualitative Study. Del Pozo P, Tovar A, Carpintero EG, Huertas AC, de Vinaspre RR, Martínez A, Chover E et al. JMIR Nursing. 2025 January 01. 8DOI:10.2196/71921. PMID:40540428.

41. Point-of-Care Ultrasound over Punchlines: Rethinking the Cardiology-Nephrology Standoff in the Era of MedEd Humor. Koratala A, Argaiz ER, De La Espriella R, Marcos MC, Romero González G. CardioRenal Medicine. 2025 January 01. 15 (1):423-426. DOI:10.1159/000546388. PMID:40383115.

42. Changes in Renal Venous Flow and Liberation from Renal Replacement Therapy in Patients with Acute Heart Failure. Husain F, Vaughan L, Bauer P, Tello K, Richter MJ, Gall H, De la Espriella R et al. CardioRenal Medicine. 2025 January 01. 15 (1):535-543. DOI:10.1159/000546851. PMID:40494318.

43. Clinical features, mutation spectrum and factors related to reaching molecular diagnosis in a cohort of patients with distal myopathies. Muelas N, Carretero L, Martí P, Azorín I, Frasquet M, Poyatos J, Portela S et al. JOURNAL OF NEUROLOGY. 2025 January 01. 272 (1):97-97. DOI:10.1007/s00415-024-12821-3. PMID:39775307.

44. Workplace Health Interventions Targeting Cardiovascular Diseases and Diabetes Mellitus for Blue-Collar Workers: Protocol for a Scoping Review. Di C, Lipiak A, Franco M, Kaczmarek K, Romaniuk P, Muñoz C, Arroyo A et al. JMIR Research Protocols. 2025 January 01. 14DOI:10.2196/74248. PMID:41106820.

45. First Contact With Care Through Clinical Simulation in Nursing Students: Qualitative Study. Carpintero EG, Del Pozo P, Hernández MD, Rodríguez M, Navas N, Chover E, Martinez A et al. JMIR Nursing. 2025 January 01. 8DOI:10.2196/81617. PMID:41103180.

46. Prevalence of daily family meals among children and adolescents from 43 countries. López JF, Smith L, Tully MA, Alvarez J, Gómez SF, Schröder H. Maternal and Child Nutrition. 2025 January 01. 21 (1):DOI:10.1111/mcn.13706. PMID:39186933.

47. Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT. Battipaglia G, Polverelli N, Tuffnell J, Chiusolo P, Robin M, Gambella M, Broers A et al. *Current Research in Translational Medicine*. 2025 January 01. 73 (1):DOI:10.1016/j.retram.2024.103476. PMID:39461096.

48. Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia. Shimoni A, Peczynski C, Labopin M, Kulagin A, Meijer E, Cornelissen J, Choi G et al. *LEUKEMIA*. 2025 January 01. 39 (1):222-228. DOI:10.1038/s41375-024-02445-x. PMID:39482353.

49. A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX. Rodríguez E, Rodríguez R, Soria E, Bergua JM, Caballero T, Arnán M, Vives S et al. *CANCER*. 2025 January 01. 131 (1):DOI:10.1002/cncr.35618. PMID:39476204.

50. Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study. Lloret P, Boluda B, Martínez J, Bergua J, Arbolí ER, Labrador J, Sossa C et al. *CANCER*. 2025 January 02. 131 (1):DOI:10.1002/cncr.35696. PMID:39748608.

51. Clinical outcomes and anti-inflammatory mechanisms predict maximum heart rate improvement after physical activity training in individuals with psychiatric disorders and comorbid obesity. Soldevila P, Sánchez JV, Correa P, Balanzá V, Selva G, Sanchis R, Iglesias N et al. *PLoS One*. 2025 January 03. 20 (1):DOI:10.1371/journal.pone.0313759. PMID:39752432.

52. How Do Psychiatry Residents View Their Training in Spain? A Mixed-Method Survey. Carrasco JP, Etxeandia JI, Esteve J, Aguilar EJ. *ACTAS ESPANOLAS DE PSIQUIATRIA*. 2025 January 05. 53 (1):26-37. DOI:10.62641/aep.v53i1.1760. PMID:39801409.

53. Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial. Esteban A, Recio A, López R, de Lara G, Barrantes M, Gómez I, Nuñez J et al. *Frontiers in Cardiovascular Medicine*. 2025 January 06. 111504427-1504427. DOI:10.3389/fcvm.2024.1504427. PMID:39850382.

54. Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin following an Admission for Acute Heart Failure. Miñana G, de la Espriella R, Lorenzo M, Rodríguez E, Mollar A, Palau P, Fernández A et al. *CardioRenal Medicine*. 2025 January 08. 15 (1):122-132. DOI:10.1159/000543417. PMID:39778554.

55. Cardiorenal Disease and Heart Failure with Preserved Ejection Fraction: Two Sides of the Same Coin. Núñez Marín G, Santas E. *CardioRenal Medicine*. 2025 January 08. 15 (1):108-121. DOI:10.1159/000543390. PMID:39778558.

56. Differences in association between hypoalbuminaemia and mortality among younger versus older patients on haemodialysis. Sanz C, Rodríguez M, Gorriz JL, Martín B, Floege J, Díaz B, Palomo C et al. *Clinical Kidney Journal*. 2025 January 08. 18 (1):DOI:10.1093/ckj/sfae339. PMID:39781478.

57. Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. Oñate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M, Diaz M et al. *Blood Cancer Journal*. 2025 January 11. 15 (1):4-4. DOI:10.1038/s41408-024-01205-5. PMID:39799145.

58. Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program. Bertolín C, Merenciano H, Marcos V, Martínez ML, Alberola J, Pérez N, López L et al. *Reviews in Cardiovascular Medicine*. 2025 January 13. 26 (1):25399-25399. DOI:10.31083/RCM25399. PMID:39867202.

59. Psychological Risk and Protective Factors for the Development of Prolonged Grief in Mourners. Ribera O, Pérez M, Valero S. *Family Journal*. 2025 January 13. DOI:10.1177/10664807241312201.

60. The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden. Revuelta E, de la Espriella R, Miñana G, Santas E, Villar S, Sanchis J, Bayés A et al. *Scientific Reports*. 2025 January 14. 15 (1):1905-1905. DOI:10.1038/s41598-024-84622-7. PMID:39809935.

61. Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Harrington K, Kitano S, Gambardella V, Parkes EE, Moreno I, Alonso G, Doi T et al. *Future Oncology*. 2025 January 14. 21 (2):195-200. DOI:10.1080/14796694.2024.2441107. PMID:39817655.

62. Efficacy of N-Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. Viña I, Viña JR, Carranza M, Mariscal G. *Nutrients*. 2025 January 14. 17 (2):DOI:10.3390/nu17020284. PMID:39861414.

63. Ammonia and beyond - biomarkers of hepatic encephalopathy. Gallego JJ, Ballester MP, Fiorillo A, Casanova Fer-

rer F, López Gramaje A, Urios A, Arenas YM et al. *METABOLIC BRAIN DISEASE*. 2025 January 15. 40 (1):100-100. DOI:10.1007/s11011-024-01512-7. PMID:39812958.

64. Estimating SARS-CoV-2 Omicron XBB.1.5 Spike-Directed Functional Antibody Levels From an Anti-Receptor Binding Domain Wuhan-Hu-1-Based Commercial Immunoassay Results. Sánchez A, Cuevas E, Fernández D, Grau B, Albert E, Giménez E, Avilés AI et al. *JOURNAL OF MEDICAL VIROLOGY*. 2025 January 15. 97 (1):DOI:10.1002/jmv.70130. PMID:39812228.

65. Current evidence on powered versus manual circular staplers in colorectal surgery: a systematic review and meta-analysis. Martin J, Moro D, Pérez L, López F, Peña CJ, Asins J, Rodrigo DC et al. *INTERNATIONAL JOURNAL OF COLORECTAL DISEASE*. 2025 January 15. 40 (1):13-13. DOI:10.1007/s00384-025-04807-y. PMID:39814974.

66. Gait physiotherapy with motor imagery in people with Parkinson's disease: a protocol for randomized control GAITimagery trial. Valenzuela CS, Murcia ER, Aznar E, Sotolongo DG, Rosas R, Sánchez ML. *Frontiers in Neurology*. 2025 January 17. 151508043-1508043. DOI:10.3389/fneur.2024.1508043. PMID:39895907.

67. Non-canonical imprinting, manifesting as post-fertilization placenta-specific parent-of-origin dependent methylation, is not conserved in humans. Daskeviciute D, Chappell L, Sainty B, Arnaud P, Iglesias I, Simon C, Okae H et al. *HUMAN MOLECULAR GENETICS*. 2025 January 17. 34 (7):626-638. DOI:10.1093/hmg/ddaf009. PMID:39825493.

68. Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL. Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland JB, Brieghel C, Andersen MK et al. *HemaSphere*. 2025 January 20. 9 (1):DOI:10.1002/hem3.70065. PMID:39840379.

69. Mapping Human Uterine Disorders Through Single-Cell Transcriptomics. Boldu S, Lliberos C, Simon C, Mas A. *Cells*. 2025 January 21. 14 (3):DOI:10.3390/cells14030156. PMID:39936948.

70. Healthcare worker views on antimicrobial resistance in chronic respiratory disease. Ananth S, Adeoti AO, Ray A, Middleton PG, Ekkelenkamp M, Thee S, Shah A et al. *Antimicrobial Resistance and Infection Control*. 2025 January 22. 14 (1):1-1. DOI:10.1186/s13756-025-01515-8. PMID:39844291.

71. Development of a checklist for cognitive assessment requirements (CARE) based on a Delphi consensus study. Nejati V, Estaji R, Balanzá V, Balota DA, Barker S, Bell M,

Berry JH et al. *Scientific Reports*. 2025 January 24. 15 (1):3146-3146. DOI:10.1038/s41598-025-87380-2. PMID:39856338.

72. Epigenome-wide DNA methylation profiling in septic and non-septic patients with similar infections: potential use as sepsis biomarkers. López I, García JL, Madrazo M, García J, Piles L, Pallardó FV, Artero A. *Frontiers in Cellular and Infection Microbiology*. 2025 January 24. 141532417-1532417. DOI:10.3389/fcimb.2024.1532417. PMID:39926115.

73. Relationship between psychological empowerment, physical activity enjoyment, and response to a HIIT Program in physically inactive young women: a prospective multicentre study. Ferrando I, Núñez R, López L, Alcántara E, Calatayud J, Casaña J, Parcina I et al. *BMC Womens Health*. 2025 January 27. 25 (1):38-38. DOI:10.1186/s12905-025-03576-8. PMID:39871301.

74. Editorial: Molecular and cellular pathways leading to mitochondrial dysfunction and neurodegeneration: lessons from in vivo models, volume II. Hannan SB, De Lazzari F, Gomez Duran A, Navarro JA, Brea Calvo G, Sanchez Martinez A. *Frontiers in Neuroscience*. 2025 January 29. 191557013-1557013. DOI:10.3389/fnins.2025.1557013. PMID:39944887.

75. Lesbian, gay, bisexual, and transgender clinical competence of health professionals in Poland and Spain: results of the health exclusion research in Europe (HERE) study. Karniej P, Dissen A, Pietrzykowski L, Juárez R, Sabater AM, Kulinska J, Zielinski J et al. *BMC Medical Education*. 2025 January 29. 25 (1):144-144. DOI:10.1186/s12909-025-06744-4. PMID:39881315.

76. Effects of Eleclazine (GS6615) on the proarrhythmic electrophysiological changes induced by myocardial stretch. Chorro FJ, Such L, Cuñat S, Arias O, Genovés P, Zarzoso M, Alberola A et al. *Frontiers in Physiology*. 2025 January 31. 161525836-1525836. DOI:10.3389/fphys.2025.1525836. PMID:39958692.

77. Ondansetron blocks fluoxetine effects in immature neurons in the adult rat piriform cortex layer II. Recatalá M, Hidalgo P, Nàcher J, Blasco JM, Crespo C, Varea E. *NEUROSCIENCE LETTERS*. 2025 January 31. 847138099-138099. DOI:10.1016/j.neulet.2024.138099. PMID:39732189.

78. Unraveling the Mechanisms Behind Exercise Intolerance and Recovery in Long COVID. Palau P, Calvo B, Sastre C, Domínguez E, Marín P, Flor C, Núñez J et al. *American Journal of Medicine*. 2025 February 01. 138 (2):362-367. DOI:10.1016/j.amjmed.2024.04.023. PMID:38648998.

79. Beyond nest size: the clinicopathological spectrum of large nested melanocytic tumours and the value of comparative genomic hybridisation and messenger RNA expression analysis. Mosquera A, Pérez S, Porcar S, Casabó G, Martínez M, Garzón MJ, García E et al. *PATHOLOGY*. 2025 February 01. 57 (1):40-48. DOI:10.1016/j.pathol.2024.08.002. PMID:39489642.

80. Microbiota Co-Metabolism Alterations Precede Changes in the Host Metabolism in the Early Stages of Diet-Induced MASLD in Wistar Rats. Martín M, Casanova P, Moreno L, Morales JM, Marrachelli VG, Monleón D. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*. 2025 February 01. 26 (3):DOI:10.3390/ijms26031288. PMID:39941056.

81. Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia. Muñoz I, Pérez R, Castillo N, Cordero T, Ochando A, Ortega S, Parras M et al. *NATURE MEDICINE*. 2025 February 01. 31 (2):502-513. DOI:10.1038/s41591-024-03407-7. PMID:39775038.

82. High-risk neuroblastoma: ATRX and TERT as prognostic markers and therapeutic targets. Review and update on the topic. Gonzales Céspedes G, Navarro S. *Revista Espanola de Patologia*. 2025 February 01. 58 (1):100790-100790. DOI:10.1016/j.patol.2024.100790. PMID:39793153.

83. Obesity and Adipose-Derived Extracellular Vesicles: Implications for Metabolic Regulation and Disease. Malaguarnera M, Cauli O, Cabrera Pastor A. *Biomolecules*. 2025 February 01. 15 (2):DOI:10.3390/biom15020231. PMID:40001534.

84. Targeting Inflammation and Iron Deficiency in Heart Failure: A Focus on Older Adults. Maidana D, Arroyo Álvarez A, Barreres Martín G, Arenas Oriente A, Cepas Guillen P, Brigolin Garofo RT, Caravaca Pérez P et al. *Biomedicines*. 2025 February 01. 13 (2):DOI:10.3390/biomedicines13020462. PMID:40002874.

85. Tackling ALT-positive neuroblastoma: is it time to redefine risk classification systems? A systematic review with IPD meta-analysis. Avinent Pérez M, Westermann F, Navarro S, López Carrasco A, Noguera R. *NEOPLASIA*. 2025 February 01. 60101106-101106. DOI:10.1016/j.neo.2024.101106. PMID:39733691.

86. Propensity Score Analysis of the Utility of Supervised Perioperative Abdominal Wall Exercises for the Prevention of Parastomal Hernia. López VA, Yuste A, Murad M, Navarro R, Pérez L, Martín J, Moro D et al. *Nursing Reports*. 2025 February 01. 15 (2):DOI:10.3390/nursrep15020062. PMID:39997798.

87. Factors Associated with Workplace Injuries Among Shift Work Nurses: A Cross-Sectional Study in an Ecuadorian Sample. Prados G, Mendoza A, Holguín M, Cambil J, Fernández L. *Nursing Reports*. 2025 February 01. 15 (2):DOI:10.3390/nursrep15020044. PMID:39997780.

88. HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry. Calafat M, Suria C, Mesonero F, de Francisco R, Caballero CY, Peña L, Hernández A et al. *AMERICAN JOURNAL OF GASTROENTEROLOGY*. 2025 February 01. 120 (2):431-439. DOI:10.14309/ajg.0000000000002965. PMID:39888687.

89. DNA methylation shapes the Polycomb landscape during the exit from naive pluripotency. Richard J, Urli T, Monteagudo A, Le A, Sultanova A, David A, Scarpa M et al. *NATURE STRUCTURAL & MOLECULAR BIOLOGY*. 2025 February 01. 32 (2):346-357. DOI:10.1038/s41594-024-01405-4. PMID:39448850.

90. Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypND and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study. Lordick F, Mauer ME, Stocker G, Cella CA, Ben I, Piessen G, Wyrwicz L et al. *ANNALS OF ONCOLOGY*. 2025 February 01. 36 (2):197-207. DOI:10.1016/j.annonc.2024.10.829. PMID:39542422.

91. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. Ramírez MJ, Pujol R, Minguillón J, Bogliolo M, Persico I, Caveiro D, de la Cal A et al. *AMERICAN JOURNAL OF HEMATOLOGY*. 2025 February 01. 100 (2):272-284. DOI:10.1002/ajh.27520. PMID:39562502.

92. Risk of developing neuroblastoma influenced by maternal stressful life events during pregnancy and congenital pathologies. Benavent N, Cañete A, Moreno L, Gros L, Verdú J, Salinas JA, Navarro S et al. *PEDIATRIC BLOOD & CANCER*. 2025 February 01. 72 (2):DOI:10.1002/pbc.31402. PMID:39618320.

93. Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention. Pagano G, Lyakhovich A, Thomas PJ, Catalayud FVP, Tiano L, Zatterale A, Trifuoggi M. *INFLAMMOPHARMACOLOGY*. 2025 February 01. 33 (2):431-441. DOI:10.1007/s10787-024-01613-w. PMID:39656417.

94. Altered mitochondrial unfolded protein response and protein quality control promote oxidative distress in down syndrome brain. Lanzillotta S, Esteve D, Lanzillot-

ta C, Tramutola A, Lloret A, Forte E, Pesce V et al. *FREE RADICAL BIOLOGY AND MEDICINE*. 2025 February 01. 22780-93. DOI:10.1016/j.freeradbiomed.2024.11.043. PMID:39586382.

95. Medical Nutrition Therapy and Physical Exercise for Acute and Chronic Hyperglycemic Patients with Sarcopenia. Abad A, Veses S, Pla M, Civera M, García K, Sánchez C, Artero A et al. *Nutrients*. 2025 February 01. 17 (3):DOI:10.3390/nu17030499. PMID:39940355.

96. Emotional Contagion Among Adolescents with Type 1 Diabetes Mellitus (T1DM) and Their Primary Caregivers: Benefits of Psychological Support for Family Systems in Pilot Study. Rodríguez P, Martín J, Rodríguez E, Valero S, Montoya I, Pérez M. *Children-Basel*. 2025 February 01. 12 (2):DOI:10.3390/children12020151. PMID:40003253.

97. Different impact of chronic kidney disease in older patients with heart failure according to frailty. Díez P, Jiménez C, Pérez A, Caballero EB, López J, Ortiz C, Bonanad C et al. *European Journal of Internal Medicine*. 2025 February 01. 13290-96. DOI:10.1016/j.ejim.2024.12.001. PMID:39648049.

98. Optimal dose and pattern of physical activity to prevent diagnosed depression: prospective cohort study. Andersen LL, López R, Kandola A, Núñez R, López L, Calatayud J. *PSYCHOLOGICAL MEDICINE*. 2025 February 04. 55DOI:10.1017/S003329172400343X. PMID:39901870.

99. Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. Bastos Oreiro M, Iacoboni G, Garcés VN, Caballero AC, Martínez N, Delgado J, Balaguer A et al. *HemaSphere*. 2025 February 04. 9 (2):DOI:10.1002/hem3.70077. PMID:39906687.

100. Sodium valproate reverses aortic hypercontractility in acute myocardial infarction in rabbits. Guerra S, Suarez A, Belmonte B, Marchio P, Genoves P, Arias OJ, Aldasoro Met al. *European Journal of Pharmacology*. 2025 February 05. 988177216-177216. DOI:10.1016/j.ejphar.2024.177216. PMID:39706463.

101. Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study. Peña R, Bermejo B, Pollán M, Díaz A, Jerez Y, Ponce JJ, Fernández A et al. *npj Breast Cancer*. 2025 February 08. 11 (1):12-12. DOI:10.1038/s41523-025-00718-x. PMID:39922815.

102. Seasonal and cyclical variations in short-term postoperative outcomes of colorectal cancer: a time series analysis. Martín J, Moro D, García S, Pérez L, Casado D,

Garzón LP, Castillejos F et al. *Scientific Reports*. 2025 February 12. 15 (1):5161-5161. DOI:10.1038/s41598-025-88782-y. PMID:39939658.

103. Differential association of selenium exposure with insulin resistance and β -cell function in middle age and older adults. Rodríguez Z, Bel J, Moreno B, Grau M, Redon J, Gomez JL, Garcia T et al. *Nutrition & Diabetes*. 2025 February 13. 15 (1):5-5. DOI:10.1038/s41387-025-00361-2. PMID:39948355.

104. Impact on Quality of Life of Full-time and Night-time Braces in Adolescent Idiopathic Scoliosis A Randomized Clinical Trial. Peiro A, Garcia RG, Martin V, Vilalta I, Gonzalez L, Martin JM, Silvestre A. *SPINE*. 2025 February 15. 50 (4):231-237. DOI:10.1097/BRS.00000000000005228. PMID:39632385.

105. Exploring plant virus diversity in wastewater and reclaimed water through metagenomic analysis. Cuevas E, Sánchez G, Pérez A. *WATER RESEARCH*. 2025 February 15. 270122827-122827. DOI:10.1016/j.watres.2024.122827. PMID:39602961.

106. Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial. Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, González L et al. *Vaccine*. 2025 February 15. 47DOI:10.1016/j.vaccine.2024.126685. PMID:39809095.

107. Epidemiological trends of mechanically ventilated acute respiratory distress syndrome in the twenty-first century: a nationwide, population-based retrospective study. Bardaji M, López R, Aguilar G, Arroyo I, Gómez E, Camporota L, Villar J et al. *Journal of Intensive Care*. 2025 February 17. 13 (1):9-9. DOI:10.1186/s40560-025-00781-3. PMID:39962546.

108. Digital analysis of ovarian tissue: generating a standardized method of follicle analysis. McDowell H, Martí IV, VanZanten M, Pant S, Kubo H, Saunders DC, Laronda MM et al. *BIOLOGY OF REPRODUCTION*. 2025 February 20. 112 (3):416-419. DOI:10.1093/biolre/iaof022. PMID:39903671.

109. Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors. Luke JJ, Pinato DJ, Juric D, Lorusso P, Hosein PJ, Desai AM, Haddad R et al. *Journal for ImmunoTherapy of Cancer*. 2025 February 20. 13 (2):DOI:10.1136/jitc-2024-010511. PMID:39979069.

110. Potential of Pterostilbene as an Antioxidant Therapy for Delaying Retinal Damage in Diabetic Retinopathy. de las Matas RBS, Torres I, Millán I, Desco MD, Oblaré C, Asen-

si M, Mena S et al. Antioxidants. 2025 February 20. 14 (3):DOI:10.3390/antiox14030244. PMID:40227230.

111. Effects of a Multimodal Program on Frailty Syndrome and Psychological Alterations in Breast Cancer Women Treated with Aromatase Inhibitors. Céspedes P, Martínez FM, Torregrosa MD, Cauli O, Buigues C. Clinics and Practice. 2025 February 21. 15 (3):DOI:10.3390/clinpract15030041. PMID:40136577.

112. Familial Hypercholesterolemia Screening in a Cardiac Rehabilitation Program After Myocardial Infarction. Bertolín C, Marcos V, Merenciano H, Mas MLM, Alberola J, Perez N, Bueno LL et al. Cardiogenetics. 2025 February 24. 15 (1):DOI:10.3390/cardiogenetics15010006.

113. Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma. Camacho L, Iacoboni G, Kwon M, Bailén R, Hernani R, Benzaquén A, López L et al. JAMA Network Open. 2025 February 25. 8 (2):DOI:10.1001/jamanetworkopen.2024.61683. PMID:39998830.

114. Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids. Papaccio F, Cabeza M, García B, Gimeno F, Zúñiga S, Gambardella V, Gutiérrez MF et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2025 February 28. 44 (1):77-77. DOI:10.1186/s13046-025-03308-8. PMID:40022181.

115. Use of Team Management software to optimize communication and organization of a psychiatry clinical placement. Rojo LM, Ortiz CS, Pradas FB, Rodríguez PB, Alarcón VS, García E. Spanish Journal of Medical Education. 2025 February 28. 6 (2):DOI:10.6018/edumed.647621.

116. Role of spot urinary sodium in outpatients with heart failure. Lorenzo M, De la Espriella R, Miñana G, Núñez G, Carratalá A, Rodríguez E, Santas E et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 March 01. 78 (3):185-195. DOI:10.1016/j.rec.2024.07.002. PMID:39038750.

117. Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Martínez B, Camblor DG, Martín J, Carbonell JA, García B, Gambardella V, Huerta M et al. ANNALS OF ONCOLOGY. 2025 March 01. 36 (3):263-276. DOI:10.1016/j.annonc.2024.12.006. PMID:39675560.

118. The impact of hypoalbuminemia on the long-term prognosis of patients with acute heart failure: The modifying role of carbohydrate antigen 125. Llàcer P, Croset F, De la Espriella R, García M, Miñana G, Campos J, Santas E et al. European Journal of Internal Medicine. 2025 March 01. 13371-77. DOI:10.1016/j.ejim.2024.12.024. PMID:39753436.

119. Detection rate of herpes simplex virus DNA in the lower respiratory tract of critical care patients with or without coinfection determined by the Biofire® pneumonia plus panel. Cano S, Clari MA, Albert E, Villar E, Sánchez BQ, Carbonell N, Navarro D. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2025 March 01. 111 (3):116721-116721. DOI:10.1016/j.diagmicrobio.2025.116721. PMID:39889437.

120. Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression. Martinez C, Barros R, Caballero C, Boggino H, Alarcón L, Peleteiro B, Ruiz E et al. Gastric Cancer. 2025 March 01. 28 (2):160-173. DOI:10.1007/s10120-024-01578-3. PMID:39755998.

121. Anti-PD-1 treatment for MSI-H/MMRD tumors. A journey from genomics to transformative patient breakthroughs. Argilés G, Arnold D, Cervantes A. ANNALS OF ONCOLOGY. 2025 March 01. 36 (3):231-232. DOI:10.1016/j.annonc.2025.01.018. PMID:39984220.

122. Searching for sexually transmitted infections by midstream urine pooling after exclusion of urinary tract infection: A cost-effectiveness analysis. Castaño MJ, Guillem J, Ripoll JJ, Navarro D, Albert E. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2025 March 01. 111 (3):116700-116700. DOI:10.1016/j.diagmicrobio.2025.116700. PMID:39874858.

123. Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project. Dienstmann R, Ruiz E, Alsina M, Ruiz F, Groen TS, Martínez C, Fernández EA et al. ESMO Open. 2025 March 01. 10 (3):104482-104482. DOI:10.1016/j.esmoop.2025.104482. PMID:40036904.

124. Genetic interaction between oxidative stress and body mass index in a Spanish population. Lara F, Melero R, Quiroz ME, Moya C, Gallardo MD, Alvarez L, Valarezo IL et al. Redox Biology. 2025 March 01. 80103531-103531. DOI:10.1016/j.redox.2025.103531. PMID:39923398.

125. Specific immune-inflammatory profiles and neurocognitive deficits predict illness trajectories in people with type 2 diabetes mellitus or psychiatric disorders. Sánchez JV, Correa P, Balanzá V, Selva G, Victor VM, Valenzuela CS, Soldevila P et al. Brain Behavior & Immunity-Health. 2025 March 01. 44100962-100962. DOI:10.1016/j.bbih.2025.100962. PMID:40046177.

126. Extracorporeal liver support and liver transplantation for acute-on-chronic liver failure. Ballester MP, Elshabrawi A, Jalan R. LIVER INTERNATIONAL. 2025 March 01. 45 (3):DOI:10.1111/liv.15647. PMID:37312660.

127. A novel TAP73-inhibitory compound counteracts stemness features of glioblastoma stem cells. Villoch J, Martínez N, Martín M, Maeso L, López L, Vazquez A, Muñoz L et al. Molecular Oncology. 2025 March 01. 19 (3):852-877. DOI:10.1002/1878-0261.13694. PMID:39090849.

128. Coping behaviors to reduce anxiety and depressive symptoms: A prospective repeated assessment study. Fortea L, Solanes A, Pomarol E, Garcia MA, Fortea A, Torrent C, Varo C et al. Spanish Journal of Psychiatry and Mental Health. 2025 March 01. 18 (1):42-50. DOI:10.1016/j.sjpmh.2024.08.003. PMID:39226994.

129. Relationship of sociodemographic and clinical characteristics to mechanical restraint used in a psychiatric hospital in Spain. Ros MC, Fernández IA, Madrigal MM, Delegido AB, Ibañez CL, Haro G. JOURNAL OF ADVANCED NURSING. 2025 March 01. 81 (3):1300-1311. DOI:10.1111/jan.16305. PMID:39046147.

130. Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin. Teng NM, Malfettone A, Dalby MJ, Kiu R, Seki D, Robinson T, Gion M et al. Microbiome Research Reports. 2025 March 01. 4 (1):4-4. DOI:10.20517/mrr.2024.49. PMID:40207279.

131. Articular cartilage regeneration with a microgel as a support biomaterial. A rabbit knee model. Zurriaga J, Antolinos CM, Ródenas J, Milián L, Pla J, Oguir Z, Sancho M et al. Biomaterials Advances. 2025 March 01. 168214125-214125. DOI:10.1016/j.bioadv.2024.214125. PMID:39615373.

132. Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living Guideline. Candia L, Cervantes A, Martinelli E, ESMO Guidelines Committee. ANNALS OF ONCOLOGY. 2025 March 01. 36 (3):342-344. DOI:10.1016/j.annonc.2024.11.015. PMID:39643158.

133. Perception of medical care among women living with HIV aged 40 years or older-A European-wide survey. Miron VD, Sabin CA, Sandulescu O, Lourida G, Kyrychenko T, Dragovic G, Kowalska J et al. HIV MEDICINE. 2025 March 01. 26 (3):451-464. DOI:10.1111/hiv.13749. PMID:39675750.

134. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Biesma NC, Graus M, Cirkel GA, Besselink MG, de Groot JWB, Koerkamp BG, Herbschleb KH et al. EJSO. 2025 March 01. 51 (3):109544-109544. DOI:10.1016/j.ejso.2024.109544. PMID:39689462.

135. Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC. Escamilla V, García V, Alcalde P, Astibia B, Chinea A, López L, Acera M et al. BONE MARROW TRANSPLANTATION. 2025 March 01. 60 (3):353-362. DOI:10.1038/s41409-024-02483-0. PMID:39663471.

136. Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies. Kardassis D, Vindis C, Stancu CS, Toma L, Gafencu AV, Georgescu A, Alexandru N et al. VASCULAR PHARMACOLOGY. 2025 March 01. 158107452-107452. DOI:10.1016/j.vph.2024.107452. PMID:39667548.

137. Naltrexone for Alcohol Use Disorder in Cirrhosis: Bridging the Gap in an Understudied Population. Vergara Quispe R, Martí Aguado D, Bataller R. Journal of Clinical and Experimental Hepatology. 2025 March 01. 15 (2):102509-102509. DOI:10.1016/j.jceh.2025.102509. PMID:40027174.

138. Age-threshold for increased risk of developing back disorders: prospective cohort with 74 000 individuals from the UK Biobank. López R, Andersen LL, Núñez R, López L, Suso L, Villafañe JH, Salazar J et al. EUROPEAN SPINE JOURNAL. 2025 March 01. 34 (3):861-868. DOI:10.1007/s00586-025-08686-3. PMID:39870984.

139. The importance of data: Monitoring variables in causal inference with medical imaging. Silva CMB, Gironés PMM, Bordera AG, Cerdá L, Martí D, Villar CG, Martí L. RADIOLOGIA. 2025 March 01. 67 (2):226-230. DOI:10.1016/j.rx.2024.08.003. PMID:40187815.

140. How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force. de la Fouchardiére C, Cammarota A, Svrcek M, Alsina M, Fleitas Kanonnikoff T, Obermannová RL, Wagner AD et al. CANCER TREATMENT REVIEWS. 2025 March 01. 134102890-102890. DOI:10.1016/j.ctrv.2025.102890. PMID:39933210.

141. Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study. Boluda B, Rodriguez R, Sargas C, Ayala R, Larráyoiz MJ, Chillón MC, Soria E et al. Cancers. 2025 March 01. 17 (5):DOI:10.3390/cancers17050854. PMID:40075701.

142. Preoperative management of patients with oesophageal cancer: Expert recommendations. Bruna M, Pérez R, Acosta MA, García A, group E. CIRUGIA ESPANOLA. 2025 March 01. 103 (3):156-164. DOI:10.1016/j.cireng.2024.12.003. PMID:39706475.

143. Safety and Antitumor Activity of a Novel aCD25 Treg Depletor RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors. Gambardella V, Ong M, Rodriguez ME, Machiels JP, Sanmamed MF, Galvao V, Spreafico A et al. Cancer Research Communications. 2025 March 01. 5 (3):422-432. DOI:10.1158/2767-9764.CRC-24-0638. PMID:39983024.

144. ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/ carboplatin in patients with squamous non-small cell lung cancer. Bosch J, Estévez P, Martín P, Sabatier R, Nadal E, Sais E, Gascón P et al. LUNG CANCER. 2025 March 01. 201108105-108105. DOI:10.1016/j.lungcan.2025.108105. PMID:39983444.

145. DeepCERES: A deep learning method for cerebellar lobule segmentation using ultra-high resolution multimodal MRI. Morell S, Ruiz M, Gadea M, Vivo R, Rubio G, Aparici F, de la Iglesia M et al. NEUROIMAGE. 2025 March 01. 308121063-121063. DOI:10.1016/j.neuroimage.2025.121063. PMID:39922330.

146. Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain. Calles A, Alonso M, Martín P, Gómez A, de Castro J, Martínez M, Estival A et al. Cancer Treatment and Research Communications. 2025 March 01. 43DOI:10.1016/j.ctarc.2025.100905. PMID:40154161.

147. Interrelationships between polygenic risk scores, cognition, symptoms, and functioning in first-episode psychosis: A network analysis approach. Gil GJ, Segura AG, Sánchez AM, Amoretti S, Giné E, Vieta E, Mezquida G et al. EUROPEAN NEUROPSYCHOPHARMACOLOGICAL. 2025 March 01. 9252-61. DOI:10.1016/j.euroneuro.2024.12.002. PMID:39721378.

148. Recurrence patterns and post-recurrence survival of patients with bilobar colorectal liver metastases: international multicentre retrospective study. Siriwardena AK, Serrablo A, Novotny A, Know A, Kourdouli A, Belli A, Laurenzi A et al. BJS-British Journal of Surgery. 2025 March 03. 112 (3):DOI:10.1093/bjs/znaf003. PMID:40037797.

149. Depression, Anxiety, and Quality of Life in a Cardiac Rehabilitation Program Without Dedicated Mental Health Resources Post-Myocardial Infarction. Bertolín C, Marcos V, Merenciano H, Mas MLM, Alberola J, Perez N, López L et al. Journal of Cardiovascular Development and Disease. 2025 March 04. 12 (3):DOI:10.3390/jcdd12030092. PMID:40137090.

150. Anemia Management in the Cardiorenal Patient: A Nephrological Perspective. Vidas MM, Portolés J, Cobo M,

Gorritz JL, Nuñez J, Cases A. Journal of the American Heart Association. 2025 March 04. 14 (5):DOI:10.1161/JAHA.124.037363. PMID:40028884.

151. Prognostic value of routine blood biomarkers in 3-year survival of resectable colorectal cancer patients: a prognostic nomogram for clinical practice. Moro D, Martín J, Cózar C, García S, Pérez L, Casado D, Martínez C et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2025 March 05. 40 (1):58-58. DOI:10.1007/s00384-025-04848-3. PMID:40045061.

152. Nutrition, Lifestyle, and Environmental Factors in Lung Homeostasis and Respiratory Health. Pouptsis A, Zaragoza R, García Trevijano ER, Viña JR, Ortiz Zapater E. Nutrients. 2025 March 09. 17 (6):DOI:10.3390/nu17060954. PMID:40289995.

153. Rotational Atherectomy, Lithotripsy, or Laser for Calcified Coronary Stenosis: The ROLLER COASTR-EPIC22 Trial. Jurado A, Gómez A, Rivero B, Amat IJ, Jiménez S, Caballero J, Ojeda S et al. JACC-Cardiovascular Interventions. 2025 March 10. 18 (5):606-618. DOI:10.1016/j.jcin.2024.11.012. PMID:39918495.

154. Non-Pharmacological Interventions for Managing the Symptoms of Depression in Women with Breast Cancer: A Literature Review of Clinical Trials. Mafla MA, Cauli O. Diseases. 2025 March 11. 13 (3):DOI:10.3390/diseases13030080. PMID:40136619.

155. The Effect of Transversus Abdominis Plane Block on Pain-Related Outcomes in Kidney Transplantation: A Systematic Review with Meta-Analysis and Trial Sequential Analysis. Videman D, Aubakirova M, Nabidollayeva F, Aryngazin A, Romero N, Badenes R, Abdildin YG. Journal of Clinical Medicine. 2025 March 11. 14 (6):DOI:10.3390/jcm14061879. PMID:40142687.

156. Extended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study. EuroSurg and STARSurg C. BJS-British Journal of Surgery. 2025 March 11. 112 (3):DOI:10.1093/bjs/znaf005. PMID:40067192.

157. Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients. El WS, Bresson C, Wunder F, Carneiro BA, Dizon DS, Warner JL, Graff SL et al. Oncotarget. 2025 March 12. 16140-162. DOI:10.18632/oncotarget.28703. PMID:40073368.

158. Small extracellular vesicles from young adipose-derived stem cells ameliorate age-related changes in the heart of old mice. Sanz J, Huete J, Mas C, Romero N, Dromant M,

van M, Janssens GE et al. Stem Cell Research & Therapy. 2025 March 13. 16 (1):138-138. DOI:10.1186/s13287-025-04255-z. PMID:40082997.

159. Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge. Botello M, Tarrasó J, Mulet A, Presa L, Fernández E, Portal J, Ros JA et al. JOURNAL OF MEDICAL VIROLOGY. 2025 March 15. 97 (3):DOI:10.1002/jmv.70289. PMID:40088077.

160. Unlocking athletic potential: Exploring exercise physiology from mechanisms to performance. Gómez Cabrera MC, Handschin C. FREE RADICAL BIOLOGY AND MEDICINE. 2025 March 16. 23048-49. DOI:10.1016/j.freeradbiomed.2025.01.036. PMID:39889892.

161. Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure. Kosiborod MN, Cherney D, Desai AS, Testani JM, Verma S, Chinnakondapalli K, Dolling D et al. JACC-Journal of the American College of Cardiology. 2025 March 18. 85 (10):971-984. DOI:10.1016/j.jacc.2024.11.014. PMID:39566872.

162. Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR-T Therapy. Hernani R, Ventura L, Heras B, Serrano A, Rivada M, Martínez C, Benzaquén A et al. eJHaem. 2025 March 19. 6 (2):DOI:10.1002/jha2.70015. PMID:40110072.

163. Accuracy of the "Timed Up and Go" Test for Predicting Low Muscle Mass in a Preoperative Prehabilitation Program for Colorectal Cancer. Pérez L, Garzón LP, Martín J, Pla V, Moro D, Casado D, Riera M et al. Journal of Clinical Medicine. 2025 March 19. 14 (6):DOI:10.3390/jcm14062088. PMID:40142896.

164. Bcl-xL overexpression in T cells preserves muscle mitochondrial structure and function and prevents frailty in old mice. Mas C, Román A, Sanz J, Romero N, Huete J, Dromant M, Cuervo AM et al. Science Advances. 2025 March 19. 11 (12):DOI:10.1126/sciadv.adr1378. PMID:40106552.

165. SSX and SS18-SSX Antibodies as Additional Tools for Diagnosing Undifferentiated Neoplasms With the EWS-R1::SSX3 Fusion. Machado I, Llombart Bosch A, Fumagalli C, Antonescu CR. GENES CHROMOSOMES & CANCER. 2025 March 22. 64 (3):DOI:10.1002/gcc.70044. PMID:40119747.

166. Usefulness of Arterial Stiffness as an Integrated Marker of Cardiovascular Risk. Prado G, Forner MJ, Calaforra O, Vela S, Bea C, Pichler G, de Gracia A et al. Journal of Clinical Hypertension. 2025 March 24. 27 (3):DOI:10.1111/jch.70038. PMID:40127411.

167. Growth and gastrointestinal tolerance of healthy formula-fed infants: a multicentre, prospective observational study. Blesa L, Albors A, Samblas P, Maragat U, Coronel C, Abad B, Viciano E et al. BMC Pediatrics. 2025 March 25. 25 (1):229-229. DOI:10.1186/s12887-025-05446-6. PMID:40128711.

168. Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer. Lameirinhas A, Torres S, Garrido I, Hernando C, Martínez MT, Rovira A, Albanell J et al. MOLECULAR MEDICINE. 2025 March 25. 31 (1):116-116. DOI:10.1186/s10020-025-01163-z. PMID:40133809.

169. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC). Medina A, Muntanola A, Crespo M, Ramírez A, Hernández JA, Abrisqueta P, Alcoceba M et al. MEDICINA CLINICA. 2025 March 28. 164 (6):1-18. DOI:10.1016/j.medcli.2024.10.018. PMID:39799061.

170. Reply to: Recompensation After TIPS for Patients With Advanced Cirrhosis: A New Way to Reverse the Outcomes?. Sánchez J, González S, Lluch P, Ballester MP. LIVER INTERNATIONAL. 2025 April 01. 45 (4):DOI:10.1111/liv.16166. PMID:39535389.

171. Use of HSALR female mice as a model for the study of myotonic dystrophy type I. Carrascosa M, Colom A, González I, Pérez R, García A, Piqueras D, Ballestar A et al. LAB ANIMAL. 2025 April 01. 54 (4):92-102. DOI:10.1038/s41684-025-01506-7. PMID:40016516.

172. Poor glycaemic control in type 2 diabetes compromises leukocyte oxygen consumption rate, OXPHOS complex content and neutrophil-endothelial interactions. Cacace J, Luna C, Hermo A, Pesantes C, Hernández OA, Bañuls C, Apostolova N et al. Redox Biology. 2025 April 01. 81103516-103516. DOI:10.1016/j.redox.2025.103516. PMID:39986115.

173. Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis. Martínez BI, Insa A, Ygual GC, Gascón F, Moran J, Martín P. LUNG CANCER. 2025 April 01. 202108464-108464. DOI:10.1016/j.lungcan.2025.108464. PMID:40058137.

174. Single-cell technology: the key to an improved understanding of the human endometrium in health and disease. Gonzalez Fernandez J, Zaragozano S, Monteagudo Sánchez A, Simon C, Vilella F. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025 April 01. 232 (4):44-54. DOI:10.1016/j.ajog.2024.08.042. PMID:40253082.

175. Histological and morphometric changes in cardiac conduction fibers after spontaneous myocardial infarction in horses and dogs. Gómez F, Ballesteros L, Ruíz A. Veterinary World. 2025 April 01. 18 (4):827-836. DOI:10.14202/vetworld.2025.827-836. PMID:40453948.

176. Asherman syndrome at single-cell resolution. Pardo Figueres M, Simon C, Santamaria X. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025 April 01. 232 (4):148-159. DOI:10.1016/j.ajog.2024.12.023. PMID:40253078.

177. Biomarkers of lung congestion and injury in acute heart failure. Guazzi M, Novello G, Bursi F, Caretti A, Furlotti N, Arena R, Argiento P et al. ESC Heart Failure. 2025 April 01. 12 (2):781-789. DOI:10.1002/ehf2.14982. PMID:39118416.

178. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. García P, García JM, Lozano A, Yun S, García A, Gavira JJ, Aibar MÁ et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 April 01. 78 (4):301-310. DOI:10.1016/j.rec.2024.07.005. PMID:39089574.

179. Geriatric conditions and invasive management in frail patients with NSTEMI. A subgroup analysis of a randomized clinical trial. Sanchis J, Bueno H, García S, Gómez JA, Martí D, Martínez M, Domínguez L et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 April 01. 78 (4):319-326. DOI:10.1016/j.rec.2024.08.006. PMID:39270775.

180. Neuropsychological profiles in first-episodes psychosis and their relationship with clinical, metacognition and social cognition variables. Espinosa V, Bagaeva A, López R, Barajas A, Barrigón ML, Birulés I, Frígola E et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE. 2025 April 01. 275 (3):701-713. DOI:10.1007/s00406-024-01813-z. PMID:38806850.

181. A Survey on the Management of Patients with Severe Traumatic Brain Injury During Pregnancy: The MAMA Study. Picetti E, Vavilala MS, Coimbra R, Badenes R, Antonini MV, Augustin G, Armonda R et al. Neurocritical Care. 2025 April 01. 42 (2):474-484. DOI:10.1007/s12028-024-02113-z. PMID:39266866.

182. Phenotypic upregulation of hexacylceramides and ether-linked phosphocholines as markers of human extreme longevity. Fernández A, Sol J, Galo JD, Mota N, Mas C, Belenguer A, Obis É et al. AGING CELL. 2025 April 01. 24 (4):DOI:10.1111/accel.14429. PMID:39639682.

183. Negative symptoms and sex differences in first episode schizophrenia: What's their role in the functional outcome? A longitudinal study. Amoretti S, Mezquida G,

Verdolini N, Bioque M, Sánchez AM, Pina L, Zorrilla I et al. Spanish Journal of Psychiatry and Mental Health. 2025 April 01. 18 (2):91-99. DOI:10.1016/j.sjpmh.2023.04.001. PMID:38591832.

184. Frailty and invasive management of NSTEMACS: lights and shadows. Response. Sanchis J, Bueno H, Ariza A. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 April 01. 78 (4):385-386. DOI:10.1016/j.rec.2024.12.002. PMID:39675418.

185. Caring for Coma after Severe Brain Injury: Clinical Practices and Challenges to Improve Outcomes: An Initiative by the Curing Coma Campaign. Murtaugh B, Olson DM, Badjatia N, Lewis A, Aiyagari V, Sharma K, Creutzfeldt CJ et al. Neurocritical Care. 2025 April 01. 42 (2):325-333. DOI:10.1007/s12028-024-02116-w. PMID:39433705.

186. Proposed Practical Guidelines to Improve Glycaemic Management by Reducing Glycaemic Variability in People with Type 1 Diabetes Mellitus. de Torres Sánchez A, Ampudia Blasco FJ, Murillo S, Bellido V, Amor AJ, Mezquita Raya P. Diabetes Therapy. 2025 April 01. 16 (4):569-589. DOI:10.1007/s13300-025-01703-0. PMID:40019699.

187. FibroScan-AST Score vs Liver Stiffness for the Prediction of Liver Events After HCV Cure. Corma A, Corona D, Martín J, Galindo MJ, Camacho A, Martín C, Gallo M et al. Open Forum Infectious Diseases. 2025 April 01. 12 (4):DOI:10.1093/ofid/ofae628. PMID:40201720.

188. Clinical characteristics and management of type 2 diabetes in primary care in Spain. SED2 Study. Antonio V, Camins BF, Vlachos B, Barrot J, Pérez JN, Torre EM, Mauricio D et al. Endocrinología Diabetes y Nutrición. 2025 April 01. 72 (4):501543-501543. DOI:10.1016/j.endien.2025.501543. PMID:40180835.

189. Practical cancer nutrition, from guidelines to clinical practice: a digital solution to patient-centred care. Hustad KS, Koteng LH, Urrizola A, Arends J, Bye A, Dajani O, Deliens L et al. ESMO Open. 2025 April 01. 10 (4):104529-104529. DOI:10.1016/j.esmoop.2025.104529. PMID:40179818.

190. How to view the female reproductive tract through single-cell looking glasses. Llera Oyola J, Pérez Moraga R, Parras M, Rosón B. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025 April 01. 232 (4):21-43. DOI:10.1016/j.ajog.2024.08.040. PMID:40253081.

191. Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. Tan DHS, Antinori A, Eu B, Puerto MJG, Kinder C, Sweet D, Van CN et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2025 April 01. 98 (4):401-409. DOI:10.1097/QAI.0000000000003584. PMID:39676239.

192. Current situation of pediatric cystic fibrosis-related liver disease: results of a Spanish nationwide study. Vicente S, Tabares A, Gascón C, Tutau C, Alvarez M, Muñoz RA, Rubio M et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 2025 April 01. 37 (4):505-509. DOI:10.1097/MEG.0000000000002917. PMID:39976013.

193. Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology. Montero N, Oliveras L, Martínez A, Gorris JL, Soler MJ, Fernández B, Quero M et al. NEFROLOGIA. 2025 April 01. 451-26. DOI:10.1016/j.nefro.2024.11.002. PMID:40222774.

194. Alterations in intestinal bile acid transport provide a therapeutic target in patients with post-bariatric hypoglycaemia. Chaudhari SN, Chen YJ, Ferraz R, Cummings C, Sheehan A, Querol PC, Ozturk B et al. Nature Metabolism. 2025 April 01. 7 (4):792-807. DOI:10.1038/s42255-025-01262-5. PMID:40186075.

195. Status of Sepsis Care in European Hospitals Results from an International Cross-Sectional Survey. Scheer CS, Giamarellos EJ, Ferrer R, Idelevich EA, Annane D, Artigas A, Aslan AT et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2025 April 01. 211 (4):587-599. DOI:10.1164/rccm.202406-1167OC. PMID:39787606.

196. Hemodynamic Management Guided by the Hypotension Prediction Index in Abdominal Surgery: A Multicenter Randomized Clinical Trial. Ripollés J, Tomé JL, Zorrilla A, Aldecoa C, Colomina MJ, Bassas E, Lorente JV et al. ANESTHESIOLOGY. 2025 April 01. 142 (4):639-654. DOI:10.1097/ALN.0000000000005355. PMID:39746186.

197. GLI1::FOXO4-rearranged kidney tumors: a potentially distinct renal subtype within the spectrum of GLI1-altered tumors?. Pancsa T, Klubíková N, Dashti NK, Machado I, Llombart A, Linos K, Mosaieby E et al. VIRCHOWS ARCHIV. 2025 April 01. 486 (4):751-757. DOI:10.1007/s00428-024-03998-z. PMID:39688667.

198. Exosomal miR-302b as a novel strategy for reversing cellular senescence and promoting healthy aging. Borr C. Extracellular Vesicles and Circulating Nucleic Acids. 2025 April 02. 6 (1):191-194. DOI:10.20517/evcna.2025.24. PMID:40852595.

199. Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study. Díaz J, Saurí I, Redon J, Navarro J, Fernández G, Hurtado C, Ferreira K et al. Journal of Clinical Medi-

cine. 2025 April 03. 14 (7):DOI:10.3390/jcm14072441. PMID:40217891.

200. A Sex-Specific Minimal CpG-Based Model for Biological Aging Using ELOVL2 Methylation Analysis. Ibáñez JS, Sandoval J, Pallardó FV, García JL, Mena S. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 April 04. 26 (7):DOI:10.3390/ijms26073392. PMID:40244262.

201. Usefulness of the CDC/AAP and the EFP/AAP Criteria to Detect Subclinical Atherosclerosis in Subjects with Diabetes and Severe Periodontal Disease. Montenegro GC, Bea C, Ampudia FJ, González H, Real JT, Peñarocha M, Martínez S. Diagnostics. 2025 April 04. 15 (7):DOI:10.3390/diagnostics15070928. PMID:40218278.

202. Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies. Lopez S, Pollán M, Carrasco E, Andrés R, Martín M, Servitja S, Bermejo B et al. ONCOLOGIST. 2025 April 04. 30 (4):DOI:10.1093/oncolo/oyaf040. PMID:40183599.

203. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation. Raposeiras S, Amat IJ, Rossello X, González R, González I, Lopez D, Nombela L et al. NEW ENGLAND JOURNAL OF MEDICINE. 2025 April 10. 392 (14):1396-1405. DOI:10.1056/NEJMoa2500366. PMID:40162639.

204. Psychometric properties and cultural adaptation of the Spanish version of the Lesbian, Gay, Bisexual, and Transgender Development of Clinical Skills Scale (LGBT-DOCSS-ES). Karnie P, Juárez R, Dissen A, Martinez A, Del Pozo P, Gea V, Echániz E et al. Advances in Clinical and Experimental Medicine. 2025 April 11. 34 (12):2163-2174. DOI:10.17219/acem/203430. PMID:40214213.

205. Psychometric Properties of the Spanish Version of the Caregiver Contribution to Self-Care of Diabetes Inventory (CC-SCODI). Martínez J, Santolalla I, Gea V, A, Martínez A, Sánchez M, Di M et al. Nursing Reports. 2025 April 12. 15 (4):DOI:10.3390/nursrep15040129. PMID:40333084.

206. Emerging cardiovascular risk factors in childhood and adolescence: a narrative review. De Blas Zapata A, Sastre Albiach JM, Baixauli López L, Lopez Ruiz R, Alvarez Pitti J. EUROPEAN JOURNAL OF PEDIATRICS. 2025 April 14. 184 (5):298-298. DOI:10.1007/s00431-025-06102-y. PMID:40229626.

207. Evaluation of the VIDAS Cytomegalovirus (CMV)-IGRA for Assessing CMV-Specific T-Cell Responses in Immunocompetent and Immunosuppressed Individuals. Giménez E, Albert E, Colomer E, Pérez A, Montomoli M, Piñana JL, Sanchis I et al. JOURNAL OF MEDICAL VIROLOGY. 2025 April 15. 97 (4):DOI:10.1002/jmv.70355. PMID:40232234.

208. No Impact of HIV Coinfection on Mortality in Patients With Hepatitis C Virus Infection After Sustained Virological Response. Martín J, Corma A, Téllez F, Arenga D, Serrano M, Morano L, Corona D et al. CLINICAL INFECTIOUS DISEASES. 2025 April 15. 80 (4):835-841. DOI:10.1093/cid/ciae473. PMID:39293030.

209. Valproate Damaging Effect on Erythrocyte Metabolism as a Decisive Factor in the Development of Encephalopathy. Tikhonova L, Maevsky E, Montoliu C, Kosenko E. Biomolecules. 2025 April 15. 15 (4):DOI:10.3390/biom15040588. PMID:40305337.

210. The Chagas non-endemic (ChaNoE) cohort: Aims and study protocol. Bosch P, Herrero JM, Arsuaga M, Chamorro S, Carrillo I, Bea C, Llenas J et al. PLoS One. 2025 April 15. 20 (4):DOI:10.1371/journal.pone.0320637. PMID:40233055.

211. Caplacizumab treatment in elderly patients with iTTP: Experience from the Spanish TTP Registry. Gómez I, Cid J, Lozano M, Mingot ME, Pascual C, del Castillo LMG, Estevez JMV et al. HemaSphere. 2025 April 16. 9 (4):DOI:10.1002/hem3.70109. PMID:40242663.

212. Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study. Pérez Lamas L, Diaz AS, Delgado RG, Alvarez Larrán A, Senin MA, Mora E, Fox ML et al. Blood Cancer Journal. 2025 April 17. 15 (1):67-67. DOI:10.1038/s41408-025-01275-z. PMID:40246837.

213. The Role of Antigen Carbohydrate 125 in Modulating Soluble ST2: Prognostic-Related Effects in Acute Heart Failure. Martí A, Núñez J, López H, Revuelta E, Mollar A, Peiró M, Sanchis J et al. Biomolecules. 2025 April 18. 15 (4):DOI:10.3390/biom15040602. PMID:40305342.

214. Antimicrobial Dosing During Continuous Venovenous Hemodiafiltration in Septic Shock Patients: A Prospective, Multicenter Study Protocol. Harwood A, Fernández MM, Garin CE, Alvarez FJ, Herrero RL, TaMay E, Aguilar G. Antibiotics-Basel. 2025 April 21. 14 (4):DOI:10.3390/antibiotics14040420. PMID:40298573.

215. Gay affirmative practices among healthcare professionals in Poland and Spain: results of Health Exclusion Research in Europe (HERE) study. Karniej P, Dissen A, del Pozo P, Juárez R, Martínez A, Gea V, Echaniz E et al. Frontiers in Public Health. 2025 April 22. 131568486-1568486. DOI:10.3389/fpubh.2025.1568486. PMID:40331116.

216. Neurological outcomes and mortality following hyperoxemia in adult patients with acute brain injury: an updated meta-analysis and meta-regression. Romero N, Robba C, Monleón B, Ruiz A, Pascual M, Ruiz A, Perdomo

F et al. CRITICAL CARE. 2025 April 23. 29 (1):167-167. DOI:10.1186/s13054-025-05387-7. PMID:40270034.

217. Virus Detection by CRISPR-Cas9-Mediated Strand Displacement in a Lateral Flow Assay. Montagud R, Marquez R, Ruiz R, Martínez A, Ballesteros R, Navarro D, Campins P et al. ACS Applied Bio Materials. 2025 April 24. 8 (5):4221-4229. DOI:10.1021/acsabm.5c00307. PMID:40273314.

218. Gingival Inflammation Modulates NLRP3 Inflammasome Signalling in Peripheral Blood Mononuclear Cells of PCOS Patients: A Case-Control Study. Márquez CF, Pelechá M, Fernández M, Silvestre FJ, Perea L, Hermenejildo J, Abad Z et al. Antioxidants. 2025 April 24. 14 (5):DOI:10.3390/antiox14050507. PMID:40427389.

219. The Spanish Polygenic Score reference distribution: a resource for personalized medicine. Carmona R, Roldán G, Fernández JL, Navarro A, Peña M, Crowdsourcing CSVS, Dopazo J et al. EUROPEAN JOURNAL OF HUMAN GENETICS. 2025 April 24. 34270-277. DOI:10.1038/s41431-025-01850-9. PMID:40275119.

220. High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy. Manubens A, Paiva B, Gutiérrez NC, Fernandez M, Calasanz MJ, Rosiñol L, Oriol A et al. HemaSphere. 2025 April 24. 9 (4):DOI:10.1002/hem3.70127. PMID:40276216.

221. Machine-learning analysis identifies “elite” viral controllers with increased survival and homeostatic responses in critical COVID-19. García N, Álvaro A, Postigo T, Ortega A, de la de la Fuente A, Almansa R, Jorge N et al. Clinical and Translational Medicine. 2025 April 25. 15 (5):DOI:10.1002/ctm2.70241. PMID:40285348.

222. The Prognostic Impact of the Tumor Immune Microenvironment in Synovial Sarcoma: An Immunohistochemical Analysis Using Digital Pathology and Conventional Interpretation. Medina E, Giner F, Machado I, Heras B, Espino M, Navarro S, Llombart A. Journal of Personalized Medicine. 2025 April 25. 15 (5):DOI:10.3390/jpm15050169. PMID:40423041.

223. Protocol for an open labelled observational study in children&adolescentswith severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM). Gupta A, Messa ID, Valverde J, Murray CS, Moral L, Borrego JT, Pike K et al. PLoS One. 2025 April 25. 20 (12):DOI:10.1371/journal.pone.0335399. PMID:41417800.

224. Redox signaling in the pancreas in health and disease. Sastre J, Pérez S, Sabater L, Rius S. Physiological Reviews. 2025 April 26. 105 (2):593-650. DOI:10.1152/physrev.00044.2023. PMID:39324871.

225. Direct and Indirect Radionuclide Cystography: Can They Predict the Absence of Infectious Complications in Vesicoureteral Reflux?. Panach J, Esteve P, Valls L, Rodríguez H, Ferrando S, Marín J, Gil R et al. ARCHIVOS ESPANOL DE UROLOGIA. 2025 April 28. 78 (3):272-279. DOI:10.56434/j.arch.esp.urol.20257803.37. PMID:40340991.

226. Extracellular Vesicles as Epigenetic Regulators of Redox Homeostasis: A Systematic Review and Meta-Analysis. Mas Bagues C, Huete Acevedo J, Arnal Forné M, Sireno L, Pérez V, Borrás C. Antioxidants. 2025 April 29. 14 (5):DOI:10.3390/antiox14050532. PMID:40427414.

227. Editorial: Standardizing cognitive endophenotype profiling in bipolar disorder and schizophrenia. Soldevila Matias P, de Filippis R, Sanchez Orti JV, Fuentes Dura I, Ayesa Arriola R, Correa Ghisays P. Frontiers in Psychology. 2025 April 30. 161606517-1606517. DOI:10.3389/fpsyg.2025.1606517. PMID:40376496.

228. Efficacy of three lung cancer prediction models in diagnosing benign and malignant pulmonary nodules. Wu H, Chen X, Feng X, He W, Divisi D, Efird JT, Franco J et al. Translational Cancer Research. 2025 April 30. 14 (4):2410-2420. DOI:10.21037/tcr-2025-468. PMID:40386274.

229. CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases. González L, Castellet H, Martínez C, González N, Guijarro F, Lloveras N, Pratorcorona M et al. Diagnostic Pathology. 2025 April 30. 20 (1):DOI:10.1186/s13000-025-01655-w. PMID:40307896.

230. Prognostic role of persistent angina after percutaneous revascularization in chronic coronary syndrome with altered angiography and stress CMR. Pérez N, de Dios E, Monmeneu JV, López MP, Gavara J, Ríos C, Marcos V et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 May 01. 78 (5):425-436. DOI:10.1016/j.rec.2024.09.004. PMID:39370100.

231. Assessment of the Immunodeficiency Scoring Index for Predicting Outcomes After Respiratory Syncytial Virus Infection in Allogeneic Stem Cell Transplant Recipients. Micó M, Pérez A, Montoro J, Chorão P, Gómez D, Hernani R, Guerreiro M et al. Transplantation and Cellular Therapy. 2025 May 01. 31 (5):3251-32517. DOI:10.1016/j.jtct.2025.02.012. PMID:39947432.

232. Extended tumor area-based stratification score combining tumor budding and stroma identifies a high-risk, immune-depleted group in localized microsatellite-stable colon cancer patients. De Lucas BP, Heras B, Tarazona N, Ortega M, Huerta M, Moro D, Roselló S et al. PATHOLOGY RESEARCH AND PRACTICE. 2025 May 01.

269155871-155871. DOI:10.1016/j.prp.2025.155871. PMID:40107009.

233. Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients. Fornas G, Montón Bueno J, Tortajada T, Pérez P, Guimerá A, González D, Iglesias B et al. ESMO Open. 2025 May 01. 10 (5):105064-105064. DOI:10.1016/j.esmoop.2025.105064. PMID:40233657.

234. Early ribavirin reduce RSV symptoms duration in post-allogeneic stem cell transplant: challenges in symptoms duration assessment. Piñana JL, Micó Cerdá M, Gómez D, Pérez A, Montoro J, Hernani R, Choroa P et al. BONE MARROW TRANSPLANTATION. 2025 May 01. 60 (5):740-742. DOI:10.1038/s41409-025-02549-7. PMID:40119132.

235. Association of miR-126-3p, miR-1260b and miR-374a-5p with the incidence of heart failure in a population-based cohort: the Hortega Follow-Up Study. Grau M, Martinez O, Rubia M, Flores A, Rodriguez Z, Fernández P, Gonzalez A et al. European Journal of Internal Medicine. 2025 May 01. 135118-125. DOI:10.1016/j.ejim.2025.03.022. PMID:40155222.

236. Ventricular arrhythmogenic remodelling in diet-induced metabolic syndrome driven by right-to-left regional differences in action potential duration and dominant frequency gradients. Arias OJ, Calvo CJ, Bizey A, Ortiz JE, Such L, Such L, Alberola A et al. JOURNAL OF PHYSIOLOGY-LONDON. 2025 May 01. 603 (10):2979-3000. DOI:10.1113/JP286516. PMID:40320918.

237. Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents. Mato S, Carità L, ColmJanuary A, Andrés M, Balagué O, Andión M, Astigarraga I et al. BRITISH JOURNAL OF HAEMATOLOGY. 2025 May 01. 206 (5):1390-1396. DOI:10.1111/bjh.20012. PMID:40011029.

238. From food to alcohol: Why some patients develop new addictions after bariatric surgery. Alvarado E, Bataller R, Marti D. Gastroenterologia y Hepatologia. 2025 May 01. 48 (5):502430-502430. DOI:10.1016/j.gastrohep.2025.502430. PMID:40107607.

239. Development of a New Urethral Lubrication Device for Paediatric Patients: A Prospective Randomised Study. Panach Navarrete J, Valls González L, Martínez Jabaloyas JM. ARCHIVOS ESPANOL DE UROLOGIA. 2025 May 01. 78 (4):519-521. DOI:10.56434/j.arch.esp.urol.20257804.69. PMID:40495511.

240. Multicentre cohort study on the prevalence of postoperative delirium 48 hours after surgery: ?DELPO study?

protocol. Durán MV, Pérez RN, Martínez OD, Fadrique SM, Gómez ET, Quiles RB. *Revista Espanola de Anestesiologia y Reanimacion*. 2025 May 01. 72 (5):DOI:10.1016/j.redar.2025.501727. PMID:39961535.

241. Intraoperative endoscopy in bariatric surgery. Lapena Rodríguez M, Martí Fernández R, Alfonso Ballester R, Cassinello Fernández N. *CIRUGIA ESPANOLA*. 2025 May 01. 103 (5):312-313. DOI:10.1016/j.ciresp.2024.12.013. PMID:39971190.

242. Geographic and dietary differences of urinary uranium levels in the Strong Heart Family Study. Patterson KP, Nigra AE, Olmedo P, Grau M, O'Leary R, O'Leary M, Fretts AM et al. *Journal of Exposure Science and Environmental Epidemiology*. 2025 May 01. 35 (3):393-402. DOI:10.1038/s41370-024-00695-6. PMID:38961273.

243. Gingival inflammation and leukocyte-endothelium cell interactions in women with polycystic ovary syndrome. Márquez CF, Silvestre FJ, Fernández M, López S, Hermenejildo J, Abad Z, Silvestre J et al. *JOURNAL OF PERIODONTOLOGY*. 2025 May 01. 96 (5):478-489. DOI:10.1002/JPER.24-0148. PMID:39403884.

244. Reply to: "The HDL criterion for MetALD can misclassify patients with cirrhosis". Marti Aguado D, Calleja JL, Bataller R, Crespo J, Arias Loste MT. *JOURNAL OF HEPATOLOGY*. 2025 May 01. 82 (5):267-268. DOI:10.1016/j.jhep.2025.01.022. PMID:39914745.

245. Extracellular vesicles from *Lactocaseibacillus paracasei* reduce neuroinflammation in hippocampus and restore some cognitive functions in hyperammone-mic rats. Izquierdo P, Arenas YM, Montoliu C, Pérez G, Llansola M, Felipe V. *MICROBIOLOGICAL RESEARCH*. 2025 May 01. 294128101-128101. DOI:10.1016/j.micres.2025.128101. PMID:39978142.

246. Methylation profile scores of environmental exposures and risk of relapse after a first episode of schizophrenia. Segura AG, Prohens L, Julià L, Amoretti S, Ribero M, Pino L, Cano G et al. *EUROPEAN NEUROPSYCHOPHARMACOLOGY*. 2025 May 01. 944-15. DOI:10.1016/j.euroneuro.2025.02.003. PMID:39956014.

247. Improvement in the detection, diagnosis, and early treatment of chronic kidney disease in Spain. The InterKit Project. Górriz JL, Gil FA, López M, Soto AB, Cabrera FJC, Cisnerosf A, Guerrerog SC et al. *NEFROLOGIA*. 2025 May 01. 45 (5):351-359. DOI:10.1016/j.nefro.2025.02.001. PMID:40436675.

248. Sex-based differences in adverse left ventricular remodelling and clinical outcomes after ST-segment elevation myocardial infarction. Tello AA, Sambola A, Valente

F, Sao A, Ródenas E, Rello P, Maymi M et al. *European Heart Journal-Cardiovascular Imaging*. 2025 May 01. 26 (5):775-783. DOI:10.1093/ehjci/jeaf048. PMID:39928570.

249. Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy. Iacoboni G, Rejeski K, Navarro V, van T, Rampotas A, Martin AA, Bastos M et al. *LEUKEMIA*. 2025 May 01. 39 (5):1196-1205. DOI:10.1038/s41375-025-02582-x. PMID:40169762.

250. The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT. Pagliuca S, Malard F, Mooyaart JE, Daskalakis M, Gabellier L, Yakoub I, Ram R et al. *BLOOD REVIEWS*. 2025 May 01. 71101272-101272. DOI:10.1016/j.blre.2025.101272. PMID:39986989.

251. Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience. Serrano J, Martínez D, Gil C, Bernal T, Tormo M, Martínez P, Rodríguez C et al. *Transplantation and Cellular Therapy*. 2025 May 01. 31 (5):2991-29914. DOI:10.1016/j.jtct.2025.02.011. PMID:39956320.

252. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Rangelova E, Stoop TF, van T, Ali M, van EA, Javed AA, Hashimoto D et al. *ANNALS OF ONCOLOGY*. 2025 May 01. 36 (5):529-542. DOI:10.1016/j.annonc.2024.12.015. PMID:39814200.

253. From Genetics to Psychosocial Functioning: Unraveling the Mediating Roles of Cognitive Reserve, Cognition, and Negative Symptoms in First-Episode Psychosis. Forte MF, Clougher D, Segura ÀG, Mezquida G, Sánchez AM, Vieta E, Garriga M et al. *ACTA PSYCHIATRICA SCANDINAVICA*. 2025 May 01. 151 (5):600-612. DOI:10.1111/acps.13779. PMID:39722475.

254. Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials. González C, Lopes T, Morgades M, Fuster F, Montesinos P, Medina CR, Hermosin L et al. *HemaSphere*. 2025 May 01. 9 (5):DOI:10.1002/hem3.70148. PMID:40420999.

255. Use of an electrospun bioveil is safe and does not decrease skin graft take on burn wounds: A randomised, controlled clinical trial. Pérez MD, Vanaclocha N, Sanchis PS, Blanes M, Marco B, Estrada RB, Ximénez E et al. *BURNS*. 2025 May 01. 51 (4):107427-107427. DOI:10.1016/j.burns.2025.107427. PMID:40014884.

256. Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma. Nadal E, Martín P, Benítez JC, Sala MÁ, Cedrés S, Álvarez C, Dómine M et al. *LUNG CANCER*. 2025 May 01. 203108545-108545. DOI:10.1016/j.lungcan.2025.108545. PMID:40253943.

257. Impact of HIV infection on the dynamics of liver stiffness in patients with hepatitis C virus chronic infection after sustained virological response. Martín J, Corma A, Moyano JM, Téllez F, Arenga D, Serrano M, Vázquez A et al. *EClinicalMedicine*. 2025 May 01. 83DOI:10.1016/j.eclinm.2025.103227. PMID:40474999.

258. Peripheral neuroblastic tumors behaving badly: an update on high-risk morphologic and molecular groupings. Jarzembowski JA, Navarro S, Shimada H. *VIRCHOWS ARCHIV*. 2025 May 01. 486 (5):895-903. DOI:10.1007/s00428-025-04083-9. PMID:40158050.

259. Strengthening trauma resuscitation education and training in low-resource settings: A call for global inclusion. Lulic I, Mesquita C, Lulic D, Simoes RL, Ferreira L, Kolda P, Baptista S et al. *Resuscitation Plus*. 2025 May 01. 23DOI:10.1016/j.resplu.2025.100935. PMID:40235927.

260. Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults. Laue T, Ballester MP, Meoli L, Grabitz C, Uson E, D'Antiga L, McLin V et al. *Transplantation Direct*. 2025 May 01. 11 (5):DOI:10.1097/TXD.0000000000001787. PMID:40309027.

261. International consensus statement on routine blood testing in primary ciliary dyskinesia. Altaraihi S, Marthin JK, Anagnostopoulou P, Boon M, Carr SB, Castillo S, Dehlink E et al. *ERJ Open Research*. 2025 May 01. 11 (3):DOI:10.1183/23120541.01071-2024. PMID:40551794.

262. Natural variability of lung function in primary ciliary dyskinesia: longitudinal analysis from the PROVALF-PCD cohort. Zhang KW, Kant A, Boon M, Borrelli M, Constant C, Corullon SC, Cutrera R et al. *ERJ Open Research*. 2025 May 01. 11 (3):DOI:10.1183/23120541.01115-2024. PMID:40551797.

263. Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis. Villacampa G, Eminowicz G, Navarro V, Carità L, García D, Oaknin A, Pérez JA. *EUROPEAN JOURNAL OF CANCER*. 2025 May 02. 220115329-115329. DOI:10.1016/j.ejca.2025.115329. PMID:40031426.

264. Characterization of Chronic Lymphocytic Leukemia Immunoglobulin Rearrangements from Partial Read Se-

quencing. Fuentes A, Serrano A, Ferrer B, Ventura L, Seda E, García AB, Navarro B et al. *GENOMICS PROTEOMICS & BIOINFORMATICS*. 2025 May 02. 23 (2):DOI:10.1093/gp-bjnl/qzaf041. PMID:40315014.

265. Brexucabtagene Autoleucl versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma. Liebers N, Boumendil A, Finel H, Edelmann D, Kobbe G, Baermann B, Serroukh Y et al. *Blood Cancer Discovery*. 2025 May 05. 6 (3):182-190. DOI:10.1158/2643-3230.BCD-24-0178. PMID:39913291.

266. Carbohydrate antigen 125 determined on arrival at the emergency department correlates with severity of decompensation and adverse outcomes in patients with acute heart failure. Miró O, Núñez J, Trullàs JC, Noceda J, Bibiano C, Alquézar A, Jacob J et al. *Internal and Emergency Medicine*. 2025 May 05. 21 (1):231-241. DOI:10.1007/s11739-025-03932-4. PMID:40325282.

267. Treatment-Related Adverse Events in Extended Stage Small Cell Lung Cancer Patients Receiving First-Line Chemoimmunotherapy Versus Chemotherapy Alone: A Systematic Review and Meta-Analysis. Vitale E, Rizzo A, Maistrello L, Guven DC, Cauli O, Galetta D, Longo V. *Cancers*. 2025 May 05. 17 (9):DOI:10.3390/cancers17091571. PMID:40361497.

268. Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination. Sánchez A, Panizo N, Giménez E, Albert E, Montomoli M, Sanchis I, Kanter J et al. *JOURNAL OF MEDICAL VIROLOGY*. 2025 May 06. 97 (5):DOI:10.1002/jmv.70382. PMID:40326950.

269. Genomic surveillance reveals different transmission patterns between third-generation cephalosporin and carbapenem resistance in *Klebsiella pneumoniae* in the Comunidad Valenciana (Spain), 2018-2020. García N, Beamud B, Sevilla J, Sánchez V, Vidal I, Rodríguez JC, Fuster B et al. *Antimicrobial Resistance and Infection Control*. 2025 May 07. 14 (1):DOI:10.1186/s13756-025-01553-2. PMID:40336117.

270. Effect of exercise training in patients with chronotropic incompetence and heart failure with preserved ejection fraction: the TRAINING-HR randomized clinical trial. Palau P, de Amo I, Núñez G, Flor C, de la Espriella R, García C, Berlanga SE et al. *European Journal of Preventive Cardiology*. 2025 May 09. 33 (2):265-275. DOI:10.1093/eurjpc/zwaf269. PMID:40294211.

271. Normal Weight, Overweight and Obesity Conditions Associated to Prostate Neoplasm Stages-A Systematic Review and Meta-Analysis. Vitale E, Rizzo A, Halemani K, Shetty AP, Cauli O, Massari F, Santoni M. *Biomedicines*. 2025 May 13. 13 (5):DOI:10.3390/biomedicines13051182. PMID:40427009.

272. Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. Bedard PL, Jhaveri KL, Accordino MK, Cervantes A, Gambardella V, Hamilton E, Italiano A et al. *EUROPEAN JOURNAL OF CANCER*. 2025 May 15. 221115397-115397. DOI:10.1016/j.ejca.2025.115397. PMID:40203765.

273. Clinical outcomes following endometrial receptivity assessment-guided personalized euploid embryo transfer in patients with previous implantation failures. Ruiz M, Gómez C, Stankewicz T, Castellón JA, Díez A, Gómez E, Rubio C et al. *Scientific Reports*. 2025 May 15. 15 (1):DOI:10.1038/s41598-025-01056-5. PMID:40374667.

274. Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence. van TS, Cabeza M, Ferreira RM, Martínez C, Barros R, Santos J, Costa A et al. *BRITISH JOURNAL OF CANCER*. 2025 May 18. 132 (9):783-792. DOI:10.1038/s41416-025-02979-6. PMID:40113862.

275. Grief and Psychopathology in Bereaved Caregivers of Palliative Care Patients: The Mediating and Moderating Roles of Distress, Burden and Social Support. Ribera O, Pérez M, Valero S. *JOURNAL OF ADVANCED NURSING*. 2025 May 19. 821382-1394. DOI:10.1111/jan.17018. PMID:40387389.

276. Frequency and Distribution of KIR Genotypes of Donors-Recipient Pairs in the Haploidentical Haematopoietic Stem Cell Transplantation Setting: Collaborative Study by the Spanish Working Group in Histocompatibility and Transplant Immunology (GETHIT) and the Spanish Haematopoietic Transplantation and Cell Therapy Group (GETH-TC). Luis M, Planelles D, Piñana JL, Carbonell J, Amat P, Gómez I, Guerreiro M et al. *HLA*. 2025 May 21. 105 (5):DOI:10.1111/tan.70248. PMID:40396700.

277. Fluid Overload in Cardiorenal Medicine: From Bench to Bedside. Marcos MC, Romero González G, Núñez J. *CardioRenal Medicine*. 2025 May 23. 15 (1):427-429. DOI:10.1159/000546349. PMID:40414200.

278. Salivary 1,5-Anhydroglucitol and AGEs Are Associat-

ed with Postural Instability in Diabetic Foot Patients. Brognara L, Sempere M, Cauli O. *Medicina-Lithuania*. 2025 May 23. 61 (6):DOI:10.3390/medicina61060968. PMID:40572656.

279. Exploring Psychoemotional Well-Being in Caregivers of Adolescents With Type 1 Diabetes Mellitus: Results From the "10Vida" Intervention Program. Rodríguez P, Martín J, Rodríguez E, Valero S, Montoya I, Pérez M. *Family Journal*. 2025 May 23. DOI:10.1177/10664807251343898.

280. Positional Profiling of Anthropometric, Baropodometric, and Grip Strength Traits in Male Volleyball Players: Insights from a National Colombian Study. de la Rosa A, Camacho MA, Millan F, Saavedra JC, Okoshi MP, Pagan LU. *Journal of Functional Morphology and Kinesiology*. 2025 May 29. 10 (2):DOI:10.3390/jfmk10020197. PMID:40566447.

281. Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Polverelli N, Hernández JC, Onida F, Gurnari C, Raj K, Czerw T, Kenyon M et al. *BLOOD*. 2025 May 29. 145 (22):2561-2573. DOI:10.1182/blood.2024028000. PMID:40106773.

282. Glucose-Fueled Gated Nanomotors: Enhancing In Vivo Anticancer Efficacy via Deep Drug Penetration into Tumors. Escudero A, Hicke FJ, Lucena E, Pradana S, Esteve JJ, Sanz V, Garrido I et al. *ACS Nano*. 2025 May 30. 19 (22):20932-20955. DOI:10.1021/acsnano.5c03799. PMID:40444744.

283. Cancer Epithelial Cells Participate in the Self-Organization of Lung Tumor Spheroids: A Morphological Approach. Monleón I, Bravo L, Milián L, Sancho M, Llop M, Galbis JM, Cremades A et al. *CELLS TISSUES ORGANS*. 2025 June 01. 214 (3):219-241. DOI:10.1159/000541524. PMID:39383853.

284. Validated HPLC-UV Detection Method for Cefiderocol Quantification in a Critical Patient Receiving Fetcroja and Treated With Extracorporeal Replacement Therapies. Ezquer C, Ferriols R, Alós M, Carbonell JA, Hurtado L, García L, Aguilar G. *BIOMEDICAL CHROMATOGRAPHY*. 2025 June 01. 39 (6):DOI:10.1002/bmc.70104. PMID:40320257.

285. Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Martín J, Gimeno F, Henriksen TV, García B, Martínez B, Gambardella V, Martínez C et al. *Nature Cancer*. 2025 June 01. 6 (6):1000-1016. DOI:10.1038/s43018-025-00960-z. PMID:40301653.

286. Impact of continuous moderate-intensity aerobic exercise on glycemic control according to different phases of the menstrual cycle in females with type 1 diabetes. Agustín RMS, Pino AC, Sanz A, Rossetti P, Bondia J, Ampudia FJ. *DIABETES RESEARCH AND CLINICAL PRACTICE*. 2025 June 01. 224112192-112192. DOI:10.1016/j.diabres.2025.112192. PMID:40254185.

287. Oxidative stress and central metabolism pathways impact epigenetic modulation in inflammation and immune response. García Giménez JL, Cánovas Cervera I, Nacher Sendra E, Dolz Andrés E, Sánchez Bernabéu A, Agúndez AB, Hernández Gil J et al. *FREE RADICAL BIOLOGY AND MEDICINE*. 2025 June 01. 233378-399. DOI:10.1016/j.freeradbiomed.2025.04.004. PMID:40185167.

288. Rapid Screening and Monitoring of UBA1 Mutations in VEXAS Syndrome. Martín I, Mora E, Hernani R, Cervera JV, Fernandez MJ, Ferrer B, Such E et al. *JOURNAL OF MOLECULAR DIAGNOSTICS*. 2025 June 01. 27 (6):431-437. DOI:10.1016/j.jmoldx.2025.03.004. PMID:40239805.

289. Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study. Lozano FP, Marcos AR, Fernández RC, Rodrigo AB, Martínez S, Ampudia FJ. *Endocrinología Diabetes y Nutrición*. 2025 June 01. 72 (6):DOI:10.1016/j.endien.2025.501574. PMID:40450456.

290. Wet colostomy - A surgical technique for combined urinary and faecal diversion-A video vignette. Puente Monserrat J, Castelló Porcar A, Pérez Santiago L, Moro Valdezate D, Pla Martí V, García Botello SA. *Colorectal Disease*. 2025 June 01. 27 (6):DOI:10.1111/codi.70143. PMID:40537923.

291. New risk classification adapting SCAI shock stages to patients with pulmonary embolism (RISA-PE). Párraga R, Real C, Jiménez J, Vázquez ME, Valero E, Velázquez M, Tébar D et al. *Minerva Cardiology and Angiology*. 2025 June 01. 73 (3):304-314. DOI:10.23736/S2724-5683.24.06609-2. PMID:39315892.

292. A real-world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations. Suay G, Martín P, Aparisi F, Arnal M, Guirado M, Azkárate A, Garde J et al. *Clinical & Translational Oncology*. 2025 June 01. 27 (6):2568-2578. DOI:10.1007/s12094-024-03776-y. PMID:39499485.

293. Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study. Navarro P, Beato C, Rodríguez JF, Ruiz S, Mielgo X, Pineda E, Navarro

M et al. *Clinical & Translational Oncology*. 2025 June 01. 27 (6):2719-2730. DOI:10.1007/s12094-024-03745-5. PMID:39485597.

294. Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography. Marti D, Carot JM, Villalba A, Siddiqi H, Vallejo RM, Lara C, Martín M et al. *Clinical Gastroenterology and Hepatology*. 2025 June 01. 23 (7):DOI:10.1016/j.cgh.2024.10.014. PMID:39551253.

295. Salt repletion and diuretic response: The role of serum chloride. A post-hoc analysis of the SALT-HF trial on furosemide and hypertonic saline solution administration in ambulatory patients with worsening heart failure. Núñez J, Miñana G, de la Espriella R, Zegrí I, Comín J, Gracia JR, Morales JL et al. *EUROPEAN JOURNAL OF HEART FAILURE*. 2025 June 01. 27 (6):960-971. DOI:10.1002/ehf.3597. PMID:39933832.

296. Design and rationale of the eLym™ System for Decomensation of Excess Lymphatic Fluid via the Thoracic Duct in Acute Heart Failure (DELTA-HF). Biegus J, Lindenfeld J, Felker GM, Bakris G, Jonas M, Lala A, Kereselidze Z et al. *ESC Heart Failure*. 2025 June 01. 12 (3):1719-1726. DOI:10.1002/ehf2.15192. PMID:39716986.

297. Web Analytics to Objectively Measure the Success of Educational Resources in Human Anatomy. Alberola P, Zaragoza R, Gimeno A, Sánchez D. *Medical Science Educator*. 2025 June 01. 35 (3):1305-1312. DOI:10.1007/s40670-025-02304-z. PMID:40625958.

298. Individualised Therapy for Obstructive Sleep Apnoea: Predictive Models and Anatomical Phenotyping of Mandibular Advancement Devices Responses. Camañes S, Montiel JM, García M, Plaza A, Pérez T, Paredes V, Bellot C et al. *Orthodontics & Craniofacial Research*. 2025 June 01. 28 (3):485-495. DOI:10.1111/ocr.12900. PMID:39853867.

299. Dysplasia screening in inflammatory bowel disease patients: to whom, when and how. Ballester MP, de Célix CR, Madero L, Calafat M, Baston I, Brunet E, Grupo Joven de G. *Gastroenterología y Hepatología*. 2025 June 01. 48 (6):502373-502373. DOI:10.1016/j.gastrohep.2025.502373. PMID:39922457.

300. Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study. González I, Castellón VE, Medina J, España S, Mujika K, Majem M, Aguado C et al. *MELANOMA RESEARCH*. 2025 June 01. 35 (3):170-175. DOI:10.1097/CMR.0000000000001020. PMID:39918334.

301. Diagnosis and Management of Early Stages of ALD. Gratacós J, Alvarado E, Martí D, López H, Bataller R, Pose E. SEMINARS IN LIVER DISEASE. 2025 June 01. 45 (02):195-209. DOI:10.1055/a-2541-2892. PMID:39965759.

302. Blood ammonia and eye-hand coordination negatively affect health-related quality of life in women with minimal hepatic encephalopathy. Batallas D, Gallego JJ, Casanova F, Fiorillo A, Rivas P, López A, Arenas YM et al. QUALITY OF LIFE RESEARCH. 2025 June 01. 34 (6):1669-1682. DOI:10.1007/s11136-025-03920-3. PMID:40167844.

303. Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD). Díaz LA, Tavaglione F, Mittal N, Bettencourt R, Amangurbanova M, Johnson A, Martí D et al. Hepatology Communications. 2025 June 01. 9 (6):DOI:10.1097/HCG.0000000000000718. PMID:40377491.

304. Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC. Peña M, Martínez DF, Paviglianiti A, Balaguer A, Sanz J, Pascual MJ, Herruzo B et al. BONE MARROW TRANSPLANTATION. 2025 June 01. 60 (6):795-803. DOI:10.1038/s41409-025-02559-5. PMID:40175656.

305. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03. Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A et al. Journal of Thoracic Oncology. 2025 June 01. 20 (6):799-808. DOI:10.1016/j.jtho.2024.12.028. PMID:39755168.

306. Phase II study of elraglusib (9-ING-41), a GSK-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer. Mahalingam D, Saeed A, Powell SF, Huerta M, Sahai V, Covelev AL, Davis EJ et al. ESMO Open. 2025 June 01. 10 (6):105122-105122. DOI:10.1016/j.esmoop.2025.105122. PMID:40403387.

307. Comparing PANSS-6 and PANSS-30 for clinical and functional outcomes in first-episode psychosis: A 2-year follow-up in a Spanish cohort. Llorca V, Garriga M, Mezquida G, García C, Vieta E, Díaz CM, Bernardo M et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2025 June 01. 959-13. DOI:10.1016/j.euroneuro.2025.03.011. PMID:40215572.

308. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Westphalen CB, Boscolo L, Aftimos P, Beltran H, Benary M, Chakravarty

D, Collienne M et al. ANNALS OF ONCOLOGY. 2025 June 01. 36 (6):614-625. DOI:10.1016/j.annonc.2025.02.009. PMID:40194904.

309. Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study. López A, Mínguez A, Nieves C, Ruibal M, Sánchez NM, Navarro MP, Alpuente A et al. HEADACHE. 2025 June 01. 65 (6):994-1004. DOI:10.1111/head.14913. PMID:40135519.

310. Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer. Nag S, Coquard IR, Gupta S, Pathak A, Li N, Sari RM, Harano K et al. ESMO Open. 2025 June 01. 10 (6):105125-105125. DOI:10.1016/j.esmoop.2025.105125. PMID:40494042.

311. Factors associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors after an episode of acute heart failure and prognostic impact. Llorens P, Haro A, Gil V, Alquézar A, Jacob J, Espinosa B, de la Torre M et al. REVISTA CLINICA ESPANOLA. 2025 June 01. 225 (6):DOI:10.1016/j.rce.2025.502300. PMID:40316136.

312. Multidisciplinary discussion in upper GI tumours: management of a patient with a locally advanced Siewert II gastroesophageal junctional adenocarcinoma. Petrillo A, Fleitas Kanonnikoff T, Nilsson M, Leong T, van Laarhoven HWM. ESMO Gastrointestinal Oncology. 2025 June 01. 8DOI:10.1016/j.esmogo.2025.100176. PMID:41646278.

313. Multidisciplinary discussion on upper GI tumours: management of a patient with a middle-third locally advanced squamous-cell carcinoma. Petrillo A, Fleitas Kanonnikoff T, Nilsson M, Leong T, van Laarhoven HWM. ESMO Gastrointestinal Oncology. 2025 June 01. 8DOI:10.1016/j.esmogo.2025.100175. PMID:41646281.

314. Protective ileostomy creation after anterior resection of the rectum (PICARR): a decision-making exploring international survey. Balla A, Saraceno F, Rullo M, Morales S, Targarona EM, Di S, Guerrieri M et al. Updates in Surgery. 2025 June 01. 77 (3):805-823. DOI:10.1007/s13304-025-02111-6. PMID:40121358.

315. Primary cutaneous rhabdomyosarcoma with EWSR1/FUS::TFCP2 fusion: four new cases with distinctive morphology, immunophenotypic, and genetic profile. Machado I, Wardelmann E, Zhao M, Song J, Wang YL, Braun SA, Catasús L et al. VIRCHOWS ARCHIV. 2025 June 01. 486 (6):1187-1198. DOI:10.1007/s00428-024-04007-z. PMID:39692858.

316. Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive,

HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study. Escrivá S, Cejalvo JM, Alba E, Friedmann J, Rodríguez A, Savard MF, Pezo RC et al. LANCET ONCOLOGY. 2025 June 01. 26 (6):745-758. DOI:10.1016/S1470-2045(25)00140-8. PMID:40339592.

317. Bronchopulmonary colonization patterns in Spanish people with cystic fibrosis: Results of a national multicentre study. Maruri A, Quintana E, Michelena M, Pastor MD, Alvarez A, Girón R, Alarcón T et al. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2025 June 01. 43 (6):309-316. DOI:10.1016/j.eimc.2024.08.013. PMID:40461090.

318. Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia. Castellet H, Ramil G, Carricondo M, Oñate G, Garrido A, Artigas A, Pratorcorona M et al. EUROPEAN JOURNAL OF HAEMATOLOGY. 2025 June 01. 114 (6):1052-1054. DOI:10.1111/ejh.14402. PMID:39988452.

319. Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer. González S, García J, Cascales PA, Gonzalez A, Manzanedo I, Pereira F, Díaz D et al. JAMA Network Open. 2025 June 02. 8 (6):DOI:10.1001/jamanetworkopen.2025.17676. PMID:40569595.

320. Extracellular Vesicles from Peripheral Blood Mononuclear Cells of Hyperammonemic Rats Induce Neuroinflammation in Hippocampus, Impairing Memory and Learning in Normal Rats. Izquierdo P, López A, Pedrosa MA, Sebestyén VE, Vazquez L, Martinez M, Llansola M et al. Journal of Neuroimmune Pharmacology. 2025 June 07. 20 (1):65-65. DOI:10.1007/s11481-025-10225-2. PMID:40481977.

321. Chagas Disease in a Non-Endemic Setting: Clinical Profile, Treatment Outcomes, and Predictors of Cure in a 15-Year Cohort Study. Bea C, de Gracia AI, Llenas J, Vela S, Belmonte A, Pinto C, Ferrer A et al. Tropical Medicine and Infectious Disease. 2025 June 11. 10 (6):DOI:10.3390/tropicalmed10060161. PMID:40559728.

322. Association Between Lycopene and Metabolic Disease Risk and Mortality: Systematic Review and Meta-Analysis. Viña I, Robles A, Viña JR. Life-Basel. 2025 June 12. 15 (6):DOI:10.3390/life15060944. PMID:40566597.

323. Low-Density Lipoprotein Cholesterol Reduction and Therapeutic Adherence During Cardiac Rehabilitation After Myocardial Infarction. Bertolín C, Merenciano H, Marcos V, Mas MLM, Alberola J, Civera JM, Reig MV et al. Journal of Clinical Medicine. 2025 June 14. 14 (12):DOI:10.3390/jcm14124242. PMID:40565987.

324. Development of 2-and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome. Villarreal C, Martínez M, García A, Vila L, Zibar K, Schiel MA, Hennuyer N et al. BIOORGANIC CHEMISTRY. 2025 June 15. 160108450-108450. DOI:10.1016/j.bioorg.2025.108450. PMID:40215945.

325. Validation, Content Validity, and Reliability of the Spanish SE-OAM Questionnaire: Assessing Nursing Self-Efficacy in Oral Anticoagulant Therapy Management. de JR, Valera R, Chover E, Fernández L, Caballero A, Martínez A. Clinics and Practice. 2025 June 16. 15 (6):DOI:10.3390/clinpract15060111. PMID:40558229.

326. Baseline serum ferritin predicts myocardial iron uptake following intravenous iron therapy - a hypothesis-generating study. Nunez J, Mollar A, Vera M, Kabir S, Shah AK, Polzella P, Desborough M et al. EUROPEAN JOURNAL OF HEART FAILURE. 2025 June 16. 27 (11):2352-2356. DOI:10.1002/ehf.3730. PMID:40521677.

327. Circulating histones as clinical biomarkers in critically ill conditions. García Gimenez JL, Ruiz Rodríguez JC, Ferrer R, Durá R, Artigas A, Bajarña I, de Andujar DBL et al. FEBS LETTERS. 2025 June 17. 599 (22):3174-3195. DOI:10.1002/1873-3468.70093. PMID:40527588.

328. Rotavirus alphagastroenteritidis: Circulating Strains After the Introduction of the Rotavirus Vaccine (Rotarix®) in Lunda Province of Angola. Vita DG, Santiso C, Lemos M, Neto Z, Fortes E, Brito M, Sebastiao CS et al. Viruses-Basel. 2025 June 17. 17 (6):DOI:10.3390/v17060858. PMID:40573449.

329. Validation of the Somnolyzer 24x7 automatic scoring system in children with suspected obstructive sleep apnea. Boira I, Esteban V, Sancho JN, Pastor E, Fernández P, Torba A, Chiner E. Frontiers in Medicine. 2025 June 18. 12DOI:10.3389/fmed.2025.1617530. PMID:40606446.

330. Altered volume of thalamic nuclei and genetic expression in first-episode psychotic patients, and their association with childhood adversity. Elvira U, Rivero O, Postiguillo A, García G, Escarti MJ, Aguilar EJ, David J et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY. 2025 June 20. 139111371-111371. DOI:10.1016/j.pnpbp.2025.111371. PMID:40250785.

331. Evaluation of [18F]FDG distribution and uptake via micro PET/CT in a murine model of myocardial infarction. Ayoub ME, Rios C, Sanjuan MM, Diaz A, Bodi V, Giménez FP, Otero MR. Ars Pharmaceutica. 2025 June 20. 66 (3):335-348. DOI:10.30827/ars.v66i3.32674.

332. Pomegranate Extract Modulates Oxidative Stress by Reducing Basal ROS Levels and Protecting White Blood

Cells from Induced Oxidative Damage in Aging Mice. Verdú D, Valls A, Serna M, Herrera G, Ezzeddin M, Mauricio MD, Viña J et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 June 20. 26 (13):DOI:10.3390/ijms26135957. PMID:40649737.

333. Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Sánchez A, Carretero D, Grau B, Martínez M, Albert E, Giménez E, Colomer E et al. JOURNAL OF MEDICAL VIROLOGY. 2025 June 22. 97 (6):DOI:10.1002/jmv.70463. PMID:40545672.

334. The Associations Between Chronotype and Mental Health in Nursing Students. Ibáñez V, Navarro R, Cauli O. Journal of Clinical Medicine. 2025 June 23. 14 (13):DOI:10.3390/jcm14134440. PMID:40648814.

335. Insomnia Subtypes in Clinical Population According to the Insomnia Type Questionnaire (ITQ): A Multi-Centre Study in Spanish Sleep Clinics. Canellas F, de Entrambasaguas M, Romero O, Alvarez A, Wix R, Puertas FJ, Pujol J et al. JOURNAL OF SLEEP RESEARCH. 2025 June 25. 35 (1):DOI:10.1111/jsr.70116. PMID:40562392.

336. Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis. Hernández JC, Mosquera A, Gras L, Koster L, Tuffnell J, Kröger N, Gambella M et al. BLOOD. 2025 June 26. 145 (26):3139-3152. DOI:10.1182/blood.2024027287. PMID:40145857.

337. Isocitrate Dehydrogenase-Wildtype Glioma Adapts Toward Mutant Phenotypes and Enhanced Therapy Sensitivity Under D-2-Hydroxyglutarate Exposure. Rocha G, Francés C, Megías J, Muñoz L, Casanova P, Haro JF, Teruel V et al. Biomedicine. 2025 June 28. 13 (7):DOI:10.3390/biomedicine13071584. PMID:40722659.

338. Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression. Garcia de Herreros M, Jiménez N, Padrosa J, Aversa C, Ferrer L, García S, Rodríguez L et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 June 28. 26 (13):DOI:10.3390/ijms26136244. PMID:40650023.

339. CT-based clinical-radiomics model to predict progression and drive clinical applicability in locally advanced head and neck cancer. Bruixola G, Dualde D, Jimenez A, Nogué A, Bellvis F, Fuster A, Alfaro C et al. EUROPEAN RADIOLOGY. 2025 July 01. 35 (7):4277-4288. DOI:10.1007/s00330-024-11301-6. PMID:39706922.

340. Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women. Garrido I,

Tapia M, Carbonell J, Pena C, Torres S, Agreda A, Lameirinhas A et al. Cancer Communications. 2025 July 01. 45 (7):789-793. DOI:10.1002/cac2.70019. PMID:40207642.

341. Sex differences in the mediating role of brain-derived neurotrophic factor between inflammation and memory in cirrhotic patients with minimal hepatic encephalopathy. Batallas D, Gallego JJ, Casanova F, López A, Rivas P, Megías J, Escudero D et al. Brain Behavior & Immunity-Health. 2025 July 01. 46100998-100998. DOI:10.1016/j.bbih.2025.100998. PMID:40343108.

342. NT-proBNP to guide risk stratification after cardiac rehabilitation in patients with ST-segment elevation myocardial infarction. Pérez N, De Dios E, Gavara J, Ríos C, Marcos V, Merenciano H, Bertolín C et al. European Journal of Internal Medicine. 2025 July 01. 13783-89. DOI:10.1016/j.ejim.2025.04.027. PMID:40316461.

343. Analysis of the Association Between Symptoms of Inattention and Hyperactivity-Impulsivity and Substance Abuse in University Students. Ibáñez D, Cauli O. Psychiatry International. 2025 July 01. 6 (3):DOI:10.3390/psychiatryint6030078.

344. Silent complications: Liquid silicone granuloma in a patient after unregulated cosmetic mammary augmentation. Lillo Albert G, Muñoz Sornosa E, Adrianzén Vargas M, López Flor V, Buch Villa E. Revista de Senología y Patología Mamaria. 2025 July 01. 38 (3):DOI:10.1016/j.senol.2025.100701.

345. Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer. Perez A, Schmalfeldt B, George A, Gourley C, Pignata S, Lorusso D, Barretina MP et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2025 July 01. 35 (7):101863-101863. DOI:10.1136/ijgc-2024-005497. PMID:39448084.

346. Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes. Novoa S, Huber S, Gabarrós M, Chen TH, Torres S, Carrillo S, Santiago M et al. LEUKEMIA. 2025 July 01. 39 (7):1791-1794. DOI:10.1038/s41375-025-02629-z. PMID:40335618.

347. Treatment-resistant depression and intranasal esketamine: Spanish clinical consensus on practical aspects. Ramos JA, Mora F, Arostegui S, Cardoner N, Etxeandia JI, Gómez R, Gómez M et al. EUROPEAN JOURNAL OF PSYCHIATRY. 2025 July 01. 39 (3):DOI:10.1016/j.ejpsy.2025.100313.

348. Pneumonia definition in allogeneic hematopoietic cell transplant recipients: Update and challenges in 2024.

Recommendations from the EBMT Infectious Diseases Working Party and Practice Harmonization and Guidelines committee. Neofytos D, Verweij PE, Averbuch D, Mikulska M, Styczynski J, Pinana JL, Cesaro S et al. Current Research in Translational Medicine. 2025 July 01. 73 (3):103509-103509. DOI:10.1016/j.retram.2025.103509. PMID:40157135.

349. ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker. Thorvaldsdottir B, Mansouri L, Sutton LA, Nadeu F, Meggendorfer M, Parker H, Brieghel C et al. LEUKEMIA. 2025 July 01. 39 (7):1650-1660. DOI:10.1038/s41375-025-02615-5. PMID:40275070.

350. Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Pagano L, Maschmeyer G, Lamoth F, Blennow O, Xhaard A, Spadea M, Busca A et al. LEUKEMIA. 2025 July 01. 39 (7):1547-1557. DOI:10.1038/s41375-025-02586-7. PMID:40200079.

351. Rotational Atherectomy, Lithotripsy, or Laser for Calcified Coronary Stenosis: One-Year Outcomes From the ROLLER COASTER-EPIC22 Trial. Basile M, Gómez A, Rivero B, Amat IJ, Jiménez S, Caballero J, Ojeda S et al. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. 2025 July 01. 106 (1):702-710. DOI:10.1002/ccd.31529. PMID:40392192.

352. Reprieve System for the Treatment of Patients With Acute Decompensated Heart Failure. Ivey JB, Rao VS, Shaburishvili T, Verulava I, Khabeishvili N, Petrie MC, Butler J et al. JOURNAL OF CARDIAC FAILURE. 2025 July 01. 31 (7):1085-1089. DOI:10.1016/j.cardfail.2025.02.002. PMID:39947422.

353. Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry. Colmenares R, Alvarez N, Barragan E, Boluda B, Larrayoz MJ, Chillon MC, Soria E et al. HAEMATOLOGICA. 2025 July 01. 110 (7):1623-1627. DOI:10.3324/haematol.2024.286311. PMID:40013390.

354. Effects of children's microbiota on adipose and intestinal development in sex-matched mice persist into adulthood following a single fecal microbiota transplantation. La Rosa F, Guzzardi MA, Pardo M, Barone M, Ruocco C, Conti G, Panetta D et al. Molecular Metabolism. 2025 July 01. 97102157-102157. DOI:10.1016/j.molmet.2025.102157. PMID:40288637.

355. Diagnostic Evaluation and Clinical Findings in Children With Persistent Tachypnea of Infancy/Neuroendocrine

Cell Hyperplasia of Infancy A European Multicenter Retrospective Study. Marczak H, Krenke K, Griesse M, Peradzynska J, Lange J, Kulus M, Grochowska M et al. CHEST. 2025 July 01. 168 (1):171-182. DOI:10.1016/j.chest.2025.02.023. PMID:40054602.

356. Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). Gambardella V, Accordino MK, Bedard PL, Cervantes A, Hamilton E, Italiano A, Kalinsky K et al. ESMO Open. 2025 July 01. 10 (7):105303-105303. DOI:10.1016/j.esmoop.2025.105303. PMID:40513140.

357. Transcriptomic Predictors of Survival for Palbociclib plus Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEL-CAM/2013-02 PEARL Trial. Agrawal YN, Fernández A, Gil M, Zielinski C, Ruiz M, Ciruelos EM, Muñoz M et al. JCO Precision Oncology. 2025 July 01. 9DOI:10.1200/PO-24-00937. PMID:40632974.

358. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial. Jabbour E, Lussana F, Martínez P, Torrent A, Rifón JJ, Agrawal V, Tormo M et al. Lancet Haematology. 2025 July 01. 12 (7):529-541. DOI:10.1016/S2352-3026(25)00144-9. PMID:40532723.

359. Consensus document on neurosonological techniques in headaches. Vico JR, Domínguez JF, Villaverde FJJ, García NG, Fernández CGC, Sanchez AJ, Martín OA et al. NEUROLOGIA. 2025 July 01. 40 (6):599-607. DOI:10.1016/j.nrl.2024.06.001. PMID:40550312.

360. Which risk factors are related to failure to rescue in left pancreatectomy? Mixed cohort study (ERPANDIS and SPANDISPAN projects). Ramia JM, Villodre C, del Río JV, Blanco G, Rotellar F, Sabater L, Busquets J et al. CURRENT PROBLEMS IN SURGERY. 2025 July 01. 68DOI:10.1016/j.cpsurg.2025.101780. PMID:40500034.

361. Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2-breast cancer uncovers biomarkers of tumour response. López JI, Manzano S, Elorriaga K, Otaño M, Lahuerta A, Alvarez L, Etxabe I et al. Translational Oncology. 2025 July 01. 57DOI:10.1016/j.tranon.2025.102407. PMID:40349505.

362. Standardizing the Definition of Each Colon Cancer Segment: Delphi Consensus on Clinical Decision-Making for Oncologic Outcomes. Kuzu MA, Benlice C, Parvaiz A, Gorgun E, Bertelsen CA, Wexner S, Dozois EJ et al. DISEASES OF THE COLON & RECTUM. 2025 July 01.

68 (7):835-844. DOI:10.1097/DCR.0000000000003739. PMID:40214091.

363. Does the type of neoplasm influence the development of postoperative complications following distal pancreatectomy? A multicenter prospective snapshot study from the Spanish distal pancreatectomy project (SPANDISPAN). Sanchez B, Alcazar CF, Serradilla M, Villodres C, Hernández B, Santoyo JS, Ramia JM et al. Asian Journal of Surgery. 2025 July 01. 48 (7):4137-4143. DOI:10.1016/j.asjsur.2025.04.182.

364. Factors related to hemorrhage after distal pancreatectomy (SPANDISPAN project). de la Cuesta MR, Villodre C, Serradilla M, de la Cuesta ER, Alcazar C, Ramia JM, Proyecto SPANDISPAN. CIRUGIA ESPANOLA. 2025 July 01. 103 (7):DOI:10.1016/j.ciresp.2025.800105.

365. Is t(11;14) Always aStandard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Trials. Moreno DF, Oriol A, de la Rubia J, Hernández MT, Iñigo MB, Palomera L, de Arriba F et al. Clinical Lymphoma Myeloma & Leukemia. 2025 July 01. 25 (7):494-504. DOI:10.1016/j.clml.2025.01.014. PMID:39955256.

366. De Novo Heterozygous GATA3 Missense Variant Causes an Unexpected Phenotype of Non-Syndromic Hearing Impairment with Apparently Recessive Inheritance. Domínguez M, Garrido G, Martínez P, Del Castillo FJ, Villamar M, Gómez E, Moreno MA et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 July 02. 26 (13):DOI:10.3390/ijms26136363. PMID:40650141.

367. Breastfeeding and early Bifidobacterium-driven microbial colonization shape the infant gut resistome. Samarra A, Alcañiz AJ, Martínez C, Marina A, Comas I, Segata N, Quijada NM et al. Nature Communications. 2025 July 02. 16 (1):6099-6099. DOI:10.1038/s41467-025-61154-w. PMID:40603287.

368. When breast cancer spreads below the belt - A case of rectal metastasis from invasive lobular carcinoma. Puente J, Pérez L, Terrádez L, Pla V, Casado D, Martín J, Moro D et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 2025 July 04. 117 (9):543-544. DOI:10.17235/reed.2025.11378/2025. PMID:40613528.

369. Predictors of long-term survival in patients with a first episode of acute heart failure. Romero C, Alquézar A, Núñez J, Gil V, Jacob J, Aguirre A, Villarejo A et al. Polish Heart Journal-Kardiologia Polska. 2025 July 04. 83 (9):1020-1026. DOI:10.33963/v.phj.107033. PMID:40613593.

370. Does revascularization improve survival in adult frail patients with acute coronary syndrome?. Sanchis J, Bue-

no H, Ariza A. EUROPEAN HEART JOURNAL. 2025 July 07. 46 (26):2598-2599. DOI:10.1093/eurheartj/ehaf275. PMID:40256881.

371. Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GEL-TAMO study. Bento L, Gutiérrez A, Martinez C, Verdet M, Sorribes M, Caballero AC, Peña M et al. Blood Advances. 2025 July 08. 9 (13):3281-3292. DOI:10.1182/bloodadvances.2024015415. PMID:40163764.

372. CXCL16/CXCR6 axis arises as a potential peripheral biomarker of early COPD development - results from a pilot study. Marques P, Bocigas I, Domingo E, Francisco V, Tarrasó J, Piqueras L, Signes J et al. Frontiers in Medicine. 2025 July 09. 121636360-1636360. DOI:10.3389/fmed.2025.1636360. PMID:40703254.

373. WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Heterologous): heterologous rodent models. Hull ML, Gomez R, Nothnick WB, Gruemmer R, Burns KA, Johan MZ, Land IR et al. MOLECULAR HUMAN REPRODUCTION. 2025 July 09. 31 (3):DOI:10.1093/molehr/gaaf022. PMID:40628402.

374. WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Pain): methods to assess pain behaviour in rodent models of endometriosis. Dodds KN, Fattori V, Andrews NA, Appleyard CB, Christianson JA, Gomez R, McAllister SL et al. MOLECULAR HUMAN REPRODUCTION. 2025 July 09. 31 (3):DOI:10.1093/molehr/gaaf023. PMID:40628399.

375. WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Organoids): endometrial organoids as an emerging technology for endometriosis research. Marr EE, Gnecco JS, Missmer SA, Hawkins SM, Osteen KG, Hummelshoj L, Greaves E et al. MOLECULAR HUMAN REPRODUCTION. 2025 July 09. 31 (3):DOI:10.1093/molehr/gaaf024. PMID:40628401.

376. WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Homologous): homologous rodent models. Burns KA, Peterse D, Appleyard CB, Chandler R, Guo SW, Pearson A, Persoons E et al. MOLECULAR HUMAN REPRODUCTION. 2025 July 09. 31 (3):DOI:10.1093/molehr/gaaf021. PMID:40628400.

377. Inhibiting miR-200a-3p Increases Sirtuin 1 and Mitigates Kidney Injury in a Tubular Cell Model of Diabetes and Hypertension-Related Renal Damage. Martinez O, Flores

A, Mendez M, Garcia L, Escrivá L, Forner MJ, Redón J et al. Biomolecules. 2025 July 11. 15 (7):DOI:10.3390/biom15070995. PMID:40723868.

378. Extracellular vesicles in clinical chemistry: A focus on biomarkers. Mas C, Huete J, Arnal M, Atencia S, Borrás C. Advances in Clinical Chemistry. 2025 July 12. 1281-81. DOI:10.1016/bs.acc.2025.06.001. PMID:40849183.

379. A Comparison of Developmental Profiles of Preschool Children with Down Syndrome, Global Developmental Delay, and Developmental Language Disorder. Ahulló MA, Sánchez ML, Monterrubio A, Ruescas MA. Healthcare. 2025 July 13. 13 (14):DOI:10.3390/healthcare13141684. PMID:40724709.

380. The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations. Higgins K, Nyssen OP, Southern J, Laponogov I, AIDA C, Veselkov D, Gisbert JP et al. Nature Communications. 2025 July 14. 16 (1):6472-6472. DOI:10.1038/s41467-025-61329-5. PMID:40659612.

381. Sex-Dependent Effects of Aging and Insulin Resistance on Skeletal Muscle Function and Structure in Rats. Sosa P, Angulo J, Sánchez A, Gómez MC, Fernández A, Rodríguez L, El Assar M. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 July 15. 26 (14):DOI:10.3390/ijms26146783. PMID:40725034.

382. Natural Killer (NK) Cell Alloreactivity in Haploidentical Stem Cell Transplantation. Luis M, Piñana JL, Solano C, Planelles D. Cells. 2025 July 16. 14 (14):DOI:10.3390/cells14141091. PMID:40710344.

383. Invited Authors' Reply to: Letter to the Editor regarding 'Effect of exercise training in patients with chronotropic incompetence and heart failure with preserved ejection fraction: the TRAINING-HR randomized clinical trial'. Palau P, López L, Núñez J. European Journal of Preventive Cardiology. 2025 July 22. 33 (6):988-989. DOI:10.1093/eurjpc/zwaf359. PMID:40567178.

384. Cardiotoxicity in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia. Torres L, Boluda B, Solana A, Rodríguez R, Cano I, Acuña E, Navarro I et al. Cancers. 2025 July 22. 17 (15):DOI:10.3390/cancers17152413. PMID:40805116.

385. Combining QSAR and Molecular Docking for the Methodological Design of Novel Radiotracers Targeting Parkinson's Disease. Castillo JA, Soria M, Mena K, Romero M, Pérez V, Torrens F, Pérez F. Applied Sciences-Basel. 2025 July 22. 15 (15):DOI:10.3390/app15158134.

386. Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study. Roncaglia E, Gaffo E, Calabret-

to G, Fürstenau M, Rogers KA, Baliakas P, Cui CH et al. Journal of Hematology & Oncology. 2025 July 22. 18 (1):DOI:10.1186/s13045-025-01725-y. PMID:40691637.

387. Non-Viral Therapy in COVID-19: Where Are We Standing? How Our Experience with COVID May Help Us Develop Cell Therapies for Long COVID Patients. Gonzaga A, Martinez Navarrete G, Macia L, Anton Bonete M, Cahuana G, Tejedo JR, Zorrilla Muñoz V et al. Biomedicines. 2025 July 23. 13 (8):DOI:10.3390/biomedicines13081801. PMID:40868058.

388. Extracellular vesicles as a biomarkers in traumatic brain injury: a systematic review of animal and clinical studies. Romero N, Ruiz A, Huete J, Monleón B, Vicente A, Mas C, Sanz J et al. CRITICAL CARE. 2025 July 24. 29 (1):324-324. DOI:10.1186/s13054-025-05477-6. PMID:40707934.

389. Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-Effectiveness Analysis. Bodoque J, Fernández J, Martínez S, Pérez MJ, Carles M, Pallarés RM, Salazar JJ et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2025 July 24. 111405-417. DOI:10.1210/clinem/dgaf399. PMID:40650885.

390. Association of Lycopene and Male Reproductive Health: Systematic Review and Meta-Analysis. Viña I, Viña JR. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 July 25. 26 (15):DOI:10.3390/ijms26157224. PMID:40806357.

391. Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study. Chorão P, Avendaño A, Heras I, Aiello F, Micó M, Arrufat A, Garcia V et al. BMC INFECTIOUS DISEASES. 2025 July 25. 25 (1):944-944. DOI:10.1186/s12879-025-11302-w. PMID:40713537.

392. Resilience in aging. Haynes L, Siow RC, Borrás C, Reid K, Zhang J, Agrawal A. Frontiers in Aging. 2025 July 28. 61667378-1667378. DOI:10.3389/fragi.2025.1667378. PMID:40791244.

393. Impact of capacitive resistive monopolar radiofrequency prior to a therapeutic physical exercise program on morphology and functionality in women with rectus diastasis: a randomized controlled trial. Fuentes L, Muñoz E, Mollà S, Moreno N, Inglés M. DISABILITY AND REHABILITATION. 2025 July 30. 481-12. DOI:10.1080/09638288.2025.2540068. PMID:40740146.

394. The Mitochondrial Puzzle: Why Obesity Affects Insulin Sensitivity Differently in Black and White Women. Vezza T, Víctor VM. JOURNAL OF CLINICAL ENDOCRINOLOGY

& METABOLISM. 2025 August 01. 110 (8):2793-2794. DOI:10.1210/clinem/dgae686. PMID:39353066.

395. Complete Mobilization of the Splenic Flexure of the Colon: Five Laparoscopic Approaches and Standardization of the Technique. Moro D, García S, Martín J. DISEASES OF THE COLON & RECTUM. 2025 August 01. 68 (8):DOI:10.1097/DCR.0000000000003726. PMID:40152329.

396. Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis. Cobo M, De la Espriella R, Zegri I, Llacer P, Rubio J, Comín J, Morales JL et al. ESC Heart Failure. 2025 August 01. 12 (4):2460-2466. DOI:10.1002/ehf2.15275. PMID:40152188.

397. Epithelial elements in superficial angiomyxomas: mimicry of adnexal development, and mesenchymal-to-epithelial transition. Monteagudo C, Terrádez L, Alvarez E, Masiá P, Espino M, Ortega M. HISTOPATHOLOGY. 2025 August 01. 87 (2):321-328. DOI:10.1111/his.15478. PMID:40462396.

398. Cost-utility analysis of sequential therapies for pediatric-onset eosinophilic esophagitis. Arcos JV, Crehuá E, Martínez C. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. 2025 August 01. 81 (2):295-303. DOI:10.1002/jpn3.70106. PMID:40485534.

399. Hypertension in children with intellectual disabilities: a population not to be overseen. Wyszynska J, Luszczki E, Seeman T, Simonetti GD, Nyankovska O, Wójcik M, Kozioł Kozakowska A et al. JOURNAL OF HYPERTENSION. 2025 August 01. 43 (8):1277-1285. DOI:10.1097/HJH.0000000000004052. PMID:40421509.

400. Therapeutic role of venous leg compression in worsening heart failure with predominant extravascular congestion: a case report. Mínguez S, Civera J, de la Espriella R, Iraola D, Núñez J. European Heart Journal-Case Reports. 2025 August 01. 9 (8):DOI:10.1093/ehjcr/ytaf343. PMID:40800557.

401. A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer. Prieto C, Carbonell JA, Bueno A, Gómez A, Busto M, Alcolado AB, Jimenez A et al. ESMO Open. 2025 August 01. 10 (8):105495-105495. DOI:10.1016/j.esmoop.2025.105495. PMID:40674919.

402. Multidisciplinary Delphi study on residual risk in patients with chronic kidney disease and type 2 diabetes mellitus. Ortiz A, Cebrián A, Soto A, Reyes A, Górriz JL. NEFROLOGIA. 2025 August 01. 45 (7):501338-501338. DOI:10.1016/j.nefro.2025.501338. PMID:40945994.

403. Beyond frequency: duration, intensity, and quality of life in Ménière's disease. Pérez T, Orts M, Pérez V, Pla I, Es-

pina C, Aragonés M, Marco J. JOURNAL OF LARYNGOLOGY AND OTOTOLOGY. 2025 August 01. 139 (8):723-729. DOI:10.1017/S0022215125102624. PMID:40552577.

404. Primary Visceral Ewing Sarcoma (Gastric and Bladder) with KIT Expression: A Report of Two Patients and a Differential Diagnostic Approach. Chaachou A, Bagué S, Medina CM, Lavernia J, Claramunt R, Guerrero J, Navarro S et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY. 2025 August 01. 33 (5):1299-1316. DOI:10.1177/10668969241308205. PMID:39865727.

405. Relationship between clinical congestion and worsening renal function after intravenous initiation of furosemide in patients with acute heart failure. Espinosa B, Llauger L, Gil V, Escoda R, Jacob J, Aguirre A, Mojarro EM et al. Internal and Emergency Medicine. 2025 August 01. 20 (5):1553-1564. DOI:10.1007/s11739-024-03796-0. PMID:39472392.

406. Homozygous Familial Hypercholesterolemia in Spain: Data From Registry of the Spanish Atherosclerosis Society. Sánchez RM, Ibarretxe D, Fuentes F, Martínez S, Blanco A, Cortés B, Rodríguez G et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2025 August 01. 110 (8):2280-2287. DOI:10.1210/clinem/dgae784. PMID:39514762.

407. Effects of routine invasive management on reinfarction risk in older adults with frailty and non-ST-segment elevation myocardial infarction: a subanalysis of a randomised clinical trial. Sanchis J, Bueno H, Sánchez DM, Martinez M, Villanueva PD, Barrabes JA, Marin F et al. HEART. 2025 August 01. 111 (16):786-792. DOI:10.1136/heart-jnl-2024-325254. PMID:39922692.

408. Serum chloride and the response to combining loop and thiazide diuretics for acute heart failure: the ALCALOTIC study. Núñez J, Miñana G, Villalonga M, Asenjo M, Carreira M, Epelde F, Gil M et al. Internal and Emergency Medicine. 2025 August 01. 20 (5):1399-1409. DOI:10.1007/s11739-025-03961-z. PMID:40379935.

409. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, Sadowska A et al. LANCET INFECTIOUS DISEASES. 2025 August 01. 25 (8):451-462. DOI:10.1016/S1473-3099(25)00069-6. PMID:40188837.

410. ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0). Cherny NI, Oosting SF, Dafni U, Latino NJ, Galotti M, Zygoura P, Dimopoulou G et al. AN-

NALS OF ONCOLOGY. 2025 August 01. 36 (8):866-908. DOI:10.1016/j.annonc.2025.04.006. PMID:40409995.

411. To proceed or delay? The dilemma of community-acquired respiratory viruses in adults and pediatrics before allogeneic stem cell transplantation and chimeric-antigen-receptor T-cell therapy. Pinana JL, Martino R, Cesaro S, Averbuch D, Lujgman P. CURRENT OPINION IN INFECTIOUS DISEASES. 2025 August 01. 38 (4):290-299. DOI:10.1097/QCO.0000000000001120. PMID:40471062.

412. Associations Between Urinary Metal Levels and Incident Heart Failure A Multi-Cohort Analysis. Martinez I, Domingo A, Mayer M, Schilling K, Glabonjat RA, McGraw K, Sanchez TR et al. JACC-Heart Failure. 2025 August 01. 13 (8):102510-102510. DOI:10.1016/j.jchf.2025.03.046. PMID:40532446.

413. Maternal diet shapes infant microbiota and defensive capacity against infections in early life via differential human milk composition. Rio K, Selma M, Cabrera R, González S, Martínez C, Castell M, Rodríguez MJ et al. EBioMedicine. 2025 August 01. 118105850-105850. DOI:10.1016/j.ebiom.2025.105850. PMID:40737758.

414. Evaluation of the PAN-PROMISE Symptom Scale in a Randomized Controlled Trial of Fluid Resuscitation in Acute Pancreatitis. Guilabert L, Cárdenas K, Buxbaum JL, de Paredes A, Vaillo A, Donate J, Hernández ET et al. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2025 August 01. 120 (8):1852-1859. DOI:10.14309/ajg.0000000000003570. PMID:40471836.

415. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial. Cascone T, Bonanno L, Guisier F, Insa A, Liberman M, Bylicki O, Livi L et al. NATURE MEDICINE. 2025 August 01. 31 (8):2788-2796. DOI:10.1038/s41591-025-03746-z. PMID:40450142.

416. Clinical guidelines and strategic plan for the prevention, diagnosis and treatment of delirium: The Zero Delirium Project. de la Varga O, Badenes R, Gordaliza C, Manso SD, Castillo G, Aragon CA, Castro MF et al. Revista Española de Anestesiología y Reanimación. 2025 August 01. 72 (7):DOI:10.1016/j.redar.2025.501805.

417. Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry. Alonso GL, Martínez A, Aguiar D, Esteban A, Viéitez JM, Del Prado S, Górriz J et al. ESC Heart Failure. 2025 August 01. 12 (4):3163-3172. DOI:10.1002/ehf2.15260. PMID:40017333.

418. Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute

coronary syndrome. Cordero A, Gonzalez JR, Olmo RF, Fernandez L, Manzano S, Bonanad C, Alvarez B et al. Journal of Clinical Lipidology. 2025 August 01. 19 (4):827-834. DOI:10.1016/j.jacl.2025.04.193. PMID:40483194.

419. Integration of an OS-Based Machine Learning Score (AS Score) and Immunoscore as Ancillary Tools for Predicting Immunotherapy Response in Sarcomas. Machado I, López R, Giner E, Fernández A, Requena C, Llombart B, Giner F et al. Cancers. 2025 August 01. 17 (15):DOI:10.3390/cancers17152551. PMID:40805246.

420. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3,-label, multicentre, randomised clinical trial. Mateos MV, Paiva B, Cedena MT, Puig N, Sureda AM, de la Calle VG, Oriol A et al. Lancet Haematology. 2025 August 01. 12 (8):588-598. DOI:10.1016/S2352-3026(25)00143-7. PMID:40769684.

421. Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia. Medina D, Palomo L, Navarro V, Lázaro G, Martín B, Hernández C, Castells O et al. HAEMATOLOGICA. 2025 August 01. 110 (8):1758-1773. DOI:10.3324/haematol.2024.286663. PMID:40079085.

422. Seroepidemiology of Human Non-Species A Rotavirus Infections in Valencia, Spain. Navarro N, Aznar S, Asensio D, Luque D, Rodríguez JM, Gozalbo R, Alcaraz MJ et al. JOURNAL OF MEDICAL VIROLOGY. 2025 August 02. 97 (8):DOI:10.1002/jmv.70542. PMID:40751697.

423. "Mandibular subluxation using a putty splint: a strategy to optimize access to the distal internal carotid artery in a minimally invasive manner". Del Río DM, Casas GB, Mateo MM, Torres MP. Oral and Maxillofacial Surgery-Heidelberg. 2025 August 06. 29 (1):139-139. DOI:10.1007/s10006-025-01440-5. PMID:40768071.

424. Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial. López E, Pérez JM, Gión M, Ribelles N, Cortez P, Alonso JL, García MM et al. BREAST CANCER RESEARCH. 2025 August 06. 27 (1):141-141. DOI:10.1186/s13058-025-02089-4. PMID:40770648.

425. Fallskip® Parameters and Their Relationship with the Risk of Falls in Older Individuals with and Without Diabetes. Castillo A, Brognara L, Mafla A, Cauli O. Geriatrics. 2025 August 08. 10 (4):DOI:10.3390/geriatrics10040109. PMID:40863576.

426. Digital pathology and lipid droplet size as a key determinant of discrepancies between histology and MRI gradings in steatotic liver disease. Marti D, Alfaro C, Fernández M, Ten A, Cerdá L, Crespo A, Navarrete I et al. EUROPEAN RADIOLOGY. 2025 August 08. 36 (2):1050-1060. DOI:10.1007/s00330-025-11919-0. PMID:40781513.

427. Unraveling the potential of hypothalamic deep brain stimulation for obesity: Impacts on memory, neuroplasticity and brain metabolism in the Zucker rat. Casquero M, Llorca M, Bueno C, Romero D, Lamanna N, Winter C, Berrocoso E et al. Translational Psychiatry. 2025 August 09. 15 (1):273-273. DOI:10.1038/s41398-025-03478-1. PMID:40783486.

428. Divergent mechanisms of cardiovascular remodeling between men and women. 0000-0001-8303-7252, Gerdts E, Kararigas G. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 2025 August 11. 329 (2):505-514. DOI:10.1152/ajpheart.00129.2025. PMID:40643438.

429. TIM3(+) breast cancer cells license immune evasion during micrometastasis outbreak. Rozalén C, Sangrador I, Avasle S, Blasco S, Tzortzi P, Sanz M, Palomeque JA et al. CANCER CELL. 2025 August 11. 43 (8):DOI:10.1016/j.ccell.2025.06.015. PMID:40645187.

430. Validation and normative data for the BAC app in Spanish-speaking individuals with psychosis and healthy controls. González C, Pousa E, Reguera P, Gutiérrez A, Rodríguez R, Del M, González A et al. EUROPEAN PSYCHIATRY. 2025 August 11. 68 (1):DOI:10.1192/j.eurpsy.2025.10076. PMID:40785579.

431. Down-regulation of MIR-378A-3P expression associated with inflammation: The effects of restoring its levels. Seco M, Gisbert L, Macias DC, Ortiz D, Cosín J, Bauset C, Heras B et al. PLoS One. 2025 August 11. 20 (8):DOI:10.1371/journal.pone.0329685. PMID:40788903.

432. The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management. Moncho F, Benlloch S, Górriz JL. Clinical Kidney Journal. 2025 August 12. 18 (9):DOI:10.1093/ckj/sfaf260. PMID:40927376.

433. Smart CAR-T Nanosymbionts: archetypes and proto-models. Baena JC, Victoria JS, Toro Pedroza A, Aragón CC, Ortiz Guzman J, Garcia Robledo JE, Torres D et al. Frontiers in Immunology. 2025 August 12. 161635159-1635159. DOI:10.3389/fimmu.2025.1635159. PMID:40873579.

434. Cost Analysis of the FreeStyle Libre Systems in People with Type 2 Diabetes Mellitus on Basal Insulin with

Poor Glycemic Control: A Spanish Perspective. Ampudia FJ, de la Cuadra A, Bellido V, Cebrián AM, Mezquita P, Carretero J, Hernández AM et al. Diabetes Technology & Therapeutics. 2025 August 13. 28 (1):55-67. DOI:10.1177/15209156251363576. PMID:40803363.

435. Assessment of Muscle-Specific Strength in Oncology Patients: Anthropometry as a Reliable Alternative to DXA. Alabadi B, Amores S, Moriana M, Wu NY, García K, Pedrón JA, Monrós C et al. Life-Basel. 2025 August 15. 15 (8):DOI:10.3390/life15081300. PMID:40868947.

436. Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies. García JA, Spera G, Pollán M, Bermejo B, Ruiz M, Chan A, Martín M et al. INTERNATIONAL JOURNAL OF CANCER. 2025 August 15. 157 (4):709-721. DOI:10.1002/ijc.35432. PMID:40207789.

437. A case report on myocarditis and right chamber dilation: cardiac magnetic resonance acquisition for accurate diagnosis. Bertolín C, Baettig E, Torondel S, Santas E, Bodi V, Merenciano H, Gil J et al. Future Cardiology. 2025 August 18. 21 (11):867-871. DOI:10.1080/14796678.2025.2537562. PMID:40728502.

438. The Final Phases of Ovarian Aging: A Tale of Diverging Functional Trajectories. Bochynska S, García Pérez MÁ, Tarín JJ, Szeliga A, Meczekalski B, Cano A. Journal of Clinical Medicine. 2025 August 18. 14 (16):DOI:10.3390/jcm14165834. PMID:40869659.

439. Maintenance Treatment with 5-Azacitidine in Patients with Acute Myeloblastic Leukemia Ineligible for Intensive Treatment and with Response After Induction Chemotherapy: A Phase II Clinical Trial. Fernández AF, Fortes MG, Díaz MT, Marco MLJ, García RC, de la Fuente A, López JS et al. Cancers. 2025 August 18. 17 (16):DOI:10.3390/cancers17162678. PMID:40867307.

440. Muscular excitation and oxygen extraction responses in power-generating and stabilizing muscles during a graded cycling test. Sendra C, Encarnación A, Murias JM, de la Fuente C, Salvador R, Martín F, Priego JI. JOURNAL OF SPORTS SCIENCES. 2025 August 18. 43 (16):1675-1684. DOI:10.1080/02640414.2025.2518015. PMID:40509629.

441. Gender identity stories: Experiences and perspectives of transgender people about healthcare system in Spain. Martínez A, Chover E, Pozo PD, Tovar A, Cano N, Araujo M, Curto J et al. Advances in Clinical and Experimental Medicine. 2025 August 19. 34 (12):2077-2089. DOI:10.17219/acem/208133. PMID:40827933.

442. Management of the Axilla in Older Patients with Breast Cancer: Reassessing the Role of Sentinel Lymph Node Biopsy. Ibáñez FC, Sornosa EM, Flor VL, Vargas MA, Martínez MTM, Villa EB. Cancers. 2025 August 24. 17 (17):DOI:10.3390/cancers17172758. PMID:40940855.

443. Effect of Volume on Postoperative Outcomes After Left Pancreatectomy: A Multicenter Prospective Snapshot Study (SPANDISPAN Project). Aparicio D, Ramia JM, Vilodre C, Rubio JJ, Hernández B, Busquets J, Secanella L et al. Journal of Clinical Medicine. 2025 August 25. 14 (17):DOI:10.3390/jcm14176013. PMID:40943773.

444. TLR7/8 ligands R848 and imiquimod induce differentiation of bone marrow cells from patients with myelodysplastic syndrome towards mature neutrophils. Villamón E, Guerrero P, Gil ML, Martín I, Amat P, Gozalbo D, Yáñez A. Scientific Reports. 2025 August 26. 15 (1):31496-31496. DOI:10.1038/s41598-025-15859-z. PMID:40858756.

445. Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement. Verstovsek S, Kiladjian JJ, Vannucchi AM, Patel JL, Rambaldi A, Shomali WE, Oh ST et al. NEJM Evidence. 2025 August 26. 4 (9):DOI:10.1056/EVIDoa2500017. PMID:40856555.

446. Extracellular matrix dysfunction and synaptic alterations in schizophrenia. Unzueta P, Cuesta E, Barrena R, Olabarrieta E, Recio M, Horrillo I, Mentxaka O et al. MOLECULAR PSYCHIATRY. 2025 August 27. 31 (1):396-406. DOI:10.1038/s41380-025-03154-2. PMID:40858782.

447. Evaluation of carbohydrate antigen 125 in heart failure with preserved ejection fraction diagnosis. de Juan J, Severo A, de la Espriella R, Valero MJ, García D, de Antonio M, Segura de la Cal T et al. HEART. 2025 August 28. 112 (4):223-230. DOI:10.1136/heartjnl-2025-326053. PMID:40877030.

448. Uterine Myxoid Mesenchymal Tumor With a Novel SS18::VEZF1 Gene Fusion, Lacking Worrisome Histological Features. Machado I, Claramunt R, López S, Aliaga J, Garrigós E, Martín I, Romero I et al. GENES CHROMOSOMES & CANCER. 2025 August 28. 64 (8):DOI:10.1002/gcc.70079. PMID:40878061.

449. Association Between Sleep Disturbance and Behavioral Feeding Problems in Children and Adolescents with Autism Spectrum Disorder. Fuentes M, Mafía MA, Martínez J, Cauli O. Diseases. 2025 August 29. 13 (9):DOI:10.3390/diseases13090280. PMID:41002716.

450. Effects of Physical Training on Heart Rate Variability in Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis. Ortiz JE, Sánchez M, Prieto L, Arias OJ, Bizy A, Calvo CJ, Alberola A et al. Journal of

Clinical Medicine. 2025 August 29. 14 (17):DOI:10.3390/jcm14176129. PMID:40943888.

451. Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease. Bakker WM, Heerspink HJL, Berger SP, Wanner C, Badve S, Arnott C, Abrahams AC et al. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025 August 29. 40 (9):1746-1755. DOI:10.1093/ndt/gfaf046. PMID:40053493.

452. Training-Induced Metabolic Adaptations in Skeletal Muscle. Garcia E, Gomez MC, Gonzalez GO. Advances in Experimental Medicine and Biology. 2025 August 30. 1478491-510. DOI:10.1007/978-3-031-88361-3_21. PMID:40879953.

453. Modulating Effect of Carbohydrate Antigen 125 on the Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure. Santas E, Martí A, Revuelta E, Villar S, De la Espriella R, Palau P, Llàcer P et al. Biomolecules. 2025 August 30. 15 (9):DOI:10.3390/biom15091260. PMID:41008566.

454. A machine learning approach for type 2 diabetes diagnosis and prognosis using tailored heterogeneous feature subsets. Navarro JR, Pons P, Arnal L, Arlandis J, Llobet R, Perez JC, Lara F et al. MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING. 2025 September 01. 63 (9):2733-2752. DOI:10.1007/s11517-025-03355-5. PMID:40198441.

455. Heart Failure in Advanced Chronic Kidney Disease Overlooked No More. De la Espriella R, Górriz JL, Cobo M, Marques M, Seller J, Méndez A, Soler MJ et al. JACC-Heart Failure. 2025 September 01. 13 (9):102581-102581. DOI:10.1016/j.jchf.2025.102581. PMID:40730127.

456. Adenovirus Burden in Allogeneic Hematopoietic Stem Cell Transplantation: Monitoring Versus Symptoms-Based Testing-A Cost-Effectiveness Analysis. Giménez E, Piñana JL, Albert E, Torres I, Pérez A, Hernández JC, Solano C et al. Transplant Infectious Disease. 2025 September 01. 27 (5):DOI:10.1111/tid.70089. PMID:40778511.

457. Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study. Giménez E, Cadenas IG, Piñana JL, Albert E, Vázquez L, Avendaño A, Cabrero M et al. Transplant Infectious Disease. 2025 September 01. 27 (5):DOI:10.1111/tid.70080. PMID:40674366.

458. A comparative study between two ultrasound classifications for postnatal urinary tract dilatation. Panach

J, Hernández P, Valls L, Gil R, Ferrando S, Marín J, Rodríguez H et al. RADIOLOGIA. 2025 September 01. 67 (5):DOI:10.1016/j.rx.2024.02.009.

459. Effects of L-Arginine on Bone Metabolism: Evidence from In Vitro and In Vivo Models. Pertusa C, Carrasco A, Aliaga R, Suay L, Alonso E, Cano A, Tarin JJ et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 September 01. 26 (17):DOI:10.3390/ijms26178484. PMID:40943405.

460. Gastrointestinal bleeding secondary to multiple duoden jejunal GISTs in a patient with neurofibromatosis type 1. Ibañez FC, Fernández Moreno MC, Ciarpaglini CM, Mateo RG, Carvajal MEB. CIRUGIA ESPANOLA. 2025 September 01. 103 (9):DOI:10.1016/j.ciresp.2025.800191.

461. Impact of Nirsevimab immunoprophylaxis on professional exhaustion during two epidemics of respiratory syncytial virus. Barrés A, Calderon C, Ferrando S, Castillo S, Fullana M, González SI, Arcos JV. Journal of Pediatric Nursing-Nursing Care of Children & Families. 2025 September 01. 8482-87. DOI:10.1016/j.pedn.2025.05.018. PMID:40414172.

462. Hypochloremia in chronic and acute heart failure scenarios: Prevalence and risk factors. Llàcer P, Marcos MC, Croset F, Zegri I, de la Espriella R, Ordás JG, Forti A et al. European Journal of Internal Medicine. 2025 September 01. 139106357-106357. DOI:10.1016/j.ejim.2025.05.022. PMID:40500604.

463. The impact of enhancing vascular access care quality through monitoring and training: A multicentre observational study. Casanova S, García P, López P, Gil MJ, Hevilla EB, Solaz V, Valdelvira B et al. Journal of Vascular Access. 2025 September 01. 26 (5):1661-1672. DOI:10.1177/11297298241296163. PMID:39582190.

464. Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Maqueda MA, Quintáns AT, Cuatrecasas M, Aceñero MJF, Montes AF, Martín CG, Fonseca PJ et al. Clinical & Translational Oncology. 2025 September 01. 27 (9):3580-3594. DOI:10.1007/s12094-025-03865-6. PMID:40072752.

465. Accuracy of FreeStyle Libre 3 During Moderate-Intensity Continuous Aerobic Exercise at Different Phases of the Menstrual Cycle in Females with Type 1 Diabetes. Pino A, Sanz A, Díez JL, Rossetti P, Romero CM, Ampudia FJ, Bondia J et al. Diabetes Technology & Therapeutics. 2025 September 01. 27 (9):687-695. DOI:10.1089/dia.2024.0558. PMID:40256792.

466. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hofheinz RD, Fokas E, Benhaim L, Price TJ, Arnold D, Beets R, Guren MG et al. ANNALS OF ONCOLOGY. 2025 September 01. 36 (9):1007-1024. DOI:10.1016/j.annonc.2025.05.528. PMID:40412553.

467. Role of mitochondrial function in the oxidative stress profile of children with Prader-Willi syndrome. Carrasco A, Herrera G, de Graaff LCG, Visser JA, Dasí F, Codóñer P. FREE RADICAL BIOLOGY AND MEDICINE. 2025 September 01. 237397-402. DOI:10.1016/j.freeradbiomed.2025.06.014. PMID:40513997.

468. Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10). Cesaro S, Ljungman P, Mikulska M, Hirsch HH, Navarro D, Cordonnier C, Mehra V et al. LEUKEMIA. 2025 September 01. 39 (9):2061-2071. DOI:10.1038/s41375-025-02649-9. PMID:40456838.

469. Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms. Nadeu F, Shuai S, Clot G, Hilton LK, Diaz A, Martin S, Royo R et al. LEUKEMIA. 2025 September 01. 39 (9):2076-2086. DOI:10.1038/s41375-025-02667-7. PMID:40588565.

470. Evaluation of TRPA1 as a Therapeutic Target in MYCN-Amplified Neuroblastoma. Seger A, Adamic D, Olmos EM, Nilsson J, Granados S, Vieco I, Esfandyari J et al. PEDIATRIC BLOOD & CANCER. 2025 September 01. 72 (9):DOI:10.1002/pbc.31875. PMID:40556352.

471. American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. Batista MV, Chaer FE, Englund JA, Boeckh M, Carpenter PA, Dadwal SS, Waghmare A et al. Transplantation and Cellular Therapy. 2025 September 01. 31 (9):624-638. DOI:10.1016/j.jtct.2025.06.016. PMID:40516922.

472. Blood pressure values in healthy normal weight children and adolescents in eight European countries: auscultatory and oscillometric measurements. E L, RO C, GM, D, E S, VHC, ZK et al. European Journal of Internal Medicine. 2025 September 01. 139106382-106382. DOI:10.1016/j.ejim.2025.06.011. PMID:40541458.

473. Lifestyle-based interventions targeting neurocognition in bipolar disorders-a systematic review of randomized controlled trials. Balanzá Martínez V, Galdámez Huertas A, Sánchez Ortí JV, Kapczinski F, De Boni RB, Pomarol

Clotet E, Van Rheenen TE. PSYCHIATRY RESEARCH. 2025 September 01. 351116618-116618. DOI:10.1016/j.psychres.2025.116618. PMID:40639301.

474. Current status and challenges of multi-omics research using animal models of atherosclerosis. Mitic T, Georgescu A, Alexandru N, Davies MJ, Vindis C, 0000-0001-8303-7252, Gerdtts E et al. Journal of Molecular and Cellular Cardiology Plus. 2025 September 01. 13100476-100476. DOI:10.1016/j.jmccpl.2025.100476. PMID:40726539.

475. Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials. Blasco A, López S, Urruticoechea A, Carrasco E, Spera G, Martín M, Bermejo B et al. ONCOLOGIST. 2025 September 01. 30 (9):DOI:10.1093/oncolo/oyaf263. PMID:40838872.

476. Author's Reply to the correspondence: ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration by Focosi et al. Cesaro S, Ljungman P, Mikulska M, Hirsch HH, Navarro D, Cordonnier C, Mehra V et al. LEUKEMIA. 2025 September 01. 39 (9):2304-2305. DOI:10.1038/s41375-025-02721-4. PMID:40759772.

477. GDF15 is associated with hepatocellular senescence and correlates with mortality in patients with alcohol-associated hepatitis. Rubio T, Martí D, Blaya D, Ariño S, Aguilar B, Martínez García de la Torre RA, Miravet M et al. JHEP Reports. 2025 September 01. 7 (9):101478-101478. DOI:10.1016/j.jhepr.2025.101478. PMID:40810108.

478. Between-subject factors influencing hand skin temperature response after cold stress test in a general adult population. Priego JI, Domingo M, Canada M, de Anda R, Garcia V, Bellot C. JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY. 2025 September 01. 150 (17):13193-13200. DOI:10.1007/s10973-025-14577-y.

479. Data set for reporting of peripheral neuroblastic tumours: recommendations from the international collaboration on cancer reporting (ICCR). Jarzembowski JA, Webster F, Beiske K, Cohn SL, de Krijger RR, Irwin MS, Navarro S et al. HISTOPATHOLOGY. 2025 September 01. 87 (3):343-356. DOI:10.1111/his.15424. PMID:39989174.

480. Surgical approach and postoperative outcomes after left pancreatectomy (SPANDISPAN prospective project). Hernández B, Ramia JM, Busquets J, Secanella L, Peláez N, Alkorta M, Hervás ID et al. CIRUGIA ESPANOLA. 2025 September 01. 103 (9):DOI:10.1016/j.ciresp.2025.800197. PMID:40780556.

481. FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial. Rojo F, Taylor CR, Barrios C, Torrecillas L, Ruiz M, Perez S, Bines J et al. CLIN-

ICAL CANCER RESEARCH. 2025 September 02. 31 (17):3715-3724. DOI:10.1158/1078-0432.CCR-25-0338. PMID:40569606.

482. Trends in HCV Infection Prevalence Among People with HIV in Spain Over Two Decades (2002-2023). Berenguer J, Fanciulli C, Arcos MM, Vivancos MJ, Domingo P, Hernandez A, Barrado J et al. CLINICAL INFECTIOUS DISEASES. 2025 September 03. 82DOI:10.1093/cid/ciaf407. PMID:40708503.

483. Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain. Fidalgo AP, Alonso P, Andiñ M, Cañete A, Collado E, Colino CG, Codina JG et al. Clinical & Translational Oncology. 2025 September 04. 28 (3):860-879. DOI:10.1007/s12094-025-04047-0. PMID:40908428.

484. EFFECTS OF AGING MODULATING REDOX MEDICINE ON HEALTH AND LIFESPAN: Therapies targeting redox balance improve wound healing: a systematic review and meta-analysis. Arnal Forné M, Borrás C. Redox Experimental Medicine. 2025 September 05. 2025 (1):DOI:10.1530/REM-25-0008.

485. miR-107 represses DMPK and is sequestered by CUG repeats triggering the MSI2/miR-7 pathogenesis axis in myotonic dystrophy. Moreno N, Sabater M, Espinosa J, Mulet L, García E, González J, Seoane D et al. Molecular Therapy Nucleic Acids. 2025 September 09. 36 (3):102584-102584. DOI:10.1016/j.omtn.2025.102584. PMID:40599975.

486. Temporal and Spatial Dynamics in the Regulation of Myocardial Metabolism During the Ischemia-Reperfusion Process. De Dios E, Forteza MJ, Perez N, Molina T, Gavara J, Marcos V, Jimenez M et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 September 10. 26 (18):DOI:10.3390/ijms26188820. PMID:41009389.

487. Non-Invasive Redox Biomarkers Detected in Organ Preservation Outflow Solution Enable Early Prediction of Human Liver Allograft Dysfunction. Vidal D, Caballero MJ, Muñoz AM, Mateo SV, Jover M, Alconchel F, Martinez L et al. Antioxidants. 2025 September 10. 14 (9):DOI:10.3390/antiox14091104. PMID:41009009.

488. A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer. Manso L, Sánchez R, Guerra JA, Cortés A, Cejalvo JM, García JA, Morales S et al. Cancer Research Communications. 2025 September 10. 5 (9):1728-1737. DOI:10.1158/2767-9764.CRC-25-0428. PMID:40928353.

489. Characterizing Respiratory Virus Infections during the Peri-engraftment Period of Allogeneic Hematopoietic Cell Transplant. Piñana JL, Martínez C, Choroa P, Perez A, Gómez D, Sanz J, de la Asunción CS et al. Transplant Infectious Disease. 2025 September 11. 27DOI:10.1111/tid.70101. PMID:40932461.

490. Exercise as a Therapy for Successful Aging. Ara I, Gómez Cabrera MC, Garatachea N. SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS. 2025 September 11. 35 (9):DOI:10.1111/sms.70133. PMID:40932041.

491. Response to “Use of the Allium stent for management of ureteral pathology: A real-world clinical practice study”. Panach Navarrete J, Martinez Jabaloyas JM. Urologia Journal. 2025 September 12. 93135-136. DOI:10.1177/03915603251378593. PMID:40937696.

492. Community-Acquired Respiratory Virus Infections: A Threat to Long-Term Survivors After Allogeneic Stem Cell Transplant?. Piñana JL, Carbonell JA, Gómez D, Montoro J, Pérez A, Hernani R, Chorão P et al. CLINICAL INFECTIOUS DISEASES. 2025 September 15. 81 (3):570-580. DOI:10.1093/cid/ciae602. PMID:39657017.

493. Fecal Metabolomics for the Diagnosis of Clostridioides difficile Infection. Bea C, Belmonte A, Pinto C, Ferrer A, Vela S, de Gracia AI, de Castro A et al. Diagnostics. 2025 September 15. 15 (18):DOI:10.3390/diagnostics15182331. PMID:41008703.

494. Distinct cytokine profiles in plasma and tears highlight ophthalmologic inflammation in type 2 diabetes without retinopathy. Jiménez R, Martín L, Gutiérrez ÁM, Carmo-na A, Mora B, Sánchez AM, Fernández L et al. Frontiers in Medicine. 2025 September 15. 121631334-1631334. DOI:10.3389/fmed.2025.1631334. PMID:41030257.

495. The analysis of the gut microbiome during liver disease progression led to the identification of biomarkers for related mild cognitive impairment. Giner L, Gallego JJ, Giménez C, Batallas D, Jarquín VH, Casanova F, Fiorillo A et al. Frontiers in Microbiology. 2025 September 16. 161670512-1670512. DOI:10.3389/fmicb.2025.1670512. PMID:41035890.

496. The Effects of FemmeBalance Supplement on Symptoms of Premenstrual Syndrome: A Four-Cycle Single-Arm Observational Study of a Novel Nutritional Supplement. Viña I, Viña JR. Life-Basel. 2025 September 17. 15 (9):DOI:10.3390/life15091454. PMID:41010396.

497. Array genotyping of transfusion-relevant blood cell antigens in 6946 ancestrally diverse study participants. Gleadall NS, Koets L, Shamardina O, Gollub J, Gottschalk AJ, Razeghi O, Ochoa G et al. BLOOD. 2025 September 18.

146 (12):1511-1524. DOI:10.1182/blood.2025028902. PMID:40499009.

498. Effects of continuous and interval training on inflammatory and vascular adhesion markers in sedentary individuals with type 1 diabetes. Hermo A, Brugnara L, Murillo S, Servitja JM, Victor VM, Novials A, Rovira S. EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY. 2025 September 19. 126 (2):1141-1151. DOI:10.1007/s00421-025-05983-z. PMID:40973820.

499. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed MF, Alese OB, Sayehli CM et al. JOURNAL OF CLINICAL ONCOLOGY. 2025 September 20. 43 (27):3021-3031. DOI:10.1200/JCO-25-00363. PMID:40706016.

500. Anticonvulsant Use in Older Age Bipolar Disorder in a Global Sample from the Global Aging and Geriatric Experiments in Bipolar Disorder Project: Utilisation d'anticonvulsivants pour le traitement des troubles bipolaires du sujet âgé auprès d'un échantillon mondial provenant du projet GAGE-BD. Bodenstern KC, Lesage M, Lavin P, Schouws S, Orhan M, Beunders A, Almeida OP et al. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE. 2025 September 22. 71 (7):489-497. DOI:10.1177/07067437251372190. PMID:40984046.

501. Changes in prescription patterns of antidiabetic medication in patients newly diagnosed with type 2 diabetes in Spain: an observational study. Cea L, Moreno A, Calonge M, Rivas A, Pulido J, Colchero MC, Artola S et al. BMJ Open. 2025 September 22. 15 (9):DOI:10.1136/bmjopen-2025-106069. PMID:40983582.

502. Cytomegalovirus UL21-5 mRNAemia as a Marker of Active Virus Replication in Allogeneic Hematopoietic Transplant Recipients. de la Asunción CS, Ocete MD, Gimenez E, Albert E, Gimeno C, Piñana JL, Solano C et al. JOURNAL OF MEDICAL VIROLOGY. 2025 September 23. 97 (10):DOI:10.1002/jmv.70617. PMID:40985324.

503. Heart Failure Biomarkers for Atrial Fibrillation Prediction Why Not CA125?. Cordero A, de la Espriella R, Nuñez J. JACC-Journal of the American College of Cardiology. 2025 September 23. 86 (12):103-104. DOI:10.1016/j.jacc.2024.10.128. PMID:40962379.

504. Comparing the effectiveness of prophylactic strategies for parastomal hernia prevention: a network meta-analysis. Martin Arevalo J, López Callejon VA, Moro Valdezate D, Perez Santiago L, López Mozos F, Asins JAC, Rodrigo

DC et al. Techniques in Coloproctology. 2025 September 25. 29 (1):169-169. DOI:10.1007/s10151-025-03211-6. PMID:40996571.

505. Evaluation of Paediatric Nursing Students' Medication Calculation Competence: An Observational Study Using a Gamified Contest. Sainz PB, Balaguer E, García P, Martínez PG. Nursing Open. 2025 September 25. 12 (9):DOI:10.1002/nop.2.70295. PMID:40996097.

506. Factors Associated with Elective and Emergency Tracheostomy in an Otorhinolaryngology Department: A Retrospective Study. Jimenez A, Perez T, Escorihuela V, Marco J. Indian Journal of Otolaryngology and Head & Neck Surgery. 2025 September 26. 77 (12):5654-5659. DOI:10.1007/s12070-025-06037-8.

507. Sex differences and gender-oriented characteristics in intensive care unit admissions for patients with traumatic brain injury in Spain. Cruz M, Juárez R, Chover E, Navas N, Czaplá M, Ballestar ML, Martínez RM et al. Frontiers in Medicine. 2025 September 26. 121622422-1622422. DOI:10.3389/fmed.2025.1622422. PMID:41080953.

508. Increased CX3CL1/CX3CR1 Axis Is Related to Atherosclerosis in Subjects with Familial Combined Hyperlipidaemia, Which Is Modulated by Insulin Resistance but Not by Sex. Jiménez E, Espinosa C, Alabadi B, Hurtado G, Enrique A, Martín S, Casas V et al. Biomedicines. 2025 September 28. 13 (10):DOI:10.3390/biomedicines13102378. PMID:41153665.

509. Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement. Ospina AV, González JL, Nadal E, Tranco FH, Bosch J, Calvo V, Bolufer S et al. Translational Lung Cancer Research. 2025 September 28. 14 (9):DOI:10.21037/tlcr-2025-619. PMID:41132973.

510. Cytokine Networks and Heart Failure Outcomes: CA125 as a Bridge Between Congestion and Inflammation. Santas E, Martí A, Villar S, De la Espriella R, Rodríguez E, Revuelta E, González A et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 September 29. 26 (19):DOI:10.3390/ijms26199527. PMID:41096793.

511. Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer. Balko JM, Licata L, Wang XQ, Dugo M, Huang CS, Egle D, Bermejo B et al. npj Breast Cancer. 2025 September 29. 11 (1):103-103. DOI:10.1038/s41523-025-00828-6. PMID:41022779.

512. Estimating Caloric Intake per Breastfeeding Session in Infants: A Probabilistic Approach. Barrés A, Arcos JV,

Castillo S, González SI, Fullana M, Ferrando S. Nutrients. 2025 September 30. 17 (19):DOI:10.3390/nu17193136. PMID:41097213.

513. Experimental Airway Allogenic Transplantation Model with Decellularized Cryopreserved Tracheas. Martínez NJ, Milián L, Mas J, Roig A, Hervás D, Mata M. Biomedicines. 2025 September 30. 13 (10):DOI:10.3390/biomedicines13102401. PMID:41153684.

514. Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy. Torrent A, Morgades M, Iacoboni G, Reguera JL, Kwon M, Corral LL, Hernani R et al. BONE MARROW TRANSPLANTATION. 2025 September 30. 60 (12):1675-1678. DOI:10.1038/s41409-025-02722-y. PMID:41028300.

515. Inflammation and weight change related to neurocognitive and functional impairment in diabetes and psychiatric disorders. Sánchez JV, Balanzá V, Correa P, Selva G, Vila J, Magdalena R, San C et al. Spanish Journal of Psychiatry and Mental Health. 2025 October 01. 18 (4):256-265. DOI:10.1016/j.sjpmh.2024.05.001. PMID:38740330.

516. Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium. Carbonell JA, Jiménez E, Romero S, García E, Miralles A, Lopez B, Huerta M et al. JOURNAL OF CANCER EDUCATION. 2025 October 01. 40 (5):804-811. DOI:10.1007/s13187-025-02578-2. PMID:39939517.

517. Exosomal Specificity of MiR-15a-5p as Marker of Activity, Renal Damage, and Disease Flares in Systemic Lupus Erythematosus. Flores A, Martinez O, Puertes A, Vela S, Gorriz JL, Solis MA, Terradez L et al. AMERICAN JOURNAL OF NEPHROLOGY. 2025 October 01. 56 (5):529-542. DOI:10.1159/000544854. PMID:40081350.

518. Prognostic effect of the combined use of thiazides and loop diuretics at discharge following a hospitalization for acute heart failure. Miñana G, Trullàs JC, de la Espriella R, Núñez R, Gasull A, López JB, Montiel J et al. Clinical Research in Cardiology. 2025 October 01. 114 (10):1366-1376. DOI:10.1007/s00392-025-02631-6. PMID:40100326.

519. Off-label use of the BIOFIRE® Blood Culture Identification 2 Panel for multidrug-resistant bacteria colonization surveillance in critical care unit patients: A retrospective study. Cano S, Clari MA, Colomina J, García L, Sanchis C, Torres I, Aguilar G et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2025 October 01. 113 (2):116930-116930. DOI:10.1016/j.diagmicrobio.2025.116930. PMID:40449156.

520. Molecular mechanism involved in sarcopenia and frailty, diagnosis and therapy. Viña J, Gomez Cabrera MC. MOLECULAR ASPECTS OF MEDICINE. 2025 October 01. 105101387-101387. DOI:10.1016/j.mam.2025.101387. PMID:40781035.

521. Ubiquitous calpains show differential dynamics and function during adipocyte differentiation. Rodríguez L, Zaragoza R, Viña JR, García ER. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS. 2025 October 01. 772110557-110557. DOI:10.1016/j.abb.2025.110557. PMID:40701348.

522. Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations. Seguí V, Carbonell JA, Martín J, García M, Grimalt N, Martinez C, Gonzalez JF et al. ESMO Open. 2025 October 01. 10 (10):105771-105771. DOI:10.1016/j.esmoop.2025.105771. PMID:40997747.

523. Prospective evaluation of CAR-T cell therapy-related proteinuria and kidney dysfunction. Moncho F, Hernani R, Juan I, Benzaquén A, Solís MA, Pérez A, Navarro JF et al. Clinical Kidney Journal. 2025 October 01. 18 (10):DOI:10.1093/ckj/sfaf270. PMID:41059413.

524. Multicenter Validation of the Kidney Failure Risk Equation (KFRE) in Spanish Patients with Advanced Chronic Kidney Disease. Montomoli M. NEFROLOGIA. 2025 October 01. 45 (8):DOI:10.1016/j.nefro.2025.501389.

525. The Urgent Need to Update the Educational Pathway of Medical Degrees. Cortés ME, González MJM, San Miguel T. REVISTA MEDICA DE CHILE. 2025 October 01. 153 (10):742-744. DOI:10.4067/s0034-98872025001000742. PMID:41021862.

526. The puzzling Spitz tumours: is artificial intelligence the key to their understanding?. Launet L, Colomer A, Mosquera Zamudio A, Monteagudo C, Naranjo V. HISTOPATHOLOGY. 2025 October 01. 87 (4):489-502. DOI:10.1111/his.15428. PMID:39976082.

527. RiscAP Project: Cardiovascular risk assessment in the nephrology service for primary care physicians. Górriz JL, Matalí A, Sánchez S, Ríos F. Atencion Primaria. 2025 October 01. 57 (10):103263-103263. DOI:10.1016/j.aprim.2025.103263. PMID:40199070.

528. Hemostasis management optimization in patients with advanced chronic liver disease. Fernández A, Alventosa C, Martí D, Castelló I, Latorre M, Urquijo JJ. Gastroenterologia y Hepatologia. 2025 October 01. 48 (8):502453-502453. DOI:10.1016/j.gastrohep.2025.502453. PMID:40252804.

529. Next generation sequencing unravels a gliosarcoma mimicking cerebral osteosarcoma. Marti C, Navarro L, San T, Megias J, Carbonell J, Sanchez M, Roselló E.

Revista Espanola de Patologia. 2025 October 01. 58 (4):100825-100825. DOI:10.1016/j.patol.2025.100825. PMID:40349619.

530. Assessing the Potential Difficulty of Left Pancreatotomy: International Modified Delphi Consensus. Ramia JM, Villodre C, Serradilla M, Alcazar C, Blanco G, Rotellar F, Sabater L et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS. 2025 October 01. 241 (4):626-635. DOI:10.1097/XCS.0000000000001438. PMID:40341349.

531. Identification of phenotypes in heart failure with preserved ejection fraction among 8161 patients from 3 Spanish cohorts. Miró Ò, Peyrony O, Trullàs JC, Alquézar A, Núñez J, López P, Jacob J et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 October 01. 78 (10):896-905. DOI:10.1016/j.rec.2025.02.021. PMID:40311842.

532. Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols. Ruiz N, Morgades M, Blanco L, Costa D, Espinet B, Talavera E, Triviño E et al. MEDICINA CLINICA. 2025 October 01. 165 (4):107106-107106. DOI:10.1016/j.medcli.2025.107106. PMID:40694935.

533. Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead. Buzón Martín L, Cabello A, Díaz de Santiago A, Galindo MJ, Hidalgo Tenorio C, Romero Palacios A, Troya J. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2025 October 01. 80 (10):2565-2586. DOI:10.1093/jac/dkaf246. PMID:40794804.

534. Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study. Penack O, Bacigalupo A, Gavrilaki E, Greinix H, Malard F, Michonneau D, Olivieri A et al. BONE MARROW TRANSPLANTATION. 2025 October 01. 60 (10):1398-1401. DOI:10.1038/s41409-025-02687-y. PMID:40696076.

535. Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial. Seguí E, Brasó F, Pascual T, Sanfeliu E, Victoria I, Saura C, Hierro C et al. ESMO Open. 2025 October 01. 10 (10):105838-105838. DOI:10.1016/j.esmoop.2025.105838. PMID:41033278.

536. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Tai D, Conroy T, Lee JJX, Chee CE, Hao CY, Wijaya I, Aggarwal S et al. ESMO Open. 2025 October 01. 10 (10):105826-105826. DOI:10.1016/j.esmoop.2025.105826. PMID:41067164.

537. COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib. Peled N, Tufman A, Sequist LV, Pasello G, Wang Q, Antonuzzo L, González J et al. ESMO Open. 2025 October 01. 10 (10):105807-105807. DOI:10.1016/j.esmoop.2025.105807. PMID:41139117.

538. Defining bloodstream and central venous catheter-related infections in patients following haematopoietic cell transplantation: position paper of the European Blood and Marrow Transplantation Society Infectious Diseases Working Party and Practice Harmonization and Guidelines Committee. Averbuch D, Mikulska M, Styczynski J, Bergeron A, Cesaro S, Greco R, Neofytos D et al. CLINICAL MICROBIOLOGY AND INFECTION. 2025 October 01. 31 (10):DOI:10.1016/j.cmi.2025.06.037. PMID:40701237.

539. Patient and Physician Perspectives on Cardiovascular Risk: A Multicenter Survey of Communication Gaps Among Hospitalized Patients in Spain. Górriz J, Maruri R, Elorriaga A, Salterain N, Prieto A, Rubia RG, Sánchez IM et al. Circulation-Cardiovascular Quality and Outcomes. 2025 October 01. 18 (10):DOI:10.1161/CIRCOUTCOMES.124.011837. PMID:40916807.

540. Differential effect of triglycerides on the prognosis of patients with a first versus recurrent acute coronary syndrome. Cordero A, Fernandez R, González JR, Fernández LA, Manzano S, Bonanad C, Cortez G et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2025 October 01. 55 (10):DOI:10.1111/eci.70072. PMID:40377168.

541. Development of a Clinical Prediction Model for Anastomotic Leakage in Colorectal Surgery. Ochs V, Taha S, Lavanchy JL, Steinemann D, Müller BP, Rosenberg R, Flaifel M et al. JAMA Network Open. 2025 October 01. 8 (10):DOI:10.1001/jamanetworkopen.2025.38267. PMID:41114976.

542. Consensus on the Diagnosis and Management of Patients with Breakthrough Cancer Pain (BTcP), Including Procedural BTcP: DIOPRO Study. Alarcón MDL, Estévez FV, Martínez JC, Albiach CF, Peidro JRP, Casterá MJT, Rivera IV. JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY. 2025 October 02. 39 (4):1-13. DOI:10.1080/15360288.2025.2546104. PMID:40823980.

543. Is bronchial asthma a risk factor for emotional well-being in adolescence? A comparative study. Valero S, Montoya I, Pérez M. PSYCHOLOGY & HEALTH. 2025 October 03. 40 (10):1685-1702. DOI:10.1080/08870446.2024.2349644. PMID:38715417.

544. Patterns of immune recovery after axicabtagene ciloleucel for aggressive B-cell lymphoma. Pardal AA,

Benzaquén A, Granados P, Amat P, Hernani R, Balaguer A, Pérez A et al. HemaSphere. 2025 October 05. 9 (10):DOI:10.1002/hem3.70229. PMID:41054768.

545. Unravelling the effect of parity on immunoglobulins, cytokines and adipokines in human transitional milk and their association with infant infections during the first 6 months of life. Rio K, Martínez C, Castell M, Rodríguez MJ, Collado MC, Pérez FJ. International Breastfeeding Journal. 2025 October 06. 20 (1):75-75. DOI:10.1186/s13006-025-00770-0. PMID:41053869.

546. The Hidden Players of the Fecal Metabolome: Metabolic Dysregulation Beyond SCFAs Under a High-Fat Diet. Martín M, Casanova P, Morales JM, Marrachelli VG, Monleón D. Metabolites. 2025 October 07. 15 (10):DOI:10.3390/metabo15100660. PMID:41149638.

547. EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism. Olmedo J, Granado E, Delgado D, Lobo L, Jordan C, Monteiro AT, Ehlers AC et al. ONCOGENE. 2025 October 07. 44 (38):3537-3552. DOI:10.1038/s41388-025-03496-9. PMID:40721661.

548. Results of the international audit for faecal incontinence on behalf of the European Society of Coloproctology (ESCP) collaborating group. Dulskas A, Cerkaskaite D, El A, Gallo G, Dardanov D, Svagzdys S, Singh B et al. Colorectal Disease. 2025 October 07. 27 (10):DOI:10.1111/codi.70245. PMID:41058106.

549. Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis. San Martín C, Gallego JJ, Urios A, Correa P, Tabares R, Montoliu C. PLoS One. 2025 October 08. 20 (10):DOI:10.1371/journal.pone.0333029. PMID:41060950.

550. Patterns of circulating cytokines after 2 types of exercise in active type-1 diabetic patients. Herranz M, Agustín RM, Olivares M, Pardines L, Pino A, Bondia J, Rossetti P et al. JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY. 2025 October 10. 81 (4):1335-1344. DOI:10.1007/s13105-025-01123-5. PMID:41068547.

551. Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study. Campos J, Llàcer P, Croset F, García M, Pérez C, Pérez A, Vergara M et al. ESC Heart Failure. 2025 October 13. 12 (6):4336-4348. DOI:10.1002/ehf2.15436. PMID:41078081.

552. Predicting Response to Pro-Cognitive Interventions in Mood Disorders: A Systematic Review by the International Society for Bipolar Disorders Targeting Cognition

Task Force. Tsapekos D, Kalfas M, Schandorff JM, Del Mar Bonnin C, Bowie CR, Balanzá Martínez V, Burdick KE et al. ACTA PSYCHIATRICA SCANDINAVICA. 2025 October 13. 153 (5):374-401. DOI:10.1111/acps.70038. PMID:41083219.

553. Response to editorial comments - Manuscript: Multi-center validation of the Kidney Failure Risk Equation (KFRE) in Spanish patients with advanced chronic kidney disease. Montomoli M. NEFROLOGIA. 2025 October 14. 45 (8):501389-501389. DOI:10.1016/j.nefro.2025.501389. PMID:41093672.

554. Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. Bonanad C, García S, Amat I, Gonzalez R, Sanchís J, López D, Nombela L et al. JACC-Journal of the American College of Cardiology. 2025 October 14. 86 (15):1128-1138. DOI:10.1016/j.jacc.2025.07.051. PMID:41062227.

555. Prescriber-recorded indications for antipsychotic use in children and adolescents in Spain, 2015-2023: a population-based, real-world study. García A, Hurtado I, Robles C, Carrillo MF, Lluch A, Tabarés R, Baeza I et al. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY. 2025 October 15. 35 (3):785-795. DOI:10.1007/s00787-025-02875-7. PMID:41091176.

556. Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2-Advanced Breast Cancer: Results from SERENA-1. Baird RD, de las Heras BB, Ruiz M, Vaklavas C, Moreno I, Oliveira M, Armstrong A et al. CLINICAL CANCER RESEARCH. 2025 October 15. 31 (20):4244-4254. DOI:10.1158/1078-0432.CCR-25-1198. PMID:40788187.

557. Interference of functional dual-tasks on static posturography in people with Parkinson's disease. Monleón S, Valenzuela CSM, Aranda V, Villanueva M, Tomás JM. PHYSIOTHERAPY THEORY AND PRACTICE. 2025 October 17. 42 (3):1-13. DOI:10.1080/09593985.2025.2574388. PMID:41094708.

558. Maternal plasma cell-free RNA as a predictor of early and late-onset preeclampsia throughout pregnancy. Castillo N, Cordero T, Igual M, Muñoz I, Gómez C, Bernat N, Gaspar A et al. Nature Communications. 2025 October 20. 16 (1):9208-9208. DOI:10.1038/s41467-025-64215-2. PMID:41115885.

559. Are Needlestick and Sharp Injuries Associated with Shift Work and Sleep Problems in Nurses? A Systematic Review. Fernández Puerta L, Prados G, Mendoza Vincas A. WESTERN JOURNAL OF NURSING

RESEARCH. 2025 October 23. 47 (12):1225-1236. DOI:10.1177/01939459251377955. PMID:41126779.

560. Differential contribution of T-type voltage-gated calcium channels to vascular reactivity in the aorta and renal artery of healthy rabbits. Suarez A, Guerra S, Zarzoso M, Serna M, Vila JM, Serna E, Mauricio MD. EXPERIMENTAL PHYSIOLOGY. 2025 October 27. 111 (3):1498-1512. DOI:10.1113/EP093044. PMID:41145982.

561. Prevalence of high blood pressure and hypertension among children and adolescents in Europe: a systematic review and meta-analysis. Rietz H, Svärdhagen G, Wuehl E, Lurbe E, Brunström M. ARCHIVES OF DISEASE IN CHILDHOOD. 2025 October 28. 111264-271. DOI:10.1136/archdischild-2025-329073. PMID:41161717.

562. The Length of Lactation and Model of Weaning Modulate Key Regulatory Nodes of Murine Mammary Gland Involution. Puebla S, Gimeno A, Ortíz E, Zaragoza R, Viña JR, García ER. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 October 29. 26 (21):DOI:10.3390/ijms262110501. PMID:41226539.

563. The chloride paradigm shift in heart failure: From neglected ion to keystone of precision diuretic therapy. Mazón Ruiz J, Banegas Deras EJ, Fernández Rodríguez JM, Domingo M, de la Espriella R, Liàcer P, Cobo Marcos M et al. EUROPEAN JOURNAL OF HEART FAILURE. 2025 October 29. 273084-3095. DOI:10.1002/ehj.70081. PMID:41159486.

564. Tropistry: A registry-based modular platform to improve care of neglected tropical diseases in nonendemic settings-Study protocol with two targeted conditions: acute schistosomiasis and cutaneous/mucocutaneous leishmaniasis. Bea C, Alcedo S, Berens N, van S, van J, Van Den Broucke S, Soentjens P et al. PLoS One. 2025 October 30. 20 (10):DOI:10.1371/journal.pone.0335032. PMID:41166314.

565. The Long-Term Outcomes of Corticosteroid Use in COVID-19 Patients with Cardiovascular Disease: A Propensity-Matched Analysis from the Multi-Center International Prospective Registry (HOPE-2). García J, Vazirani R, Feltes G, Sánchez R, Viana MC, Raposeiras S, Romero R et al. Biomedicines. 2025 October 30. 13 (11):DOI:10.3390/biomedicines13112665. PMID:41301758.

566. Impact of High-Intensity Interval Exercise With Elastic Bands Versus Continuous Moderate-Intensity Aerobic Exercise on Glycemic Control in People With Type 1 Diabetes. Martín R, Del Pino AC, Sanz A, Palanca A, Rossetti P, Romero CM, Bondia J et al. Sports Health-A Multidisciplinary Approach. 2025 November 01. 17 (6):1252-1260. DOI:10.1177/19417381251316247. PMID:39905638.

567. Use of the Allium stent for management of ureteral pathology: A real-world clinical practice study. Panach J, Valls L, Lloret MA, Diéguez L, Martínez JM. Urologia Journal. 2025 November 01. 92 (4):650-656. DOI:10.1177/03915603251341399. PMID:40413607.

568. Effect of left bundle branch block on maximal functional capacity in asymptomatic individuals without structural heart disease. Palau P, Domínguez E, Mínguez S, Núñez G, Santas E, García C, de Amo I et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 November 01. 78 (11):957-966. DOI:10.1016/j.rec.2025.03.001. PMID:40122231.

569. Synthesis of 2-(3-aminopropyl)benzopyrans as potential antipsychotic agents targeting D2/D3 and 5-HT2A receptors. Bernabeu Á, Varela MJ, García A, Villarroel C, Vila L, Loza MI, Brea J et al. BIOORGANIC & MEDICINAL CHEMISTRY. 2025 November 01. 129118300-118300. DOI:10.1016/j.bmc.2025.118300. PMID:40633512.

570. Different Regulation of Alpha-1 Antitrypsin Production in Neutrophils of ZZ-AATD Patients Under Hypoxic Conditions. Magallón M, Bañuls L, Castillo S, Romero T, Martínez C, Pellicer D, Herrejón A et al. ARCHIVOS DE BRONCONEUMOLOGIA. 2025 November 01. 61 (11):707-709. DOI:10.1016/j.arbres.2025.06.007. PMID:40617754.

571. Fusobacterium nucleatum is not significantly present in eutopic endometrium from patients with minimal-mild and moderate-severe endometriosis. Graciano MDC, Barnhart K, Gonzalez M, Arenas M, Legro RS, Thomas TR, Rush MA et al. FERTILITY AND STERILITY. 2025 November 01. 124 (5):1071-1081. DOI:10.1016/j.fertnstert.2025.06.035. PMID:40588151.

572. Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life. Airoidi M, Roselló S, Tarazona N, Huerta M, Pérez Santiago L, Fleitas T, Pla Martí V et al. CANCER TREATMENT REVIEWS. 2025 November 01. 140103015-103015. DOI:10.1016/j.ctrv.2025.103015. PMID:40858040.

573. Refractory congestion in heart failure: when standard therapies fall short. De la Espriella R. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 November 01. 78 (11):1007-1009. DOI:10.1016/j.rec.2025.06.010. PMID:40818646.

574. Eccrine Coil Elastosis: A New Dermatopathological Feature Associated With Prediabetes and Diabetes. Monteagudo C, Martínez M, García E, Pérez S, Terrádez L, Álvarez E, Martín JM. JOURNAL OF CUTANEOUS PATHOLOGY. 2025 November 01. 52 (11):720-727. DOI:10.1111/cup.14864. PMID:40889882.

575. Blumgart Anastomosis Versus Invaginating Pancreatogastrostomy for Reconstruction after Pancreatodu-

odenectomy. Dorcaratto D, Garcés M, Palomares S, Sánchez S, Suárez G, Jorba R, Blanco G et al. ANNALS OF SURGERY. 2025 November 01. 282 (5):699-708. DOI:10.1097/SLA.0000000000006873. PMID:40747945.

576. Prevalence and risk factors of dependence-related skin lesions in neonatal units: A multicentre study across Spanish hospitals. Balaguer E, Mora IM, Buck Sainz P, Rodríguez MC, Plá L, García P. Journal of Tissue Viability. 2025 November 01. 34 (4):100945-100945. DOI:10.1016/j.jtv.2025.100945. PMID:40848669.

577. Incidence and risk factors of postoperative delirium after surgery in the spanish population: The DELPO study. de la Varga O, Navarro R, López R, Montesinos S, Almoguera J, Alonso M, Artiaga M et al. Journal of Clinical Anesthesia. 2025 November 01. 107112018-112018. DOI:10.1016/j.jclinane.2025.112018. PMID:41066966.

578. The DEPRE'5 study: pragmatic, multicentre, five-arm, parallel-group randomised controlled trial with blinded assessment to compare treatment strategies in major depression after a failed selective serotonin reuptake inhibitor treatment. Pérez V, Puigdemont D, de Diego J, Elices M, Leal I, Cabello M, Rodriguez R et al. BRITISH JOURNAL OF PSYCHIATRY. 2025 November 01. 227 (5):1-8. DOI:10.1192/bjp.2025.13. PMID:40530754.

579. Comprehensive profiling of the mutational landscape of hidradenoma papilliferum validates key role of alterations in the PI3K/AKT pathway. Cheema S, van der Weyden L, Wong K, Del Castillo Velasco M, Billington J, Vermes I, Anderson E et al. BRITISH JOURNAL OF DERMATOLOGY. 2025 November 01. 193 (5):1004-1007. DOI:10.1093/bjd/ljaf257. PMID:40580495.

580. Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial. Borlaug BA, Testani JM, Petrie MC, Wang Z, Cunningham J, Adams KFJR, Amir O et al. NATURE MEDICINE. 2025 November 01. 31 (11):3853-3861. DOI:10.1038/s41591-025-03939-6. PMID:40887551.

581. Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee. Savarese G, Izquierdo MJ, Bonanad C, Wong A, Schmitt R, Ferraro PM, Dentali F et al. European Heart Journal-Cardiovascular Pharmacotherapy. 2025 November 01. 11 (7):630-637. DOI:10.1093/ehjcvp/pvaf055. PMID:40685253.

582. Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT. Hernández JC, Sheth V, Iacobel-

li S, Koster L, Kröger N, Chiusolo P, Schroeder T et al. AMERICAN JOURNAL OF HEMATOLOGY. 2025 November 01. 100 (11):2028-2039. DOI:10.1002/ajh.70049. PMID:40879525.

583. SEOM-SOGUG clinical guideline for urothelial cancer (2025). Puente J, Rodriguez A, Sevillano E, Estevez SV, Fernández CA, Chirivella I, Climent MA et al. Clinical & Translational Oncology. 2025 November 01. 27 (11):4142-4159. DOI:10.1007/s12094-025-04045-2. PMID:40960583.

584. Pathophysiology and clinical applications of PEEP in acute brain injury. Iavarone IG, Rocco PRM, Grieco DL, Rosà T, Pellegrini M, Badenes R, Stevens RD et al. INTENSIVE CARE MEDICINE. 2025 November 01. 51 (11):2104-2116. DOI:10.1007/s00134-025-08111-9. PMID:40982016.

585. Biological Sex and Cardiovascular Disease Prevention in Systemic Arterial Hypertension. Gerdtz E, 0000-0001-8303-7252, Devaux Y, Magni P, Marti HP, Sopic M, Kararigas G. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2025 November 01. 45 (11):1973-1982. DOI:10.1161/ATVBAHA.125.322092. PMID:40931835.

586. Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry. Alfonso A, Martinez D, Rodríguez R, Gil C, Martínez P, Bernal T, Benavente C et al. LEUKEMIA. 2025 November 01. 39 (11):2686-2696. DOI:10.1038/s41375-025-02744-x. PMID:40890512.

587. Polygenic risk score of glycemic homeostasis, Type 2 Diabetes Mellitus and glycemic components in first episode psychosis. Segura AG, Verdolini N, Valli I, Garcia C, Diaz CM, Vieta E, Mezquida G et al. Schizophrenia Research. 2025 November 01. 285265-275. DOI:10.1016/j.schres.2025.09.019. PMID:41075679.

588. Semaglutide and Exercise Function in Obesity-Related HFpEF Insights From the STEP-HFpEF Program. Borlaug BA, Kitzman DW, Patel S, Chinnakondepalli KM, Butler J, Davies MJ, Petrie MC et al. JACC-Heart Failure. 2025 November 01. 13 (11):102660-102660. DOI:10.1016/j.jchf.2025.102660. PMID:41045908.

589. The importance of disease coding following the diagnosis of chronic kidney disease: from ICD-10 code N18.9 to the role of clinical laboratories. Troya MI, Bover J, Hidalgo AC, Malumbres S, Sánchez Bayá M, Masso E, Coll Brito V et al. NEFROLOGIA. 2025 November 01. 45 (9):DOI:10.1016/j.nefro.2025.501410.

590. Promoting equitable access to financial services to end

financial discrimination against cancer survivors in Europe: scientific and ethical reasons. André F, Soldato D, Vaz I, Cervantes A, Peters S, Harbeck N, de Azambuja E et al. ESMO Open. 2025 November 01. 10 (11):105767-105767. DOI:10.1016/j.esmoop.2025.105767. PMID:41320341.

591. Surfactant Protein D Mediates the Association Between Smoking and Type 2 Diabetes Mellitus Incidence in the Spanish Adult Population: Di@bet.es Study. Oualla W, Lago A, García E, Maldonado C, Doulatram V, García M, Martín F et al. Journal of Xenobiotics. 2025 November 01. 15 (6):DOI:10.3390/jox15060184. PMID:41283421.

592. Perception and knowledge of CVD among women in Spain: national survey on awareness, risk, and lifestyle. Fernández L, Pedreira M, Campuzano R, Gámez JM, Rodríguez L, Ortiz C, Scientific Committee of the Woman and Heart project of the S et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2025 November 01. 78 (11):1014-1017. DOI:10.1016/j.rec.2025.02.018. PMID:40216303.

593. Global anaesthesia practice using inguinal hernia surgery as a tracer condition: a secondary analysis of an international prospective cohort study. NIHR Global Health Research Group on Environmentally Sustainable Hospitals in L. ANAESTHESIA. 2025 November 01. 80 (11):1343-1351. DOI:10.1111/anae.16686. PMID:40923367.

594. Global hospital-based disease management of acute diverticulitis: a prospective, international cohort study. DAMASCUS C. EClinicalMedicine. 2025 November 01. 89103548-103548. DOI:10.1016/j.eclinm.2025.103548. PMID:41079028.

595. 288(th) ENMC International Workshop. Towards better diagnosing, understanding and treating gastrointestinal symptoms in myotonic dystrophy: extended insights and practical recommendations. 16-18 May 2025, Hoofddorp, the Netherlands. Scholten S, Peterson J, Orriëns LB, Pastorelli L, Meola G, Schoser B, Braakman HMH et al. NEUROMUSCULAR DISORDERS. 2025 November 01. 56-57106250-106250. DOI:10.1016/j.nmd.2025.106250. PMID:41130821.

596. A new genotype of the IDH3A gene causes retinitis pigmentosa, generating functional dyschromatopsia from early childhood. Rosell N, Sierra A, Tortosa J, Monferrer C, Montero J, Espinós C, Rodríguez R. OPHTHALMIC GENETICS. 2025 November 02. 46 (6):707-712. DOI:10.1080/13816810.2025.2563909. PMID:40993038.

597. Do predictors of abstinence change in the medium-and long-term follow-up of smokers who have quit smoking? A prospective cohort study. De Granda JI, Jiménez CA,

Cristóbal MI, Rábade C, Vaquero P, Pérez E, Gorordo MI et al. Tobacco Prevention & Cessation. 2025 November 03. 11DOI:10.18332/tpc/208884. PMID:41190051.

598. Personalized management and decision-making for non-ST-segment elevation acute coronary syndrome in vulnerable populations. Díez P, Jiménez C, Cepas P, Vilches L, Rivero F, García H, Sanchís J et al. Expert Review of Cardiovascular Therapy. 2025 November 06. 23 (12):1-12. DOI:10.1080/14779072.2025.2583939. PMID:41182898.

599. Comparing [(18)F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial. García JJ, Pérez JM, Ruiz M, Stradella A, Bermejo B, Escrivá S, Calvo L et al. ESMO Open. 2025 November 06. 10 (11):105875-105875. DOI:10.1016/j.esmoop.2025.105875. PMID:41202503.

600. The importance of disease coding following the diagnosis of chronic kidney disease: From ICD-10 code N18.9 to the role of clinical laboratories. Troya MI, Bover J, Cia Hidalgo A, Malumbres S, Sánchez Bayá M, Massó E, Coll Brito V et al. NEFROLOGIA. 2025 November 06. 45 (9):501410-501410. DOI:10.1016/j.nefroe.2025.501410. PMID:41203527.

601. Cost-Utility Analysis of FreeStyle Libre Systems in People with Type 2 Diabetes Mellitus on Treatment with Basal Insulin and Poor Glycemic Control in Spain. Robles M, Gómez F, Bellido V, Ampudia FJ, Carretero J, Cebrián AM, de la Cuadra A et al. Diabetes Therapy. 2025 November 07. 17 (1):73-92. DOI:10.1007/s13300-025-01816-6. PMID:41201573.

602. Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations. Martinez N, García JÁ, Pernas S, Bermejo B, Morales S, Guerra J, Silva J et al. npj Precision Oncology. 2025 November 07. 9 (1):343-343. DOI:10.1038/s41698-025-01106-1. PMID:41203797.

603. Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation. Marcos Garcés V, Bertolín Boronat C, Merenciano González H, Mas MLM, Alberola JIC, Lopez Bueno L, Rubio AP et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025 November 12. 26 (22):DOI:10.3390/ijms262210964. PMID:41303447.

604. Ventilator-associated lower respiratory tract infections and bacteremia in medical and surgical critical care pa-

tients colonized by multidrug-resistant bacteria. Torres I, Ferrer J, Colomina J, Clari MA, Olea B, Giménez E, Albert E et al. BMC INFECTIOUS DISEASES. 2025 November 14. 25 (1):1583-1583. DOI:10.1186/s12879-025-12027-6. PMID:41239254.

605. Synthetic biology-driven optoelectronic biosensor for rapid and highly sensitive norovirus detection in fecal samples. Martorell S, Santiso C, Gozalbo R, Quintero P, Luque D, Maquieira Á, Rodríguez J et al. BIOSENSORS & BIO-ELECTRONICS. 2025 November 15. 288117787-117787. DOI:10.1016/j.bios.2025.117787. PMID:40674850.

606. Learning curve for direct nasofibrolaryngoscopy in an endocrine surgery unit. Fernández NC, Cardona MR, Silvestre AJ, Ballester RA, Fernández RMM, Rodríguez ML. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES. 2025 November 17. 40 (2):1288-1296. DOI:10.1007/s00464-025-12359-z. PMID:41249536.

607. Nutritional Supplementation for Obsessive-Compulsive Disorder: Protocol for a Systematic Review of Randomized Controlled Trials. Soldevila P, Sánchez JV, Correa P, Balanzá V, Macías Saint D, Fuentes I, Tabarés R. JMIR Research Protocols. 2025 November 18. 14DOI:10.2196/80240. PMID:41252714.

608. Golexanolone Attenuates Neuroinflammation, Fatigue, and Cognitive and Motor Impairment in Diverse Neuroinflammatory Disorders. Llansola M, Mincheva G, Arenas YM, Izquierdo Altarejos P, Pedrosa MA, Blackburn TP, Bäckström T et al. Pharmaceuticals. 2025 November 18. 18 (11):DOI:10.3390/ph18111757. PMID:41304999.

609. Validation of the virtual reality functional capacity assessment tool (VRFCAT) in a Spanish sample of individuals with psychosis and healthy controls. González C, López R, Bobes T, Catalán A, Aymerich C, Rodriguez R, Gutiérrez A et al. EUROPEAN PSYCHIATRY. 2025 November 18. 68 (1):DOI:10.1192/j.eurpsy.2025.10134. PMID:41249148.

610. Sex-Specific Differences and a Predictive Model Based on Clinical and Biochemical Parameters for Minimal Hepatic Encephalopathy. Gallego JJ, Casanova F, Fiorillo A, Benlloch S, Urios A, López A, Oliver M et al. LIVER INTERNATIONAL. 2025 November 19. 45 (12):DOI:10.1111/liv.70452. PMID:41255242.

611. Glucose Responses to Aerobic Exercise Are Influenced by Glucose Levels before the Exercise and Menstrual Cycle Phase in Adults with Type 1 Diabetes on Multiple Daily Insulin Injections. Cossu L, Rossetti P, Martín R, Ampudia FJ, Díez JL, Facchinetti A, Bondia J. Diabetes Technology & Therapeutics. 2025 November 21. 28 (5):463-471. DOI:10.1177/15209156251395037. PMID:41271221.

612. Capturing aberrant cell behaviors producing defects in human embryos via live imaging. Akizawa H, Domingo A, Pardo M, Hernandez B, Ardestani G, Skory RM, Venturas M et al. *Science Advances*. 2025 November 21. 11 (47):DOI:10.1126/sciadv.ady6402. PMID:41259532.

613. Characterization of Infarct Size and Remodeling Using CMR and PET in Mice Models of Reperfused and Non-Reperfused Myocardial Infarction. Gavara J, Molina T, Ezzeddin M, Diaz A, Perez N, Ortega M, Marcos V et al. *Diagnostics*. 2025 November 22. 15 (23):DOI:10.3390/diagnostics15232960. PMID:41374341.

614. Physical activity during COVID-19 pandemic: A 5-year retrospect. Woods JA, Hutchinson NT, Powers SK, Gomez MC, Radak Z, Leeuwenburgh C, Cacciatore S et al. *Sports Medicine and Health Science*. 2025 November 22. 7 (6):405-418. DOI:10.1016/j.smhs.2025.11.001. PMID:41496808.

615. Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. Martínez A, Górriz JL, Fernández B, Soler MJ, Navarro JF. *Journal of Clinical Medicine*. 2025 November 23. 14 (23):DOI:10.3390/jcm14238326. PMID:41375628.

616. LIVERATION trial: a multicentre European randomised study on radiofrequency margin coagulation and its impact on oncological outcomes after liver surgery - study protocol. Villalobos EL, Ielpo B, Aldrighetti L, Anselmo A, Beghdadi N, Berardi G, Briceño F et al. *BMJ Open*. 2025 November 24. 15 (11):DOI:10.1136/bmjopen-2025-100518. PMID:41290310.

617. Towards safer colorectal surgery worldwide: Outcomes and benchmarks from the ESCP CORREA 2022 audit. European Society of Coloproctology (ESCP) CORREA Collaborating Group 2022. *Colorectal Disease*. 2025 November 24. 27 (11):DOI:10.1111/codi.70281. PMID:41286435.

618. Prognostic value of whole lymph node molecular analysis in colorectal cancer: a prospective multicenter study. Liu Q, Lopez S, de Gordo KS, Rodrigo M, Martin JR, Romo A, Pinilla I et al. *CLINICAL AND EXPERIMENTAL MEDICINE*. 2025 November 25. 26 (1):34-34. DOI:10.1007/s10238-025-01936-0. PMID:41286178.

619. Cost-Effectiveness Analysis of Aztreonam-Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain. Aguilar G, Ruiz P, Parraga LP, Maroto M, de Ceano MD, Lordan AV, Gonzalo SA et al. *Infectious Diseases and Therapy*. 2025 November 26. 15 (1):265-284. DOI:10.1007/s40121-025-01257-5. PMID:41291119.

620. Weight loss increases circadian gene expression and emotional well-being in individuals with obesi-

ty. Grau C, Bosch N, Hermo A, Lopez S, Rocha M, Víctor VM, Morillas C et al. *Frontiers in Nutrition*. 2025 November 26. 121722428-1722428. DOI:10.3389/fnut.2025.1722428. PMID:41383341.

621. Extrachromosomal Circular DNA and Transposable Elements in Type 2 Diabetes. Moya Valera C, Arita AF, Lara Hernández F, García AB, Chaves FJ. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*. 2025 November 27. 26 (23):DOI:10.3390/ijms262311516. PMID:41373670.

622. Next-Generation Sequencing Reveals a Diagnostic and Prognostic Role of the TP53 R273C Mutation in Lower-Grade, IDH-Mutant Astrocytomas. Navarro L, Megías J, Salazar I, Sánchez M, Rosello E, San T. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*. 2025 November 27. 26 (23):DOI:10.3390/ijms262311483. PMID:41373636.

623. Unilateral Versus Bilateral Spreader Grafts to Correct Cartilaginous Deviations in Structural Rhinoplasty: A Comparative Study on the Aesthetic and Functional Outcomes. Gimeno L, Calvo J, Pérez T, Rosello MV, Vallejo A, Marrero JC, Marco J. *FACIAL PLASTIC SURGERY*. 2025 November 27. DOI:10.1055/a-2750-9411. PMID:41265885.

624. Cross-Sectional Study of Bone Mineral Density in Chronic Stroke According to Walking Speed. Ruescas MA, Sánchez ML, Ahulló M, Ballester C, Iosa M. *Journal of Clinical Medicine*. 2025 November 27. 14 (23):DOI:10.3390/jcm14238426. PMID:41375729.

625. Evidence for Wnt/ β -Catenin-Activated Rosette-Forming Carcinoma Arising in Rb-Inactivated Bowen Disease. Naharro MJ, Rojas N, Gegúndez H, Monteagudo C. *JOURNAL OF CUTANEOUS PATHOLOGY*. 2025 November 28. 53 (3):230-236. DOI:10.1111/cup.70024. PMID:41315892.

626. Metabolomics in Prostate Cancer: A Minimally Invasive Method Using Urine after Prostatic Massage to Predict Gleason Grade. Panach J, González V, Morales JM, García F, Sales MÁ, Monleón D, Martínez JM. *ARCHIVOS ESPAÑOLES DE UROLOGIA*. 2025 November 28. 78 (9):1132-1142. DOI:10.56434/j.arch.esp.urol.20257809.148. PMID:41339219.

627. SCOUT® Radar Reflector for Nonpalpable Breast Lesion Localization: Clinical Outcomes from a Single-Center Experience. Puente J, Muñoz E, Lopez V, Adrianzén M, Huntley D, Kadzhaya G, Soriano D et al. *Cancers*. 2025 November 28. 17 (23):DOI:10.3390/cancers17233816. PMID:41375017.

628. Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group. Fernández N, Mateos M, Pertejo A, Cacho JD, Juan MJ, Chirivella I, Arruti M et al. *BMC CANCER*. 2025 November 28. 25 (1):1835-1835. DOI:10.1186/s12885-025-15264-9. PMID:41316036.

629. NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC. Pulido I, Garcia JC, Rodriguez ML, Becker JH, López A, Aupi M, Aparisi S et al. *CANCER LETTERS*. 2025 November 28. 633DOI:10.1016/j.canlet.2025.218032. PMID:40935282.

630. Fucose dependent rotavirus and norovirus require fucosidase activity for optimal replication. Peña N, Santos N, Llanos S, Melero A, Cárcamo R, López S, Santiso C et al. *npj Viruses*. 2025 November 29. 3 (1):80-80. DOI:10.1038/s44298-025-00164-3. PMID:41318816.

631. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025). de la Peña FA, Novoa SA, Gregori JG, Cortijo LG, Carrasco FH, Martínez MT, Estévez CM et al. *Clinical & Translational Oncology*. 2025 November 29. 28 (1):105-125. DOI:10.1007/s12094-025-04139-x. PMID:41317270.

632. Urine metabolic analysis as a non-invasive method to predict biochemical recurrence in prostate cancer. Panach J, González V, Morales JM, García F, Sales MÁ, Monleón D, Martínez JM. *Translational Andrology and Urology*. 2025 November 30. 14 (11):3708-3717. DOI:10.21037/tau-2025-592. PMID:41368247.

633. Fertility preservation counselling and practice among women with lymphomas: a retrospective study. Martínez MH, Tudela CL, Gamón BC, Navarro LG. *JOURNAL OF OBSTETRICS AND GYNAECOLOGY*. 2025 December 01. 45 (1):2449679-2449679. DOI:10.1080/014433615.2025.2449679. PMID:39810553.

634. Longitudinal Assessment of Spot Urinary Sodium as Predictor of Clinical Outcomes in Chronic Heart Failure. Lorenzo M, Núñez E, De la Espriella R, Carratalá A, Rodríguez E, Górriz JL, Valls N et al. *JACC-Heart Failure*. 2025 December 01. 13 (12):102467-102467. DOI:10.1016/j.jchf.2025.03.028. PMID:40372298.

635. Effect of antimicrobial therapy on bacterial burden in endotracheal aspirates from mechanically ventilated critical care patients with severe lower respiratory tract infection as assessed by the BIOFIRE® Filmarray® Pneumonia plus panel. Cano S, Clari MÁ, Bolado D, Carbonell N, Navarro D. *DIAGNOSTIC MICROBIOLOGY AND INFEC-*

TIOUS DISEASE. 2025 December 01. 113 (4):117029-117029. DOI:10.1016/j.diagmicrobio.2025.117029. PMID:40753698.

636. Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma. Merino V, April C, Segarra G, Ballester MP, Tosca J, Aguilar P, Medina P et al. *HEPATOLOGY RESEARCH*. 2025 December 01. 55 (12):1663-1674. DOI:10.1111/hepr.70026. PMID:40848271.

637. Pre-infusion cytomegalovirus T-cell immunity for predicting the risk of virus DNAemia in patients undergoing chimeric antigen receptor T-cell therapies. Albert E, Hernani R, Gimenez E, Colomer E, Benzaquen A, Piñana JL, Solano C et al. *BRITISH JOURNAL OF HAEMATOLOGY*. 2025 December 01. 207 (6):2602-2605. DOI:10.1111/bjh.70162. PMID:40936479.

638. Mechanisms by which neuroinflammation modulates GABAergic neurotransmission in the hippocampus of hyperammonemic rats. Sancho M, Izquierdo P, Mincheva G, Llansola M, Felipe V. *NEUROTOXICOLOGY*. 2025 December 01. 111103345-103345. DOI:10.1016/j.neuro.2025.103345. PMID:41205708.

639. Taking a closer look at the early onset of childhood obesity risk. Lurbe E, Álvarez J, Sastre JM, Aguilar F. *ANALES DE PEDIATRIA*. 2025 December 01. 103 (6):504037-504037. DOI:10.1016/j.anpede.2025.504037. PMID:41271536.

640. Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer. Bruixola G, Martín J, Gimeno F, Carbonell JA, García B, Martínez B, González D et al. *ESMO Open*. 2025 December 01. 10 (12):105904-105904. DOI:10.1016/j.esmoop.2025.105904. PMID:41270698.

641. "Reflexiones sobre los orígenes del riesgo de obesidad infantil. Lurbe E, Alvarez J, Sastre JM, Aguilar F. *ANALES DE PEDIATRIA*. 2025 December 01. 103 (6):DOI:10.1016/j.anpedi.2025.504037."

642. Highlights in oesophagogastric cancers from ESMO congress 2025. Petrillo A, Pietrantonio F, Fleitas Kanonnikoff T. *ESMO Gastrointestinal Oncology*. 2025 December 01. 11100275-100275. DOI:10.1016/j.esmog.2025.100275. PMID:41994007.

643. Infectious disease risk after the October 2024 flash flood in Valencia, Spain: Disaster evolution, strategic scenario analysis, and extrapolative baseline for a One Health assessment. Mas S, Artigas P, Cuervo PF, De Elías A, Fantozzi MC, Colangeli G, Córdoba A et al. *One Health*. 2025 December 01. 21101093-101093. DOI:10.1016/j.onehit.2025.101093. PMID:40584224.

644. Cardiorespiratory fitness as a key predictor of metabolic, inflammatory, and oxidative stress biomarkers in adults with different physical activity levels. Hernández OA, Murillo B, Luna C, Cacace J, Hermo A, Ramírez V, Guevara M et al. FREE RADICAL BIOLOGY AND MEDICINE. 2025 December 01. 240735-744. DOI:10.1016/j.freeradbiomed.2025.08.058. PMID:40889726.

645. SEOM-GEICO clinical guidelines on endometrial cancer (2025). Ramirez SP, Fidalgo AP, Ginesta MPB, Ferre AD, Madrid LF, Martinez AG, Montosa FG et al. Clinical & Translational Oncology. 2025 December 01. 27 (12):4368-4380. DOI:10.1007/s12094-025-04046-1. PMID:40986254.

646. An Unforeseen, Existential Threat to Oncological Research in Europe. Blay JY, Cervantes A, André F, Peters S, Harbeck N, Azambuja E, Curigliano G. ANNALS OF ONCOLOGY. 2025 December 01. 36 (12):1550-1552. DOI:10.1016/j.annonc.2025.09.009. PMID:41016598.

647. Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial. Salinas P, Romaguera R, Gómez J, Brugaletta S, Gómez A, Martín P, Romero M et al. HEART. 2025 December 01. 111 (24):1191-1198. DOI:10.1136/heartjnl-2025-325773. PMID:40562528.

648. Optimising clinical trial management in Spain: The CARABELA-Clinical trials framework integrating healthcare models and subject experiences. Almonacid C, Cosio BG, Gall XM, Vila MS, Signes J, Garrido JLV, Luz M et al. Contemporary Clinical Trials Communications. 2025 December 01. 48DOI:10.1016/j.conctc.2025.101544. PMID:41635712.

649. CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients. Martinez C, Ortega M, Pérez S, Bolea A, Casado B, Herencia C, Tornero P et al. VIRCHOWS ARCHIV. 2025 December 01. 487 (6):1337-1346. DOI:10.1007/s00428-025-04247-7. PMID:41206380.

650. Prospective evaluation of copy number alterations validates chromosome 1q gain as an independent marker of poor prognosis in localized Ewing sarcoma. Díaz J, Ranft A, Blanquer M, Noguera R, Salguero C, Delgado D, Romero L et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY. 2025 December 01. 144105008-105008. DOI:10.1016/j.yexmp.2025.105008. PMID:41252851.

651. Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.

Kuemmel S, Jung KH, Andrade L, Assad D, de la Cruz L, Freitas R, Hegg R et al. ESMO Open. 2025 December 01. 10 (12):105869-105869. DOI:10.1016/j.esmoop.2025.105869. PMID:41297162.

652. Chaperone-mediated autophagy sustains muscle stem cell regenerative functions but declines with age. Ramírez I, Campanario S, Chavda B, Santiago O, Flández M, Grima M, Cisneros A et al. Nature Metabolism. 2025 December 01. 7 (12):2571-2588. DOI:10.1038/s42255-025-01411-w. PMID:41339968.

653. Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. Elez E, Siena S, Sartore A, Ros J, Ciardello F, Martinelli E, Steeghs N et al. ESMO Open. 2025 December 01. 10 (12):105892-105892. DOI:10.1016/j.esmoop.2025.105892. PMID:41337858.

654. Dartos muscle flap for radiation-induced rectourethral fistula - A video vignette. Pérez Santiago L, Gracia NA, Puente Monserrat J, Igual LE, García Botello SA, Espí Macías A. Colorectal Disease. 2025 December 01. 27 (12):DOI:10.1111/codi.70323. PMID:41332017.

655. Patterns and predictors of postoperative complications and recurrence after ileocecal resection for Crohn's disease: a national multicenter longitudinal study. Soler A, Sánchez L, Blanco F, Barber X, Millán M, REIC G. Techniques in Coloproctology. 2025 December 01. 29 (1):61-61. DOI:10.1007/s10151-024-03054-7. PMID:39921815.

656. Muscle Oxygen Saturation to Determine Lactate Thresholds in Spinal Cord Injury Population. Sánchez JL, Sendra C, de Anda R, Vazquez M, Priego JI, Aparicio I. INTERNATIONAL JOURNAL OF SPORTS MEDICINE. 2025 December 01. 46 (14):1080-1086. DOI:10.1055/a-2637-7212. PMID:40527490.

657. Vasopressor use after noncardiac surgery: an international observational study. Jammer I, Martin P, Wunsch H, Debouche S, Harlet P, Moonesinghe R, Forni L et al. BRITISH JOURNAL OF ANAESTHESIA. 2025 December 01. 135 (6):1609-1617. DOI:10.1016/j.bja.2025.07.034. PMID:40796492.

658. Individual and combined effects of chemical and mechanical power on postoperative pulmonary complications: a secondary analysis of the REPEAT study. Müller LM, Lilien TA, Patterson WM, Ott S, Francis R, Gama de Abreu M, Serpa A et al. ANAESTHESIA. 2025 December 01. 80 (12):1510-1518. DOI:10.1111/anae.16725. PMID:40827607.

659. Association of intraoperative end-tidal CO(2) levels with postoperative outcomes: a patient-level analysis of two

randomised clinical trials. Nasa P, van DMP, Paulus F, Ferrando C, Bluth T, Gama de Abreu M, Ball L et al. BRITISH JOURNAL OF ANAESTHESIA. 2025 December 01. 135 (6):1761-1769. DOI:10.1016/j.bja.2025.07.076. PMID:40930872.

660. Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study. Visentin A, Gaffo E, Fürstenau M, Rogers KA, Panagiotis B, Cui CH, Miller C et al. LEUKEMIA. 2025 December 01. 39 (12):2957-2967. DOI:10.1038/s41375-025-02755-8. PMID:40973766.

661. Mapping the Antibiofilm Peptide Space with Similarity Networks and Curated Negative Sets. Castillo K, Marrero Y, Marquez EA, Garcia JL, Antunes A, Aguero G. ACS Omega. 2025 December 02. 10 (49):60457-60476. DOI:10.1021/acsomega.5c07679. PMID:41427215.

662. Linking Personality Traits to Mediterranean Diet Adherence and Exploring Gene-Diet Interactions in Neuroticism. Sorlí JV, Ortega C, Coltell O, Fernández R, Asensio EM, Portolés O, Perez A et al. Nutrients. 2025 December 03. 17 (23):DOI:10.3390/nu17233791. PMID:41374081.

663. Primary Care Records and Population Prevalence of Chronic Insomnia: Do They Match?. Pujol J, García C, de Entrambasaguas M, Malla M, Martínez J. Healthcare. 2025 December 03. 13 (23):DOI:10.3390/healthcare13233152. PMID:41373368.

664. Ultrasound Assessment of the Tibial Nerve at the Retromalleolar Level: Influence of Anthropometric Characteristics and Clinical Implications. Benimeli M, Macián C, Carbonell L, Chiva MJ, Montiel JM, Almerich JM, Cibrian R et al. Clinics and Practice. 2025 December 03. 15 (12):DOI:10.3390/clinpract15120227. PMID:41440478.

665. Noninvasive Ventilation Effectiveness in Amyotrophic Lateral Sclerosis. Sancho J, Ferrer S, Signes Costa J. Journal of Clinical Medicine. 2025 December 04. 14 (23):DOI:10.3390/jcm14238609. PMID:41375912.

666. Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP. Bazarbachi A, Galimard JE, Abou I, Labopin M, Sanz J, Huang H, Mayer J et al. BONE MARROW TRANSPLANTATION. 2025 December 05. 61 (3):282-293. DOI:10.1038/s41409-025-02770-4. PMID:41345260.

667. Relationship between anastomotic technique, incisional hernia, and quality of life-the Minimally Invasive Right Colectomy Anastomosis STudy (MIRCAST). Gómez M, MIRCAST study group (. BJS-British Journal of Surgery. 2025 December 08. 112 (12):DOI:10.1093/bjs/znaf250. PMID:41355692.

668. A New Perspective on Torquetenovirus DNAemia as a Biomarker of Immunosuppression and Inflammation. Navarro D. JOURNAL OF MEDICAL VIROLOGY. 2025 December 15. 97 (12):DOI:10.1002/jmv.70752. PMID:41395777.

669. Outcomes of surgical techniques for parastomal hernia repair: a bayesian network meta-analysis. Martín Arévalo J, Lopez Callejon VA, Moro Valdezate D, Garcia Botello SA, Perez Santiago L, Millan M, Lopez Mozos F et al. Hernia. 2025 December 15. 30 (1):40-40. DOI:10.1007/s10029-025-03534-1. PMID:41396324.

670. Interobserver variability of histopathological assessment in pT1 colorectal carcinoma. de Gordo KS, Daca M, Rodrigo M, Archilla I, Lopez S, Aguirre JJ, Alarcón L et al. HISTOPATHOLOGY. 2025 December 15. 88 (4):868-880. DOI:10.1111/his.70043. PMID:41392996.

671. Cellular neurothekeoma is driven by copy number deletions, providing potential diagnostic and therapeutic avenues. Sousa A, Billington J, Del Castillo Velasco M, Wong K, Cheema S, Vermes I, Anderson E et al. BRITISH JOURNAL OF DERMATOLOGY. 2025 December 16. 194 (3):593-595. DOI:10.1093/bjd/ljaf487. PMID:41365817.

672. Development of the Undergraduate Rotation Satisfaction Questionnaire and its Validation in a Psychiatry Clerkship. Rojo LM, Carrasco JP, Granda AR, Martinez J, Aguilar Garcia EJ. ACTAS ESPANOLAS DE PSIQUIATRIA. 2025 December 17. 53 (6):1308-1319. DOI:10.62641/aep.v53i6.1955. PMID:41437756.

673. Pre- and postsynaptic upregulation of FasII synergistically underlies neuropathological and behavioral phenotypes in a Drosophila model of myotonic dystrophy. Koon AC, Yeung KYW, Wu Y, Leong LI, Cheung JTP, Chen ZS, Peng SI et al. Nature Communications. 2025 December 18. 17 (1):DOI:10.1038/s41467-025-67738-w. PMID:41413387.

674. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic retinopathy in type 2 diabetes: a network meta-analysis of randomised clinical trials. Ortiz Seller A, Ortiz Seller D, Morcillo E, Ortiz JL. International Journal of Clinical Pharmacy. 2025 December 19. 48 (1):80-92. DOI:10.1007/s11096-025-02071-2. PMID:41417177.

675. OAS1 and OAS3 genetic variants enhance inflammatory responses to SARS-CoV-2. DeDiego ML, López R, Pedragosa J, López D, Nogales A, Durbán J, Cardona F et al. iScience. 2025 December 19. 28 (12):DOI:10.1016/j.isci.2025.113966. PMID:41438061.

676. Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a

Phase Ib/II Trial. Hutchings M, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, Terol MJ et al. JOURNAL OF CLINICAL ONCOLOGY. 2025 December 20. 43 (36):3788-3798. DOI:10.1200/JCO-25-00992. PMID:41115257.

677. Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. Pacheco V, Obispo B, Tomas E, de Torres CS, Quintanar T, Paez D, Leon L et al. Clinical & Translational Oncology. 2025 December 23. 28 (6):2409-2422. DOI:10.1007/s12094-025-04171-x. PMID:41436708.

678. Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial. Provencio M, Campos B, Guirado M, Vila L, Campelo RG, Dorta M, Estévez SV et al. Nature Communications. 2025 December 23. 16 (1):DOI:10.1038/s41467-025-66097-w. PMID:41436730.

679. Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40. Tapper WJ, Dawoud A, Score J, Chase AJ, Baxter EJ, Ewing J, Wallis L et al. BLOOD. 2025 December 25. 146 (26):DOI:10.1182/blood.2025028489. PMID:41026930.

680. Ureteral Realignment with Allium Ureteral Stent as Treatment for Complete Ureteral Transection. Panach J, Valls L, Esteve P, Ortiz D, Martínez JM. ARCHIVOS ESPAÑOLES DE UROLOGIA. 2025 December 28. 78 (10):1501-1508. DOI:10.56434/j.arch.esp.urol.20257810.195. PMID:41492683.

681. Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice. Aguilar L, Flores GD, Nacher J, Morales JC, Flores G. NEURO-CHEMICAL RESEARCH. 2025 December 29. 51 (1):23-23. DOI:10.1007/s11064-025-04627-0. PMID:41460391.

682. Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids. Santiso C, Randazzo W, Carmona N, Peña N, Cárcamo R, Lopez S, Navarro N et al. Gut Microbes. 2025 December 31. 17 (1):2469716-2469716. DOI:10.1080/19490976.2025.2469716. PMID:40032727.

683. Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). Rodero BS, Martínez C, Nadal E, Molina M, Campelo RG, Gil A, Massuti B et al. Oncoimmunology. 2025 December 31. 14 (1):2513109-2513109. DOI:10.1080/2162402X.2025.2513109. PMID:40468805.

684. Genetic variants of the androgen receptor and frailty in postmenopausal women. Monllor A, García MA, Tarín JJ, García A, Artero A, Cano A. GYNECOLOGICAL ENDOCRINOLOGY. 2025 December 31. 41 (1):2565238-2565238. DOI:10.1080/09513590.2025.2565238. PMID:41047731.

685. Antigen carbohydrate 125 as a prognostic biomarker in patients with stable chronic heart failure. Guedes P, Martínez M, Romero A, Vicente N, García A, Gomez MJ, Castillo J et al. Cardiovascular Diagnosis and Therapy. 2025 December 31. 15 (6):1161-1173. DOI:10.21037/cdt-2025-244. PMID:41509622.

686. Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study. López MJ, Vazquez MD, Alvarez M, Arribas JR, Arana E, Muñoz P, Navarro J et al. Human Vaccines & Immunotherapeutics. 2025 December 31. 21 (1):DOI:10.1080/21645515.2025.2474775. PMID:40304691.

